Extended Version . This Link Downloads a File

Published by: IDIBAPS Rosselló, 149-153 08036 Barcelona

Editorial board IDIBAPS Scientiﬁc Coordination Office

Art direction & graphic design Marc Montalà www.marcmontala.com

Cover photo © Mar Petit

INDEX

08 Foreword IDIBAPS About IDIBAPS Staff Research and innovation outputs Funding Scientiﬁc facilities Institutional projects Training Communications and public engagement News

50 Area 1 Biological aggression and response mechanisms

88 Area 2 Respiratory, cardiovascular and renal pathobiology and bioengineering

138 Area 3 Liver, digestive system and metabolism

202 Area 4 Clinical and experimental neuroscience

258 Area 5 Oncology and haematology

314 Transversal research groups

325 Team and group leaders index ANNUAL SCIENTIFIC REPORT 2017

FOREWORD IDIBAPS

The Institut d’Investigacions Additionally, 3 transversal groups perform Biomèdiques August Pi i Sunyer research in Primary Care, Nursing, (IDIBAPS) is a biomedical research Pharmacology and Clinical Trials. institute of excellence. It combines clinical and basic research in order to accelerate Scientific breakthroughs are never the result the translation of the knowledge to the of chance. They are the fruit of long-term benefit of the patients. IDIBAPS is a commitments that involve not only CERCA (Research Centers of Catalonia) researchers, but also society as a whole. center and was first accredited as Instituto de Investigación Sanitaria (Instituto de IDIBAPS is a consortium that has made such Salud Carlos III) in 2009. a commitment, to encourage translational research, innovation and technological Founded in 1996, it is a public consortium progress in the field of biomedicine, through formed by the Generalitat de Catalunya, different programmes addressing diseases Hospital Clínic de Barcelona, Faculty of with a high prevalence, morbidity and mortality Medicine and Health Sciences of the in our society. University of Barcelona and, as an associated partner, the CSIC’s Barcelona Biomedical The data presented in this Annual Scientific Research Institute. Report details the ever-growing scientific achievements made by IDIBAPS investigators The Fundació Clínic per a la Recerca and their capacity for attracting public and Biomèdica (FCRB) is a key institution to private funding. This enormous potential for understand the functioning of IDIBAPS as a capturing resources and their translation into whole. It is a non-profit foundation that applied results for clinical practice constitute provides researchers with administrative and the best guarantee for securing the future of management support. The IDIBAPS research the Institute and its impact on society and community is composed of more than 1,500 industry. people, grouped into 107 research groups organized across 5 different areas of knowledge.

AREA 1 Biological aggression and response mechanisms

AREA 2 Respiratory, cardiovascular and renal pathobiology and bioengineering

AREA 3 Liver, digestive system and metabolism

AREA 4 Clinical and experimental neuroscience

AREA 5 Oncology and haematology

9 FOREWORD IDIBAPS

Organisation chart

IDIBAPS requires a solid administrative infrastructure to support the state-of-the-art research developed by its researchers.

For this reason, IDIBAPS works together with the Fundació Clínic per a la Recerca Biomèdica (FCRB) to ensure efficiency and quality in the services offered to its research staff, in particular, in the areas of research project management and administration.

Elías Campo, MD PhD Marga Nadal, PhD Rosa Vilavella Director of IDIBAPS and of FCRB Director of Strategy General Manager

Gemma Pedrola Arantxa Fernández Laura Lopera Secretary Secretary Secretary [email protected] [email protected] [email protected] T. +34 93 312 94 11 T.+34 93 227 18 30 T. +34 93 227 18 42 CEK, mezzanine floor CEK, mezzanine floor CEK, mezzanine floor

Gemma Llaverías Marta Fernández Head of the Scientiﬁc Head of the Human Resources Office Coordination Office Sònia Meléndez Elisenda Vendrell Head of the Accounting and Finance Office Head of the KTT Office Ernest Costa Daniel Arbós Head of the TIC Office Head of the Communication Office Juan Suero Gemma Pascual Head of the Purchasing Head of the Institutional Actions Office and General Services Office

Sandra Piquer Guillem Masdeu Coordinator of IDIBAPS laboratories Head of the Legal Office

Anna Bosch RESEARCH MANAGEMENT OFFICE Head of IDIBAPS core facilities Sandra Pérez and Biobank coordinator Head of the Pre-Award Office for National Grants

Maria Carol Head of the Pre-Award Office for International Grants

Judit Martínez Head of the Post-award Grants Office

10 Governance and structure

Governance is exercised through the following boards and committees:

THE BOARD OF GOVERNORS THE SCIENTIFIC ADVISORY BOARD Miguel Ángel del Pozo Centro Nacional de Investigaciones Conformed by representatives of the External leading scientists chosen by the Cardiovasculares(CNIC), Madrid different institutions of the consortium, Board of Governors, compose this board supervises IDIBAPS actions, budget and to advise IDIBAPS on the different Ciril Rozman results. Its mission is to take scientific scientific issues affecting its activities. Hospital Clínic de Barcelona, decisions in consultation with the These leading scientists have in-depth Universitat de Barcelona Scientific Advisory Board, and to evaluate knowledge of the Spanish, European the implementation of the strategic plan. and/or American R+D+I systems as they Jesús San Miguel hold positions in prestigious research Hospital Clínico de Salamanca CHAIRMAN institutions. Francesc Subirada Francisco Sánchez-Madrid General Director, Direcció General de CHAIRMAN Hospital La Princesa, Madrid Recerca, Departament d’ Empresa i Jesús Ávila Coneixement. Generalitat de Catalunya Centro de Biología Molecular Eugenio Santos Severo Ochoa (CBM), Madrid Centro de Investigación del Cáncer (CIC), VICE-CHAIRMAN Salamanca José Carlos Fernández Checa BOARD MEMBERS Director, Instituto de Investigaciones Fernando Arenzana-Seisdedos Antonio Vidal-Puig Biomédicas de Barcelona (IIBB-CSIC) Institut Pasteur, Shangai, China School of Clinical Medicine, University of Cambridge, UK BOARD MEMBERS Bartolomé Celli Albert Barberà Harvard University, Cambridge, UK General Director, Direcció General de Recerca I Innovació en Salut, Departament Francisco Fernández Avilés de Salut, Generalitat de Catalunya Hospital Gregorio Marañón, Madrid

Domènec Espriu Guadalupe García-Tsao Research Vice-Dean, Universitat de Barcelona Yale Liver Center, New Haven, US

Lluís Calvo Ramon Gomis Institutional Coordinator, Consejo Superior de IDIBAPS, Barcelona Investigaciones Cientíﬁcas (CSIC) in Catalonia Roberto Groszmann Francesc Cardellach Yale University School of Medicine, Dean of the School of Medicine, Universitat de West Haven, US Barcelona José López Barneo Elías Campo Instituto de Biomedicina de Sevilla (IBiS) Director, IDIBAPS Carlos López Otín Josep Maria Campistol Universidad de Oviedo General Manager, Hospital Clínic de Barcelona Carlos Macaya Antoni Castells Hospital Clínico San Carlos, Madrid Medical Director, Hospital Clínic de Barcelona Óscar Marín SECRETARY King's College London, UK Lluís Rovira Director, CERCA José M. Mato Centro de Investigación Cooperativa en Biociencias (CIC bioGUNE), Bizcaya

Federico Mayor Centro de Biología Molecular Severo Ochoa, Madrid

Angel Pellicer NYU School of Medicine, New York, US

11 FOREWORD IDIBAPS

THE STEERING COMMITTEE THE INTERNAL ADVISORY COMMITTEE GUEST MEMBERS Montserrat Batlle Which is responsible for the supervision IDIBAPS researchers representing all Works Committee President of the progress achieved by the ﬁve research areas advise the IDIBAPS director IDIBAPS research areas, the recruitment to implement the strategic decisions taken Jaume Bosch of new scientists within the framework of by the Board of Governors. Researcher different research programmes, and the Hepatic hemodynamics and portal hypertension evaluation of IDIBAPS training CHAIRMAN programmes. Elías Campo Francesc Cardellach Director Dean of the School of Medicine CHAIRMAN Universitat de Barcelona Elías Campo STEERING COMMITTEE REPRESENTATIVES Director Josep Maria Llovet Fàtima Crispi Group Leader Researcher MEMBERS Translational research in hepatic oncology Fetal and perinatal medicine Neus Agell Vice-Dean of School of Medicine Joan Carles García-Pagán José Carlos Fernández-Checa and Health Sciences Group Leader Director Universitat de Barcelona Hepatic hemodynamics and portal hypertension Instituto de Investigaciones Biomédicas de Research Deputy Director Barcelona (IIBB-CSIC) Cristina Fillat Hospital Clínic de Barcelona Group Leader Josep M. Gatell Gene therapy and cancer INSTITUTIONAL REPRESENTATIVES National Coordinator of the RETIC on AIDS Joan Cid Joan Carles García-Pagán Physicians’ Representatives Francesc Graus Group Leader Hospital Clínic de Barcelona Cellex building representative Hepatic hemodynamics and portal hypertension Research Deputy Director Guadalupe Mengod Anna Novials Hospital Clínic de Barcelona Deputy Director Group Leader Instituto de Investigaciones Biomédicas Pathogenesis and prevention of diabetes Josep Maria Llovet de Barcelona (IIBB-CSIC) Group Leader Carmen Peralta Translational research in hepatic oncology AREA REPRESENTATIVES Group Leader AREA 1 Liver transplantation and graft viability Anna Planas Josep Maria Miró, Coordinator Coordinator of the IDIBAPS Research Area 4 Maria Cinta Cid, Representative Azucena Salas Researcher Rosa Vilavella AREA 2 Inﬂammatory bowel disease (IBD) General Manager Ramón Farré, Coordinator Joan Albert Barberà, Representative Antonio Sisó

SECRETARY CAPSBE, Primary Care Marga Nadal AREA 3 Research Coordinator Strategy Director Jordi Bruix, Coordinator Francesc Balaguer, Representative Gisela Sugranyes Junior Group Leader AREA 4 Multimodal neuroimaging in high risk Anna Planas, Coordinator and early psychosis Josep Dalmau, Representative SECRETARY AREA 5 Marga Nadal Dolors Colomer, Coordinator Strategy Director Aleix Prat, Representative

TRAINING COORDINATOR Neus Agell Vice-Dean of School of Medicine and Health Sciences Universitat de Barcelona

12 Staff

M TOTAL 38% 1,560 W 62%

1. PREDOCTORAL RESEARCHERS (R1) 8 26% 7 64% WOMEN 36% MAN

1 2. POSTDOCTORAL RESEARCHERS (R2) 6 18%

35% WOMEN 65% MAN

5 3. RESEARCHERS (R3A) 4 23% 2 51% WOMEN 49% MAN

3 4. JUNIOR GROUP LEADERS (R3B) 1%

31% WOMEN 69% MAN

1. PREDOCTORAL RESEARCHERS (R1) 5. GROUP LEADERS (R4) 2. POSTDOCTORAL RESEARCHERS (R2) 6% 3. RESEARCHERS (R3A) 4. JUNIOR GROUP LEADERS (R3B) 24% WOMEN 76% MAN 5. GROUP LEADERS (R4) 6. TECHNICAL SUPPORT 6. TECHNICAL SUPPORT 17% 7. CORE FACILITIES 8. MANAGEMENT STAFF 81% WOMEN 19% MAN

7. CORE FACILITIES 3%

78% WOMEN 22% MAN

8. MANAGEMENT STAFF 6%

66% WOMEN 34% MAN

13 FOREWORD IDIBAPS

Recruitment and retention of talent programs

INSTITUCIÓ CATALANA DE RECERCA IDIBAPS 80/20 PROGRAMME IDIBAPS 50/50 PROGRAMME I ESTUDIS AVANÇATS (ICREA) To strengthen translational clinical With the final mission to strengthen research IDIBAPS launched this program translational clinical research, IDIBAPS in 2013. The 80/20 researchers are and Hospital Clinic of Barcelona started in consolidated clinical investigators from 2012 this pioneering program designed to Hospital Clinic and IDIBAPS with no facilitate the combination of research and reductions in the care load but with clinical activity. The 50/50 researchers are strategic research projects to develop. young medical staff specialists (MD) with a The beneficiaries of this program release strong research career (PhD) built up, at ICREA, the Catalan Institute for Research 30 hours devoted to weekly care activities least in part, in the most prestigious foreign and Advanced Studies, is a foundation (80% of a full-time dedication) to dedicate research centers. These junior group supported by the Catalan Government that this time to research. It consists in a 3-year leaders are called to be the future clinical recruits top scientists for the Catalan R&D position extendable for 2 years additional research group leaders that this institution system. Currently IDIBAPS has five ICREA prior a positive evaluation. will need. Research Professors:

Maria Cinta Cid Felicia Alexandra Hanzu Josep Dalmau Systemic vasculitis Endocrine disorders: crosstalk between Pathogenesis of autoimmune neuronal molecular and metabolic determinants disorders Dolors Colomer Physiopathology and molecular bases in Ignacio Revuelta Josep M. Llovet hematology Translational research in posttransplant Translational research in hepatic oncology neoplasia Josep M. Miró Albert Pol Endocarditis. Cardiovascular infections. Isabel Blanco Lipid trafficking and disease Experimental model Translational research in pulmonary vascular diseases: cell proliferation and apoptotic Antonio Postigo mechanisms in pulmonary arterial Transcriptional regulation of gene expression hypertension

María Victoria Sánchez-Vives Gisela Sugranyes Systems neuroscience Multimodal neuroimaging in high risk and early psychosis

Carlos Fernández de Larrea Mechanisms of progression in monoclonal gammopathies

Eduard Guasch Arrhythmias and physical activity

Sara Llufriu Advanced imaging in neuroimmunological diseases (ImaginEM)

14 PHD4MD PROGRAMME Irene López PROJECT Splicing factor mutations in hematological malignancies. PRINCIPAL INVESTIGATORS Dolors Colomer (IDIBAPS) and Juan Valcárcel (CRG)

Alexandra Pérez The objective of the PhD4MD Programme PROJECT (https://phd4md.crg.eu) is to provide Multiple system atrophy: synuclein medical doctors with advanced hands-on regulation and biomarkers discovery. training on the latest ﬁelds of research and PRINCIPAL INVESTIGATORS cutting-edge technologies. Ultimately, the M José Martí (IDIBAPS) and Gian Tartaglia medical professionals enrolled in the (CRG) program will obtain their PhD from one of the associated Universities. Medical professionals who enroll in the PhD4MD programme will carry out a project in translational research jointly coordinated by a basic and a clinical research investigator, belonging to one of the four participating institutions: the CRG (Centre for Genomic Regulation), the IRB Barcelona, the IDIBAPS and the VHIR (Vall d'Hebron Research Institute). The PhD4MD programme was launched for the ﬁrst time in 2015 and 3 new positions were awarded in 2017. There are currently 5 awardees of the programme working at IDIBAPS.

Juan Miguel Cejalvo PROJECT Uncovering the molecular and cellular mechanisms of metastatic dormancy in luminal breast cancer. PRINCIPAL INVESTIGATORS Aleix Prat (IDIBAPS) and Roger Gomis (IRB Barcelona)

Csaba Fehér PROJECT Systems vaccinology to guide effective and safe hiv therapeutic vaccines. PRINCIPAL INVESTIGATORS Felipe García / Mireia Arnedo (IDIBAPS) and Patrick Aloy (IRB Barcelona)

Elisa Pose PROJECT A systems biology approach to understanding the molecular pathogenesis of chronic liver disease progression. PRINCIPAL INVESTIGATORS Pere Ginés (IDIBAPS) and Patrick Aloy (IRB Barcelona)

15 FOREWORD IDIBAPS

Research Scientiﬁc and publications innovation outputs

Publication output and indicators.

OUTPUT IF MEAN IF %Q1 %D1

Original articles 1.127 6.895 6,12 69% 32%

Reviews 188 1.108 5,89 64% 29%

Editorials 62 415 6,69 68% 42%

Clinical guidelines 39 299 7,67 69% 56%

Case reports 43 124 2,89 33% 7%

Letters 100 883 8,83 72% 45%

Consortium publications 41 509 12,40 80% 54%

FIGURE LEGEND Output % Q1 Total number of documents published in scholarly % of publications published in journals ranked in the first journals indexed in the ISI Web of Science. quartile (top 25%) of their category as ordered by the 2016 Journal Citation Reports. Total IF Accumulated impact factor of all the scientific % D1 publications. % of publications published in journals ranked in the first decile (top 10%) of their category as ordered by the 2016 Mean IF Journal Citation Reports. Mean impact factor of all the scientific publications.

16 Evolution of the total number of original articles (A) and the total number of original articles per area (B).

A) Number of original articles

1.127 1.092 1.025 1.005 1.004

2013 2014 2015 2016 2017

B) Number of original articles per area 319 296 289 292 282 280 280 267 262 249 249 259 241 229 227 223 225 194 201 179 180 165 169 156

107 2015 2015 2015 2015 2015 2013 2014 2016 2017 2013 2014 2016 2017 2013 2014 2016 2017 2013 2014 2016 2017 2013 2014 2016 2017

AREA 1 AREA 2 AREA 3 AREA 4 AREA 5

FIGURE LEGEND Only original articles were taken into consideration. Publications resulting from collaboration between teams from different areas have been counted once for each area, so the sum of the articles per area is higher than the total.

Evolution of the mean IF (A) and % Q1 (B).

A) Mean IF B) % Q1

6,1 72% 69% 69% 69% 5,7 5,6 5,6 5,5 66%

2013 2014 2015 2016 2017 2013 2014 2015 2016 2017

FIGURE LEGEND Only original articles were taken into consideration. %Q1: % of publications published in journals ranked in the ﬁrst quartile (top 25%) of their category as ordered by the 2016 Journal Citation Reports.

17 FOREWORD IDIBAPS

Original articles in the highest impact TABLE A factor journals (IF>10).

TOTAL JOURNAL IF ORIGINAL ARTICLES New england journal of medicine 72,406 6 Lancet 47,831 2 Number of original articles 138 in IF>10 journals. Nature 40,137 2 (see table A). Nature nanotechnology 38,986 1 Lancet oncology 33,900 6 Cell 30,410 4 Nature medicine 29,886 1 Originals with IDIBAPS 47 main contribution. Nature genetics 27,959 1 (see table B). Lancet neurology 26,284 2 Journal of clinical oncology 24,008 5 European heart journal 20,212 5 Nature cell biology 20,060 1 Journal of the american college of cardiology 19,896 3 Lancet infectious diseases 19,864 1 Circulation 19,309 4 Lancet respiratory medicine 19,287 3 Gastroenterology 18,392 5 Cell metabolism 18,164 2 Nature neuroscience 17,839 1 Annals of internal medicine 17,202 3 Gut 16,658 7 Hepatology 13,246 12 Molecular psychiatry 13,204 1 American journal of respiratory and critical care medicine 13,204 2 Blood 13,164 3 Journal of allergy and clinical immunology 13,081 3 Annals of the rheumatic diseases 12,811 4 Journal of the national cancer institute 12,589 2 Journal of hepatology 12,486 10 Acta neuropathologica 12,213 1 Nature communications 12,124 8 Intensive care medicine 12,015 2 Plos medicine 11,862 1 Annals of oncology 11,855 3 Leukemia 11,702 9 Biological psychiatry 11,412 1 European respiratory journal 10,569 6 Nucleic acids research 10,162 4 Jama neurology 10,029 1 TOTAL 138

18 TABLE B

TEAMS AUTHORS TITLE REFERENCE IF INVOLVED

Sandborn, William J.; Su, Chinyu; Sands, Bruce E.; Tofacitinib as Induction and Maintenance New england journal 72,406 3.7 D'Haens, Geert R.; Vermeire, Severine; Schreiber, Therapy for Ulcerative Colitis. of medicine. Stefan; Danese, Silvio; Feagan, Brian G.; Reinisch, 376(18):1723-1736 Walter; Niezychowski, Wojciech; Friedman, Gary; Lawendy, Nervin; Yu, Dahong; Woodworth, Deborah; Mukherjee, Arnab; Zhang, Haiying; Healey, Paul; Panes, Julian; OCTAVE Induction 1 OCTAVE Inductio

Bruix, Jordi; Qin, Shukui; Merle, Philippe; Granito, Regorafenib for patients with hepatocellular Lancet. 47,831 3.5 Alessandro; Huang, Yi-Hsiang; Bodoky, Gyrogy; Pracht, carcinoma who progressed on sorafenib 389(10064):56-66 Marc; Yokosuka, Osamu; Rosmorduc, Olivier; Breder, treatment (RESORCE): a randomised, Valeriy; Gerolami, Rene; Masi, Gianluca; Ross, Paul J.; double-blind, placebo-controlled, phase Song, Tianqiang; Bronowicki, Jean-Pierre; Ollivier- 3 trial. Hourmand, Isabelle; Kudo, Masatoshi; Cheng, Ann-Lii; Llovet, Josep M.; Finn, Richard S.; LeBerre, Marie-Aude; Baumhauer, Annette; Meinhardt, Gerold; Han, Guohong; Resorce Investigators

Singha S., Shao K., Yang Y., Clemente-Casares X., Solé P., Peptide–MHC-based nanomedicines for Nature 38,986 3.14 Clemente A., Blanco J., Dai Q., Song F., Liu S., Yamanouchi autoimmunity function as T-cell receptor nanotechnology. J., Umeshappa C., Nanjundappa R., Detampel P., Amrein M., microclustering devices. 12(7):701-710 Fandos C., Tanguay R., Newbigging S., Serra P., Khadra A., Chan W., Santamaria P.

Llombart-Cussac, Antonio; Cortes, Javier; Pare, Laia; HER2-enriched subtype as a predictor of Lancet oncology. 30,410 5.13 Galvan, Patricia; Bermejo, Begona; Martinez, Noelia; pathological complete response following 18(4):545-554 Vidal, Maria; Pernas, Sonia; Lopez, Rafael; Munoz, trastuzumab and lapatinib without Montserrat; Nuciforo, Paolo; Morales, Seraﬁn; Oliveira, chemotherapy in early-stage HER2-positive Mafalda; de la Pena, Lorena; Pelaez, Alexandra; Prat, Aleix breast cancer (PAMELA): An open-label, single-group, multicentre, phase 2 trial.

Hebbandi Nanjundappa R., Ronchi F., Wang J., A Gut Microbial Mimic that Hijacks Cell. 171(3):655-667 30,410 3.7; 3.14 Clemente-Casares X., Yamanouchi J., Sokke Diabetogenic Autoreactivity to Suppress Umeshappa C., Yang Y., Blanco J., Bassolas-Molina H., Colitis. Salas A., Khan H., Slattery R., Wyss M., Mooser C., Macpherson A., Sycuro L., Serra P., McKay D., McCoy K., Santamaria P.

Scott DW, Abrisqueta P, Wright GW, Slack GW, Mottok New Molecular Assay for the Proliferation Journal of clinical 24,008 5.1 A, Villa D, Jares P, Rauert-Wunderlich H, Royo C, Clot G, Signature in Mantle Cell Lymphoma oncology. Pinyol M, Boyle M, Chan FC, Braziel RM, Chan WC, Applicable to Formalin-Fixed 35(15):1668-1677 Weisenburger DD, Cook JR, Greiner TC, Fu K, Ott G, Paraffin-Embedded Biopsies. Delabie J, Smeland EB, Holte H, Jaffe ES, Steidl C, Connors JM, Gascoyne RD, Rosenwald A, Staudt LM, Campo E, Rimsza LM, Lymphoma/Leukemia Molecular Proﬁling Project

Arbelo E, Brugada J, Blomström-Lundqvist C, Laroche Contemporary management of patients European heart 20,212 2.2 C, Kautzner J, Pokushalov E, Raatikainen P, Efremidis M, undergoing atrial fibrillation ablation: journal. Hindricks G, Barrera A, Maggioni A, Tavazzi L, Dagres N, Inhospital and 1-year follow-up findings 38(17):1303-1316 on the behalf of the ESC-EHRA Atrial Fibrillation from the ESC-EHRA atrial fibrillation Ablation Long-term Registry Investigators ablation long-term registry.

Brugada J, Delnoy PP, Brachmann J, Reynolds D, Contractility sensor-guided optimization of European heart 20,212 2.2 Padeletti L, Noelker G, Kantipudi C, Rubin Lopez JM, cardiac resynchronization therapy: Results journal. Dichtl W, Borri-Brunetto A, Verhees L, Ritter P, Singh JP, from the RESPOND-CRT trial. 38(10):730-738 RESPOND CRT Investigators

Hernandez-Ojeda J, Arbelo E, Borras R, Berne P, Patients With Brugada Syndrome and Journal of the 19,896 2.2 Tolosana JM, Gomez-Juanatey A, Berruezo A, Implanted Cardioverter-Deﬁbrillators: american college Campuzano O, Sarquella-Brugada G, Mont L, Brugada Long-Term Follow-Up. of cardiology. R, Brugada J 70(16):1991-2002

Forns X, Lee SS, Valdes J, Lens S, Ghalib R, Aguilar H, Glecaprevir plus pibrentasvir for chronic Lancet infectious 19,864 3.3 Felizarta F, Hassanein T, Hinrichsen H, Rincon D,Morillas hepatitis C virus genotype 1, 2, 4, 5, or 6 diseases. R, Zeuzem S, Horsmans Y, Nelson DR, Yu Y, Krishnan P, infection in adults with compensated 17(10):1062-1068 Lin CW, Kort JJ, Mensa FJ cirrhosis (EXPEDITION-1): a single-arm, open-label, multicentre phase 3 trial.

19 FOREWORD IDIBAPS

Agustí A., Noell G., Brugada J., Faner R. Lung function in early adulthood and health The lancet. 19,287 2.2; 2.9 in later life: a transgenerational cohort Respiratory medicine. analysis. 5(12):935-945

Lens S, Alvarado-Tapias E, Mariño Z, Londoño MC, Effects of All-oral Anti-viral Therapy on Gastroenterology. 18,392 3.3; 3.6 LLop E, Martinez J, Fortea JI, Ibañez L, Ariza X, Baiges A, HVPG and Systemic Hemodynamics in 153(5):1273-1283 Gallego A, Bañares R, Puente A, Albillos A, Calleja JL, Patients with Hepatitis C Virus-associated Torras X, Hernández-Gea V, Bosch J, Villanueva C, Cirrhosis. Forns X, García-Pagán JC

Sia D, Jiao Y, Martinez-Quetglas I, Kuchuk O, Identiﬁcation of an Immune-speciﬁc Class Gastroenterology. 18,392 3.5 Villacorta-Martin C, Castro de Moura M, Putra J, of Hepatocellular Carcinoma, Based on 153(3):812-826 Camprecios G, Bassaganyas L, Akers N, Losic B, Molecular Features. Waxman S, Thung SN, Mazzaferro V, Esteller M, Friedman SL, Schwartz M, Villanueva A, Llovet JM

Silva-Junior G, Turon F, Baiges A, Cerda E, Timing Affects Measurement of Portal Gastroenterology. 18,392 3.6 García-Criado Á, Blasi A, Torres F, Hernandez-Gea V, Pressure Gradient After Placement of 152(6):1358-1365 Bosch J, Garcia-Pagan JC Transjugular Intrahepatic Portosystemic Shunts in Patients With Portal Hypertension.

Akerman, Ildem; Tu, Zhidong; Beucher, Anthony; Human Pancreatic β Cell lncRNAs Control Cell metabolism. 18,164 3.13 Rolando, Delphine M. Y.; Sauty-Colace, Claire; Benazra, Cell-Speciﬁc Regulatory Networks. 25(2):400-411 Marion; Nakic, Nikolina; Yang, Jialiang; Wang, Huan; Pasquali, Lorenzo; Moran, Ignasi; Garcia-Hurtado, Javier; Castro, Natalia; Gonzalez-Franco, Roser; Stewart, Andrew F.; Bonner, Caroline; Piemonti, Lorenzo; Berney, Thierry; Groop, Leif; Kerr-Conte, Julie; Pattou, Francois; Argmann, Carmen; Schadt, Eric; Ravassard, Philippe; Ferrer, Jorge;

Ramírez S, Gómez-Valadés AG, Schneeberger M, Mitochondrial Dynamics Mediated by Cell metabolism. 18,164 3.14; 3.15 Varela L, Haddad-Tóvolli R, Altirriba J, Noguera E, Mitofusin 1 Is Required for POMC Neuron 25(6):1390-1399 Drougard A, Flores-Martínez Á, Imbernón M, Chivite I, Glucose-Sensing and Insulin Release Pozo M, Vidal-Itriago A, Garcia A, Cervantes S, Gasa R, Control. Nogueiras R, Gama-Pérez P, Garcia-Roves PM, Cano DA, Knauf C, Servitja JM, Horvath TL, Gomis R, Zorzano A, Claret M

Miro, Oscar; Rossello, Xavier; Gil, Victor; Predicting 30-Day Mortality for Patients Annals of internal 17,202 1.7 Martin-Sanchez, Francisco Javier; Llorens, Pere; With Acute Heart Failure in the Emergency medicine. 167(10):698 Herrero-Puente, Pablo; Jacob, Javier; Bueno, Hector; Department A Cohort Study. Pocock, Stuart J.;ICA-SEMES Res Grp

Dotti I., Mora-Buch R., Ferrer-Picón E., Planell N., Jung P., Alterations in the epithelial stem cell Gut. 16,658 3.7 Masamunt M., Leal R., De Carpi J., Llach J., Ordás I., compartment could contribute to 66(12):2069-2079 Batlle E., Panés J., Salas A. permanent changes in the mucosa of patients with ulcerative colitis.

Garcia-Pras E, Gallego J, Coch L, Mejias M, Role and therapeutic potential of vascular Gut. 66(7):1306-1320 16,658 3.6 Fernandez-Miranda G, Pardal R, Bosch J, Mendez R, stem/progenitor cells in pathological Fernandez M neovascularisation during chronic portal hypertension.

Panés J, Sandborn WJ, Schreiber S, Sands BE, Tofacitinib for induction and maintenance Gut. 66:1049-1059 16,658 3.7 Vermeire S, D'Haens G, Panaccione R, Higgins PDR, therapy of Crohn's disease: results of two Colombel JF, Feagan BG, Chan G, Moscariello M, Wang phase IIb randomised placebo-controlled W, Niezychowski W, Marren A, Healey P, Maller E trials.

Tovar, Victoria; Cornella, Helena; Moeini, Agrin; Vidal, Tumour initiating cells and IGF/FGF Gut. 66(3):530-539 16,658 3.5 Samuel; Hoshida, Yujin; Sia, Daniela; Peix, Judit; signalling contribute to sorafenib Cabellos, Laia; Alsinet, Clara; Torrecilla, Sara; resistance in hepatocellular carcinoma. Martinez-Quetglas, Iris; Jose Lozano, Juan; Desbois-Mouthon, Christele; Sole, Manel; Domingo-Domenech, Josep; Villanueva, Augusto; Llovet, Josep M.;

De Barrios O., Gyorffy B., Fernández-Aceñero M., ZEB1-induced tumourigenesis requires Gut. 66(4):666-682 16,658 3.1; 5.1; 5.8 Sánchez-Tilló E., Sánchez-Moral L., Siles L., senescence inhibition via activation of Esteve-Arenys A., Roué G., Casal J., Darling D., Castells DKK1/mutant p53/Mdm2/CtBP and A., Postigo A. repression of macroH2A1.

20 Altamirano J, López-Pelayo H, Michelena J, Jones PD, Alcohol abstinence in patients surviving an Hepatology. 13,246 3.4; 3.9; 4.7 Ortega L, Ginès P, Caballería J, Gual A, Bataller R, episode of alcoholic hepatitis: Prediction 66(6):1842-1853 Lligoña A and impact on long-term survival.

Berzigotti A, Albillos A, Villanueva C, Genescá J, Ardevol Effects of an intensive lifestyle intervention Hepatology. 13,246 3.6 A, Augustín S, Calleja JL, Bañares R, García-Pagán JC, program on portal hypertension in patients 65(4):1293-1305 Mesonero F, Bosch J, Ciberehd SportDiet Collaborative with cirrhosis and obesity: The sportdiet Group study.

Perea L, Coll M, Sanjurjo L, Blaya D, Taghdouini AE, Pentraxin-3 Modulates LPS-induced Hepatology. Rodrigo-Torres D, Altamirano J, Graupera I, Inﬂammatory Response and Attenuates 66(3):953-968 13,246 3.4; 3.9 Aguilar-Bravo B, Llopis M, Vallverdú J, Caballeria J, van Liver Injury. Grunsven LA, Sarrias MR, Ginès P, Sancho-Bru P

Alcaraz-Quiles J, Titos E, Casulleras M, Pavesi M, López- Polymorphisms in the IL-1 gene cluster Hepatology. 13,246 3.4 Vicario C, Rius B, Lopategi A, de Gottardi A, Graziadei I, inﬂuence systemic inﬂammation in patients 65(1):202-216 Gronbaek H, Ginès P, Bernardi M, Arroyo V, Clària J. at risk for acute-on-chronic liver failure.

Vilaseca M., García-Calderó H., Lafoz E., García-Irigoyen The anticoagulant rivaroxaban lowers Hepatology. 13,246 3.6; 5.9 O., Avila M., Reverter J., Bosch J., Hernández-Gea V., portal hypertension in cirrhotic rats mainly 65(6):2031-2044 Gracia-Sancho J., García-Pagán J. by deactivating hepatic stellate cells.

Ranzani OT, Prina E, Menéndez R, Ceccato A, Cilloniz C, New Sepsis Deﬁnition (Sepsis-3) and American journal of 13,204 2.6 Méndez R, Gabarrus A, Barbeta E, Bassi GL, Ferrer M, Community-acquired Pneumonia Mortality respiratory and Torres A. A Validation and Clinical Decision-Making critical care medicine. Study. 196(10):1287-1297

Balsas P, Palomero J, Eguileor Á, Rodríguez ML, SOX11 promotes tumor protective Blood. 130(4):501-513 13,16 1.2; 5.1 Vegliante MC, Planas-Rigol E, Sureda-Gómez M, Cid microenvironment interactions through MC, Campo E, Amador V. CXCR4 and FAK regulation in mantle cell lymphoma.

Planas-Rigol E., Terrades-Garcia N., Corbera-Bellalta Endothelin-1 promotes vascular smooth Annals of the 12,811 1.2 M., Lozano E., Alba M., Segarra M., Espígol-Frigolé G., muscle cell migration across the artery wall: rheumatic diseases. Prieto-González S., Hernández-Rodríguez J., Preciado A mechanism contributing to vascular 76(9):1624-1634 S., Lavilla R., Cid M. remodelling and intimal hyperplasia in giant-cell arteritis.

Brito-Zerón P, Acar-Denizli N, Zeher M, Rasmussen A, Inﬂuence of geolocation and ethnicity on the Annals of the 12,811 1.2 Seror R, Theander E, Li X, Baldini C, Gottenberg JE, phenotypic expression of primary Sjögren's rheumatic diseases. Danda D, Quartuccio L, Priori R, Hernandez-Molina G, syndrome at diagnosis in 8310 patients: a 76(6):1042-1050 Kruize AA, Valim V, Kvarnstrom M, Sene D, Gerli R, cross-sectional study from the Big Data Praprotnik S, Isenberg D, Solans R, Rischmueller M, Sjögren Project Consortium. Kwok SK, Nordmark G, Suzuki Y, Giacomelli R, Devauchelle-Pensec V, Bombardieri M, Hofauer B, Bootsma H, Brun JG, Fraile G, Carsons SE, Gheita TA, Morel J, Vollenveider C, Atzeni F, Retamozo S, Horvath IF, Sivils K, Mandl T, Sandhya P, De Vita S, Sanchez-Guerrero J, van der Heijden E, Trevisani VFM, Wahren-Herlenius M, Mariette X, Ramos-Casals M, EULAR-SS Task Force Big Data Consortium

Pascasio JM, Vinaixa C, Ferrer MT, Colmenero J, Rubin Clinical outcomes of patients undergoing Journal of 12,486 3.3; 3.10 A, Castells L, Manzano ML, Lorente S, Testillano M, Xiol antiviral therapy while awaiting liver hepatology. X, Molina E, González-Diéguez L, Otón E, Pascual S, transplantation. 67:1168-1176 Santos B, Herrero JI, Salcedo M, Montero JL, Sánchez-Antolín G, Narváez I, Nogueras F, Giráldez Á, Prieto M, Forns X, Londoño MC.

Guixé-Muntet S, de Mesquita FC, Vila S, Cross-talk between autophagy and KLF2 Journal of 12,486 3.6; 3.10 Hernández-Gea V, Peralta C, García-Pagán JC, Bosch determines endothelial cell phenotype and hepatology. J, Gracia-Sancho J. microvascular function in acute liver injury. 66(1):86-94

Fernandez, Inmaculada; Munoz-Gomez, Raquel; Pascasio, Efficacy and tolerability of interferon-free Journal of 12,486 3.3 Juan M.; Baliellas, Carme; Polanco, Natalia; Esforzado, antiviral therapy in kidney transplant hepatology. Nuria; Arias, Ana; Prieto, Martin; Castells, Lluis; recipients with chronic hepatitis c. 66(4):718-723 Cuervas-Mons, Valentin; Hernandez, Olga; Crespo, Javier; Calleja, Jose L.; Forns, Xavier; Londono, Maria-Carlota.

Moeini A, Sia D, Zhang Z, Camprecios G, Stueck A, Dong Mixed hepatocellular cholangiocarcinoma Journal of 12,486 3.5 H, Montal R, Torrens L, Martinez-Quetglas I, Fiel MI, Hao tumors: Cholangiolocellular carcinoma is a hepatology. K, Villanueva A, Thung SN, Schwartz ME, Llovet JM distinct molecular entity. 66(5):952-961

21 FOREWORD IDIBAPS

Lencioni R, Montal R, Torres F, Park JW, Decaens T, Objective response by mRECIST as a Journal of 12,486 3.5 Raoul JL, Kudo M, Chang C, Ríos J, Boige V, Assenat E, predictor and potential surrogate end-point hepatology. Kang YK, Lim HY, Walters I, Llovet JM. of overall survival in advanced HCC. 66(6):1166-1172

Bruix J, Cheng AL, Meinhardt G, Nakajima K, Prognostic Factors and Predictors of Journal of 12,486 3.5 De Sanctis Y, Llovet J. Sorafenib Beneﬁt in Patients With hepatology. Hepatocellular Carcinoma: Analysis of 67(5):999-1008 Two Phase 3 Studies.

Torrecilla S, Sia D, Harrington AN, Zhang Z, Cabellos L, Trunk events present minimal intra- and Journal of 12,486 3.5 Cornella H, Moeini A, Camprecios G, Leow WQ, Fiel MI, inter-tumoral heterogeneity in hepatology. Hao K, Bassaganyas L, Mahajan M, Thung SN, hepatocellular carcinoma. 67:1222-1231 Villanueva A, Florman S, Schwartz ME, Llovet JM.

Villanueva, Eneko; Navarro, Pilar; Rovira-Rigau, Maria; Translational reprogramming in tumour Nature 12,124 3.11 Sibilio, Annarita; Mendez, Raul; Fillat, Cristina cells can generate oncoselectivity in viral communications. therapies. 8:14833

Li Bassi G; Panigada M; Ranzani O; Zanella A; Berra L; Randomized, multicenter trial of lateral Intensive care 12,015 2.6 Cressoni M; Parrini V; Kandil H; Salati G; Selvaggi P; Trendelenburg versus semirecumbent body medicine. Amatu A; Sanz-Moncosi M; Biagioni E; Tagliaferri F; position for the prevention of 43(11):1572-1584 Furia M; Mercurio G; Costa A; Manca T; Lindau S; Babel ventilator-associated pneumonia. J; Cavana M; Chiurazzi C; Martí J; Consonni D; Gattinoni L; Pesenti A; Wiener-Kronish J; Bruschi C; Ballotta A; Salsi P; Livigni S; Iotti G; Fernandez J; Girardis M; Barbagallo M; Moise G; Antonelli M; Caspani M; Vezzani A; Meybohm P.

Magnano L, Balagué O, Dlouhy I, Rovira J, Karube K, Clinicobiological features and prognostic Annals of oncology. 11,855 5.1; 5.7; 5.8 Pinyol M, Rivas-Delgado A, Costa D, Martínez-Trillos A, impact of diffuse large B-cell lymphoma 28(11):2799-2805 González-Farre B, Martínez-Pozo A, Giné E, Colomer D, component in the outcome of patients with Delgado J, Villamor N, Campo E, López-Guillermo A. previously untreated follicular lymphoma.

Rosinol, L.; Oriol, A.; Teruel, A. I.; de la Guia, A. L.; Bortezomib and thalidomide maintenance Leukemia. 11,702 5.7 Blanchard, Ma J.; de la Rubia, J.; Granell, M.; Sampol, Ma after stem cell transplantation for multiple 31(9):1922-1927 A.; Palomera, L.; Gonzalez, Y.; Etxebeste, Ma A.; myeloma: a PETHEMA/GEM trial. Martinez-Martinez, R.; Hernandez, M. T.; de Arriba, F.; Alegre, A.; Cibeira, Ma T.; Mateos, Ma V.; Martinez-Lopez, J.; Lahuerta, J. J.; Miguel, J. San; Blade, J.;Programa Espanol Tratamientos Hema

Sellares J, Ferrer M, Anton A, Loureiro H, Bencosme C, Discontinuing noninvasive ventilation in European respiratory 10,569 2.6 Alonso R, Martinez-Olondris P, Sayas J, Peñacoba P, severe chronic obstructive pulmonary journal. 50(1) Torres A. disease exacerbations: a randomised controlled trial.

Munoz-Cano R, Torrego A, Bartra J, Sanchez-Lopez J, Follow-up of patients with uncontrolled European respiratory 10,569 2.8 Palomino R, Picado C, Valero A. asthma: clinical features of asthma patients journal. 49(3) according to the level of control achieved (the COAS study).

Noell, Guillaume; Cosio, Borja G.; Faner, Rosa; Monso, Multi-level differential network analysis of European respiratory 10,569 2.9 Eduard; Peces-Barba, German; de Diego, Alfredo; COPD exacerbations. journal. Esteban, Cristobal; Gea, Joaquim; Rodriguez-Roisin, 50(3):1700075 Robert; Garcia-Nunez, Marian; Pozo-Rodriguez, Francisco; Kalko, Susana G.; Agusti, Alvar.

Gozal D, Khalyfa A, Qiao Z, Almendros I, Farré R. Temporal trajectories of novel object European respiratory 10,569 2.5 recognition performance in mice exposed journal. 50(6) to intermittent hypoxia.

Perearnau A., Orlando S., Islam A., Gallastegui E., P27Kip1, PCAF and PAX5 cooperate in the Nucleic acids 10,162 5.11 Martínez J., Jordan A., Bigas A., Aligué R., Pujol M., Bachs O. transcriptional regulation of speciﬁc target research. genes. 45(9):5086-5099

22 Translation of knowledge and innovation

CLINICAL GUIDELINES

As a general perspective of IDIBAPS’ impact in society, it is worth mentioning that every year our researchers participate in the Clinical guidelines elaboration of international clinical guides. published in 2017. These guidelines have a remarkable impact 39 in patients’ care and medical practice.

TEAMS AUTHORS TITLE REFERENCE IF Q/D1 INVOLVED

Lip, Gregory Y. H.; Coca, Antonio Hypertension and cardiac arrhythmias. European heart 20,212 Q1/D1 2.4 journal.38(4):223-225

Badimon, Lina; Bugiardini, Raffaele; Cenko, Edina; Cubedo, Position paper of the European Society of European heart 20,212 Q1/D1 2.4 Judit; Dorobantu, Maria; Duncker, Dirk J.; Estruch, Ramon; Cardiology-working group of coronary journal. 38(25):1951 Milicic, Davor; Tousoulis, Dimitris; Vasiljevic, Zorana; Vilahur, pathophysiology andmicrocirculation: Gemma; De Wit, Cor; Koller, Akos obesity and heart disease.

Alfred Witjes J., Lebret T., Compérat E., Cowan N., De Updated 2016 EAU Guidelines on European urology. 16,265 Q1/D1 2.10 Santis M., Bruins H., Hernández V., Espinós E., Dunn J., Muscle-invasive and Metastatic Bladder 71(3):462-475 Rouanne M., Neuzillet Y., Veskimäe E., van der Heijden Cancer. A., Gakis G., Ribal M.

Garcia-Tsao G, Abraldes JG, Berzigotti A, Bosch J. Portal hypertensive bleeding in cirrhosis: Hepatology. 13,246 Q1/D1 3.6 Risk stratiﬁcation, diagnosis, and 65(1):310-335 management: 2016 practice guidance by the American Association for the study of liver diseases.

Vogelmeier CF, Criner GJ, Martinez FJ, Anzueto A, Global Strategy for the Diagnosis, American journal of 13,204 Q1/D1 2.7; 2.9 Barnes PJ, Bourbeau J, Celli BR, Chen R, Decramer M, Management, and Prevention of Chronic respiratory and Fabbri LM, Frith P, Halpin DM, López Varela MV, Obstructive Lung Disease 2017 Report: critical care medicine. Nishimura M, Roche N, Rodriguez-Roisin R, Sin DD, GOLD Executive Summary. 195(5):557-582 Singh D, Stockley R, Vestbo J, Wedzicha JA, Agustí A.

Brozek J., Bousquet J., Agache I., Agarwal A., Bachert C., Allergic Rhinitis and its Impact on Asthma Journal of allergy and 13,081 Q1/D1 2.8 Bosnic-Anticevich S., Brignardello-Petersen R., (ARIA) guidelines-2016 revision. clinical immunology. Canonica G., Casale T., Chavannes N., Correia de Sousa 140(4):950-958 J., Cruz A., Cuello-Garcia C., Demoly P., Dykewicz M., Etxeandia-Ikobaltzeta I., Florez I., Fokkens W., Fonseca J., Hellings P., Klimek L., Kowalski S., Kuna P., Laisaar K., Larenas-Linnemann D., Lødrup Carlsen K., Manning P., Meltzer E., Mullol J., Muraro A., O'Hehir R., Ohta K., Panzner P., Papadopoulos N., Park H., Passalacqua G., Pawankar R., Price D., Riva J., Roldán Y.

Van Vollenhoven R., Voskuyl A., Bertsias G., Aranow C., A framework for remission in SLE: Annals of the 12,811 Q1/D1 1.2 Aringer M., Arnaud L., Askanase A., Balážová P., Bonfa Consensus ﬁndings from a large rheumatic diseases. E., Bootsma H., Boumpas D., Bruce I., Cervera R., Clarke international task force on deﬁnitions of 76(3):554-561 A., Coney C., Costedoat-Chalumeau N., Czirják L., remission in SLE (DORIS). Derksen R., Doria A., Dörner T., Fischer-Betz R., Fritsch-Stork R., Gordon C., Graninger W., Györi N., Houssiau F., Isenberg D., Jacobsen S., Jayne D., Kuhn A., Le Guern V., Lerstrøm K., Levy R., MacHado-Ribeiro F., Mariette X., Missaykeh J., Morand E., Mosca M., Inanc M., Navarra S.

Andreoli L., Bertsias G., Agmon-Levin N., Brown S., EULAR recommendations for women's Annals of the 12,811 Q1/D1 1.2 Cervera R., Costedoat-Chalumeau N., Doria A., health and the management of family rheumatic diseases. Fischer-Betz R., Forger F., Moraes-Fontes M., planning, assisted reproduction, pregnancy 76(3):476-485 Khamashta M., King J., Lojacono A., Marchiori F., Meroni and menopause in patients with systemic P., Mosca M., Motta M., Ostensen M., Pamﬁl C., Raio L., lupus erythematosus and/or Schneider M., Svenungsson E., Tektonidou M., Yavuz S., antiphospholipid syndrome. Boumpas D., Tincani A.

23 FOREWORD IDIBAPS

European Ass Study Liver EASL Recommendations on Treatment of Journal of hepatology. 12,486 Q1/D1 3.3 Hepatitis C 2016. 66(1):153-194

Dreyling M; Campo E; Hermine O; Jerkeman M; Le Gouill Newly diagnosed and relapsed mantle cell Annals of oncology. 11,855 Q1/D1 5.1 S; Rule S; Shpilberg O; Walewski J; Ladetto M. lymphoma: ESMO Clinical Practice 28:iv62-iv71 Guidelines for diagnosis, treatment and follow-up.

Graham BL, Brusasco V, Burgos F, Cooper BG, Jensen 2017 ERS/ATS standards for single-breath European respiratory 10,569 Q1/D1 2.7 R, Kendrick A, MacIntyre NR, Thompson BR, Wanger J. carbon monoxide uptake in the lung. journal. 49 (1)

Graham BL, Brusasco V, Burgos F, Cooper BG, Jensen Executive Summary: 2017 ERS/ATS European respiratory 10,569 Q1/D1 2.7 R, Kendrick A, MacIntyre NR, Thompson BR, Wanger J. standards for single-breath carbon journal. 49(1) monoxide uptake in the lung.

Vogelmeier CF, Criner GJ, Martinez FJ, Anzueto A, Global Strategy for the Diagnosis, European respiratory 10,569 Q1/D1 2.7; 2.9 Barnes PJ, Bourbeau J, Celli BR, Chen R, Decramer M, Management, and Prevention of Chronic journal. 49(3) Fabbri LM, Frith P, Halpin DM, López Varela MV, Obstructive Lung Disease 2017 Report: Nishimura M, Roche N, Rodriguez-Roisin R, Sin DD, GOLD Executive Summary. Singh D, Stockley R, Vestbo J, Wedzicha JA, Agusti A.

Montejo, Angel L.; Arango, Celso; Bernardo, Miquel; Multidisciplinary consensus on the Frontiers in 9,425 Q1/D1 4.7 Carrasco, Jose L.; Crespo-Facorro, Benidicto; Cruz, therapeutic recommendations for neuroendocrinology. Juan J.; Del Pino-Montes, Javier; Garcia-Escudero, iatrogenic hyperprolactinemia secondary 45:25-34 Miguel A.; Garcia-Rizo, Clemente; Gonzalez-Pinto, Ana; to antipsychotics. Hernandez, Ana I.; Martin-Carrasco, Manuel; Mayoral-Cleries, Fermin; Mayoral-van Son, Jaqueline; Mories, M. Teresa; Pachiarotti, Isabella; Perez, Jesus; Ros, Salvador; Vieta, Eduard

Giacomelli R., Afeltra A., Alunno A., Baldini C., International consensus: What else can we Autoimmunity 8,961 Q1/D1 1.2 Bartoloni-Bocci E., Berardicurti O., Carubbi F., Cauli A., do to improve diagnosis and therapeutic reviews. 16(9):911-924 Cervera R., Ciccia F., Cipriani P., Conti F., De Vita S., Di strategies in patients affected by Benedetto P., Doria A., Drosos A., Favalli E., Gandolfo S., autoimmune rheumatic diseases Gatto M., Grembiale R., Liakouli V., Lories R., Lubrano E., (rheumatoid arthritis, spondyloarthritides, Lunardi C., Margiotta D., Massaro L., Meroni P., Minniti A., systemic sclerosis, systemic lupus Navarini L., Pendolino M., Perosa F., Pers J., Prete M., erythematosus, antiphospholipid syndrome Priori R., Puppo F., Quartuccio L., Ruffatti A., Ruscitti P., and Sjogren's syndrome)?: The unmet Russo B., Sarzi-Puttini P. needs and the clinical grey zone in autoimmune disease management.

Zignego AL, Ramos-Casals M, Ferri C, Saadoun D, International therapeutic guidelines for Autoimmunity 8,961 Q1/D1 1.2 Arcaini L, Roccatello D, Antonelli A, Desbois AC, patients with HCV-related extrahepatic reviews. Comarmond C, Gragnani L, Casato M, Lamprecht P, disorders. A multidisciplinary expert 16(5):523-541 Mangia A, Tzioufas AG, Younossi ZM, Cacoub P, statement. ISG-EHCV

Rehm J, Anderson P, Prieto JAA, Armstrong I, Aubin HJ, Towards new recommendations to reduce BMC medicine. 8,097 Q1/D1 4.7 Bachmann M, Bastus NB, Brotons C, Burton R, Cardoso the burden of alcohol-induced hypertension 15(1):173 M, Colom J, Duprez D, Gmel G, Gual A, Kraus L, Kreutz in the European Union. R, Liira H, Manthey J, Møller L, Okruhlica L’, Roerecke M, Scafato E, Schulte B, Segura-Garcia L, Shield KD, Sierra C, Vyshinskiy K, Wojnar M, Zarco J.

Hellings PW, Fokkens WJ, Bachert C, Akdis CA, Bieber Positioning the principles of precision Allergy. 7,361 Q1/D1 2.8 T, Agache I, Bernal-Sprekelsen M, Canonica GW, medicine in care pathways for allergic 72(9):1297-1305 Gevaert P, Joos G, Lund V, Muraro A, Onerci M, rhinitis and chronic rhinosinusitis – A Zuberbier T, Pugin B, Seys SF, Bousquet J, ARIA and EUFOREA-ARIA-EPOS-AIRWAYS ICP EPOS working groups statement.

Vuitton L., Peyrin-Biroulet L., Colombel J., Pariente B., Deﬁning endoscopic response and Alimentary 7,286 Q1/D1 3.7 Pineton de Chambrun G., Walsh A., Panes J., Travis S., remission in ulcerative colitis clinical trials: pharmacology and Mary J., Marteau P. an international consensus. therapeutics. 45(6):801-813

Dumonceau JM, Deprez PH, Jenssen C, Iglesias-Garcia Indications, results, and clinical impact of Endoscopy. 6,107 Q1/D1 3.11 J, Larghi A, Vanbiervliet G, Aithal GP, Arcidiacono PG, endoscopic ultrasound (EUS)-guided 49(7):695-714 Bastos P, Carrara S, Czakó L, Fernández-Esparrach G, sampling in gastroenterology: European Fockens P, Ginès À, Havre RF, Hassan C, Vilmann P, van Society of Gastrointestinal Endoscopy Hooft JE, Polkowski M. (ESGE) Clinical Guideline - Updated January 2017.

24 Polkowski, Marcin; Jenssen, Christian; Kaye, Philip; Carrara, Technical aspects of endoscopic ultrasound Endoscopy. 6,107 Q1/D1 3.11 Silvia; Deprez, Pierre; Gines, Angels; Fernandez-Esparrach, (EUS)-guided sampling in gastroenterology: 49(10):989-1006 Gloria; Eisendrath, Pierre; Aithal, Guruprasad P.; European Society of Gastrointestinal Arcidiacono, Paolo; Barthet, Marc; Bastos, Pedro; Fornelli, Endoscopy (ESGE) Technical Guideline Adele; Napoleon, Bertrand; Iglesias-Garcia, Julio; Seicean, March 2017. Andrada; Larghi, Alberto; Hassan, Cesare; van Hooft, Jeanin E.; Dumonceau, Jean-Marc

Danese S., Fiorino G., Raine T., Ferrante M., Kemp K., ECCO Position statement on the use of Journal of crohn's and 5,813 Q1 3.7 Kierkus J., Lakatos P., Mantzaris G., van der Woude J., biosimilars for inﬂammatory bowel colitis. 11(1):26-34 Panes J., Peyrin-Biroulet L. disease-an update.

Perez-Martinez, Pablo; Mikhailidis, Dimitri P.; Athyros, Lifestyle recommendations for the Nutrition reviews. 5,291 Q1/D1 2.4 Vasilios G.; Bullo, Monica; Couture, Patrick; Covas, Maria prevention and management of metabolic 75(5):307-326 I.; de Koning, Lawrence; Delgado-Lista, Javier; syndrome: an international panel Diaz-Lopez, Andres; Drevon, Christian A.; Estruch, recommendation. Ramon; Esposito, Katherine; Fito, Montserrat; Garaulet, Marta; Giugliano, Dario; Garcia-Rios, Antonio; Katsiki, Niki; Kolovou, Genovefa; Lamarche, Benoit; Maiorino, Maria Ida; Mena-Sanchez, Guillermo; Munoz-Garach, Araceli; Nikolic, Dragana; Ordovas, Jose M.; Perez-Jimenez, Francisco; Rizzo, Manfredi; Salas-Salvado, Jordi; Schroder, Helmut; Tinahones, Francisco J.; de la Torre, Rafael; van Ommen, Ben; Wopereis, Suzan; Ros, Emilio; Lopez-Miranda, Jose

Calkins, Hugh; Hindricks, Gerhard; Cappato, Riccardo; 2017 HRS/EHRA/ECAS/APHRS/SOLAECE Heart rhythm. 14 4,825 Q1 2.2 Kim, Young-Hoon; Saad, Eduardo B.; Aguinaga, Luis; expert consensus statement on catheter (10):e445-e494 Akar, Joseph G.; Badhwar, Vinay; Brugada, Josep; and surgical ablation of atrial ﬁbrillation: Camm, John; Chen, Peng-Sheng; Chen, Shih-Ann; Executive summary. Chung, Mina K.; Nielsen, Jens Cosedis; Curtis, Anne B.; Davies, D. Wyn; Day, John D.; d'Avila, Andre; de Groot, N. M. S. (Natasja); Di Biase, Luigi; Duytschaever, Mattias; Edgerton, James R.; Ellenbogen, Kenneth A.; Ellinor, Patrick T.; Ernst, Sabine; Fenelon, Guilherme; Gerstenfeld, Edward P.; Haines, David E.; Haissaguerre, Michel; Helm, Robert H.; Hylek, Elaine; Jackman, Warren M.; Jalife, Jose; Kalman, Jonathan M.; Kautzner, Josef; Kottkamp, Hans; Kuck, Karl Heinz; Kumagai, Koichiro; Lee, Richard; Lewalter, Thorsten; Lindsay, Bruce D.; Macle, Laurent; Mansour, Moussa; Marchlinski, Francis E.; Michaud, Gregory F.; Nakagawa, Hiroshi; Natale, Andrea; Nattel, Stanley; Okumura, Ken; Packer, Douglas; Pokushalov, Evgeny; Reynolds, Matthew R.; Sanders, Prashanthan; Scanavacca, Mauricio; Schilling, Richard; Tondo, Claudio; Tsao, Hsuan-Ming; Verma, Atul; Wilber, David J.; Yamane, Teiichi

Calkins H, Hindricks G, Cappato R, Kim YH, Saad EB, 2017 HRS/EHRA/ECAS/APHRS/SOLAECE Heart rhythm. 14 4,825 Q1 2.2 Aguinaga L, Akar JG, Badhwar V, Brugada J, Camm J, Expert Consensus Statement on Catheter (10):e445-e494 Chen PS, Chen SA, Chung MK, Nielsen JC, Curtis AB, and Surgical Ablation of Atrial Fibrillation. Davies DW, Day JD, d'Avila A, de Groot NMSN, Di Biase L, Duytschaever M, Edgerton JR, Ellenbogen KA, Ellinor PT, Ernst S, Fenelon G, Gerstenfeld EP, Haines DE, Haissaguerre M, Helm RH, Hylek E, Jackman WM, Jalife J, Kalman JM, Kautzner J, Kottkamp H, Kuck KH, Kumagai K, Lee R, Lewalter T, Lindsay BD, Macle L, Mansour M, Marchlinski FE, Michaud GF, Nakagawa H, Natale A, Nattel S, Okumura K, Packer D, Pokushalov E, Reynolds MR, Sanders P, Scanavacca M, Schilling R, Tondo C, Tsao HM, Verma A, Wilber DJ, Yamane T.

Lip, Gregory Y. H.; Coca, Antonio; Kahan, Thomas; Boriani, Hypertension and cardiac arrhythmias: a Europace. 4,521 Q1 2.4 Giuseppe; Manolis, Antonis S.; Olsen, Michael Hecht; Oto, consensus document fromthe European 19(6):891-911 Ali; Potpara, Tatjana S.; Steffel, Jan; Marin, Francisco; de Heart RhythmAssociation (EHRA) and ESC Oliveira Figueiredo, Marcio Jansen; de Simone, Giovanni; Council on Hypertension, endorsed by the Tzou, Wendy S.; Chiang, Chern-En; Williams, Bryan; Dan, Heart RhythmSociety (HRS), Asia-Paciﬁc Gheorghe-Andrei; Gorenek, Bulent; Fauchier, Laurent; Heart RhythmSociety (APHRS) and Savelieva, Irina; Hatala, Robert; van Gelder, Isabelle; Sociedad Latinoamericana de Estimulacion Brguljan-Hitij, Jana; Erdine, Serap; Lovic, Dragan; Kim, Cardiaca y Electroﬁsiologia (SOLEACE). Young-Hoon; Salinas-Arce, Jorge; Field, Michael

25 FOREWORD IDIBAPS

Mont L, Pelliccia A, Sharma S, Biffi A, Borjesson M, Brugada Pre-participation cardiovascular evaluation European journal of 3,606 Q2 2.2 Terradellas J, Carré F, Guasch E, Heidbuchel H, La Gerche for athletic participants to prevent sudden preventive A, Lampert R, McKenna W, Papadakis M, Priori SG, death: Position paper from the EHRA and cardiology. Scanavacca M, Thompson P, Sticherling C, Viskin S, the EACPR, branches of the ESC. Endorsed 24(1):41-69 Wilson M, Corrado D,, Lip GY, Gorenek B, Blomström by APHRS, HRS, and SOLAECE. Lundqvist C, Merkely B, Hindricks G, Hernández-Madrid A, Lane D, Boriani G, Narasimhan C, Marquez MF, Haines D, Mackall J, Manuel Marques-Vidal P, Corra U, Halle M, Tiberi M, Niebauer J, Piepoli M Reviewers

Diez-Perez A., Naylor K., Abrahamsen B., Agnusdei D., International Osteoporosis Foundation and Osteoporosis 3,591 Q2 3.8 Brandi M., Cooper C., Dennison E., Eriksen E., Gold D., European Calciﬁed Tissue Society Working international. Guañabens N., Hadji P., Hiligsmann M., Horne R., Josse Group. Recommendations for the screening 28(3):767-774 R., Kanis J., Obermayer-Pietsch B., Prieto-Alhambra D., of adherence to oral bisphosphonates. Reginster J., Rizzoli R., Silverman S., Zillikens M., Eastell R.

Stahl, Stephen M.; Morrissette, Debbi A.; Faedda, Gianni; Guidelines for the recognition and CNS spectrums. 3,589 Q1 4.7 Fava, Maurizio; Goldberg, Joseph F.; Keck, Paul E.; Lee, management of mixed depression. 22(2):203-219 Yena; Malhi, Gin; Marangoni, Ciro; McElroy, Susan L.; Ostacher, Michael; Rosenblat, Joshua D.; Sole, Eva; Suppes, Trisha; Takeshima, Minoru; Thase, Michael E.; Vieta, Eduard; Young, Allan; Zimmerman, Mark; McIntyre, Roger S.

Vogelmeier CF, Criner GJ, Martinez FJ, Anzueto A, Global Strategy for the Diagnosis, Respirology. 3,256 Q2 2.7; 2.9 Barnes PJ, Bourbeau J, Celli BR, Chen R, Decramer M, Management, and Prevention of Chronic 22(3):575-601 Fabbri LM, Frith P, Halpin DM, López Varela MV, Obstructive Lung Disease 2017 Report: Nishimura M, Roche N, Rodriguez-Roisin R, Sin DD, GOLD Executive Summary. Singh D, Stockley R, Vestbo J, Wedzicha JA, Agusti A.

Quirce S, Delgado J, Entrenas LM, Grande M, Llorente Quality indicators of asthma care derived Journal of 3,094 Q2 2.8 C, López Viña A, Martínez Moragón E, Mascarós E, from the spanish guidelines for asthma investigational Molina J, Olaguibel JM, Pérez de Llano LA, Perpiñá management (GEMA 4.0): A allergology and Tordera M, Quintano JA, Rodríguez M, multidisciplinary team report. clinical immunology. Román-Rodriguez M, Sastre J, Trigueros JA, Valero AL, 27(1):69-73 Zoni AC, Plaza V, ASMAFORUM II Group

Vogelmeier CF, Criner GJ, Martínez FJ, Anzueto A, Global Strategy for the Diagnosis, Archivos de 2,979 Q2 2.7; 2.9 Barnes PJ, Bourbeau J, Celli BR, Chen R, Decramer M, Management, and Prevention of Chronic bronconeumologia. Fabbri LM, Frith P, Halpin DM, López Varela MV, Obstructive Lung Disease 2017 Report: 53(3):128-149 Nishimura M, Roche N, Rodríguez-Roisin R, Sin DD, GOLD Executive Summary. Singh D, Stockley R, Vestbo J, Wedzicha JA, Agustí A.

Guillem, V.; Camps, C.; Carrato, A.; Diaz-Rubio, E.; European edition of the NCCN clinical Clinical and 2,353 Q3 5.10 Gascon, P. practice guidelines: relevance of the translational oncology. translation and adaptation into Spanish. 19(3):288-290

Calkins, Hugh; Hindricks, Gerhard; Cappato, Riccardo; 2017 HRS/EHRA/ECAS/APHRS/SOLAECE Journal of 1,826 Q3 2.2 Kim, Young-Hoon; Saad, Eduardo B.; Aguinaga, Luis; expert consensus statement on catheter interventional cardiac Akar, Joseph G.; Badhwar, Vinay; Brugada, Josep; and surgical ablation of atrial ﬁbrillation: electrophysiology. Camm, John; Chen, Peng-Sheng; Chen, Shih-Ann; Executive summary. 50(1):1-55 Chung, Mina K.; Nielsen, Jens Cosedis; Curtis, Anne B.; Davies, D. Wyn; Day, John D.; d'Avila, Andre; de Groot, N. M. S. (Natasja); Di Biase, Luigi; Duytschaever, Mattias; Edgerton, James R.; Ellenbogen, Kenneth A.; Ellinor, Patrick T.; Ernst, Sabine; Fenelon, Guilherme; Gerstenfeld, Edward P.; Haines, David E.; Haissaguerre, Michel; Helm, Robert H.; Hylek, Elaine; Jackman, Warren M.; Jalife, Jose; Kalman, Jonathan M.; Kautzner, Josef; Kottkamp, Hans; Kuck, Karl Heinz; Kumagai, Koichiro; Lee, Richard; Lewalter, Thorsten; Lindsay, Bruce D.; Macle, Laurent; Mansour, Moussa; Marchlinski, Francis E.; Michaud, Gregory F.; Nakagawa, Hiroshi; Natale, Andrea; Nattel, Stanley; Okumura, Ken; Packer, Douglas; Pokushalov, Evgeny; Reynolds, Matthew R.; Sanders, Prashanthan; Scanavacca, Mauricio; Schilling, Richard; Tondo, Claudio; Tsao, Hsuan-Ming; Verma, Atul; Wilber, David J.; Yamane, Teiichi

26 Ariza, Javier; Cobo, Javier; Baraia-Etxaburu, Josu; Executive summary of management of Enfermedades 1,714 Q3 1.3 Benito, Natividad; Bori, Guillermo; Cabo, Javier; Corona, prosthetic joint infections. Clinical practice infecciosas y Pablo; Esteban, Jaime; Horcajada, Juan Pablo; guidelines by the Spanish Society of microbiologia clinica. Lora-Tamayo, Jaime; Murillo, Oscar; Palomino, Julian; Infectious Diseases and Clinical 35(3):189-195 Parra, Jorge; Pigrau, Carlos; del Pozo, Jose Luis; Riera, Microbiology (SEIMC). Melchor; Rodriguez, Dolores; Sanchez-Somolinos, Mar; Soriano, Alex; del Toro, M. Dolores; de la Torre, Basilio;Spanish Network Study Infect Dis; Spanish Soc Infect Dis Clin Microb

De Cueto M., Aliaga L., Alós J., Canut A., Los-Arcos I., Executive summary of the diagnosis Enfermedades 1,714 Q3 1.3 Martínez J., Mensa J., Pintado V., Rodriguez-Pardo D., and treatment of urinary tract infection: infecciosas y Yuste J., Pigrau C. Guidelines of the Spanish Society of Clinical microbiologia clinica. Microbiology and Infectious Diseases 35(5):314-320 (SEIMC).

Santiago Moreno Guillén, Antonio Antela López, Felipe Executive summary: Pre-exposure Enfermedades 1,714 Q3 1.3 García Alcaide, Julia del Amo Valero, Vicente Boix, Pep prophylaxis for prevention of HIV infection infecciosas y Coll, Claudia Fortuny Guasch, Juan Luis Gómez Sirvent, in adults in Spain: July 2016. microbiologia clinica. Félix Gutiérrez Rodero, José Antonio Iribarren Loyarte, 35(6):377-383 Josep Maria Llibre Codina, Juan Carlos López Bernaldo de Quirós, Juan Emilio Losa García, Ana Belén Lozano Serrano, Michael Meulbroek, Julián Olalla Sierra, Ferran Pujol, Federico Pulido, Manuel Crespo Casal, Juan González García, José López Aldeguer, José A. Pérez Molina, Daniel Podzamczer Palter, Antonio Rivero Román

Gerard Espinosa Garriga, Santiago Muñoz Fernández, Documento de recomendaciones de Medicina clinica. 1,525 Q3 1.2 José María García Ruiz de Morales, José María tratamiento de la uveítis anterior no 149(12):552-552 Herreras Cantalapiedra, Miguel Cordero infecciosa.

27 FOREWORD IDIBAPS

CLINICAL TRIALS PATENTS AND LICENSE AGREEMENTS

The IDIBAPS constitutes the ideal setting Clinical trials The Institute currently manages 52 patent for completing a number of the crucial by research area (%) families and 8 proprietary software, 38 steps in the development of new medical license agreements have been signed with products. Basic biomedical research and several industry partners. applied clinical research, together with specialized healthcare practice, are 9% During 2017 12 patent applications were ﬁled (5 aspects of IDIBAPS that may be very priority patents and 7 PCTs) and 1 entered in useful for the development of drugs. 14% National Phases in several countries. Besides, 6 new license agreements were signed with local The adjacent graphics summarize the number and international companies. 51% of active clinical trials in 2017. 11% In 2017, 201 new clinical trials were opened Dr. Chamorro and overall, there were 496 active clinical trials. Two Patents were licensed to the spin-off Most of these clinical trials correspond to FreeOx phase III (49%). 15% Dr. Gracia-Sancho One Patent was licensed to the spin-off BLB

300 Dr. Serra 250 AREA 1 A Monoclonal antibody was licensed to an 200 AREA 2 international company 150 AREA 3 100 AREA 4 Dr. Berruezo 50 AREA 5 One Patent was licensed to the spin out

0 Galgo Medical

PHASE I PHASE II PHASE III PHASE IV Dr. Pavia A proprietary software was licensed to a By scientiﬁc areas, most of the trials are national company performed in the area of hemato-oncology.

28 PORTFOLIO OF SPIN-OFFS

The activity of IDIBAPS researchers gave rise to 2 new companies based on the knowledge from IDIBAPS/HCB: FreeOx and BLB.

IDIBAPS researchers have founded 10 spin-offs since 2008, 9 of which are active companies that together employ more than 50 people.

Spinoffs from IDIBAPS researchers Spinoffs from IDIBAPS researchers were IDIBAPS or FCRB participate were IDIBAPS or FCRB do not participate as shareholders: as shareholders:

TRANSPLANT BIOMEDICALS TRANSMURAL BIOTECH https://www.transplantbiomed.com/ www.transmuralbiotech.com Dr. Carmen Peralta Dr. Gratacós

VIRTUAL BODY WORKS BIONURE https://virtualbodyworks.com/ www.bionure.com Dr. Mavi Sánchez Peralta Dr. Villoslada

BARCELONA LIVER BIOSERVICES AELIX THERAPEUTICS http://liver.barcelona/ www.aelixtherapeutics.com Dr. Jordi Gracia-Sancho Dr. Gatell

ESTIMTRACK FREEOX BIOTECH http://www.estimtrack.com/ www.freeoxbiotech.com Dr. Balust Dr. Chamorro

OWL METABOLOMICS http://www.owlmetabolomics.com/ Dr. Caballeria

29 FOREWORD IDIBAPS

Funding

From a ﬁnancial and managerial 6 7 5 IDIBAPS EXECUTED FUNDS perspective, IDIBAPS and FCRB are 4 managed in a global and consolidated 1 COMPETITIVE PROJECTS 18,289,778 € manner. 3 2 GENERALITAT DE CATALUNYA 5,971,000 € The two institutions share the principal 3 PRIVATE PROJECTS 2,369,189 € investigators (PI) accredited by 4 CAPITAL GRANT 1,265,018 € 5 CORE FACILITIES 635,056 € IDIBAPS, who have funds, projects 6 OTHER INCOME 310,823 € 1 and resources in both entities. 2 7 FINANCIAL INCOME 77,180 € Annually, the research executed by IDIBAPS accredited PIs is almost 90% TOTAL 28,918,044 € of the executed research activity, with the remaining 10% executed by non-accredited PIs.

In 2017, the two entities recorded 54,4 M€ of 9 7 8 FCRB EXECUTED FUNDS income and 54,5 M€ of expenditure, of which 6 46.2 M€ were directly related to the execution 1 CLINICAL TRIALS AND PRIVATE PROJECTS 18,289,778 € 5 2 COMPETITIVE PROJECTS 6,430,741 € of research projects. 1 3 DONATIONS AND PATRONAGE 4,350,662 € Around 10% of this amount corresponds to 4 INTERCOMPANY SERVICES 1,854,391 € 4 the contribution of the Generalitat de 5 TEACHING FUNDING 1,481,480 € Catalunya from the Departament d’Empresa 6 RENTAL INCOME 1,247,824 € 7 CAPITAL GRANT 1,140,890 € i Coneixement and the Departament de Salut. 8 MANAGEMENT CLINICAL TRIAL 368,384 € 3 9 FINANCIAL INCOME 2,794 €

2 TOTAL 27,692,189 €

2 IDIBAPS EXTERNAL FUNDING PER SOURCE

1 NATIONAL 15,011,115 € 2 INTERNATIONAL 5,647,8521 €

TOTAL 20,658,967 € 1

6 1 EXTERNAL FUNDING BY RESEARCH AREA 2 1 BIOLOGICAL AGGRESSION AND... 1,989,702 € 5 2 RESPIRATORY, CARDIOVASCULAR AND... 2,086,382 € 3 LIVER, DIGESTIVE SYSTEM AND METABOLISM 7,171,323 € 4 CLINICAL AND EXPERIMENTAL NEURO... 4,738,390 € 5 ONCOLOGY AND HAEMATOLOGY 2,882,674 € 6 OTHERS 1,790,496 € 3

TOTAL 20,658,967 € 4

30 New competitive projects

This external funding supports research projects and human resources grants. Some of these projects also fund equipments or facilities. The European Regional Development Fund (ERDF) co-funds many of these activities.

TOTAL 183 101 82

PROJECTS HUMAN RESOURCES GRANTS

PROJECTS (5 EC COORDINATED) 16 INTERNATIONAL 17 HUMAN RESOURCES GRANT 1

PROJECTS 66 SPANISH 118 HUMAN RESOURCES GRANTS 52

PROJECTS 19 CATALAN 48 HUMAN RESOURCES GRANTS 29

31 FOREWORD IDIBAPS

The following table classiﬁes the 183 new competitive projects obtained in 2017 by funding agency. Additionally, the funding institutions are grouped in two sections, public and private:

COMPETITIVE PUBLIC FUNDING NUMBER OF PROJECTS TOTAL 156 Catalan institutions 41 Agència de Gestió d’Ajuts Universitaris i de Recerca (AGAUR) 7 Agència per a la Competitivitat de l'Empresa (ACCIÓ) 2 Fundació Institució Centres de Recerca de Catalunya (I-CERCA) 3 Generalitat de Catalunya 29

National institutions 101 Instituto de Salud Carlos III (ISCIII) 78 Ministerio de Economía, Industria y Competitividad (MINECO) 19 Ministerio de Educación, Cultura y Deporte (MECD) 2 Ministerio de Sanidad, Servicios sociales e Igualdad (MSSSI) 2

International institutions 14 European Commission 14

COMPETITIVE PRIVATE FUNDING NUMBER OF PROJECTS

TOTAL 27 Catalan institutions 7 Fundació Academia de Ciències Mèdiques i de la Salut de Catalunya i Balears 1 Fundació Catalana de Neurologia 1 Fundació Catalana de Transplantament 1 Fundació La Marató de TV3 3 Fundació Santiago Dexeus Font 1

National institutions 17 Asociación Española de Gastroenterología (AEG) 1 Fundación Astrazéneca 1 Fundación Bancaria “La Caixa” 3 Fundación Cientíﬁca Asociación Española Contra el Cáncer (AECC) 3 Fundación Merck Salud 1 GILEAD Sciencies 6 Laboratorio Stada SL 1 Sociedad Española de Cardiología 1

International institutions 3 European Academy of Dermatology and Venereology (EADV) 1 European Foundation for the Study of Diabetes (EASD) 1 European Hematology Association 1

32 Active competitive projects

In 2017, IDIBAPS researchers participated in 592 active competitive projects, 153 initiated their activity during the year.

TOTAL 592 454 138

PROJECTS HUMAN RESOURCES GRANTS

PROJECTS 80 54 EC > 12 COORDINATED 5 NIH INTERNATIONAL 85 21 OTHER INTERNATIONAL AGENCIES

HUMAN RESOURCES GRANT 5

PROJECTS 293 SPANISH 393 HUMAN RESOURCES GRANTS 100

PROJECTS 81 CATALAN 114 HUMAN RESOURCES GRANTS 33

33 FOREWORD IDIBAPS

Leadership in EU funded projects

European projects led by IDIBAPS researchers are presented below:

CLEVER SloW-Dyn INTEGRATE Contrast-enhanced uLtrasound for Dinámica de las oscilaciones lentas: Joint Action on integrating prevention, testing livEr-disease eValuation: development experimentos, análisis, modelos e and linkage to care strategies acros HIV, viral and validation of a novel E-Health-software intervenciones terapéuticas. hepatitis, TB and STIs in Europe. for Risk-stratiﬁcation. Dr. Maria Victoria Sanchez Vives Dr. Agata Raquel León Dr. Jaume Bosch 2015 – 2018 2017 – 2020 2013 - 2017 Call: FlaG-ERA ministerio de Economía y Call: HP-JA-2016 Call: CE_PEOPLE-2013-IAPP Competividad (MINECO) Official code: 761319 Official code: 612273 Official code: PCIN-2015-162-C02-01

LIVERHOPE EuCOLONGENE Sys4MS Simvastatin and rifaximin as new therapy for Cooperation Studies on Cuidado personalizado de salud en la patients with decompensated cirrhosis. Inherited Susceptibility to Esclerosis Múltiple usando herramientas Colorectal Cancer. de medicina de sistemas. Dr. Pere Ginès 2017 – 2022 Dr. Sergi Castellví Dr. Pablo Villoslada Call: H2020-SC1-2016-RTD 2013 - 2017 2016 – 2019 Official code: 731875 Call: CE-COST-2012 Call: ERANET 2015 Official code: OC-2012-1-11711 Official code: ID43 TWIST Capacity building in the application of EU drug iHIVarna HIVACAR research – Training With STakeholders. Therapeutic TriMix / mRNA based Vaccine Evaluating a Combination of in Chronic HIV-1 Infected Patients Receiving Immune-based Therapies to Achieve Dr. Antoni Gual Antiretroviral Therapy. a Functional Cure of HIV Infection 2017 – 2018 Call: CE_JUST-2016-AG-DRU Dr. Felipe Garcia Dr. Felipe Garcia Official code: 759685 2013 – 2017 2017 – 2021 Call: CE-FP7-HEALTH-IN1-13 Call: H2020-SC1-2016-RTD Official code: 602570 Official code: 731626

34 Scientiﬁc CEK, CELLEX, facilities Esther Koplowitz Biomedical Research Center Research Center

Inaugurated by the end of 2010 and with Since 2013, CELLEX center is a space space for more than 350 researchers, the with four floors located in the UB School CEK building receives international of Medicine. Thanks to the collaboration scientists and PhD students, fostering the between the public and private sectors exchange of experience and professional 2,290 m2 of laboratories, scientific and synergies. technological services and other spaces are available to the research developed at The building has a laboratory area of 4,860 m2 IDIBAPS and the University of Barcelona. on the ground. In the basement three underground floors offer a total area of The renovation and adaptation of these areas 2,485 m2, including space for scientific core is mainly the result of a donation from the facilities, a category 2 radioactive CELLEX Foundation. non-encapsulated sources type facility Part of the contribution of the IDIBAPS has (IRA-3029), and a BSL-3 laboratory GMO been funded with ERDF funds from the notified (A/ES/13/I-11). Generalitat de Catalunya and the rest comes The CEK building was made possible thanks from specific calls by the Instituto de Salud to the contribution of several public and private Carlos III.These IDIBAPS facilities home over institutions, the Generalitat de Catalunya, the 200 researchers. Ministerio de Economía y Competitividad, and the Instituto de Salud Carlos III, as well as from the support of other donors such as the Fundación Esther Koplowitz, Fundació Privada Cellex, Acció Sardà Farriol para la Investigación en Diabetes and Laboratorios Esteve.

35 FOREWORD IDIBAPS

Core facilities

Excellent biomedical research requires the use of high-cost techniques and SERVICES equipment. IDIBAPS has ﬁve core facilities NEW NEW TOTAL to provide all researchers with big INTERNAL USERS EXTERNAL USERS ATTENDED USERS infrastructures and high quality technical expertise: BIOBANK 33 32 145

- Biobank of Hospital Clínic-IDIBAPS CYTOMETRY 5 3 69 - Cytometry and cell sorting - Functional Genomics GENOMICS 16 12 81 - Magnetic Resonance Imaging MAGNETIC - Medical Statistics 14 3 51 RESONANCE MEDICAL On the other hand, IDIBAPS has an 10 5 177 agreement with its consortium partners to STATISTICS optimise investments in infrastructures so duplicities are avoided and a wider spectrum of scientiﬁc services can be offered to the community. Universitat de Barcelona at the Clinic RESEARCH Campus, provides researchers with some complementary infrastructures such as ACKNOWLEDGED microscopy, animal facility, library and proteomics. PUBLICATIONS PUBLICATIONS

BIOBANK 29 19 PEOPLE Anna Bosch, PhD Head of core facilities CYTOMETRY - 6

GENOMICS Meritxell Rufet 6 4 Administrative support MAGNETIC 24 4 RESONANCE

Soraya Pérez MEDICAL 27 - Administrative support STATISTICS

36 Biobank of Hospital Clínic - IDIBAPS

Scientific director FOR FURTHER INFORMATION PEOPLE DESCRIPTION www.clinicbiobanc.org TUMOUR BANK [email protected] The Biobank coordinates the collection, Raquel Bermudo, PhD processing, storage and transfer of human NEUROLOGICAL TISSUE BANK Coordinator biological samples to promote biomedical [email protected] research of the highest standard. With the aim Míriam Cuatrecasas, MD, PhD (HCB) of optimizing the human resources and TUMOUR BANK Clinical Advisor equipment in the Biobank, this facility offers a [email protected] wide range of services for the processing and Amanda Denuc, PhD analysis of the samples gathered by the BLOOD AND FLUID BANK Laboratory Technician research groups. All the procedures biobanc.fl[email protected] performed at the Biobank are carried out Laura Gelabert under a quality management certification Laboratory Technician (ISO9001). PEOPLE The Biobank’s catalogue of samples is formed BIOBANK Mónica Marín (HCB) by the samples collected by three large banks, Laboratory Technician all of which have extensive experience in Joan Albert Barberà, MD, PhD (HCB) research with human samples and which are Scientific director (Until April 2017) Marta Valor available for scientific purposes for the Laboratory Technician consolidation of personalised medicine: Joan Carles García Pagán, MD, PhD (HCB) Scientific director (Since May 2017) Mercedes Gonzalez-Ruiz Neurological tissue bank Laboratory Technician A nervous tissue repository (brain and spinal Anna Bosch, PhD cord) created from donations from deceased Head of core facility Ángela Martín donors with or without neurological disorders. Informed Consent Manager Brain tissue samples are sent to scientific researchers worldwide, in order to help to PEOPLE increase the understanding of the human NEUROLOGICAL TISSUE BANK PEOPLE brain and to develop therapies for neurological BLOOD AND FLUIDS BANK diseases. Ellen Gelpí, MD, PhD Coordinator/Neuropathologist Verónica Fernández, PhD Tumour bank and anatomical pathology (Until June 2017) Coordinator collections It is a repository of tumoural and non-tumoural Teresa Ximelis Anna Morales frozen tissue samples from around 12.000 Coordinator (Since July 2017) Laboratory Technician cancer patients. Additionally, the Anatomical Pathology collection consists of paraffin- Raquel Sánchez-Valle, MD, PhD (HCB) Regina Cañaveras embedded tissue samples from tumors and Clinical Coordinator Laboratory Technician other diseases, which gathers more than two million tissue blocks. All these samples are Laura Molina, MD, PhD Roser Mas surplus to diagnostic requirements from the Neurologist Brain Donor Program Laboratory Technician Department of Anatomical Pathology in the (Since July 2017) Hospital Clínic and are essential for current Mercedes Gonzalez-Ruiz large-scale tissue research projects. Different Iban Aldecoa, MD, PhD Laboratory Technician diagnosis consultants from Hospital Clinic help Neuropathologist (Since July 2017, HCB) us in the histopathological evaluation of samples. Sara Charif Laboratory Technician Blood and fluids bank This repository contains samples of, among Verónica Santiago others, metabolic, inflammatory bowel, Laboratory Technician oncological, digestive, psychiatric and maternal and foetal diseases. It houses a large Abel Muñoz range of samples of scientific interest, primarily Autopsy Assistant DNA, serum and plasma, which are provided by doctors’ surgeries and laboratories where Leire Etxarri blood and fluids are taken for lab tests and Autopsy Assistant blood and fluids donation.

37 FOREWORD IDIBAPS

SERVICES Molecular techniques Blood and fluids bank - DNA extraction from peripheral blood. - Programmable freezer with a controlled The Biobank of Hospital Clínic – IDIBAPS - DNA and RNA extraction from tissue rate freezer. offers a wide variety of human biological (frozen and paraffin- embedded). - Chemagic MSM1® automated device for samples along with technical services. The - WGA. obtaining DNA from large volumes of blood. scientific community may make full use of the - Serum and plasma isolation. - QIAcube for automatization of QIAGEN bank’s equipment and professional staff to - Immunohistochemistry. spin columns (DNA, RNA, Protein achieve their most ambitious goals. The work extraction from different sample origin). of the biobank goes beyond simply providing - TwoTecan EvO150® automated stations samples; they offer support to researchers EQUIPMENT for sample aliquoting. during the various stages of projects requiring - TC Automated Cell Counter (Bio Rad). the use of biological samples. - -20ºC, -80ºC and -150ºC freezers with - Cabinets for isolating cells under sterile safety systems. conditions. Human biological sample provision - Vapour phase liquid nitrogen tanks. - Cell immortalisation platform. - Brain and spinal cord tissue and CSF from - Computer systems for managing samples donors affected by neurologic diseases. Neurological tissue bank and related data. - Frozen and paraffin-embedded tissues - Biological safety cabinets for processing - Epoch Micro-Volume Spectrophotometer representing the most common neoplasms fresh brain tissue. System. and paraffin-embedded samples from a - Biological safety cabins for prion diseases - Trinean DropSense96 UV/VIS droplet wide variety of diseases. western-blotting. reader. - DNA, serum, plasma, urine and PBMCs - Microtomes and equipment for formalin from different diseases as well as from fixation and paraffin embedding (Leica control donors. Microsystems). - Cryostat (Leica Microsystems). Technical and scientific advice - Gas filtration cabinet. - Creation and management of new - Automated immunostainer (DAKO collections. autostainer plus). - Methodology (technical guidance). - Refrigerator and -20ºC freezer. - Experimental design with human and - Autoclave. animal tissue samples. - 5-headed microscope. - Design and interpretation of immunohistochemical studies. Tumour bank - Harmonization of quality procedures - Tissue microarrayer TMA Master for the handling of DNA samples. (3Dhistech) (UB Faculty of Medicine / FEDER). Private collections management - Laser microdissector system LMD7000 - Collection management for multicentre (Leica Microsystems). studies. - 2 Microtomes and 2 cryostats (Leica - Storage of pre-existing collections. Microsystems). - Coverslipper for glass slides (Dako) Histological techniques - Tissue processor (Leica Microsystems). - Processing of frozen and - Bond Max III for automated paraffin-embedded tissues (macroscopy, immunohistochemistry (Leica cryopreservation, paraffin blocks, Microsystems). histological sections). - Digital slide scanner Pannoramic Desk - Histological staining. (3Dhistech). - Definitive neuropathological diagnosis of - Multiobserver microscope BX43 with a neurological diseases. 12Mpx photographic camera and the - Laser microdissection. morphometric analysis software CellSens - Tissue microarray construction (TMA). Dimension (Olympus). - Slide scan and morphometric analysis. - QIAcube for automatization of QIAGEN spin column protocols (DNA, RNA, Protein Cellular techniques extraction from different sample origin). - Purification and cryopreservation of mononuclear cells. - Immortalization of B lymphocytes. - Erythrocyte isolation from whole blood. - Cell counting.

38 Flow cytometry Functional and cell sorting genomics

FOR FURTHER INFORMATION FOR FURTHER INFORMATION BRIEF DESCRIPTION [email protected] [email protected] The Functional Genomics core facility PEOPLE PEOPLE provides access to different high throughput genomic technologies to the researchers. Crespo, Isabel, PhD Pedro Jares, PhD The facility manages samples for genomic Head of core facility Scientific director analysis including transcriptional profiling, low density and large-scale genotyping, gene copy López, Cristina, PhD Magda Pinyol, PhD number analysis and gene-panel sequencing Laboratory Technician Head of core facility using different technological platforms such as real-time PCR, digital quantification, microarrays Ozcoz, Sara Helena Suàrez, PhD and next-generation sequencing. In addition, the Laboratory Technician Transcriptomics Coordinator facility offers advice on experimental design and application of genomic techonologies. Anna Enjuanes, PhD BRIEF DESCRIPTION NGS Coordinator SERVICES The Flow Cytometry core facility provides Montse Sànchez high quality state-of-the-art flow cytometry Laboratory Technician - Quantification of nucleic acids and multiparameter cell sorting (Nanodrop, Qubit). instrumentation as well as associated Laura Pla - Qualitative analysis of nucleic acids expertise and services to all investigators at Laboratory Technician (Bioanalyzer 2100, TapeStation 4200). IDIBAPS and other outside customers. - Expression or Genotyping analysis by Skilled staff provide help with experimental Real-time PCR (BioMark, Fluidigm). design, sample acquisition, data analysis, - Digital PCR (BioMark, Fluidigm). sorting and help with interpreting the data - Digital quantification of nucleic acids and producing figures for publication. (nCounter, Nanostring). - Genome Wide Expression analysis and Copy Number Variations analysis by SERVICES microarrays (GeneChip System, Affymetrix). - Flow cytometer analysis of fluorescently - Genome Wide Expression analysis and labelled samples, detecting up to Genome Wide Genotyping analysis (GWAS) 20-parameters in a single sample. by microarrays (GeneTitan System, Affymetrix). - Cell sorting of fluorescently labelled - CGH-Arrays (Agilent). samples, detecting up to 20-parameter. - Fragmentation of nucleic acids and Sorting into an array of up to 4 tubes, plates chromatin (Covaris S220). and slides. - Pyrosequencing (PyroMark Q24, QIAGEN). - I maging in flow analysis of fluorescently - Next generation Pyrosequencing (MiSeq, labelled cells with up to 12-fluorescent labels. Illumina). - Magnetic cell sorting. - Training is available to enable investigators and their staff to run the analysers EQUIPMENT independently. - Synergy2. - NanoDrop 1000 . EQUIPMENT - Qubit. - Bioanalyzer 2100 (Agilent). - BD FACSCalibur - TapeStation 4200 (Agilent). 2 LASER. Up to 4 fluorescence. - BioMark (Fluidigm). - BD FACSCantoII - nCounter (Nanostring). Up to 3 LASER. Up to 8 fluorescence. - GeneChip System (Affymetrix). - BD LSRFortessa SORP + HTS - GeneTitan System (Affymetrix). Up to 5 LASER, Up to 18 fluorescence. - Liquids Robot Biomek FX (Beckman). - AMNIS ISX - Microarrays Agilent platform . 2 digital cameras, Up to 12 fluorescence - PyroMark Q24 (QIAGEN). channels. - Covaris S220. - BD FACSAria SORP/ARIAII - MiSeq (Illumina). Up to 5 LASER, Up to 18 fluorescence. - Magnetic cell sorter autoMACSPro

39 FOREWORD IDIBAPS

Magnetic resonance imaging

FOR FURTHER INFORMATION BRIEF DESCRIPTION EQUIPMENT [email protected] The MRI core facility is equipped with a PRISMA ﬁt 3 Tesla Siemens for clinical PEOPLE PRISMA 3 Tesla magnet for humans and a 7 imaging: Tesla Bruker magnet for small animal imaging. - Gradient system XR: ( 80/200), with E11c Núria Bargalló MD, PhD (HCB) In 2017, the Magnetom TRIO 3T magnet was software. Head of core facility upgraded to a Magnetom PRISMA 3T - Head/ neck coli 20 channels 440 mm × becoming a more powerful system which 330 mm × 370 mm. Clinical 3T MRI Unit enables to get better imaging capabilities and - Head coli 32 channels 300 mm × 390 mm × Núria Bargalló MD, PhD (HCB) long-lasting stability. 315 mm. Coordinator This upgrade was possible thanks to own - Head/ neck coli 64 channels 435 mm × funds and funds obtained from Ministerio de 395 mm × 350 mm. César Garrido (HCB) Economia y Competitividad and FEDER - Body coil 18 channels. Radiographer (European Funds for regional development). - Spine coil 32 channels. - Visuastim digital . Sandra Pineda The main objectives of this - Visual and auditory stimuli presentation Radiographer Core Facility are: system with Presentation® license. - To provide services related to medical - Screen to Project visual stimuli with the 32 Experimental 7T MRI Unit imaging techniques for researchers from channels head coil . Guadalupe Soria, PhD IDIBAPS and other institutions, and to - Remote controlling buttons for responding. Coordinator industries connected with health. in fMRI studies. - To perform ﬁrst-rate basic and clinical Xavier López Gil research into medical imaging using Biospec 70/30 Brukermaget for small Laboratory Technician structural and functional magnetic animal imaging: resonance imaging, magnetic resonance - Gradient system of 400 mT/m, Image Analysis Advisors spectroscopy, molecular imaging, other withParavision 6.0 software. Emma Muñoz Moreno, PhD types of medical imaging and image - Volume coil for mouse body: inner diameter Engineer Analyst processing. of 35 mm . - Training of the users and keeping the state - Volume coil for rat body: inner diameter of José Carlos Pariente of art in MRI techniques to enable researchers 72 mm. Image Analysis conducting experimental and clinical studies, - Volume coil for guinea pig or small rabbit: thereby allowing them to explore the inner diameter of 154 mm. Sara Andrés Caballero advantages of translational research. - Rat brain 2 x 2 surface array coils . Image Analysis - To complement this infrastructure we - Mouse brain surface coil . count with the Laboratory of Image - Rat cardiac 4 x 1 surface array coil (with Raúl Tudela, PhD (CIBER-BBN) Analysis where the users have different CINE acquisition sequence). Image Analysis workstations available to use with the most - Electric stimulator for fMRI. common softwares used in the MR Field - Inhalation anaesthetic system including installed. animal monitoring. - 4 PC for image processing and analysis.

SERVICES Image Processing Lab: - 2 dedicated workstations (linux) and 7 - Anatomical imaging (body, brain and heart). standard performance. - T1, T2 Relaxometry techniques. - PC (5 dual windows-linux, 2 windows) for - Diffusion Tensor Imaging. image postprocessing. - BOLD fMRI . - 10 low performance PC. - Arterial Spin Labeling . - Software licences: 10 Matlab (with 2 Image - Perfusion techniques (brain and heart). processing toolbox and 2 signal processing - Body and brain 1H spectrometry. toolbox), 2 LcModel, 1 AnalyzeDirect, - Susceptibility weighted imaging. 1 Syntetic MRI. - Time of ﬂight and contrast angiography. - Cardiac Imaging. - MR coronariography. - MR colonography. - MR enterography. - Body and extremities angiography. - Plaque characterization.

40 Medical statistics

FOR FURTHER INFORMATION DESCRIPTION EQUIPMENT [email protected] Medical Statistics is an IDIBAPS core facility The facility is fully equipped with the latest PEOPLE that provides methodological and statistical software for statistics and data support for IDIBAPS research projects and management, including: Ferran Torres, MD, PhD those of allied institutions. Head of core facility The main objective is to promote clinical a) SAS, East,Stata, SPSS, JMP, NCSS and R research excellence and facilitate resources statistical programs. José Ríos, PhD to achieve this. b) nQueryand PASS for sample sizes, Coordinator The platform’s tasks are conducted in c) electronic Clinical Trials data collection: compliance with the International Conference MACRO. Gema Domenech of Harmonisation guidelines, European and d) WinNonLin for PK/PD analysis. Statistician local laws, as well as with the regulatory recommendations. Standard Operating Georgina Casanovas (FCRB) Procedures (SOPs) are in place to fulﬁl those Statistician standards.

Rafel Barceló (FCRB) Statistician SERVICES

Sandra Serrano Assessments and consultancy Services. Data Manager Short-term statistical and methodological assessments, including (a) statistical design Alex Bernalte (FCRB) of studies, (b) sample size calculation, (c) Data Manager assessment of data collection for the analysis (d) methodological and statistical assessment Juanjo Aragonés (FCRB) of research projects. Data Manager Sample projects. Enric Marin (FCRB) - Creation and maintenance of a clinical Data Management Assistant trials database: (a) creation of the eCRF (electronic cases report form), (b) creation of data management and validation plans and consensus with the research team, (c) traceable data exportation analysis systems. - Statistical analysis of clinical trials or other projects: (a) creation of and consensus on the most appropriate statistical analysis plans according to the type of data and the study objective, (b) creation of the most suitable statistical program for the study objective, with emphasis on the traceability of results, (c) preparation of statistical reports, and collaboration in writing and supervising articles on monitoring studies.

41 FOREWORD IDIBAPS

Institutional projects

BITRECS SIMPACT HRS4R

Biomedicine international training Synergies in International Management Human Resources Strategy for research programme for excellent and Promotion Activities for a Common Researchers. clinician-scientists. Success Leadership Strategy in R&D&I . WEB WEB PARTICIPANTS www.idibaps.org/research-career/en_ www.bitrecs.idibaps.org IDIBAPS (Coordinator) and Clinic hrs4r.html Foundation for Biomedical Research, FCRB.

SIMPACT is the 3-year collaborative project (2015-2018) between IDIBAPS and FCRB to increase the participation, success and leadership of both institutions in Europe and worldwide. It is supported by the Spanish BITRECS is a 60-month research and training Ministry of Economy and Competitiveness IDIBAPS is awarded with the logo fellowship programme having as main aim to (MINECO). “HR Excellence in research” since 2015. recruit 10 excellent and highly motivated postdoctoral clinician-scientists through The speciﬁc objectives of the project are: In 2017 some of activities included in the international peer-reviewed calls. 2015-2018 Action Plan have been The program was launched in 2017 as a 1) To increase the visibility and recognition of implemented. Moreover, a complete analysis pioneer initiative in clinician-scientist the Institute internationally. of its performance has also been developed promotion, with the support of the 2) To improve the quality of the institutional with the purpose to submit to the European European Commission. management support in European Projects. Commission both the interim assessment and 3) To create new synergies and long-term the Updated Action Plan (2017-2020). A 36-month contract will be offered to the collaborations with actors of the private selected fellows. They will implement their sector. own research project ﬁtted into one of the IDIBAPS research lines while performing Many activities performed during 2017 one of the two available mobility schemes. have provided results that contribute to the IDIBAPS’ purpose of becoming an international referent Institute in translational research.

This project has received funding from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 754550

Europa Redes y Gestores, reference EUC2014-C-51553

42 Training Doctoral theses

Doctoral theses 117 defended in 2017.

Theses with 20 European mention.

THESIS AUTHOR TITLE THESIS DIRECTORS

Functional and metabolic interplay between methionine metabolites, acid sphingomyelinase Fernández-Checa JC, Cristina Alarcón Vila and phosphatidylcholine: Impact in steatohepatitis García-Ruiz MC

Ethylglucururoide replacing ethanol in the routine screening of alcohol depenent Gual A, Vieta E Pablo Barrio Gimenez outpatients: clinical implications

Marc Catalán Garcia Mitochondrial proﬁle and amyloidogenic molecules in sporadic inclusion body myositis Grau JM, Garrabou G

Development of combined screening test for the prediction of preeclampsia and Francesca Crovetto Gratacós E, Figueras F intrauterine growth restriction in the ﬁrst trimester of pregnancy

Characterization of the pulmonary and systemic immune response in relation with lung stem Tamara Cruz Santa Cruz García-Navarro A, Faner R cells in patients with COPD

Elﬁ Egmond Health related quality of life and risk factors in hepatitis C patients Martín-Santos R, Navinés R

Miriam Illa Armengol Brain effects of fetal growth restriction and their prevention in an animal model Gratacós E, Figueras F

Marta Matamala Gomez The use of immersive virtual reality in neurorehabilitation and its impact on neuroplasticity Sanchez Vives MV

Fenotipo y Genotipo de los Síntomas Negativos en la Esquizofrenia: Conceptualización, Gisela Mezquida Mateos Bernardo M, Penadés R Evaluación y su Relación con el Polimorﬁsmo VAL66MET del BDNF

Agrin Moeini Mortazavi Liver cancer: Molecular classiﬁcation of Cholangiocarcinoma Llovet JM

New insignhts into the colorectal carciongenesis: from early precursor lesions to the roele of Isabel Quintanilla Pellisé M, Camps J aneuploidy

Synaptic and non-synaptic propagation of slow waves and their modulation by endogenous Beatriz Rebollo González Sanchez Vives MV electric ﬁelds

Role of specialized pro-resolving lipid mediators and ER stress in obesity derived Bibiana Rius Boadas Clària J non-alcoholic fatty liver disease

Characterization of the spectrum of cardiac adaptation to endurance exercise: impact of Maria Sanz de la Garza Sitges M gender and training load

Nicola Sarbu Advanced and conventional magnetic resonance imaging techniques: biomarkers in reurolupus Bargalló N

Ines Tadeus Simoes Characterization of the in vivo immunomodulatory properties of CD5 and CD6. Lozano F, Martínez V

Keyvan Torabi Asensio La disomia uniparental adquirida en el càncer colorectal Camps J, Miró R, Ponsa I

Imma Torres Vilamajo Comorbilidad entre el trastorno bipolar y el trastorno por déﬁcit de atención e hiperactividad Goikolea JM, Martinez-Aran A en el adulto Optimization of meropenem and piperacillin dosing in critically ill patients with septic shock Marta Ulldemolins Gómez and acute kidney injury requiring continuous renal replacement therapy: a pharmacokinetic Soy D, Martín I and pharmacodynamic study

Antoni Vilaseca Cabo Molecular and clinical response of renal cell carcinoma to intermittent hypoxia Musquera M, Almendros I

43 FOREWORD IDIBAPS

Robert Albero Gallego Mantle Cell Lymphoma pathogenesis: another turn of the screw to cyclin D1 overexpression Campo E, Jares P

Rafael Alcalá Vida PKC and nuclear lamina alterations: Involvement in Huntington’s disease pathophysiology Pérez E

Rosanel Amaro Rodríguez Nuevas consideraciones en el pronóstico de la neumonía adquirida en la comunidad Torres A

Lidia Argüello Viudez Pólipos gástricos: tipos, tratamiento endoscópico y complicaciones asociadas Fernández Esparrach G, Ginés MA

Marta Arigita Lastra Valor de la translucencia nucal y ductus venoso, en la detección de malformaciones, translocaciones Borrell A disbalanceadas y enfermedades monogénicas en la ecografía de las 11-14 semanas

Helena Ariño Rodríguez Neurological syndromes associated with antibodies against the glutamic acid Graus F, Saiz A decarboxylase (GAD)

Angela Arranz Betegón Evaluación de un programa de intervención prenatal para embarazadas con fetos pequeños Botet F, Gratacós E para la edad gestacional

Josep Maria Augé Fradera Estimació del risc de neoplàsia colorectal avançada a partir de la quantiﬁcació de Castells A, Molina R l'hemoglobina fecal en el cribratge del càncer de còlon i recte

Mariona Balfegó Díaz Diabetes mellitus tipus 2: impacte metabòlic d'una dieta rica en sardina Gomis R

Cervical consistency index and quantitative cervical texture analysis by ultrasound to predict Núria Baños López Palacio M, Gratacós E spontaneous preterm birth

Anton Baranov Scarred Uterus: Subsequent pregnancy and delivery Vikhareva O, Figueras F

Deployment of novel integrated care services to promote healthy lifestyle: physical activity Anael Barberán Garcia Roca J, Blanco I as a use case

Xoana Barros Freiria FGF23 y vitamina D tras el trasplante renal Campistol JM

Nuria Berrocal Izquierdo Frecuencia y factores de riesgo de enfermedad cerebrovascular en pacientes con Bernardo M esquizofrenia y trastornos relacionados

Delia Blaya Diez de Revenga Estudio de los microRNAs en la ﬁsiopatología de la hepatitis alcoholic Sancho-Bru P, Ginés P

Laia Bonjoch Gassol Estudi dels exosomes com a mecanisme de comunicació intercel·lular en patologies Closa D, Pastor M pancreàtiques

Bibiana Cabrera Llorca Neurocognición y Biomarcadores Inﬂamatorios en Primeros Episodios Psicóticos Bernardo M

Factores virológicos, inmunológicos y epidemiológicos relacionados con la hepatitis C Noelia Caro Pérez Pérez del Pulgar S, Londoño MC y su tratamiento

Vanessa Casas López Proteome characterization of Brachyspira strains. Identiﬁcation of bacterial antigens Abián J, Carrascal M

Oscilaciones lentas en la red cortical alterada:una caracterización de los modelos murinos Patricia Castaño Prat Sanchez Vives MV 3xTg-AD, SAMP8 y Fmr1KO

Aida Castellanos Esparraguera Role of K2p channel TRESK in nocicepive and chronic pain Gasull X

Ana Lucía Castillo Figueroa The impact of nutrients on clock genes and metabolism: their role for the prevention Gomis R and treatment of metabolic diseases

Marta Catalán Adell Ateroesclerosis Preclínica en pacientes con Diabetes tipo 2 de reciente diagnóstico Sisó A

El uso de la TAC abdominal para el diagnóstico de los estadios tempranos del desarrollo de Alexandru Ciudin Alcaraz J, Luque Mª la enfermedad litiásica

Mercè Comes Forastero Impacto del trastorno bipolar en pacientes de edad avanzada Vieta E

44 Marlies Cortés Hinojosa Role of ZEB1 in macrophages during homeostasis, inﬂammation and cancer Postigo A

Oriol de Barrios Barri Role of ZEB1 in tumor progression: regulation of cell invasion and senescence Postigo A, Castells A

Anna Esteve Arenys Innovative targeted therapies for chemo-refractory B cell non-Hodgkin lymphomas Roué G

Nuevos factores del hospedador en la ﬁsiopatología y la respuesta al tratamiento antiviral de la Carlos Fernández Carrillo Pérez del Pulgar S, Diez J infección por el virus de la hepatitis C

Andrea Fernández Vidal ACSL3 role in the metabolism of Lipid Droplets and implications in hepatic regeneration Pol A

Identiﬁcació de mutacions en gens implicats en el metabolisme de l’àcid lipòic en l’acidúrica Ribes A Xènia Ferrer Cortès 3- metilglutacònica

Laura Foj Capell Nous biomarcadors per la detecció i pronòstic del càncer de pròstata Filella X

Papel de la vía de IGF y de metaloproteasa-7 en la resistencia adquirida al tratamiento con Mª Rosa Gallego Sánchez Maurel J quimioterapia y con anticuerpos anti-EGFR en cáncer colorrectal metastático

Manel Garabito Montoya Mechanisms for sex-associated differences of vascular aging Roque M, Dantas AP

Jéssica García Lucio Remodelat vascular a les malalties pulmonars: perﬁl d’expressió gènica i biomarcadors Barberà JA, Peinado V

Orlando García Bosch Diagnostic and therapeutic strategies in inﬂammatory bowel disease Panés J

Gemma Garrido García Estudi de l'eﬁcàcia d'un programa de rehabilitació neuropsicològica en pacients amb Penadés R, Barrios MT esquizofrènia

Eduardo Garrido Sagarzazu New strategies of inhibition of K-Ras and study of the K-Ras/CaM interaction Agell N, Rubio J

Júlia Gasull Camós Role of the infralimbic cortex in depression: Functional connectivity and behavioral phenotypes Artigas F, Castañé A

Análisis de factores pronóstico y estratiﬁcación del riesgo en pacientes con insuﬁciencia Víctor Luis Gil Espinosa Miró Ò, Llorens P cardiaca aguda atendidos en los servicios de urgencias

Sofía González Ortiz Resonancia magnética funcional aplicada al manejo de tumores cerebrales en el entorno clínico Bargalló N

Síndromes linfoproliferativos asociados a inmunodeﬁciencias secundarias: papel de la Blanca González Farré Campo E, Martínez A infección por virus herpes oncogénicos y la diferenciación plasmocelular

Ulises Granados Oliveros Utilidad de PET/TC con 18F-ﬂuorodesoxiglucosa en la detección de infecciones Fuster D, Pons F cardiovasculares y embolias sépticas hematógenas

Enfermedades priónicas y otras demencias rápidamente progresivas: caracterización Oriol Grau Rivera Sanchez-Valle R, Gelpi E clínico-patológica, neuroinmunológica y mediante neuroimagen por resonancia magnética

Isabel Graupera Garcia-Milà Inﬂamació sistémica i cirrosi. Valor pronòstic de biomarcadors inﬂammatoris enla cirrosi Ginés P, Villanueva C descompensada

Gonzalo Grazioli Prevención de muerte súbita en el deporte mediante el cribado pre-participativo Sitges M

Inés Guardia Pena Caracterización de factores implicados en el desarrollo estriatal Canals JM, Martín R

Efectividad de una alerta en la historia clínica informatizada de atención primaria para Carolina Guiriguet Capdevila Castells A, Caballeria L aumentar la participación en un programa poblacional de cribado de cárcer colorectal

Sergi Guixé Muntet Disfunció microcirculatòria sinusoïdal hepàtica en la cirrosi i dany per isquèmia/reperfusió: Gracia-Sancho J, Bosch J mecanismes involucrats i noves dianes terapèutiques

Anna Sandra Hernández Aguado Perinatal outcomes, mitochondrial toxicity and apoptosis in hiv-treated pregnant women Coll O, Garrabou G and in utero exposed newborns

45 FOREWORD IDIBAPS

Factores pronóstico de recidiva en pacientes con artritis reumatoide y artritis psoriásica José Esteban Inciarte Mundo Sanmartí R en remisión o baja actividad de la enfermedad durante el tratamiento biológico

Cristina López Ferraz Seguimiento del paciente sometido a ventilación mecánica; detección de complicaciones Torres A, Ramírez P infecciosas

Alícia López García Autologous hematopoyetic stem cell transplant in refractory Crohn’s disease Panés J

Caracterizaciónbiológica y molecular de síndromesteratozoospérmicoscausantes de la Olga López Rodrigo Bassas L, Oliva R infertilidadmasculina

Detección e identiﬁcación de biomarcadores precoces de ﬁbrosis hepática mediante Jiménez W Santiago Marfà Bruix técnicas proteómicas de alto rendimiento

Inflamación, estrés oxidativo y sistema inmune en el desarrollo de disfunción endotelial Susana Martín Rodríguez Díaz-Ricart M, Escolar G asociada a enfermedades inflamatorias crónicas Desarrollo de una metodología de reconstrucción de fibras de sustancia blanca en difusión Eloy Martínez de las Heras por RM y su aplicación al estudio de la relación entre la conectividad estructural cerebral y el Llufriu S, Prats A rendimiento cognitivo en pacientes con EM

Pablo Martínez-Vicente Homólogos de inmunoreceptores de la familia SLAM codiﬁcados por citomegalovirus Angulo A

Manel Mata Cases Evolución de la atención a la diabetes tipo 2 en Catalunya, 1993-2013 Novials A, Franch N

Nuevos instrumentos subjetivos y objetivos para evaluar la fase preclínica de la enfermedad Maria Antonella Mollica Molinuevo J, Rami L de Alzheimer

Ester Mora Claramunt Neuropsicologia i factors neurobiològics en el trastorn bipolar Vieta E

Factores determinantes de la concentración plasmática de linezolid. Implicaciones Laura Morata Ruiz Martínez JA, Soriano A terapéuticas

Birgit Nierula Multisensory processing and agency in VR embodiment; interactions through BCI and their Sanchez Vives MV, Slater M therapeutic applications

Nuria Nieto Nicolau Terapia celular para la reparación y regeneración de la superﬁcie ocular: potencial Casaroli-Marano R terapéutico de las células progenitoras mesenquimales.

Extrasistolia ventricular frecuente en pacientes con disfunción ventricular izquierda. Diego Penela Maceda Berruezo A Implicaciones clínicas y beneﬁcio de la ablación mediante radiofrecuencia

Maria Francesca Perelló Serra Nous marcadors clínics i tractament immunològic de l’endometriosi Carmona F, Martínez Zamora MA

Enterococcus faecalis infective endocarditis: epidemiological, clinical and therapeutic Juan Manuel Pericas Pulido Miró JM, García de la Mària C changes at the turn of the 21st century

Sonia Pernas simon Marcadores predictivos de respuesta a quimioterapia primaria + trastuzumab en cáncer de Prat A mama HER2-positivo

Fenotips dd’immunodeﬁciència comuna variable (IDCV) en pacients pediàtrics. Correlació Mònica Piquer Gibert Martín MA, Juan M genotip-fenotip en l’evolució clínica i el tractament dels pacients

Lluís Pujades Mestres Apixaban en la prevención de complicaciones trombóticas: Mecanismos adicionales de Escolar G, López I su acción antihemostática

Arturo Renú Jornet Daño de la barrera hematoencefálica en el ictus isquémico agudo: Marcadores de Chamorro Á, Amaro S neuroimagen y significado pronóstico Estudio proteómico en pacientes con metástasis hepáticas de cáncer colo-rectal. Adalgiza Reyes Romero Identificación de diferentes perfiles proteómicos en relación a los criterios clínico Forner A patológicos convencionales de gravedad

Caracterización de células tumorales circulantes en pacientes con carcinoma Ana Carolina Rhodes Cabrerizo Bruix J hepatocelular. Función de EpCAM en la metástasis

Enrique Antonio Rijo Mora Análisis de la expresión de las moléculas relacionadas con el complejo principal de histocompatibilidad Alcaraz J, Lloreta J de clase I Gen A (MICA) y de NKG2D como respuesta al estrés celular en el cáncer urotelial de vejiga

Elena Rioja Peñaranda Hallazgos clínicos y radiológicos tras la cirugía endoscópica de la base de cráneo Alobid I, Enseñat J

46 Amelia Rodriguez Aranda Individualized training in ART Fàbregues F, Vassena R

Mérida Rodriguez López Dynamics of cardiovascular remodeling in relation to fetal growth restriction across life course Crispi F, Gratacós E

Implicació pronóstica de la infecció per virus del papiloma humà en tumors d’orofaringe i cavitat oral Victor Rodriguez Freixinos Prat A localment avançats irresecables

Evaluación y optimización del tratamiento de los tumores hepáticos primarios de pequeño Bruix J, Forner A Carlos Rodríguez de Lope López tamaño (< 2 cm)

Análisis de los perfiles de expresión de genes codificantes y no codificantes en linfomas Alejandro Roisman Hernández L, Slavutsky I no- Hodgkin

Caracterísitiques clíniques i neuropsicològiques en nens i adolescents amb trastorn Mireia Rosa Justicia Calvo R, Lázaro L de l’espectre autista d’alt funcionament i en els seus germans

Adenovirus oncoselectius pel tractament de càncer de pàncrees. Combinació d’estratègies Maria Rovira Rigau Fillat C de direccionament a tumor i bioselecció de microRNAs potenciadors de l’activitat adenoviral

Impacte de la cèl·lula d’origen i de la mutació de MYD88 en la resposta i supervivencia dels Jordina Rovira Solé López Guillermo A pacients amb linfoma difús de cèl·lues grans B

Estudi de l'exercici físic intens i la síndrome de l'apnea del son com a factors de risc emergents Cira Rubies Espinalt Batlle M, Guasch E per a patologia cardiovascular. Caracterització en models animals

Adela Saco Álvarez Microscopía virtual en diagnóstico y docencia en un hospital universitario Ordi J,Ramirez J

Ana Sánchez Escuredo Empleo sistemático de biopsias renales pre-implante en donantes de criterios expandidos Oppenheimer F

Improving empathy in domestic violence offenders through perspective-taking in Soﬁa Seinfeld Sanchez Vives MV, Slater M immersive virtual reality

Anne-Maria Siegert Membrane trafficking of TGF-beta and transcriptomic analysis in Marfan syndrome Egea G

Role of ZEB1 in skeletal muscle: regulation of cell differentiation, response to tissue damage Laura Siles Mena Postigo A and regeneration

Diferenciación plasmocelular en linfomas no-Hodgkin de células B: implicaciones clínicas Carla Solé Cañadas Martinez A, Roué G y terapéuticas

Afectación neurológica en el lupus eritematoso sistémico: Alteraciones en la neuroimagen Pilar Toledano Sierra Cervera R, Espinosa G y caracterización de la afectación del sistema nervioso periférico

Emergent rhythmic activity and functional connectivity in the thalamocortical circuit at Núria Tort Colet Sanchez Vives MV, Mattia M different brain states

García-Ruiz MC, Mª del Carmen Vallejo Valdivia Interacción cholesterol-gangliósido GD3 en ﬁbrosis hepática Fernández-Checa JC

Anna Vidal Crespo Targeting the crosstalk between tumor cells and microenvironment: a new therapeutic Perez-Galan P, Campo E approach for the treatment of lymphoid neoplasms

Maria Vila Casadesús Design of Bioinformatic Tools for Integrative Analysis of microRNA-mRNA interactome Lozano J, Gironella M applied to digestive cancers

García-Pagán JC, Marina Vilsaeca Barceló Mecanismes involucrats en la regulació de la resistència vascular intrahepàtica en la cirrosi: paper dels anticoagulants i antioxidants Gracia-Sancho J

Cintia Zimerman De Meireles Simvastatina como fármaco hepatoprotector Bosch J

47 FOREWORD IDIBAPS

Seminars Stepping-stone training programme

It is a training programme that seeks to provide predoctoral (R1) and postdoctoral (R2) researchers at IDIBAPS with non-scientiﬁc tools and skills which Institutional are key for the development of their careers. 58 Seminars

IDIBAPS SEMINAR Sessions in 2017 9 8

IN -HOUSE SEMINARS 9

NEUROSCIENCES SEMINAR 18

CAMPUS CLINIC CANCER SEMINAR 10 CORE FACILITY SEMINAR 6

IIBB-CSIC/IDIBAPS SEMINAR 2

LIVER SEMINAR 4

September 4th - 15.00h October 4th - 16.00h Mechanisms Acute on of normal and impaired chronic 2017 consciousness liver failure in epilepsy Rajiv Jalan, MD PhD IDIBAPS Hal Blumenfeld, MD PhD Professor of Hepatology Director, Yale Clinical Neuroscience at University College London AUTUMN ------Imaging Center. Professor of Neurology, 1 Neuroscience and Neurosurgery. October 9th - 13.15h SEMINARS Yale University School of Medicine Integrative genomics ------September 13th - 16.00h identifies positionally- Hepatic conserved lncRNAs macrophages necessary for the specification of SEPTEMBER in liver diseases pancreatic lineages in OCTOBER Frank Tacke, MD PhD development and disease Professor of Medicine University Hospital Aachen, Germany Luís Arnes, PhD ------Department of Systems Biology September 26th - 15.00h Columbia University Medical Center Venue Blood brain barrier ------Esteve Auditorium October 18th - 15.00h idibaps-CEK Building disruption in acute ischemic stroke: IL-6/IL12 superfamily Rosselló 149-153, Barcelona of cytokines and [email protected] assessment with perfusion neuroimaging vascular inflammation and clinical relevance in giant-cell arteritis Maria Cinta Cid, MD PhD Sergio Amaro, MD PhD IDIBAPS Group Leader IDIBAPS Researcher Systemic vasculitis Brain ischemia: clinical and IDIBAPS SEMINAR ------experimental studies October 25th - 15.00h IDIBAPS IN-HOUSE SEMINAR Multimodal assessment NGS target NEUROSCIENCES SEMINAR of visual pathway: enrichment solutions (the power of NGS CAMPUS CLINIC CANCER SEMINAR an opportunity to understand and targeted resequencing) IDIBAPS CORE FACILITY SEMINAR monitor MS Anna Enjuanes, PhD Next Generation Sequencing Specialist IDIBAPS LIVER SEMINARS Elena Hernández Martínez IDIBAPS Functional Genomics Core de Lapiscina, MD Phd Facility IDIBAPS Researcher ------2 Pathogenesis and new treatments October 27th - 13.00h in multiple sclero ------Fecal Microbiota September 27th - 15.00h Transplantation (FMT) Computational in the 21st century approaches to Alan C. Moss, MD Venue understand the neural Beth Israel Deaconess Medical Center 1. Sala 1, planta baixa CEK mechanisms of Harvard Medical School 2. Sala Farreras Valentí (HCB) Alex Soriano, MD Phd psychosis. Evidence IDIBAPS Group Leader from fMRI, PET and Nosocomial infection study group behavioural studies Guillermo Horga, MD PhD Assistant Professor of Clinical Psychiatry University of Columbia

48 Communications News and public engagement

MEDIA RELATIONS PUBLIC RELATIONS PUBLIC ENGAGEMENT JANUARY Joan Rodés, founder and ﬁrst director of Press Events Activities IDIBAPS, passed away. 38 releases 24 organised 33 organised Hospital Clinic-IDIBAPS leads a European project to ﬁght against cirrhosis within the Media 20 Talks Horizon 2020 program. 549 appearances

10 Visits MARCH IDIBAPS creates 3 new research groups: 3 Others Vascular biology of the liver (Group leader: Jordi Gracia-Sancho), Biomedical epigenomics (Group leader: José Ignacio SOCIAL MEDIA Martin-Subero) and Liver cell plasticity and tissue repair (Group leader: Pau Facebook Sancho-Bru) 1739 page likes*

APRIL Twitter Elías Campo replaces Ramon Gomis as 6456 followers* director of IDIBAPS Linkedin MAY 937 followes* The European Commission co-ﬁnances *at december 31 Bitrecs, a new program to incorporate clinicians-scientists at IDIBAPS.

The bank of neurological tissues of Clínic-IDIBAPS reaches the 2,000 donors on its 25th anniversary.

JUNE Josep Dalmau, awarded with the 2017 Rey Jaime I prize in the Medical Research category.

JULY Eduard Vieta, best researcher of the year by the World Federation of Psychiatry.

OCTOBER Barcelona Liver Bioservices (BLB), a spin-off of IDIBAPS for the design and development of pre-clinical studies in the ﬁelds of liver disease and hepatotoxicity, is constituted.

NOVEMBER The Clínic-IDIBAPS is the Spanish biomedical research institution with more scientists in the list of world's most inﬂuential scientist, according to the Clarivate Analytics Highly Cited Researchers 2017 list.

49 ANNUAL SCIENTIFIC REPORT 2017

AREA 1

BIOLOGICAL AGGRESSION AND RESPONSE MECHANISMS 1

BIOLOGICAL AGGRESSION AND RESPONSE MECHANISMS

1.1 Inﬂammatory joint diseases (IJDs) 52 Raimon Sanmartí

1.2 Systemic autoimmune diseases 55 Ricard Cervera

1.3 Infectious diseases and AIDS 62 Josep M. Miró

1.4 Immune receptors of the innate and adaptive system 72 Francisco Lozano

1.6 Immunogenetics of the autoinﬂammatory response 75 Jordi Yagüe

1.7 Emergencies: processes and pathologies 78 Oscar Miró

1.8 Molecular and cellular bases of inﬂammation. 83 Structural and biological mass spectrometry Daniel Closa

1.9 Ocular inﬂammation: clinical and experimental studies 85 Alfredo Adán

51 AREA 1 BIOLOGICAL AGGRESSION AND RESPONSE MECHANISMS

Inﬂammatory joint 1.1 diseases (IJDs)

- Search of biomarkers of clinical reactivation and radiographic progression. LOCATION

HCB building 3. Immunopathology of synovitis in chronic arthritis - Utility in pathogenesis, differential diagnosis and prognosis of rheumatoid arthritis and psoriatic arthritis. Immuno pathological changes induced by KEYWORDS biological treatments. Mechanism of 1. Rheumatoid arthritis TEAM LEADER action of targeted therapies. Synovial 2. Psoriatic arthritis Raimon Sanmartí (HCB) response biomarkers. 3. Pathogenesis T. 93 227 54 00 (Ext.: 2236/2604) 4. Biomarkers 4. Pharmacogenomics of chronic [email protected] 5. Targeted therapies arthritis - Genetic biomarkers associated to biological therapy response in rheuma RESEARCHERS toid arthritis and psoriatic arthritis Juan D. Cañete (HCB)

Original publications POST-DOCTORAL RESEARCHERS from 2015 to 2017 Raquel Celis (FCRB) PUBLICATIONS M. Victoria Hernández (HCB) YEAR I.F. TOTAL Q1 Q2 Julio Ramirez (FCRB) Originals / I.F.: 85.962 Virginia Ruiz-Esquide (FCRB) 2015 38.89 9 4 4 1. Rauber S, Luber M, Weber S, Maul L, Soare 2016 58.21 14 8 5 PRE-DOCTORAL RESEARCHERS A, Wohlfahrt T, Lin NY, Dietel K, Bozec A, 2017 85.96 16 7 5 Raul Castellanos (HCB) Herrmann M, Kaplan MH, Weigmann B, Zaiss Andrea Cuervo (FCRB) MM, Fearon U, Veale DJ, Cañete JD, Distler O, Rivellese F, Pitzalis C, Neurath MF, McKenzie ANJ, Wirtz S, Schett G, Distler JHW, Ramming A. Resolution of inflammation by TEAM INVOLVED IN STRATEGIC OBJECTIVES interleukin-9-producing type 2 innate RIER lymphoid cells. NATURE MEDICINE. Promotion of research into the most 23(8):938-944. I.F.: 29.886 prevalent chronic forms of immune mediated inflammatory arthritis: rheumatoid arthritis 2. Calvo-Río V., Santos-Gómez M., Calvo I., (RA) and spondyloarthritis, including psoriatic González-Fernández M., López-Montesinos arthritis. B., Mesquida M., Adán A., Hernández M., Maíz O., Atanes A., Bravo B., Modesto C., Díaz-Cordovés G., Palmou-Fontana N., MAIN LINES OF RESEARCH Loricera J., González-Vela M., Demetrio-Pablo R., Hernández J., 1. Prognostic factors in early arthritis González-Gay M., Blanco R.. - Prognostic factors (clinical and immuno Anti–Interleukin-6 Receptor genetic) in patients with recent-onset Tocilizumab for Severe Juvenile rheumatoid arthritis. Idiopathic Arthritis–Associated Uveitis - Production of new synthetic citrullinated Refractory to Anti–Tumor Necrosis peptides for the design of immunoassa Factor Therapy: A Multicenter Study of ys with diagnostic and prognostic value Twenty-Five Patients. ARTHRITIS AND in recent-onset rheumatoid arthritis and RHEUMATOLOGY. 69(3):668-675. I.F.: 6.918 palindromic rheumatism. 3. Levels, Maria J.; Van Tok, Melissa N.; 2. Clinical and sonographic Cantaert, Tineke; Canete, Juan D.; Kroese, characterization of clinical remission Frans G. M.; Germar, Kristine; Spits, Hergen; - Definition and clinical characterization of Baeten, Dominique L. P.; Yeremenko, Nataliya subclinical “active synovitis” G.. The Transcriptional Coactivator Bob1 Is - Immunopathological and molecular Associated With Pathologic B Cell characterization of subclinical “active Responses in Autoimmune Tissue synovitis”. Inflammation.

52 INFLAMMATORY JOINT DISEASES (IJDS) 1.1

ARTHRITIS AND RHEUMATOLOGY. ARTHRITIS RESEARCH AND THERAPY. CLINICAL AND EXPERIMENTAL 69(4):750-762. I.F.:6.918 19(1):141. I.F.: 4.121 RHEUMATOLOGY. 35(5):816-822. I.F.: 2.634

4. García-Doval I, Hernández MV, Vanaclocha 9. Desthieux C, Granger B, Balanescu AR, 14. Iannone F., Courvoisier D., Gottenberg J., F, Sellas A, de la Cueva P, Montero D, Balint P, Braun J, Canete JD, Heiberg T, Hernandez M., Lie E., Canhão H., Pavelka K., BIOBADADERM and BIOBADASER study Helliwell PS, Kalyoncu U, Kvien TK, Kiltz U, Hetland M., Turesson C., Mariette X., groups. Should tumour necrosis factor Niedermayer D, Otsa K, Scrivo R, Smolen J, Choquette D., Finckh A.. Body mass does antagonist safety information be applied Stamm TA, Veale DJ, de Vlam K, de Wit M, not impact the clinical response to from patients with rheumatoid arthritis Gossec L. Determinants of intravenous abatacept in patients with to psoriasis? Rates of serious adverse patient-physician discordance in global rheumatoid arthritis. Analysis from the events in the prospective rheumatoid assessment in psoriatic arthritis: a “pan-European registry collaboration for arthritis BIOBADASER and psoriasis multicenter European study. ARTHRITIS abatacept (PANABA). CLINICAL BIOBADADERM cohorts. BRITISH CARE AND RESEARCH. 69(10):1606-1611. I.F.: RHEUMATOLOGY. 36(4):773-779. I.F.: 2.365 JOURNAL OF DERMATOLOGY. 3.319 176(3):643-649. I.F.: 4.706 15. Pato E., Martin-Martinez M., Castelló A., 10. Chatzidionysiou K., Lie E., Lukina G., Méndez-Fernandez R., Muñoz-Fernández S., 5. Ramírez J, Narváez JA, Ruiz-Esquide V, Hetland M., Hauge E., Pavelka K., Gabay C., Cordero-Coma M., Martinez-Costa L., Valls E., Hernández-Gañán J, Cuervo A, Scherer A., Nordström D., Canhao H., Santos Reyes M., Francisco F., Esteban M., Fonollosa Inciarte-Mundo J, Hernández MV, M., Tomsic M., Rotar Z., Hernández M., A., Sanchez-Alonso F., Fernández-Espartero Sampayo-Cordero M, Pablos JL, Sanmartí R, Gomez-Reino J., Ancuta I., Kvien T., Van C., Diaz-Valle T., Carrasco J., Beltran-Catalán Cañete JD. Clinical and sonographic Vollenhoven R.. Rituximab retreatment in E., Hernández-Garfella M., Hernández M., biomarkers of structural damage rheumatoid arthritis in a real-life cohort: Pelegrin L., Blanco R., Diaz-Valle D.. progression in RA patients in clinical Data from the CERERRA collaboration. Development of an activity disease score remission: A prospective study with 12 JOURNAL OF RHEUMATOLOGY. in patients with uveitis (UVEDAI). months follow-up. SEMINARS IN 44(2):162-169. I.F.: 3.150 RHEUMATOLOGY INTERNATIONAL. ARTHRITIS AND RHEUMATISM. 37(4):647-656. I.F.: 1.824 47(3):303-309. I.F.: 4.498 11. Perrotti P., Aterido A., Fernández-Nebro A., Cañete J., Ferrándiz C., Tornero J., Gisbert J., 16. Fernández-Gutiérrez B., Perrotti P., Gisbert 6. Del Rey M., Valín Á., Usategui A., Domènech E., Fernández-Gutiérrez B., J., Domènech E., Fernández-Nebro A., Cañete García-Herrero C., Sánchez-Aragó M., Gomollón F., García-Planella E., Fernández E., J., Ferrándiz C., Tornero J., García-Sánchez V., Cuezva J., Galindo M., Bravo B., Cañete J., Sanmartí R., Gratacós J., Martínez-Taboada Panés J., Fonseca E., Blanco F., Blanco F., Criado G., Pablos J.. Hif-1α V., Rodríguez-Rodríguez L., Palau N., Tortosa Rodríguez-Moreno J., Carreira P., Julià A., Knockdown Reduces Glycolytic R., Corbeto M., Lasanta M., Marsal S., Julià A, Marsal S., Rodriguez-Rodriguez L., IMID Metabolism and Induces Cell Death of IMID Consortium. Genetic variation Consortium. Cardiovascular disease in Human Synovial Fibroblasts under associated with cardiovascular risk in immune-mediated inflammatory Normoxic Conditions. SCIENTIFIC autoimmune diseases. PLOS ONE. diseases: A cross-sectional analysis of 6 REPORTS. 7(1):3644. I.F.: 4.259 12(10):e0185889. I.F.: 2.806 cohorts. MEDICINE (UNITED STATES). 96(26):e7308. I.F.: 1.803 7. Queiro R., Cañete J., Montilla C., Abad M., 12. Ramírez J, Inciarte-Mundo J, Cuervo A, Montoro M., Gómez S., Cábez A., Torre Alonso Ruiz-Esquide V, Hernández MV, Sanmartí R, J., Román-Ivorra J., Sanz J., Salvatierra J., Cañete JD. Differing local and systemic Review / I.F.: 23.863 Calvo-Alén J., Sellas A., Rodriguez F., inflammatory burden in polyarticular Bermúdez A., Romero M., Riesco M., Cobeta psoriatic arthritis and rheumatoid 1. Orr C, Vieira-Sousa E, Boyle DL, Buch MH, J., Medina F., Aragón A., García M., arthritis patients on anti-TNF treatment Buckley CD, Cañete JD, Catrina AI, Choy EHS, Urruticoechea A., González C., Judez E., in clinical remission. CLINICAL AND Emery P, Fearon U, Filer A, Gerlag D, Humby F, González B., Fernández P., Pantoja L., Morlá R.. EXPERIMENTAL RHEUMATOLOGY. Isaacs JD, Just SA, Lauwerys BR, Le Goff B, MAAPS study group. Minimal disease 35(1):74-79. I.F.: 2.634 Manzo A, McGarry T, McInnes IB, Najm A, activity and impact of disease in psoriatic Pitzalis C, Pratt A, Smith M, Tak PP, Thurlings arthritis: A Spanish cross-sectional 13. Acebes C, Andreu JL, Balsa A, Batlle E, de R, Fonseca JE, Veale DJ, Tas SW. Synovial multicenter study. ARTHRITIS RESEARCH Toro-Santos J, García Llorente F, Hernández tissue research: a state-of-the-art AND THERAPY. 19(1):72. I.F.: 4.121 MV, Fernández-Gutiérrez B, Hidalgo-Calleja C, review. NATURE REVIEWS Mayordomo L, Naredo E, Narváez FJ, Ortiz RHEUMATOLOGY. 13(8):463-475. I.F.: 12.188 8. Cabrera-Villalba S., Gomara M., Cañete J., AM, Pablos JL, Pérez-Sandoval T, Ramírez J., Salvador G., Ruiz-Esquide V., Rodríguez-Lozano C, Sánchez-Pernaute O, 2. Villaverde-Garcia, Virginia; Cobo-Ibanez, Hernández M., Inciarte-Mundo J., Haro I., Usón J, Negrón JB, Loza E, Carmona L, Tatiana; Candelas-Rodriguez, Gloria; Sanmartí R.. Differing specificities and Gómez Castro S, Montoro Alvarez M. Seoane-Mato, Daniel; del Campo-Fontecha, isotypes of anti-citrullinated Exploring the remission concept in Petra Diaz; Guerra, Mercedes; peptide/protein antibodies in rheumatoid arthritis with patients and Munoz-Fernandezb, Santiago; Canete, Juan palindromic rheumatism and rheumatoid rheumatologists: time for a new D.;. The effect of smoking on clinical and arthritis. approach? structural damage in patients with axial

53 AREA 1 BIOLOGICAL AGGRESSION AND RESPONSE MECHANISMS

spondyloarthritis: A systematic literature DOCTORAL THESES review. SEMINARS IN ARTHRITIS AND RHEUMATISM. 46(5):569-583. I.F.: 4.498 Sanmartí R: Factores pronóstico de recidiva en pacientes con artritis 3. Cañete JD, Hernández MV, Sanmartí R. reumatoide y artritis psoriásica en Safety proﬁle of biological therapies for remisión o baja actividad de la treating rheumatoid arthritis. EXPERT enfermedad durante el tratamiento OPINION ON BIOLOGICAL THERAPY. biológico. 17(9):1089-1103. I.F.: 3.684 PhD student: José Esteban Inciarte Mundo

4. Bastida, Carla; Ruiz, Virginia; Pascal, Mariona; Yague, Jordi; Sanmartí, Raimon; Soy, Dolors. Is there potential for therapeutic drug monitoring of biologic agents in rheumatoid arthritis? BRITISH JOURNAL OF CLINICAL PHARMACOLOGY. 83(5):962-975. I.F.: 3.493

Letters / I.F.: 11.855

1. Aya F, Ruiz-Esquide V, Viladot M, Font C, Prieto-González S, Prat A, Arance A. Vasculitic neuropathy induced by pembrolizumab. ANNALS OF ONCOLOGY. 28(2):433-434. I.F.: 11.855

GRANTS FOR RESEARCH IN PROGRESS

Cañete JD. Red de Investigación en Inﬂamación y Enfermedades Reumáticas (RIER). Sponsored by: Instituto de Salud Carlos III (ISCIII). RD12/0009/0016 Duration: 01/01/2013 – 31/12/2018

Cañete JD. Clinical validation of genetic markers to predict persistent remission in rheumatoid arthritis patients treated with biological therapy (REMRABIT). Sponsored by: Fundación Profesor Novoa Santos. PMP15/00032 Duration: 01/01/2016-31/12/2019

Cañete JD. Red Temática de Investigación Cooperativa en Salud - Inﬂamación y enfermedades reumáticas. Sponsored by: Instituto de Salud Carlos III (ISCIII). RD16/0012/0010 Duration: 01/01/2017 - 31/12/2021

54 SYSTEMIC AUTOIMMUNE DISEASES 1.2

Systemic 1.2 autoimmune diseases

PRE-DOCTORAL RESEARCHERS Roser Alba (IDIBAPS) LOCATION Emmanuel Coloma (HCB) HCB building Pamela Doti (HCB) CELLEX building, 4B Nerea Iniesta-Arandia (HCB) Alba Jerez (HCB) Ignasi Rodríguez-Pintó (HCB) Carolina Sánchez (HCB) Nekane Terrades (IDIBAPS)

KEYWORDS ADMINISTRATIVE STAFF TEAM LEADER 1. Systemic autoimmune diseases Ricard Cervera (HCB) Isabel Chaves (HCB) 2. Systemic lupus erythematosus T. 93 227 57 74 COLLABORATORS 3. Systemic vasculitis [email protected] 4. Antiphospholipid syndrome Xavier Bosch (HCB) Antoni Sisó (EAP Les Corts) 5. Sjögren's syndrome GROUP LEADER Maria Cinta Cid (HCB) VISITING SCIENTISTS T. 93 227 57 74 Gloria de la Red (Hospital de l'Esperit Sant, Spain) [email protected] Hoda Gheitasi (Hospital de Teherán, Iran) Maria Kourilovich (Hospital Mongte Sinaí, Ecuador) Original publications RESEARCHERS Prakash Pispati (Jaslok Hospital, Mumbai, India) from 2015 to 2017 Ricardo P. Casaroli-Marano (HCB) Miguel Angel Plasín (Hospital de Mollet, Spain) Georgina Espígol (IDIBAPS) Joan Plaza (Hospital de Viladecans, Spain) YEAR I.F. TOTAL Q1 Q2 Gerard Espinosa (IDIBAPS) Isaac Pons (Hospital d'Igualada, Spain) 2015 191.76 38 20 11 Ana García (HCB) Guillermo Pons-Estel (Hospital General de 2016 150.05 28 15 10 José Hernández (HCB) Catalunya, Spain) Laura Pelegrín (HCB) Rosanna Quintana (Hospital Provincial de 2017 331.90 35 20 6 Manuel Ramos (HCB) Rosario, Argentina) Rosa Serrano (Hospital General de POST-DOCTORAL RESEARCHERS Catalunya, Spain) Marc Corbera (IDIBAPS) Pilar Toledano (Hospital Provincial de Toledo, Ester Planas (IDIBAPS) Spain) TEAM INVOLVED IN AGAUR_SGR14 Sergio Prieto (HCB) Cristian Vera-Kellet (Pontifícia Universidad Maxime Sanson (IDIBAPS) Católica de Chile, Chile)

AWARDS Premi Bartolomé Cabré Institution: Societat Catalano-Balear de Medicina Interna Awardee/s: Dr. Sergio Prieto Ricard Cervera

TEAM

55 AREA 1 BIOLOGICAL AGGRESSION AND RESPONSE MECHANISMS

STRATEGIC OBJECTIVES RESEARCH GROUP Tocilizumab in Giant-Cell Arteritis. NEW SYSTEMIC VASCULITIS ENGLAND JOURNAL OF MEDICINE. The research team promotes clinical and 377(4):317-328. I.F.: 72.406 translational research on systemic autoimmune diseases in a multidisciplinary 2. Wechsler, M. E.; Akuthota, P.; Jayne, D.; manner, with the participation of members of Khoury, P.; Klion, A.; Langford, C. A.; Merkel, P. the Departments of Autoimmune Diseases, A.; Moosig, F.; Specks, U.; Cid, M. C.; Luqmani, Ophthalmology, Nephrology, Immunology, R.; Brown, J.; Mallett, S.; Philipson, R.; Yancey, S. Hemostasis, Obstetrics and Dermatology, W.; Steinfeld, J.; Weller, P. F.; Gleich, G. J.;EGPA among others. These activities are carried out GROUP LEADER Mepolizumab Study Team. Mepolizumab in collaboration with many international Maria Cinta Cid (HCB) or Placebo for Eosinophilic working groups. Granulomatosis with Polyangiitis. NEW We are interested in investigating ENGLAND JOURNAL OF MEDICINE. mechanisms involved in vascular inflammation 376(20):1921-1932. I.F.: 72.406 MAIN LINES OF RESEARCH and remodelling in systemic vasculitis with the ultimate goal of identifying biomarkers of 3. Balsas P, Palomero J, Eguileor Á, Rodríguez 1. Systemic lupus erythematosus, disease activity and therapeutic targets. ML, Vegliante MC, Planas-Rigol E, antiphospholipid syndrome and We are also interested in delimitating clinical Sureda-Gómez M, Cid MC, Campo E, Amador systemic sclerosis: phenotypes and outcomes as well as in V. SOX11 promotes tumor protective - Epidemiological studies on the clinical therapeutic innovation with targeted microenvironment interactions through manifestations and long-term evolution of therapies, participating in the design and CXCR4 and FAK regulation in mantle cell these diseases. development of innovative international lymphoma. BLOOD. 130(4):501-513. I.F.: 13.164 - Clinical trials in new biological therapies. clinical trials. The group also participates in massive genotyping and national and 4. Vento-Tormo R, Álvarez-Errico D, 2. Sjögren’s syndrome, autoimmune international registries of systemic vasculitis, Garcia-Gomez A, Hernández-Rodríguez J, manifestations of hepatitis C virus as well as in the development of international Buján S, Basagaña M, Méndez M, Yagüe J, infection and biological therapies: guidelines and recommendations for the Juan M, Aróstegui JI, Ballestar E. DNA - Study of IgG4 disease associated with definitions, classification and management of demethylation of inflammasome - Sjögren’s. systemic vasculitis and related diseases. associated genes is enhanced in patients - Validation of ESSDAI and ESSPRI activity with cryopyrin-associated periodic scores, syndromes. JOURNAL OF ALLERGY AND - Development of new international PUBLICATIONS CLINICAL IMMUNOLOGY. 139(1):202-211. classification criteria for Sjögren’s. I.F.: 13.081 Originals / I.F.: 331.903 3. Systemic vasculitis: 5. Alberici F., Smith R., Fonseca M., Willcocks - Investigation of the mechanisms involved in 1. Stone JH, Tuckwell K, Dimonaco S, L., Jones R., Holle J., Wieczorek S., Neumann vascular inflammation and remodelling in Klearman M, Aringer M, Blockmans D, T., Martorana D., Gregorini G., Sinico R., systemic vasculitis. Identification of Brouwer E, Cid MC, Dasgupta B, Rech J, Bruchfeld A., Gunnarsson I., Ohlsson S., biomarkers and new therapeutic targets. Salvarani C, Schett G, Schulze-Koops H, Baslund B., Tesar V., Hruskova Z., Cid M., - Development of ex-vivo culture models for Spiera R, Unizony SH, Collinson N. Trial of Vaglio A., Lyons P., Smith K., Jayne D. studying factors implicated in the perpetuation of inflammation and in vascular remodelling.in giant-cell arteritis - Clinical trials investigating targeted therapies in the management of systemic vasculitis. - Clinical phenotypes and outcomes in systemic vasculitis - Immunogenetics of systemic vasculitis

4. Autoinﬂammatory diseases: - Epidemiological studies on the clinical manifestations and long-term evolution of these diseases. Maria Cinta Cid

GROUP

56 SYSTEMIC AUTOIMMUNE DISEASES 1.2

Association of a TNFSF13B (BAFF) P4HA2 Associated with Giant Cell estimate of cancer in patients with primary regulatory region single nucleotide Arteritis. AM J HUM GENET. 100: 64-74. Sjögren syndrome. JOURNAL OF polymorphism with response to I.F.: 4.818 HEMATOLOGY AND ONCOLOGY. 10(1):90. rituximab in antineutrophil cytoplasmic I.F.: 6.350 antibody–associated vasculitis. 10. Toledano P., Orueta R., Rodríguez-Pintó I., JOURNAL OF ALLERGY AND CLINICAL Valls-Solé J., Cervera R., Espinosa G.. Peripheral 16. Rajaram, Sujatha; Valls-Pedret, Cinta; Cofan, IMMUNOLOGY. 139(5):1684-1687. I.F.: 13.081 nervous system involvement in systemic Montserrat; Sabate, Joan; Serra-Mir, Merce; lupus erythematosus: Prevalence, clinical Perez-Heras, Ana M.; Arechiga, Adam; 6. Brito-Zerón P, Acar-Denizli N, Zeher M, and immunological characteristics, Casaroli-Marano, Ricardo P.; Alforja, Socorro; Rasmussen A, Seror R, Theander E, Li X, treatment and outcome of a large cohort Sala-Vila, Aleix; Domenech, Monica; Roth, Irene; Baldini C, Gottenberg JE, Danda D, Quartuccio from a single centre. AUTOIMMUNITY Freitas-Simoes, Tania M.; Calvo, Carlos; L, Priori R, Hernandez-Molina G, Kruize AA, REVIEWS. 16(7):750-755. I.F.: 8.961 Lopez-Illamola, Anna; Haddad, Ella; Bitok, Valim V, Kvarnstrom M, Sene D, Gerli R, Edward; Kazzi, Natalie; Huey, Lynnley; Fan, Praprotnik S, Isenberg D, Solans R, 11. Pelegrin, Laura; Hernandez-Rodriguez, Joseph; Ros, Emilio. The Walnuts and Healthy Rischmueller M, Kwok SK, Nordmark G, Jose; Espinosa, Gerard; Llorenc, Victor; Aging Study (WAHA): Protocol for a Suzuki Y, Giacomelli R, Devauchelle-Pensec Sainz-de-la-Maza, Maite; Fontenla, Jose R.; Nutritional Intervention Trial with Walnuts on V, Bombardieri M, Hofauer B, Bootsma H, Martinez, Jose A.; Cid, Maria C.; Adan, Alfredo. Brain Aging. FRONTIERS IN AGING Brun JG, Fraile G, Carsons SE, Gheita TA, Characterization of isolated retinal vasculitis. NEUROSCIENCE. 8(JAN):333. I.F.: 4.504 Morel J, Vollenveider C, Atzeni F, Retamozo Analysis of a cohort from a single center and S, Horvath IF, Sivils K, Mandl T, Sandhya P, literature review. AUTOIMMUNITY REVIEWS. 17. Tuckwell K, Collinson N, Dimonaco S, De Vita S, Sanchez-Guerrero J, van der 16(3):237-243. I.F.: 8.961 Klearman M, Blockmans D, Brouwer E, Cid Heijden E, Trevisani VFM, Wahren-Herlenius MC, Dasgupta B, Rech J, Salvarani C, Unizony M, Mariette X, Ramos-Casals M, EULAR-SS 12. Bonacci M, Lens S, Londoño MC, Mariño Z, SH, Stone JH, GiACTA Investigators. Newly Task Force Big Data Consortium. Influence Cid MC, Ramos-Casals M, Sánchez-Tapias diagnosed vs. relapsing giant cell arteritis: of geolocation and ethnicity on the JM, Forns X, Hernández-Rodríguez J. Baseline data from the GiACTA trial. phenotypic expression of primary Virologic, Clinical, and Immune Response SEMINARS IN ARTHRITIS AND Sjögren's syndrome at diagnosis in Outcomes of Patients With Hepatitis C RHEUMATISM. 46(5):657-664. I.F.: 4.498 8310 patients: a cross-sectional study Virus-Associated Cryoglobulinemia from the Big Data Sjögren Project Treated With Direct-Acting Antivirals. 18. Burillo-Sanz S., Montes-Cano M., Consortium. ANN RHEUM DIS. CLINICAL GASTROENTEROLOGY AND García-Lozano J., Ortiz-Fernández L., 76(6):1042-1050. I.F.: 12.811 HEPATOLOGY. 15(4):575-583. I.F.: 7.398 Ortego-Centeno N., García-Hernández F., Espinosa G., Graña-Gil G., Sánchez-Bursón J., 7. Planas-Rigol E., Terrades-Garcia N., 13. Ruiz-Ortiz, Estibaliz; Iglesias, Estibaliz; Rosa Juliá M., Solans R., Blanco R., Corbera-Bellalta M., Lozano E., Alba M., Soriano, Alessandra; Bujan-Rivas, Segundo; Barnosi-Marín A., Gómez De La Torre R., Fanlo Segarra M., Espígol-Frigolé G., Prieto-González Espanol-Rego, Marta; Castellanos-Moreira, P., Rodríguez-Carballeira M., Rodríguez- S., Hernández-Rodríguez J., Preciado S., Lavilla Raul; Tome, Adria; Yague, Jordi; Anton, Jordi; Rodríguez L., Camps T., Castañeda S., R., Cid M. Endothelin-1 promotes vascular Hernandez-Rodriguez, Jose. Disease Alegre-Sancho J., Martín J., González- smooth muscle cell migration across the Phenotype and Outcome Depending on Escribano M. Mutational profile of rare artery wall: A mechanism contributing to the age at Disease Onset in Patients variants in inflammasome-related genes vascular remodelling and intimal carrying the R92Q low-Penetrance Variant in Behçet disease: A Next Generation hyperplasia in giant-cell arteritis. ANNALS in TNFRSF1A gene. FRONTIERS IN Sequencing approach. SCIENTIFIC OF THE RHEUMATIC DISEASES. IMMUNOLOGY. 8:299. I.F.: 6.429 REPORTS. 7(1):8453. I.F.: 4.259 76(9):1624-1634. I.F.: 12.811 14. Carrizosa J., Aponte J., Cartagena D., Cervera 19. David Carmona, F.; Coit, Patrick; 8. Langefeld, Carl D.; Ainsworth, Hannah C.; R., Ospina M., Sanchez A. Factors associated Saruhan-Direskeneli, Guher; Graham, Deborah S. Cunninghame; Kelly, with mortality in patients with autoimmune Hernandez-Rodriguez, Jose; Cid, Maria C.; Jennifer A.; Comeau, Mary E.; Marion, Miranda diseases admitted to the intensive care unit Solans, Roser; Castaneda, Santos; Vaglio, C.; Howard, Timothy D.; Ramos, Paula S.; in Bogota, Colombia. FRONTIERS IN Augusto; Direskeneli, Haner; Merkel, Peter A.; Croker, Jennifer A.; Morris, David L.; Sandling, IMMUNOLOGY. 8:337. I.F.: 6.429 Boiardi, Luigi; Salvarani, Carlo; Gonzalez-Gay, Johanna K.; (…) Timothy J. Transancestral Miguel A.; Martin, Javier; Sawalha, Amr mapping and genetic load in systemic 15. Brito-Zerón P, Kostov B, Fraile G, H.;Spanish GCA Study Grp; Italian GCA Study lupus erythematosus. NATURE Caravia-Durán D, Maure B, Rascón FJ, Grp; Turkish Takayasu Study Grp; Vasculitis COMMUNICATIONS. 8:16021. I.F.: 12.124 Zamora M, Casanovas A, Lopez-Dupla M, Clinical Res Consortium. Analysis of the Ripoll M, Pinilla B, Fonseca E, Akasbi M, de la common genetic component of 9. Carmona FD, Vaglio A, Mackie SL, Red G, Duarte-Millán MA, Fanlo P, large-vessel vasculitides through a Hernández-Rodríguez J, Monach PA, Guisado-Vasco P, Pérez-Alvarez R, Chamorro meta-Immunochip strategy. SCIENTIFIC Castañeda S, Solans R, Morado IC, Narváez J, AJ, Morcillo C, Jiménez-Heredia I, REPORTS. 7(43953). I.F.: 4.259 Ramentol-Sintas M,...... , Martín JA. Sánchez-Berná I, López-Guillermo A, Genome-wide Association Study Ramos-Casals M, SS Study Group 20. García-Carrasco M., Mendoza-Pinto C., Identifies Risk Alleles in Plasminogen and GEAS-SEMI. Characterization and risk León-Vázquez M., Méndez-Martínez S.,

57 AREA 1 BIOLOGICAL AGGRESSION AND RESPONSE MECHANISMS

Etchegaray-Morales I., Montiel-Jarquín Á., sclerosis from 1990 to 2009 from the 31. Delas B., Julio G., Fernández-Vega Á., Enriquez-Guerra M., Muñóz-Guarneros M., nationwide Spanish Scleroderma Registry Casaroli-Marano R., Nadal J. Reduction of Gálvez-Romero J., Soto-Santillán P., Cervera (RESCLE). CLINICAL AND EXPERIMENTAL foveal bulges and other anatomical R.Incidence of Vertebral Fractures in RHEUMATOLOGY. 35(4):S40-S47. I.F.: 2.634 changes in fellow eyes of patients with Women with Systemic Lupus unilateral idiopathic macular hole without Erythematosus After 8 Years of Follow-Up. 26. Fernández Morales A., Iniesta N., vitreomacular pathologic changes. CALCIFIED TISSUE INTERNATIONAL. Fernández-Codina A., Vaz de Cunha J., Pérez GRAEFES ARCHIVE FOR CLINICAL AND 101(3):291-299. I.F.: 3.124 Romero T., Hurtado García R., Simeón-Aznar EXPERIMENTAL OPHTHALMOLOGY. C., Fonollosa V., Cervera R., Espinosa G. 255(11):2141-2146. I.F.: 2.349 21. Sisó-Almirall A., Kostov B., González M., Cardiac tamponade and severe pericardial Salami D., Jiménez A., Soleâ R., Saumell C., effusion in systemic sclerosis: report of 32. Méndez-Martínez S., García-Carrasco M., Bach L., Martí M., Paz L., Riera R., Alonso V., nine patients and review of the literature. Cedillo-Ramírez M., Mendoza-Pinto C., Acar-Denizli N., Almacellas M., Ramos-Casals INTERNATIONAL JOURNAL OF RHEUMATIC Etchegaray-Morales I., Gil-Juárez C., M., Àreu J. Abdominal aortic aneurysm DISEASES. 20(10):1582-1592. I.F.: 2.624 Montiel-Jarquín Á., Taboada-Cole A., screening program using hand-held Jiménez-Herrera E., Muñóz-Guarneros M., ultrasound in primary healthcare. PLOS 27. Choi MY, Clarke AE, St Pierre Y, Hanly JG, Cervera R. Genital Mycoplasma infection ONE. 12(4):e0176877. I.F.: 2.806 Urowitz MB, Romero-Diaz J, Gordon C, Bae among Mexican women with systemic SC, Bernatsky S, Wallace DJ, Merrill JT, lupus erythematosus. INTERNATIONAL 22. Sentís A; Diekmann F; Llobell A; de Moner Isenberg DA, Rahman A, Ginzler EM, Petri M, JOURNAL OF GYNECOLOGY AND N; Espinosa G; Yague J; Campistol J; Mirapeix Bruce IN, Dooley MA, Fortin P, Gladman DD, OBSTETRICS. 138(1):17-22. I.F.: 2.174 E; Juan M. Kinetic analysis of changes in Sanchez-Guerrero J, Steinsson K, T- and B-lymphocytes after anti-CD20 Ramsey-Goldman R, Khamashta MA, Aranow 33. Pato E., Martin-Martinez M., Castelló A., treatment in renal pathology. C, Alarcón GS, Manzi S, Nived O, Zoma AA, Méndez-Fernandez R., Muñoz-Fernández S., IMMUNOBIOLOGY. 222(4):620-630. I.F.: 2.720 van Vollenhoven RF, Ramos-Casals M, Cordero-Coma M., Martinez-Costa L., Valls E., Ruiz-Irastorza G, Lim SS, Kalunian KC, Inanc Reyes M., Francisco F., Esteban M., Fonollosa 23. Agmon-Levin N., Dagan A., Peri Y., Anaya M, Kamen DL, Peschken CA, Jacobsen S, A., Sanchez-Alonso F., Fernández-Espartero J., Selmi C., Tincani A., Bizzaro N., Stojanovich Askanase A, Buyon J, Mahler M, Fritzler MJ. C., Diaz-Valle T., Carrasco J., Beltran-Catalán L., Damoiseaux J., Tervaert J., Mosca M., The prevalence and determinants of E., Hernández-Garfella M., Hernández M., Cervera R., Shoenfeld Y. The interaction anti-DFS70 autoantibodies in an Pelegrin L., Blanco R., Diaz-Valle D. between anti-Ro/SSA and anti-La/SSB international inception cohort of systemic Development of an activity disease score autoantibodies and anti-infectious lupus erythematosus patients. LUPUS. in patients with uveitis (UVEDAI). antibodies in a wide spectrum of 26(10):1051-1059. I.F.: 2.454 RHEUMATOLOGY INTERNATIONAL. auto-immune diseases: Another angle of 37(4):647-656. I.F.: 1.824 the autoimmune mosaic. CLINICAL AND 28. Amengual O., Forastiero R., EXPERIMENTAL RHEUMATOLOGY. Sugiura-Ogasawara M., Otomo K., Oku K., 34. Montori-Palacín E, Prieto-González S, 35(6):929-935. I.F.: 2.634 Favas C., Delgado Alves J., Žigon P., Ambrožič Carrasco-Miserachs I, Altes-Capella J, A., Tomšič M., Ruiz-Arruza I., Ruiz-Irastorza G., Compta Y, López-Soto A, Bosch X. Quick 24. Arandia N; Simeón-Aznar C; del Castillo A; Bertolaccini M., Norman G., Shums Z., Arai J., outpatient diagnosis in small district or Argüelles D; Rubio-Rivas M; Martinez L; Murashima A., Tebo A., Gerosa M., Meroni P., general tertiary hospitals: A comparative Hernandez F; Comet L; Arberas M; Rodriguez-Pintó I., Cervera R., Swadzba J., observational study. MEDICINE Ortego-Centeno N; Freire M; Alfonso B; Hitos Musial J., Atsumi T. Evaluation of (BALTIMORE). 96(22):e6886. I.F.: 1.804 J; Blanco J; Parra J; Rodríguez-Carballeira M; phosphatidylserine-dependent Ballvé A; Fernandez A; Salas X; Vuelta A; antiprothrombin antibody testing for the 35. Gómez-Gómez A, Loza E, Rosario MP, Munoz M; Plá V; Espinosa G; RESCLE diagnosis of antiphospholipid syndrome: Espinosa G, García Ruiz de Morales JM, investigators, Autoimmune Diseases Study Results of an international multicentre Herreras JM, Muñoz-Fernández S, Group (GEAS). Inﬂuence of antibody proﬁle study. LUPUS. 26(3):266-276. I.F.: 2.454 Cordero-Coma M. Efficacy and safety of in clinical features and prognosis in a immunomodulatory drugs in patients with cohort of Spanish patients with systemic 29. Sarbu N, Toledano P, Calvo A, Roura E, anterior uveitis. A systematic literature sclerosis. CLINICAL AND EXPERIMENTAL Sarbu MI, Espinosa G, Lladó X, Cervera R, review. MEDICINE (BALTIMORE). RHEUMATOLOGY. 35(4):98-105. I.F.: 2.634 Bargalló N. Advanced MRI techniques: 96: e8045. I.F.: 1.804 biomarkers in neuropsychiatric lupus. 25. Rubio-Rivas, M.; Simeon-Aznar, C. P.; LUPUS. 26(5):510-516. I.F.: 2.454 Velasco, C.; Mari-Alfonso, B.; Espinosa, G.; Review / I.F.: 82.542 Corbella, X.; Colunga-Arguelles, D.; 30. Silva L, Arantes T, Casaroli-Marano R, Vaz Egurbide-Arberas, M. V.; Ortego-Centeno, N.; T, Belfort R, Muccioli C. Quality of Life and 1. Ramos-Casals M., Zignego A., Ferri C., Vargas-Hitos, J. A.; Freire, M.; Rios-Blanco, J. J.; Psychological Aspects in Patients with Brito-Zerón P., Retamozo S., Casato M., Trapiella-Martinez, L.; Rodriguez-Carballeira, Visual Impairment Secondary to Uveitis: A Lamprecht P., Mangia A., Saadoun D., Tzioufas M.; Fonollosa-Pla, V.;RESCLE Investigators Clinical Study in a Tertiary Care Hospital in A., Younossi Z., Cacoub P., International Study Autoimmune. Changes in the pattern of Brazil. OCULAR IMMUNOLOGY AND Group of Extrahepatic Manifestations related death of 987 patients with systemic INFLAMMATION. 11:1-9. I.F.: 2.453 to HCV (ISG-EHCV). Evidence-based

58 SYSTEMIC AUTOIMMUNE DISEASES 1.2

recommendations on the management of 16(11):1255-1271. I.F.: 3.439 2. Castellanos-Moreira R., Rodríguez-García extrahepatic manifestations of chronic S., López-Sobrino T., Capdevila A., hepatitis C virus infection. JOURNAL OF 9. Retamozo S., Brito-Zerón P., Quartuccio L., Prieto-González S., Espinosa G. Successful HEPATOLOGY. 66(6):1282-1299. I.F.: 12.486 De Vita S., Ramos-Casals M.. Introducing Extracorporeal Membrane Oxygenation in treat-to-target strategies of autoimmune a Patient With Fulminant Lupus 2. Dahan S., Segal Y., Watad A., Azrielant S., extrahepatic manifestations of chronic Myocarditis. REVISTA ESPAÑOLA DE Shemer A., Maymon D., Stroev Y., Sobolevskaya P., hepatitis C virus infection. EXPERT REVIEW CARDIOLOGIA. 70(11):1013-1014. I.F.: 4.485 Korneva E., Blank M., Gilburd B., Shovman O., Amital OF CLINICAL PHARMACOLOGY. H., Ehrenfeld M., Tanay A., Kivity S., Pras E., 10(10):1085-1101. I.F.: 2.932 3. Carbajal S., Zamora-Martínez C., Chapman J., Damoiseaux J., Cervera R., Putterman Prieto-González S., Quintana L., Espinosa G., C., Shapiro I., Mouthon L., Perricone R., Bizzaro N., 10. Cervera R. Antiphospholipid syndrome. Cervera R. Systemic lupus erythematous Koren O., Riemekasten G., Chereshnev V., Mazurov THROMBOSIS RESEARCH. 151:S43-S47. exacerbation following cessation of V., Goloviznin M., Gurevich V., Churilov L., I.F.: 2.650 belimumab treatment: comments on the Shoenfeld Y. Novelties in the field of article by Furer et al. SCANDINAVIAN autoimmunity – 1st Saint Petersburg 11. Dapena M; Rivera A; Sopeña B; Vilella C; JOURNAL OF RHEUMATOLOGY. congress of autoimmunity, the bridge Guillén-Del Castillo A; Argüelles D; Rubio J; 46(3):250-251. I.F.: 2.667 between east and west. AUTOIMMUNITY Rivas M; Martinez L; Parra J; Carballeira M; REVIEWS. 16(12):1175-1184. I.F.: 8.961 Arandia N; Hernandez F; Arberas M; Comet L; 4. Espinosa G, Coloma Bazán E, Cervera R. Hitos J; Blanco J; Ballvé A; Salas X; Vuelta A; Cessation of oral anticoagulants in 3. Doria A., Cervera R., Gatto M., Chehab G., Munoz M; Plá V; Aznar C; Boldova R; Callejas antiphospholipid syndrome. LUPUS. Schneider M. The new targeted therapy in Moraga E; Callejas Rubio J; Castillo M; 26(12):1347-1348. I.F.: 2.454 systemic lupus erythematosus: Is the glass Colunga D; Egurbide M; Escobedo J; Espinosa half-full or half-empty? AUTOIMMUNITY G; Fonollosa V; Freire M; García Hernández F; REVIEWS. 16(11):1119-1124. I.F.: 8.961 Guillén del Castillo A; Iniesta N; Madroñero A; Editorial / I.F.: 1.125 Mari B; Marin A; Moreno Higueras M. 4. Sciascia S., Coloma-Bazán E., Radin M., Clinical and epidemiological differences 1. Ricard Cervera Segura. La investigación Bertolaccini M., López-Pedrera C., Espinosa between men and women with systemic sobre tratamientos biológicos en el lupus G., Meroni P., Cervera R., Cuadrado M. Can we sclerosis: A study in a Spanish systemic eritematoso sistémico. MEDICINA CLINICA. withdraw anticoagulation in patients with sclerosis cohort and literature review. 148(2):67-68. I.F.: 1.125 antiphospholipid syndrome after CLINICAL AND EXPERIMENTAL seroconvertion? AUTOIMMUNITY RHEUMATOLOGY. 35(106):89-97. I.F.: 2.634 REVIEWS. 16(11):1109-1114. I.F.: 8.961 Case Reports / I.F.: 8.316 12. Watad A., Quaresma M., Brown S., Cohen 5. Garcia-Carrasco M., Jiménez-Herrera E., Tervaert J., Rodríguez-Pint I., Cervera R., 1. Ripoll E, Prieto-González S, Balagué O, Gálvez-Romero J., de Lara L., Mendoza-Pinto Perricone C., Shoenfeld Y. Marco-Hernández J, Miró JM, Darnell A, Cid C., Etchegaray-Morales I., Munguía-Realpozo Autoimmune/inflammatory syndrome MC, Hernández-Rodríguez J. Occlusive P., Ruíz-Argüelles A., Jose R., induced by adjuvants (Shoenfeld's vasculopathy in human immunodeficiency Vera-Recabarren M., Cervera R. Vitamin D syndrome) - An update. LUPUS. virus (HIV)-associated vasculitis: unusual and Sjögren syndrome. AUTOIMMUNITY 26(7):675-681. I.F.: 2.454 clinical and imaging course. CLINICAL AND REVIEWS. 16(6):587-593. I.F.: 8.961 EXPERIMENTAL RHEUMATOLOGY. 13. Gómez-Gómez A., Loza E., Rosario M., 103(1):185-188. I.F.: 2.634 6. Samson M, Corbera-Bellalta M, Audia S, Espinosa G., Morales J., Herreras J., Planas-Rigol E, Martin L, Cid MC, Bonnotte B. Munõz-Fernández S., Cordero-Coma M. Efficacy 2. Fervienza A., Bodro M., Castro P., Recent advances in our understanding of and safety of immunomodulatory drugs in Hernández S., Teixidó I., Espinosa G., Cervera giant cell arteritis pathogenesis. patients with anterior uveitis. MEDICINE R. Brain abscess due to Listeria AUTOIMMUNITY REVIEWS. 16(8):833-844. (UNITED STATES). 96(42):e8045. I.F.: 1.803 monocytogenes after HELLP syndrome in I.F.: 8.961 a patient with antiphospholipid syndrome. 14. Espinosa G, Rodríguez-Pintó I, Cervera R. LUPUS. 26(9):1002-1004. I.F.: 2.454 7. Pons-Estel G., Andreoli L., Scanzi F., Cervera Catastrophic antiphospholipid syndrome: R., Tincani A.. The antiphospholipid an update. PANMINERVA MEDICA. 3. Falgàs N., Borrego S., Llull L., Espinosa G., syndrome in patients with systemic lupus 59(3):254-268. I.F.: 1.698 López-Rueda A., Blasco J., Cervera A. erythematosus. JOURNAL OF Recurrent dural arteriovenous fistulas in a AUTOIMMUNITY. 76:10-20. I.F.: 7.641 patient with Behçet's disease. Letters / I.F.: 21.461 NEUROLOGIA. 32(9):623-626. I.F.: 2.103 8. Pérez-De-Lis M, Retamozo S, Flores-Chávez A, Kostov B, Perez-Alvarez R, Brito-Zerón P, 1. Aya F, Ruiz-Esquide V, Viladot M, Font C, 4. Pujol-López M, Prieto-González S, Prat- Ramos-Casals M. Autoimmune diseases Prieto-González S, Prat A, Arance A. González S, Hernández-Rodríguez J. induced by biological agents. A review of Vasculitic neuropathy induced by [Eosinophilic granulomatosis with 12,731 cases (BIOGEAS Registry). pembrolizumab. ANNALS OF ONCOLOGY. polyangitis (Churg-Strauss) and severe EXPERT OPINION ON DRUG SAFETY. 28(2):433-434. I.F.: 11.855 pericardial effusion].

59 AREA 1 BIOLOGICAL AGGRESSION AND RESPONSE MECHANISMS

MEDICINA CLINICA. 149(9):e53. I.F.: 1.125 autoimmune rheumatic diseases Sjögren's Syndrome Criteria Working (rheumatoid arthritis, spondyloarthritides, Group. 2016 American College of systemic sclerosis, systemic lupus Rheumatology/European League Clinical Guidelines / I.F.: 44.669 erythematosus, antiphospholipid syndrome Against Rheumatism Classification and Sjogren's syndrome)?: The unmet needs Criteria for Primary Sjögren's 1. Van Vollenhoven R., Voskuyl A., Bertsias G., and the clinical grey zone in autoimmune Syndrome: A Consensus and Aranow C., Aringer M., Arnaud L., Askanase A., disease management. AUTOIMMUNITY Data-Driven Methodology Involving Balážová P., Bonfa E., Bootsma H., Boumpas REVIEWS. 16(9):911-924. I.F.: 8.961 Three International Patient Cohorts. D., Bruce I., Cervera R., Clarke A., Coney C., 76: 9-16. ANNALS OF THE RHEUMATIC Costedoat-Chalumeau N., Czirják L., Derksen 4. Zignego A., Ramos-Casals M., Ferri C., DISEASES. I.F.: 12.811 R., Doria A., Dörner T., Fischer-Betz R., Saadoun D., Arcaini L., Roccatello D., Fritsch-Stork R., Gordon C., Graninger W., Antonelli A., Desbois A., Comarmond C., 4. Steinberg WM, Buse JB, Ghorbani MLM, Györi N., Houssiau F., Isenberg D., Jacobsen S., Gragnani L., Casato M., Lamprecht P., Mangia Ørsted DD, Nauck MA; LEADER Steering Jayne D., Kuhn A., Le Guern V., Lerstrøm K., A., Tzioufas A., Younossi Z., Cacoub P. Committee; LEADER Trial Investigators. Levy R., MacHado-Ribeiro F., Mariette X., International therapeutic guidelines for Amylase, lipase, and acute pancreatitis Missaykeh J., Morand E., Mosca M., Inanc M., patients with HCV-related extrahepatic in people with type 2 diabetes treated Navarra S., Van Vollenhoven R., Voskuyl A., disorders. A multidisciplinary expert with liraglutide: results from the LEADER Bertsias G., Aranow C., Aringer M., Arnaud L., statement. AUTOIMMUNITY REVIEWS. randomized trial. DIABETES CARE. 40: Askanase A., Balážová P., Bonfa E., Bootsma 16(5):523-541. I.F.: 8.961 966-972. I.F.: 11.857 H., Boumpas D., Bruce I., Cervera R., Clarke A., Coney C., Costedoat-Chalumeau N., Czirják L., 5. Gerard Espinosa Garriga, Santiago 5. Shiboski C., Shiboski S., Seror R., Criswell Derksen R. A framework for remission in Muñoz Fernández, José María García Ruiz L., Labetoulle M., Lietman T., Rasmussen A., SLE: Consensus findings from a large de Morales, José María Herreras Scofield H., Vitali C., Bowman S., Mariette X., international task force on definitions of Cantalapiedra, Miguel Cordero. International Sjögren's Syndrome Criteria remission in SLE (DORIS). ANNALS OF THE Documento de recomendaciones de Working Group. 2016 American College of RHEUMATIC DISEASES. 76(3):554-561. tratamiento de la uveítis anterior no Rheumatology/European League Against I.F.: 12.811 infecciosa. MEDICINA CLINICA. Rheumatism Classification Criteria for 149(12):552-552. I.F.: 1.125 Primary Sjögren's Syndrome: A 2. Andreoli L., Bertsias G., Agmon-Levin N., Consensus and Data-Driven Methodology Brown S., Cervera R., Costedoat-Chalumeau Involving Three International Patient N., Doria A., Fischer-Betz R., Forger F., Consortium Publications / I.F.: 135.092 Cohorts. ARTHRITIS AND Moraes-Fontes M., Khamashta M., King J., RHEUMATOLOGY. 69(1):35-45. I.F.: 6.918 Lojacono A., Marchiori F., Meroni P., Mosca M., 1. Mann, Johannes F. E.; Orsted, David D.; Motta M., Ostensen M., Pamfil C., Raio L., Brown-Frandsen, Kirstine; Marso, Steven P.; 6. Clowse, Megan E. B.; Wallace, Daniel J.; Schneider M., Svenungsson E., Tektonidou M., Poulter, Neil R.; Rasmussen, Soren; Tornoe, Furie, Richard A.; Petri, Michelle A.; Pike, Yavuz S., Boumpas D., Tincani A. EULAR Karen; Zinman, Bernard; Buse, John Marilyn C.; Leszczynski, Piotr; Neuwelt, C. recommendations for women's health and B.;LEADER Steering Comm Investigators. Michael; Hobbs, Kathryn; Keiserman, Mauro; the management of family planning, assisted Liraglutide and Renal Outcomes in Type Duca, Liliana; Kalunian, Kenneth C.; Galateanu, reproduction, pregnancy and menopause in 2 Diabetes. NEW ENGLAND JOURNAL OF Catrinel; Bongardt, Sabine; Stach, Christian; patients with systemic lupus erythematosus MEDICINE. 377(9):839-848. I.F.: 72.406 Beaudot, Carolyn; Kilgallen, Brian; Gordon, and/or antiphospholipid syndrome. ANNALS Caroline;EMBODY Investigator Grp. Efficacy OF THE RHEUMATIC DISEASES. 2. Fisher B., Jonsson R., Daniels T., and Safety of Epratuzumab in Moderately 76(3):476-485. I.F.: 12.811 Bombardieri M., Brown R., Morgan P., to Severely Active Systemic Lupus Bombardieri S., Ng W., Tzioufas A., Vitali Erythematosus Results From Two Phase 3. Giacomelli R., Afeltra A., Alunno A., Baldini C., C., Shirlaw P., Haacke E., Costa S., Bootsma III Randomized, Double-Blind, Bartoloni-Bocci E., Berardicurti O., Carubbi F., H., Devauchelle-Pensec V., Radstake T., Placebo-Controlled Trials. ARTHRITIS AND Cauli A., Cervera R., Ciccia F., Cipriani P., Conti Mariette X., Richards A., Stack R., Bowman RHEUMATOLOGY. 69(2):362-375. I.F.: 6.918 F., De Vita S., Di Benedetto P., Doria A., Drosos S., Barone F., Sjögren's histopathology A., Favalli E., Gandolfo S., Gatto M., Grembiale workshop group (appendix) from 7. Inciarte, A.; Leal, L.; Gonzalez, E.; Leon, A.; R., Liakouli V., Lories R., Lubrano E., Lunardi C., ESSENTIAL (EULAR Sjögren's syndrome Lucero, C.; Mallolas, J.; Torres, B.; Laguno, M.; Margiotta D., Massaro L., Meroni P., Minniti A., study group). Standardisation of labial Rojas, J.; Martinez-Rebollar, M.; Navarini L., Pendolino M., Perosa F., Pers J., salivary gland histopathology in clinical Gonzalez-Cordon, A.; Cruceta, A.; Arnaiz, J. A.; Prete M., Priori R., Puppo F., Quartuccio L., trials in primary Sjögren's syndrome. Gatell, J. M.; Garcia, F.;STRIBPEP Study Grp. Ruffatti A., Ruscitti P., Russo B., Sarzi-Puttini P., ANNALS OF THE RHEUMATIC DISEASES. Tenofovir disoproxil fumarate/ Giacomelli R., Afeltra A., Alunno A., Baldini C., 76(7):1161-1168. I.F.: 12.811 emtricitabine plus ritonavir-boosted Bartoloni-Bocci E., Berardicurti O., Carubbi F., lopinavir or cobicistat-boosted elvitegravir Cauli A., Cervera R., Ciccia F., Cipriani P. 3. Shiboski C., Shiboski S., Seror R., as a single-tablet regimen for HIV International consensus: What else can we Criswell L., Labetoulle M., Lietman T., post-exposure. JOURNAL OF do to improve diagnosis and therapeutic Rasmussen A., Scofield H., Vitali C., ANTIMICROBIAL CHEMOTHERAPY. strategies in patients affected by Bowman S., Mariette X., International 72(10):2857-2861. I.F.: 5.071

60 SYSTEMIC AUTOIMMUNE DISEASES 1.2

8. Aydin S., Direskeneli H., Merkel P., Sponsored by: Ministerio de Economía y International Delphi on Disease Activity Competitividad. SAF 2014-57708-R Assessment in Large-vessel Vasculitis. Duration: 01/01/2015-30/06/2018 Assessment of disease activity in large-vessel vasculitis: Results of an Cid MC. Dilatació d'aorta ascendent i international delphi exercise. JOURNAL OF aneurismes coronaris en pacients amb RHEUMATOLOGY. 44(12):1928-1932. I.F.: 3.150 vasculitis sistèmiques (arteritis de cèlules gegants i malaltia de Kawasaki). Rol de la 9. Bossini-Castillo L, Campillo-Davó D, via HIF en remodelatge/inflamació López-Isac E, Carmona FD, Simeon CP, vascular. Carreira P, Callejas-Rubio JL, Castellví I, Sponsored by: Fundació la Marató de TV3. Fernández-Nebro A, Rodríguez-Rodríguez L, 20150730 Rubio-Rivas M, García-Hernández FJ, Duration: 10/05/2016-09/05/2019 Madroñero AB, Beretta L, Santaniello A, Lunardi C, Airó P, Hoffmann-Vold AM, Kreuter EspÍgol G. Vasculitis de pequeño vaso A, Riemekasten G, Witte T, Hunzelmann N, rodeando a una arteria temporal Vonk MC, Voskuyl AE, de Vries-Bouwstra J, preservada: significado clínico y búsqueda Shiels P, Herrick A, Worthington J, Radstake de biomarcadores de utilidad diagnóstica. TRDJ, Martin J, NULL Spanish Scleroderma Sponsored by: Instituto de Salud Carlos III Group. An MIF Promoter Polymorphism Is (ISCIII). PI15/00092 Associated with Susceptibility to Duration: 01/01/2016-31/12/2018 Pulmonary Arterial Hypertension in Diffuse Cutaneous Systemic Sclerosis. JOURNAL OF RHEUMATOLOGY. DOCTORAL THESES 44(10):1453-1457. I.F.: 3.150 Cervera R, Espinosa G: Afectación neurológica en el lupus eritematoso GRANTS FOR RESEARCH IN PROGRESS sistémico: Alteraciones en la neuroimagen y caracterización de la afectación del Casaroli-Marano R. Cell Therapy in ocular sistema nervioso periférico. surface: Role and biosubstitutive PhD student: Pilar Toledano applications of human adult mesenchymal stem cells (ADS and BMDS) for corneal Casaroli-Marano R: Terapia celular para la regeneration. reparación y regeneración de la superficie Sponsored by: Fundació La Marató de TV3. ocular: potencial terapéutico de las células 120630 progenitoras mesenquimales. Duration: 21/01/2013-20/01/2017 PhD stdent: Nuria Nieto Nicolau

Casaroli-Marano R. Potencial terapéutico de las células progenitoras pluripotentes inducidas (IPSC) y las células progenitoras mesenquimales del estroma de la médula ósea (MSCs) nestina positivas para la regeneración de la superﬁcie ocular. Sponsored by: Instituto de Salud Carlos III (ISCIII). PI14/00196 Duration: 01/01/2015-31/12/2017

Cervera R. Molecular Reclassiﬁcation to Find Clinically Useful Biomarkers for Systemic Autoimmune Diseases. Sponsored by: Fundación Progreso y Salud. 115565 Duration: 01/02/2014-31/01/2019

Cid MC. Crosstalk between lymphocytes and their microenvironment in chronic inﬂammatory diseases and lymphoproliferative disorders as a target for new therapeutic intervention.

61 AREA 1 BIOLOGICAL AGGRESSION AND RESPONSE MECHANISMS

Infectious diseases 1.3 and AIDS

RESEARCHERS Mireia Arnedo (IDIBAPS) LOCATION José Luis Blanco (HCB) CELLEX building 4a Marta Bodro (HCB) Ana del Río (HCB) Felipe García (HCB) Carolina García (HCB)

WEB Josep Mª Gatell (HCB) www.idibaps.org/aidsresearch Montserrat Laguno (HCB) Agata Raquel León (IDIBAPS) Esteban Martínez (HCB) TEAM LEADER Josep M. Miró (HCB) José Antonio Martínez (HCB) Josep Mensa (HCB) T. 93 227 54 00 (Ext.: 2765) Montserrat Plana (IDIBAPS) [email protected] KEYWORDS HIV POST-DOCTORAL RESEARCHERS 1. Juan Ambrosioni (HCB) 2. AIDS Alberto Crespo (FCRB) 3. Endocarditis GROUP LEADERS Josep Mallolas (HCB) David Fuster (HCB) 4. Nosocomial infections T. 93 227 54 00 (Ext.: 3312) Cristina García (FCRB) 5. Immune suppressed patients [email protected] Laura Linares (IDIBAPS) Jaume Llopis (UB) Josep M. Miró (HCB) Christian Manzardo (FCRB) T. 93 227 54 00 (Ext.: 2765) María Martínez (HCB) [email protected] Laura Morata (FCRB) Juan Manuel Pericas (FCRB) Original publications Asunción Moreno (HCB) Eduardo Quintana (HCB) from 2015 to 2017 T. 93 227 54 00 (Ext.: 2657) Elena Sandoval (HCB) [email protected] Jose M. Tolosana (HCB) YEAR I.F. TOTAL Q1 Q2 Berta Torres (FCRB) 2015 421.94 69 54 5 Alex Soriano (HCB) Olívia Tort (IDIBAPS) Barbara Vidal (HCB) 2016 308.79 64 45 9 T. 93 227 54 00 (Ext.: 5708) [email protected] 2017 344.32 67 48 12

TEAM INVOLVED IN RIS AGAUR_SGR14 Josep M. Miró

TEAM

62 INFECTIOUS DISEASES AND AIDS 1.3

PRE-DOCTORAL RESEARCHERS - Immuno-pathogenesis of HIV infection RESEARCH GROUP Manel Almela (HCB) and development of preventive and AIDS AND HIV INFECTION Celia Cardozo (HCB) therapeutic vaccines Yoshiki Eto (FCRB) - Primary HIV infection: eradication and Csaba Feher (IDIBAPS) functional cure strategies Javier Garcia-Gonzalez (FCRB) - Opportunistic diseases: tuberculosis, Ana González (FCRB) human papillomavirus, anal cancer Marta Hernández (FCRB) - Solid organ transplantation in HIV-infec Alexy Junior Inciarte (IDIBAPS) ted patients Lorna Anabel Leal (IDIBAPS) - Epidemiological studies based on cohorts GROUP LEADER Pedro Puerta (FCRB) (PISCIS, ART-CC, COHERE, EuroSida) Josep Mallolas (HCB) Olga Rodriguez (HCB) - Antiretroviral treatment: Efficacy and Jhon Fredy Rojas (FCRB) safety of new antiretroviral drugs. Studies This group studies the clinical, diagnostic, Maria Fernanda Solano (FCRB) of resistance. New antiretroviral therapeutic and preventive aspects of HIV Adrián Tellez (FCRB) strategies infection and HIV-HCV coinfection.The scientific - Prevention strategies: PEP and PrEP contribution of this line of research is very TECHNICIANS - Incidence and management of non-AIDS competitive and is internationally renowned. This Manuel Enric Bargalló (IDIBAPS) defining events. Aging. STDs group of investigators focuses on exploration of Pilar Callau (FCRB) - HCV and HBV coinfection. Efficacy and the potential for eradicating HIV infection and on Tuixent Escriba (IDIBAPS) safety of new direct-antiviral drugs (DAA) reconstruction of the immune system, including Tania Gonzàlez (IDIBAPS) against HCV the development of preventive and therapeutic Carmen Hurtado (FCRB) - New health-care strategies: telemedicine, vaccines. Dr. Mallolas is currently the Co-director Athina Kilpelainen (FCRB) shared health-care unit with primary care of the HIVACAT project on research therapeutic M. José Maleno (FCRB) and OPAT programs and preventive vaccines against HIV infection. Laia Miralles (IDIBAPS) Cristina Rovira (FCRB) 2. In the general infections field: Montserrat Sola (FCRB) - Clinical and experimental endocarditis. RESEARCH GROUP Cohort studies (ICE, GAMES) (Dr J.M. Miró) ENDOCARDITIS. CARDIOVASCULAR ADMINISTRATIVE STAFF - Infections in solid organ transplant INFECTIONS. EXPERIMENTAL MODEL Carmen Mensa (IDIBAPS) recipients (Dr A. Moreno) Irene Ruiz (IDIBAPS) - Non-nosocomial and nosocomial health-care associated infections and COLLABORATORS community-acquired infections. Carlos Falces (HCB) Evaluation of new antibiotic and Joan Joseph (FCRB) antifungal drugs (Dr A. Soriano) Sonsoles Sánchez-Palomino (FCRB)

Narcís Saubí (IDIBAPS) GROUP LEADER Josep M. Miró (HCB)

STRATEGIC OBJECTIVES

1. In the AIDS ﬁeld: - HIV immune-pathogenesis and HIV vaccines, new antiretrovirals, non-AIDS deﬁning diseases, aging. - New direct-antiviral drugs (DAA) against HCV in HCV/HIV-coinfected patients.

2. In the general infections ﬁeld: - Infective endocarditis, including experi mental endocarditis in animal models. - Infection in solid-organ transplant recipients, including HIV-infected patients. - Nosocomial infections. Antimicrobial use.

MAIN LINES OF RESEARCH

1. In the AIDS ﬁeld: Josep M. Miró - Pharmacogenomics and pharmacoki

netics. GROUP

63 64 projects fundedbytheFIS. (REIPI) andactivelyparticipateinmulticenter Spanish InfectiousDiseasesResearchNetwork Diseases). Itscomponentsaremembersofthe Units (InstitutesofDigestive,RenalandCardiac Immunology, andwiththedifferentTransplant researchers specializedinMicrobiologyand These studieshavebeencarriedoutjointlywith infec an increaseintheprevalenceofbacterial We haveshownthatMBLandTLRcondition (kidney, liver,heartandrenal-pancreas). undergoing transplantationofsolidorgans bacteremia, especiallyMDR,inpatients clinical andevolutivecharacteristicsof In recentyears,thisgrouphasstudiedthe Asunción Moreno GROUP LEADER TRANSPLANT RECIPIENTS INFECTIONS INSOLID-ORGAN RESEARCH GROUP telavancin, ceftaroline,andothers. or newantibioticssuchasdaptomycin, combinations (phosphomycinandimipenem), evaluated theactivityofnewantibiotic resistant Staphylococcusaureus(GISA)have MRSA andglyc experimental modelofendocarditisdueto respectively). Studiesusingthe Staphylococcus aureus(MSSAandMRSA, methicillin-sensitive and-resistant endocarditis producedby (ICE) thathaverevealedanincreasein of local,nationalorinternationalcohorts endocarditis. Thisisdonebasedonstudies therapeutic aspectsofinfectious clinical, diagnostic,preventiveand This groupstudiestheepidemiological, AREA 1 tion andCMVdisease.

BIOLOGICAL AGGRESSION ANDRESPONSEMECHANISMS opeptide intermediate- (HCB)

GROUP Alex Soriano STUDY GROUP NOSOCOMIAL INFECTION RESEARCH GROUP tuberculosis infection, comparedwithan C-Tb skintestto diagnoseMycobacterium Working Group. L., OrcauA.,AndersenP.,CayláJ.,TESEC Millet J.,MorenoA.,CobosN.,Miró Roldan Martínez-Lacasa X.,TuñezM.,Fernández V., Rodrigo-Pendás J.,Noguera-Julian A., Souza-Galvão M.,SánchezF., Kromann I.,PenasA.,AnibarroL.,de S., VillateJ.,BorregaardB.,Martinez 1. Originals / PUBLICATIONS and infectionsrelatedtoorthopedicimplants. bacteremia, infectionsinIntensiveCareUnits, in thetreatmentandmanagementof scientiﬁc contributionisparticularlynotorious nosocomial (in-hospital)infections.The therapeutic andpreventiveaspectsof This groupstudiestheclinical,diagnostic, Alex Soriano GROUP LEADER RuhwaldM.,AggerbeckH.,GallardoR.,Hoff I.F.:344.324 (HCB) Safety andefficacyofthe A., RoldanE.,MussiniC.,MiroJ.,KonopnickiD., Peters L.,SpagnuoloV.,AmmassariA.,Antinori Schommers P.,ThorntonA.,BerenguerJ., Sambatakou H.,BonnetF.,SmitC., 3. 167(10):689-697. I.F.:17.202 infection. rifapentine treatmentoflatenttuberculosis observedonce-weeklyisoniazidand directly Borisov A.. Scott N.,ArevaloB.,MiroJ.,VillarinoM.,Weiner J., MartinsonN.,WrightA.,ChenM.,MoroR., 2. 5(4):259-268. I.F.:19.287 THE LANCET.RESPIRATORYMEDICINE. double-blind, randomised,controlledtrial. tuberculin skintest:Aphase3, interferon I., PulidoF.,Guardiola J.,RubioR.,OrtegaE., Quereda C.,Sanz J.,BarrosC.,TuralSantos Galindo M.,MallolasJ.,CrespoTéllez M., Carrero A.,VonWichmannM.,Montero M., 4. 166(1):9-17. I.F.:17.202 ANNALS OFINTERNALMEDICINE. HIV-infected patients:Acohortstudy. and riskfornon-hodgkinlymphomain Chronic hepatitisBandCvirusinfection Research Europe(COHERE)inEuroCoord. of ObservationalHIVEpidemiological Lymphoma projectteamfortheCollaboration Hepatitis CoinfectionandNonHodgkin Fehr J.,CampbellM.,TermoteBucher, Belknap R.,HollandD.,FengP.,MilletJ.,Cayla WangQ.,DeLucaA.,SmithC.,ZangerleR., BerenguerJ.,Rodríguez-Castellano E., ANNALS OFINTERNALMEDICINE. Self-administered versus γ releaseassayandthe

INFECTIOUS DISEASES AND AIDS 1.3

Montes M., Jusdado J., Gaspar G., Esteban H., Davis JS, Palomino J, Neut D, Clark BM, García-Rosado D., Martínez-Monzonis A., de Bellón J., González-García J., GESIDA Gottlieb T, Trebše R, Soriano A, Bahamonde la Torre J., García-Pavía P.. Prognostic HIV/HCV Cohort Study Group. Eradication A, Guío L, Rico A, Salles MJC, Pais MJG, factors of infective endocarditis in patients of hepatitis C virus and non-liver-related Benito N, Riera M, Gómez L, Aboltins CA, on hemodialysis: A case series from a non–acquired immune deficiency Esteban J, Horcajada JP, O'Connell K, Ferrari National Multicenter Registry. syndrome–related events in human M, Skaliczki G, Juan RS, Cobo J, INTERNATIONAL JOURNAL OF immunodeficiency virus/hepatitis C virus Sánchez-Somolinos M, Ramos A, Giannitsioti CARDIOLOGY. 241:295-301. I.F.: 6.189 coinfection. HEPATOLOGY. 66(2):344-356. E, Jover-Sáenz A, Baraia-Etxaburu JM, I.F.: 13.246 Barbero JM, Choong PFM, Asseray N, Ansart 13. Ceccato A, Torres A, Cilloniz C, Amaro R, S, Moal GL, Zimmerli W, Ariza J, Group of Gabarrus A, Polverino E, Prina E, Garcia-Vidal 5. Caniglia EC, Cain LE, Sabin CA, Robins JM, Investigators for Streptococcal Prosthetic C, Muñoz-Conejero E, Mendez C, Cifuentes I, Logan R, Abgrall S, Mugavero MJ, Joint Infection . The Not-So-Good Prognosis Puig de la Bella Casa J, Menendez R, Niederman Hernández-Díaz S, Meyer L, Seng R, Drozd of Streptococcal Periprosthetic Joint MS. Invasive Disease vs Urinary Antigen - DR, Seage GR, Bonnet F, Dabis F, Moore RD, Infection Managed by Implant Retention: Confirmed Pneumococcal Community- Reiss P, van Sighem A, Mathews WC, Del Amo The Results of a Large Multicenter Study. Acquired Pneumonia. CHEST. 151(6):1311-1319. J, Moreno S, Deeks SG, Muga R, Boswell SL, CLINICAL INFECTIOUS DISEASES. I.F.: 6.147 Ferrer E, Eron JJ, Napravnik S, Jose S, Phillips 64(12):1742-1752. I.F.: 8.216 A, Justice AC, Tate JP, Gill J, Pacheco A, 14. Cillóniz C, Torres A, Manzardo C, Gabarrús Veloso VG, Bucher HC, Egger M, Furrer H, 9. Cuervo G, Garcia-Vidal C, Puig-Asensio M, A, Ambrosioni J, Salazar A, García F, Ceccato Porter K, Touloumi G, Crane H, Miro JM, Vena A, Meije Y, Fernández-Ruiz M, A, Mensa J, de la Bella Casa JP, Moreno A, Sterne JA, Costagliola D, Saag M, Hernán MA, González-Barberá E, Blanco-Vidal MJ, Miró JM. Community-Acquired HIV-CAUSAL Collaboration, Centers for AIDS Manzur A, Cardozo C, Gudiol C, Montejo JM, Pneumococcal Pneumonia in Research Network of Integrated Clinical Pemán J, Ayats J, Aguado JM, Muñoz P, Virologically Suppressed HIV-Infected Systems. Comparison of dynamic Marco F, Almirante B, Carratalà J, for Grupo Adult Patients: A Matched Case-Control monitoring strategies based on CD4 cell de Estudio de Micología Médica Study. CHEST. 152(2):295-303. I.F.: 6.147 counts in virally suppressed, HIV-positive (GEMICOMED), Sociedad Española de individuals on combination antiretroviral Enfermedades Infecciosas y Microbiología 15. Gonzalez-Farre B, Martinez D, therapy in high-income countries: a Clínica (SEIMC); and Red Española de Lopez-Guerra M, Xipell M, Monclus E, Rovira J, prospective, observational study. THE Investigación en Patología Infecciosa Garcia F, Lopez-Guillermo A, Colomo L, LANCET HIV. 4(6):E251-E259. I.F.: 9.842 (REIPI). Echinocandins Compared to Campo E, Martinez A. HHV8-related Fluconazole for Candidemia of a Urinary lymphoid proliferations: a broad spectrum 6. Pelegrin, Laura; Hernandez-Rodriguez, Tract Source: A Propensity Score of lesions from reactive lymphoid Jose; Espinosa, Gerard; Llorenc, Victor; Analysis. CLINICAL INFECTIOUS DISEASES. hyperplasia to overt lymphoma. MOD Sainz-de-la-Maza, Maite; Fontenla, Jose R.; 64(10):1374-1379. I.F.: 8.216 PATHOL. 30(5):745-760. I.F.: 5.728 Martinez, Jose A.; Cid, Maria C.; Adan, Alfredo. Characterization of isolated retinal vasculitis. 10. Chêne G., Phillips A., Costagliola D., Sterne 16. Gómara M; Pérez-Pomeda I; Gatell J; Analysis of a cohort from a single center and J., Furrer H., del Amo J., Mocroft A., Monforte Sanchez-Merino V; Yuste E; Haro I. Lipid literature review. AUTOIMMUNITY REVIEWS. A., Dabis F., Miro J., Barger D., Termote M., raft-like liposomes used for targeted 16(3):237-243. I.F.: 8.961 Schwimmer C., Brandt R., Friis-Moller N., Raben delivery of a chimeric entry-inhibitor D., Haerry D., Egger M., Weller I., De Wit S. Cohort peptide with anti-HIV-1 activity. 7. Cordero E, Roca-Oporto C, Bulnes-Ramos profile: Collaboration of Observational HIV NANOMEDICINE: NANOTECHNOLOGY, A, Aydillo T, Gavaldà J, Moreno A, Epidemiological Research Europe BIOLOGY, AND MEDICINE. 13(2):601-609. Torre-Cisneros J, Montejo JM, Fortun J, (COHERE) in EuroCoord. INT J EPIDEMIOL. I.F.: 5.720 Muñoz P, Sabé N, Fariñas MC, Blanes-Julia M, 46(3):797-1120. I.F.: 7.738 López-Medrano F, Suárez-Benjumea A, 17. Boyle, Thomas A.; Uslan, Daniel Z.; Prutkin, Martinez-Atienza J, Rosso-Fernández C, 11. Vitalle, Joana; Zenarruzabeitia, Olatz; Jordan M.; Greenspon, Arnold J.; Baddour, Pérez-Romero P, TRANSGRIPE 1–2 Study Terren, Inigo; Plana, Montserrat; Guardo, Larry M.; Danik, Stephan B.; Tolosana, Jose M.; Group. Two Doses of Inactivated Influenza Alberto C.; Leal, Lorna; Pena, Jose; Garcia, Le, Katherine; Miro, Jose M.; Peacock, James; Vaccine Improve Immune Response in Solid Felipe; Borrego, Francisco;RISVAC-03 Study Sohail, Muhammad R.; Vikram, Holenarasipur Organ Transplant Recipients: Results of Grp. Monocytes Phenotype and Cytokine R.; Carrillo, Roger G. Reimplantation and TRANSGRIPE 1-2, a Randomized Controlled Production in Human Immunodeficiency Repeat Infection After Cardiac- Clinical Trial. CLINICAL INFECTIOUS Virus-1 Infected Patients Receiving a Implantable Electronic Device Infections DISEASES. 64(7):829-838. I.F.: 8.216 Modified Vaccinia Ankara-Based HIV-1 Experience From the MEDIC (Multicenter Vaccine: Relationship to CD300 Molecules Electrophysiologic Device Infection 8. Lora-Tamayo J, Senneville É, Ribera A, Expression. FRONTIERS IN IMMUNOLOGY. Cohort) Database. CIRCULATION. Bernard L, Dupon M, Zeller V, Li HK, Arvieux C, 8(836). I.F.: 6.429 ARRHYTHMIA AND ELECTROPHYSIOLOGY. Clauss M, Uçkay I, Vigante D, Ferry T, Iribarren 10(3):e004822. I.F.: 5.410 JA, Peel TN, Sendi P, Miksic NG, 12. Ramos-Martínez A., Roque F., Fariñas M., Rodríguez-Pardo D, Del Toro MD, Muñoz P., Verde E., Cuerpo G., de Alarcón A., 18. Garcia-Vidal C., Sanchez-Rodriguez I., Fernández-Sampedro M, Dapunt U, Huotari K, Lepe J., Miró J., Plata A., Goenaga M., Simonetti A., Burgos J., Viasus D., Martin M.,

65 AREA 1 BIOLOGICAL AGGRESSION AND RESPONSE MECHANISMS

Falco V., Carratalà J.. Levofloxacin versus CHEMOTHERAPY. 72(8):2290-2296. I.F.: 5.071 Gonzalez-Cordon A., Blanco J., Blanch J., Marcos azithromycin for treating legionella M., Lonca M., Martinez-Rebollar M., Laguno M., pneumonia: A propensity score analysis. 23. Nicolás D, Ambrosioni J, Sued O, Brunet Tricas A., Rodriguez A., Mallolas J., Gatell J., Martinez CLINICAL MICROBIOLOGY AND INFECTION. M, López-Diéguez M, Manzardo C, Agüero F, E. Tolerability of integrase inhibitors in a 23(9):653-658. I.F.: 5.292 Tuset M, Plana M, Guardo AC, Mosquera MM, real-life setting. JOURNAL OF Muñoz-Fernández MÁ, Caballero M, Marcos ANTIMICROBIAL CHEMOTHERAPY. 19. Pericàs JM, Messina JA, Garcia- de-la- MÁ, Gatell JM, de Lazzari E, Gallart T, Miró JM. 72(6):1752-1759. I.F.: 5.071 Mària C, Park L, Sharma-Kuinkel BK, Marco F, Cyclosporine A in addition to standard ART Wray D, Kanafani ZA, Carugati M, Durante- during primary HIV-1 infection: pilot 29. Gatell JM, Assoumou L, Moyle G, Waters L, Mangoni E, Tattevin P, Chu VH, Moreno A, randomized clinical trial. JOURNAL OF Johnson M, Domingo P, Fox J, Martinez E, Fowler VG, Miró JM, International ANTIMICROBIAL CHEMOTHERAPY. Stellbrink HJ, Guaraldi G, Masia M, Gompels M, Collaboration on Endocarditis Microbiology 72(3):829-836. I.F.: 5.071 De Wit S, Florence E, Esser S, Raffi F, Pozniak AL, Investigators. Influence of Vancomycin NEAT022 Study Group*. Switching from a Minimum Inhibitory Concentration on the 24. Ambrosioni J, Nicolás D, Manzardo C, ritonavir-boosted protease inhibitor to a Outcome of Methicillin-Susceptible Agüero F, Blanco JL, Mosquera MM, Peñafiel J, dolutegravir-based regimen for Staphylococcus aureus Left-Sided Gatell JM, Marcos MA, Miró JM. Integrase maintenance of HIV viral suppression in Infective Endocarditis Treated with strand-transfer inhibitor polymorphic and patients with high cardiovascular risk. Anti-staphylococcal Beta-Lactam accessory resistance substitutions in AIDS. 31(18):2503-2514. I.F.: 5.019 Antibiotics; a Prospective Cohort Study patients with acute/recent HIV infection. by the International Collaboration on JOURNAL OF ANTIMICROBIAL 30. Montserrat M, Plana M, Guardo AC, Andrés Endocarditis. CLIN MICROBIOL INFECT. CHEMOTHERAPY. 72(5):205-209. I.F.: 5.071 C, Climent N, Gallart T, Leal L, Gatell JM, 23(8):544-549. I.F.: 5.292 Sánchez-Palomino S, García F. Impact of 25. Inciarte, A.; Leal, L.; Gonzalez, E.; Leon, A.; long-term antiretroviral therapy 20. Ripa M., Rodríguez-Núñez O., Cardozo C., Lucero, C.; Mallolas, J.; Torres, B.; Laguno, M.; interruption and resumption on viral Naharro-Abellán A., Almela M., Marco F., Rojas, J.; Martinez-Rebollar, M.; Gonzalez- reservoir in HIV-1 infected patients. AIDS. Morata L., De La Calle C., Del Rio A., Cordon, A.; Cruceta, A.; Arnaiz, J. A.; Gatell, J. M.; 31(13):1895-1897. I.F.: 5.019 Garcia-Vidal C., Ortega M., Guerrero-León M., Garcia, F.;STRIBPEP Study Grp. Tenofovir Feher C., Torres B., Puerta-Alcalde P., Mensa disoproxil fumarate/emtricitabine plus 31. Guardo AC, Joe PT, Miralles L, Bargalló ME, J., Soriano A., Martínez J. Influence of ritonavir-boosted lopinavir or Mothe B, Krasniqi A, Heirman C, García F, empirical double-active combination cobicistat-boosted elvitegravir as a Thielemans K, Brander C, Aerts JL, Plana M, antimicrobial therapy compared with single-tablet regimen for HIV post-exposure. iHIVARNA consortium. Preclinical evaluation active monotherapy on mortality in JOURNAL OF ANTIMICROBIAL of an mRNA HIV vaccine combining patients with septic shock: A propensity CHEMOTHERAPY. 72(10):2857-2861. I.F.: 5.071 rationally selected antigenic sequences score-adjusted and matched analysis. and adjuvant signals (HTI-TriMix). AIDS. JOURNAL OF ANTIMICROBIAL 26. Guitart-Mampel, Mariona; Sandra 31(3):321-332-332. I.F.: 5.019 CHEMOTHERAPY. 72(12):3443-3452. I.F.: 5.071 Hernandez, A.; Moren, Constanza; Catalan-Garcia, Marc; Tobias, Ester; 32. Hernandez S., Moren C., Catalán-García M., 21. Pericàs JM, García-de-la-Mària C, Brunet Gonzalez-Casacuberta, Ingrid; Juarez-Flores, Lopez M., Guitart-Mampel M., Coll O., Garcia L., M, Armero Y, García-González J, Casals G, Diana L.; Gatell, Josep M.; Cardellach, Francesc; Milisenda J., Justamante A., Gatell J., Cardellach Almela M, Quintana E, Falces C, Ninot S, Milisenda, Jose C.; Grau, Josep M.; Gratacos, F., Gratacos E., Miro Ò., Garrabou G. Fuster D, Llopis J, Marco F, Moreno A, Miró Eduard; Figueras, Francesc; Garrabou, Gloria. Mitochondrial toxicity and caspase JM, Hospital Clinic Endocarditis Study Group. Imbalance in mitochondrial dynamics and activation in HIV pregnant women. Early in vitro development of daptomycin apoptosis in pregnancies among JOURNAL OF CELLULAR AND MOLECULAR non-susceptibility in high-level HIV-infected women on HAART with MEDICINE. 21(1):26-34. I.F.: 4.499 aminoglycoside-resistant Enterococcus obstetric complications. JOURNAL OF faecalis predicts the efficacy of the ANTIMICROBIAL CHEMOTHERAPY. 33. Morén C., González-Casacuberta I., combination of high-dose daptomycin plus 72(9):2578-2586. I.F.: 5.071 Álvarez-Fernández C., Bañó M., Catalán-Garcia ampicillin in an in vivo model of M., Guitart-Mampel M., Juárez-Flores D., Tobías experimental endocarditis. J ANTIMICROB 27. Navarro J., Laguno M., Vilchez H., Guardiola J., E., Milisenda J., Cardellach F., Gatell J., CHEMOTHER. 72(6):1714-1722. I.F.: 5.071 Carrion J., Force L., Cairó M., Cifuentes C., Vilaró J., Sánchez-Palomino S., Garrabou G..HIV-1 Cucurull J., Marco A., Roget M., Erice E., Crespo M., promonocytic and lymphoid cell lines: An 22. Yim J, Smith JR, Singh NB, Rice S, Ortiz J., Aparicio C., Mallolas J., Rebollar M., Puigvehí in vitro model of in vivo mitochondrial and Stamper K, Garcia de la Maria C, Bayer AS, M., Barrufet P., Sempere G., Pérez M., Sarriera C., apoptotic lesion. JOURNAL OF CELLULAR Mishra NN, Miró JM, Tran TT, Arias CA, Sullam Valls I. Efficacy and safety of direct antiviral AND MOLECULAR MEDICINE. 21(2):402-409. P, Rybak MJ. Evaluation of daptomycin agents in a cohort of cirrhotic I.F.: 4.499 combinations with cephalosporins or HCV/HIV-coinfected patients. JOURNAL gentamicin against Streptococcus mitis OF ANTIMICROBIAL CHEMOTHERAPY. 34. Pericàs J., Corredoira J., Moreno A., group strains in an in vitro model of 72(10):2850-2856. I.F.: 5.071 García-País M., Falces C., Rabuñal R., Mestres C., simulated endocardial vegetations (SEVs). Alonso M., Marco F., Quintana E., Almela M., Paré JOURNAL OF ANTIMICROBIAL 28. Peñafiel J., De Lazzari E., Padilla M., Rojas J., J., Llopis J., Castells A., Miró J. Relationship

66 INFECTIOUS DISEASES AND AIDS 1.3

Between Enterococcus faecalis Infective Cytidylyltransferase (CdsA) Mediate Investigators. Human immunodeficiency Endocarditis and Colorectal Neoplasm: Daptomycin Resistance in Streptococcus virus-infected liver transplant recipients with Preliminary Results From a Cohort of 154 mitis by a Novel Mechanism. ANTIMICROB incidental hepatocellular carcinoma: A Patients. REVISTA ESPAÑOLA DE AGENTS CHEMOTHER. 61(4). I.F.: 4.302 prospective multicenter nationwide cohort CARDIOLOGIA. 70(6):451-458. I.F.: 4.485 study. LIVER TRANSPL. 23(5):645-651. I.F.: 3.910 40. Garcia-de-la-Maria C, Xiong YQ, Pericas JM, 35. Temkin E, Torre-Cisneros J, Torre-Cisneros Armero Y, Moreno A, Mishra NN, Rybak MJ, Tran 45. Amadori C, van der Velden Y, Bonnard D, J, Beovic B, Benito N, Benito N, Giannella M, TT, Arias CA, Sullam PM, Bayer AS, Miro JM. Orlov I, van Bel N, Le Rouzic E, Miralles L, Brias J, Gilarranz R, Jeremiah C, Loeches B, Machuca I, Impact of High-Level Daptomycin Chevreuil F, Spehner D, Chasset S, Ledoussal B, Machuca I, Jiménez-Martín MJ, Martínez JA, Resistance in the Streptococcus mitis Mayr L, Moreau F, García F, Gatell J, Zamborlini Mora-Rillo M, Navas E, Osthoff M, Pozo JC, Ramos Group on Virulence and Survivability A, Emiliani S, Ruff M, Klaholz B, Moog C, Berkhout Ramos JC, Rodriguez M, Sánchez-García M, Viale during Daptomycin Treatment in B, Plana M, Benarous R. The HIV-1 P, Wolff M, Wolff M, Carmeli Y, Carmeli Y. Experimental Infective Endocarditis. integrase-LEDGF allosteric inhibitor Ceftazidime-Avibactam as Salvage Therapy ANTIMICROBIAL AGENTS AND MUT-A: Resistance profile, impairment of for Infections Caused by Carbapenem- CHEMOTHERAPY. 61(5). I.F.: 4.302 virus maturation and infectivity but without Resistant Organisms. ANTIMICROB AGENTS influence on RNA packaging or virus CHEMOTHER. 61(2). I.F.: 4.302 41. Amaro R; Sellarés J; Polverino E; Cilloniz C; immunoreactivity. RETROVIROLOGY. Ferrer M; Fernández-Barat L; Mensa J; 14(1):50. I.F.: 3.867 36. Garrabou G, Soriano À, Pinós T, Niederman M; Torres A. Antibiotic therapy Casanova-Mollà J, Pacheu-Grau D, Morén C, prior to hospital admission is associated 46. Bouteloup, V.; Sabin, C.; Mocroft, A.; Gras, L.; García-Arumí E, Morales M, Ruiz-Pesini E, with reduced septic shock and need for Pantazis, N.; Le Moing, V.; d'Arminio Monforte, A.; Catalán-Garcia M, Milisenda JC, Lozano E, mechanical ventilation in patients with Mary-Krause, M.; Roca, B.; Miro, J. M.; Battegay, Andreu AL, Montoya J, Mensa J, Cardellach F. community-acquired pneumonia. M.; Brockmeyer, N.; Berenguer, J.; Morlat, P.; Influence of Mitochondrial Genetics on the JOURNAL OF INFECTION. 74(5):442-449. I.F.: 4.201 Obel, N.; De Wit, S.; Faetkenheuer, G.; Zangerle, Mitochondrial Toxicity of Linezolid in R.; Ghosn, J.; Perez-Hoyos, S.; Campbell, M.; Blood Cells and Skin Nerve Fibers. 42. Winston A; Stöhr W; Antinori A; Amieva H; Prins, M.; Chene, G.; Meyer, L.; Dorrucci, M.; Torti, ANTIMICROBIAL AGENTS AND Perré P; De Wit S; Reynes J; Gompels M; C.; Thiebaut, R.;Stand Reference Distribution CHEMOTHERAPY. 61(9): e00542-17. I.F.: 4.302 Monforte AD; Gatell J-M; Grarup J; Pozniak A; CD4 R. Reference curves for CD4 T-cell Babiker A; Raffi F; Richert L; the NEAT 001ANRS count response to combination 37. Del Barrio-Tofiño E, López-Causapé C, 143 Study Group. Changes in Cognitive antiretroviral therapy in HIV-1-infected Cabot G, Rivera A, Benito N, Segura C, Montero Function Over 96 weeks in Naïve Patients treatment-naïve patients. HIV MEDICINE. MM, Sorlí L, Tubau F, Gómez-Zorrilla S, Tormo N, Randomised to Darunavir-ritonavir plus 18(1):33-44. I.F.: 3.257 Durá-Navarro R, Viedma E, Resino-Foz E, either Raltegravir or Tenofovir- Fernández-Martínez M, González-Rico C, Emtricitabine: a substudy of the 47. Cilloniz C, Ewig S, Gabarrus A, Ferrer M, Puig Alejo-Cancho I, Martínez JA, Labayru-Echverria NEAT001/ANRS143 trial. JOURNAL OF de la Bella Casa J, Mensa J, Torres A. C, Dueñas C, Ayestarán I, Zamorano L, ACQUIRED IMMUNE DEFICIENCY Seasonality of pathogens causing Martinez-Martinez L, Horcajada JP, Oliver A. SYNDROMES. 74(2):185-192. I.F.: 3.935 community-acquired pneumonia. Genomics and Susceptibility Profiles of RESPIROLOGY. 22(4):778-785. I.F.: 3.256 Extensively Drug-Resistant (XDR) 43. Winston, Alan; Stoehr, Wolfgang; Antinori, Pseudomonas aeruginosa from Spain. Andrea; Amieva, Helene; Perre, Philippe; De Wit, 48. Ambrosioni J, Artigues F, Nicolás D, Peñafiel ANTIMICROBIAL AGENTS AND Stephane; Reynes, Jacques; Gompels, Mark; J, Agüero F, Manzardo C, Mar Mosquera M, CHEMOTHERAPY. 61(11). I.F.: 4.302 Monforte, Antonella d'Arminio; Gatell, Sánchez-Palomino S, De Lazzari E, Marcos MA, Jose-Maria; Grarup, Jesper; Pozniak, Anton; Plana M, Miró JM, Hospital Clinic PHI 38. Castañeda X, García-de-la-Mària C, Gasch Babiker, Abdel; Raffi, Francois; Richert, Investigators. Neurological involvement in O, Pericas JM, Armero Y, Soy D, Laura;NEAT 001 ANRS 143 Study Grp. patients with acute/recent HIV-1 infection. García-González J, Falces C, Ninot S, Almela M, Changes in Cognitive Function Over 96 A case-control study. JOURNAL OF Ambrosioni J, Quintana E, Vidal B, Fuster D, Weeks in Naive Patients Randomized to NEUROVIROLOGY. 23(5):679-685. I.F.: 3.206 Llopis J, Soto S, Moreno A, Marco F, Miró JM, Darunavir-Ritonavir Plus Either Raltegravir Hospital Clinic Endocarditis Study Group. or Tenofovir-Emtricitabine: A Substudy of 49. Wouthuyzen-Bakker M., Tornero E., Claret AUC/MIC Pharmacodynamic Target Is Not the NEAT001/ANRS143 Trial. JOURNAL G., Bosch J., Martinez-Pastor J., Combalia A., a Good Predictor of Vancomycin Efficacy OF ACQUIRED IMMUNE DEFICIENCY Soriano A.. Withholding Preoperative in Methicillin-Resistant Staphylococcus SYNDROMES. 74(2):185-192. I.F.: 3.935 Antibiotic Prophylaxis in Knee Prosthesis aureus Experimental Endocarditis. Revision: A Retrospective Analysis on ANTIMICROBIAL AGENTS AND 44. Agüero F, Forner A, Valdivieso A, Blanes M, Culture Results and Risk of Infection. CHEMOTHERAPY. 61(6):e02486. I.F.: 4.302 Barcena R, Manzardo C, Rafecas A, Castells L, JOURNAL OF ARTHROPLASTY. Abradelo M, Barrera-Baena P, González- 32(9):2829-2833. I.F.: 3.055 39. Mishra NN, Tran TT, Seepersaud R, Diéguez L, Salcedo M, Serrano T, Jiménez- Garcia-de-la-Maria C, Faull K, Yoon A, Proctor R, Pérez M, Herrero JI, Gastaca M, Aguilera V, 50. Caro-Pérez N; Martínez-Rebollar M; Gregori Miro JM, Rybak MJ, Bayer AS, Arias CA, Sullam Fabregat J, Del Campo S, Bilbao I, Romero CJ, J; Quer J; González P; Gambato M; García- PM. Perturbations of Phosphatidate Moreno A, Rimola A, Miro JM, FIPSE González N; González-Candelas F; Costa J;

67 AREA 1 BIOLOGICAL AGGRESSION AND RESPONSE MECHANISMS

Esteban J; Mallolas J; Forns X; Laguno M; RISVAC02boost study. Safety and profiling. JOURNAL OF IMMUNOLOGICAL Perez-Del-Pulgar S. Phylogenetic analysis of vaccine-induced HIV-1 immune responses METHODS. 442:12-19. I.F.: 2.100 an epidemic outbreak of acute hepatitis C in healthy volunteers following a late in HIV-infected patients by ultra-deep MVA-B boost 4 years after the last 62. Fernández-Cruz A., Muñoz P., Sandoval pyrosequencing. JOURNAL OF CLINICAL immunization. PLOS ONE. C., Fariñas C., Gutiérrez-Cuadra M., Pericás VIROLOGY. 92:42-47. I.F.: 3.051 12(10):e0186602-1120. I.F.: 2.806 Pulido J., Miró J., Goenaga-Sánchez M., De Alarcón A., Bonache-Bernal F., Rodríguez M., 51. López-Aladid R., Guiu A., Sanclemente G., 56. Fehér C, Múñez Rubio E, Merino Amador Noureddine M., Bouza Santiago E., Spanish López-Medrano F., Cofán F., Mosquera M., P, Delgado-Iribarren Garcia-Campero A, Collaboration on Endocarditis (GAMES). Torre-Cisneros J., Vidal E., Moreno A., Aguado J., Salavert M, Merino E, Maseda Garrido E, Infective endocarditis in patients with Cordero E., Martin-Gandul C., Pérez-Romero P., Díaz-Brito V, Álvarez M, Mensa J. The cancer: A consequence of invasive Carratalá J., Sabé N., Niubó J., Cervera C., Cervilla efficacy of fidaxomicin in the treatment of procedures or a harbinger of neoplasm? A A., Bodro M., Muñoz P., Fariñas C., Codina M., Clostridium difficile infection in a prospective, multicenter cohort. MEDICINE Aranzamendi M., Montejo M., Len O., Marcos M., real-world clinical setting: a Spanish (UNITED STATES). 96(38):e7913. I.F.: 1.804 Group for Study of Infection in Transplantation of multi-centre retrospective cohort. the Spanish Society of Infectious Diseases EUROPEAN JOURNAL OF CLINICAL 63. Yong C., Gathe J., Knecht G., Orrell C., Clinical Microbiology GESITRA-SEIMC Spanish MICROBIOLOGY AND INFECTIOUS Mallolas J., Podzamczer D., Trottier B., Zhang Network for Research in Infectious. Detection of DISEASES. 36(2):295-303. I.F.: 2.727 W., Sabo J., Vinisko R., Drulak M., Quinson A. cytomegalovirus drug resistance mutations Pharmacokinetic analysis of nevirapine in solid organ transplant recipients with 57. García-Goez J., Munera G., Rojas V., extended release 400 mg once daily vs suspected resistance. JOURNAL OF Pacheco R., Caylá J., Miro J.. Tuberculosis in nevirapine immediate release 200 mg CLINICAL VIROLOGY. 90:57-63. I.F.: 3.051 recipients of solid-organ transplants twice daily formulation in treatment-naïve during 1995–2015 in Cali, Colombia. patients with HIV-1 infection. HIV CLINICAL 52. Rosas-Umbert, Miriam; Mothe, Beatriz; INTERNATIONAL JOURNAL OF TRIALS. 18(5-6):189-195. I.F.: 1.778 Noguera-Julian, Marc; Bellido, Rocio; Puertas, TUBERCULOSIS AND LUNG DISEASE. Maria C.; Carrillo, Jorge; Rodriguez, C.; 21(11):1155-1159. I.F.: 2.468 64. Saumoy M, Tiraboschi JM, Perez-Alvarez, Nuria; Cobarsi, Patricia; Ordoñez-Llanos J, Ribera E, Domingo P, Gomez, Carmen E.; Esteban, Mariano; Luis 58. Cristelli MP, Cofán F, Rico N, Trullàs JC, Mallolas J, Curto J, Gatell JM, Podzamczer D. Jimenez, Jose; Garcia, Felipe; Blanco, Julia; Manzardo C, Agüero F, Bedini JL, Moreno A, Atherogenic properties of LDL particles Martinez-Picado, Javier; Paredes, Roger; Oppenheimer F, Miro JM, CKD-H. Clinic after switching from Truvada or Kivexa Brander, Christian;. Virological and Investigators. Estimation of renal function plus lopinavir/r to lamivudine plus immunological outcome of treatment by CKD-EPI versus MDRD in a cohort of lopinavir/r: OLE-MET substudy. HIV CLIN interruption in HIV-1-infected subjects HIV-infected patients: a cross-sectional TRIALS. 18(2):49-53. I.F.: 1.778 vaccinated with MVA-B. PLOS ONE. analysis. BMC NEPHROLOGY. 18(1):58. I.F.: 2.289 12(9):e0184929-1120. I.F.: 2.806 65. Cristelli MP, Cofán F, Tedesco-Silva H, 59. Ramos-Martínez A, Vicente-López N, Trullàs JC, Santos DWCL, Manzardo C, Agüero 53. Cilloniz C; Ceccato A; De La Calle C; Sánchez-Romero I, Padilla B, Merino-Amador F, Moreno A, Oppenheimer F, Diekmann F, Gabarrús A; Garcia-Vidal C; Almela M; Soriano A; P, Garnacho-Montero J, Ruiz-Camps I, Medina-Pestana JO, Miro JM, Sao Martinez J; Marco F; Vila J; Torres A. Time to Montejo M, Salavert M, Mensa J, Paulo-Barcelona Renal Transplant in HIV blood culture positivity as a predictor of Cuenca-Estrella M, Members of the Investigators. Regional differences in the clinical outcomes and severity in adults with CANDIPOP Project from GEIH-GEMICOMED management and outcome of kidney bacteremic pneumococcal pneumonia. (SEIMC) and REIPI. Epidemiology and transplantation in patients with human PLOS ONE. 12(8):e0182436. I.F.: 2.806 prognosis of candidaemia in elderly immunodeficiency virus infection: A 3-year patients. MYCOSES. 60(12):808-817. I.F.: 2.252 retrospective cohort study. TRANSPLANT 54. Garriga C., Manzanares-Laya S., García INFECTIOUS DISEASE. 19(4). I.F.: 1.719 De Olalla P., Gorrindo P., Lens S., Solà R., 60. Mahant A; Saubí N; Eto Y; Guitart N; Gatell Martínez-Rebollar M., Laguno M., Navarro J., J; Hanke T; Joseph J. Preclinical 66. Rivero A., Pérez-Molina J., Blasco A., Arribas Torras X., Gurguí M., Barberá M., Quer J., development of BCG.HIVA2auxo.int, J., Crespo M., Domingo P., Estrada V., Iribarren J., Masdeu E., Simón P., Ros M., De Andrés A., harboring an integrative expression Knobel H., Lázaro P., López-Aldeguer J., Lozano Caylà J.. Evolution of acute hepatitis C virus vector, for a HIV-TB Pediatric vaccine. F., Moreno S., Palacios R., Pineda J., Pulido F., infection in a large European city: Trends Enhancement of stability and specific Rubio R., de la Torre J., Tuset M., Gatell J. Costs and new patterns. PLOS ONE. HIV-1 T-cell immunity. HUMAN VACCINES & and cost-efficacy analysis of the 2016 12(11):e0187893. I.F.: 2.806 IMMUNOTHERAPEUTICS. 13(8):1798-1810. GESIDA/Spanish AIDS National Plan I.F.: 2.157 recommended guidelines for initial 55. Guardo AC, Gómez CE, Díaz-Brito V, Pich antiretroviral therapy in HIV-infected adults. J, Arnaiz JA, Perdiguero B, García-Arriaza J, 61. Bargalló ME, Guardo AC, Maleno MJ, ENFERMEDADES INFECCIOSAS Y González N, Sorzano COS, Jiménez L, Miralles L, Egaña-Gorroño L, Escribà T, García F, MICROBIOLOGIA CLINICA. 35(2):88-99. I.F.: 1.714 Jiménez JL, Muñoz-Fernández MÁ, Gatell JM, Gatell JM, Arnedo M, Plana M. Utility of Alcamí J, Esteban M, López Bernaldo de Systematic Isolation of immune cell subsets 67. Cervera C, Sanroma P, González-Ramallo Quirós JC, García F, Plana M, from HIV-infected individuals for miRNA V, García de la María C, Sanclemente G,

68 INFECTIOUS DISEASES AND AIDS 1.3

Sopena N, Pajarón M, Segado A, Mirón M, substitutions in patients with acute/recent Cardozo C, Soriano A. Clinical experience Antón F, Basterretxea A, Cuende A, Miró JM, HIV infection-authors' response. JOURNAL with ceftazidime/avibactam in patients DAPTODOM Investigators. Safety and OF ANTIMICROBIAL CHEMOTHERAPY. with severe infections, including efficacy of daptomycin in outpatient 72(5):1547-1548. I.F.: 5.071 meningitis and lung abscesses, caused by parenteral antimicrobial therapy: a extensively drug-resistant Pseudomonas prospective and multicenter cohort study 3. Combalia A., To-Figueras J., Laguno M., aeruginosa. INTERNATIONAL JOURNAL OF (DAPTODOM trial). INFECT DIS (LOND). Martínez-Rebollar M., Aguilera P.. ANTIMICROBIAL AGENTS. 49(2):266-268. 49(3):200-207. I.F.: 1.119 Direct-acting antivirals for hepatitis C virus I.F.: 4.307 induce a rapid clinical and biochemical remission of porphyria cutanea tarda. 2. Xipell M, Bodro M, Marco F, Martínez JA, Review / I.F.: 15.865 BRITISH JOURNAL OF DERMATOLOGY. Soriano A. Successful treatment of three 177(5):e183-e184. I.F.: 4.706 severe MDR or XDR Pseudomonas 1. Wouthuyzen-Bakker M, Benito N, Soriano A. aeruginosa infections with The effect of preoperative antimicrobial 4. Soriano A. CORR Insights®: Vancomycin ceftolozane/tazobactam. FUTURE prophylaxis on intraoperative culture Prophylaxis for Total Joint Arthroplasty: MICROBIOLOGY. 12(14):1323-1326. I.F.: 3.374 results in patients with a suspected or Incorrectly Dosed and Has a Higher Rate of confirmed prosthetic joint infection. Periprosthetic Infection Than Cefazolin. 3. Ripoll E, Prieto-González S, Balagué O, A systematic review. JOURNAL OF CLINICAL ORTHOPAEDICS AND RELATED Marco-Hernández J, Miró JM, Darnell A, Cid CLINICAL MICROBIOLOGY. RESEARCH. 475(7):1775-1778. I.F.: 3.897 MC, Hernández-Rodríguez J. Occlusive 55(9):2765-2774. I.F.: 3.712 vasculopathy in human immunodeficiency 5. Fernandez, Sara; Nicolas, David; Pericas, Juan virus (HIV)-associated vasculitis: unusual 2. Leal L, Lucero C, Gatell JM, Gallart T, Plana M.; Castro Rebollo, Pedro; Vila, Jordi; Miro, Josep clinical and imaging course. CLINICAL AND M, García F. New challenges in therapeutic M.; Blanco, Jose L.; Nicolas, Josep M. A case of EXPERIMENTAL RHEUMATOLOGY. vaccines against HIV infection. EXPERT Mycoplasma hominis disseminated infection 103(1):185-188. I.F.: 2.634 REVIEW OF VACCINES. 16(6):587-600. in a human immunodeficiency I.F.: 3.555 virus-1-infected pregnant woman with 4. Fervienza A., Bodro M., Castro P., hypogammaglobulinemia. JOURNAL OF Hernández S., Teixidó I., Espinosa G., Cervera 3. Coiras M, Ambrosioni J, Cervantes F, Miró MICROBIOLOGY, IMMUNOLOGY AND R. Brain abscess due to Listeria JM, Alcamí J. Tyrosine kinase inhibitors: INFECTION. 50(1):118-119. I.F.: 2.973 monocytogenes after HELLP syndrome in potential use and safety considerations in a patient with antiphospholipid syndrome. HIV-1 infection. EXPERT OPINION ON DRUG 6. Puerta-Alcalde P, Cuervo G, Simonetti AF, LUPUS. 26(9):1002-1004. I.F.: 2.454 SAFETY. 16(5):547-559. I.F.: 3.439 Gracia-Sánchez L, Ortiz D, Garcia-Vidal C. PET/CT added to Duke criteria facilitates 5. Lagunes L, Len O, Sandiumenge A, 4. Mallolas J. Darunavir Stands Up as diagnosis and monitoring of long-term Martínez-Saez E, Pumarola T, Bodro M, Macías Preferred HIV Protease Inhibitor. AIDS suppressive therapy of prosthetic A, Silva JT, Nuvials FX, Charco R, Moreso F, Pont REVIEWS. 19(2):105-112. I.F.: 3.244 endocarditis. INFECT DIS (LOND). T. Successful multiple organ donation after 49(9):698-701. I.F.: 1.119 donor brain death due to Actinomyces 5. Ambrosioni J., Hernandez-Meneses M., israelii meningitis. TRANSPLANT INFECTIOUS Téllez A., Pericàs J., Falces C., Tolosana J., DISEASE. 19(4). I.F.: 1.719 Vidal B., Almela M., Quintana E., Llopis J., Editorial / I.F.: 10.416 Moreno A., Miro J. The Changing Epidemiology of Infective Endocarditis in 1. Erba PA, Habib G, Glaudemans AWJM, Miro Clinical Guidelines / I.F.: 5.142 the Twenty-First Century. CURRENT JM, Slart RHJA. The round table approach in INFECTIOUS DISEASE REPORTS. 19(5):21. infective endocarditis & cardiovascular 1. De Cueto M., Aliaga L., Alós J., Canut A., I.F.: 1.915 implantable electronic devices infections: Los-Arcos I., Martínez J., Mensa J., Pintado V., make your e-Team come true. EUROPEAN Rodriguez-Pardo D., Yuste J., Pigrau C. JOURNAL OF NUCLEAR MEDICINE AND Executive summary of the diagnosis and Letters / I.F.: 22.837 MOLECULAR IMAGING. 44(7):1107-1108. treatment of urinary tract infection: I.F.: 7.277 Guidelines of the Spanish Society of 1. Ambrosioni J., Mosquera M., Miró J.. Clinical Microbiology and Infectious Comment on: Efficacy of elvitegravir/ 2. Ambrosioni J., Coiras M., Alcamí J., Miró J.. Diseases (SEIMC). ENFERMEDADES cobicistat/emtricitabine/tenofovir Potential role of tyrosine kinase inhibitors INFECCIOSAS Y MICROBIOLOGIA CLINICA. disoproxil fumarate as treatment for during primary HIV-1 infection. EXPERT 35(5):314-320. I.F.: 1.714 primary or recent HIV infection. JOURNAL REVIEW OF ANTI-INFECTIVE THERAPY. OF ANTIMICROBIAL CHEMOTHERAPY. 15(5):421-423. I.F.: 3.139 2. Ariza, Javier; Cobo, Javier; Baraia-Etxaburu, 72(5):1548-1549. I.F.: 5.071 Josu; Benito, Natividad; Bori, Guillermo; Cabo, Javier; Corona, Pablo; Esteban, Jaime; 2. Ambrosioni J, Mosquera MM, Miró JM. Case Reports / I.F.: 14.488 Horcajada, Juan Pablo; Lora-Tamayo, Jaime; Integrase strand-transfer inhibitor Murillo, Oscar; Palomino, Julian; Parra, Jorge; polymorphic and accessory resistance 1. Xipell M, Bodro M, Marco F, Losno RA, Pigrau, Carlos; del Pozo, Jose Luis; Riera,

69 AREA 1 BIOLOGICAL AGGRESSION AND RESPONSE MECHANISMS

Melchor; Rodriguez, Dolores; Sanchez- Eric; Sedlacek, Dalibor; Stellbrink, for rifampicin-and isoniazid-susceptible Somolinos, Mar; Soriano, Alex; del Toro, M. Hans-Juergen; Uzdaviniene, Vilma; Tomazic, tuberculosis in Eastern Europe, Western Dolores; de la Torre, Basilio;Spanish Network Janez; Gargalianos-Kakolyris, Panagiotis; Europe, and Latin America. AIDS. Study Infect Dis; Spanish Soc Infect Dis Clin Schmid, Patrick; Orkin, Chloe; Pedersen, Court; 31(3):375-384. I.F.: 5.019 Microb. Executive summary of Leen, Clifford; Pradier, Christian; Mulcahy, Fiona; management of prosthetic joint infections. … …. Mocroft, Amanda; EuroSIDA. 9. De Mendoza C., Caballero E., Aguilera A., Clinical practice guidelines by the Spanish Antiretrovirals, Fractures, and Requena S., De Lejarazu R., Pirón M., Society of Infectious Diseases and Clinical Osteonecrosis in a Large International HIV González R., Jiménez A., Roc L., Treviño A., Microbiology (SEIMC). ENFERMEDADES Cohort. CLINICAL INFECTIOUS DISEASES. Benito R., Fernández-Alonso M., Aguinaga A., INFECCIOSAS Y MICROBIOLOGIA CLINICA. 64(10):1413-1421. I.F.: 8.216 Rodríguez C., García-Costa J., Blanco L., 35(3):189-195. I.F.: 1.714 Ramos J., Calderón E., Eirós J., Sauleda S., 4. Trickey, Adam; May, Margaret T.; Barreiro P., Soriano V., Spanish HTLV 3. Santiago Moreno Guillén, Antonio Antela Schommers, Philipp; Tate, Jan; Ingle, Suzanne Network. Human T-lymphotropic virus type López, Felipe García Alcaide, Julia del Amo M.; Guest, Jodie L.; Gill, M. John; Zangerle, 1 infection and disease in Spain. AIDS. Valero, Vicente Boix, Pep Coll, Claudia Fortuny Robert; Saag, Mike; Reiss, Peter; Monforte, 31(12):1653-1663. I.F.: 5.019 Guasch, Juan Luis Gómez Sirvent, Félix Antonella d'Arminio; Johnson, Margaret; Lima, Gutiérrez Rodero, José Antonio Iribarren Viviane D.; Sterling, Tim R.; Cavassini, Matthias; 10. Judd A, Lodwick R, Noguera-Julian A, Gibb Loyarte, Josep Maria Llibre Codina, Juan Wittkop, Linda; Costagliola, Dominique; DM, Butler K, Costagliola D, Sabin C, van Carlos López Bernaldo de Quirós, Juan Emilio Sterne, Jonathan A. C.;Antiretroviral Therapy Sighem A, Ledergerber B, Torti C, Mocroft A, Losa García, Ana Belén Lozano Serrano, Cohort. CD4:CD8 Ratio and CD8 Count as Podzamczer D, … … Phillips A, Pursuing Later Michael Meulbroek, Julián Olalla Sierra, Ferran Prognostic Markers for Mortality in Human Treatment Options II (PLATO II) Project Team Pujol, Federico Pulido, Manuel Crespo Casal, Immunodeficiency Virus-Infected Patients for the Collaboration of Observational HIV Juan González García, José López Aldeguer, on Antiretroviral Therapy: The Antiretroviral Epidemiological Research Europe (COHERE) José A. Pérez Molina, Daniel Podzamczer Therapy Cohort Collaboration (ART-CC). in EuroCoord. Higher rates of triple-class Palter, Antonio Rivero Román. Executive CLINICAL INFECTIOUS DISEASES. virological failure in perinatally HIV- summary: Pre-exposure prophylaxis for 65(6):959-966. I.F.: 8.216 infected teenagers compared with prevention of HIV infection in adults in heterosexually infected young adults Spain: July 2016. ENFERMEDADES 5. Rohner, Eliane; Butikofer, Lukas; Schmidlin, in Europe. HIV MEDICINE. 18(3):171-180. INFECCIOSAS Y MICROBIOLOGIA CLINICA. Kurt; Sengayi, Mazvita; Maskew, Mhairi; Giddy, I.F.: 3.257 35:377-383. I.F.: 1.714 Janet; Garone, Daniela; Moore, Richard D.; D'Souza, Gypsamber; … ... Bohlius, Julia;The 11. Casadella, Maria; Cozzi-Lepri, Alessandro; Aids-Defining Cancer Project; Cohere In Phillips, Andrew; Noguera-Julian, Marc; Bickel, Consortium Publications / I.F.: 71.092 EuroCoord. Comparison of Kaposi Markus; Sedlacek, Dalibor; Zilmer, Kai; Clotet, Sarcoma Risk in Human Bonaventura; Lundgren, Jens D.; Paredes, 1. Antiretroviral Therapy Cohort Collaboration. Immunodeficiency Virus-Positive Adults Roger; EuroSIDA EuroCOORD. Plasma HIV-1 Survival of HIV-positive patients starting Across 5 Continents: A Multiregional Tropism and the Risk of Short-Term antiretroviral therapy between 1996 and Multicohort Study. CLINICAL INFECTIOUS Clinical Progression to AIDS or Death. 2013: a collaborative analysis of cohort DISEASES. 65(8):1316-1326. I.F.: 8.216 PLOS ONE. 12(1):e0166613. I.F.: 2.806 studies. THE LANCET HIV. 4(8):e349-e356. I.F.: 9.842 6. Requena S., Treviño A., Cabezas T., 12. Cooper, Vanessa; Clatworthy, Jane; Garcia-Delgado R., Amengual M., Lozano A., Harding, Richard; Whetham, Jennifer; Emerge 2. Dominguez-Molina, Beatriz; Tarancon-Diez, Peñaranda M., Fernández J., Soriano V., de Consortium. Measuring quality of life among Laura; Hua, Stephane; Abad-Molina, Cristina; Mendoza C., Spanish HIV-2 Study Group. Drug people living with HIV: a systematic review Rodriguez-Gallego, Esther; Machmach, resistance mutations in HIV-2 patients failing of reviews. HEALTH AND QUALITY OF LIFE Kawthar; Vidal, Francesc; Tural, Cristina; raltegravir and influence on dolutegravir OUTCOMES. 15(1):220. I.F.: 2.143 Moreno, Santiago; Goni, Maria Jose; de response. JOURNAL OF ANTIMICROBIAL Arellano, Elena Ramirez; del Val, Margarita; CHEMOTHERAPY. 72(7):2083-2088. I.F.: 5.071 Gonzalez-Escribano, Maria Francisca; Del GRANTS FOR RESEARCH IN PROGRESS Romero, Jorge; Rodriguez, Carmen; Capa, 7. Ghosn J; Bayan T; Meixenberger K; Tran L; Laura; Viciana, Pompeyo; Alcami, Jose; Yu, Xu Frange P; Monforte A; Zangerle R; De Mendoza Arnedo M. Implicación del colesterol y G.; Walker, Bruce D.; Leal, Manuel; Lichterfeld, C; Krastinova E; Porter K; Meyer L; Chaix M; ácidos grasos en macrofagos infectados Mathias; Ruiz-Mateos, Ezequiel;Spanish AIDS CASCADE Collaboration in EuroCoord. por VIH. Una aproximación lipidómica en el Res Network HIV-Contr. HLA-B*57 and CD4 T cell decline following HIV campo de la aterosclerosis y la infección IFNL4-related polymorphisms are seroconversion in individuals with and por el VIH. associated with protection against HIV-1 without CXCR4-tropic virus. JOURNAL OF Sponsored by: Instituto de Salud Carlos III. disease progression in controllers. ANTIMICROBIAL CHEMOTHERAPY. PI15/00708 CLINICAL INFECTIOUS DISEASES. 72(10):2862-2868. I.F.: 5.071 Duration: 01/01/2016-31/12/2018 64(5):621-628. I.F.: 8.216 8. TB:HIV Study writing Group. One-year García F. Therapeutic TriMix / mRNA based 3. Borges, Alvaro H.; Hoy, Jennifer; Florence, mortality of HIV-positive patients treated Vaccine in Chronic HIV-1 Infected Patients

70 INFECTIOUS DISEASES AND AIDS 1.3

Receiving Antiretroviral Therapy. PI15/00641 nueva formulación de mRNA con Sponsored by: European Commission. 602570 Duration: 01/01/2016-31/12/2018 nanopartículas. Duration: 01/12/2013-30/11/2017 Sponsored by: Instituto de Salud Carlos III. León A. Evaluating mHealth technology in PI15/00480 García C. Impacto de un paquete de HIV to improve Empowerment and Duration: 01/01/2016-31/12/2018 intervenciones basadas en la evidencia en healthcare utilisation: Research and la calidad de la atención y el pronóstico de innovation to Generate Evidence for Plana M. Design of Human Influenza la candidemia. personalised care. vaccines using multifunctional micelles Sponsored by: Instituto de Salud Carlos III. Sponsored by: Ministerio De Sanidad, Politica harnessing innate immunity. PI15/00744 Social E Igualdad. CE_H2020-PHC-2014-1s Sponsored by: Instituto de Salud Carlos III. Duration: 05/07/2016-31/12/2018 Duration: 01/05/2015-30/04/2020 AC16/00051 Duration: 01/01/2017-31/12/2019 García F. Utilización de medicina de León A. Joint Action on integrating sistemas para la predicción de la prevention, testing and linkage to care Soriano A. Estudio de estabilidad y inmunogenicidad y eficacia de vacunas strategies acros HIV, viral hepatitis, TB viabilidad de la microbiota intestinal terapéuticas frente a VIH. and STIs in Europe. liofilizada y su utilidad en el tratamiento de Sponsored by: Ministerio de Economia y Sponsored by: EUROPEAN COMISSION la infección por Clostridium difficile. Competitividad. SAF2015-66193-R CE_HP-JA-2016. 761319 Sponsored by: Instituto de Salud Carlos III. Duration: 01/01/2016-31/12/2018 Duration: 01/09/2017-31/08/2020 PI16/01023 Duration: 01/01/2017-31/12/2019 García F. European HIV Vaccine Alliance Martínez EJ. Seguridad, tolerabilidad y (EHVA): a EU platform for the discovery eficacia de dos estrategias de Soriano A. Diseño y evaluación de pruebas and evaluation of novel prophylactic and simplificación basadas en dolutegravir en para el diagnóstico de biopelículas therapeutic vaccine candidates. pacientes infectados por VIH con bacterianas sobre biomateriales. Sponsored by: INSERM - ANRS Institut supresión virológica sostenida. Aplicación en infecciones sobre prótesis National de la Santé. 681032 Sponsored by: Instituto de Salud Carlos III. articulares. Duration: 01/01/2016-31/12/2020 PI16/01085 Sponsored by: Instituto de Salud Carlos III. Duration: 01/01/2017-31/12/2019 PI13/01754 García F. Evaluating a Combination of Duration: 01/01/2014-31/12/2016 Immune-based Therapies to Achieve a Miro J.M. Estudio clínico y experimental de Functional Cure of HIV Infection (HIVACAR). la asociación entre la CMI de vancomicina Sponsored by: H2020-SC1-2016-RTD. 731626 en Staphylococcus aureus sensible a DOCTORAL THESES Duration: 01/01/2017-31/12/2021 meticilina (SASM) y el pronóstico de la endocarditis infecciona (EI) izquierda Martínez JA, Soriano A: Factores Gracía F. Red Temática de Investigación causada por dicho microorganismo. determinantes de la concentración Cooperativa en Salud - SIDA. Sponsored by: Instituto de Salud Carlos III plasmática de linezolid. Implicaciones Sponsored by: Instituto de Salud Carlos III (ISCIII). PI043573 terapéuticas. (ISCIII). RD16/0025/0002 Duration: 01/01/2015- 31/03/2019 PhD student: Laura Morata Ruiz Duration: 01/01/2017-31/12/2021 Miró JM. Estudi clínic i experimental de la Miró JM, García de la Mària C: Enterococcus Gatell J.M. Papel de las células dendríticas relació entre la CMI a la vancomicina en faecalis infective endocarditis: en la protección y control de la infección Staphylococcus aureus sensibles a la epidemiological, clinical and therapeutic por el VIH. Avanzando hacia la remisión sin meticil·lina (MSSA) i el pronòstic de la changes at the turn of the 21st century. tratamiento antirretroviral o la curación endocarditis infecciosa esquerra per PhD student: Juan Manuel Pericas Pulido funcional. MSSA. Sponsored by: Instituto de Salud Carlos III Sponsored by: Fundació la Marató de TV3. (ISCIII). PI12/01247 20152610 Duration: 01/01/2013-30/06/2017 Duration: 03/06/2016-02/06/2019

Gatell JM. NEAT22 – EACS. Moreno A. Impacto de las variaciones Sponsored by: European Aids Clinical Society genéticas de los TLR 2, 4 y 9 en el riesgo Chu Saint Pierre. 16/524 de infección por citomegalovirus Duration: 14/09/2016-31/12/2020 postrasplante y su utilidad en la prevención. Gatell JM. Inmunoterapia frente al VIH con Sponsored by: Instituto de Salud Carlos III. una vacuna terapéutica más interferón PI12/01743 para modiﬁcar el reservorio viral y Duration: 01/01/2013-30/06/2017 eventualmente alcanzar una remisión sin antiretrovirales. Plana M. Desarrollo de una vacuna Sponsored by: Instituto de Salud Carlos III. terapéutica frente al VIH basada en una

71 AREA 1 BIOLOGICAL AGGRESSION AND RESPONSE MECHANISMS

Immune receptors of the 1.4 innate and adaptive system

TECHNICIANS Noelia Armiger (IDIBAPS) LOCATION Adriana Lázaro (UB) CEK building ﬂoor 1

STRATEGIC OBJECTIVES

1. Identification and characterization of functionally relevant genetic variations of KEYWORDS immunoreceptors regulating innate and/or 1. Innate and adaptive immune adaptive immune responses. TEAM LEADER 2. response Francisco Lozano (HCB/UB) Functional characterization of the ligand-receptor interactions responsible for 2. Immune receptor-ligand interactions T. 93 227 42 17 intercellular communication between 3. Immunomodulation and immuno fl[email protected] therapy components from the innate and adaptive immune system. Host-pathogen interaction 4. 3. Understanding of host-pathogen 5. Immunevasion interactions mediated by lymphoid and RESERACHERS non-lymphoid receptors. Ana Angulo (UB) 4. Development of novel immunomodulatory Pablo Engel (UB) strategies in experimental models of Carles Serra (HCB-UB) autoimmunity, infection and cancer. 5. Characterization of cytomegalovirus Original publications POST-DOCTORAL RESEARCHERS (CMV) biology and pathogenesis. from 2015 to 2017 Fernando Aranda (IDIBAPS) Esther Carreras (IDIBAPS) YEAR I.F. TOTAL Q1 Q2 Marta Consuegra (IDIBAPS) MAIN LINES OF RESEARCH 2015 30.23 8 4 1 Pablo Martínez (UB) 2016 42.52 7 6 1 1. Molecular and functional characterization PRE-DOCTORAL RESEARCHERS of the SLAM (Signaling Lymphocytic 2017 57.10 11 10 1 Guillem Angulo (UB) Activation Molecule) and SAP Joan Boix (UB) (SLAM-Associated Protein) leukocyte Sergi Casadó (IDIBAPS) receptor families. Cristina Català (IDIBAPS) 2. Study of the molecules that intervene in Joan Puñet (UB) leukocyte adhesion and inflammation. TEAM INVOLVED IN Manuel Sáez (UB) 3. Immunogenetics of receptors and Infect-ERA (SRecognite project) Ines Tadeu Simoes (IDIBAPS) molecules implicated in the regulation of AGAUR_SGR17 María Velasco de Andrés (IDIBAPS) innate and adaptive immune responses. Francisco Lozano TEAM

72 IMMUNE RECEPTORS OF THE INNATE AND ADAPTIVE SYSTEM 1.4

4. Study of the role of the lymphoid 5. Consuegra-Fernández M, Julià M, Review / I.F.: 20.4 scavenger-like receptors CD5 and CD6 as Martínez-Florensa M, Aranda F, Català C, immunomodulators in infection, Armiger-Borràs N, Arias MT, Santiago F, 1. Vanpouille-Box C., Lhuillier C., Bezu L., autoimmunity and cancer. Guilabert A, Esteve A, Muñoz C, Ferrándiz C, Aranda F., Yamazaki T., Kepp O., Fucikova J., 5. Molecular and functional characterization Carrascosa JM, Pedrosa E, Romaní J, Alsina Spisek R., Demaria S., Formenti S., Zitvogel L., of nonlymphoid members of the M, Mascaró-Galy JM, Lozano F. Genetic and Kroemer G., Galluzzi L. Trial watch: Immune superfamily of receptors with extracellular experimental evidence for the checkpoint blockers for cancer therapy. domains rich in cysteine (SRCR, Scavenger involvement of the CD6 lymphocyte ONCOIMMUNOLOGY. 6(11):1373237.. I.F.: 7.719 Receptor Cysteine-Rich) residues. receptor in psoriasis. CELLULAR AND 6. Characterization of the mechanisms that MOLECULAR IMMUNOLOGY. . I.F.: 5.897 2. Vasquez M, Simões I, Consuegra- regulate CMV gene expression and Fernández M, Aranda F, Lozano F, Berraondo identification of functions encoded by CMV. 6. Delgado J., Bielig T., Bonet L., P. Exploiting scavenger receptors in 7. Study of CMV modulation of the immune Carnero-Montoro E., Puente X., Colomer D., cancer immunotherapy: Lessons from response and viral immune evasion Bosch E., Campo E., Lozano F. Impact of the CD5 and SR-B1. EUROPEAN JOURNAL OF strategies functional CD5 polymorphism A471V on IMMUNOLOGY. 47(7):1108-1118. I.F.: 4.227 the response of chronic lymphocytic leukaemia to conventional chemotherapy 3. Farre D; Martínez-Vicente P; Engel P; PUBLICATIONS regimens. BRITISH JOURNAL OF Angulo A. Immunoglobulin superfamily HAEMATOLOGY. 177(1):142-156. I.F.: 5.670 members encoded by viruses and their Originals / I.F.: 57.104 multiple roles in immune evasion. 7. Simões I., Aranda F., Carreras E., Velasco-de EUROPEAN JOURNAL OF IMMUNOLOGY. 1. Pupuleku A; Costa-García M; Farre D; Andrés M., Casadó-Llombart S., Martinez V., 47(5):780-796. I.F.: 4.227 Hengel H; Angulo A; Muntasell A; Lopez-Botet Lozano F. Immunomodulatory effects of M. Elusive role of the CD94/NKG2C NK cell soluble CD5 on experimental tumor 4. Cossarizza, Andrea; Chang, Hyun-Dong; receptor in the response to models. ONCOTARGET. Radbruch, Andreas; Akdis, Mubeccel; Andrae, cytomegalovirus: Novel experimental 8(64):108156-108169. I.F.: 5.168 Immanuel; Annunziato, Francesco; Bacher, observations in a reporter cell system. Petra; Barnaba, Vincenzo; Battistini, Luca; FRONTIERS IN IMMUNOLOGY. 8. Rodríguez N., Morer A., González-Navarro Bauer, Wolfgang M.;… …; Zimmermann, Jakob. 8(OCTOBER):Article 1317. I.F.: 6.429 E., Serra-Pages C., Boloc D., Torres T., Guidelines for the use of flow cytometry García-Cerro S., Mas S., Gassó P., Lázaro L. and cell sorting in immunological studies. 2. Dantoft W, Martínez-Vicente P, Jafali J, Inflammatory dysregulation of monocytes EUROPEAN JOURNAL OF IMMUNOLOGY. Pérez-Martínez L, Martin K, Kotzamanis K, in pediatric patients with obsessive- 47(10):1584-1797. I.F.: 4.227 Craigon M, Auer M, Young N, Walsh P, compulsive disorder. JOURNAL OF Marchant A, Angulo A, Forster T, Ghazal P. NEUROINFLAMMATION. 14(1):261. I.F.: 5.102 Genomic programming of human neonatal Letters / I.F.: 12.858 dendritic cells in congenital systemic and 9. Martínez-Florensa M, in vitro cytomegalovirus infection reveal Consuegra-Fernández M, Aranda F, 1. Consuegra-Fernandez, Marta; Isamat, plastic and robust immune pathway Armiger-Borràs N, Di Scala M, Carrasco E, Marcos; Lozano, Francisco. Commentary: biology responses. FRONTIERS IN Pachón J, Vila J, González-Aseguinolaza G, CD6 as a Potential target for treating multiple IMMUNOLOGY. 8(SEPTEMBER):Article 1146. Lozano F. Protective Effects of Human and Sclerosis. FRONTIERS IN IMMUNOLOGY. I.F.: 6.429 Mouse Soluble Scavenger-Like CD6 8(SEPTEMBER):1217. I.F.: 6.429 Lymphocyte Receptor in a Lethal Model of 3. Carrasco, Esther; Escoda-Ferran, Cristina; Polymicrobial Sepsis. ANTIMICROB AGENTS 2. Lozano, Francisco; Martinez-Florensa, Climent, Nuria; Miro-Julia, Cristina; Simoes, CHEMOTHER. 61(1):e01391. I.F.: 4.302 Mario. Commentary: The Scavenger Ines T.; Martinez-Florensa, Mario; Sarukhan, Receptor SSc5D Physically Interacts with Adelaida; Carreras, Esther; Lozano, Francisco. 10. Bautista-Rodriguez C., Launes C., Jordan I., Bacteria through the SRCR-Containing Human CD6 Down-Modulation following Andres M., Arias M., Lozano F., Garcia-Garcia N-Terminal Domain. FRONTIERS IN T-Cell Activation Compromises J., Muñoz-Almagro C. Mannose-binding IMMUNOLOGY. 8(MAR):Article 366. I.F.: 6.429 Lymphocyte Survival and Proliferative lectin-deficient genotypes as a risk factor Responses. FRONTIERS IN IMMUNOLOGY. of pneumococcal meningitis in infants. 8(JUN):Article 769. I.F.: 6.429 PLOS ONE. 12(5):0178377. I.F.: 2.806 GRANTS FOR RESEARCH IN PROGRESS

4. Consuegra-Fernández M., 11. Perelló M, González-Foruria I, Castillo P, Angulo A. Caracterización funcional de Martínez-Florensa M., Aranda F., de Salort J., Martínez-Florensa M, Lozano F, Balasch J, nuevas proteínas del citomegalovirus que Armiger-Borràs N., Lozano T., Casares N., Carmona F. Oral Administration of interﬁeren en la respuesta inmune del Lasarte J., Engel P., Lozano F. Relevance of Pentoxifylline Reduces huésped. CD6-mediated interactions in the Endometriosis-Like Lesions in a Nude Sponsored by: Ministerio de Economía y regulation of peripheral T-cell responses Mouse Model. REPRODUCTIVE SCIENCES. Competitividad. SAF2014-55683-R and tolerance. FRONTIERS IN 24(6):911-918. I.F.: 2.443 Duration: 01/01/2015-31/12/2017 IMMUNOLOGY. 8(MAY):Article 594. I.F.: 6.429

73 AREA 1 BIOLOGICAL AGGRESSION AND RESPONSE MECHANISMS

Engel P. SLAM Gene Family Controlled Pathways to SLE. Sponsored by: NIH (USA). 2P01AI065687-06A1 Duration 01/08/2012-31/07/2017

Lozano F. Red Española de Investigación en Patología Infecciosa. Sponsored by: Instituto de Salud Carlos III (ISCIII). RD12/0015/0018 Duration: 01/01/2013-30/04/2017

Lozano F. Soluble scavenger-like lymphocyte receptors as novel immunomodulatory agents in cancer. Sponsored by: Fundació La Marató TV3. TV3_Cancer_13. 20131930 Duration: 08/05/2014-31/12/2017

Lozano F. CD5 y CD6 como dianas de inmunomodulación en modelos experimentales de autoinmunidad e infección. Sponsored by: Ministerio de Economía y Competitividad. SAF2013-46151-R Duration: 01/01/2014-30/06/2017

Lozano F. Proteínas SRCR como receptores reconocedores de microorganismos: un amplio rastreo de interacciones con bacterias patogénicas. Sponsored by: Ministerio de Economía y Competitividad. PI044058 Duration: 01/12/2015- 30/11/2018

Lozano F. Aproximaciones experimentales al estudio de las propiedades inmunomoduladores de receptores linfocitarios tipo scavenger en patología inmunomediada. Sponsored by: Ministerio de Economia y Competitividad. SAF2016-80535-R Duration: 30/12/2016-29/12/2019

DOCTORAL THESES

Lozano F, Martínez V. Characterization of the in vivo immunomodulatory properties of CD5 and CD6. PhD student: Ines Tadeus Simoes

Angulo A. Homólogos de inmunoreceptores de la familia SLAM codiﬁcados por citomegalovirus. PhD student: Pablo Martínez-Vicente

74 IMMUNOGENETICS OF THE AUTOINFLAMMATORY RESPONSE 1.6

Immunogenetics of the 1.6 autoinﬂammatory response

STRATEGIC OBJECTIVES

LOCATION In the field of autoinflammatory diseases: HCB building Promotion of basic, clinical and translation research in the physiopathology of autoinflammatory and immunomediated diseases as a model for gaining in-depth knowledge of the regulation of the normal inflammatory response, its dysfunctions, and KEYWORDS its effects upon the immune response. 1. Autoinflammation TEAM LEADER 2. Immunogenetics Jordi Yagüe (HCB) In the field of immune response: 3. Inflammasome T. 93 227 54 00 (Ext.: 2155) Determination of the components of normal 4. Immunotherapy [email protected] and pathological inflammatory response is 5. Immunodeficiencies essential for modulating the specific recognition phenomena of the immune response and developing immunotherapy. RESEARCHERS Juan Ignacio Aróstegui (HCB) Manel Juan Otero (HCB) MAIN LINES OF RESEARCH Original publications from 2015 to 2017 PRE-DOCTORAL RESEARCHERS In the field of autoinflammatory diseases: Sergi Betriu (FCRB) - Determination of the genetic and molecular YEAR I.F. TOTAL Q1 Q2 Berta Marzal (IDIBAPS) bases of the autoinflammatory process. 2015 75.24 13 9 4 Anna Mensa (HCB) - Characterization of the regulatory mechanisms of the inflammasome and its 2016 59.39 15 8 2 COLLABORATORS dysfunction. 2017 90.93 15 10 1 Daniel Benítez (HCB) - Characterization of the specific Miguel Caballero (HCB) transcriptional profiles of autoinflammatory Azucena Europa (HCB) diseases. Eva González (HCB) - Isolation of new genes responsible for Eduard Palou (HCB) hereditary autoinflammatory diseases and TEAM INVOLVED IN Estíbaliz Ruiz (HCB) identification of genetic susceptibility AGAUR_SGR14 factors for the development of polygenic autoinflammatory processes. - Definition of new therapeutic targets for the treatment of autoinflammatory diseases Jordi Yagüe TEAM

75 AREA 1 BIOLOGICAL AGGRESSION AND RESPONSE MECHANISMS

In the field of immune responses: 5. Rowczenio, Dorota M.; Gomes, Sonia Melo; OF EXPERIMENTAL AND CLINICAL - Assessing the role of HLA-DRB3/4/5 loci in Arostegui, Juan I.; Mensa-Vilaro, Anna; INVESTIGATION : THE OFFICIAL JOURNAL the immune response against infection, Omoyinmi, Ebun; Trojer, Hadija; Baginska, OF THE INTERNATIONAL SOCIETY OF transplantation and autoimmune response. Anna; Baroja-Mazo, Alberto; Pelegrin, Pablo; AMYLOIDOSIS. 24(4):245-252. I.F.: 3.373 - Cell immunotherapy (mainly in cancer): Savic, Sinisa; Lane, Thirusha; Williams, Rene; CAR Ts, DCs and TILs Brogan, Paul; Lachmann, Helen J.; Hawkins, 11. Lasigliè D, Mensa-Vilaro A, Ferrera D, Philip N.. Late-Onset Cryopyrin-Associated Caorsi R, Penco F, Santamaria G, Di Duca M, Periodic Syndromes Caused by Somatic Amico G, Nakagawa K, Antonini F, Tommasini PUBLICATIONS NLRP3 Mosaicism - UK Single Center A, Consolini R, Insalaco A, Cattalini M, Obici L, Experience. FRONTIERS IN IMMUNOLOGY. Gallizzi R, Santarelli F, Del Zotto G, Severino M, Originals / I.F.: 90.931 8(OCT):1410. I.F.: 6.429 Rubartelli A, Ravazzolo R, Martini A, Ceccherini I, Nishikomori R, Gattorno M, Arostegui J, 1. Vento-Tormo R, Álvarez-Errico D, 6. Esteve-Sole, Ana; Teixido, Irene; Borghini S. Cryopyrin-associated periodic Garcia-Gomez A, Hernández-Rodríguez J, Deya-Martinez, Angela; Yague, Jordi; syndromes in Italian Patients: Evaluation of Buján S, Basagaña M, Méndez M, Yagüe J, Plaza-Martin, Ana M.; Juan, Manel; Alsina, Laia. the rate of somatic NLRP3 mosaicism and Juan M, Aróstegui JI, Ballestar E. DNA Characterization of the Highly Prevalent phenotypic characterization. JOURNAL OF demethylation of inflammasome- Regulatory CD24(hi)CD38(hi) B-Cell RHEUMATOLOGY. 44(11):1667-1673. I.F.: 3.150 associated genes is enhanced in patients Population in Human Cord Blood. with cryopyrin-associated periodic FRONTIERS IN IMMUNOLOGY. 12. Sentís A; Diekmann F; Llobell A; de Moner syndromes. JOURNAL OF ALLERGY AND 8(MAR):201-67. I.F.: 6.429 N; Espinosa G; Yague J; Campistol J; Mirapeix CLINICAL IMMUNOLOGY. 139(1):202-211. E; Juan M. Kinetic analysis of changes in T- I.F.: 13.081 7. Esteve-Sole, Ana; Deya-Martinez, Angela; and B-lymphocytes after anti-CD20 Teixido, Irene; Ricart, Elena; Gompertz, treatment in renal pathology. 2. Moghaddas F, Llamas R, De Nardo D, Macarena; Torradeflot, Maria; de Moner, IMMUNOBIOLOGY. 222(4):620-630. I.F.: 2.720 Martinez-Banaclocha H, Martinez-Garcia JJ, Noemi; Azucena Gonzalez, Europa; Maria Mesa-Del-Castillo P, Baker PJ, Gargallo V, Plaza-Martin, Ana; Yague, Jordi; Juan, Manel; 13. Bujan-Rivas S, Basagaña M, Sena F, Mensa-Vilaro A, Canna S, Wicks IP, Pelegrin P, Alsina, Laia;. Immunological Changes in Méndez M, Dordal MT, Gonzalez-Roca E, Arostegui JI, Masters SL. A novel Blood of Newborns Exposed to Ruiz-Ortiz E, Mensa-Vilaró A, Plaza S, Pyrin-Associated Autoinflammation with Anti-TNF-alpha during Pregnancy. Modesto C, Ordi-Ros J, Yagüe J, Neutrophilic Dermatosis mutation further FRONTIERS IN IMMUNOLOGY. 8(SEP):1123. Martínez-Valle F, Aróstegui JI. Novel defines 14-3-3 binding of pyrin and I.F.: 6.429 evidences of atypical manifestations in distinction to Familial Mediterranean cryopyrin-associated periodic syndromes. Fever. ANNALS OF THE RHEUMATIC 8. Ruiz-Ortiz, Estibaliz; Iglesias, Estibaliz; CLINICAL AND EXPERIMENTAL DISEASES. 76(12):2085-2094. I.F.: 12.811 Soriano, Alessandra; Bujan-Rivas, Segundo; RHEUMATOLOGY. 35(6 (Suppl 108)): Espanol-Rego, Marta; Castellanos-Moreira, S27-S31. I.F.: 2.634 3. Sintes, Jordi; Gentile, Maurizio; Zhang, Raul; Tome, Adria; Yague, Jordi; Anton, Jordi; Shuling; Garcia-Carmona, Yolanda; Magri, Hernandez-Rodriguez, Jose;. Disease 14. Camprubí D, Mitjavila F, Arostegui JI, Giuliana; Cassis, Linda; Segura-Garzon, Phenotype and Outcome Depending on Corbella X. Efficacy of anakinra in an adult Daniel; Ciociola, Alessandra; Grasset, Emilie K.; the age at Disease Onset in Patients patient with recurrent pericarditis and Bascones, Sabrina; Comerma, Laura; Pybus, carrying the R92Q low-Penetrance Variant cardiac tamponade as initial Marc; Llige, David; Puga, Irene; Gutzeit, Cindy; in TNFRSF1A gene. FRONTIERS IN manifestations of tumor necrosis factor He, Bing; DuBois, Wendy; Crespo, Marta; IMMUNOLOGY. 8:299. I.F.: 6.429 receptor-associated periodic syndrome Pascual, Julio; Mensa, Anna; Ignacio Arostegui, due to the R92Q TNFRSF1A variant. Juan; Juan, Manel; Yague, Jordi; Serrano, 9. Rodríguez-Lobato LG, Fernández de INTERNATIONAL JOURNAL OF RHEUMATIC Sergi; Lloreta, Josep; Meffre, Eric; Hahne, Larrea C, Cibeira MT, Tovar N, Aróstegui JI, DISEASES. 20(4):510-514. I.F.: 2.624 Michael; Cunningham-Rundles, Charlotte; Rosiñol L, Díaz T, Lozano E, Elena M, Yagüe J, Mock, Beverly A.; Cerutti, Andrea. mTOR Bladé J. Impact of Autologous Stem Cell 15. Martinez-Valdez, Libny; Deya-Martinez, intersects antibody-inducing signals from Transplantation on the Incidence and Angela; Giner, Maria T.; Berrueco, Ruben; TACI in marginal zone B cells. NATURE Outcome of Oligoclonal Bands in Patients Esteve-Sole, Ana; Juan, Manel; Plaza-Martin, COMMUNICATIONS. 8(1):1462. I.F.: 12.124 with Light-Chain Amyloidosis. BIOLOGY OF Ana M.; Alsina, Laia. Evans Syndrome as BLOOD AND MARROW TRANSPLANTATION. First Manifestation of Primary 4. Arostegui JI, Anton J, Calvo I, Robles A, 23(8):1269-1275. I.F.: 4.704 Immunodeficiency in Clinical Practice. Iglesias E, López-Montesinos B, Banchereau JOURNAL OF PEDIATRIC HEMATOLOGY/ R, Hong S, Joubert Y, Junge G, Pascual V, 10. Rodríguez-Lobato L; Fernandez De Larrea ONCOLOGY. 39(7):490-494. I.F.: 1.076 Yagüe J. Open-label, Phase II Study to C; Cibeira M; Tovar N; Isola I; Aróstegui J; Assess Efficacy and Safety of Rosinol L; Diaz T; Lozano E; Yague J; Blade J. Canakinumab Treatment in Active Prognostic impact of immunoparesis at Review / I.F.: 3.493 Hyperimmunoglobulinemia D with diagnosis and after treatment onset in Periodic Fever Syndrome. ARTHRITIS AND patients with light-chain amyloidosis. 1. Bastida, Carla; Ruiz, Virginia; Pascal, RHEUMATOLOGY. 69(8):1679-1688. I.F.: 6.918 AMYLOID : THE INTERNATIONAL JOURNAL Mariona; Yague, Jordi; Sanmarti, Raimon; Soy,

76 IMMUNOGENETICS OF THE AUTOINFLAMMATORY RESPONSE 1.6

Dolors;. Is there potential for therapeutic DOCTORAL THESES drug monitoring of biologic agents in rheumatoid arthritis? BRITISH JOURNAL Martín MA, Juan M. Fenotips OF CLINICAL PHARMACOLOGY. dd’immunodeﬁciència comuna variable 83(5):962-975. I.F.: 3.493 (IDCV) en pacients pediàtrics. Correlació genotip-fenotip en l’evolució clínica i el tractament dels pacients. GRANTS FOR RESEARCH IN PROGRESS PhD student: Mònica Piquer Gibert

Arostegui JI. A comprehensive clinical and experimental approach to personalized molecular medicine in patient autoinﬂammatory disorders. Sponsored by: Instituto de Salud Carlos III (ISCIII). AC15/00027 Duration: 01/01/2016-31/12/2018

Arostegui JI. A comprehensive clinical and experimental approach to personalized molecular medicine in patients with defined and undefined autoinflammatory disorders. Sponsored by: Istituto Giannina Gaslini. E-RARE_JTC_2015_07 Duration: 01/05/2016-30/04/2019

Arostegui JI. Contribución de nuevos mecanismos genéticos a la ﬁsiopatología de las inmunodeﬁciencias primarias. Sponsored by: Ministerio de Economia y Competitividad. SAF2015-68472-C2-1-R Duration: 01/01/2016-31/12/2018

Arostegui JI. Estudio multicéntrico nacional para la evaluación de la deﬁciencia humana de lacasa en la ﬁsiopatología de la artritis idiopática juvenil. Sponsored by: Sociedad Española de Reumatología Pediátrica. SERPE-2015-AROSTEGUI Duration: 05/02/2016-31/12/2018

Juan M. Mejoras en el protocolo de tratamiento con linfocitos T transducidos con CART19 (receptor antigénico quimérico anti-CD19) en síndromes linfoproliferativos B: de la valoración epigenética a la introducción de genes suicidas. Sponsored by: Instituto de Salud Carlos III (ISCIII). PI13/00676 Duration: 01/01/2014-31/12/2017

Juan M. Acceleradora pel desenvolupament de Teràpies Avançades a Catalunya. Sponsored by: Universitat de Barcelona. COMRDI15-1-0013-13 Duration: 01/02/2016-31/01/2019

77 AREA 1 BIOLOGICAL AGGRESSION AND RESPONSE MECHANISMS

Emergencies: 1.7 processes and pathologies

PRE-DOCTORAL RESEARCHERS Sira Aguiló (HCB) LOCATION Pablo Burbano (UB) HCB building Javier Cabrera (UB) Francesc Xavier Escalada (UB) Inés María Fernández-Guerrero (UB) Lluís Llauger (UB) Javier López-Piedra (UB) Sònia Moreno (UB) KEYWORDS

1. Emergency department organization NURSING STAFF TEAM LEADER 2. Acute heart failure Òscar Miró (HCB) Sofía Calderón (HCB) Helena Morera (HCB) 3. Toxicology T. 93 227 54 00 (Ext.: 3153) 4. Chest pain [email protected] 5. Arrhythmia COLLABORATORS Xavier Alemany (HCB) Ana García (HCB) RESERACHERS Arrate Placer (HCB) Blanca Coll-Vinent (HCB) Milagrosa Perea (HCB) Sònia Jiménez (HCB) Santiago Nogué (HCB) Original publications Rafael Perelló (HCB) STRATEGIC OBJECTIVES from 2015 to 2017 Miguel Sánchez (HCB)

YEAR I.F. TOTAL Q1 Q2 The study of all processes and pathologies POST-DOCTORAL RESEARCHERS inherent to the emergency setting, with a 2015 94.44 28 18 8 Josep Ramon Alonso (HCB) patient-centred approach and focusing on the 2016 37.46 14 8 5 Montserrat Amigó (HCB) acute process leading to emergency 2017 235.95 39 29 8 Albert Antolín (HCB) consultation. The ﬁrst few hours of emergency Ernest Bragulat (HCB) disease conditions are exclusively addressed Rosa Escoda (HCB) by the Emergency Department, where clinical Miguel Galicia (HCB) research has not classically been considered. Victor Gil (HCB) This makes this group unique in Catalonia and

TEAM INVOLVED IN Elisenda Gómez (HCB) Spain. AGAUR_SGR14 Carolina Inostoza (HCB) Francesc Xavier Jiménez (UB) Beatriz López (HCB) Mar Ortega (HCB) Emilio Salgado (HCB) Òscar Miró TEAM

78 EMERGENCIES: PROCESSES AND PATHOLOGIES 1.7

MAIN LINES OF RESEARCH JOURNAL OF THE AMERICAN COLLEGE OF RELAHF study. EUROPEAN JOURNAL OF CARDIOLOGY. 70(12):1532-1534. I.F.: 19.896 HEART FAILURE. 19(9):1205-1209. I.F.: 6.968 1. Functional aspects of Hospital Emergency Departments. 4. Kaier, Thomas E.; Twerenbold, Raphael; 8. Arrigo M., Gayat E., Parenica J., Ishihara S., 2. Clinical aspects of intoxicated patients. Puelacher, Christian; Marjot, Jack; Zhang J., Choi D., Park J., Alhabib K., Sato N., 3. Treatment of arrhythmias in the Imambaccus, Nazia; Boeddinghaus, Jasper; Miro O., Maggioni A., Zhang Y., Spinar J., emergency room. Nestelberger, Thomas; Badertscher, Patrick; Cohen-Solal A., Iwashyna T., Mebazaa A. 4. Evaluation of chest pain in the Emergency Sabti, Zaid; Gimenez, Maria Rubini; Wildi, Karin; Precipitating factors and 90-day outcome Department. Hillinger, Petra; Grimm, Karin; Loeffel, Sarah; of acute heart failure: A report from the 5. Diffusion of the teaching of Shrestha, Samyut; Widmer, Dayana Flores; intercontinental GREAT registry. cardiopulmonary resuscitation maneuvers Cupa, Janosch; Kozhuharov, Nikola; Miro, EUROPEAN JOURNAL OF HEART FAILURE. among the general population Oscar; Javier Martin-Sanchez, F.; Morawiec, 19(2):201-208. I.F.: 6.968 6. Emergency medical care for problems Beata; Rentsch, Katharina; Lohrmann, Jens; caused by drug abuse. Kloos, Wanda; Osswald, Stefan; Reichlin, 9. Jacob J, Tost J, Miró Ò, Herrero P, 7. Acute heart failure Tobias; Weber, Ekkehard; Marber, Michael; Martín-Sánchez FJ, Llorens P, ICA-SEMES 8. Attention to infectious diseases in Mueller, Christian. Direct Comparison of Research Group. Impact of chronic Emergency Departments. Cardiac Myosin-Binding Protein C With obstructive pulmonary disease on clinical 9. Dynamics of teaching and research in Cardiac Troponins for the Early Diagnosis course after an episode of acute heart Emergency Medicine. of Acute Myocardial Infarction. failure. EAHFE-COPD study. INT J CIRCULATION. 136(16):1495-1508. I.F.: 19.309 CARDIOL. 227:450-456. I.F.: 6.189

PUBLICATIONS 5. Boeddinghaus, Jasper; Nestelberger, 10. Miró Ò, Gil V, Martín-Sánchez FJ, Thomas; Twerenbold, Raphael; Wildi, Karin; Herrero-Puente P, Jacob J, Mebazaa A, Originals / I.F.: 235.953 Badertscher, Patrick; Cupa, Janosch; Burge, Harjola VP, Ríos J, Hollander JE, Peacock WF, Tobias; Machler, Patrick; Corbiere, Sydney; Llorens P, ICA-SEMES Research Group(?). 1. Ortiz, Mercedes; Martin, Alfonso; Arribas, Grimm, Karin; Gimenez, Maria Rubini; Morphine Use in the ED and Outcomes of Fernando; Coll-Vinent, Blanca; del Arco, Puelacher, Christian; Shrestha, Samyut; Patients With Acute Heart Failure: A Carmen; Peinado, Rafael; Almendral, Widmer, Dayana Flores; Fuhrmann, Jakob; Propensity Score-Matching Analysis Jesus;PROCAMIO Study Investigators. Hillinger, Petra; Sabti, Zaid; Honegger, Ursina; Based on the EAHFE Registry. CHEST. Randomized comparison of intravenous Schaerli, Nicolas; Kozhuharov, Nikola; 152(4):821-832. I.F.: 6.147 procainamide vs. intravenous amiodarone Rentsch, Katharina; Miro, Oscar; Lopez, for the acute treatment of tolerated wide Beatriz; Javier Martin-Sanchez, F.; 11. Coll-Vinent B, Martín A, Sánchez J, QRS tachycardia: the PROCAMIO study. Rodriguez-Adrada, Esther; Morawiec, Beata; Tamargo J, Suero C, Malagón F, Varona M, EUROPEAN HEART JOURNAL. Kawecki, Damian; Ganovska, Eva; Parenica, Cancio M, Sánchez S, Carbajosa J, Ríos J, 38(17):1329-1335. I.F.: 20.212 Jiri; Lohrmann, Jens; Kloos, Wanda; Buser, Casanovas G, Ràfols C, Del Arco C, Andreas; Geigy, Nicolas; Keller, Dagmar I.; EMERG-AF Investigators. Beneﬁts of 2. Nestelberger, Thomas; Boeddinghaus, Osswald, Stefan; Reichlin, Tobias; Mueller, Emergency Departments' Contribution to Jasper; Badertscher, Patrick; Twerenbold, Christian. Direct Comparison of 4 Very Early Stroke Prophylaxis in Atrial Fibrillation: Raphael; Wildi, Karin; Breitenbuecher, Dominik; Rule-Out Strategies for Acute Myocardial The EMERG-AF Study (Emergency Sabti, Zaid; Puelacher, Christian; Gimenez, Infarction Using High-Sensitivity Cardiac Department Stroke Prophylaxis and Maria Rubini; Kozhuharov, Nikola; Strebel, Ivo; Troponin I. CIRCULATION. 135(17):1597-1611. Guidelines Implementation in Atrial Sazgary, Lorraine; Schneider, Deborah; Jann, I.F.: 19.309 Fibrillation). STROKE A JOURNAL OF Janina; de lavallaz, Jeanne du Fay; Miro, Oscar; CEREBRAL CIRCULATION. 48(5):1344-1352. Javier Martin-Sanchez, F.; Morawiec, Beata; 6. Miro, Oscar; Rossello, Xavier; Gil, Victor; I.F.: 6.032 Kawecki, Damian; Muzyk, Piotr; Keller, Dagmar Martin-Sanchez, Francisco Javier; Llorens, I.; Geigy, Nicolas; Osswald, Stefan; Reichlin, Pere; Herrero-Puente, Pablo; Jacob, Javier; 12. Badertscher, Patrick; Nestelberger, Tobias; Mueller, Christian; APACE Bueno, Hector; Pocock, Stuart J.;ICA-SEMES Thomas; de Lavallaz, Jeanne du Fay; Investigators. Effect of Deﬁnition on Res Grp. Predicting 30-Day Mortality for Morawiec, Beata; Kawecki, Damian; Miro, Incidence and Prognosis of Type 2 Patients With Acute Heart Failure in the Oscar; Lopez, Beatriz; Martin-Sanchez, F. Myocardial Infarction. JOURNAL OF THE Emergency Department A Cohort Study. Javier; Bustamante, Jose; Geigy, Nicolas; AMERICAN COLLEGE OF CARDIOLOGY. ANNALS OF INTERNAL MEDICINE. Christ, Michael; Di Somma, Salvatore; 70(13):1558-1568. I.F.: 19.896 167(10):698-705. I.F.: 17.202 Peacock, W. Frank; Cullen, Louise; Sarasin, Francois; Flores, Dayana; Tschuck, Michael; 3. Twerenbold, Raphael; Badertscher, Patrick; 7. Herrero-Puente P, Prieto-García B, Boeddinghaus, Jasper; Twerenbold, Raphael; Boeddinghaus, Jasper; Nestelberger, García-García M, Llorens P, Martín-Sánchez Wildi, Karin; Sabti, Zaid; Puelacher, Christian; Thomas; Wildi, Karin; Gimenez, Maria Rubini; FJ, Jacob J, Mebazaa A, Mueller C, Maisel AS, Gimenez, Maria Rubini; Kozhuharov, Nikola; Miro, Oscar; Martin-Sanchez, F. Javier; Gil V, García-Hernandez P, Miró Ò. The Shrestha, Samyut; Strebel, Ivo; Rentsch, Reichlin, Tobias; Mueller, Christian. Effect of relationship of circulating relaxin-2 Katharina; Keller, Dagmar I.; Poepping, Imke; the FDA Regulatory Approach on the 0/1-h concentrations with short-term prognosis Buser, Andreas; Kloos, Wanda; Lohrmann, Jens; Algorithm for Rapid Diagnosis of MI. in patients with acute heart failure: the Kuehne, Michael; Osswald, Stefan; Reichlin,

79 AREA 1 BIOLOGICAL AGGRESSION AND RESPONSE MECHANISMS

Tobias; Mueller, Christian. Prohormones in the 17. Hernandez S., Moren C., Catalán-García 29(6):373-383. I.F.: 3.028 Early Diagnosis of Cardiac Syncope. M., Lopez M., Guitart-Mampel M., Coll O., JOURNAL OF THE AMERICAN HEART Garcia L., Milisenda J., Justamante A., Gatell J., 23. Jacob, Javier; Gene, Emili; Alonso, ASSOCIATION. 6(12):e006592. I.F.: 4.425 Cardellach F., Gratacos E., Miro Ò., Garrabou Gilberto; Rimbau, Pere; Zorrilla, Jose; G.. Mitochondrial toxicity and caspase Casarramona, Francesc; Netto, Cristina; 13. Miró Ò., Gil V., Xipell C., Sánchez C., Aguiló activation in HIV pregnant women. Sanchez, Pere; Hernandez, Ricard; Escalada, S., Martín-Sánchez F., Herrero P., Jacob J., JOURNAL OF CELLULAR AND MOLECULAR Xavier; Miro, Oscar. Occupational aspects of Mebazaa A., Harjola V., Llorens P. MEDICINE. 21(1):26-34. I.F.: 4.499 emergency medicine practice in Catalonia: IMPROV-ED study: outcomes after the OPENCAT opinion survey. discharge for an episode of 18. Hernández S, Catalán-García M, Morén C, EMERGENCIAS. 29(6):403-411. I.F.: 3.028 acute-decompensated heart failure and García-Otero L, López M, Guitart-Mampel M, comparison between patients discharged Milisenda J, Coll O, Cardellach F, Gratacós E, 24. Burbano Santos P., Fernández-Guerrero I., from the emergency department and Miró Ò, Garrabou G. Placental Mitochondrial Martín-Sánchez F., Burillo G., Miró Ò. Analysis hospital wards. CLINICAL RESEARCH IN Toxicity, Oxidative Stress, Apoptosis And of Spanish research collaboration in CARDIOLOGY. 106(5):369-378. I.F.: 4.760 Adverse Perinatal Outcomes In emergency medicine: 2010-2014. Hiv-Pregnancies Under Antiretroviral EMERGENCIAS. 29(5):320-326. I.F.: 3.028 14. Boeddinghaus, Jasper; Reichlin, Tobias; Treatment Containing Zidovudine. Nestelberger, Thomas; Twerenbold, JOURNAL OF ACQUIRED IMMUNE 25. Fernández-Guerrero I., Martín-Sánchez F., Raphael; Meili, Yvette; Wildi, Karin; Hillinger, DEFICIENCY SYNDROMES. 75(4): Burillo-Putze G., Miró Ò. Scientific Petra; Gimenez, Maria Rubini; Cupa, E113-E119. I.F.: 3.935 publication output of Spanish emergency Janosch; Schumacher, Lukas; Schubera, physicians from 2005 to 2014: A Marie; Badertscher, Patrick; Corbiere, 19. Miro O; Galicia M; Dargan P; Dines A; comparative study. EMERGENCIAS. Sydney; Grimm, Karin; Puelacher, Christian; Giraudon I; Heyerdahl F; Hovda K; Yates C; 29(5):327-334. I.F.: 3.028 Sabti, Zaid; Widmer, Dayana Flores; Wood D. Intoxication by gamma Schaerli, Nicolas; Kozhuharov, Nikola; hydroxybutyrate and related analogues: 26. Vicente V, Martín A, Lecumberri R, Shrestha, Samyut; Burge, Tobias; Machler, Clinical characteristics and comparison Coll-Vinent B, Suero C, González-Porras J, Patrick; Buchi, Michael; Rentsch, Katharina; between pure intoxication and that Marco P, Mateo J, Roldán V, Soulard S, Miro, Oscar; Lopez, Beatriz; Javier combined with other substances of abuse. Crespo C, Camats M. Clinical perspectives Martin-Sanchez, F.; Rodriguez-Adrada, TOXICOLOGY LETTERS. 277:84-91. I.F.: 3.858 on the management of bleeding in patients Esther; Morawiec, Beata; Kawecki, Damian; on oral anticoagulants: The DECOVER Ganovska, Eva; Parenica, Jiri; Lohrmann, 20. Martín-Sánchez FJ, Rodríguez-Adrada E, Study (DElphi Consensus on oral Jens; Buser, Andreas; Keller, Dagmar I.; Vidan MT, Llopis García G, González Del COagulation and therapy action reVERsa. Osswald, Stefan; Mueller, Christian. Early Castillo J, Rizzi MA, Alquezar A, Piñera P, EMERGENCIAS. 29(1):18-26. I.F.: 3.028 diagnosis of acute myocardial infarction Lázaro Aragues P, Llorens P, Herrero P, Jacob in patients with mild elevations of cardiac J, Gil V, Fernández C, Bueno H, Miró Ò, 27. López Altimiras X, Gené Tous E, De Giorgi A, troponin. CLINICAL RESEARCH IN Representing the members of the OAK Gadea Polo A, Martín Horcajo R, Jiménez CARDIOLOGY. 106(6):457-467. Register Investigators. Impact of Frailty and Hernández S. Nontherapeutic international I.F.: 4.760 Disability on 30-Day Mortality in Older normalized ratio results in hospital Patients With Acute Heart Failure. emergency patients on vitamin K 15. Hillinger, Petra; Twerenbold, Raphael; AMERICAN JOURNAL OF CARDIOLOGY. antagonists: prevalence and associated Wildi, Karin; Rubini Gimenez, Maria; Jaeger, 120(7):1151-1157. I.F.: 3.398 factors. EMERGENCIAS. 29(2):93-98. I.F.: 3.028 Cedric; Boeddinghaus, Jasper; Nestelberger, Thomas; Grimm, Karin; Reichlin, Tobias; 21. Miró Ò., Llorens P., Escalada X., Herrero P., 28. Moreno Barriga, Elvira; Pueyo Ferrer, Stallone, Fabio; Puelacher, Christian; Sabti, Jacob J., Gil V., Xipell C., Sánchez C., Aguiló S., Irene; Sanchez Sanchez, Miguel; Martin Zaid; Kozhuharov, Nikola; Honegger, Ursina; Martín-Sánchez F. Prehospital emergency Baranera, Montserrat; Masip Utset, Josep. A Ballarino, Paola; Miro, Oscar; Denhaerynck, care of patients with acute heart failure in new artificial intelligence tool for assessing Kris; Ekrem, Temizel; Kohler, Claudia; Spain: The semica study (Emergency symptoms in patients seeking emergency Bingisser, Roland; Osswald, Stefan; Mueller, medical response systems for patients department care: the Mediktor application. Christian. Gender-specific uncertainties in with acute heart failure). EMERGENCIAS. EMERGENCIAS. 29(6):391-396. I.F.: 3.028 the diagnosis of acute coronary syndrome. 29(4):223-230. I.F.: 3.028 CLINICAL RESEARCH IN CARDIOLOGY. 29. Miro O; Carbajosa V; Peacock W; Llorens 106(1):28-37. I.F.: 4.760 22. Del Arco Galán C., Rodríguez Miranda B., P; Herrero P; Jacob J; Collins S; Fernandez C; González del Castillo J., Ruiz Grinspan M., Pastor A; Martín-Sánchez F. The effect of a 16. Blanco-Hinojo L, Pujol J, Harrison BJ, Carballo C., Bibiano Guillén C., Artillo S., Miró short-stay unit on hospital admission and Macià D, Batalla A, Nogué S, Torrens M, Farré Ò., Martín-Sánchez F. Physical structure, length of stay in acute heart failure: M, Deus J, Martín-Santos R. Attenuated human resources, and health care quality REDUCE-AHF study. EUROPEAN JOURNAL frontal and sensory inputs to the basal indicators in public hospital emergency OF INTERNAL MEDICINE. 40:30-36. I.F.: 2.960 ganglia in cannabis users. ADDICTION departments in the autonomous BIOLOGY. 22(4):1036-1047. I.F.: 4.603 communities of Madrid and Catalonia: 30. Martín-Sánchez FJ, Rodríguez-Adrada E, A comparative study. EMERGENCIAS. Mueller C, Vidán MT, Christ M, Frank Peacock

80 EMERGENCIES: PROCESSES AND PATHOLOGIES 1.7

W, Rizzi MA, Alquezar A, Piñera P, Aragues PL, Herrero P, Martín-Sanchez FJ, Möckel M, medicine perspective. EUROPEAN Llorens P, Herrero P, Jacob J, Fernández C, Müller C, Llorens P, ICA-SEMES Research JOURNAL OF EMERGENCY MEDICINE. Miró Ò. The effect of frailty on 30-day Group. EAHFE - TROPICA2 study. 24(1):2-12. I.F.: 2.025 mortality risk in older patients with acute Prognostic value of troponin in patients heart failure attended in the Emergency with acute heart failure treated in Spanish Department. ACADEMIC EMERGENCY hospital emergency departments. Letters / I.F.: 10.541 MEDICINE. 24(3):298-307. I.F.: 2.925 BIOMARKERS. 22(3-4):337-344. I.F.: 2.006 1. Trullàs J; Miro O. About the Specialty 31. Herrero-Puente P, Prieto-García B, 37. Miro, Oscar; Burbano, Pablo; Graham, Treating Patients With Heart Failure. García-García M, Jacob J, Martín-Sánchez FJ, Colin A.; Cone, David C.; Ducharme, James; REVISTA ESPAÑOLA DE CARDIOLOGIA. Pascual-Figal D, Bueno H, Gil V, Llorens P, Brown, Anthony F. T.; Javier Martin-Sanchez, 70(7):611-611. I.F.: 4.485 Vázquez-Alvarez J, Romero-Pareja R, Francisco. Analysis of h-index and other Sanchez-Gonzalez M, Miró Ò. Predictive bibliometric markers of productivity and 2. Miro, Oscar. Contribution of authors, capacity of a multimarker strategy to repercussion of a selected sample of financing and ethical responsibilities. determine short-term mortality in patients worldwide emergency medicine EMERGENCIAS. 29(1):65-65. I.F.: 3.028 attending a hospital emergency researchers. EMERGENCY MEDICINE department for acute heart failure. JOURNAL. 34(3):175-181. I.F.: 1.861 3. Nogué Xarau S, Velasco V, Marambio M, BIO-EAHFE study. CLIN CHIM ACTA. López L. Stings from jellyfish and other 466:22-30. I.F.: 2.873 38. Jimenez S., Ruiz-Artacho P., Merlo M., venomous marine life: impact on beach Suero C., Antolin A., Casal J., Sanchez M., lifeguard services. EMERGENCIAS. 32. Domínguez-Rodríguez A; Burillo-Putze G; Ortega-Duarte A., Genis M., Piñera P. Risk 29(6):426-427. I.F.: 3.028 Garcia-Saiz M; Aldea-Perona A; Harmand M; profile, management, and outcomes of Miro O; Abreu-Gonzalez P; Pinillos-Echeverría patients with venous thromboembolism M; Rizzi M; Martín-Sánchez F; Suero-Mendez attended in Spanish Emergency Editorial / I.F.: 10.135 C; Calvo-Rodriguez R; Carballo-Carmona C; Departments. MEDICINE (UNITED Gil V; Herrero P; Bajo A; Salmeron P. Study STATES). 96(48):e8796. I.F.: 1.804 1. Miro, Oscar. An amazing 10 years. Design and Rationale of “A Multicenter, EMERGENCIAS. 29(5):297-300. I.F.: 3.028 Open-Labeled, Randomized Controlled 39. Fuenzalida C, Hernández G, Ferro I, Trial Comparing MIdazolam Versus Siches C, Ambrós À, Coll-Vinent B. Long-term 2. Miro, Oscar. Emergencias: holding our own MOrphine in Acute Pulmonary Edema”: benefits of education by emergency care in the top quarter. EMERGENCIAS. MIMO Trial. CARDIOVASCULAR DRUGS nurses at discharge of patients with atrial 29(4):217-220. I.F.: 3.028 AND THERAPY. 31(2):209-213. I.F.: 2.820 fibrillation. INTERNATIONAL EMERGENCY NURSING. 35:7-12. I.F.: 1.298 3. Miro, Oscar; Gil, Victor; Peacock, W. Frank. 33. Miró, Òscar; Rizzi, Miguel A.; Herrero, Morphine in acute heart failure: good in Pablo; Jacob, Javier; Martin-Sanchez, relieving symptoms, bad in improving Francisco J.; Gil, Victor; Alquezar, Aitor; Review / I.F.: 19.352 outcomes. JOURNAL OF THORACIC Escoda, Rosa; Llorens, Pere; ICA-SEMES Res DISEASE. 9(9):E871-E874. I.F.: 2.365 Group. OBESICA study: relationship 1. Price, Susanna; Platz, Elke; Cullen, Louise; between BMI and acute heart failure Tavazzi, Guido; Christ, Michael; Cowie, Martin 4. Miro O. The challenge of infectious outcome. EUROPEAN JOURNAL OF R.; Maisel, Alan S.; Masip, Josep; Miro, Oscar; diseases in the emergency department: EMERGENCY MEDICINE. 24(5):326-332. McMurray, John J.; Peacock, W. Frank; Javier Presentation of 3 cases. ENFERMEDADES I.F.: 2.025 Martin-Sanchez, F.; Di Somma, Salvatore; INFECCIOSAS Y MICROBIOLOGIA CLINICA. Bueno, Hector; Zeymer, Uwe; Mueller, 35(4):205-207. I.F.: 1.714 34. Miró, Òscar; Busca, Pablo;. Emergency Christian; European Soc Cardiology Acute physician sex and emergency department Card. Echocardiography and lung resource use. EUROPEAN JOURNAL OF ultrasonography for the assessment and Consortium publications / I.F.: 116.811 EMERGENCY MEDICINE. 24(4):277-283. management of acute heart failure. I.F.: 2.025 NATURE REVIEWS CARDIOLOGY. 1. Packer, M.; O'Connor, C.; McMurray, J. J. V.; 14(7):426-440. I.F.: 14.299 Wittes, J.; Abraham, W. T.; Anker, S. D.; 35. Miró Ò, González de la Presa B, Dickstein, K.; Filippatos, G.; Holcomb, R.; Krum, Herrero-Puente P, Fernández Bonifacio R, 2. Aguirre Tejedo A; Miro O. Precipitating H.; Maggioni, A. P.; Mebazaa, A.; Peacock, W. Möckel M, Mueller C, Casals G, Sandalinas S, factors in acute heart failure: A review. F.; Petrie, M. C.; Ponikowski, P.; Ruschitzka, F.; Llorens P, Martín-Sánchez FJ, Jacob J, Bedini EMERGENCIAS. 29(3):185-193. I.F.: 3.028 van Veldhuisen, D. J.; Kowarski, L. S.; JL, Gil V. The GALA study: relationship Schactman, M.; Holzmeister, J.;TRUE-AHF between galectin-3 serum levels and 3. Miró Ò, Levy PD, Möckel M, Pang PS, Investigators. Effect of Ularitide on short- and long-term outcomes of patients Lambrinou E, Bueno H, Hollander JE, Harjola Cardiovascular Mortality in Acute Heart with acute heart failure. BIOMARKERS. VP, Diercks DB, Gray AJ, DiSomma S, Papa Failure. NEW ENGLAND JOURNAL OF 22(8):731-739. I.F.: 2.006 AM, Collins SP. Disposition of emergency MEDICINE. 376(20):1956-1964. I.F.: 72.406 department patients diagnosed with acute 36. Jacob J, Roset A, Miró Ò, Alquézar A, heart failure: an international emergency 2. Freund Y, Lemachatti N, Krastinova E, Van

81 AREA 1 BIOLOGICAL AGGRESSION AND RESPONSE MECHANISMS

Laer M, Claessens YE, Avondo A, Occelli C, Feral-Pierssens AL, Truchot J, Ortega M, Carneiro B, Pernet J, Claret PG, Dami F, Bloom B, Riou B, Beaune S. French Society of Emergency Medicine Collaborators Group. Prognostic Accuracy of Sepsis-3 Criteria for In-Hospital Mortality Among Patients With Suspected Infection Presenting to the Emergency Department. JAMA. 317(3):301-308. I.F.: 44.405

GRANTS FOR RESEARCH IN PROGRESS

Miró O. Identificació a urgències dels pacients amb insuficiència cardiaca aguda de baix risc i desenvolupament d'una escala per identificar-los i millorar l'evolució dels que són donats d'alta des d'urgències. Sponsored by: Fundació la Marató de TV3. 20152510 Duration: 09/03/2016-08/03/2019

Miró O. Diseño de programas de intervención y escalas de riesgo con marcadores y biológicos de fragilidad para la insuﬁciencia cardiaca aguda en los servicios de urgencia españoles. Sponsored by: Instituto de Salud Carlos III. PI15/01019 Duration: 01/01/2016-31/12/2018

DOCTORAL THESES

Miró Ò, Llorens P. Análisis de factores pronóstico y estratiﬁcación del riesgo en pacientes con insuﬁciencia cardiaca aguda atendidos en los servicios de urgencias. PhD student: Víctor Luis Gil Espinosa

82 MOLECULAR AND CELLULAR BASES OF INFLAMMATION. STRUCTURAL AND BIOLOGICAL MASS SPECTROMETRY 1.8

Molecular and cellular bases of inﬂammation. Structural and 1.8 biological mass spectrometry

STRATEGIC OBJECTIVES

LOCATION 1. Molecular and cellular bases of IIBB-CSIC labs inflammation: Study of inflammatory response in experimental models of acute pancreatitis, lung fibrosis and pancreatic cancer.

2. Structural and biological mass KEYWORDS spectrometry: 1. Inﬂammation TEAM LEADER Development of techniques for the analysis 2. Fibrosis Daniel Closa (IIBB-CSIC ) of biomolecules by mass spectrometry and 3. Proteomics T. 93 363 83 43 more especially for proteomics studies. 4. Macrophages [email protected] Application to the characterization of post-translational modiﬁcations involved in signal transduction and of therapeutic targets and markers of disease.

RESEARCHERS MALDI-imaging. Joaquín Abián (IIBB-CSIC) Original publications Montserrat Carrascal (IIBB-CSIC) MAIN LINES OF RESEARCH from 2015 to 2017 Anna Serrano (IIBB-CSIC)

YEAR I.F. TOTAL Q1 Q2 POST-DOCTORAL RESEARCHER 1. Molecular and cellular bases of inflammation: 2015 23.47 5 3 1 Albert Casanovas (IIBB-CSIC) - Mechanisms involved in the development 2016 28.35 6 6- TECHNICIAN of systemic inflammatory processes. 2017 18.57 4 4 - Oscar Gallardo (IIBB-CSIC) - New therapies for idiopathic pulmonary Laura López (IIBB-CSIC) fibrosis. Roberto Pinto (IIBB-CSIC) - Study of cell communication in pancreatic Ester Sánchez (IIBB-CSIC) cancer. Ignacio Sánchez (IIBB-CSIC) - Exosomes in inflammatory diseases.

2. Structural and biological mass spectrometry: - Phosphoproteome, acetylome, ubiquitinome and modiﬁcation crosstalking on the human t-lymphocyte. Daniel Closa TEAM

83 AREA 1 BIOLOGICAL AGGRESSION AND RESPONSE MECHANISMS

- Diagnostic and prognostic markers in 2. Lopez-Rodriguez E; Gay-Jordi G; Mucci A; cancer and other diseases. Lachmann N; Serrano-Mollar A. Lung - External scientiﬁc-technical services. surfactant metabolism: early in life, early - MALDI-Imaging. in disease and target in cell therapy. CELL AND TISSUE RESEARCH. 367(3):721-735. I.F.: 2.787 PUBLICATIONS

Originals / I.F.: 18.569 GRANTS FOR RESEARCH IN PROGRESS

1. Casanovas, Albert; Pinto-Llorente, Roberto; Closa D. Exosomas como mediadores de la Carrascal, Montserrat; Abian, Joaquin;. progresión sistémica en la pancreatitis Large-Scale Filter-Aided Sample aguda; papel fisiopatológico y potencial Preparation Method for the Analysis of the como marcadores pronóstico. Ubiquitinome. ANALYTICAL CHEMISTRY. Sponsored by: Instituto de Salud Carlos III 89(7):3840-3846. I.F.: 6.320 (PI16/00060) Duration 01/1/2017-31/12/2019 2. Bonjoch L, Gironella M, Iovanna JL, Closa D. REG3β modifies cell tumor function by Closa D. Importancia de los microRNAs impairing extracellular vesicle uptake. transportados por exosomas en la SCIENTIFIC REPORTS. 7(1):3143. I.F.: 4.259 progresión de la inflamación sistémica durante la pancreatitis aguda. 3. Casas V, Rodríguez-Asiain A, Pinto- Sponsored by: Asociación Española de Llorente R, Vadillo S, Carrascal M, Abian J. Gastroenterología (Beca Gonzalo Miño 2017) Brachyspira hyodysenteriae and B. Duration 09/3/2017-09/03/2020 pilosicoli Proteins Recognized by Sera of Challenged Pigs. FRONTIERS IN MICROBIOLOGY. 8:723. I.F.: 4.076 DOCTORAL THESES

4. Vialas V, Colomé-Calls N, Abian J, Aloria K, Closa D, Pastor M. Estudi dels exosomes Alvarez-Llamas G, Antúnez O, Arizmendi JM, com a mecanisme de comunicació Azkargorta M, Barceló-Batllori S, Barderas intercel·lular en patologies pancreàtiques. MG, Blanco F, Casal JI, Casas V, de la Torre C, PhD student: Laia Bonjoch Gassol Chicano-Gálvez E, Elortza F, Espadas G, Estanyol JM, Fernandez-Irigoyen J, Abián J, Carrascal M. Proteome Fernandez-Puente P, Fidalgo MJ, Fuentes M, characterization of Brachyspira strains. Gay M, Gil C, Hainard A, Hernaez ML, Ibarrola Identiﬁcation of bacterial antigens. N, Kopylov AT, Lario A, Lopez JA, PhD student: Vanessa Casas López López-Lucendo M, Marcilla M, Marina-Ramírez A, Marko-Varga G, Martín L, Mora MI, Morato-López E, Muñoz J, Odena MA, de Oliveira E, Orera I, Ortea I, Pasquarello C, Ray KB, Rezeli M, Ruppen I, Sabidó E, Del Pino MMS, Sancho J, Santamaría E, Vazquez J, Vilaseca M, Vivanco F, Walters JJ, Zgoda VG, Corrales FJ, Canals F, Paradela A. A multicentric study to evaluate the use of relative retention times in targeted proteomics. J PROTEOMICS. 152:138-149. I.F.: 3.914

Review / I.F.: 10.506

1. Iovanna, Juan L.; Closa, Daniel. Factors released by the tumor far microenvironment are decisive for pancreatic adenocarcinoma development and progression. ONCOIMMUNOLOGY. 6(11):e1358840. I.F.: 7.719

84 OCULAR INFLAMMATION: CLINICAL AND EXPERIMENTAL STUDIES 1.9

Ocular inﬂammation: clinical and experimental 1.9 studies

NURSING STAFF Victoria Hernández (FCRB) LOCATION MATERNITAT building COLLABORATORS Javier Zarranz-Ventura (HCB)

STRATEGIC OBJECTIVES

KEYWORDS The research of the Ocular Inflammation 1. Uveitis Group focuses on how the retina responds to TEAM LEADER injury, inflammation and degeneration. Our 2. Inflammation Alfredo Adán (HCB) 3. Immunology main goal is to promote the investigation on T. 93 227 56 67 ocular inflammatory diseases with special 4. Biomarkers [email protected] interest in the study of pathological 5. Biological therapies mechanisms, immune response, and development of new therapies.

RESEARCHERS Elena Millá (HCB) MAIN LINES OF RESEARCH Maria Teresa Sáinz (HCB) Original publications 1. Prognostic factors in patients with from 2015 to 2017 POST-DOCTORAL RESEARCHERS macular edema associated with Víctor Llorens (HCB) non-infectious uveitis: Assessment YEAR I.F. TOTAL Q1 Q2 Marina Mesquida (HCB) of the clinical, biological and imaging 2015 30.22 12 3 8 Blanca Molins (FCRB) factors involved in the pathogenesis of 2016 38.31 13 66 Marta Pazos (HCB) uveitic macular edema and its response to treatment. 2017 40.96 8 7- PRE-DOCTORAL RESEARCHERS Marc Figueras (HCB) 2. New biologic therapies for the Jessica Matas (HCB) treatment of non-infectious uveitis: Sara Romero (FCRB) Assessment of the efficacy and safety of Anna Sala (HCB) new biologic therapies including TEAM INVOLVED IN anti-TNF-alpha, anti-IL-1beta, and OFTARED (RETIC) TECHNICIANS anti-IL-6 receptor monoclonal antibodies Jesus Gascon (FCRB) for treating patients with non-infectious Anna Montasell (FCRB) uveitis. Alfredo Adán TEAM

85 AREA 1 BIOLOGICAL AGGRESSION AND RESPONSE MECHANISMS

3. Genetic polymorphisms predisposing 69(3):668-675. I.F.: 6.918 glaucoma: A meta-analysis. SURVEY OF to uveitis: Multicentric study that OPHTHALMOLOGY. 62(4):446-461. I.F.: 3.374 investigates genetic polymorphisms as 4. Márquez A., Cordero-Coma M., Martín-Villa potential risk factors for developing uveitis J., Gorroño-Echebarría M., Blanco R., Valle D., 3. Mesquida M., Llorens V., Adán A. New and its complications. del Rio M., Blanco A., Olea J., Cordero Y., imaging techniques in retinal vasculitis. Capella M., Díaz-Llopis M., Ortego-Centeno N., URGENCIAS EN PEDIATRÍA. 149(6):261-266. 5. Tuberculosis-related uveitis: Ruiz-Arruza I., Llorenç V., Adán A., Fonollosa A., I.F.: 1.125 Development of epidemiological, clinical Berge J., Atan D., Dick A., De Boer J., Kuiper J., and experimental studies Rothova A., Martín J. New insights into the genetic component of non-infectious Letters / I.F.: 2.453 6. Macular pathology in diabetic patients: uveitis through an Immunochip strategy. Development of clinical and experimental JOURNAL OF MEDICAL GENETICS. 1. Mesquida M, Llorenç V, Adán A. In studies to investigate the pathogenesis of 54(1):38-46. I.F.: 5.451 Response to: 'Deuter CM, Zierhut M, diabetic macular edema, as well as its Igney-Oertel A, et al. Tocilizumab in Uveitic response to different therapeutic 5. Molins, Blanca; Anna Pascual, Mendez; Macular Edema Refractory to Previous approaches. Llorenc, Victor; Zarranz-Ventura, Javier; Immunomodulatory Treatment. OCULAR Mesquida, Marina; Adan, Alfredo; Martorell, IMMUNOLOGY AND INFLAMMATION. 7. Molecular basis of age-related macular Jordi. C-reactive protein isoforms 25(2):221-222. I.F.: 2.453 degeneration (AMD): Study of the differentially affect outer blood-retinal contribution of chronic inflammation and in barrier integrity and function. AMERICAN particular, C-reactive protein and JOURNAL OF PHYSIOLOGY - CELL GRANTS FOR RESEARCH IN PROGRESS complement Factor H to the progression PHYSIOLOGY. 312(3):C244-C253. I.F.: 3.602 of AMD. Adán A. Prevención, detección precoz y 6. Cocho, Lidia; Fernandez, Itziar; Calonge, tratamiento de la patología ocular Margarita; Sainz de la Maza, Maite; Rovira, prevalente degenerativa y crónica. PUBLICATIONS Montserrat; Stern, Michael E.; Sponsored by: Instituto de Salud Carlos III Garcia-Vazquez, Carmen; (ISCIII). RD16/0008/0013 Originals / I.F.: 40.957 Enriquez-de-Salamanca, Amalia. Duration: 01/01/2017-31/12/2021 Prehematopoietic Stem Cell 1. Pelegrin, Laura; Hernandez-Rodriguez, Transplantation Tear Cytokines as Adán A. Prevención, detección precoz y Jose; Espinosa, Gerard; Llorenc, Victor; Potential Susceptibility Biomarkers for tratamiento de la patología ocular Sainz-de-la-Maza, Maite; Fontenla, Jose R.; Ocular Chronic Graft-Versus-Host prevalente, degenerativa y crónica. Martinez, Jose A.; Cid, Maria C.; Adan, Alfredo. Disease. INVESTIGATIVE Sponsored by: Instituto de Salud Carlos III Characterization of isolated retinal OPHTHALMOLOGY AND VISUAL SCIENCE. (ISCIII). RD12/0034/0005 vasculitis. Analysis of a cohort from a 58(11):4836-4846. I.F.: 3.303 Duration: 01/01/2013-30/06/2017 single center and literature review. AUTOIMMUNITY REVIEWS. 7. Figueras-Roca M., Molins B., Adán A. Estudio de factores clínicos, 16(3):237-243. I.F.: 8.961 Sala-Puigdollers A., Matas J., Vinagre I., Ríos J., hallazgos de tomografía de coherencia Adán A. Peripheral blood metabolic and óptica y biomarcadores como factores 2. Pazos M., Dyrda A., Biarnés M., Gómez A., inflammatory factors as biomarkers to pronósticos de la agudeza visual en el Martín C., Mora C., Fatti G., Antón A. ocular findings in diabetic macular edema. edema macular secundario a uveítis. Diagnostic Accuracy of Spectralis SD OCT PLOS ONE. 12(3):e0173865. I.F.: 2.806 Sponsored by: Instituto de Salud Carlos III Automated Macular Layers Segmentation (ISCIII). PI13/00217 to Discriminate Normal from Early 8. Milla, Elena; Gamundi, Maria Jose; Duch, Duration: 01/01/2014-30/04/2017 Glaucomatous Eyes. OPHTHALMOLOGY. Susana; Rios, Jose; Carballo, Miguel;EMEIGG 124(8):1218-1228. I.F.: 8.204 Study Grp. Phenotypic Description of the Spanish Multicentre Genetic Glaucoma 3. Calvo-Río V., Santos-Gómez M., Calvo I., Group Cohort. JOURNAL OF González-Fernández M., López-Montesinos OPHTHALMOLOGY. 2017:1907454. I.F.: 1.712 B., Mesquida M., Adán A., Hernández M., Maíz O., Atanes A., Bravo B., Modesto C., Díaz-Cordovés G., Palmou-Fontana N., Review / I.F.: 13.46 Loricera J., González-Vela M., Demetrio-Pablo R., Hernández J., González-Gay M., Blanco R. 1. Mesquida M, Molins B, Llorenç V, de la Maza Anti–Interleukin-6 Receptor Tocilizumab MS, Adán A. Targeting interleukin-6 in for Severe Juvenile Idiopathic Arthritis– autoimmune uveitis. AUTOIMMUNITY Associated Uveitis Refractory to REVIEWS. 16(10):1079-1089. I.F.: 8.961 Anti–Tumor Necrosis Factor Therapy: A Multicenter Study of Twenty-Five Patients. 2. Fallon M., Valero O., Pazos M., Antón A. ARTHRITIS AND RHEUMATOLOGY. Diagnostic accuracy of imaging devices in

86 ANNUAL SCIENTIFIC REPORT 2017

AREA 2 2

RESPIRATORY, CARDIOVASCULAR AND RENAL PATHOBIOLOGY AND BIOENGINEERING

2.1 Atherosclerosis, coronary disease and heart failure 90 Manel Sabaté

2.2 Arrhythmias, resynchronization and cardiac imaging 96 Josep Brugada

2.3 Nephro-urological diseases and kidney transplantation 106 Fritz Diekmann

2.4 Cardiovascular, nutrition and aging unit 110 Ramon Estruch

2.5 Respiratory biophysics and bioengineering 115 Ramon Farré

2.6 Applied research in infectious respiratory diseases, critically 118 ill patients and lung cancer Antoni Torres

2.7 Physiopathological mechanisms of respiratory illnesses 122 Joan Albert Barberà

2.8 Clinical and experimental respiratory immunoallergy 126 Joaquim Mullol

2.9 Inﬂammation and repair in respiratory illnesses 131 Alvar Agustí

2.10 Genetic and urological tumors 134 Antonio Alcaraz

89 AREA 2 RESPIRATORY, CARDIOVASCULAR AND RENAL PATHOBIOLOGY AND BIOENGINEERING

Atherosclerosis, coronary 2.1 disease and heart failure

Marco Hernández (FCRB) Gustavo Jiménez (FCRB) LOCATION LuÍs Ortega (HCB) CELLEX building 2A Margarida Pujol (HCB)

TECHNICIANS Nadia Castillo (FCRB)

ADMINISTRATIVE STAFF KEYWORDS Mª Ángeles Álvarez (HCB) 1. Acute myocardial infarction TEAM LEADER Eva Maria Trelliso (FCRB) 2. Percutaneous coronary Manel Sabaté (HCB) intervention. Stent. Biodegrada T. 93 227 93 05 NURSING STAFF Anna Barrabés (FCRB) ble device [email protected] 3. Therapeutic hypothermia Elisabet Codina (FCRB) 4. Stem cell therapy Elisabet de Mingo (FCRB) 5. Heart failure 6. Structural heart disease RESERACHERS COLLABORATOR Xavier Bosch (HCB) Marta Farrero (HCB) Salvatore Brugaletta (HCB) Xavier Freixa (HCB) Carlos Falces (HCB) Susanna Prat (HCB) Ana García (HCB) Ander Regueiro (HCB) Victoria Martín (HCB) Núria Solanes (IDIBAPS) Mònica Masotti (HCB) Original publications Joan Carles Pare (HCB) from 2015 to 2017 Félix Pérez (HCB) STRATEGIC OBJECTIVES

YEAR I.F. TOTAL Q1 Q2 Josep Lluís Pomar (HCB) Montserrat Rigol (IDIBAPS) - To identify the pathophysiological 2015 284.89 40 22 15 Mercè Roqué (HCB) mechanisms of accelerated 2016 336.25 43 27 13 Ana Paula Villela (IDIBAPS) atherosclerosis. - To evaluate the safety and efficacy of 2017 277.20 39 26 11 POST-DOCTORAL RESEARCHERS regenerative cell therapy. Hirofumi Hioki (FCRB) - To increase the understanding of genetics, Laura Novensa (IDIBAPS) pathophysiology, diagnosis and treatment of heart failure and ischaemic heart PRE-DOCTORAL RESEARCHERS disease. TEAM INVOLVED IN AGAUR_SGR17 Joaquim Bobi (IDIBAPS) - To evaluate the clinical implications of Eduardo Flores (HCB) diagnostic imaging techniques and types of Manuel Garabito (IDIBAPS) treatment in structural heart disease and John García (FCRB) heart failure. Manel Sabaté TEAM

90 ATHEROSCLEROSIS, CORONARY DISEASE AND HEART FAILURE 2.1

MAIN LINES OF RESEARCH Moreno R, Cruz-Gonzalez I, Hoole SP, Ej West Cortese, Bernardo; Testa, Luca; Menichelli, N, Piek JJ, Zaman A, Fath-Ordoubadi F, Maurizio; Tamburino, Corrado; Gori, - To study the regulatory mechanisms and Stables RH, Appleby C, van Mieghem N, van Tommaso; Kimura, Takeshi; Serruys, Patrick efficacy of stem cell therapy in Geuns RJ, Uren N, Zueco J, Buszman P, W.; Brugaletta, Salvatore; Sabate, Manel; Gao, experimental models and in clinical Iñiguez A, Goicolea J, Hildick-Smith D, Ochala Run-Lin. Clinical, Angiographic, and contexts. A, Dudek D, Hanratty C, Cavalcante R, Procedural Correlates of Acute, Subacute, - To perform experimental models of Kappetein AP, Taggart DP, van Es GA, Morel and Late Absorb Scaffold Thrombosis. neointimal hyperplasia, endothelialization, MA, de Vries T, Onuma Y, Farooq V, Serruys JACC: CARDIOVASCULAR vascular inflammation and thrombosis. PW, Banning AP. Clinical outcomes of INTERVENTIONS. 10(18):1809-1815. I.F.: 8.841 - To evaluate the influence of hormonal state-of-the-art percutaneous coronary factors, gender and aging in ischemic heart revascularization in patients with de novo 7. Yamaji, Kyohei; Brugaletta, Salvatore; disease three vessel disease: 1-year results of the Sabate, Manel; Iniguez, Andres; Jensen, - To design experimental and clinical studies SYNTAX II study. EUROPEAN HEART Lisette Okkels; Cequier, Angel; Hofma, Sjoerd to evaluate the performance of novel JOURNAL. 38(42):3124-3134. I.F.: 20.212 H.; Christiansen, Evald Hoj; Suttorp, Maarten; devices and strategies to treat coronary van Es, Gerrit Anne; Sotomi, Yohei; Onuma, artery disease, including chronic and acute 3. Ielasi, Alfonso; Campo, Gianluca; Rapetto, Yoshinobu; Serruys, Patrick W.; Windecker, coronary syndromes, cardiogenic shock Claudio; Varricchio, Attilio; Cortese, Bernardo; Stephan; Raber, Lorenz. Effect of and cardiac arrest. Brugaletta, Salvatore; Geraci, Salvatore; Post-Dilatation Following Primary PCIWith - To evaluate neurohormonal activation, Vicinelli, Paolo; di Uccio, Fortunato Scotto; Everolimus-Eluting Bioresorbable fibrotic process, genetic and environmental Secco, Gioel Gabrio; Poli, Arnaldo; Nicolini, Scaffold Versus Everolimus-Eluting factors associated with ventricular Elisa; Ishida, Kohki; Latib, Azeem; Tespili, Metallic Stent Implantation An remodeling in dilated cardiomyopathy. Maurizio. A Prospective Evaluation of a Angiographic and Optical Coherence - To determine the safety, efficacy and Pre-Specified Absorb BVS Implantation Tomography TROFI II Substudy. JACC: efficiency of new transcatheter and Strategy in ST-Segment Elevation CARDIOVASCULAR INTERVENTIONS. minimally invasive devices to treat Myocardial Infarction The BVS STEMI 10(18):1867-1877. I.F.: 8.841 structural and congenital heart disease and STRATEGY-IT Study. JACC: the role of imaging techniques. CARDIOVASCULAR INTERVENTIONS. 8. Brugaletta S, Scalone G, Dantas AP, - To evaluate new pharmacological and 10(18):1855-1864. I.F.: 8.841 Ortega-Paz L, Garabito M, Roqué M, Martin V, invasive treatments for pulmonary Masotti M, Freixa X, Sabaté M. Endothelial hypertension. 4. Geraci, Salvatore; Kawamoto, Hiroyoshi; function impairment in STEMI patients Caramanno, Giuseppe; Ruparelia, Neil; with out-of-hospital cardiac arrest under Capodanno, Davide; Brugaletta, Salvatore; therapeutic hypothermia treatment. INT J Gori, Tommaso; Nef, Holger; Sabate, Manel; CARDIOL. 232:70-75. I.F.: 6.189 PUBLICATIONS Mehilli, Julinda; Lesiak, Maciej; Naber, Christoph; Di Mario, Carlo; Capranzano, Piera; 9. Tarradas, Anna; Pinsach-Abuin, Mel Lina; Originals / I.F.: 277.20 Wiebe, Jens; Araszkiewicz, Aleksander; Mackintosh, Carlos; Llora-Batlle, Oriol; Pyxaras, Stelios; Mattesini, Alessio; Muenzel, Perez-Serra, Alexandra; Batlle, Montserrat; 1. Davies, J. E.; Sen, S.; Dehbi, H. -M.; Al-Lamee, Thomas; Tamburino, Corrado; Colombo, Perez-Villa, Felix; Zimmer, Thomas; R.; Petraco, R.; Nijjer, S. S.; Bhindi, R.; Lehman, S. Antonio; Latib, Azeem. Bioresorbable Garcia-Bassets, Ivan; Brugada, Ramon; J.; Walters, D.; Sapontis, J.; Janssens, L.; Vrints, Everolimus-Eluting Vascular Scaffold for Beltran-Alvarez, Pedro; Pagans, Sara. C. J.; Khashaba, A.; Laine, M.; Van Belle, E.; Long Coronary Lesions A Subanalysis of Transcriptional regulation of the sodium Krackhardt, F.; Bojara, W.; Going, O.; Harle, T.; the International, Multicenter GHOST-EU channel gene (SCN5A) by GATA4 in Indolfi, C.; Niccoli, G.; Ribichini, F.; Tanaka, N.; Registry. JACC: CARDIOVASCULAR human heart. JOURNAL OF MOLECULAR Yokoi, H.; Takashima, H.; Kikuta, Y.; Erglis, A.; INTERVENTIONS. 10(6):560-568. I.F.: 8.841 AND CELLULAR CARDIOLOGY. 102:74-82. Vinhas, H.; Silva, P. Canas; Baptista, S. B.; I.F.: 5.680 Alghamdi, A.; Hellig, F.; Koo, B. -K.; Nam, C. -W.; 5. Alfonso F., Cuesta J., Pérez-Vizcayno M., Shin, E. -S.; Doh, J. -H.; Brugaletta, S.; García del Blanco B., Rumoroso J., Bosa F., 10. Cubedo J, Suades R, Padro T, Alegria-Barrero, E.; Meuwissen, M.; Piek, J. J.; Pérez de Prado A., Masotti M., Moreno R., Martin-Yuste V, Sabate-Tenas M, Cinca J, van Royen, N.; Sezer, M.; Di Mario, C.; Gerber, Cequier A., Gutiérrez H., García Touchard A., Sans-Rosello J, Sionis A, Badimon L. R. T.; Malik, I. S.; Sharp, A. S. P.; Talwar, S.; Tang, López-Mínguez J., Zueco J., Martí V., Erythrocyte-heme proteins and STEMI: K.; Samady, H.; Altman, J.; Seto, A. H.; Singh, J.; Velázquez M., Morís C., Bastante T., implications in prognosis. THROMBOSIS Jeremias, A.; Matsuo, H.; Kharbanda, R. K.; García-Guimaraes M., Rivero F., Fernández C. AND HAEMOSTASIS. 117(10):1970-1980. Patel, M. R.; Serruys, P.; Escaned, J. Use of the Bioresorbable Vascular Scaffolds for I.F.: 5.627 Instantaneous Wave-free Ratio or Patients With In-Stent Restenosis. The Fractional Flow Reserve in PCI. NEW RIBS VI Study. JACC: CARDIOVASCULAR 11. García-Ruiz J., Galán-Arriola C., ENGLAND JOURNAL OF MEDICINE. INTERVENTIONS. 10(18):1841-1851. I.F.: 8.841 Fernández-Jiménez R., Aguero J., 376(19):1824-1834. I.F.: 72.406 Sánchez-González J., García-Alvarez A., 6. Ellis, Stephen G.; Steffenino, Giuseppe; Nuno-Ayala M., Dubé G., Zafirelis Z., 2. Escaned J, Collet C, Ryan N, De Maria GL, Kereiakes, Dean J.; Stone, Gregg W.; van López-Martín G., Bernal J., Lara-Pezzi E., Walsh S, Sabate M, Davies J, Lesiak M, Geuns, R. J.; Abizaid, Alexandre; Nef, Holger; Fuster V., Ibáñez B. Bloodless reperfusion

91 AREA 2 RESPIRATORY, CARDIOVASCULAR AND RENAL PATHOBIOLOGY AND BIOENGINEERING

with the oxygen carrier HBOC-201 in acute bioabsorbable polymer-coated, 21. Onetti Y, Dantas AP, Pérez B, McNeish AJ, myocardial infarction: a novel platform for everolimus-eluting coronary stent in Vila E, Jiménez-Altayó F. Peroxynitrite cardioprotective probes delivery. BASIC patients with diabetes: The EVOLVE II formed during a transient episode of brain RESEARCH IN CARDIOLOGY. 112(2):467. diabetes substudy. EUROINTERVENTION. ischemia increases endothelium-derived I.F.: 5.306 12(16):1987-1994. I.F.: 5.165 hyperpolarization-type dilations in thromboxane/prostaglandin receptor- 12. Jiménez-Brítez G, Freixa X, 17. Varenne, Olivier; Cuisset, Thomas; Chaib, stimulated rat cerebral arteries. ACTA Flores-Umanzor E, San Antonio R, Caixal G, Aures; Morice, Marie-Claude; Sabate, Manel; PHYSIOLOGICA. 220(1):150-166. I.F.: 4.867 Garcia J, Hernandez-Enriquez M, Andrea R, Koh, Tian-Hai; Durand-Zaleski, Isabelle; Regueiro A, Masotti M, Brugaletta S, Martin V, Hanon, Olivier; Bogaerts, Kris; Sinnaeve, Peter. 22. Penela D, Fernández-Armenta J, Sabaté M. Out-of-hospital cardiac arrest The SYNERGY II Everolimus elutiNg stent Aguinaga L, Tercedor L, Ordoñez A, Bisbal F, and stent thrombosis: Ticagrelor versus In patients Older than 75 years undergoing Acosta J, Rossi L, Borras R, Doltra A, clopidogrel in patients with primary coronary Revascularisation associated Ortiz-Pérez JT, Bosch X, Perea RJ, percutaneous coronary intervention under with a short dual antiplatelet therapy Prat-González S, Soto-Iglesias D, Tolosana mild therapeutic hypothermia. (SENIOR) trial: rationale and design of a JM, Vassanelli F, Cabrera M, Linhart M, RESUSCITATION. 114:141-145. I.F.: 5.230 large-scale randomised multicentre study. Martinez M, Mont L, Berruezo A. Clinical EUROINTERVENTION. 12(13):1614-1622. recognition of pure premature ventricular 13. Ortega-Paz L, Brugaletta S, Giacchi G, I.F.: 5.193 complex-induced cardiomyopathy at Ishida K, Cequier A, Iñiguez A, Serra A, presentation. HEART RHYTHM. Jiménez-Quevedo P, Mainar V, Campo G, 18. García-Touchard A., Goicolea J., Sabaté 14(12):1864-1870. I.F.: 4.866 Tespili M, den Heijer P, Valgimigli M, Serruys M., Alfonso F., Ruiz-Salmerón R., Bethencourt PW, Sabaté M. Impact of stent overlapping A., Gonzalo N., Miranda F., Del Blanco B., 23. Penela D, Acosta J, Andreu D, Ortiz-Perez on long-term clinical outcomes in patients Jiménez-Mazuecos J., Melgares R., JT, Bosch X, Perea RJ, de Caralt TM, with ST-segment elevation myocardial Martínez-Romero P., Hernandez-García J., Fernández-Armenta J, Soto-Iglesias D, infarction: insights from the 5-year Lezaún R., Bullones J., Fernández-Portales J., Prat-Gonzalez S, Borràs R, Mont L, Hervas V, follow-up of the EXAMINATION trial. Rumoroso J., Ortas R., Valdés M., Trillo R., Morales-Ruiz M, Jiménez W, Mira A, Donnelly EUROINTERVENTION. 13(5):557-563. I.F.: 5.193 Brugaletta S., Otzuki S., Hernández-Pérez F., J, Ekinci O, Lasalvia L, Berruezo A. Alonso-Pulpón L. A randomised trial of Identiﬁcation of the Potentially 14. Schnorbus B, Wiebe J, Capodanno D, paclitaxel-eluting balloon after bare metal Arrhythmogenic Substrate in the Acute Brugaletta S, Geraci S, Mehilli J, Latib A, Lesiak stent implantation vs. bare metal stent in Phase of ST-elevation Myocardial M, Jensen C, Mattesini A, Münzel T, ST-elevation myocardial infarction (the Infarction. HEART RHYTHM. 14(4):592-598. Capranzano P, Di Mario C, Naber C, PEBSI study). EUROINTERVENTION. I.F.: 4.866 Araszkiewicz A, Colombo A, Caramanno G, 12(13):1587-1594. I.F.: 5.193 Sabate M, Tamburino C, Nef H, Gori T. 12 24. García-Blas S, Bonanad C, Llàcer P, months outcomes after Bioresorbable 19. Baumbach, Andreas; Heg, Dik; Raeber, Ventura S, Núñez JM, Sánchez R, Chamorro Vascular Scaffold implantation in Patients Lorenz; Ostoijc, Miodrag; Brugaletta, C, Fácila L, de la Espriella R, Vaquer JM, with Acute Coronary Syndromes. Data Salvatore; Strange, Julian W.; Johnson, Cordero A, Roqué M, Ortiz V, Racugno P, Bodí from the European Multicentre GHOST-EU Thomas W.; Jueni, Peter; Engstrom, Thomas; V, Valero E, Santas E, Moreno MDC, Miñana G, Extended Registry. EUROINTERVENTION. Serruys, Patrick W.; Sabate, Manel; Windecker, Carratalá A, Bondanza L, Payá A, Cardells I, 13(9):e1104-e1111. I.F.: 5.193 Stephan. Selective use of contemporary Heredia R, Pellicer M, Valls G, Palau P, Bosch drug-eluting scents in primary angioplasty MJ, Raso R, Sánchez A, Bertomeu-González 15. Ortega-Paz L, Capodanno D, Gori T, Nef H, for ST-elevation myocardial infarction: V, Bertomeu-Martínez V, Montagud-Balaguer Latib A, Caramanno G, Di Mario C, Naber C, pooled analysis of COMFORTABLE AMI V, Albiach-Montañana C, Pendás-Meneau J, Lesiak M, Capranzano P, Wiebe J, Mehilli J, and EXAMINATION. EUROINTERVENTION. Marcaida G, Cervantes-García S, San Antonio Araszkiewicz A, Pyxaras S, Mattesini A, Geraci 12(13):1577-1586. I.F.: 5.193 R, de Mingo E, Chorro FJ, Sanchis J, Núñez J, S, Naganuma T, Colombo A, Münzel T, Sabaté IMPROVE-HF Investigators. Diuretic M, Tamburino C, Brugaletta S. Predilation, 20. Pericàs JM, García-de-la-Mària C, Strategies in Acute Heart Failure and Renal sizing and post-dilation scoring in patients Brunet M, Armero Y, García-González J, Dysfunction: Conventional vs undergoing everolimus-eluting Casals G, Almela M, Quintana E, Falces C, Carbohydrate Antigen 125-guided bioresorbable scaffold implantation for Ninot S, Fuster D, Llopis J, Marco F, Moreno A, Strategy. Clinical Trial Design. REVISTA prediction of cardiac adverse events: Miró JM, Hospital Clinic Endocarditis Study ESPAÑOLA DE CARDIOLOGIA. development and internal validation of the Group. Early in vitro development of 70(12):1067-1073. I.F.: 4.485 PSP score. EUROINTERVENTION. daptomycin non-susceptibility in 12(17):2110-2117. I.F.: 5.193 high-level aminoglycoside-resistant 25. Pericàs J., Corredoira J., Moreno A., Enterococcus faecalis predicts the García-País M., Falces C., Rabuñal R., Mestres 16. Kereiakes D., Meredith I., Masotti M., Carrié efficacy of the combination of high-dose C., Alonso M., Marco F., Quintana E., Almela M., D., Moreno R., Erglis A., Mehta S., Elhadad S., daptomycin plus ampicillin in an in vivo Paré J., Llopis J., Castells A., Miró J. Berland J., Stein B., Airaksinen J., Jobe R., model of experimental endocarditis. Relationship Between Enterococcus Reitman A., Janssens L., Christen T., Dawkins J ANTIMICROB CHEMOTHER. faecalis Infective Endocarditis and K., Windecker S. Safety and efficacy of a 72(6):1714-1722. I.F.: 5.071 Colorectal Neoplasm: Preliminary Results

92 ATHEROSCLEROSIS, CORONARY DISEASE AND HEART FAILURE 2.1

From a Cohort of 154 Patients. REVISTA Sánchez-González J, García-Álvarez A, 35. Ortega-Paz L, Capodanno D, Giacchi G, ESPAÑOLA DE CARDIOLOGIA. Sabaté M, Roura S, Ibáñez B, Rigol M. Gori T, Nef H, Latib A, Caramanno G, Di Mario 70(6):451-458. I.F.: 4.485 Intracoronary Administration of Allogeneic C, Naber C, Lesiak M, Capranzano P, Wiebe J, Adipose Tissue-Derived Mesenchymal Mehilli J, Araszkiewicz A, Pyxaras S, Mattesini 26. De la Torre Hernández JM, Brugaletta S, Stem Cells Improves Myocardial Perfusion A, Geraci S, Naganuma T, Colombo A, Münzel Gómez Hospital JA, Baz JA, Pérez de Prado A, But Not Left Ventricle Function, in a T, Sabaté M, Tamburino C, Brugaletta S. López Palop R, Cid B, García Camarero T, Translational Model of Acute Myocardial Impact of overlapping on 1-year clinical Diego A, Gimeno de Carlos F, Fernández Díaz Infarction. JOURNAL OF THE AMERICAN outcomes in patients undergoing JA, Sanchis J, Alfonso F, Blanco R, Botas J, HEART ASSOCIATION. 6(5):e005771. I.F.: 4.425 everolimus-eluting bioresorbable Navarro Cuartero J, Moreu J, Bosa F, Vegas scaffolds implantation in routine clinical Valle JM, Elízaga J, Arrebola AL, Ruiz Arroyo 31. Castañeda X, García-de-la-Mària C, practice: Insights from the European JR, Hernández-Hernández F, Salvatella N, Gasch O, Pericas JM, Armero Y, Soy D, multicenter GHOST-EU registry. Monteagudo M, Gómez Jaume A, Carrillo X, García-González J, Falces C, Ninot S, Almela CATHETERIZATION AND Martín Reyes R, Lozano F, Rumoroso JR, M, Ambrosioni J, Quintana E, Vidal B, Fuster D, CARDIOVASCULAR INTERVENTIONS. Andraka L, Domínguez AJ. Primary Llopis J, Soto S, Moreno A, Marco F, Miró JM, 89(5):812-818. I.F.: 2.602 Angioplasty in Patients Older Than 75 Hospital Clinic Endocarditis Study Group. Years. Proﬁle of Patients and Procedures, AUC/MIC Pharmacodynamic Target Is Not 36. Ferko N, Ferrante G, Hasegawa JT, Outcomes, and Predictors of Prognosis in a Good Predictor of Vancomycin Efficacy Schikorr T, Soleas IM, Hernandez JB, Sabaté the ESTROFA IM+75 Registry. REVISTA in Methicillin-Resistant Staphylococcus M, Kaiser C, Brugaletta S, de la Torre ESPANOLA DE CARDIOLOGIA (ENGLISH aureus Experimental Endocarditis. Hernandez JM, Galatius S, Cequier A, Eberli F, ED.). 70(2):81-87. I.F.: 4.485 ANTIMICROBIAL AGENTS AND de Belder A, Serruys PW, Valgimigli M. CHEMOTHERAPY. 61(6):e02486. I.F.: 4.302 Cost-effectiveness of percutaneous 27. Di Marco A, Anguera I, Rodríguez M, Sionis coronary intervention with A, Bayes-Genis A, Rodríguez J, Ariza-Solé A, 32. Alfonso F, Pérez-Vizcayno MJ, García Del cobalt-chromium everolimus eluting Sánchez-Salado JC, Díaz-Nuila M, Masotti M, Blanco B, García-Touchard A, López-Mínguez stents versus bare metal stents: Results Villuendas R, Dallaglio P, Gómez-Hospital JA, JR, Sabaté M, Zueco J, Melgares R, from a patient level meta-analysis of Cequier Á. Assessment of Smith Hernández R, Moreno R, Domínguez A, randomized trials. CATHETERIZATION AND Algorithms for the Diagnosis of Acute Sanchís J, Moris C, Moreu J, Cequier A, CARDIOVASCULAR INTERVENTIONS. Myocardial Infarction in the Presence of Romaguera R, Rivero F, Cuesta J, Gonzalo N, 89(6):994-1002. I.F.: 2.602 Left Bundle Branch Block. REVISTA Jiménez-Quevedo P, Cárdenas A, Fernández ESPANOLA DE CARDIOLOGIA (ENGLISH C, Spanish Society of Cardiology. Usefulness 37. Ielasi A, Varricchio A, Campo G, Leoncini ED.). 70(7):559-1120. I.F.: 4.485 of Drug-Eluting Balloons for Bare-Metal M, Cortese B, Vicinelli P, Brugaletta S, di Uccio and Drug-Eluting In-Stent Restenosis FS, Latib A, Tespili M. A prospective 28. Fernandez-Friera, Leticia; Manuel (from the RIBS IV and V Randomized evaluation of a standardized strategy for Garcia-Ruiz, Jose; Garcia-Alvarez, Ana; Trials). AMERICAN JOURNAL OF the use of a polymeric everolimus-eluting Fernandez-Jimenez, Rodrigo; CARDIOLOGY. 119(7):983-990. I.F.: 3.398 bioresorbable scaffold in ST-segment Sanchez-Gonzalez, Javier; Rossello, Xavier; elevation myocardial infarction: Rationale Gomez-Talavera, Sandra; Lopez-Martin, 33. Moscarella E., Spitaleri G., Brugaletta S., and design of the BVS STEMI Gonzalo J.; Pizarro, Gonzalo; Fuster, Valentin; Sentí Farrarons S., Pernigotti A., Ortega-Paz L., STRATEGY-IT study. CATHETERIZATION Ibanez, Borja. Accuracy of Area at Risk Cequier A., Iñiguez A., Serra A., AND CARDIOVASCULAR INTERVENTIONS. Quantiﬁcation by Cardiac Magnetic Jiménez-Quevedo P., Mainar V., Campo G., 89(7):1129-1138. I.F.: 2.602 Resonance According to the Myocardial Tespili M., den Heijer P., Bethencourt A., Infarction Territory. REVISTA ESPAÑOLA Vazquez N., Valgimigli M., Serruys P., Sabaté 38. Sitges M., Merino B., Butakoff C., de la DE CARDIOLOGIA. 70(5):323-330. I.F.: 4.485 M. Impact of Body Mass Index on 5-Year Garza M., Paré C., Montserrat S., Vidal B., Clinical Outcomes in Patients With Azqueta M., Sarquella G., Gutierrez J., Canal R., 29. Ariotti S, van Leeuwen M, Brugaletta S, ST-Segment Elevation Myocardial Brugada J., Bijnens B. Characterizing the Leonardi S, Akkerhuis KM, Rexhaj E, Janssens Infarction After Everolimus-Eluting or spectrum of right ventricular remodelling G, Ortega-Paz L, Rizzotti D, van den Berge JC, Bare-Metal Stent Implantation. AMERICAN in response to chronic training. Heg D, Francolini G, Windecker S, Valgimigli M, JOURNAL OF CARDIOLOGY. INTERNATIONAL JOURNAL OF HI-TECH Investigators. Rationale and design 120(9):1460-1466. I.F.: 3.398 CARDIOVASCULAR IMAGING. of the Hunting for the off-target propertIes 33(3):331-339. I.F.: 1.896 of Ticagrelor on Endothelial function and 34. Gutacker, Nils; Bloor, Karen; Cookson, other Circulating biomarkers in Humans Richard; Gale, Chris P.; Maynard, Alan; Pagano, 39. Fernández-Rodríguez D., Regueiro A., (HI-TECH) trial. AMERICAN HEART Domenico; Pomar, Jose; Bernal-Delgado, Cevallos J., Bosch X., Freixa X., Trilla M., JOURNAL. 189:128-136. I.F.: 4.436 Enrique;ECHO Collaboration. Hospital Brugaletta S., Martín-Yuste V., Sabaté M., Surgical Volumes and Mortality after Bosa-Ojeda F., Masotti M. Gender gap in 30. Bobi J, Solanes N, Fernández-Jiménez R, Coronary Artery Bypass Grafting: Using medical care in ST segment elevation Galán-Arriola C, Dantas AP, Fernández-Friera International Comparisons to Determine a myocardial infarction networks: Findings L, Gálvez-Montón C, Rigol-Monzó E, Agüero J, Safe Threshold. HEALTH SERVICES from the Catalan network Codi Infart. Ramírez J, Roqué M, Bayés-Genís A, RESEARCH. 52(2):863-878. I.F.: 3.089 MEDICINA INTENSIVA. 41(2):70-77. I.F.: 1.231

93 AREA 2 RESPIRATORY, CARDIOVASCULAR AND RENAL PATHOBIOLOGY AND BIOENGINEERING

Review / I.F.: 13.975 Shabu Use: An Emerging Drug in Europe. John; Pomar, Jose L.; Hazekamp, Mark; REVISTA ESPAÑOLA DE CARDIOLOGIA. Padalino, Massimo; Stellin, Giovanni; Meyns, 1. García Del Blanco B, Jiménez Quevedo P, 70(11):1014-1016. I.F.: 4.485 Bart; Laufer, Guenther; Andreas, Martin; Diaz JD, Hernández F, Rumoroso JR, Sabaté Hubler, Michael; Schmiady, Martin; Ciubotaru, M, de la Torre Hernandez JM, Serrador A, 5. Jiménez Brítez G, Sabaté M, Robles C, Anatol; Horke, Alexander; Cebotari, Serghei; Pérez de Prado A, Goicolea J, Trillo R, Pan M. García-Granja PE, Amat-Santos IJ, Brugaletta Tudorache, Igor; ARISE-Trial-Investigators. Spain: coronary and structural heart S. Functional and Morphological Every like is not the same to the Editor. interventions from 2010 to 2015. Assessment of Left Anterior Descending JOURNAL OF THORACIC AND EUROINTERVENTION. 13(z):Z64-Z69-Z69. Artery in Patients With Tako-tsubo CARDIOVASCULAR SURGERY. I.F.: 5.165 Syndrome. REVISTA ESPAÑOLA DE 153(6):1553-1555. I.F.: 4.446 CARDIOLOGIA. I.F.: 4.485 2. Pujol-Lopez, Margarida; Ortega-Paz, Luis; Garabito, Manel; Brugaletta, Salvatore; 6. Freixa X; Hernández-Enríquez M; Sanchis L; Case Reports / I.F.: 8.456 Sabate, Manel; Paula Dantas, Ana. miRNA Regueiro A; Sabate M; Sitges M. Tricuspid Update: A Review Focus on Clinical Percutaneous Repair With the MitraClip 1. San Antonio R., Pujol López M., Perea R., Implications of miRNA in Vascular System: First Implant in Spain. REVISTA Sabaté M. ST-segment elevation Remodeling. HUMAN BRAIN MAPPING. ESPAÑOLA DE CARDIOLOGIA. I.F.: 4.485 mimicking myocardial infarction after 4(1):99-112. I.F.: 4.530 hydrochloric acid ingestion: Acute caustic myocarditis. JOURNAL OF 3. Pernigotti A; Moscarella E; Spitaleri G; Editorial / I.F.: 42.322 CARDIOVASCULAR COMPUTED Scardino C; Ishida K; Brugaletta S. Methods TOMOGRAPHY. 11(1):71. I.F.: 3.185 to assess bioresorbable vascular scaffold 1. Sabate, Manel. Bioresorbable Vascular devices behaviour after implantation. Scaffold Implantation To Whom and How? 2. Hernández-Enríquez M., Brugaletta S., JOURNAL OF THORACIC DISEASE. 9(Suppl JACC: CARDIOVASCULAR Andreu D., Macià-Muñoz G., Castrejón-Subirá 9):S959-S968. I.F.: 2.365 INTERVENTIONS. 10(18):1865-1866. I.F.: 8.841 M., Fernández-Suelves S., Hernández-Obiols M., Dantas A., Freixa X., Martin-Yuste V., 4. Ambrosioni J., Hernandez-Meneses M., 2. Brugaletta S, Sabate M. Percutaneous Camara O., Sabaté M. Three-dimensional Téllez A., Pericàs J., Falces C., Tolosana J., Treatment of Extremely Small Coronary printing of an aortic model for Vidal B., Almela M., Quintana E., Llopis J., Moreno Vessels: Does Size Matter in Terms of transcatheter aortic valve implantation: A., Miro J. The Changing Epidemiology of Performance? JACC: CARDIOVASCULAR possible clinical applications. Infective Endocarditis in the Twenty-First INTERVENTIONS. 10(14):1389-1391. I.F.: 8.841 INTERNATIONAL JOURNAL OF Century. CURRENT INFECTIOUS DISEASE CARDIOVASCULAR IMAGING. REPORTS. 19(5):21. I.F.: 1.915 3. Brugaletta S, Sabate M. A longer look at 33(2):283-285. I.F.: 1.896 trial evidence of bioresorbable vascular scaffolds.HEART. 103(14):1061-1062. I.F.: 6.059 3. Flores-Umanzor EJ, San Antonio R, Letters / I.F.: 29.72 Pujol-Lopez M, Perea RJ. An unusual cause 4. Brugaletta, Salvatore; Ortega-Paz, Luis; of thoracic pain: Cardiac perforation 1. Josue Flores-Umanzor, Eduardo; Onuma, Yoshinobu. Data from real-world associated with a pacemaker. MEDICINA Hernandez-Enriquez, Marco; Caldentey, registries: can it guide development of the CLINICA. 149(6):e26. I.F.: 1.125 Guillem; San Antonio, Rodolfo; Pare, Carles. bioresorbable scaffolds of tomorrow? Radiation-Induced Cardiac Valve Disease. EUROINTERVENTION. 13(11):1259-1262. 4. Jiménez-Brítez G., Flores Umanzor E., AMERICAN JOURNAL OF MEDICINE. I.F.: 5.193 Martín V., Sabate M. Acute coronary 130(3):E99-E100. I.F.: 5.550 syndrome in dextrocardia and situs 5. Sabaté M. No Country for Old Men With inversus patient. MEDICINA CLINICA. 2. Flores-Umanzor E., Hernández-Enríquez ST-segment Elevation Myocardial 148(12):e69. I.F.: 1.125 M., Caldentey G., San Antonio R., Paré C. Infarction. REVISTA ESPANOLA DE The Reply. AMERICAN JOURNAL OF CARDIOLOGIA (ENGLISH ED.). 70(2):70-71. 5. Pujol-López M, Prieto-González S, MEDICINE. 130(10):e465. I.F.: 5.550 I.F.: 4.485 Prat-González S, Hernández-Rodríguez J. Eosinophilic granulomatosis with 3. Hernández-Enríquez M., Brugaletta S., 6. Fernando Alfonso, Alessandro Sionis, polyangitis (Churg-Strauss) and severe Andrea R., Sabaté M. Propensity-matched Héctor Bueno, Borja Ibáñez, Manel Sabaté pericardial effusion. MEDICINA CLINICA. comparison of percutaneous and surgical Tenas, Angel Cequier, José A. Barrabés, Juan 149(9):e53. I.F.: 1.125 cut-down approaches in transfemoral Sanchis Forés, Emad Abu Assi, Jaime Aboal. transcatheter aortic valve implantation using Comentarios a la guía ESC 2017 sobre el a balloon-expandable valve. Moving to the tratamiento del infarto agudo de miocardio GRANTS FOR RESEARCH IN PROGRESS percutaneous approach. en pacientes con elevación del segmento EUROINTERVENTION. 13(11):1365-1366. I.F.: 5.165 ST. REVISTA ESPAÑOLA DE CARDIOLOGIA. Dantas AP. Potential prognostic and 70(12):1039-1045. I.F.: 4.485 therapeutic role of exosomal miRNAs 4. Pujol-López M., Ortega-Paz L., Roqué M., derived from circulating cells (Endothelial Bosch X. Severe Cardiac Complications of 7. Sarikouch, Samir; Haverich, Axel; Pepper, Progenitor, Platelets and Neutrophils) in

94 ATHEROSCLEROSIS, CORONARY DISEASE AND HEART FAILURE 2.1

acute coronary syndrome. Sponsored by: Instituto de Salud Carlos III. PI16/00742 Duration: 01/01/2017-31/12/2019

García A. Tractament agonista adrenèrgic en la hipertensió pulmonar crònica secundària a insuﬁciència cardíaca: assaig clínic fase 2 aleatoritzat i controlat amb placebo. Sponsored by: Fundació la Marató de TV3. 20151730 Duration: 21/07/2016-20/07/2019

Pomar JL. Aortic Valve Replacement using Individualised Regenerative Allografts: Bridging the Therapeutic Gap. Sponsored by: HORIZONS 2020. Duration: 01/01/2015-31/03/2019

Roqué M. Cardiovascular net. HERACLES Programme: Research programme on prevention of cardiovascular diseases and study of hypertension mechanisms. Sponsored by: Instituto de Salud Carlos III. RD12/0042/0006 Duration: 01/01/2013-31/12/2017

Roqué M. Acute myocardical infarction in young patients. Analysis of prothrombotic, inﬂammatory and epigenetic factors. Effect of miRNA expressión modulation in a porcine model. Sponsored by: Instituto de Salud Carlos III. PI15/00553 Duration: 01/01/2016-31/12/2018

Sabaté, M. Desarrollo de biosensores sobre tecnología ﬂexible y rígida para la detección de marcadores cardíacos. Sponsored by: Ministerio de Economía. RTC-2015-4184-1 Duration: 01/07/2015-30/06/2018

DOCTORAL THESES

Roque M. Dantas AP. Mechanisms for sex-associated differences of vascular aging. PhD student: Manel Garabito Montoya

95 AREA 2 RESPIRATORY, CARDIOVASCULAR AND RENAL PATHOBIOLOGY AND BIOENGINEERING

Arrhythmias, resynchronization 2.2 and cardiac imaging

RESEARCHERS Elena Arbelo (HCB) LOCATION Antonio Berruezo (HCB) HCB building M. Ángeles Castel (HCB) CELLEX building 2A M. Teresa de Caralt (HCB) Silvia Montserrat (HCB) José Tomés Ortiz (HCB) Rosario Jesús Perea (HCB) Susana Prat (HCB) Bárbara Vidal (HCB) KEYWORDS TEAM LEADER 1. Atrial ﬁbrillation POST-DOCTORAL RESEARCHERS Josep Brugada (HCB) Montserrat Batlle (IDIBAPS) 2. Ventricular tachycardia T. 93 227 57 33 Adelina Doltra (HCB) 3. Sudden death [email protected] Gonzalo Grazioli (FCRB) 4. Cardiac imaging Laura Sanchís (HCB) 5. Resynchronization therapy Gemma Sangüesa (CIBER) Maria Sanz (HCB) GROUP LEADERS José M. Tolosana (HCB) Gustavo Egea (UB) T. 93 402 19 09 PRE-DOCTORAL RESEARCHERS [email protected] Francisco Alarcón (FCRB) Eva Benito (IDIBAPS) Original publications Fabio Bonorino (UB) from 2015 to 2017 Eduard Guasch (HCB-IDIBAPS) T. 93 227 48 05 Gal.la Caixal (HCB) YEAR I.F. TOTAL Q1 Q2 [email protected] Glara Gunturiz (CIBER) Beatriz Jauregui (IDIBAPS-UB) 2015 193.84 38 28 8 Lluis Mont (HCB) Paloma Jorda (FCRB) 2016 275.53 47 31 14 T.93 227 17 78 Markus Linhart (IDIBAPS) 2017 315.23 56 42 8 [email protected] Julia López (UB) Mikel Martínez (FCRB) Marta Sitges (HCB) Maria Elisa Matiello (HCB) T. 93 227 17 94 Loredana Nunno (IDIBAPS) [email protected] Rodolfo San Antonio (FCRB) TEAM INVOLVED IN Ana Maria Siegert (UB) RIC David Soto (IDIBAPS) AGAUR_SGR14 Maria Emilce Trucco (FCRB) AGAUR_ SGR17 Antonia Vaquer (FCRB) CIBERCV

AWARDS Emili Letang (best medical residency prize) Institution: HCB Awardee/s: Gal·la Caixal Vila Josep Brugada TEAM

96 slals aigadsbuaeu deﬁbrillators. asleadlesspacing andsubcutaneous method.We test innovativedevicessuch multipointpacing andthefusion-optimized atimprovingsuccessratethrough - newtherapeuticsforAF. theSteeringCommitteeoftrialsassessing onimagingtechniques.Weparticipatein individualizedablationapproachesbased - models. extremetraininginclinicalandmurine remodellingandthedeleteriouseffectsof sport - ablationforBrugadasyndrome. arrhythmias,andtheefficacyofepicardial geneticsandprognosisofinherited - MAIN LINESOFRESEARCH enterprises. network withresearchgroupsand within anationalandinternationalcollaborative cardiovascular diseases.Thisisperformed the prevention,diagnosisandtherapyof (from benchtobedside),eventuallyaimingat vessels throughatranslationalperspective biochemical remodellingoftheheartand electrophysiological, mechanicaland Our researchteamfocusesonthestudyof STRATEGIC OBJECTIVES Fatima Zaraket(FCRB) Vladimir Syrovnev(FCRB) Hael Fernandez(FCRB) José A.Apolo(FCRB) COLLABORATORS Silvia Vidorreta(HCB-FCRB) Mireia Niebla(HCB) Laura Merino(HCB-IDIBAPS) Rebeca Domingo(HCB) Maite Coll(HCB-IDIBAPS) Celia Baños(IDIBAPS) NURSING STAFF Carolina Sanroman(FCRB) Neus Portella(FCRB) Mariona deTorres(FCRB) ADMINISTRATIVE STAFF Nadia Castillo(FCRB) Laura Barbera(IDIBAPS) TECHNICIANS In resynchronizationandpacing In atrialﬁbrillation In adaptationandconsequencesof In geneticdiseases , westudyexercise-inducedcardiac edvlp , wedevelop efcso h , wefocusonthe , weaim

GROUP Gustavo Egea transduction, (3)themembranetraffickingof extracellular matrixintermsofmechano- between vascularsmoothmusclecellsand (1) theoxidativestress,(2)crosstalk respect, wearefocusoninthecontributionof: particularly inMarfansyndrome.Inthis syndromic thoracicaortaaneurysms impaired intheformationandprogressionof understand whicharethemolecularbases The mainobjectiveofthisgroupisto Gustavo Egea GROUP LEADER VASCULAR CELLBIOLOGY RESEARCH GROUP aneurysm signalling,andmechanicalforcesin progression. biology,membranetrafficking,cell Marfan syndrome - characteristics. valveheartdisease,andfailure structuralandfunctionalremodellingin - antiarrhythmic andcomparetheefficacyofablationwith drugs. remodellingregressionafterPVCablation analysisinmagneticresonance,evaluate predictsuddencardiacdeathbysubstrate - Inremodellinginheartdisease, In vascularcellandmolecularbiologyof In ventriculartachycardia (UB) eadesrdx , weaddressredox , weworkto ARRHYTHMIAS, RESYNCHRONIZATION ANDCARDIAC IMAGING westudy animal (mice)experimentalmodels. patients subjectedtoreparatorysurgeryand aortic aneurysmsamplesfromofMarfan aortic aneurysm.Toalltheseaims,weuse treatments topreventtheformationof prove-of-concept pharmacologicalandgenic Marfan syndrome,and(6)tocarryout are thebehavioralalterationsassociatedto progression oftheaneurysms,and(5)which impact ofthephysicalexercisein TGF-beta andsubsequentsignaling,(4)the 2.2 97 AREA 2 RESPIRATORY, CARDIOVASCULAR AND RENAL PATHOBIOLOGY AND BIOENGINEERING

RESEARCH GROUP ARRYTHMIAS AND PHYSICAL ACTIVITY

GROUP LEADER Eduard Guasch (HCB-IDIBAPS)

The Arrhythmias and Physical Activity group led by Dr. Eduard Guasch was officially established in 2015 under the IDIBAPS 50/50 program. Main research topics include the

study of the etiology, pathophysiology and Eduard Guasch therapy of cardiac atrial and ventricular arrhythmias through a multifactorial approach GROUP involving animal models, ex vivo and in vitro techniques and studies in humans. In this regard, the group has developed a special interest in the study of extreme intensity exercise (regarded as excessive) as an emerging cause of cardiovascular diseases, including arrhythmias such as atrial ﬁbrillation.

RESEARCH GROUP ATRIAL FIBRILLATION BIOPATHOLOGY AND THERAPY Lluís Mont

GROUP LEADER GROUP Lluis Mont (HCB)

Our group focuses in the study of the etiologic factors of atrial fibrillation to understand its mechanisms and prevent its development. In this regard, we are assessing the association of the sympathetic/parasympathetic balance to analyze the relationship between stature and autonomic balance. Furthermore, we aim at testing how fibrosis identification in cardiac magnetic resonance can help in therapy personalization and ablation tailoring. We also participate in multicenter studies testing different therapeutic strategies and novel drugs. This work is performed within UFA (Unitat de Fibril·lació Auricular), a multidisciplinary unit led by Dr. Mont including clinicians and Marta Sitges researchers (https://ufaclinic.cat/ca). GROUP

98 ARRHYTHMIAS, RESYNCHRONIZATION AND CARDIAC IMAGING 2.2

RESEARCH GROUP Abraham W., Borer J., Dickstein K., Gras D., Petr; Botman, Cornelis; Angeles Castel, Maria; CARDIAC IMAGING Brugada J., Robertson M., Ford I., Krum H., D'Onofrio, Antonio; de Borst, Gert J.; Solomon, Holzmeister J., Ruschitzka F., Gorcsan J. Scott; Stein, Kenneth M.; Schubert, Bernd; Prognostic implications of left ventricular Stalsberg, Kevin; Wold, Nicholas; Ruble, global longitudinal strain in heart failure Stephen; Zannad, Faiez. Long-term vagal patients with narrow QRS complex treated stimulation for heart failure: Eighteen with cardiac resynchronization therapy: A month results from the NEural Cardiac subanalysis of the randomized EchoCRT TherApy foR Heart Failure (NECTAR-HF) trial. EUROPEAN HEART JOURNAL. trial. INTERNATIONAL JOURNAL OF GROUP LEADER 38(10):720-726. I.F.: 20.212 CARDIOLOGY. 244:229-234. I.F.: 6.189 Marta Sitges (HCB) 4. Hernandez-Ojeda J, Arbelo E, Borras R, 10. Donal E, Delgado V, Magne J, Our group has a pluridisciplinary team of Berne P, Tolosana JM, Gomez-Juanatey A, Bucciarelli-Ducci C, Leclercq C, Cosyns B, people dedicated to non-invasive cardiac Berruezo A, Campuzano O, Sarquella- Sitges M, Edvardsen T, Sade E, Stankovic I, imaging and its application in the knowledge Brugada G, Mont L, Brugada R, Brugada J. Agricola E, Galderisi M, Lancellotti P, and research into cardiovascular Patients With Brugada Syndrome and Hernandez A, Plein S, Muraru D, pathophysiology and therapy within the field Implanted Cardioverter-Defibrillators: Schwammenthal E, Hindricks G, Popescu BA, of cardiac mechanics and remodelling in Long-Term Follow-Up. JOURNAL OF THE Habib G. Rational and design of EuroCRT: cardiovascular diseases. Our lines of research AMERICAN COLLEGE OF CARDIOLOGY. an international observational study on include the application of cardiac imaging in 70(16):1991-2002. I.F.: 19.896 multi-modality imaging and cardiac the study of cardiac mechanics and function resynchronization therapy. EUROPEAN and analysis of cardiac remodelling in order to 5. Agustí A., Noell G., Brugada J., Faner R. HEART JOURNAL-CARDIOVASCULAR detect latent cardiac dysfunction. Additionally, Lung function in early adulthood and IMAGING. 18(10):1120-1127. I.F.: 5.990 our collaboration with bioengineering groups health in later life: a transgenerational allows for better quantification and cohort analysis. THE LANCET. 11. Ramos J, Monteagudo JM, identification of patterns of cardiac RESPIRATORY MEDICINE. 5(12):935-945. González-Alujas T, Fuentes ME, Sitges M, adaptations to disease and understanding of I.F.: 19.287 Peña ML, Carrasco-Chinchilla F, Echeverría T, their underlying physiopathology. Bouzas A, Forteza Alberti JF, Mesa D, De La 6. Nägele M., Steffel J., Robertson M., Singh J., Hera JM, Zamorano JL. Large-scale Flammer A., Bax J., Borer J., Dickstein K., Ford assessment of aortic stenosis: facing the I., Gorcsan J., Gras D., Krum H., Sogaard P., next cardiac epidemic? EUROPEAN HEART PUBLICATIONS Holzmeister J., Abraham W., Brugada J., JOURNAL-CARDIOVASCULAR IMAGING. Ruschitzka F. Effect of cardiac I.F.: 5.990 Originals / I.F.: 315.234 resynchronization therapy in patients with diabetes randomized in EchoCRT. 12. Redondo-Angulo I, Mas-Stachurska A, 1. Arbelo E, Brugada J, Blomström-Lundqvist EUROPEAN JOURNAL OF HEART FAILURE. Sitges M, Tinahones FJ, Giralt M, Villarroya F, C, Laroche C, Kautzner J, Pokushalov E, 19(1):80-87. I.F.: 6.968 Planavila A. Fgf21 is required for cardiac Raatikainen P, Efremidis M, Hindricks G, remodeling in pregnancy. Barrera A, Maggioni A, Tavazzi L, Dagres N, on 7. Campuzano O., Sanchez-Molero O., CARDIOVASCULAR RESEARCH. the behalf of the ESC-EHRA Atrial Fibrillation Fernandez A., Mademont-Soler I., Coll M., 113(13):1574-1584. I.F.: 5.878 Ablation Long-term Registry Investigators. Perez-Serra A., Mates J., del Olmo B., Pico F., Contemporarymanagement of patients Nogue-Navarro L., Sarquella-Brugada G., 13. Tarradas, Anna; Pinsach-Abuin, Mel Lina; undergoing atrial fibrillation ablation: Iglesias A., Cesar S., Carro E., Borondo J., Mackintosh, Carlos; Llora-Batlle, Oriol; Inhospital and 1-year follow-up findings Brugada J., Castellà J., Medallo J., Brugada R. Perez-Serra, Alexandra; Batlle, Montserrat; from the ESC-EHRA atrial fibrillation Sudden Arrhythmic Death During Perez-Villa, Felix; Zimmer, Thomas; ablation long-term registry. EUROPEAN Exercise: A Post-Mortem Genetic Garcia-Bassets, Ivan; Brugada, Ramon; HEART JOURNAL. 38(17):1303-1316. Analysis. SPORTS MEDICINE. Beltran-Alvarez, Pedro; Pagans, Sara. I.F.: 20.212 47(10):2101-2115. I.F.: 6.832 Transcriptional regulation of the sodium channel gene (SCN5A) by GATA4 in 2. Brugada J, Delnoy PP, Brachmann J, 8. Sarvari SI, Rodriguez-Lopez M, human heart. JOURNAL OF MOLECULAR Reynolds D, Padeletti L, Noelker G, Kantipudi Nuñez-Garcia M, Sitges M, Sepulveda- AND CELLULAR CARDIOLOGY. 102:74-82. C, Rubin Lopez JM, Dichtl W, Borri-Brunetto A, Martinez A, Camara O, Butakoff C, Gratacos E, I.F.: 5.680 Verhees L, Ritter P, Singh JP, RESPOND CRT Bijnens B, Crispi F. Persistence of Cardiac Investigators. Contractility sensor-guided Remodeling in Preadolescents With Fetal 14. Boyle, Thomas A.; Uslan, Daniel Z.; Prutkin, optimization of cardiac resynchronization Growth Restriction. CIRC CARDIOVASC Jordan M.; Greenspon, Arnold J.; Baddour, therapy: Results from the RESPOND-CRT IMAGING. 10(1):e005270. I.F.: 6.803 Larry M.; Danik, Stephan B.; Tolosana, Jose M.; trial. EUROPEAN HEART JOURNAL. Le, Katherine; Miro, Jose M.; Peacock, James; 38(10):730-738. I.F.: 20.212 9. De Ferrari, Gaetano M.; Stolen, Craig; Sohail, Muhammad R.; Vikram, Holenarasipur Tuinenburg, Anton E.; Wright, D. Jay; Brugada, R.; Carrillo, Roger G. Reimplantation and 3. Bax J., Delgado V., Sogaard P., Singh J., Josep; Butter, Christian; Klein, Helmut; Neuzil, Repeat Infection After

99 AREA 2 RESPIRATORY, CARDIOVASCULAR AND RENAL PATHOBIOLOGY AND BIOENGINEERING

Cardiac-Implantable Electronic Device Bosch X, Perea RJ, Prat-González S, JOURNAL OF PHYSIOLOGY. Infections Experience From the MEDIC Soto-Iglesias D, Tolosana JM, Vassanelli F, 595(22):6993-7008. I.F.: 4.739 (Multicenter Electrophysiologic Device Cabrera M, Linhart M, Martinez M, Mont L, Infection Cohort) Database. CIRCULATION. Berruezo A. Clinical recognition of pure 26. Rodríguez-López M, Cruz-Lemini M, ARRHYTHMIA AND ELECTROPHYSIOLOGY. premature ventricular complex-induced Valenzuela-Alcaraz B, Garcia-Otero L, Sitges 10(3):e004822. I.F.: 5.410 cardiomyopathy at presentation. HEART M, Bijnens B, Gratacós E, Crispi F. Descriptive RHYTHM. 14(12):1864-1870. I.F.: 4.825 analysis of the different phenotypes of 15. Pappone, Carlo; Brugada, Josep; cardiac remodeling in fetal growth Vicedomini, Gabriele; Ciconte, Giuseppe; 20. Penela D, Acosta J, Andreu D, Ortiz-Perez restriction. ULTRASOUND IN OBSTETRICS Manguso, Francesco; Saviano, Massimo; JT, Bosch X, Perea RJ, de Caralt TM, AND GYNECOLOGY. 50(2):207-214. I.F.: 4.710 Vitale, Raffaele; Cuko, Amarild; Giannelli, Luigi; Fernández-Armenta J, Soto-Iglesias D, Calovic, Zarko; Conti, Manuel; Pozzi, Paolo; Prat-Gonzalez S, Borràs R, Mont L, Hervas V, 27. Valenzuela-Alcaraz B, Crispi F, Natalizia, Andrea; Crisa, Simonetta; Borrelli, Morales-Ruiz M, Jiménez W, Mira A, Donnelly Cruz-Lemini M, Bijnens B, García-Otero L, Valeria; Brugada, Ramon; Sarquella-Brugada, J, Ekinci O, Lasalvia L, Berruezo A. Sitges M, Balasch J, Gratacós E. Differential Georgia; Guazzi, Marco; Frigiola, Alessandro; Identification of the Potentially effect of assisted reproductive Menicanti, Lorenzo; Santinelli, Vincenzo. Arrhythmogenic Substrate in the Acute technologies and small-for-gestational- Electrical Substrate Elimination in 135 Phase of ST-elevation Myocardial age on fetal cardiac remodeling. Consecutive Patients With Brugada Infarction. HEART RHYTHM. 14(4):592-598. ULTRASOUND IN OBSTETRICS AND Syndrome. CIRCULATION. ARRHYTHMIA I.F.: 4.825 GYNECOLOGY. 50(1):63-70. I.F.: 4.710 AND ELECTROPHYSIOLOGY. 10(5):e005053. I.F.: 5.410 21. Roberts PR, Clementy N, Al Samadi F, 28. Loughlin G, Avila P, Martinez-Ferrer JB, Garweg C, Martinez-Sande JL, Iacopino S, Alzueta J, Vinolas X, Brugada J, Arizon JM, 16. Milman, Anat; Andorin, Antoine; Gourraud, Johansen JB, Vinolas Prat X, Kowal RC, Klug Fernandez-Lozano I, García-Campo E, Jean-Baptiste; Sacher, Frederic; Mabo, D, Mont L, Steffel J, Li S, Van Osch D, El-Chami Basterra N, Fernandez De La Concha J, Philippe; Kim, Sung-Hwan; Maeda, Shingo; MF. A Leadless Pacemaker in the Real- Arenal A. Association of cardiac Takahashi, Yoshihide; Kamakura, Tsukasa; World Setting: The Micra Transcatheter resynchronization therapy with the Aiba, Takeshi; … … ; Belhassen, Bernard. Age of Pacing System Post- Approval Registry. incidence of appropriate implantable First Arrhythmic Event in Brugada HEART RHYTHM. 14(9):1375-1379. I.F.: 4.825 cardiac defibrillator therapies in ischaemic Syndrome Data From the SABRUS and non-ischaemic cardiomyopathy. (Survey on Arrhythmic Events in Brugada 22. Lloyd M, Reynolds D, Sheldon T, EUROPACE. 19(11):1818-1825. I.F.: 4.521 Syndrome) in 678 Patients. CIRCULATION. Stromberg K, Hudnall JH, Demmer WM, Omar ARRHYTHMIA AND ELECTROPHYSIOLOGY. R, Ritter P, Hummel J, Mont L, Steinwender C, 29. Benito, Eva M.; Carlosena-Remirez, Alicia; 10(12):e005222. I.F.: 5.410 Duray GZ. Rate adaptive pacing in an Guasch, Eduard; Prat-Gonzalez, Susana; intracardiac pacemaker. HEART RHYTHM. Perea, Rosario J.; Figueras, Rosa; Borras, 17. Jiménez-Brítez G, Freixa X, Flores- 14(2):200-205. I.F.: 4.825 Roger; Andreu, David; Arbelo, Elena; Maria Umanzor E, San Antonio R, Caixal G, Garcia J, Tolosana, J.; Bisbal, Felipe; Brugada, Josep; Hernandez-Enriquez M, Andrea R, Regueiro A, 23. Boriani G, Tukkie R, Biffi M, Mont L, Ricci R, Berruezo, Antonio; Mont, Lluis. Left atrial Masotti M, Brugaletta S, Martin V, Sabaté M. Pürerfellner H, Botto GL, Manolis AS, fibrosis quantification by late gadolinium- Out-of-hospital cardiac arrest and stent Landolina M, Gulizia M, Hudnall JH, Mangoni L, enhanced magnetic resonance: a new thrombosis: Ticagrelor versus clopidogrel Grammatico A, Padeletti L, MINERVA method to standardize the thresholds for in patients with primary percutaneous Investigators. Atrial antitachycardia pacing reproducibility. EUROPACE. 19(8):1272-1279. coronary intervention under mild and atrial remodeling: a substudy of the I.F.: 4.521 therapeutic hypothermia. international, randomized MINERVA trial. RESUSCITATION. 114:141-145. I.F.: 5.230 HEART RHYTHM. 14(10):1476-1484. I.F.: 4.825 30. Di Biase L, Callans D, Hæusler KG, Hindricks G, Al-Khalidi H, Mont L, Cosedis 18. Duray, Gabor Z.; Ritter, Philippe; El-Chami, 24. Andreu D; Penela D; Acosta J; Nielsen J, Piccini JP, Schotten U, Kirchhof P. Mikhael; Narasimhan, Calambur; Omar, Razali; Fernandez-Armenta J; Perea R; Soto-Iglesias Rationale and design of AXAFA-AFNET 5: Tolosana, Jose M.; Zhang, Shu; Soejima, D; De Caralt T; Ortiz-Pérez J; Prat-González S; an investigator-initiated, randomized, Kyoko; Steinwender, Clemens; Rapallini, Borras R; Guasch E; Tolosana J; Mont L; open, blinded outcome assessment, Leonardo; Cicic, Aida; Fagan, Dedra H.; Liu, Berruezo A. Cardiac magnetic resonance- multi-centre trial to comparing continuous Shufeng; Reynolds, Dwight; Micra aided scar dechanneling: Influence on apixaban to vitamin K antagonists in Transcatheter Pacing Study. Long-term acute and long-term outcomes. HEART patients undergoing atrial fibrillation performance of a transcatheter pacing RHYTHM. 14(8):1121-1128. I.F.: 4.825 catheter ablation. EUROPACE. 19(1):132-138. system: 12-Month results from the Micra I.F.: 4.521 Transcatheter Pacing Study. HEART 25. Gaitán-Peñas H, Apaja PM, Arnedo T, RHYTHM. 14(5):702-709. I.F.: 4.825 Castellanos A, Elorza-Vidal X, Soto D, Gasull X, 31. Berruezo A, Acosta J, Fernández-Armenta Lukacs GL, Estévez R. J, Pedrote A, Barrera A, Arana-Rueda E, 19. Penela D, Fernández-Armenta J, Aguinaga Leukoencephalopathy- causing CLCN2 Bodegas AI, Anguera I, Tercedor L, Penela D, L, Tercedor L, Ordoñez A, Bisbal F, Acosta J, mutations are associated with impaired Cl- Andreu D, Perea RJ, Prat-González S, Mont L. Rossi L, Borras R, Doltra A, Ortiz-Pérez JT, channel function and trafficking. Safety, long-term outcomes and

100 ARRHYTHMIAS, RESYNCHRONIZATION AND CARDIAC IMAGING 2.2

predictors of recurrence after first-line Insights From an Animal Model. JOURNAL Incremental diagnostic value and combined endoepicardial ventricular OF THE AMERICAN HEART ASSOCIATION. cost-effectiveness of diagnostic tests. tachycardia substrate ablation in 6(9):e006438. I.F.: 4.425 EUROPEAN JOURNAL OF PREVENTIVE arrhythmogenic cardiomyopathy. Impact CARDIOLOGY. 24(13):1446-1454. I.F.: 3.606 of arrhythmic substrate distribution 37. Chun, K. R. Julian; Brugada, Josep; Elvan, pattern. A prospective multicentre study. Arif; Geller, Laszlo; Busch, Matthias; Barrera, 43. Sangüesa G, Baena M, Hutter N, EUROPACE. 19(4):607-616. I.F.: 4.521 Alberto; Schilling, Richard J.; Reynolds, Montañés J, Sánchez R, Roglans N, Laguna J, Matthew R.; Hokanson, Robert B.; Holbrook, Alegret M. The addition of liquid fructose to 32. Sarvari SI, Sitges M, Sanz M, Tolosana Viu Reece; Brown, Benedict; Schlueter, Michael; a western-type diet in LDL-R−/−mice JM, Edvardsen T, Stokke TM, Mont L, Bijnens Kuck, Karl-Heinz;FIRE ICE Investigators. The induces liver inflammation and B. Left ventricular dysfunction is related to Impact of Cryoballoon Versus fibrogenesis markers without disrupting the presence and extent of a septal flash in Radiofrequency Ablation for Paroxysmal insulin receptor signalling after an insulin patients with right ventricular pacing. Atrial Fibrillation on Healthcare Utilization challenge. NUTRIENTS. 9(3). I.F.: 3.550 EUROPACE. 19(2):289-296. I.F.: 4.521 and Costs: An Economic Analysis From the FIRE AND ICE Trial. JOURNAL OF THE 44. Sangüesa G, Shaligram S, Akther F, 33. Acosta J, Cabanelas N, Penela D, AMERICAN HEART ASSOCIATION. Roglans N, Laguna J, Rahimian R, Alegret M. Fernández-Armenta J, Andreu D, Borràs R, 6(8):e006043. I.F.: 4.425 Type of supplemented simple sugar, not Korshunov V, Cabrera M, Vasanelli F, Arbelo E, merely calorie intake, determines adverse Guasch E, Martínez M, Tolosana JM, Mont L, 38. Castañeda X, García-de-la-Mària C, effects on metabolism and aortic function Berruezo A. Long-term benefit of first-line Gasch O, Pericas JM, Armero Y, Soy D, in female rats. AMERICAN JOURNAL OF peri-implantable cardioverter-defibrillator García-González J, Falces C, Ninot S, Almela PHYSIOLOGY - HEART AND CIRCULATORY implant ventricular tachycardia-substrate M, Ambrosioni J, Quintana E, Vidal B, Fuster D, PHYSIOLOGY. 312(2):H289-H304. I.F.: 3.348 ablation in secondary prevention patients. Llopis J, Soto S, Moreno A, Marco F, Miró JM, EUROPACE. 19(6):976-982. I.F.: 4.521 Hospital Clinic Endocarditis Study Group. 45. Sanz-de la Garza M, Rubies C, Batlle M, AUC/MIC Pharmacodynamic Target Is Not Bijnens BH, Mont L, Sitges M, Guasch E. 34. Baena M, Sangüesa G, Hutter N, Beltrán J, a Good Predictor of Vancomycin Efficacy Severity of structural and functional right Sánchez R, Roglans N, Alegret M, Laguna J. in Methicillin-Resistant Staphylococcus ventricular remodeling depends on Liquid fructose in Western-diet-fed mice aureus Experimental Endocarditis. training load in an experimental model of impairs liver insulin signaling and causes ANTIMICROBIAL AGENTS AND endurance exercise. AMERICAN JOURNAL cholesterol and triglyceride loading CHEMOTHERAPY. 61(6):e02486. I.F.: 4.302 OF PHYSIOLOGY - HEART AND without changing calorie intake and body CIRCULATORY PHYSIOLOGY. weight. JOURNAL OF NUTRITIONAL 39. López-Guimet J, Andilla J, Loza-Alvarez P, 313(3):459-468. I.F.: 3.348 BIOCHEMISTRY. 40:105-115. I.F.: 4.518 Egea G. High-Resolution Morphological Approach to Analyse Elastic Laminae 46. Mademont-Soler I., Mates J., Yotti R., 35. García-Blas S, Bonanad C, Llàcer P, Injuries of the Ascending Aorta in a Murine Espinosa M., Pérez-Serra A., Fernandez-Avila Ventura S, Núñez JM, Sánchez R, Chamorro Model of Marfan Syndrome. SCIENTIFIC A., Coll M., Méndez I., Iglesias A., Del Olmo B., C, Fácila L, de la Espriella R, Vaquer JM, REPORTS. 7(1):1505. I.F.: 4.259 Riuró H., Cuenca S., Allegue C., Campuzano O., Cordero A, Roqué M, Ortiz V, Racugno P, Bodí Picó F., Ferrer-Costa C., Álvarez P., Castillo S., V, Valero E, Santas E, Moreno MDC, Miñana G, 40. Jimenez-Altayo, Francesc; Siegert, Garcia-Pavia P., Gonzalez-Lopez E., Carratalá A, Bondanza L, Payá A, Cardells I, Anna-Maria; Bonorino, Fabio; Meirelles, Padron-Barthe L., De Bustamante A., Heredia R, Pellicer M, Valls G, Palau P, Bosch Thayna; Barbera, Laura; Dantas, Ana P.; Vila, Darnaude M., González-Hevia J., Brugada J., MJ, Raso R, Sánchez A, Bertomeu-González Elisabet; Egea, Gustavo. Differences in the Fernandez-Aviles F., Brugada R. Additional V, Bertomeu-Martínez V, Montagud-Balaguer Thoracic Aorta by Region and Sex in a value of screening for minor genes and V, Albiach-Montañana C, Pendás-Meneau J, Murine Model of Marfan Syndrome. copy number variants in hypertrophic Marcaida G, Cervantes-García S, San Antonio FRONTIERS IN PHYSIOLOGY. 8(NOV):Article cardiomyopathy. PLOS ONE. R, de Mingo E, Chorro FJ, Sanchis J, Núñez J, 933. I.F.: 4.134 12(8):e0181465. I.F.: 2.806 IMPROVE-HF Investigators. Diuretic Strategies in Acute Heart Failure 41. Varela, Marta; Bisbal, Felipe; Zacur, 47. Sanchis L, Sanz-de La Garza M, Bijnens B, and Renal Dysfunction: Conventional vs Ernesto; Berruezo, Antonio; Aslanidi, Oleg V.; Giraldeau G, Grazioli G, Marin J, Gabrielli L, Carbohydrate Antigen 125-guided Mont, Lluis; Lamata, Pablo. Novel Montserrat S, Sitges M. Gender influence on Strategy. Clinical Trial Design. REVISTA Computational Analysis of Left Atrial the adaptation of atrial performance to ESPAÑOLA DE CARDIOLOGIA. Anatomy Improves Prediction of Atrial training. EUROPEAN JOURNAL OF SPORT 70(12):1067-1073. I.F.: 4.485 Fibrillation Recurrence after Ablation. SCIENCE. 17(6):720-726. I.F.: 2.690 FRONTIERS IN PHYSIOLOGY. 8(FEB):Article 36. Mas-Stachurska A, Siegert AM, Batlle M, 68. I.F.: 4.134 48. Sanz-de la Garza M, Giraldeau G, Marin J, Gorbenko Del Blanco D, Meirelles T, Rubies C, Grazioli G, Esteve M, Gabrielli L, Brambila C, Bonorino F, Serra-Peinado C, Bijnens B, 42. Grazioli G, Sanz de la Garza M, Vidal B, Sanchis L, Bijnens B, Sitges M. Influence of Baudin J, Sitges M, Mont L, Guasch E, Egea G. Montserrat S, Sarquella-Brugada G, Pi R, Til L, gender on right ventricle adaptation to Cardiovascular Benefits of Moderate Gutierrez J, Brugada J, Sitges M. Prevention endurance exercise: an ultrasound Exercise Training in Marfan Syndrome: of sudden death in adolescent athletes: two-dimensional speckle-tracking stress

101 AREA 2 RESPIRATORY, CARDIOVASCULAR AND RENAL PATHOBIOLOGY AND BIOENGINEERING

study. EUR J APPL PHYSIOL. 117(3):389-396. ventricular dyssynchrony in patients with Knowledge, Shortcomings and Open I.F.: 2.130 pulmonary artery hypertension. Questions. INTERNATIONAL JOURNAL OF ECHOCARDIOGRAPHY. 34(1):53-60. I.F.: 1.314 SPORTS MEDICINE. 38(8):573-581. I.F.: 2.084 49. Campuzano O., Sanchez-Molero O., Mademont-Soler I., Coll M., Allegue C., 55. Yzaguirre I, Grazioli G, Domenech M, 7. Ambrosioni J., Hernandez-Meneses M., Ferrer-Costa C., Mates J., Perez-Serra A., del Vinuesa A, Pi R, Gutierrez J, Coca A, Brugada Téllez A., Pericàs J., Falces C., Tolosana J., Olmo B., Iglesias A., Sarquella-Brugada G., J, Sitges M. Exaggerated blood pressure Vidal B., Almela M., Quintana E., Llopis J., Brugada J., Borondo J., Castella J., Medallo J., response to exercise and late-onset Moreno A., Miro J. The Changing Brugada R. Genetic analysis in hypertension in young adults. BLOOD Epidemiology of Infective Endocarditis in post-mortem samples with micro- PRESSURE MONITORING. 22(6):339-344. the Twenty-First Century. CURRENT ischemic alterations. FORENSIC SCIENCE I.F.: 1.248 INFECTIOUS DISEASE REPORTS. 19(5):21. INTERNATIONAL. 271:120-125. I.F.: 1.989 I.F.: 1.915 56. Huguet M., Rodas L., Blasco M., Quintana 50. Bosch C., Campuzano O., L., Mercadal J., Ortiz-Pérez J., Rovira I., Poch E. 8. Gronda, Edoardo; Francis, Darrel; Zannad, Sarquella-Brugada G., Cesar S., Perez-Serra Clinical impact of regional citrate Faiez; Hamm, Christian; Brugada, Josep; A., Coll M., Mademont I., Mates J., del Olmo B., anticoagulation in continuous renal Vanoli, Emilio. Baroreﬂex activation therapy: Iglesias A., Brugada J., Petersen V., Brugada R. replacement therapy in critically ill a new approach to the management of A novel variant in RyR2 causes familiar patients. INTERNATIONAL JOURNAL OF advanced heart failure with reduced catecholaminergic polymorphic ARTIFICIAL ORGANS. 40(12):676-682. ejection fraction. JOURNAL OF ventricular tachycardia. FORENSIC I.F.: 1.169 CARDIOVASCULAR MEDICINE. SCIENCE INTERNATIONAL. 270:173-177. 18(9):641-649. I.F.: 1.613 I.F.: 1.989 Review / I.F.: 33.698 51. Sitges M., Merino B., Butakoff C., de la Letters / I.F.: 26.541 Garza M., Paré C., Montserrat S., Vidal B., 1. Guasch E, Mont L. Diagnosis, Azqueta M., Sarquella G., Gutierrez J., Canal R., pathophysiology, and management of 1. Pujol-López M., Ortega-Paz L., Brugada J., Bijnens B. Characterizing the exercise-induced arrhythmias. NAT REV Flores-Umanzor E., Perea R., Bosch X. spectrum of right ventricular remodelling CARDIOL. 14(2):88-101. I.F.: 14.299 Cardiac Magnetic Resonance as an in response to chronic training. Alternative to Endomyocardial Biopsy to INTERNATIONAL JOURNAL OF 2. Pereira R., Campuzano O., Predict Recoverability of Left Ventricular CARDIOVASCULAR IMAGING. Sarquella-Brugada G., Cesar S., Iglesias A., Function in Methamphetamine- 33(3):331-339. I.F.: 1.896 Brugada J., Cruz Filho F., Brugada R. Short QT Associated Cardiomyopathy. JACC: syndrome in pediatrics. CLINICAL HEART FAILURE. 5(11):853-854. I.F.: 8.493 52. El-Chami M, Kowal RC, Soejima K, Ritter P, RESEARCH IN CARDIOLOGY. Duray GZ, Neuzil P, Mont L, Kypta A, Sagi V, 106(6):393-400. I.F.: 4.760 2. Berruezo A, Acosta J, Fernández-Armenta Hudnall JH, Stromberg K, Reynolds D. Impact J. Epicardial ablation may not be necessary of operator experience and training 3. Pontecorboli G, Figueras I Ventura RM, in all patients with arrhythmogenic right strategy on procedural outcomes with Carlosena A, Benito E, Prat-Gonzales S, ventricular dysplasia/cardiomyopathy and leadless pacing: Insights from the Micra Padeletti L, Mont L. Use of frequent ventricular tachycardia: author's Transcatheter pacing study. PACE - delayed-enhancement magnetic reply. EUROPACE. 19(12):2047-2048. PACING AND CLINICAL resonance imaging for ﬁbrosis detection in I.F.: 4.521 ELECTROPHYSIOLOGY. 40(7):834-842. the atria: a review. EUROPACE. I.F.: 1.486 19(2):180-189. I.F.: 4.521 3. Mont L, Pelliccia A, Sharma S, Biffi A, Borjesson M, Terradellas JB, Carré F, Guasch 53. Monteagudo Ruiz JM, Fernández-Golfín 4. Oliva A., Grassi V., Campuzano O., Brion M., E, Heidbuchel H, Gerche A, Lampert R, C, Mesa D, González-Alujas T, Sitges M, Arena V., Partemi S., Coll M., Pascali V., McKenna W, Papadakis M, Priori SG, Carrasco-Chinchilla F, Li CH, Grande-Trillo A, Brugada J., Carracedo A., Brugada R. Scanavacca M, Thompson P, Sticherling C, Martínez A, Matabuena J, Alonso-Rodríguez Medico-legal perspectives on sudden Viskin S, Wilson M, Corrado D, Lip GY, D, Aquila I, Zamorano JL. Prevalence of cardiac death in young athletes. Gorenek B, Lundqvist CB, Merkely B, optimal valve morphology for MitraClip in INTERNATIONAL JOURNAL OF LEGAL Hindricks G, Hernández-Madrid A, Lane D, patients with mitral regurgitation. MEDICINE. 131(2):393-409. I.F.: 2.382 Boriani G, Narasimhan C, Marquez MF, Haines ECHOCARDIOGRAPHY. 34(8):1122-1129. D, Mackall J, Marques-Vidal PM, Corra U, Halle I.F.: 1.314 5. Tolosana JM, Mont L. Cardiac M, Tiberi M, Niebauer J, Piepoli M . Resynchronization Therapy: How to Pre-participation cardiovascular 54. Gabrielli L, Ocaranza MP, Sitges M, Decrease Nonresponders. HEART FAILURE evaluation for athletic participants to Kanacri A, Saavedra R, Sepulveda P, CLINICS. 13(1):233-240. I.F.: 2.124 prevent sudden death: Position paper from Sepulveda L, Rossel V, Zagolin M, Verdejo HE, the EHRA and the EACPR, branches of the Baraona F, Zalaquett R, Chiong M, Lavandero 6. Mascia G, Arbelo E, Hernandez-Ojeda J, ESC. Endorsed by APHRS, HRS, and S, Castro PF. Acute effect of iloprost Solimene F, Brugada R, Brugada J. Brugada SOLAECE. EUROPACE. 19(5):883-883. inhalation on right atrial function and Syndrome and Exercise Practice: Current I.F.: 4.521

102 ARRHYTHMIAS, RESYNCHRONIZATION AND CARDIAC IMAGING 2.2

4. Mont L, Guasch E, Pelliccia A. 7. Brugada J. Atrial fibrillation ablation. TOMOGRAPHY. 11(1):71. I.F.: 3.185 Preparticipation cardiovascular evaluation Unsolved questions, many possible for athletic participants to prevents answers. REVISTA PORTUGUESA DE 8. Ciconte, Giuseppe; Conti, Manuel; sudden death: Author’s reply. EUROPACE. CARDIOLOGIA. 36:7-8. I.F.: 1.195 Vicedomini, Gabriele; Santinelli, Vincenzo; 19(5):883-883. I.F.: 4.521 Brugada, Josep; Pappone, Carlo. Intermittent alternance of Brugada ECG patterns: 5. Freixa X; Hernández-Enríquez M; Sanchis L; Case Reports / I.F.: 46.696 Insights from a unique Regueiro A; Sabate M; Sitges M. Tricuspid electrophysiological phenomenon. Percutaneous Repair With the MitraClip 1. San Antonio R, Flores Umanzor EJ, Sánchez JOURNAL OF CARDIOVASCULAR System: First Implant in Spain. REVISTA Somonte P, Caldentey G. Left atrial collapse ELECTROPHYSIOLOGY. 28(12):1482-1484. ESPAÑOLA DE CARDIOLOGIA. I.F.: 4.485 due to a giant false lumen in type B aortic I.F.: 3.068 dissection. INTENSIVE CARE MED. 43(1):133-134. I.F.: 12.015 9. Flores Umanzor E., Vannini L., San Antonio Editorial / I.F.: 31.103 R., Sanchez Somonte P., Martín-Yuste V. 2. Josue Flores-Umanzor, Eduardo; Wellens’ syndrome. INTERNAL AND 1. Berruezo A, Ortiz-Pérez J. Unraveling the Hernandez-Enriquez, Marco; Caldentey, EMERGENCY MEDICINE. 12(2):267-268. scar with cardiac magnetic resonance. Guillem; San Antonio, Rodolfo; Pare, Carles. I.F.: 2.340 CIRCULATION. CARDIOVASCULAR Radiation-Induced Cardiac Valve Disease. IMAGING. 10(9). I.F.: 6.803 AMERICAN JOURNAL OF MEDICINE. 10. Pujol-López M, San Antonio R, 130(3):E99-E100. I.F.: 5.550 Flores-Umanzor EJ, Guasch E, Azqueta M. 2. Arbelo E. Another piece of the puzzle: A rare cause of severe mitral stenosis and Assessment of mechanical dispersion by 3. Matalonga L, Bravo M, Serra-Peinado C, reversible pulmonary hypertension. magnetic resonance in long QT syndrome. García-Pelegrí E, Ugarteburu O, Vidal S, ECHOCARDIOGRAPHY. 34(10):1544-1545. HEART RHYTHM. 14(9):1398-1399. I.F.: 4.825 Llambrich M, Quintana E, Fuster-Jorge P, I.F.: 1.314 Gonzalez-Bravo MN, Beltran S, Dopazo J, 3. Mont L, Guasch E. Atrial fibrillation Garcia-Garcia F, Foulquier F, Matthijs G, Mills 11. Flores-Umanzor EJ, San Antonio R, progression: How sick is the atrium? P, Ribes A, Egea G, Briones P, Tort F, Girós M. Pujol-Lopez M, Perea RJ. An unusual cause HEART RHYTHM. 14(6):808-809. I.F.: 4.825 Mutations in TRAPPC11 are associated of thoracic pain: Cardiac perforation with a congenital disorder of glycosylation. associated with a pacemaker. MEDICINA 4. Serratosa-Fernández L, Pascual-Figal D, HUM MUTAT. 38(2):148-151. I.F.: 4.601 CLINICA. 149(6):e26. I.F.: 1.125 Masiá-Mondéjar MD, Sanz-de la Garza M, Madaria-Marijuan Z, Gimeno-Blanes JR, 4. San Antonio R, Benito EM, Tolosana JM, 12. Sánchez-Somonte P, Flores-Umanzor EJ, Adamuz C, Grupo de Cardiología del Deporte Emilce Trucco M, Mont L. Presyncopal Sitges Carreño M. Sudden cardiac death de la Sociedad Española de Cardiología. episodes after implantation of dual- secondary to severe multivessel coronary Comments on the New International chamber pacemaker programmed in spasm. MEDICINA CLINICA. 149(2):83-83. Criteria for Electrocardiographic SafeR pacing mode. EUROPACE. I.F.: 1.125 Interpretation in Athletes. REVISTA 19(5):807-807. I.F.: 4.521 ESPAÑOLA DE CARDIOLOGIA. 70(11):983-990. I.F.: 4.485 5. Benito EM, De Luna AB, Baranchuk A, Mont Clinical Guidelines / I.F.: 15.082 L. Extensive atrial fibrosis assessed by late 5. Pappone C, Brugada J. Ventricular gadolinium enhancement cardiovascular 1. Calkins H, Hindricks G, Cappato R, Kim YH, Arrhythmias Ablation in Brugada magnetic resonance associated with Saad EB, Aguinaga L, Akar JG, Badhwar V, Syndrome. Current and Future Directions. advanced interatrial block Brugada J, Camm J, … … , Yamane T. REVISTA ESPAÑOLA DE CARDIOLOGIA. electrocardiogram pattern. EUROPACE. TEMPORARY REMOVAL: 2017 10(12):1046-1049. I.F.: 4.485 19(3):377-377. I.F.: 4.521 HRS/EHRA/ECAS/APHRS/SOLAECE Expert Consensus Statement on Catheter 6. Arribas F., Roldán I., Luis Merino J., Roldán 6. Sanz de la Garza M, Lopez A, Sitges M. and Surgical Ablation of Atrial Fibrillation. V., Arenal Á., Tamargo J., Ruiz-Granell R., Mont Multiple pulmonary embolisms in a male HEART RHYTHM. 14(10):E275-E444.I.F.: 4.825 L., Anguita M., Marín F., Barrios Alonso V., marathon athlete: Is intense endurance Barón G., Esquivias, Cosín Sales J., Díaz exercise a real thrombogenic risk? 2. Calkins, Hugh; Hindricks, Gerhard; Cappato, Infante E., Escobar Cervantes C., Ferreiro SCANDINAVIAN JOURNAL OF MEDICINE Riccardo; Kim, Young-Hoon; Saad, Eduardo Gutiérrez J., Guerra Ramos J., Jiménez Candil AND SCIENCE IN SPORTS. 27(5):563-566. B.; Aguinaga, Luis; Akar, Joseph G.; Badhwar, F., Pérez Castellano N., Sambola Ayala A., I.F.: 3.331 Vinay; Brugada, Josep; Camm, … ... ; Yamane, Tello Montoliu A., San Román A., Alfonso F., Teiichi. 2017 HRS/EHRA/ECAS/APHRS/ Evangelista A., Ferreira I., Jiménez M., de Isla L., 7. San Antonio R., Pujol López M., Perea R., SOLAECE expert consensus statement on Rodríguez Padial L., Sánchez P., Sionis A., Sabaté M. ST-segment elevation catheter and surgical ablation of atrial Vázquez R. Comments on the 2016 ESC mimicking myocardial infarction after fibrillation: Executive summary. HEART Guidelines for the Management of Atrial hydrochloric acid ingestion: Acute caustic RHYTHM. 14(10):E445-E494. I.F.: 4.825 Fibrillation. REVISTA ESPAÑOLA DE myocarditis. JOURNAL OF CARDIOLOGIA. 70(1):2-8. I.F.: 4.485 CARDIOVASCULAR COMPUTED 3. Mont L, Pelliccia A, Sharma S, Biffi A,

103 AREA 2 RESPIRATORY, CARDIOVASCULAR AND RENAL PATHOBIOLOGY AND BIOENGINEERING

Borjesson M, Brugada Terradellas J, Carré F, Minimum Inhibitory Concentration on the anti-tTGFgf-beta therapeutic tool to fight Guasch E, Heidbuchel H, La Gerche A, Outcome of Methicillin-Susceptible against aortic aneurysms in marfan Lampert R, McKenna W, Papadakis M, Priori Staphylococcus aureus Left-Sided syndrome. SG, Scanavacca M, Thompson P, Sticherling Infective Endocarditis Treated with Sponsored by: The National Marfan C, Viskin S, Wilson M, Corrado D,, Lip GY, Anti-staphylococcal Beta-Lactam Foundation. NMARFANF_15_01 Gorenek B, Blomström Lundqvist C, Merkely Antibiotics; a Prospective Cohort Study by Duration: 01/01/2016-31/12/2018 B, Hindricks G, Hernández-Madrid A, Lane D, the International Collaboration on Boriani G, Narasimhan C, Marquez MF, Haines Endocarditis. CLIN MICROBIOL INFECT. Guasch E. Caracterización del remodelado D, Mackall J, Manuel Marques-Vidal P, Corra 23(8):544-549. I.F.: 5.292 a dosis crecientes de ejercicio físico como U, Halle M, Tiberi M, Niebauer J, Piepoli M sustrato para el desarrollo de patología Reviewers. Pre-participation inducida por el ejercicio. cardiovascular evaluation for athletic GRANTS FOR RESEARCH IN PROGRESS Sponsored by: Instituto de Salud Carlos III. participants to prevent sudden death: PI16/00703 Position paper from the EHRA and the Arbelo E. Estudio ANVERSO: análisis Duration: 01/01/2017-31/12/2019 EACPR, branches of the ESC. Endorsed by continuo y automático de variables APHRS, HRS, and SOLAECE. EUR J PREV electrocardiográficas en relación al riesgo Mont L. Efectos cardiovasculares del CARDIOL. 24(1):41-69. I.F.: 3.606 de muerte súbita en pacientes con exceso de ejercicio: Caracterización en el síndrome de Brugada. modelo animal, traslación al atleta. 4. Calkins, Hugh; Hindricks, Gerhard; Cappato, Sponsored by: Instituto de Salud Carlos III Sponsored by: Instituto de Salud Carlos III Riccardo; Kim, Young-Hoon; Saad, Eduardo (ISCIII). PI16/01203 (ISCIII). PI13/01580 B.; Aguinaga, Luis; Akar, Joseph G.; Badhwar, Duration: 01/01/2017-31/12/2019 Duration: 01/01/2014-31/12/2017 Vinay; Brugada, Josep; … … ; Yamane, Teiichi. 2017 HRS/EHRA/ECAS/APHRS/ Berruezo A. Caracterización automática del Mont L. Characterizing Atrial fibrillation by SOLAECE expert consensus statement on sustrato arrítmico y evaluación de su Translating its Causes into Health catheter and surgical ablation of atrial utilidad para la prevención de la muerte Modifiers in the Elderly. fibrillation: executive summary. JOURNAL súbita cardíaca y guiado de los Sponsored by: European Comission. 633196 OF INTERVENTIONAL CARDIAC procedimientos de arritmias (ADAS). Duration: 01/05/2015-30/04/2019 ELECTROPHYSIOLOGY. 50(1):1-55. I.F.: 1.826 Sponsored by: Ministerio de Economía y Competitividad. RTC-2015-3515-1 Mont JL. Caracterització no invasiva dels Duration:01/11/2015-30/06/2018 teixits de l'aurícula esquerra per guiar Consortium Publications / I.F.: 97.594 l'ablació de la fibril·lació auricular i per Berruezo A. Caracterización del sustrato predir els resultats del procediment així 1. Calkins, Hugh; Willems, Stephan; arritmogénico y evaluación de su utilidad com la progressió de la malaltia. Gerstenfeld, Edward P.; Verma, Atul; Schilling, en la predicción de eventos arrítmicos y Sponsored by: Fundació la Marató de TV3. Richard; Hohnloser, Stefan H.; Okumura, Ken; guiado de los procedimientos de ablación. 20152730 Serota, Harvey; Nordaby, Matias; Guiver, Kelly; Sponsored by: Instituto de Salud Carlos III Duration: 29/06/2016-28/06/2019 Biss, Branislav; Brouwer, Marc A.; Grimaldi, (ISCIII). PI14/00759 Massimo; RE-CIRCUIT Investigators. Duration: 01/01/2015-31/12/2017 Mont L. Ablación de fibrilación auricular Uninterrupted Dabigatran versus Warfarin guiada por resonancia magnética. Estudio for Ablation in Atrial Fibrillation. NEW Berruezo A. ABLAVIEW - Un sistema randomizado de la eficacia de la ENGLAND JOURNAL OF MEDICINE. innovador de ablación por radiofrecuencia identificación y aislamiento de las zonas de 376(17):1627-1636. I.F.: 72.406 guiado por imagen para el tratamiento de fibrosis. la fibrilación auricular. Sponsored by: Instituto de Salud Carlos III, 2. Huisman M., Rothman K., Paquette M., Sponsored by: Ministerio de Economia y PI16/00435 Teutsch C., Diener H., Dubner S., Halperin J., Competitividad. RTC-2016-5445-1 Duration: 01/01/2017-31/12/2019 Ma C., Zint K., Elsaesser A., Bartels D., Lip G., .. ... Duration: 08/03/2016-31/12/2018 , Adams L., Adragão P. The Changing Ortiz JT. Paper dels macròfags i Landscape for Stroke Prevention in AF: Brugada J. Comparative Effectiveness fibroblastes residents a la remodelació Findings From the GLORIA-AF Registry Research to Assess the Use of Primary miocàrdica i la regeneració tisular tras Phase 2. JOURNAL OF THE AMERICAN ProphylacTic Implantable Cardioverter l'infart de miocardi: contribució del sistema COLLEGE OF CARDIOLOGY. 69(7):777-785. Defibrillators in EUrope. GAS6-TAM. I.F.: 19.896 Sponsored by: European Commission. Sponsored by: Fundació la Marató de TV3. 602299-2 20153030 3. Pericàs JM, Messina JA, Garcia-de-la- Duration: 01/10/2013-30/09/2018 Duration: 26/04/2016-25/04/2019 Mària C, Park L, Sharma-Kuinkel BK, Marco F, Wray D, Kanafani ZA, Carugati M, Brugada J. Red Cardiovascular. Ortiz JT. Papel del sistema GAS6-TAM en la Durante-Mangoni E, Tattevin P, Chu VH, Sponsored by: Instituto de Salud Carlos III difeerenciación fibroblástica y el Moreno A, Fowler VG, Miró JM, International (ISCIII). RD12/0042/0044 remodelado ventricular tras el infarto de Collaboration on Endocarditis Microbiology Duration: 01/01/2013-30/06/2017 miocardio. Investigators. Influence of Vancomycin Egea G. Apolinker p144, a potential Sponsored by: Instituto de Salud Carlos III.

104 ARRHYTHMIAS, RESYNCHRONIZATION AND CARDIAC IMAGING 2.2

PI15/00531 Duration: 01/01/2016-31/12/2018

Sitges M. Adaptación del ventrículo derecho y circulación arterial pulmonar al entrenamiento físico intensivo: implicaciones en el seguimiento de deportistas. Sponsored by: Ministerio de Economía y Competitividad. DEP2013-44923-P Duration: 01/01/2014-31/12/2017

Sitges M. Predicció personalitzada i oprecoç de ﬁbrilació auricular en subjectes en risc. PREDICTAF. Sponsored by: Fundació la Marató de TV3. 20154030 Duration: 10/05/2016-09/05/2019

Sitges M. MARIE Skłodowska-CURIE ACTIONS, Innovative Training Networks - European Industrial Doctorates. “PIC – Personalised In-silico Cardiology”. Sponsored by: Horizon 2020 European Comission Project H2020-MSCA-ITN-2016. Duration: 01/09/2017-31/08/2021

DOCTORAL THESES

Sitges M. Characterization of the spectrum of cardiac adaptation to endurance exercise: impact of gender and training load. PhD student: Maria Sanz de la Garza

Batlle M. Guasch E. Estudi de l'exercici físic intens i la síndrome de l'apnea del son com a factors de risc emergents per a patologia cardiovascular. Caracterització en models animals. PhD student: Cira Rubies Espinalt

Berruezo A: Extrasistolia ventricular frecuente en pacientes con disfunción ventricular izquierda. Implicaciones clínicas y beneﬁcio de la ablación mediante radiofrecuencia. PhD student: Diego Penela Maceda

Egea G. Membrane trafficking of TGF-beta and transcriptomic analysis in Marfan syndrome. PhD student: Anne-Maria Siegert

Sitges M. Prevención de muerte súbita en el deporte mediante el cribado pre-participativo. PhD student: Gonzalo Grazioli

105 AREA 2 RESPIRATORY, CARDIOVASCULAR AND RENAL PATHOBIOLOGY AND BIOENGINEERING

Nephro-urological diseases 2.3 and kidney transplantation

TEAM LEADER Manuel Juan (HCB) Fritz Diekmann (HCB) Miguel Ángel López-Boado (HCB) LOCATION T. 93 227 54 00 (Ext.: 3428) Jaime Martorell (HCB) CELLEX building 2B [email protected] Carlos Nicolau (HCB) Eduard Palou (HCB) David Parades (HCB)

GROUP LEADER Gil Rodas (HCB) Ignacio Revuelta (HCB-IDIBAPS) Rafael Salvador (HCB) T.93 227 54 00 (Ext.: 4410) Manuel Sole (HCB) KEYWORDS [email protected] Vicenç Torregrosa (HCB) 1. Renal transplantation Ana Paula Villela (HCB) 2. Dialysis 3. Transplant immunology Posttransplant cancer STRATEGIC OBJECTIVES 4. RESEARCHERS 5. Renal regeneration Josep M. Campistol (HCB) 6. Pancreas transplantation Aleix Cases (HCB) LENIT performs translational research of renal 7. Transplant registries Martí Manyalich (HCB) diseases. Our focus is physiopathology of Federico Oppenheimer (HCB) kidney diseases and optimization of renal Esteban Poch (HCB) replacement therapy (RT) (dialysis or Luis F. Quintana (HCB) transplantation) as well as pancreas Jordi Rovira (IDIBAPS) transplantation; that’s why we are doing research on RT optimization; but we also focused on regenerative treatment as an Original publications POST-DOCTORAL RESEARCHERS alternative establishing a cure and thus avoid from 2015 to 2017 Ramon Adalia (HCB) Elisenda Bañón (FCRB) the need for these RT. YEAR I.F. TOTAL Q1 Q2 Francesc Maduell (HCB) 2015 208.92 38 18 4 María José Ramírez (FCRB) María José Ricart (HCB) MAIN LINES OF RESEARCH 2016 171.98 23 15 4

2017 116.82 19 11 3 PRE-DOCTORAL RESEARCHERS In order to achieve these challenges, it are a Marta Arias (HCB) team with well-balanced collaboration Miquel Blasco (HCB) between clinicians and medical researchers, David Cucchiari (HCB) biologists, biochemists, veterinarians and Miquel Gómez (FCRB) specialist technicians. TEAM INVOLVED IN Gastón Julio (HCB) This knowledge will enable us to personalize REDinREN Valeria Tubita (IDIBAPS-FCRB) and improve current therapies and to discover AGAUR_SGR14 Jessica Maria Ugalde (HCB) new ways of action. Scientiﬁc objectives of AGAUR_SGR17 Pedro Ventura (HCB) LENIT are focused on the following areas of Manel Vera (HCB) research: 1. TECHNICIANS Immunology of transplantation Natalia Hierro (IDIBAPS) 2. Cell therapy and renal regeneration Marta Lazo (IDIBAPS) 3. Role of immunosuppression and Daniel Moya (FCRB) immunosuppressive medications in posttransplantation oncogenesis 4. ADMINISTRATIVE STAFF Advanced therapies in renal Mireia Collado (IDIBAPS) transplantation 5. Pancreas Transplantation 6. Renal living donors psychosocial COLLABORATORS Joan Albert Barberà (HCB) follow-up Mercè Brunet (HCB) 7. Glomerular diseases and endothelial Josep Canals (HCB) disfuncion Ginés Escolar (HCB) 8. Identiﬁcation of new uremic toxins M. Ángeles García (HCB) Juan Carlos García-Pagán (HCB) Eduard Gratacós (HCB)

106 NEPHRO-UROLOGICAL DISEASES AND KIDNEY TRANSPLANTATION 2.3

50/50 PROGRAM TRANSLATIONAL RESEARCH IN POSTTRASPLANT NEOPLASIA

GROUP LEADER Ignacio Revuelta (HCB-IDIBAPS)

Alloimmunity and tumor immunity are very complex to address in solid organ transplantation. The effect of the immunosuppressive therapy, needed to avoid organ rejection, in tumor immune escape and oncogenic pathways lead to tumoral progression, angiogenesis and pre-metastatic Ignacio Revuelta

niche formation. Exosomes released from GROUP cancer cells (CaEx) or immune cells (InmEx) are crucial for intercellular communication Roca, Jordi; Maga, Elizabeth A.; Esteban, Kircelli F., Locatelli F., Maduell F., Morena M., between primary tumor, microenvironment, Concepcion Rodriguez; Berggren, W. Travis; NubÉ M., Ok E., Torres F., Hoes A., Groenwold host organs and immune cells, and their role in Nunez Delicado, Estrella; Lajara, Jeronimo; R. The importance of considering posttransplant neoplasms and organ rejection Guillen, Isabel; Guillen, Pedro; Campistol, competing treatment affecting prognosis is unknown. We aim to characterize CaEx and Josep M.; Martinez, Emilio A.; Juan Ross, in the evaluation of therapy in trials: The InmEx under different immunosuppressive Pablo; Belmonte, Juan Carlos Izpisua. example of renal transplantation in drugs and the relationship with immune, Interspecies Chimerism with Mammalian hemodialysis trials. NEPHROLOGY, stromal and pre-metastatic cells. Pluripotent Stem Cells. CELL. DIALYSIS AND TRANSPLANTATION. Understanding how CaEx and InmEx work will 168(3):473-486. I.F.: 30.410 32(suppl_2):ii31-ii39. I.F.: 4.470 give us tools for future interventions in organ transplantation. 3. Tortajada, Agustin; Gutierrez, Eduardo; 6. Nube, Menso J.; Peters, Sanne A. E.; Goicoechea de Jorge, Elena; Anter, Jaouad; Blankestijn, Peter J.; Canaud, Bernard; Segarra, Alfons; Espinosa, Mario; Blasco, Davenport, Andrew; Grooteman, Muriel P. C.; PUBLICATIONS Miquel; Roman, Elena; Marco, Helena; Asci, Gulay; Locatelli, Francesco; Maduell, Quintana, Luis F.; Gutierrez, Josue; Pinto, Francisco; Morena, Marion; Ok, Ercan; Torres, Originals / I.F.: 116.825 Sheila; Lopez-Trascasa, Margarita; Praga, Ferran; Bots, Michiel L.;HDF Pooling Project Manuel; Rodriguez de Cordoba, Santiago. Investigators. Mortality reduction by 1. Liao HK, Hatanaka F, Araoka T, Reddy P, Wu Elevated factor H-related protein 1 and post-dilution online-haemodiaﬁltration: a MZ, Sui Y, Yamauchi T, Sakurai M, O'Keefe factor H pathogenic variants decrease cause-speciﬁc analysis. NEPHROLOGY, DD, Núñez-Delicado E, Guillen P, Campistol complement regulation in IgA DIALYSIS AND TRANSPLANTATION. JM, Wu CJ, Lu LF, Esteban CR, Izpisua nephropathy. KIDNEY INTERNATIONAL. 32(3):548-555. I.F.: 4.470 Belmonte JC. In Vivo Target Gene 92(4):953-963. I.F.: 8.395 Activation via CRISPR/Cas9-Mediated 7. Cavero T., Rabasco C., López A., Román E., Trans-epigenetic Modulation. CELL. 4. De Fijter JW, Holdaas H, Øyen O, Sanders Ávila A., Sevillano Á., Huerta A., Rojas-Rivera J., 171(7):1495-1507.e15. I.F.: 30.410 JS, Sundar S, Bemelman FJ, Sommerer C, Fuentes C., Blasco M., Jarque A., García A., Pascual J, Avihingsanon Y, Pongskul C, Mendizabal S., Gavela E., Macía M., Quintana 2. Wu, Jun; Platero-Luengo, Aida; Sakurai, Oppenheimer F, Toselli L, Russ G, Wang Z, L., María Romera A., Borrego J., Arjona E., Masahiro; Sugawara, Atsushi; Antonia Gil, Lopez P, Kochuparampil J, Cruzado JM, van Espinosa M., Portolés J., Gracia-Iguacel C., Maria; Yamauchi, Takayoshi; Suzuki, Keiichiro; der Giet M, ELEVATE Study Group. Early González-Parra E., Aljama P., Morales E., Cao Bogliotti, Yanina Soledad; Cuello, Cristina; Conversion From Calcineurin Inhibitor- to M., Rodríguez De Córdoba S., Praga M. Valencia, Mariana Morales; Okumura, Daiji; Everolimus-Based Therapy Following Eculizumab in secondary atypical Luo, Jingping; Vilarino, Marcela; Parrilla, Kidney Transplantation: Results of the haemolytic uraemic syndrome. Inmaculada; Soto, Delia Alba; Martinez, Randomized ELEVATE Trial. AMERICAN NEPHROLOGY, DIALYSIS AND Cristina A.; Hishida, Tomoaki; JOURNAL OF TRANSPLANTATION. TRANSPLANTATION. 32(3):466-474. Sanchez-Bautista, Sonia; Llanos 17(7):1853-1867. I.F.: 6.165 I.F.: 4.470 Martinez-Martinez, M.; Wang, Huili; Nohalez, Alicia; Aizawa, Emi; Martinez-Redondo, 5. Hazelbag C., Peters S., Blankestijn P., Bots 8. Carmona A, Agüera ML, Luna-Ruiz C, Paloma; Ocampo, Alejandro; Reddy, Pradeep; M., Canaud B., Davenport A., Grooteman M., Buendía P, Calleros L, García-Jerez A,

107 AREA 2 RESPIRATORY, CARDIOVASCULAR AND RENAL PATHOBIOLOGY AND BIOENGINEERING

Rodríguez-Puyol M, Arias M, Arias-Guillen M, Manzardo C, Agüero F, Bedini JL, Moreno A, Samitier J., Montserrat N. Tissue engineering de Arriba G, Ballarin J, Bernis C, Fernández E, Oppenheimer F, Miro JM, CKD-H. Clinic by decellularization and 3D bioprinting. García-Rebollo S, Mancha J, Del Peso G, Investigators. Estimation of renal function MATERIALS TODAY. 20(4):166-178. Pérez E, Poch E, Portolés JM, by CKD-EPI versus MDRD in a cohort of I.F.: 21.695 Rodríguez-Puyol D, Sánchez-Villanueva R, HIV-infected patients: a cross-sectional Sarro F, Torres A, Martín-Malo A, Aljama P, analysis. BMC NEPHROLOGY. 18(1):58. 2. Lens S, Rodriguez-Tajes S, Llovet LP, Maduell Ramírez R, Carracedo J. Markers of I.F.: 2.289 F, Londoño MC. Treating Hepatitis C in endothelial damage in patients with chronic Patients with Renal Failure. DIGESTIVE kidney disease on hemodialysis. AMERICAN 15. Collado S, Coll E, Nicolau C, Azqueta M, DISEASES. 35(4):339-346. I.F.: 2.203 JOURNAL OF PHYSIOLOGY-RENAL Pons M, Cruzado JM, de la Torre B, Deulofeu PHYSIOLOGY. 312(4):F673-F681. I.F.: 3.611 R, Mojal S, Pascual J, Cases A. Serum 3. Rovira J, Diekmann F, Campistol JM, osteoprotegerin in prevalent hemodialysis Ramírez-Bajo MJ. Therapeutic application of 9. Sanchez-Escuredo, Ana; Sagasta, Amaia; patients: associations with mortality, extracellular vesicles in acute and chronic Revuelta, Ignacio; Rodas, Lida M.; Paredes, atherosclerosis and cardiac function. BMC renal injury. NEFROLOGÍA. 37(2):126-137. David; Musquera, Mireia; Diekmann, Fritz; NEPHROLOGY. 18(1):290. I.F.: 2.289 I.F.: 1.183 Campistol, Josep M.; Sole, Manel; Oppenheimer, Federico. Histopathological 16. Cristelli MP, Cofán F, Tedesco-Silva H, evaluation of pretransplant donor biopsies Trullàs JC, Santos DWCL, Manzardo C, Letters / I.F.: 7.223 in expanded criteria donors with high Agüero F, Moreno A, Oppenheimer F, kidney donor profile index a retrospective Diekmann F, Medina-Pestana JO, Miro JM, 1. Azorín S., Cibeira M., Solé M., Fernández de observational cohort study. TRANSPLANT Sao Paulo-Barcelona Renal Transplant in HIV Larrea C., Rosiñol L., Rovira M., Campistol J., INTERNATIONAL. 30(10):975-986. I.F.: 3.079 Investigators. Regional differences in the Bladé J. Renal outcomes of autologous management and outcome of kidney stem cell transplantation among patients 10. Legendre C., Campistol J., Feldkamp T., transplantation in patients with human with light-chain amyloidosis: a single Remuzzi G., Kincaid J., Lommelé Å., Wang J., immunodeficiency virus infection: A centre Spanish experience. AMYLOID. Weekers L., Sheerin N. Outcomes of patients 3-year retrospective cohort study. 24(sup1):70-71. I.F.: 3.373 with atypical haemolytic uraemic TRANSPLANT INFECTIOUS DISEASE. syndrome with native and transplanted 19(4):e12724. I.F.: 1.719 2. Carbajal S., Zamora-Martínez C., kidneys treated with eculizumab: a pooled Prieto-González S., Quintana L., Espinosa G., post hoc analysis. TRANSPLANT 17. Ferrer J., Molina V., Rull R., López-Boado Cervera R. Systemic lupus erythematous INTERNATIONAL. 30(12):1275-1283. I.F.: 3.079 M., Sánchez S., García R., Ricart M., exacerbation following cessation of Ventura-Aguiar P., García-Criado Á., Esmatjes belimumab treatment: comments on the 11. Torres, Xavier; Comas, Jordi; Arcos, Emma; E., Fuster J., Garcia-Valdecasas J. Pancreas article by Furer et al. SCANDINAVIAN Tort, Jaume; Diekmann, Fritz. Death of transplantation: Advantages of a JOURNAL OF RHEUMATOLOGY. recipients after kidney living donation retroperitoneal graft position. CIRUGIA 46(3):250-251. I.F.: 2.667 triples donors’ risk of dropping out from ESPANOLA. 95(9):513-520. I.F.: 1.276 follow-up: a retrospective study. 3. Piñeiro GJ, Nicolau C, Gaya A, Buñesch L, TRANSPLANT INTERNATIONAL. 18. Pascual, Julio; Diekmann, Fritz; Poch E. Role of kidney MRI to monitoring 30(6):603-610. I.F.: 3.079 Fernandez-Rivera, Constantino; clearance of hemosiderin deposits in Gomez-Marques, Gonzalo; Gutierrez-Dalmau, paroxysmal nocturnal hemoglobinuria. 12. Sentis, Alexis; Diekmann, Fritz; Llobell, Alex; Jose Perez-Saez, Maria; Sancho-Calabuig, NEFROLOGIA : PUBLICACION OFICIAL DE Arturo; de Moner, Noemi; Espinosa, Gerard; Asuncion; Oppenheimer, Federico. LA SOCIEDAD ESPANOLA NEFROLOGIA. Yaguee, Jordi; Maria Campistol, Josep; Recommendations for the use of everolimus 37(2):225-227. I.F.: 1.183 Mirapeix, Eduard; Juan, Manel. Kinetic in de novo kidney transplantation: False analysis of changes in T- and beliefs, myths and realities. NEFROLOGIA. B-lymphocytes after anti-CD20 treatment 37(3):253-266. I.F.: 1.183 Case Reports / I.F.: 4.498 in renal pathology. IMMUNOBIOLOGY. 222(4):620-630. I.F.: 2.720 19. Huguet M., Rodas L., Blasco M., Quintana 1. Azorín SE, Cabib CE, Campistol JM. L., Mercadal J., Ortiz-Pérez J., Rovira I., Poch E. Diflunisal compassive use in transthyretin 13. Maduell F., Varas J., Ramos R., Martin-Malo Clinical impact of regional citrate hereditary amyloid polyneuropathy: A., Pérez-Garcia R., Berdud I., Moreso F., anticoagulation in continuous renal report of a first Spanish experience. Canaud B., Stuard S., Gauly A., Aljama P., replacement therapy in critically ill patients. AMYLOID : THE INTERNATIONAL JOURNAL Merello J. Hemodiafiltration Reduces INTERNATIONAL JOURNAL OF ARTIFICIAL OF EXPERIMENTAL AND CLINICAL All-Cause and Cardiovascular Mortality in ORGANS. 40(12):676-682. I.F.: 1.169 INVESTIGATION. 24(sup1):105-106. I.F.: 3.373 Incident Hemodialysis Patients: A Propensity-Matched Cohort Study. 2. Alcubilla-Prats, Pau; Sole, Manel; Botey, Albert; AMERICAN JOURNAL OF NEPHROLOGY. Review / I.F.: 25.081 Maria Grau, Josep; Garrabou, Gloria; Poch, 46(4):288-297. I.F.: 2.542 Esteban. Kidney involvement in MELAS 1. Garreta E., Oria R., Tarantino C., Pla-Roca M., syndrome: Description of 2 cases. 14. Cristelli MP, Cofán F, Rico N, Trullàs JC, Prado P., Fernández-Avilés F., Campistol J., MEDICINA CLINICA. 148(8):357-361. I.F.: 1.125

108 NEPHRO-UROLOGICAL DISEASES AND KIDNEY TRANSPLANTATION 2.3

GRANTS FOR RESEARCH IN PROGRESS

Campistol JM. Modulación de la vía Wnt/beta-Catenina, efectos en la progresión de la disfunción crónica del injerto renal. Sponsored by: Instituto de Salud Carlos III. PI13/02052 Duration: 01/01/2014-31/12/2017

Diekmann F. Extracellular Vesicles and exosomes from adult stem cells in the regeneration of organ injury. Sponsored by: European Comission. 612224 Duration: 01/02/2014-31/01/2018

Diekmann F. Red de Investigación renal Sponsored by: Instituto de Salud Carlos III. RD16/0009/0023 Duration: 01/01/2017-31/12/2021

Manyalich M. The Effect of Differing Kidney Disease Treatment Modalities and Organ Donation and Transplantation Practices on Health Expenditure and Patient. Sponsored by: European Comission. 739495 Duration: 01/01/2017-31/12/2019

Revuelta I. Papel de los exosomas de células inmunes de memoria (InmEx) en la activación del endotelio y desarrollo precoz del rechazo mediado por anticuerpos en el trasplante renal. Sponsored by: Instituto de Salud Carlos III. PI16/00115 Duration: 01/01/2017-31/12/2019

Ricart MJ. Trasplante de páncreas – monitorización de poblaciones linfocitarias y aplicación de ecografía con contraste y elastograﬁa como preditores de rechazo y sobrevida. Sponsored by: Instituto de Salud Carlos III. PI16/00167 Duration: 01/01/2017-31/12/2019

DOCTORAL THESES

Campistol JM. FGF23 y vitamina D tras el trasplante renal. PhD studient: Xoana Barros Freiria

Oppenheimer F. Empleo sistemático de biopsias renales pre-implante en donantes de criterios expandidos. PhD student: Ana Sánchez Escuredo

109 AREA 2 RESPIRATORY, CARDIOVASCULAR AND RENAL PATHOBIOLOGY AND BIOENGINEERING

Cardiovascular, nutrition 2.4 and aging unit

NURSING STAFF Maria Gual (IDIBAPS) LOCATION Ana Jordan (HCB) CELLEX building Rosa Soriano (HCB) HCB building COLLABORATORS Marina Sadurni (IDIBAPS) Conxa Viñas (CIBER)

KEYWORDS 1. Nutrition STRATEGIC OBJECTIVES TEAM LEADER 2. Mediterranean diet Ramon Estruch (HCB) To deep in the knowledge of the effects of the 3. Cardiovascular disease T. 93 227 23 33 lifestyle (Effect of diet, alcohol and physical 4. Cardiovascular risk factors [email protected] 5. Cognition exercise) in the different stages of life (adolescence, pregnancy, elderly ...) and its role in the prevention of chronic diseases EMERITUS (hypertension, diabetes, dyslipidemia, Emilio Ros (HCB) cognitive impairment) and cancer.

RESEARCHERS Original publications Antonio Coca (HCB) MAIN LINES OF RESEARCH from 2015 to 2017 Ferran Masanés (HCB)

YEAR I.F. TOTAL Q1 Q2 Emilio Sacanella (HCB) 1. Protective Effects of Mediteranean Diet on Cristina Sierra (HCB) cardiovascular and cerebrovascular 2015 138.46 33 18 13 prevention ( chronic diseases, 2016 143.83 32 21 8 POST-DOCTORAL RESEARCHERS neurodegenerative diseases and cáncer). 2017 188.02 41 25 11 Miguel Camafort (HCB) 2. Effects of alcohol (beer or wine) Rosa Casas (CIBEROBN) compsumption on health Monica Domenech (FCRB) 3. Effects of other diet components on Dolors Estrada (HCB) healthy: olive oil, nuts, cocoa, fatty-acids, Alfonso Lopez (HCB) tomatoes…. TEAM INVOLVED IN Margarita Navarro (HCB) 4. Assesment on cardiovascular risk factors CIBEROBN on primary prevention, specially blood AGAUR_SRG17 PRE-DOCTORAL RESEARCHERS pressure management . Sara Castro (IDIBAPS) 5. Hair failure physiopathology Tania Freitas (IDIBAPS) 6. Aging Ana M. Ruiz (CIBER) 7. Thrombosis

AWARDS Premio Juan Vivancos 2017 al Mejor Trabajo Cientíﬁco Institution: Societat Catalano-Balear de Medicina Interna (SCBMI) Awardee/s: Ramon Estruch

Premio Aceite de Oliva 2017 en Investigación, Desarrollo e Innovación Institution: Interprofesional de Aceite de Oliva Awardee/s: Ramon Estruch Ramon Estruch TEAM

110 CARDIOVASCULAR, NUTRITION AND AGING UNIT 2.4

PUBLICATIONS disease and total mortality: virgin olive oil, Llorach R., Vázquez-Fresno R., Garcia-Aloy wine, and catechol-methylathion. M., Carmona F., Sanchez A., Madrid-Gambin Originals / I.F.: 188.028 AMERICAN JOURNAL OF CLINICAL F., Estruch R., Corella D., Andres-Lacueva C. NUTRITION. 105(6):1297-1304. I.F.: 6.926 Microbial metabolites are associated with 1. Wang, Dong D.; Toledo, Estefania; Hruby, a high adherence to a Mediterranean Adela; Rosner, Bernard A.; Willett, Walter C.; 6. Guasch-Ferre, Marta; Becerra-Tomas, dietary pattern using a 1H-NMR-based Sun, Qi; Razquin, Cristina; Zheng, Yan; Nerea; Ruiz-Canela, Miguel; Corella, Dolores; untargeted metabolomics approach. Ruiz-Canela, Miguel; Guasch-Ferre, Marta; Schroeder, Helmut; Estruch, Ramon; Ros, JOURNAL OF NUTRITIONAL Corella, Dolores; Gomez-Gracia, Enrique; Fiol, Emilio; Aros, Fernando; Gomez-Gracia, BIOCHEMISTRY. 48:36-43. I.F.: 4.518 Miquel; Estruch, Ramon; Ros, Emilio; Lapetra, Enrique; Fiol, Miquel; Serra-Majem, Lluis; Jose; Fito, Montserrat; Aros, Fernando; Lapetra, Jose; Basora, Josep; Martin-Calvo, 11. Rajaram, Sujatha; Valls-Pedret, Cinta; Serra-Majem, Luis; Lee, Chih-Hao; Clish, Clary Nerea; Portoles, Olga; Fito, Montserrat; Hu, Cofan, Montserrat; Sabate, Joan; Serra-Mir, B.; Liang, Liming; Salas-Salvado, Jordi; Frank B.; Forga, Lluis; Salas-Salvado, Jordi. Merce; Perez-Heras, Ana M.; Arechiga, Adam; Martinez-Gonzalez, Miguel A.; Hu, Frank B. Total and subtypes of dietary fat intake and Casaroli-Marano, Ricardo P.; Alforja, Socorro; Plasma Ceramides, Mediterranean Diet, risk of type 2 diabetes mellitus in the Sala-Vila, Aleix; Domenech, Monica; Roth, and Incident Cardiovascular Disease in the Prevencion con Dieta Mediterranea Irene; Freitas-Simoes, Tania M.; Calvo, Carlos; PREDIMED Trial ( Prevencion con Dieta (PREDIMED) study. AMERICAN JOURNAL Lopez-Illamola, Anna; Haddad, Ella; Bitok, Mediterranea). CIRCULATION. OF CLINICAL NUTRITION. 105(3):723-735. Edward; Kazzi, Natalie; Huey, Lynnley; Fan, 135(21):2028-2040. I.F.: 19.309 I.F.: 6.926 Joseph; Ros, Emilio. The Walnuts and Healthy Aging Study (WAHA): Protocol for 2. Hernáez Á., Castañer O., Elosua R., Pintó X., 7. Camacho-Barcia ML, Bulló M, a Nutritional Intervention Trial with Estruch R., Salas-Salvadó J., Corella D., Arós Garcia-Gavilán JF, Ruiz-Canela M, Corella D, Walnuts on Brain Aging. FRONTIERS IN F., Serra-Majem L., Fiol M., Ortega-Calvo M., Estruch R, Fitó M, García-Layana A, Arós F, AGING NEUROSCIENCE. 8(JAN):333. Ros E., Martínez-González M., De La Torre R., Fiol M, Lapetra J, Serra-Majem L, Pintó X, I.F.: 4.504 López-Sabater M., Fitó M. Mediterranean García-Arellano A, Vinyoles E, Sorli JV, Diet Improves High-Density Lipoprotein Salas-Salvadó J. Association of Dietary 12. Guasch-Ferre, Marta; Hu, Frank B.; Function in High-Cardiovascular-Risk Vitamin K1 Intake With the Incidence of Ruiz-Canela, Miguel; Bullo, Monica; Toledo, Individuals. CIRCULATION. 135(7):633-643. Cataract Surgery in an Adult Estefania; Wang, Dong D.; Corella, Dolores; I.F.: 19.309 Mediterranean Population: A Secondary Gomez-Gracia, Enrique; Fiol, Miquel; Estruch, Analysis of a Randomized Clinical Trial. Ramon; Lapetra, Jose; Fito, Montserrat; Aros, 3. Papadaki A, Martínez-González MÁ, JAMA OPHTHALMOLOGY. 135(6):657-661. Fernando; Serra-Majem, Lluis; Ros, Emilio; Alonso-Gómez A, Rekondo J, Salas-Salvadó I.F.: 5.625 Dennis, Courtney; Liang, Liming; Clish, Clary B.; J, Corella D, Ros E, Fitó M, Estruch R, Lapetra Martinez-Gonzalez, Miguel A.; Salas-Salvado, J, García-Rodriguez A, Fiol M, Serra-Majem L, 8. Yu, Edward; Ruiz-Canela, Miguel; Hu, Frank Jordi. Plasma Metabolites From Choline Pintó X, Ruiz-Canela M, Bulló M, Serra-Mir M, B.; Clish, Clary B.; Corella, Dolores; Pathway and Risk of Cardiovascular Sorlí JV, Arós F. Mediterranean diet and Salas-Salvado, Jordi; Hruby, Adela; Fito, Disease in the PREDIMED (Prevention risk of heart failure: results from the Montserrat; Liang, Liming; Toledo, Estefania; With Mediterranean Diet) Study. JOURNAL PREDIMED randomized controlled trial. Ros, Emilio; Estruch, Ramon; Gomez-Gracia, OF THE AMERICAN HEART ASSOCIATION. EUR J HEART FAIL. 19(9):1179-1185. Enrique; Lapetra, Jose; Aros, Fernando; 6(11):006524. I.F.: 4.425 I.F.: 6.968 Romaguera, Dora; Serra-Majem, Lluis; Guasch-Ferre, Marta; Wang, Dong D.; 13. Amor, Antonio J.; Serra-Mir, Merce; 4. Toledo E, Wang DD, Ruiz-Canela M, Clish Martinez-Gonzalez, Miguel A. Plasma Martinez-Gonzalez, Miguel A.; Corella, CB, Razquin C, Zheng Y, Guasch-Ferré M, Arginine/Asymmetric Dimethylarginine Dolores; Salas-Salvado, Jordi; Fito, Hruby A, Corella D, Gómez-Gracia E, Fiol M, Ratio and Incidence of Cardiovascular Montserrat; Estruch, Ramon; Serra-Majem, Estruch R, Ros E, Lapetra J, Fito M, Aros F, Events: A Case-Cohort Study. JOURNAL Lluis; Aros, Fernando; Babio, Nancy; Ros, Serra-Majem L, Liang L, Salas-Salvadó J, Hu OF CLINICAL ENDOCRINOLOGY AND Emilio; Ortega, Emilio; PREDIMED FB, Martínez-González MA. Plasma METABOLISM. 102(6):1879-1888. I.F.: 5.455 Investigators. Prediction of Cardiovascular lipidomic proﬁles and cardiovascular Disease by the Framingham-REGICOR events in a randomized intervention trial 9. Díez-Espino J, Basterra-Gortari FJ, Equation in the High-Risk PREDIMED with the Mediterranean diet. AMERICAN Salas-Salvadó J, Buil-Cosiales P, Corella D, Cohort: Impact of the Mediterranean Diet JOURNAL OF CLINICAL NUTRITION. Schröder H, Estruch R, Ros E, Gómez-Gracia Across Different Risk Strata.JOURNAL OF 106(4):973-983. I.F.: 6.926 E, Arós F, Fiol M, Lapetra J, Serra-Majem L, THE AMERICAN HEART ASSOCIATION. Pintó X, Babio N, Quiles L, Fito M, Marti A, 6(3):004803. I.F.: 4.425 5. De la Torre R, Corella D, Castañer O, Toledo E, PREDIMED Investigators. Egg Martínez-González MA, Salas-Salvador J, Vila consumption and cardiovascular disease 14. Storniolo C., Casillas R., Bulló M., Castañer J, Estruch R, Sorli JV, Arós F, Fiol M, Ros E, according to diabetic status: The O., Ros E., Sáez G., Toledo E., Estruch R., Serra-Majem L, Pintó X, Gómez-Gracia E, PREDIMED study. CLINICAL NUTRITION. Ruiz-Gutiérrez V., Fitó M., Martínez-González Lapetra J, Ruiz-Canela M, Basora J, Asensio 36(4):1015. I.F.: 4.548 M., Salas-Salvadó J., Mitjavila M., Moreno J. EM, Covas MI, Fitó M. Protective effect of A Mediterranean diet supplemented with homovanillyl alcohol on cardiovascular 10. Almanza-Aguilera E., Urpi-Sarda M., extra virgin olive oil or nuts improves

111 AREA 2 RESPIRATORY, CARDIOVASCULAR AND RENAL PATHOBIOLOGY AND BIOENGINEERING

endothelial markers involved in blood 20. Hu EA, Martínez-González MA, in an Elderly Population after 5 Years of pressure control in hypertensive women. Salas-Salvadó J, Corella D, Ros E, Fitó M, Follow Up (The Randomised PREDIMED EUROPEAN JOURNAL OF NUTRITION. Garcia-Rodriguez A, Estruch R, Arós F, Fiol M, Study). NUTRIENTS. 9(5):E452. I.F.: 3.550 56(1):89-97. I.F.: 4.370 Lapetra J, Serra-Majem L, Pintó X, Ruiz-Canela M, Razquin C, Bulló M, Sorlí JV, 25. García-Layana A, Ciufo G, Toledo E, 15. Colmán-Martínez M, Martínez-Huélamo M, Schröder H, Rebholz CM, Toledo E, Martínez-González MA, Corella D, Fitó M, Valderas-Martínez P, Arranz-Martínez S, PREDIMED Study and SUN Project Estruch R, Gómez-Gracia E, Fiol M, Lapetra J, Almanza-Aguilera E, Corella D, Estruch R, Investigators. Potato Consumption Does Serra-Majem L, Pintó X, Portillo MP, Sorli JV, Lamuela-Raventós RM. Trans-Lycopene Not Increase Blood Pressure or Incident Bulló M, Vinyoles E, Sala-Vila A, Ros E, from tomato juice attenuates Hypertension in 2 Cohorts of Spanish Salas-Salvadó J, Arós F. The Effect of a inflammatory biomarkers in human Adults. JOURNAL OF NUTRITION. Mediterranean Diet on the Incidence of plasma samples: an intervention trial. 147(12):2272-2281. I.F.: 4.145 Cataract Surgery. NUTRIENTS. 9(5):E453. MOLECULAR NUTRITION AND FOOD I.F.: 3.550 RESEARCH. 61(11):1600993. I.F.: 4.323 21. Yu, Edward; Ruiz-Canela, Miguel; Guasch-Ferre, Marta; Zheng, Yan; Toledo, 26. Gutiérrez-Bedmar M, Martínez-González 16. Quifer-Rada P, Chiva-Blanch G, Jáuregui Estefania; Clish, Clary B.; Salas-Salvado, Jordi; MÁ, Muñoz-Bravo C, Ruiz-Canela M, Mariscal O, Estruch R, Lamuela-Raventós RM. Liang, Liming; Wang, Dong D.; Corella, Dolores; A, Salas-Salvadó J, Estruch R, Corella D, Arós A discovery-driven approach to elucidate Fito, Montse; Gomez-Gracia, Enrique; Lapetra, F, Fito M, Lapetra J, Serra-Majem L, Pintó X, urinary metabolome changes after a Jose; Estruch, Ramon; Ros, Emilio; Cofan, Alonso-Gómez Á, Portoles O, Fiol M, Bulló M, regular and moderate consumption of beer Montserrat; Aros, Fernando; Romaguera, Castañer O, Ros E, Gómez-Gracia E. and non-alcoholic beer in subjects at high Dora; Serra-Majem, Lluis; Sorli, Jose V.; Hu, Chromium Exposure and Risk of cardiovascular risk. MOLECULAR Frank B.; Martinez-Gonzalez, Miguel A. Cardiovascular Disease in High NUTRITION AND FOOD RESEARCH. Increases in Plasma Tryptophan Are Cardiovascular Risk Subjects- Nested 61(10):1600980. I.F.: 4.323 Inversely Associated with Incident Case-Control Study in the Prevention With Cardiovascular Disease in the Prevencion Mediterranean Diet (PREDIMED) Study. 17. Hernáez Á., Castañer O., Goday A., Ros E., con Dieta Mediterranea (PREDIMED) CIRCULATION JOURNAL. 81(8):1183-1190. Pintó X., Estruch R., Salas-Salvadó J., Corella Study. JOURNAL OF NUTRITION. I.F.: 3.544 D., Arós F., Serra-Majem L., Martínez-González 147(3):314-322. I.F.: 4.145 M., Fiol M., Lapetra J., de la Torre R., 27. Creus-Cuadros A., Tresserra-Rimbau A., López-Sabater M., Fitó M. The 22. Perrone-Filardi P, Coca A, Galderisi M, Quifer-Rada P., Martínez-González M., Corella Mediterranean Diet decreases LDL Paolillo S, Alpendurada F, de Simone G, Donal D., Salas-Salvadó J., Fitó M., Estruch R., atherogenicity in high cardiovascular risk E, Kahan T, Mancia G, Redon J, Schmieder R, Gómez-Gracia E., Lapetra J., Arós F., Fiol M., individuals: A randomized controlled trial. Williams B, Agabiti-Rosei E. Noninvasive Ros E., Serra-Majem L., Pintó X., Moreno J., MOLECULAR NUTRITION AND FOOD cardiovascular imaging for evaluating Ruiz-Canela M., Sorli J., Basora J., Schröder H., RESEARCH. 61(9):1601015. I.F.: 4.323 subclinical target organ damage in Lamuela-Raventós R. Associations hypertensive patients: a consensus article between Both Lignan and Yogurt 18. Pérez-Martí A, Garcia-Guasch M, from the European Association of Consumption and Cardiovascular Risk Tresserra-Rimbau A, Carrilho-Do-Rosário A, Cardiovascular Imaging, the European Parameters in an Elderly Population: Estruch R, Salas-Salvadó J, Society of Cardiology Council on Observations from a Cross-Sectional Martínez-González MÁ, Lamuela-Raventós R, Hypertension and the European Society of Approach in the PREDIMED Study. Marrero PF, Haro D, Relat J. A low-protein Hypertension. JOURNAL OF JOURNAL OF THE ACADEMY OF diet induces body weight loss and HYPERTENSION. 35(9):1727-1741. I.F.: 4.085 NUTRITION AND DIETETICS. browning of subcutaneous white adipose 117(4):609-622.e1. I.F.: 3.399 tissue through enhanced expression of 23. Bargallo, Nuria; Gilabert, Rosa; hepatic Fibroblast Growth Factor 21 Romero-Mamani, Edwin-Saul; Cofan, 28. Casas, Rosa; Urpi-Sarda, Mireia; (FGF21). MOL NUTR FOOD RES. Montserrat; Calder, Philip C.; Fito, Montserrat; Sacanella, Emilio; Arranz, Sara; Corella, 61(8):1600725. I.F.: 4.323 Corella, Dolores; Salas-Salvado, Jordi; Dolores; Castaner, Olga; Lamuela-Raventos, Ruiz-Canela, Miguel; Estruch, Ramon; Ros, Rosa-Maria; Salas-Salvado, Jordi; Lapetra, 19. Madrid-Gambin, Francisco; Llorach, Emilio; Sala-Vila, Aleix. Red Blood Cell Jose; Portillo, Maria P.; Estruch, Ramon. Rafael; Vazquez-Fresno, Rosa; Urpi-Sarda, Eicosapentaenoic Acid Inversely Relates to Anti-Inflammatory Effects of the Mireia; Almanza-Aguilera, Enrique; MRI-Assessed Carotid Plaque Lipid Core Mediterranean Diet in the Early and Late Garcia-Aloy, Mar; Estruch, Ramon; Corella, Burden in Elders at High Cardiovascular Risk. Stages of Atheroma Plaque Development. Dolores; Andres-Lacueva, Cristina. Urinary NUTRIENTS. 9(9):E1036. I.F.: 3.550 MEDIATORS OF INFLAMMATION. H-1 Nuclear Magnetic Resonance 2017:3674390. I.F.: 3.232 Metabolomic Fingerprinting Reveals 24. Guo X, Tresserra-Rimbau A, Estruch R, Biomarkers of Pulse Consumption Related Martínez-González MA, Medina-Remón A, 29. Sasot G., Martínez-Huélamo M., to Energy-Metabolism Modulation in a Fitó M, Corella D, Salas-Salvadó J, Portillo MP, Vallverdú-Queralt A., Mercader-Martí M., Subcohort from the PREDIMED study. Moreno JJ, Pi-Sunyer X, Lamuela-Raventós Estruch R., Lamuela-Raventós R. JOURNAL OF PROTEOME RESEARCH. RM. Polyphenol Levels Are Inversely Identification of phenolic metabolites in 16(4):1483-1491. I.F.: 4.268 Correlated with Body Weight and Obesity human urine after the intake of a functional

112 CARDIOVASCULAR, NUTRITION AND AGING UNIT 2.4

food made from grape extract by a high 35. Bosch X., Montori E., Guerra-García M., 41. Gullón A., Suárez C., Díez-Manglano J., resolution LTQ-Orbitrap-MS approach. Costa-Rodríguez J., Quintanilla M., Formiga F., Cepeda J., Pose A., Camafort M., FOOD RESEARCH INTERNATIONAL. Tolosa-Chapasian P., Moreno P., Guasch N., Castiella J., Rovira E., Mostaza J. 100(3):435-444. I.F.: 3.086 López-Soto A. Haemoglobin responses to Antithrombotic treatment and transfusion in severe iron deficiency characteristics of elderly patients with 30. Bosch X, Montori E, Guerra-García M, anaemia: potential impact of non-valvular atrial fibrillation hospitalized Costa-Rodríguez J, Quintanilla MH, gastrointestinal disorders. VOX at Internal Medicine departments. Tolosa-Chapasian PE, Moreno P, Guasch N, SANGUINIS. 112(3):257-267. I.F.: 2.192 NONAVASC registry. URGENCIAS EN López-Soto A. A comprehensive evaluation PEDIATRÍA. 148(5):204-210. I.F.: 1.125 of the gastrointestinal tract in 36. Reátegui D., Tornero E., Popescu D., iron-deficiency anemia with predefined Sastre S., Camafort M., Gines G., Combalía A., hemoglobin below 9mg/dL: A prospective Lozano L. Postoperative hyperglycaemia Review / I.F.: 18.067 cohort study. DIGESTIVE AND LIVER control reduces postoperative DISEASE. 49(4):417-426. I.F.: 3.061 complications in patients subject to total 1. Sandoval-Ramírez B., Lamuela-Raventós R., knee arthroplasty. KNEE. 24(1):128-136. Estruch R., Sasot G., Doménech M., 31. Papandreou C., Bullò M., Tinahones F., I.F.: 1.976 Tresserra-Rimbau A. Beer Polyphenols and Martínez-González M., Corella D., Menopause: Effects and Mechanisms - A Fragkiadakis G., López-Miranda J., Estruch R., 37. Downer MK, Martínez-González MA, Gea Review of Current Knowledge. OXIDATIVE Fitó M., Salas-Salvadó J. Serum metabolites A, Stampfer M, Warnberg J, Ruiz-Canela M, MEDICINE AND CELLULAR LONGEVITY. in non-alcoholic fatty-liver disease Salas-Salvadó J, Corella D, Ros E, Fitó M, 2017:4749131. I.F.: 4.593 development or reversion; A targeted Estruch R, Arós F, Fiol M, Lapetra J, metabolomic approach within the Serra-Majem L, Bullo M, Sorli JV, Muñoz MA, 2. Coca A, Agabiti-Rosei E, Cifkova R, Manolis PREDIMED trial. NUTRITION AND García-Rodriguez A, Gutierrez-Bedmar M, AJ, Redón J, Mancia G. The polypill in METABOLISM. 14(1):58. I.F.: 2.974 Gómez-Gracia E, PREDIMED Study cardiovascular prevention: evidence, Investigators. Mercury exposure and risk of limitations and perspective - position 32. Rosique-Esteban, Nuria; Diaz-Lopez, cardiovascular disease: a nested paper of the European Society of Andres; Martinez-Gonzalez, Miguel A.; Corella, case-control study in the PREDIMED Hypertension. JOURNAL OF Dolores; Goday, Albert; Alfredo Martinez, J.; (PREvention with MEDiterranean Diet) HYPERTENSION. 35(8):1546-1553. I.F.: 4.085 Romaguera, Dora; Vioque, Jesus; Aros, study. BMC CARDIOVASCULAR Fernando; Garcia-Rios, Antonio; Tinahones, DISORDERS. 17(1):9. I.F.: 1.832 3. Guasch-Ferré M, Salas-Salvadó J, Ros E, Francisco; Estruch, Ramon; Carlos Estruch R, Corella D, Fitó M, Fernandez-Garcia, Jose; Lapetra, Jose; 38. Montori-Palacín E, Prieto-González S, Martínez-González MA, PREDIMED Serra-Majem, Luis; Pinto, Xavier; Tur, Josep A.; Carrasco-Miserachs I, Altes-Capella J, Investigators. The PREDIMED trial, Bueno-Cavanillas, Aurora; Vidal, Josep; Compta Y, López-Soto A, Bosch X. Quick Mediterranean diet and health outcomes: Delgado-Rodriguez, Miguel; Daimiel, Lidia; outpatient diagnosis in small district or How strong is the evidence? NUTRITION, Vazquez, Clotilde; Angel Rubio, Miguel; Ros, general tertiary hospitals: A comparative METABOLISM AND CARDIOVASCULAR Emilio; Salas-Salvado, Jordi; PREDIMED observational study. MEDICINE (UNITED DISEASES. 27(7):624-632. I.F.: 3.679 -PLUS Investigators. Leisure-time physical STATES). 96(22):e6886. I.F.: 1.804 activity, sedentary behaviors, sleep, and 4. Medina-Remón A, Casas R, cardiometabolic risk factors at baseline in 39. Razquin C, Sanchez-Tainta A, Tressserra-Rimbau A, Ros E, the PREDIMED-PLUS intervention trial: A Salas-Salvadó J, Buil-Cosiales P, Corella D, Martínez-González MA, Fitó M, Corella D, cross-sectional analysis. PLOS ONE. Fito M, Ros E, Estruch R, Arós F, Salas-Salvadó J, Lamuela-Raventos RM, 12(3):e0172253. I.F.: 2.806 Gómez-Gracia E, Fiol M, Lapetra J, Estruch R, PREDIMED Study Investigators. Serra-Majem L, Pinto X, Schröder H, Tur J, Polyphenol intake from a Mediterranean 33. Masanés F., Rojano i Luque X., Salvà A., Sorlí JV, Lamuela-Raventós RM, Bulló M, diet decreases inflammatory biomarkers Serra-Rexach J., Artaza I., Formiga F., Cuesta Bes-Rastrollo M, Martinez-Gonzalez MA, related to atherosclerosis: A sub-study of F., López Soto A., Ruiz D., Cruz-Jentoft A. PREDIMED GROUP. Dietary energy density The PREDIMED trial. BRITISH JOURNAL OF Cut-off points for muscle mass - not grip and body weight changes after 3 years in CLINICAL PHARMACOLOGY. 83(1):114-128. strength or gait speed - determine the PREDIMED study. INTERNATIONAL I.F.: 3.493 variations in sarcopenia prevalence. THE JOURNAL OF FOOD SCIENCES AND JOURNAL OF NUTRITION, HEALTH & AGING. NUTRITION. 68(7):1-8. I.F.: 1.444 5. Morales Salinas A, Coca A, Olsen MH, 21(7):825-829. I.F.: 2.772 Sanchez RA, Sebba-Barroso WK, Kones R, 40. Yzaguirre I, Grazioli G, Domenech M, Bertomeu-Martinez V, Sobrino J, Alcocer L, 34. Fernández-Cao JC, Arija V, Aranda N, Vinuesa A, Pi R, Gutierrez J, Coca A, Brugada Pineiro DJ, Lanas F, Machado CA, Basora J, Diez-Espino J, Estruch R, Fitó M, J, Sitges M. Exaggerated blood pressure Aguirre-Palacios F, Ortellado J, Perez G, Sabio Corella D, Salas-Salvadó J. Soluble response to exercise and late-onset R, Landrove O, Rodriguez-Leyva D, transferrin receptor and risk of type 2 hypertension in young adults. BLOOD Duenas-Herrera A, Rodriguez Portelles A, diabetes in the obese and non-obese. EUR PRESSURE MONITORING. 22(6):339-344. Parra-Carrillo JZ, Piskorz DL, Bryce-Moncloa J CLIN INVEST. 47(3):221-230. I.F.: 2.714 I.F.: 1.248 A, Waisman G, Yano Y, Ventura H, Orias M, Prabhakaran D, Sundström J, Wang J, Burrell

113 AREA 2 RESPIRATORY, CARDIOVASCULAR AND RENAL PATHOBIOLOGY AND BIOENGINEERING

LM, Schutte AE, Lopez-Jaramillo P, Barbosa Dragana; Ordovas, Jose M.; Perez-Jimenez, 20151230 E, Redon J, Weber MA, Lavie CJ, Ramirez A, Francisco; Rizzo, Manfredi; Salas-Salvado, Jordi; Duration: 29/06/2016-28/06/2019 Ordunez P, Yusuf S, Zanchetti A. Clinical Schroder, Helmut; Tinahones, Francisco J.; de la Perspective on Antihypertensive Drug Torre, Rafael; van Ommen, Ben; Wopereis, Estruch R. Efecto de una pérdida de peso Treatment in Adults With Grade 1 Suzan; Ros, Emilio; Lopez-Miranda, Jose. con dieta mediterránea hipocalórica y Hypertension and Low-to-Moderate Lifestyle recommendations for the promoción de la actividad física en la Cardiovascular Risk: An International prevention and management of metabolic prevención primaria cardiovascular: Expert Consultation. CURRENT syndrome: an international panel Estudio PREDIMED-PLUS. PROBLEMS IN CARDIOLOGY. 42(7):198-225. recommendation. NUTRITION REVIEWS. Sponsored by: Instituto de Salud Carlos III I.F.: 2.217 75(5):307-326. I.F.: 5.291 (ISCIII). PI044504 Duration:01/01/2017-31/12/2019 4. Lip, Gregory Y. H.; Coca, Antonio; Kahan, Letters / I.F.: 17.202 Thomas; Boriani, Giuseppe; Manolis, Antonis Estruch R. Efecto de una pérdida de peso S.; Olsen, Michael Hecht; Oto, Ali; Potpara, con dieta mediterránea hipocalórica y 1. Martinez-Gonzalez M., Estruch R., Corella D., Tatjana S.; Steffel, Jan; Marin, Francisco; de promoción de la actividad física en Ros E., Fito M., Schwingshackl L., Oliveira Figueiredo, Marcio Jansen; de prevención primaria cardiovascular: Salas-Salvado J. Effects on health outcomes Simone, Giovanni; Tzou, Wendy S.; Chiang, Estudio PREDIMED-PLUS. of a mediterranean diet with no restriction on Chern-En; Williams, Bryan; Dan, Sponsored by: Instituto de Salud Carlos III fat intake. ANNALS OF INTERNAL MEDICINE. Gheorghe-Andrei; Gorenek, Bulent; Fauchier, (ISCIII). PI16/00381 166(5):378-378. I.F.: 17.202 Laurent; Savelieva, Irina; Hatala, Robert; van Duration: 01/01/2017-31/12/2019 Gelder, Isabelle; Brguljan-Hitij, Jana; Erdine, Serap; Lovic, Dragan; Kim, Young-Hoon; Editorial / I.F.: 19.896 Salinas-Arce, Jorge; Field, Michael;. Hypertension and cardiac arrhythmias: a 1. Estruch, Ramon; Ros, Emilio. Nutrition consensus document fromthe European Intervention on Cardiovascular Risk Heart RhythmAssociation (EHRA) and Factors in Healthy Individuals Glass Half ESC Council on Hypertension, endorsed Empty or Half Full? JOURNAL OF THE by the Heart RhythmSociety (HRS), AMERICAN COLLEGE OF CARDIOLOGY. Asia-Paciﬁc Heart RhythmSociety 69(9):1113-1115. I.F.: 19.896 (APHRS) and Sociedad Latinoamericana de Estimulacion Cardiaca y Electroﬁsiologia (SOLEACE). EUROPACE. Clinical Guidelines / I.F.: 50.236 19(6):891-911. I.F.: 4.521

1. Badimon, Lina; Bugiardini, Raffaele; Cenko, Edina; Cubedo, Judit; Dorobantu, Maria; Duncker, Dirk J.; Estruch, Ramon; Milicic, GRANTS FOR RESEARCH IN PROGRESS Davor; Tousoulis, Dimitris; Vasiljevic, Zorana; Vilahur, Gemma; De Wit, Cor; Koller, Akos. Estruch R. REDIMED-PLUS: Efecto de una Position paper of the European Society of dieta mediterránea hipocalórica y Cardiology-working group of coronary promoción de la actividad física en pathophysiology andmicrocirculation: prevención primaria cardiovascular. obesity and heart disease. EUROPEAN Estudio piloto sobre marcadores HEART JOURNAL. 38(25):1951-1958. I.F.: 20.212 intermedios. Sponsored by: Instituto de Salud Carlos III 2. Lip, Gregory Y. H.; Coca, Antonio. (ISCIII). PI13/02184 Hypertension and cardiac arrhythmias. Duration: 01/01/2014-31/12/2017 EUROPEAN HEART JOURNAL. 38(4):223-225. I.F.: 20.212 Estruch R. The Moderate Alcohol and Cardiovascular Health Trial. 3. Perez-Martinez, Pablo; Mikhailidis, Dimitri P.; Sponsored by: National Institutes of Health Athyros, Vasilios G.; Bullo, Monica; Couture, (NIH). 38685 Patrick; Covas, Maria I.; de Koning, Lawrence; Duration: 30/09/2016-31/07/2021 Delgado-Lista, Javier; Diaz-Lopez, Andres; Drevon, Christian A.; Estruch, Ramon; Estruch R. Nous predictors de la Esposito, Katherine; Fito, Montserrat; Garaulet, cardiopatía coronaria: micropartículas Marta; Giugliano, Dario; Garcia-Rios, Antonio; endotelials circulants, funcionalitat de les Katsiki, Niki; Kolovou, Genovefa; Lamarche, partícules d'HDL i composició en àcids Benoit; Maiorino, Maria Ida; Mena-Sanchez, grassos de les membranes cel·lulars. Guillermo; Munoz-Garach, Araceli; Nikolic, Sponsored by: Fundació la Marató de TV3.

114 RESPIRATORY BIOPHYSICS AND BIOENGINEERING 2.5

Respiratory biophysics 2.5 and bioengineering

models and methods for the processing of biomedical images and signals. The work of LOCATION the group is based on an interdisciplinary UB School of Medicine scientiﬁc approach, promoting industrial transfer of the technological advances derived from the research work.

WEB www.ub.edu/bioﬁsica MAIN LINES OF RESEARCH

TEAM LEADER 1. Respiratory mechanics. Ramon Farré (UB) To investigate the viscoelastic properties of T. 93 402 45 15 the airways and lung tissues. The work [email protected] focuses on the study of upper airway KEYWORDS collapsibility in obstructive 1. Respiratory mechanics apnea-hypopnea and in the monitoring noninvasive mechanical ventilation. We aim 2. Lung bioengineering RESEARCHERS to improve noninvasive diagnostic 3. Neuroimaging in refractory epilepsy Isaac Almendros (UB) techniques and to optimize the treatments. 4. Neuroimaging in Parkinson’s disease Javier Pavía (HCB) Domènec Ros (UB) 2. Molecular and cellular nanomechanics. To use atomic force microscopy, magnetic POST-DOCTORAL RESEARCHERS microspheres and traction force Noelia Campillo (UB) microscopy to study cell adhesion and Maria José Menal (UB) mechanics of lung cells. We study the Original publications Aida Niñerola (UB) mechanical properties of stem cells and of from 2015 to 2017 the way in which mechanical stimuli PRE-DOCTORAL RESEARCHERS enhance differentiation. We also work on YEAR I.F. TOTAL Q1 Q2 Jair Asir (UB) lung regeneration, focusing on recreating 2015 69.76 16 10 5 Maeba Polo (CIBER) the mechanical pulmonary micro-nano 2016 51.56 12 9 3 Miguel Ángel Rodríguez (UB) environment to optimize cell differentiation.

2017 82.69 18 13 4 3. Biomedical imaging analysis. Imaging analysis focused on the STRATEGIC OBJECTIVES processing of photon emission tomography (SPECT) and positron The general objectives are the study of the emission tomography (PET) images aimed TEAM INVOLVED IN biophysical mechanisms determining at securing more precise quantiﬁcation of CIBERES respiratory function, and the development of gammagraphic (scintigraphic) studies. CIBER-BBN Ramon Farré TEAM

115 AREA 2 RESPIRATORY, CARDIOVASCULAR AND RENAL PATHOBIOLOGY AND BIOENGINEERING

Iterative algorithms are being developed for Andrade J., Gozal D. Aorta macrophage modulate endothelial wound healing in a the three-dimensional reconstruction of inflammatory and epigenetic changes in a cell culture model of sleep apnea. images and for the fusion of SPECT and murine model of obstructive sleep apnea: JOURNAL OF APPLIED PHYSIOLOGY magnetic resonance imaging (MRI) images. Potential role of CD36. SCIENTIFIC RESPIRATORY ENVIRONMENTAL AND REPORTS. 7:43648. I.F.: 4.259 EXERCISE PHYSIOLOGY. 123(5):1047-1054. I.F.: 3.351 PUBLICATIONS 7. Khalyfa A., Poroyko V., Qiao Z., Gileles-Hillel A., Akbarpour M., Almendros I., Farré R., Gozal 13. Jorba I., Menal M., Torres M., Gozal D., Originals / I.F.: 82.69 D. Exosomes and metabolic function in Piñol-Ripoll G., Colell A., Montserrat J., Navajas mice exposed to alternating dark-light D., Farré R., Almendros I. Ageing and chronic 1. Cubillos-Zapata C, Avendaño-Ortiz J, cycles mimicking night shift work intermittent hypoxia mimicking sleep Hernandez-Jimenez E, Toledano V, schedules. FRONTIERS IN PHYSIOLOGY. apnea do not modify local brain tissue Casas-Martin J, Varela-Serrano A, Torres M, 8(NOV):882. I.F.: 4.134 stiffness in healthy mice.JOURNAL OF THE Almendros I, Casitas R, Fernández-Navarro I, MECHANICAL BEHAVIOR OF BIOMEDICAL Garcia-Sanchez A, Aguirre LA, Farre R, 8. Gozal, David; Gileles-Hillel, Alex; Cortese, MATERIALS. 71:106-113. I.F.: 3.110 López-Collazo E, García-Rio F. Rene; Li, Yan; Almendros, Isaac; Qiao, Hypoxia-induced PD-L1/PD-1 crosstalk Zhuanhong; Khalyfa, Ahamed A.; Andrade, 14. Vilaseca A., Campillo N., Torres M., impairs T-cell function in sleep apnoea. Jorge; Khalyfa, Abdelnaby. Visceral White Musquera M., Gozal D., Montserrat J., Alcaraz EUROPEAN RESPIRATORY JOURNAL. Adipose Tissue after Chronic Intermittent A., Touijer K., Farré R., Almendros I. 50(4):1700833. I.F.: 10.569 and Sustained Hypoxia in Mice. AMERICAN Intermittent hypoxia increases kidney JOURNAL OF RESPIRATORY CELL AND tumor vascularization in a murine model of 2. Gozal D, Khalyfa A, Qiao Z, Almendros I, MOLECULAR BIOLOGY. 56(4):477-487. sleep apnea. PLOS ONE. 12(6):e0179444. I.F.: Farré R. Temporal trajectories of novel I.F.: 4.100 2.806 object recognition performance in mice exposed to intermittent hypoxia. 9. Buongiorno, Mariateresa; Antonelli, 15. Urbano J., Da Palma R., De Lima F., Fratini EUROPEAN RESPIRATORY JOURNAL. 50(6): Francesca; Compta, Yaroslau; Fernandez, P., Guimaraes L., Uriarte J., Alvarenga L., 1701456. I.F.: 10.569 Yolanda; Pavia, Javier; Lomena, Francisco; Miglino M., Vieira R., Prates R., Navajas D., Rios, Jose; Ramirez, Isabel; Ramon Garcia, Farrè R., Oliveira L.. Effects of two different 3. Iranzo, Alex; Santamaria, Joan; Valldeoriola, Jose; Soler, Marina; Camara, Ana; Fernandez, decellularization routes on the mechanical Francesc; Serradell, Monica; Salamero, Manel; Manel; Basora, Misericordia; Salazar, Fatima; properties of decellularized lungs. PLOS Gaig, Carles; Ninerola-Baizan, Aida; Sanchez-Etayo, Gerard; Valldeoriola, ONE. 12(6):e0178696. I.F.: 2.806 Sanchez-Valle, Raquel; Llado, Albert; De Marzi, Francesc; Raul Barrio, Jorge; Jose Marti, Roberto; Stefani, Ambra; Seppi, Klaus; Pavia, Maria. Cross-Sectional and Longitudinal 16. Vilaseca A, Nguyen DP, Vertosick EA, Javier; Hoegl, Birgit; Poewe, Werner; Tolosa, Cognitive Correlates of FDDNP PET and Corradi RB, Musquera M, Pérez M, Fossati N, Eduard; Lomena, Francisco. Dopamine CSF Amyloid-beta and Tau in Parkinson's Sjoberg DD, Farré R, Almendros I, Montserrat Transporter Imaging Deficit Predicts Early Disease. JOURNAL OF ALZHEIMER'S JM, Benfante NE, Hakimi AA, Skanderup AJ, Transition to Synucleinopathy in Idiopathic DISEASE. 55(3):1261-1272. I.F.: 3.731 Russo P, Alcaraz A, Touijer KA. Obstructive Rapid Eye Movement Sleep Behavior sleep apnea and Fuhrman grade in Disorder. ANNALS OF NEUROLOGY. 10. López-Vilanova N; Pavia J; Duch MA; patients with clear cell renal cell carcinoma 82(3):419-428. I.F.: 9.890 Catafau A; Ros D; Bullich S. Impact of treated surgically. WORLD J UROL. Region-of-Interest Delineation Methods, 35(1):51-56. I.F.: 2.743 4. Akbarpour, Mahzad; Khalyfa, Abdelnaby; Reconstruction Algorithms, and Intra- and Qiao, Zhuanghong; Gileles-Hillel, Alex; Inter-Operator Variability on Internal 17. Martínez-García MÁ, Riveiro-Falkenbach Almendros, Isaac; Farre, Ramon; Gozal, David;. Dosimetry Estimates Using PET. E, Rodríguez-Peralto JL, Nagore E, Altered CD8(+) T-Cell Lymphocyte MOLECULAR IMAGING AND BIOLOGY. Martorell-Calatayud A, Campos-Rodríguez F, Function and TC1 Cell Stemness 19(2):305-314. I.F.: 3.466 Farré R, Hernández Blasco L, Bañuls Roca J, Contribute to Enhanced Malignant Tumor Chiner Vives E, Sánchez-de-la-Torre A, Abad Properties in Murine Models of Sleep 11. Almendros, I.; Campillo, N.; Falcones, B.; Capa J, Montserrat JM, Almendros I, Pérez-Gil Apnea. SLEEP. 40(2):zsw040. I.F.: 4.923 Montserrat, J.; Gozal, D.; Obeso, A.; A, Cabriada Nuño V, Cano-Pumarega I, Corral Gallego-Martin, T.; Navajas, D.; Farre, R. Peñafiel J, Diaz Cambriles T, Mediano O, 5. Campillo N., Torres M., Vilaseca A., Nonaka Frequency And Magnitude Of Intermittent Dalmau Arias J, Gozal D, Spanish Sleep P., Gozal D., Roca-Ferrer J., Picado C., Hypoxia Modulate Endothelial Wound Network. A prospective multicenter cohort Montserrat J., Farré R., Navajas D., Almendros Healing In A Cell Culture Model Of Sleep study of cutaneous melanoma: clinical I. Role of cyclooxygenase-2 on intermittent Apnea. JOURNAL OF APPLIED staging and potential associations with hypoxia-induced lung tumor malignancy in PHYSIOLOGY. 123(5):1047-1054. I.F.: 3.351 HIF-1α and VEGF expressions. MELANOMA a mouse model of sleep apnea. SCIENTIFIC RESEARCH. 27(6):558-564. I.F.: 2.615 REPORTS. 7:44693. I.F.: 4.259 12. Campillo N, Falcones B, Montserrat JM, Gozal D, Obeso A, Gallego-Martin T, Navajas 18. Isetta V, Torres M, González K, Ruiz C, 6. Cortese R., Gileles-Hillel A., Khalyfa A., D, Almendros I, Farré R. Frequency and Dalmases M, Embid C, Navajas D, Farré R, Almendros I., Akbarpour M., Qiao Z., Garcia T., magnitude of intermittent hypoxia Montserrat JM. A New mHealth application

116 RESPIRATORY BIOPHYSICS AND BIOENGINEERING 2.5

to support treatment of sleep apnoea GRANTS FOR RESEARCH IN PROGRESS patients. JOURNAL OF TELEMEDICINE AND TELECARE. 23(1):14-18. I.F.: 2.008 Farré R. Mecanismos del aumento del crecimiento tumoral y metástasis inducido por hipoxia intermitente en modelo Review / I.F.: 6.445 celular/animal de apnea del sueño. Papel del envejecimiento y la menopausia. 1. Jorba I., Uriarte J., Campillo N., Farré R., Sponsored by: Instituto Salud Carlos III. FIS: Navajas D. Probing Micromechanical PI14/00004 Properties of the Extracellular Matrix of Duration: 01/01/2015-31/12/2017 Soft Tissues by Atomic Force Microscopy. JOURNAL OF CELLULAR PHYSIOLOGY. Farré R. Impact of sleep apnea syndrome 232(1):19-26. I.F.: 4.080 on persistent atrial ﬁbrillation and effect of intervention with continuous positive 2. Almendros, Isaac; Crespo, Andrea; airway pressure (CPAP). Role of hypoxia Tura-Ceide, Olga; Bonsignore, Maria R. and sleep fragmentation. Clinical physiology and sleep: insights from Sponsored: Fundació Marató TV3. 20143231 the European Respiratory Society Duration: 01/10/2015-31/09/2018 Congress 2017. JOURNAL OF THORACIC DISEASE. 9(suppl 16):S1532-S1536. I.F.: 2.365 DOCTORAL THESES

Letters / I.F.: 10.569 Almendros I. Molecular and clinical response of renal cell carcinoma to 1. Gallego-Martin T, Farré R, Almendros I, intermittent hypoxia. Gonzalez-Obeso E, Obeso A. Chronic PhD student: Antonio Vilaseca Cabo intermittent hypoxia mimicking sleep apnoea increases spontaneous tumorigenesis in mice. EUROPEAN RESPIRATORY JOURNAL. 49(2):1602111. I.F.: 10.569

Editorial / I.F.: 17.648

1. Almendros, Isaac; Garcia-Rio, Francisco;. Sleep apnoea, insulin resistance and diabetes: the ﬁrst step is in the fat. EUROPEAN RESPIRATORY JOURNAL. 49(4):1700179. I.F.: 10.569

2. Almendros I., Farre N. Obstructive sleep apnea and atherosclerosis: Both the gut microbiome and hypercapnia matter. AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY. 57(5):501-503. I.F.: 4.100

3. Martínez-García MÁ, Campos-Rodríguez F, Almendros I. Sleep Apnea and Tumor Agressivity. ARCHIVOS DE BRONCONEUMOLOGIA. 53(6):300-301. I.F.: 2.979

117 AREA 2 RESPIRATORY, CARDIOVASCULAR AND RENAL PATHOBIOLOGY AND BIOENGINEERING

Applied research in infectious respiratory diseases, critically 2.6 ill patients and lung cancer

PRE-DOCTORAL RESEARCHERS Victoria Alcaraz (FCRB) LOCATION Enric Barbeta (HCB) CELLEX building 2B Denise Battaglini (FCRB) Joaquim Bobí (FCRB) Adrian Ceccato (HCB) Onintza Garmendia (CIBER)

WEB Andrea Meli (FCRB) www.idibapsrespiratoryresearch.org Anna Motos (FCRB) Francesco Pagliara (FCRB) Montserrat Rigol (FCRB) TEAM LEADER Monique C Suárez (HCB) Antoni Torres (HCB) Hua Yang (FCRB) T. 93 227 54 00 (Ext.: 3037) Minlan Yang (FCRB) [email protected] KEYWORDS 1. Respiratory infections ADMINISTRATIVE STAFF Elisabeth Sancho (CIBERES) 2. Mechanical ventilation GROUP LEADER 3. Pneumonia Josep Mª Montserrat (HCB) 4. COPD, bronchiectasis T. 93 227 57 46 5. Breathing disturbances in sleep [email protected] STRATEGIC OBJECTIVES

1. To study respiratory infections, invasive RESEARCHERS and noninasive mechanical ventilation, Carles Agustí (HCB) exacerbations of chronic obstructive Joan Ramon Badia (HCB) pulmonary disease (COPD), bronchiectasis Original publications Miquel Ferrer (HCB) 2. Physiopathological and treatment studies from 2015 to 2017 Néstor Soler (HCB) in animals and humans with ventilator Dolors Soy (HCB) associated pneumonia and or ARDS YEAR I.F. TOTAL Q1 Q2 3. Human and animal model research in sleep 2015 189.70 31 22 6 POST-DOCTORAL RESEARCHERS apnea syndrome. Telemedicine and Rosanel Amaro (HCB) multcentre studies 2016 134.54 32 22 7 Catia Cilloniz (CIBER) 2017 160.19 30 20 9 Laia Fernández (CIBER) Gianluigi Li Bassi (HCB-FCRB) Carmen Lucena (HCB) Marta Torres (CIBER)

TEAM INVOLVED IN CIBERES AGAUR_SGR14 Antoni Torres TEAM

118 APPLIED RESEARCH IN INFECTIOUS RESPIRATORY DISEASES, CRITICALLY ILL PATIENTS AND LUNG CANCER 2.6

MAIN LINES OF RESEARCH PUBLICATIONS controlled trial. EUROPEAN RESPIRATORY JOURNAL. 50(1):1601448. I.F.: 10.569 1. Epidemiology, prevention and new Originals / I.F.: 160.19 treatments of: pneumonia associated with 6. Zakharkina, Tetyana; Martin-Loeches, artificial ventilation, community-acquired 1. Ranzani OT, Prina E, Menéndez R, Ceccato Ignacio; Matamoros, Sebastien; Povoa, Pedro; pneumonia. New treatments. Resistances A, Cilloniz C, Méndez R, Gabarrus A, Barbeta Torres, Antoni; Kastelijn, Janine B.; Hofstra, of microorganisms. Local and systemic E, Bassi GL, Ferrer M, Torres A. New Sepsis Jorrit J.; de Wever, B.; de Jong, Menno; Schultz, inflammatory response. Definition (Sepsis-3) and Community- Marcus J.; Sterk, Peter J.; Artigas, Antonio; Bos, 2. Etiopathogenesis, bronchial infection and acquired Pneumonia Mortality A Validation Lieuwe D. J. The dynamics of the pulmonary inflammation in the patient with chronic and Clinical Decision-Making Study. microbiome during mechanical ventilation obstructive pulmonary disease (COPD). AMERICAN JOURNAL OF RESPIRATORY in the intensive care unit and the association 3. Chronic pulmonary infections: AND CRITICAL CARE MEDICINE. with occurrence of pneumonia. THORAX. bronchiectasis not associated with cystic 196(10):1287-1297. I.F.: 13.204 72(9):803-810. I.F.: 8.272 fibrosis, immune deficiencies and cystic fibrosis in the adult. 2. Corral J, Sánchez-Quiroga MÁ, 7. Cillóniz C, Torres A, Manzardo C, Gabarrús 4. Invasive and noninvasive mechanical Carmona-Bernal C, Sánchez-Armengol Á, de A, Ambrosioni J, Salazar A, García F, Ceccato ventilation: epidemiology, cost- la Torre AS, Durán-Cantolla J, Egea CJ, Salord A, Mensa J, de la Bella Casa JP, Moreno A, effectiveness and physiopathology. N, Monasterio C, Terán J, Alonso-Alvarez ML, Miró JM. Community-Acquired Weaning from mechanical ventilation: role Muñoz-Méndez J, Arias EM, Cabello M, Pneumococcal Pneumonia in Virologically of the inflammatory response and Montserrat JM, De la Peña M, Serrano JC, Suppressed HIV-Infected Adult Patients: respiratory failure following extubation. Barbe F, Masa JF, Spanish Sleep Network. A Matched Case-Control Study. CHEST. 5. Study of the pharmacokinetics of Conventional Polysomnography is Not 152(2):295-303. I.F.: 6.147 antibiotics and other drugs in the ventilated Necessary for the Management of Most and non-ventilated patient. Patients with Suspected Obstructive 8. Ceccato A, Torres A, Cilloniz C, Amaro R, 6. Porcine model of acute pulmonary damage Sleep Apnea. AMERICAN JOURNAL OF Gabarrus A, Polverino E, Prina E, Garcia-Vidal due to methicillinresistant P. aeruginosa, S. RESPIRATORY AND CRITICAL CARE C, Muñoz-Conejero E, Mendez C, Cifuentes I, aureus and S. pneumoniae MEDICINE. 196(9):1181-1190. I.F.: 13.204 Puig de la Bella Casa J, Menendez R, 7. Chronic sleep apnea models. Niederman MS. Invasive Disease vs Urinary 8. Multicenter Study to assess the effect of 3. Li Bassi G; Panigada M; Ranzani O; Zanella Antigen-Confirmed Pneumococcal CPAP on cardiovascular diseases in A; Berra L; Cressoni M; Parrini V; Kandil H; Community-Acquired Pneumonia. CHEST. patients with sleep apnea. Salati G; Selvaggi P; Amatu A; Sanz-Moncosi 151(6):1311-1319. I.F.: 6.147 9. Telematic control of CPAP treatment in M; Biagioni E; Tagliaferri F; Furia M; Mercurio sleep apnea syndrome. G; Costa A; Manca T; Lindau S; Babel J; 9. Polverino E, Rosales-Mayor E, Dale GE, Cavana M; Chiurazzi C; Martí J; Consonni D; Dembowsky K, Torres A. The role of Gattinoni L; Pesenti A; Wiener-Kronish J; neutrophil elastase inhibitors in lung Bruschi C; Ballotta A; Salsi P; Livigni S; Iotti G; diseases. CHEST. 152(2):249-262. I.F.: 6.147 RESEARCH GROUP Fernandez J; Girardis M; Barbagallo M; Moise BREATHING DISTURBANCES IN SLEEP G; Antonelli M; Caspani M; Vezzani A; 10. Stolz, Daiana; Leeming, Diana Julie; Meybohm P. Randomized, multicenter trial Kristensen, Jacob Hull Edfort; Karsdal, Morten GROUP LEADER of lateral Trendelenburg versus A.; Boersma, Wim; Louis, Renaud; Milenkovic, Josep M. Montserrat (HCB) semirecumbent body position for the Branislava; Kostikas, Konstantinos; Blasi, prevention of ventilator-associated Francesco; Aerts, Joachim; Sand, Jannie M. B.; The main research line of this group is the pneumonia. INTENSIVE CARE MEDICINE. Wouters, Emiel F. M.; Rohde, Gernot; Prat, analysis of respiratory disturbances in sleep. 43(11):1572-1584. I.F.: 12.015 Cristina; Torres, Antoni; Welte, Tobias; Roth, Specifically, the two most important lines are Michael; Papakonstantinou, Eleni; Tamm, the following: the study of diagnostic methods 4. Martin-Loeches, Ignacio; Schultz, Marcus J.; Michael. Systemic Biomarkers of Collagen and effects of treatment in a population of Vincent, Jean-Louis; Alvarez-Lerma, and Elastin Turnover Are Associated With apneic patients in which the indication is not Francisco; Bos, Lieuwe D.; Sole-Violan, Jordi; Clinically Relevant Outcomes in COPD. clear; and the study of animal models for Torres, Antoni; Rodriguez, Alejandro;. CHEST. 151(1):47-59. I.F.: 6.147 exploring the mechanisms underlying the Increased incidence of co-infection in origin and consequences of the disorder. critically ill patients with influenza. 11. Martinez-Nicolas A, Guaita M, Santamaría Both lines are carried out in the context of INTENSIVE CARE MEDICINE. 43(1):48-58. J, Montserrat JM, Rol MÁ, Madrid JA. national multicenter clinical trials. I.F.: 12.015 Circadian impairment of distal skin Finally, the envelopment of a visrtual sleep unit temperature rhythm in patients with sleep is one of the major topic during last year as well 5. Sellares J, Ferrer M, Anton A, Loureiro H, disordered breathing: The effect of CPAP. as other telemedicine procedures to improve Bencosme C, Alonso R, Martinez-Olondris P, SLEEP. 40(6). I.F.: 4.923 the patient management and the cost Sayas J, Peñacoba P, Torres A. effectivenes. Discontinuing noninvasive ventilation in 12. Campillo, Noelia; Torres, Marta; Vilaseca, severe chronic obstructive pulmonary Antoni; Naomi Nonaka, Paula; Gozal, David; disease exacerbations: a randomised Roca-Ferrer, Jordi; Picado, Cesar; Maria

119 AREA 2 RESPIRATORY, CARDIOVASCULAR AND RENAL PATHOBIOLOGY AND BIOENGINEERING

Montserrat, Josep; Farre, Ramon; Navajas, 19. Cilloniz C, Ewig S, Gabarrus A, Ferrer M, Gabarrus, Albert; Ferrer, Miquel; Sibila, Oriol; Daniel; Almendros, Isaac. Role of Puig de la Bella Casa J, Mensa J, Torres A. Niederman, Michael S.; Torres, Antoni. cyclooxygenase-2 on intermittent Seasonality of pathogens causing Treatment with macrolides and hypoxia-induced lung tumor malignancy in community-acquired pneumonia. glucocorticosteroids in severe a mouse model of sleep apnea. SCIENTIFIC RESPIROLOGY. 22(4):778-785. I.F.: 3.256 communityacquired pneumonia: REPORTS. 7:44693. I.F.: 4.259 A post-hoc exploratory analysis of a 20. Menendez, Rosario; Pablo Espana, Pedro; randomized controlled trial. PLOS ONE. 13. Amaro R; Sellarés J; Polverino E; Cilloniz C; Perez-Trallero, Emilio; Uranga, Ane; Mendez, 12(6):e0178022. I.F.: 2.806 Ferrer M; Fernández-Barat L; Mensa J; Raul; Cilloniz, Catia; Maria Marimon, Jose; Niederman M; Torres A. Antibiotic therapy Cifuentes, Isabel; Mendez, Cristina; Torres, 26. Rosales-Mayor, Edmundo; Polverino, Eva; prior to hospital admission is associated with Antoni. The burden of PCV13 serotypes in Raguer, Laura; Alcaraz, Victoria; Gabarrus, reduced septic shock and need for hospitalized pneumococcal pneumonia in Albert; Ranzani, Otavio; Menendez, Rosario; mechanical ventilation in patients with Spain using a novel urinary antigen Torres, Antoni. Comparison of two community-acquired pneumonia. JOURNAL detection test. CAPA study. VACCINE. prognostic scores (BSI and FACED) in a OF INFECTION. 74(5):442-449. I.F.: 4.201 35(39):5264-5270. I.F.: 3.235 Spanish cohort of adult patients with bronchiectasis and improvement of the 14. Fernandez-Barat, Laia; Ferrer, Miquel; De 21. Jorba, Ignasi; Jose Menal, Maria; Torres, FACED predictive capacity for Rosa, Francesca; Gabarrus, Albert; Esperatti, Marta; Gozal, David; Pinol-Ripoll, Gerard; exacerbations. PLOS ONE. 12(4):e0175171. Mariano; Terraneo, Silvia; Rinaudo, Mariano; Li Colell, Anna; Montserrat, Josep M.; Navajas, I.F.: 2.806 Bassi, Gianluigi; Torres, Antoni. Intensive care Daniel; Farre, Ramon; Almendros, Isaac. unit-acquired pneumonia due to Ageing and chronic intermittent hypoxia 27. Vilaseca, Antoni; Campillo, Noelia; Torres, Pseudomonas aeruginosa with and mimicking sleep apnea do not modify local Marta; Musquera, Mireia; Gozal, David; without multidrug resistance. JOURNAL brain tissue stiffness in healthy mice. Montserrat, Josep M.; Alcaraz, Antonio; OF INFECTION. 74(2):142-152. I.F.: 4.201 JOURNAL OF THE MECHANICAL BEHAVIOR Touijer, Karim A.; Farre, Ramon; Almendros, OF BIOMEDICAL MATERIALS. 71:106-113. Isaac. Intermittent hypoxia increases 15. Lucena, C. M.; Rovira, M.; Gabarrus, A.; I.F.: 3.110 kidney tumor vascularization in a murine Filella, X.; Martinez, C.; Domingo, R.; Torres, A.; model of sleep apnea. PLOS ONE. Agusti, C. The clinical value of biomarkers in 22.Terán-Santos J, Egea Santaolalla C, 12(6):e0179444. I.F.: 2.806 respiratory complications in hematopoietic Montserrat JM, Masa Jiménez F, Librada SCT. BONE MARROW TRANSPLANTATION. Escribano MV, Mirabet E, Valdés Rodríguez E. 28. Menendez, Rosario; Mendez, Raul; 52(3):415-422. I.F.: 3.874 Sleep Apnea and Driving. Polverino, Eva; Rosales-Mayor, Edmundo; Recommendations for Interpreting Amara-Elori, Isabel; Reyes, Soledad; Miguel 16. Menendez, Rosario; Mendez, Raul; Spanish Regulations for Drivers. Sahuquillo-Arce, Jose; Fernandez-Barat, Laia; Polverino, Eva; Rosales-Mayor, Edmundo; ARCHIVOS DE BRONCONEUMOLOGIA. Alcaraz, Victoria; Torres, Antoni. Risk factors Amara-Elori, Isabel; Reyes, Soledad; Posadas, 53(6):336-341. I.F.: 2.979 for multidrug-resistant pathogens in Tomas; Fernandez-Barat, Laia; Torres, Antoni. bronchiectasis exacerbations. BMC Factors associated with hospitalization in 23. Huang, David B.; File, Thomas M., Jr.; INFECTIOUS DISEASES. 17(1):659. I.F.: 2.768 bronchiectasis exacerbations: A one-year Torres, Antoni; Shorr, Andrew F.; Wilcox, Mark follow-up study. RESPIRATORY H.; Hadvary, Paul; Dryden, Matthew; Corey, G. 29. Martínez-García MÁ, Riveiro-Falkenbach RESEARCH. 18(1):176. I.F.: 3.841 Ralph. A Phase II Randomized, E, Rodríguez-Peralto JL, Nagore E, Double-Blind, Multicenter Study to Martorell-Calatayud A, Campos-Rodríguez F, 17. Almendros, I.; Campillo, N.; Falcones, B.; Evaluate Efficacy and Safety of Farré R, Hernández Blasco L, Bañuls Roca J, Montserrat, J.; Gozal, D.; Obeso, A.; Intravenous Iclaprim Versus Vancomycin Chiner Vives E, Sánchez-de-la-Torre A, Abad Gallego-Martin, T.; Navajas, D.; Farre, R. for the Treatment of Nosocomial Pneumonia Capa J, Montserrat JM, Almendros I, Pérez-Gil Frequency And Magnitude Of Intermittent Suspected or Conﬁrmed to be Due to A, Cabriada Nuño V, Cano-Pumarega I, Corral Hypoxia Modulate Endothelial Wound Gram-Positive Pathogens. CLINICAL Peñaﬁel J, Diaz Cambriles T, Mediano O, Healing In A Cell Culture Model Of Sleep THERAPEUTICS. 39(8):1706-1718. I.F.: 2.947 Dalmau Arias J, Gozal D, Spanish Sleep Apnea. JOURNAL OF APPLIED Network. A prospective multicenter cohort PHYSIOLOGY. 123(5):1047-1054. I.F.: 3.351 24. Cilloniz, Catia; Ceccato, Adrian; de la Calle, study of cutaneous melanoma: clinical Cristina; Gabarrus, Albert; Garcia-Vidal, staging and potential associations with 18. Barceló A, Morell-Garcia D, Salord N, Carolina; Almela, Manel; Soriano, Alex; Antonio HIF-1α and VEGF expressions. MELANOMA Esquinas C, Pérez G, Pérez A, Monasterio C, Martinez, Jose; Marco, Francesc; Vila, Jordi; RESEARCH. 27(6):558-564. I.F.: 2.615 Gasa M, Fortuna AM, Montserrat JM, Mayos Torres, Antoni. Time to blood culture M. A randomized controlled trial: positivity as a predictor of clinical 30. Cisternas A, Aguilar F, Montserrat JM, branched-chain amino acid levels and outcomes and severity in adults with Àvila M, Torres M, Iranzo A, Berenguer J, glucose metabolism in patients with bacteremic pneumococcal pneumonia. Vilaseca I. Effects of CPAP in patients with obesity and sleep apnea. JOURNAL OF PLOS ONE. 12(8):e0182436. I.F.: 2.806 obstructive apnoea: is the presence of SLEEP RESEARCH. 26(6):773-781. I.F.: 3.259 allergic rhinitis relevant? SLEEP AND 25. Ceccato, Adrian; Cilloniz, Catia; Ranzani, BREATHING. 21(4):893-900. I.F.: 2.288 Otavio T.; Menendez, Rosario; Agusti, Carles;

120 APPLIED RESEARCH IN INFECTIOUS RESPIRATORY DISEASES, CRITICALLY ILL PATIENTS AND LUNG CANCER 2.6

Review / I.F.: 32.006 2. Torres A, Martín-Loeches I, Menéndez R. Torres A. Combatting Bacterial Resistance Research in community-acquired in Europe - Molecules Against Gram 1. Kollef, Marin H.; Bassetti, Matteo; Francois, pneumonia: the next steps. INTENSIVE Negative Infections. Bruno; Burnham, Jason; Dimopoulos, George; CARE MEDICINE. 43(9):1395-1397. I.F.: 12.015 (COMBACTE-MAGNET). Garnacho-Montero, Jose; Lipman, Jeffrey; Sponsored by: European Comission, Luyt, Charles-Edouard; Nicolau, David P.; 3. Niederman MS, Martin-Loeches I, Torres A. Innovative Medicines Iniciative (IMI_13) Postma, Maarten J.; Torres, Antonio; Welte, The research agenda in VAP/HAP: next Duration: 01/01/2015-31/12/2021 Tobias; Wunderink, Richard G. The intensive steps. INTENSIVE CARE MEDICINE. care medicine research agenda on 43(9):1389-1391. I.F.: 12.015 Torres A. Eficacia y caracterización de los multidrug-resistant bacteria, antibiotics, efectos de los corticosteroides asociados and stewardship. INTENSIVE CARE a antibióticos en un modelo animal de MEDICINE. 43(9):1187-1197. I.F.: 12.015 Consortium Publications / I.F.: 8.874 neumonía grave por streptococcus pneumoniae. 2. Hill AT, Haworth CS, Aliberti S, Barker A, 1. Cano-Pumarega, Irene; Barbe, Ferrn; Sponsored by: Instituto de Salud Carlos III. Blasi F, Boersma W, Chalmers JD, De Soyza A, Esteban, Andres; Martinez-Alonso, PI15/00506 Dimakou K, Elborn JS, Feldman C, Flume P, Montserrat; Egea, Carlos; Durn-Cantolla, Duration: 01/01/2016-31/12/2018 Goeminne PC, Loebinger MR, Menendez R, Joaquin;Spanish Sleep Network. Sleep Morgan L, Murris M, Polverino E, Quittner A, Apnea and Hypertension Are There Sex Ringshausen FC, Tino G, Torres A, Vendrell M, Differences? The Vitoria Sleep Cohort. DOCTORAL THESES Welte T, Wilson R, Wong C, O'Donnell A, CHEST. 152(4):742-750. I.F.: 6.147 Aksamit T, EMBARC/BRR definitions working Soy D, Martín I. Optimization of group. Pulmonary exacerbation in adults 2. Rello J, Diaz E, Mañez R, Sole-Violan J, meropenem and piperacillin dosing in with bronchiectasis: a consensus Valles J, Vidaur L, Zaragoza R, Gattarello S, critically ill patients with septic shock and definition for clinical research. EUROPEAN CAPUCI II Consortium. Improved survival acute kidney injury requiring continuous RESPIRATORY JOURNAL. 49(6):1700051. among ICU-hospitalized patients with renal replacement therapy: a I.F.: 10.569 community-acquired pneumonia by pharmacokinetic and pharmacodynamic unidentified organisms: a multicenter study. 3. Liapikou A, Cillóniz C, Torres A. case-control study. EUROPEAN JOURNAL PhD student: Marta Ulldemolins Gómez Investigational drugs in phase I and phase OF CLINICAL MICROBIOLOGY AND II clinical trials for the treatment of INFECTIOUS DISEASES. 33(1):123-130. I.F.: 2.727 Torres A. Nuevas consideraciones en el community-acquired pneumonia. EXPERT pronóstico de la neumonía adquirida en la OPINION ON INVESTIGATIONAL DRUGS. comunidad. 26(11):1239-1248. I.F.: 4.030 GRANTS FOR RESEARCH IN PROGRESS PhD student: Rosanel Amaro Rodríguez

4. Blasi, Francesco; Akova, Murat; Bonanni, Montserrat J.M. Aplicabilidad y coste Torres A, Ramírez P. Seguimiento del Paolo; Dartois, Nathalie; Sauty, Evelyne; eﬁciencia de un modelo de gestión para el paciente sometido a ventilación mecánica; Webber, Chris; Torres, Antoni. síndrome de apneas durante el sueño detección de complicaciones infecciosas. Community-acquired pneumonia in adults: basado en el trabajo en red y telemedicina. PhD student: Cristina López Ferraz Highlighting missed opportunities for Sponsored by: Instituto de Salud Carlos III vaccination. EUROPEAN JOURNAL OF (ISCIII). PI14/00416 INTERNAL MEDICINE. 37:13-18. I.F.: 2.960 Duration: 01/01/2015-30/06/2018

5. Lugo V, Villanueva JA, Garmendia O, Soler N. Valor diagnóstico de la Pancreatic Montserrat JM. The role of telemedicine in Stone Protein (PSP/reg) en la agudización obstructive sleep apnea management. infecciosa de la Enfermedad Pulmonar EXPERT REVIEW OF RESPIRATORY Obstructiva Crónica (EPOC): relevancia MEDICINE. 11(9):699-709. I.F.: 2.432 del microbioma. Sponsored by: Instituto de Salud Carlos III (ISCIII). PI13/02238 Letters / I.F.: 43.317 Duration: 01/01/2014-30/06/2017

1. Bermejo-Martin J, Almansa R, Soler N. Dinámica del microbioma Martin-Fernandez M, Menendez R, Torres A. pulmonar en la agudización neumónica y Immunological proﬁling to assess disease no neumónica de la EPOC y uso como severity and prognosis in community- potencial diana terapéutica: estudio acquired pneumonia. THE LANCET. discriminativo con TAC torácica de baja RESPIRATORY MEDICINE. 5(12):E35-E36. radiación. I.F.: 19.287 Sponsored by: Instituto de Salud Carlos III (ISCIII). PI16/00803 Duration: 01/01/2017-31/12/2019

121 AREA 2 RESPIRATORY, CARDIOVASCULAR AND RENAL PATHOBIOLOGY AND BIOENGINEERING

Physiopathological mechanisms of 2.7 respiratory illnesses

Jéssica García (FCRB) Elena Gimeno (IDIBAPS) LOCATION Víctor Peinado (CIBER) HCB

CELLEX building 2A PRE-DOCTORAL RESEARCHERS Eric Baltaxe (IDIBAPS) Tanya Orizaga (FCRB) Jeisson Osorio (CIBER)

WEB Lucilla Piccari (FCRB) www.idibaps.org/research/604/ Laura Sebastián (IDIBAPS) physiopathological-mechanisms-of- TEAM LEADER Valerie Smolders (UB) respiratory-illnesses Joan Albert Barberà (HCB) Akos Tenyi (IDIBAPS) T. 93 227 57 79 Yolanda Torralba (CIBER) [email protected] TECHNICIANS Cristina Bonjoch (IDIBAPS)

GROUP LEADER Maribel Marquina (IDIBAPS)

KEYWORDS Isabel Blanco (HCB-IDIBAPS) ADMINISTRATIVE STAFF 1. Pulmonary hypertension T. 93 227 57 47 [email protected] Julio Más (FCRB) 2. COPD Mària Sánchez (IDIBAPS) 3. Systems medicine M. Dolores Sanz (FCRB) 4. Endothelium EMERITUS 5. Stem cells Robert Rodríguez-Roisin (HCB) NURSING STAFF Xavier Alsina (HCB)

RESEARCHERS Concepción Gistau (HCB) Felip Burgos (HCB) María Palomo (HCB) Carme Hernández (HCB) Ana Ramírez (HCB) Graciela Martínez-Pallí (HCB) Original publications Josep Roca (HCB) COLLABORATORS from 2015 to 2017 Olga Tura (IDIBAPS) Albert Alonso (HCB) Elizabeth Zavala (HCB) Mª José Arguis (HCB) YEAR I.F. TOTAL Q1 Q2 Xavier Borrat (HCB)

2015 143.23 23 12 6 POST-DOCTORAL RESEARCHERS Marta Cascante (UB) Jorge Moisés (HCB) 2016 141.51 28 19 5 Anael Barberan (UB) Isaac Cano (IDIBAPS) Jordi Vilaró (FCRB) 2017 86.75 16 13 - Iván Guillermo Dueñas (IDIBAPS)

TEAM INVOLVED IN CIBERES RETIC Biobancos Joan Albert Barberà TEAM

122 PHYSIOPATHOLOGICAL MECHANISMS OF RESPIRATORY ILLNESSES 2.7

STRATEGIC OBJECTIVES remodelling is the major cause of the elevated underlying COPD-muscle dysfunction PVR and ultimately the right heart failure. unveiled through a systems medicine Understanding of the molecular mechanisms There is a need to identify new signaling approach. BIOINFORMATICS. 33(1):95-103. involved in the development of pulmonary pathways in the pathogenesis of PAH. We I.F.: 7.307 vascular diseases. Identification of biomarkers propose going from the bench to the bed side and therapeutic targets for pulmonary studying potential biomarkers of the disease 6. García-Lucio J, Tura-Ceide O, Del Pozo R, hypertension. Characterization of activity and progression; as well as potential Blanco I, Pizarro S, Ferrer E, Díez M, Coll-Bonfill extrapulmonary disorders in COPD. new drugs to reverse the proliferative N, Piccari L, Peinado VI, Barberà JA. Effect of Determination of intra-and extrapulmonary remodelling phenotype in PAH. targeted therapy on circulating progenitor manifestations of severe obesity. Role of stem cells in precapillary pulmonary cells in lung injury and repair mechanisms. hypertension. INT J CARDIOL. 228:238-243. Personalized medical care for chronic I.F.: 6.189 respiratory diseases from a systems medicine PUBLICATIONS strategy. 7. Martinez F., Rabe K., Ferguson G., Fabbri L., Originals / I.F.: 86.75 Rennard S., Feldman G., Sethi S., Spangenthal S., Gottschlich G., Rodriguez-Roisin R., Arora MAIN LINES OF RESEARCH 1. Coghlan JG, Galiè N, Barberà JA, Frost AE, S., Siler T., Siddiqui S., Darken P., Fischer T., Ghofrani HA, Hoeper MM, Kuwana M, Maes A., Golden M., Orevillo C., Reisner C. - Clinical research in pulmonary McLaughlin VV, Peacock AJ, Simonneau G, Efficacy and Safety of Glycopyrrolate/ hypertension: biomarkers and new Vachiéry JL, Blair C, Gillies H, Miller KL, Harris Formoterol Metered Dose Inhaler therapies JHN, Langley J, Rubin LJ, AMBITION Formulated Using Co-Suspension Delivery - Endothelial dysfunction and vascular investigators. Initial combination therapy Technology in Patients With COPD. remodeling with ambrisentan and tadalafil in CHEST. 151(2):340-357. I.F.: 6.147 - Experimental models of COPD and connective tissue disease-associated pulmonary hypertension pulmonary arterial hypertension 8. Lopez-Ruiz, Elena; Venkateswaran, - Stem and progenitor cells (CTD-PAH): Subgroup analysis from the Seshasailam; Peran, Macarena; Jimenez, - Interaction between airway, lung and AMBITION trial. ANNALS OF THE Gema; Pernagallo, Salvatore; Diaz-Mochon, systemic inflammation in COPD and RHEUMATIC DISEASES. 76(7):1219-1227. Juan J.; Tura-Ceide, Olga; Arrebola, Francisco; severe obesity I.F.: 12.811 Melchor, Juan; Soto, Juan; Rus, Guillermo; - Pathophysiology of pulmonary gas Real, Pedro J.; Diaz-Ricart, Maria; exchange 2. Noell, Guillaume; Cosio, Borja G.; Faner, Conde-Gonzalez, Antonio; Bradley, Mark; - Systems medicine Rosa; Monso, Eduard; Peces-Barba, German; Marchal, Juan A. Poly (ethylmethacrylate- de Diego, Alfredo; Esteban, Cristobal; Gea, co-diethylaminoethyl acrylate) coating Joaquim; Rodriguez-Roisin, Robert; improves endothelial repopulation, 50/50 PROGRAM Garcia-Nunez, Marian; Pozo-Rodriguez, bio-mechanical and anti-thrombogenic TRANSLATIONAL RESEARCH IN Francisco; Kalko, Susana G.; Agusti, Alvar. properties of decellularized carotid PULMONARY VASCULAR DISEASES: Multi-level differential network analysis of arteries for blood vessel replacement. CELL PROLIFERATION AND COPD exacerbations. EUROPEAN SCIENTIFIC REPORTS. 7(1):407. I.F.: 4.259 APOPTOTIC MECHANISMS IN RESPIRATORY JOURNAL. 50(3):1700075. PULMONARY ARTERIAL I.F.: 10.569 9. Tura-Ceide, Olga; Lobo, Borja; Paul, Tanja; HYPERTENSION Puig-Pey, Raquel; Coll-Bonfill, Nuria; 3. Scioscia G, Blanco I, Arismendi E, Burgos F, Garcia-Lucio, Jessica; Smolders, Valerie; Gistau C, Foschino Barbaro MP, Celli B, Blanco, Isabel; Barbera, Joan A.; Peinado, O'Donnell DE, Agustí A. Different dyspnoea Victor I. Cigarette smoke challenges bone perception in COPD patients with frequent marrow mesenchymal stem cell capacities and infrequent exacerbations. THORAX. in guinea pig. RESPIRATORY RESEARCH. 72(2):117-121. I.F.: 8.272 18(1):50. I.F.: 3.841

GROUP LEADER 4. Arbillaga-Etxarri A, Gimeno-Santos E, 10. Aldecoa I, Montironi C, Planell N, Pellise M, Isabel Blanco (HCB-IDIBAPS) Barberan-Garcia A, Benet M, Borrell E, Fernandez-Esparrach G, Gines A, Delgado S, Dadvand P, Foraster M, Marín A, Monteagudo Momblan D, Moreira L, Lopez-Ceron M, Pulmonary arterial hypertension (PAH) is a M, Rodriguez-Roisin R, Vall-Casas P, Vilaró J, Rakislova N, Martinez-Palli G, Balust J, Bombi disease of small pulmonary arteries, Garcia-Aymerich J, Urban Training Study JA, de Lacy A, Castells A, Balaguer F, characterized by gradual obliteration of the Group. Socio-environmental correlates of Cuatrecasas M. Endoscopic tattooing of arterial lumen due to the enlargement of the physical activity in patients with chronic early colon carcinoma enhances vessel wall. It results in a progressive increase obstructive pulmonary disease (COPD). detection of lymph nodes most prone of pulmonary vascular resistance (PVR) and, THORAX. 72(9):796-802. I.F.: 8.272 to harbor tumor burden. SURGICAL ﬁnally, right ventricular failure and death. While ENDOSCOPY. 31(2):723-733. I.F.: 3.747 vasoconstriction contributes, especially in 5. Marín de Mas I, Fanchon E, Papp B, Kalko S, earlier stages, the obstructive vascular Roca J, Cascante M. Molecular mechanisms

123 AREA 2 RESPIRATORY, CARDIOVASCULAR AND RENAL PATHOBIOLOGY AND BIOENGINEERING

11. Agustí A., Compte A., Faner R., Review / I.F.: 32.179 DM, López Varela MV, Nishimura M, Roche N, Garcia-Aymerich J., Noell G., Cosio B., Rodriguez-Roisin R, Sin DD, Singh D, Stockley R, Rodriguez-Roisin R., Celli B., Anto J. The EASI 1. Rodriguez-Roisin R, Han MK, Vestbo J, Vestbo J, Wedzicha JA, Agusti A. Global model: A ﬁrst integrative computational Wedzicha JA, Woodruff PG, Martinez FJ. Strategy for the Diagnosis, Management, approximation to the natural history of Chronic Respiratory Symptoms with and Prevention of Chronic Obstructive Lung COPD. PLOS ONE. 12(10):e0185502. Normal Spirometry. A Reliable Clinical Disease 2017 Report: GOLD Executive I.F.: 2.806 Entity? AM J RESPIR CRIT CARE MED. Summary. EUR RESPIR J. 49(3):1700214. I.F.: 195(1):17-22. I.F.: 13.204 10.569 12. López-Meseguer M, Quezada CA, Ramon MA, Lázaro M, Dos L, Lara A, López R, Blanco 2. Kovacs G, Herve P, Barbera JA, Chaouat A, 3. Graham BL, Brusasco V, Burgos F, Cooper I, Escribano P, Roman A, REHAP Investigators. Chemla D, Condliffe R, Garcia G, Grünig E, BG, Jensen R, Kendrick A, MacIntyre NR, Lung and heart-lung transplantation in Howard L, Humbert M, Lau E, Laveneziana P, Thompson BR, Wanger J. Executive pulmonary arterial hypertension. PLOS Lewis GD, Naeije R, Peacock A, Rosenkranz S, Summary: 2017 ERS/ATS standards for ONE. 12(11):e0187811. I.F.: 2.806 Saggar R, Ulrich S, Vizza D, Vonk Noordegraaf single-breath carbon monoxide uptake in the A, Olschewski H. An official European lung. EUR RESPIR J. 49(1):16E0016. 13. Cano I, Dueñas-Espín I, Hernandez C, de Respiratory Society statement: pulmonary I.F.: 10.569 Batlle J, Benavent J, Contel JC, Baltaxe E, haemodynamics during exercise. Escarrabill J, Fernández JM, Garcia-Aymerich EUROPEAN RESPIRATORY JOURNAL. 50(5). 4. Graham BL, Brusasco V, Burgos F, Cooper J, Mas MÀ, Miralles F, Moharra M, Piera J, I.F.: 10.569 BG, Jensen R, Kendrick A, MacIntyre NR, Salas T, Santaeugènia S, Soler N, Torres G, Thompson BR, Wanger J. 2017 ERS/ATS Vargiu E, Vela E, Roca J. Protocol for 3. Gomez-Cabrero, David; Marabita, standards for single-breath carbon regional implementation of Francesco; Tarazona, Sonia; Cano, Isaac; monoxide uptake in the lung. EUR RESPIR J. community-based collaborative Roca, Josep; Conesa, Ana; Sabatier, Philippe; 49(1):1600016. I.F.: 10.569 management of complex chronic patients. Tegner, Jesper. Guidelines for Developing NPJ PRIM CARE RESP M. 27(1):44. I.F.: 2.793 Successful Short Advanced Courses in 5. Vogelmeier CF, Criner GJ, Martinez FJ, Anzueto Systems Medicine and Systems Biology. A, Barnes PJ, Bourbeau J, Celli BR, Chen R, 14. Alberghina N, Sánchez-Montes C, Tuñón CELL SYSTEMS. 5(3):168-175. I.F.: 8.406 Decramer M, Fabbri LM, Frith P, Halpin DM, López C, Maurel J, Araujo IK, Ferrer J, Sendino O, Varela MV, Nishimura M, Roche N, Córdova H, Vaquero EC, González-Suárez B, Rodriguez-Roisin R, Sin DD, Singh D, Stockley R, Martínez-Palli G, Ginès À, Fernández- Editorial / I.F.: 10.569 Vestbo J, Wedzicha JA, Agusti A. Global Strategy Esparrach G. Endoscopic ultrasonography for the Diagnosis, Management and can avoid unnecessary laparotomies in 1. Rodriguez-Roisin R, Rabe KF, Vestbo J, Prevention of Chronic Obstructive Lung patients with pancreatic adenocarcinoma Vogelmeier C, Agustí A, all previous and Disease 2017 Report: GOLD Executive and undetected peritoneal carcinomatosis. current members of the Science Committee Summary. RESPIROLOGY. 22(3):575-601. PANCREATOLOGY. 17(5):858-864. I.F.: 2.580 and the Board of Directors of GOLD I.F.: 3.256 (goldcopd.org/committees/). Global 15. McLaughlin, Vallerie V.; Jansa, Pavel; Initiative for Chronic Obstructive Lung 6. Vogelmeier CF, Criner GJ, Martínez FJ, Anzueto Nielsen-Kudsk, Jens E.; Halank, Michael; Disease (GOLD) 20th Anniversary: a brief A, Barnes PJ, Bourbeau J, Celli BR, Chen R, Simonneau, Gerald; Gruenig, Ekkehard; Ulrich, history of time. EUROPEAN RESPIRATORY Decramer M, Fabbri LM, Frith P, Halpin DM, López Silvia; Rosenkranz, Stephan; Gomez Sanchez, JOURNAL. 50(1):1700671. I.F.: 10.569 Varela MV, Nishimura M, Roche N, Miguel A.; Pulido, Tomas; Pepke-Zaba, Rodríguez-Roisin R, Sin DD, Singh D, Stockley R, Joanna; Albert Barbera, Joan; Hoeper, Marius Vestbo J, Wedzicha JA, Agustí A. Global Strategy M.; Vachiery, Jean-Luc; Lang, Irene; Carvalho, Clinical Guidelines / I.F.: 51.146 for the Diagnosis, Management, and Francine; Meier, Christian; Mueller, Katharina; Prevention of Chronic Obstructive Lung Nikkho, Sylvia; D'Armini, Andrea M. Riociguat 1. Vogelmeier CF, Criner GJ, Martinez FJ, Disease 2017 Report: GOLD Executive in patients with chronic thromboembolic Anzueto A, Barnes PJ, Bourbeau J, Celli BR, Summary. ARCHIVOS DE pulmonary hypertension: results from an Chen R, Decramer M, Fabbri LM, Frith P, Halpin BRONCONEUMOLOGIA. 53(3):128-149. early access study. BMC PULMONARY DM, López Varela MV, Nishimura M, Roche N, I.F.: 2.979 MEDICINE. 17(1):216. I.F.: 2.435 Rodriguez-Roisin R, Sin DD, Singh D, Stockley R, Vestbo J, Wedzicha JA, Agustí A. Global 16. Rodríguez DA, Kortianou EA, Alison JA, Strategy for the Diagnosis, Management, Consortium Publications / I.F.: 7.05 Casas A, Giavedoni S, Barberan-Garcia A, and Prevention of Chronic Obstructive Lung Arbillaga A, Vilaró J, Gimeno-Santos E, Disease 2017 Report. GOLD Executive 1. Sakr, Yasser; Birri, Paolo Nahuel Rubatto; Kotﬁs, Gimeno-Santos E, Vogiatzis I, Vogiatzis I, Summary. AMERICAN JOURNAL OF Katarzyna; Nanchal, Rahul; Shah, Bhagyesh; Kluge, Rabinovich R, Roca J. Heart Rate Recovery RESPIRATORY AND CRITICAL CARE Stefan; Schroeder, Mary E.; Marshall, John C.; After 6-min Walking Test Predicts Acute MEDICINE. 195(5):557-582. I.F.: 13.204 Vincent, Jean-Louis; Intensive Care Over Nations. Exacerbation in COPD. LUNG. Higher Fluid Balance Increases the Risk of 195(4):463-467. I.F.: 1.915 2. Vogelmeier CF, Criner GJ, Martinez FJ, Death From Sepsis: Results From a Large Anzueto A, Barnes PJ, Bourbeau J, Celli BR, International Audit. CRITICAL CARE Chen R, Decramer M, Fabbri LM, Frith P, Halpin MEDICINE. 45(3):386-394. I.F.: 7.050

124 PHYSIOPATHOLOGICAL MECHANISMS OF RESPIRATORY ILLNESSES 2.7

GRANTS FOR RESEARCH IN PROGRESS Roca J. Atenció personalitzada del malalt crònic en un marc de salut digital. Barberà JA. Plataformas de apoyo a la Sponsored by: Fundació Eurecat. Investigación en Ciencias y Tecnologías de COMRDI15-1-0016-08 la Salud. Red de Biobanco. Duration: 15/10/2016-15/10/2019 Sponsored by: Instituto de Salud Carlos III (ISCIII). PT13/0010/0011 Roca J. Plataforma de innovación en Duration: 01/01/2014-30/06/2018 telemedicina y e-salud: TIC para los retos de I+i en servicios de salud. PITES-TliSS. Barberà JA. Gestión en red de pacientes Sponsored by: Instituto de Salud Carlos III. con Enfermedades Raras: la Hipertensión PI15/00576 Pulmonar como caso de uso (GERAR). Duration: 01/01/2016-31/12/2018 Sponsored by: MINECO (RETOS), Ref RTC-2015-4137-1 Roca J. Advancing Care Coordination and Duration: 01/09/2015-31/08/2018 Telehealth deployment at Scale. Sponsored by: European Commission Health Barberà JA. Proliferación celular en la Program-2015. hipertensión pulmonar: detección y Duration: 04/03/2016-03/03/2019 mecanismos de regulación epigenética. Sponsored by: Instituto de Salud Carlos III. PI15/00582 DOCTORAL THESES Duration: 01/01/2016-31/12/2018 Barberà JA, Peinado V. Remodelat vascular Blanco I. Estudio del papel de la survivina en a les malalties pulmonars: perﬁl la patogénesis de la hipertensión arterial d’expressió gènica i biomarcadors. pulmonar y su empleo como potencial PhD student: Jéssica García Lucio diana terapéutica. Sponsored by Instituto de Salud Carlos III Roca J, Blanco I. Deployment of novel (ISCIII). PI14/00782 integrated care services to promote Duration: 01/01/2015-31/12/2017 healthy lifestyle: physical activity as a use case. Martinez G. Efectividad de una intervención PhD student: Anael Barberán Garcia de entrenamiento físico personalizado (prehabilitación) en pacientes de alto riesgo quirúrgico sobre la incidencia de complicaciones postoperatorias: ensayo controlado aleatorizado. Sponsored by Instituto de Salud Carlos III (ISCIII). PI13/00425 Duration: 01/01/2014-31/12/2016

Roca J. Sustainable intEgrated care modeLs for multi-morbidity: delivery, FInancing and performance. Sponsored by: European Commission H2020_PHC-2014 Duration: 01/09/2015-30/08/2018

Roca J. Personalised Connected Care for Complex Chronic Patients. Sponsored by: European Commission H2020_PHC-2015 Duration: 01/04/2016-30/09/2019

Roca J. KONFIDO - Secure and Trusted Paradigm for Interoperable eHealth Services. Sponsored by: European Commission H2020_DS-2016 Duration: 01/11/2016-31/10/2019

125 AREA 2 RESPIRATORY, CARDIOVASCULAR AND RENAL PATHOBIOLOGY AND BIOENGINEERING

Clinical and experimental 2.8 respiratory immunoallergy

Jordi Roca (UB) Eva Serrano (FCRB) LOCATION María del Carmen Vennera (CIBER) CELLEX building 2B

PRE-DOCTORAL RESEARCHERS Giovanna Araujo (FCRB) WEB Marina Bantulà (FCRB) www.idibaps.org/research/605/ Sònia Gelis (HCB) clinical-and-experimental- Federico de la Roca (FCRB) respiratory-immunoallergy-irce Alba Garcia (FCRB) TEAM LEADER Adriana Izquierdo (UB) Joaquim Mullol (IDIBAPS) Cristóbal Langdon (HCB) T. 93 227 98 72 Eduardo Lehrer (UB) Mauricio López (HCB) [email protected] Paula Mackers (HCB) KEYWORDS 1. Chronic rhinosinusitis Arnau Navinés (UB) Paula Ribo (HCB-IDIBAPS) and nasal polyps RESEARCHERS Maria Rueda (UB) 2. Aspirin sensitive asthma Isam Alobid (HCB) Meritxell Valls (HCB) 3. Drug & food allergy Joan Bartra (HCB) 4. Urticaria and mast cells Joaquim Enseñat (HCB) TECHNICIANS 5. Endoscopic & skull base surgery Maria Concepció Marín (IDIBAPS) Sílvia Centellas (HCB) Margarita Martín (UB) Rosa Cortés (HCB) Rosa Maria Muñoz (HCB) Rossó de Lluís (FCRB) Mariona Pascal (HCB) Mireya Fuentes (IDIBAPS) César Picado (HCB) Gemma López (FCRB) Original publications Laura Pujols (IDIBAPS) Maria Pérez (FCRB) from 2015 to 2017 Antonio Valero (HCB) Antoni Xaubet (HCB) ADMINISTRATIVE STAFF YEAR I.F. TOTAL Q1 Q2 Elena Arrufat (FCRB) 2015 82.40 24 13 6 POST-DOCTORAL RESEARCHERS Paola Cucagna (FCRB) Ebymar Arismendi (CIBER) 2016 151.13 26 14 5 Joan Berenguer (HCB) VISITING SCIENTISTS 2017 152.51 35 22 9 Manuel Bernal (HCB) Carla Pereira (Universiad de Chile, Chile) Irina Bobolea (HCB) Silvia Riggioni (London Imperial College, UK) Borja Callejas (IDIBAPS) Laura Van Gerven (Leuven University, Belgium) Josep M. Guillemany (HCB) TEAM INVOLVED IN AGAUR_SGR14 AGAUR_SGR17 CIBER_CIBERES RETIC_RIRAAF RETIC_ARADYAL

AWARDS Best poster Asthma Section Institution: European Academy of Allergoly and Clinical Immunology Awardee/s: De la cruz CA, Guillen-Vera D, Revilla Y, Alonso S, Morales R, Pérez M, Diaz R, Melero C, Fernández C, Bobolea I

Best communication in Asthma Institution: Sociedad Española de Patología Respiratoria – SEPAR

Awardee/s: Bobolea I Joquim Mullol TEAM

126 CLINICAL AND EXPERIMENTAL RESPIRATORY IMMUNOALLERGY 2.8

STRATEGIC OBJECTIVES RESEARCH GROUP O'Donnell DE, Agustí A. Different dyspnoea SINONASAL INFLAMMATORY AND perception in COPD patients with frequent 1. To investigate mechanisms regulating OLFACTORY RESEARCH GROUP and infrequent exacerbations. THORAX. inflammatory response and remodelling in (INGENIO) 72(2):117-121. I.F.: 8.272 asthma, rhinitis, rhinosinusitis/polyposis. 2. To investigate mechanisms underlying 4. Bousquet J., Bewick M., Arnavielhe S., food and drug allergies. Mathieu-Dupas E., Murray R., Bedbrook A., 3. To investigate mechanisms involved in Caimmi D., Vandenplas O., Hellings P., Bachert anaphylaxis and mast cell physiology. C., … …, Devillier P. Work productivity in 4. To investigate mechanisms of smell loss: rhinitis using cell phones: The MASK pilot sinonasal inflammation, Traumatic Brain study. ALLERGY. 72(10):1475-1484. I.F.: 7.361 Injury, Parkinson Disease, iatrogenic, GROUP LEADER idiopathic. Joaquim Mullol (IDIBAPS) 5. Valero A, Quirce S, Dávila I, Delgado J, Domínguez-Ortega J. Allergic respiratory 1. Upper airway diseases (rhinitis, disease: Different allergens, different MAIN LINES OF RESEARCH rhinosinusitis, nasal polyps): A) regulation of symptoms. ALLERGY. 72(9):1306-1316. mucins and MUC genes; and B) impact on I.F.: 7.361 1. Inflammation of the Upper and quality of life. Lower respiratory mucosa. 6. Colás C, Brosa M, Antón E, Montoro J, Mechanisms involved in sinonasal and 2. Olfactory disorders and their mechanisms Navarro A, Dordal MT, Dávila I, bronchial development, inflammation, of action: A) validation of new adult (BOT-8) Fernández-Parra B, Ibáñez MDP, Lluch-Bernal and remodelling. and children (pBOT-6) olfactometries; and B) M, Matheu V, Rondón C, Sánchez MC, Valero mechanisms of smell loss and its recovery in A, Rhinoconjunctivitis Committee of the 2. Sense of smell in health and disease. sinonasal diseases, traumatic brain injury, and Spanish Society of Allergy and Clinical Mechanisms involved in olfactory neurodegenerative diseases. Immunology. Estimate of the total costs of dysfunctions (rhinitis, rhinosinusitis, allergic rhinitis in specialized care based septal perforation) and neurogenesis of 3. Human in vitro model of eosinophilic on real-world data: the FERIN Study. sinonasal diseases, Traumatic Brain Injury, inflammation to test / compare medication ALLERGY. 72(6):959-966. I.F.: 7.361 and neurodegenerative (Parkinson) antiinflammatory effects: corticosteroids, diseases. antihistamines, antileukotrienes, MP-AzeFlu. 7. Serrano-Pariente J, Plaza V, Soriano JB, Mayos M, López-Viña A, Picado C, Vigil L, 3. Food and drug allergy. 4. Stem/progenitor respiratory epithelial / CPASMA Trial Group. Asthma outcomes Genetic, immunological, and biochemical neuroepithelial cell differentiation and improve with continuous positive airway mechanisms of respiratory, food, and drug regenerative medicine in ALI culture model. pressure for obstructive sleep apnoea. allergy. ALLERGY. 72(2017):802-812. I.F.: 7.361

4. Glucocorticoid resistance. PUBLICATIONS 8. Plaschke C, Bertino G, McCaul J, Grau J, de Mechanisms and biomarkers involved in Bree R, Sersa G, Occhini A, Groselj A, Langdon glucocorticoid resistance of respiratory and Originals / I.F.: 152.506 C, Heuveling D, Cemazar M, Strojan P, non-respiratory diseases. Leemans C, Benazzo M, De Terlizzi F, Wessel 1. Faber MA; Van Gasse AL; Decuyper II; I, Gehl J. European Research on 5. Aspirin and Non-Steroidal Uyttebroek A; Sabato V; Hagendorens MM; Electrochemotherapy in Head and Neck Antiinflammatory Drug (NSAID) Bridts CH; De Clerck LS; Fernandez-Rivas M; Cancer (EURECA) project: Results from intolerance. Pascal M; Díaz-Perales A; Ebo DG. the treatment of mucosal cancers. Mechanisms of allergy and cofactors, IgE-reactivity profiles to nonspecific lipid EUROPEAN JOURNAL OF CANCER. regulation of cyclooxygenase, leukotriene transfer proteins in a northwestern 87:172-181. I.F.: 6.029 and prostaglandins (PGE2) and their European country. JOURNAL OF ALLERGY receptors. AND CLINICAL IMMUNOLOGY. 9. Caimmi D, Baiz N, Tanno LK, Demoly P, 139(2):679-682.e5. I.F.: 13.081 Arnavielhe S, Murray R, Bedbrook A, 6. Pathophysiology of eosinophils, mast Bergmann KC, De Vries G, Fokkens WJ, cells, and basophils. 2. Munoz-Cano R, Torrego A, Bartra J, Fonseca J, Haahtela T, Keil T, Kuna P, Mullol J, Anaphylactic reactions (mastocytosis, Sanchez-Lopez J, Palomino R, Picado C, Papadopoulos N, Passalacqua G, Samolinski adapter molecules in the signaling of IgE). Valero A. Follow-up of patients with B, Tomazic PV, Valiulis A, van Eerd M, Antiinflammatory drugs in eosinophils and uncontrolled asthma: clinical features of Wickman M, Annesi-Maesano I, Bousquet J, epithelial cells (corticosteroids,MP-AzeFlu), asthma patients according to the level of MASK Study Group. Validation of the and mast cell and basophils (omalizumab). control achieved (the COAS study). EUR MASK-rhinitis visual analogue scale on RESPIR J. 49(3):1501885. I.F.: 10.569 smartphone screens to assess allergic 4. Skull Base tumours. rhinitis control. CLINICAL AND Impact of skull base tumours in quality of life 3. Scioscia G, Blanco I, Arismendi E, Burgos F, EXPERIMENTAL ALLERGY. 47(12):1526-1533. and olfaction. Different surgical approaches. Gistau C, Foschino Barbaro MP, Celli B, I.F.: 5.264

127 AREA 2 RESPIRATORY, CARDIOVASCULAR AND RENAL PATHOBIOLOGY AND BIOENGINEERING

10. Martínez-Barriocanal Á, Arcas-García A, competitive swimmers: Beneficial effect of 23. Giménez A, Duch P, Puig M, Gabasa M, Magallon-Lorenz M, Ejarque-Ortíz A, a new method to reduce chlorine oxidant Xaubet A, Alcaraz J. Dysregulated Collagen Negro-Demontel ML, Comas-Casellas E, derivatives. ENVIRON RES. 152:315-321. Homeostasis by Matrix Stiffening and Schwartz S, Malhotra S, Montalban X, Peluffo I.F.: 3.835 TGF-β1 in Fibroblasts from Idiopathic H, Martín M, Comabella M, Sayós J. Effect of Pulmonary Fibrosis Patients: Role of Specific Mutations in Cd300 Complexes 17. Valls-Mateus M, Marino-Sanchez F, FAK/Akt. INT J MOL SCI. 18(11). I.F.: 3.226 Formation; Potential Implication of Ruiz-Echevarría K, Cardenas-Escalante P, Cd300f in Multiple Sclerosis. SCIENTIFIC Jiménez-Feijoo R, Blasco-Lozano J, 24. Munoz-Cano R, Ainsua-Enrich E, REPORTS. 7(1):13544. I.F.: 4.259 Giner-Muñoz MT, Haag O, Alobid I, Plaza Torres-Atencio I, Martin M, Sánchez-Lopez J, Martin AM, Mullol J. Nasal obstructive Bartra J, Picado C, Mullol J, Valero A. Effects 11. Serrano-Candelas E, Martínez-Aranguren disorders impair health-related quality of of rupatadine on Platelet activating factor R, Vega O, Gastaminza G, Bartra J, Audicana life in adolescents with persistent allergic (PAF)-induced human mast cell MT, Núñez-Córdoba JM, Algorta J, Valero A, rhinitis: a real-life study. PEDIATRIC degranulation compared with Martin M, Ferrer M. Omalizumab efficacy in ALLERGY AND IMMUNOLOGY. desloratadine and levocetirizine (The cases of chronic spontaneous urticaria is 28(5):438-445. I.F.: 3.775 MASPAF study). JOURNAL OF not explained by the inhibition of sera INVESTIGATIONAL ALLERGOLOGY AND activity in effector cells. SCIENTIFIC 18. Mariño-Sánchez FS, Valls-Mateus M, CLINICAL IMMUNOLOGY. 27(3):161-168. REPORTS. 7(1):8985. I.F.: 4.259 Ruiz-Echevarría K, Alobid I, I.F.: 3.094 Cardenas-Escalante P, Jiménez-Feijoo R, 12. Campillo, Noelia; Torres, Marta; Vilaseca, Lozano-Blasco J, Giner-Muñoz MT, 25. Pérez-Alzate D, Cornejo-García J, Antoni; Naomi Nonaka, Paula; Gozal, David; Rodríguez-Jorge J, Haag O, Plaza-Martin AM, Pérez-Sánchez N, Andreu I, García-Moral A, Roca-Ferrer, Jordi; Picado, Cesar; Maria Mullol J. Nasal obstructive disorders induce Agúndez J, Bartra J, Doña I, Torres M, Blanca Montserrat, Josep; Farre, Ramon; Navajas, medical treatment failure in paediatric M, Blanca-López N, Canto G. Immediate Daniel; Almendros, Isaac. Role of persistent allergic rhinitis (The NODPAR reactions to more than 1 NSAID must not cyclooxygenase-2 on intermittent Study). PEDIATR ALLERGY IMMUNOL. be considered cross-hypersensitivity hypoxia-induced lung tumor malignancy in 28(2):176-184. I.F.: 3.775 unless tolerance to asa is verified. a mouse model of sleep apnea. SCIENTIFIC JOURNAL OF INVESTIGATIONAL REPORTS. 7:44693. I.F.: 4.259 19. Vilaseca I, Valls-Mateus M, Nogués A, ALLERGOLOGY AND CLINICAL Lehrer E, López-Chacón M, Avilés-Jurado FX, IMMUNOLOGY. 27(1):32-39. I.F.: 3.094 13. Di Somma A, Cavallo L, De Notaris M, Blanch JL, Bernal-Sprekelsen M. Usefulness Solari D, Topczewski T, Bernal-Sprekelsen M, of office examination with narrow band 26. García S., Reyes L., Roldán P., Torales J., Enseñat J, Prats-Galino A, Cappabianca P. imaging for the diagnosis of head and neck Halperin I., Hanzu F., Langdon C., Alobid I., Endoscopic endonasal medial-to-lateral squamous cell carcinoma and follow-up of Enseñat J. Does Low-Field Intraoperative and transorbital lateral-to-medial optic premalignant lesions. HEAD AND NECK. Magnetic Resonance Improve the Results nerve decompression: An anatomical 39(9):1854-1863. I.F.: 3.376 of Endoscopic Pituitary Surgery? study with surgical implications. JOURNAL Experience of the Implementation of a OF NEUROSURGERY. 127(1):199-208. I.F.: 4.059 20. Marin C., Laxe S., Langdon C., Berenguer New Device in a Referral Center. WORLD J., Lehrer E., Mariño-Sánchez F., Alobid I., NEUROSURGERY. 102:102-110. I.F.: 2.592 14. Ruggeri A, Enseñat J, Prats-Galino A, Bernabeu M., Mullol J. Olfactory function in Lopez-Rueda A, Berenguer J, Cappelletti M, an excitotoxic model for secondary 27. Aranda, Gloria; Lopez, Cristina; De Notaris M, D'Avella E. Endoscopic neuronal degeneration: Role of Fernandez-Ruiz, Rebeca; Esteban, Yaiza; endonasal control of the paraclival internal dopaminergic interneurons. Garcia-Eguren, Guillermo; Mora, Mireia; carotid artery by Fogarty balloon catheter NEUROSCIENCE. 364:28-44. I.F.: 3.277 Halperin, Irene; Casals, Gregori; Ensenat, inflation: An anatomical study. JOURNAL Joaquim; Hanzu, Felicia A. Circulatory OF NEUROSURGERY. 126(3):872-879. 21. Quiroga-Varela A., Aguilar E., Iglesias E., Immune Cells in Cushing Syndrome: I.F.: 4.059 Obeso J., Marin C. Short- and long-term Bystanders or Active Contributors to effects induced by repeated 6-OHDA Atherometabolic Injury? A Study of 15. Dallan, Iacopo; Di Somma, Alberto; intraventricular administration: A new Adhesion and Activation of Cell Surface Prats-Galino, Alberto; Solari, Domenico; progressive and bilateral rodent model of Markers. INTERNATIONAL JOURNAL OF Alobid, Isam; Turri-Zanoni, Mario; Fiacchini, Parkinson's disease. NEUROSCIENCE. ENDOCRINOLOGY. 2017:2912763. I.F.: 2.510 Giacomo; Castelnuovo, Paolo; Catapano, 361:144-156. I.F.: 3.277 Giuseppe; de Notaris, Matteo. Endoscopic 28. Santamaría A, Langdon C, López-Chacon transorbital route to the cavernous sinus 22. Navarro, Ana M.; Delgado, Julio; M, Cordero A, Enseñat J, Carrau R, through the meningo-orbital band: a Munoz-Cano, Rosa M.; Dordal, M. Teresa; Bernal-Sprekelsen M, Alobid I. Radio- descriptive anatomical study. JOURNAL OF Valero, Antonio; Quirce, Santiago; ARD Study anatomical analysis of the pericranial flap NEUROSURGERY. 127(3):622-629. I.F.: 4.059 Grp. Allergic respiratory disease (ARD), "money box approach" for ventral skull setting forth the basics: proposals of an base reconstruction. LARYNGOSCOPE. 16. Gomà A, de Lluis R, Roca-Ferrer J, expert consensus report. CLINICAL AND 127(11):2482-2489. I.F.: 2.471 Lafuente J, Picado C. Respiratory, ocular TRANSLATIONAL ALLERGY. 7(1):16. I.F.: 3.239 and skin health in recreational and 29. Del Cuvillo, Alfonso; Santos, Vanessa;

128 CLINICAL AND EXPERIMENTAL RESPIRATORY IMMUNOALLERGY 2.8

Montoro, Javier; Bartra, Joan; Davila, Ignacio; Review / I.F.: 44.191 Manole F., Hupin C., Fokkens W., Akdis C., Ferrer, Marta; Jauregui, Ignacio; Sastre, Bachert C., Demoly P., Mullol J., Muraro A., Joaquin; Mullol, Joaquim; Valero, Antonio. 1. Klimek L, Koennecke M, Mullol J, Hellings Papadopoulos N., Pawankar R., Rombaux P., Allergic rhinitis severity can be assessed PW, Wang DY, Fokkens W, Gevaert P, Toskala E., Kalogjera L., Prokopakis E., using a visual analocue scale in mild, Wollenberg B. A possible role of stem cells Hellings P., Bousquet J. Multi-morbidities moderate and severe. RHINOLOGY. in nasal polyposis. ALLERGY. of allergic rhinitis in adults: European 55(1):34-38. I.F.: 2.350 72(12):1868-1873. I.F.: 7.361 Academy of Allergy and Clinical Immunology Task Force Report. CLINICAL 30. Izquierdo-Dominguez A, Jauregui I, Del 2. Bousquet J, Caimmi DP, Bedbrook A, AND TRANSLATIONAL ALLERGY. 7(1):17 Cuvillo A, Montoro J, Davila I, Sastre J, Bartra J, Bewick M, Hellings PW, Devillier P, Arnavielhe I.F.: 3.239 Ferrer M, Alobid I, Mullol J, Valero AL. Allergy S, Bachert C, Bergmann KC, Canonica GW, … rhinitis: similarities and differences …, Zuberbier T. Pilot study of mobile phone 8. Hellings PW, Akdis CA, Bachert C, between children and adults. RHINOLOGY. technology in allergic rhinitis in European Bousquet J, Pugin B, Adriaensen G, Advani R, 55(4):326-331. I.F.: 2.350 countries. The MASK-rhinitis study. Agache I, Anjo C, Anmolsingh R, … …, Fokkens ALLERGY. 72(6):857-865. I.F.: 7.361 WJ. EUFOREA Rhinology Research Forum 31. Caballero M, Mackers P, Reig O, Buxo E, 2016: report of the brainstorming sessions Navarrete P, Blanch JL, Grau JJ. The Role of 3. Faber MA, Pascal M, El Kharbouchi O, on needs and priorities in rhinitis and Audiometry prior to High-Dose Cisplatin in Sabato V, Hagendorens MM, Decuyper II, rhinosinusitis. RHINOLOGY. Patients with Head and Neck Cancer. Bridts CH, Ebo DG. Shellfish allergens: 55(3):1297-1305. I.F.: 2.350 ONCOLOGY. 93(2):75-82. I.F.: 2.262 Tropomyosin and beyond. ALLERGY: EUROPEAN JOURNAL OF ALLERGY AND 9. Fokkens WJ, Bachert C, Bernal-Sprekelsen 32. Klimek L, Poletti SC, Sperl A, Spielhaupter CLINICAL IMMUNOLOGY. 72(6):842-848. M, Bousquet J, Djandji M, Dorenbaum A, M, Bardenhewer C, Mullol J, Hörmann K, I.F.: 7.361 Hakimi-Mehr D, Hendry S, Hopkins C, Leunig Hummel T. Olfaction in patients with A, Mannent L, Mucha D, Onerci M, Pugin B, allergic rhinitis: an indicator of successful 4. Munoz-Cano, Rosa; Pascal, Mariona; Toppila-Salmi S, Rowe P, Seys SF, Stimson S, MP-AzeFlu therapy. INT FORUM ALLERGY Araujo, Giovanna; Goikoetxea, M. J.; Valero, Strzembosz A, Hellings PW. Rhinology RH. 7(3):287-292. I.F.: 2.135 Antonio L.; Picado, Cesar; Bartra, Joan. Future Debates, an EUFOREA Report. Mechanisms, Cofactors, and Augmenting RHINOLOGY. 55(4):298-304. I.F.: 2.350 33. Oker N, Alotaibi N, Reichelt A, Herman P, Factors Involved in Anaphylaxis. Bernal-Sprekelsen M, Albers A. European FRONTIERS IN IMMUNOLOGY. 8(SEP):1193. 10. Xaubet A, Ancochea J, Molina-Molina M. otorhinolaryngology training programs: I.F.: 6.429 Idiopathic pulmonary fibrosis. MED CLIN results of a European survey about training (BARC). 148(4):170-175. I.F.: 1.125 satisfaction, work environment and 5. López F, Triantafyllou A, Snyderman C, conditions in six countries. EUROPEAN Hunt J, Suárez C, Lund V, Strojan P, Saba N, ARCHIVES OF OTO- RHINO- LARYNGOLOGY. Nixon I, Devaney K, Alobid I, Bernal– Clinical Guidelines / I.F.: 26.515 274(11):4017-4029. I.F.: 1.660 Sprekelsen M, Hanna E, Rinaldo A, Ferlito A. Nasal juvenile angiofibroma: Current 1. Brozek J., Bousquet J., Agache I., Agarwal A., 34. Gimenez-Arnau, A.; Ferrer, M.; Bartra, J.; perspectives with emphasis on Bachert C., Bosnic-Anticevich S., Jauregui, I.; Labrador-Horrillo, M.; Ortiz de management. HEAD AND NECK. Brignardello-Petersen R., Canonica G., Casale Frutos, J.; Silvestre, J. F.; Sastre, J.; Velasco, M.; 39(5):1033-1045. I.F.: 3.376 T., Chavannes N., … …, Hellings P. Allergic Valero, A. Management of chronic Rhinitis and its Impact on Asthma (ARIA) spontaneous urticaria in routine clinical 6. Bousquet J; Onorato GL; Bachert C; guidelines-2016 revision. JOURNAL OF practice: A Delphi-method questionnaire Barbolini M; Bedbrook A; Bjermer L; de Sousa ALLERGY AND CLINICAL IMMUNOLOGY. among specialists to test agreement with JC; Chavannes NH; Cruz AA; De Manuel 140(4):950-958. I.F.: 13.081 current European guidelines statements. Keenoy E; Devillier P; Fonseca J; Hun S; ALLERGOLOGIA ET IMMUNOPATHOLOGIA. Kostka T; Hellings PW; Illario M; Ivancevich 2. Hellings PW, Fokkens WJ, Bachert C, Akdis 45(2):134-144. I.F.: 1.439 JC; Larenas-Linnemann D; Millot-Keurinck CA, Bieber T, Agache I, Bernal-Sprekelsen M, J; Ryan D; Samolinski B; Sheikh A; Canonica GW, Gevaert P, Joos G, Lund V, 35. Mariño-Sánchez F., Valls-Mateus M., Yorgancioglu A; Agache I; Arnavielhe S; Muraro A, Onerci M, Zuberbier T, Pugin B, Cardenas-Escalante P., Haag O., Bewick M; Annesi-Maesano I; Antó JM; Seys SF, Bousquet J, ARIA and EPOS working Ruiz-Echevarría K., Jiménez-Feijoo R., Bergmann KC; Bindslev-Jensen C; groups. Positioning the principles of Lozano-Blasco J., Giner-Muñoz M., Bosnic-Anticevich S. CHRODIS criteria precision medicine in care pathways for Plaza-Martin A., Mullol J. Influence of nasal applied to the MASK (MACVIA-ARIA allergic rhinitis and chronic rhinosinusitis – septum deformity on nasal obstruction, Sentinel NetworK) Good Practice in A EUFOREA-ARIA-EPOS-AIRWAYS ICP disease severity, and medical treatment allergic rhinitis: a SUNFRAIL report. statement. ALLERGY. 72(9):1297-1305. I.F.: response among children and adolescents CLINICAL AND TRANSLATIONAL 7.361 with persistent allergic rhinitis. ALLERGY. 2017(7):37. I.F.: 3.239 INTERNATIONAL JOURNAL OF PEDIATRIC 3. Quirce S, Delgado J, Entrenas LM, Grande OTORHINOLARYNGOLOGY. 95:145-154. 7. Cingi C., Gevaert P., Mösges R., Rondon C., M, Llorente C, López Viña A, Martínez I.F.: 1.159 Hox V., Rudenko M., Muluk N., Scadding G., Moragón E, Mascarós E, Molina J, Olaguibel

129 AREA 2 RESPIRATORY, CARDIOVASCULAR AND RENAL PATHOBIOLOGY AND BIOENGINEERING

JM, Pérez de Llano LA, Perpiñá Tordera M, Utilidad clínica y valor pronóstico de la Quintano JA, Rodríguez M, Román-Rodriguez periostina, en vistas al tratamiento M, Sastre J, Trigueros JA, Valero AL, Zoni AC, personalizado. Plaza V, ASMAFORUM II Group. Quality Sponsored by: Instituto de Salud Carlos III. indicators of asthma care derived from the PI14/00711 spanish guidelines for asthma Duration: 06/06/2017-31/12/2019 management (GEMA 4.0): A multidisciplinary team report. JOURNAL OF Mullol J. Función reguladora de los INVESTIGATIONAL ALLERGOLOGY AND microRNA sobre los genes diana CLINICAL IMMUNOLOGY. 27(1):69-73. involucrados en la diferenciación epitelial I.F.: 3.094 de la mucosa nasosinusal en la poliposis nasal. 4. Xaubet A, Molina-Molina M, Acosta O, Bollo Sponsored by: Instituto de Salud Carlos III. E, Castillo D, Fernández-Fabrellas E, PI15/00046 Rodríguez-Portal JA, Valenzuela C, Ancochea Duration: 01/01/2016-31/12/2018 J. Guidelines for the medical treatment of idiopathic pulmonary fibrosis. ARCH Muñoz-Cano R. Estudios de los BRONCONEUMOL. 53(5):263-269. I.F.: 2.979 mecanismos patogénicos en la anafilaxia inducida por alimentos y exacerbada oir antiinflamatorios no esteroideos (AINEs). Consortium Publications / I.F.: 3.841 Sponsored by: Instituto de Salud Carlos III. PI16/00696 1. Pérez-de-Llano L., Cosio B., Iglesias A., de Duration: 01/01/2017-31/12/2019 las Cuevas N., Soler-Cataluña J., Izquierdo J., López-Campos J., Calero C., Plaza V., Pascal M, Bartra J (Co-IPs). Síndrome LTP: Miravitlles M., Torrego A., Moragón E., Soriano identificación y caracterización clínica de J., Viña A., Bobolea I. Asthma-COPD overlap los epítopos inmunodominantes B y T y su is not a homogeneous disorder: Further presentación antigénica HLA. supporting data. RESPIRATORY Sponsored by: Instituto de Salud Carlos III. RESEARCH. 18(1):467. I.F.: 3.841 PI16/00344 Duration: 01/01/2017-31/12/2019

Pujols L. Identificación de biomarcadores GRANTS FOR RESEARCH IN PROGRESS asociados a la resistencia a los corticoides en la rinosinusitis crónica con pólipos Alobid I. El impacto de la inflamación sobre nasales. el sentido del olfato en pacientes con Sponsored by: Instituto de Salud Carlos III. poliposis nasal: el rol de los eosinófilos PI13/01228 sobre la neurogenesis del neuroepitelio Duration: 01/01/2014-31/12/2017 olfatorio. Sponsored by: Instituto de Salud Carlos III Pujols L. Caracterización funcional de (ISCIII). PI15/00262 biomarcadores asociados a la Duration: 01/01/2016-31/12/2018 insensibilidad al tratamiento con corticoides intranasales en la rinosinusitis Bartra J. Red de Investigación de crónica con pólipos nasales. Reacciones Adversas a Alérgenos y Sponsored by: Instituto de Salud Carlos III. Fármacos. PI16/00935 Sponsored by: Instituto de Salud Carlos III. Duration: 01/01/2017-31/12/2019 RD12/0013/0012 Duration:01/01/2013-30/03/2017

Bartra J. Asma, reacciones adversas y DOCTORAL THESES alérgicas (ARADYAL). Sponsored by: Instituto de Salud Carlos III. Alobid I, Enseñat J. Hallazgos clínicos y RD16/0006/0007 radiológicos tras la cirugía endoscópica de Duration: 01/01/2017-31/12/2021 la base de cráneo. PhD student: Elena Rioja Peñaranda Bobolea I. Identiﬁcación de biomarcadores no invasivos asociados a los distintos fenotipos y endotipos de asma descritos.

130 INFLAMMATION AND REPAIR IN RESPIRATORY ILLNESSES 2.9

Inﬂammation and repair 2.9 in respiratory illnesses

STRATEGIC OBJECTIVES

LOCATION The objective of the group is to investigate the CELLEX building 2A biological processed underling the clinical heterogeneity and complexity of chronic obstructive pulmonary disease (COPD) and lung cancer. To investigate the clinical functional correlation and the diagnostic, prognostic and therapeutic value the group KEYWORDS uses systems network methods. 1. COPD TEAM LEADER 2. Emphysema Alvar Agustí (HCB) 3. Inﬂammation T. 93 227 17 01 MAIN LINES OF RESEARCH 4. Networks [email protected] 5. Systems biology 1. Mechanism of abnormal repair in COPD related to the inﬂammation present in COPD patients. RESEARCHERS 2. Mechanisms of oncogenesis in COPD. Eugenio Ballester (HCB) 3. Application systems biology to COPD to Rosa Faner (CIBER) understand its natural history. Original publications Abel Gómez-Caro (HCB) Ramon Marrades (HCB) from 2015 to 2017 PRE-DOCTORAL RESEARCHERS YEAR I.F. TOTAL Q1 Q2 PUBLICATIONS Sandra Casas (FCRB) 2015 165.96 20 12 5 Tamara Cruz (FCRB) Originals / I.F.: 93.589 2016 111.89 18 11 4 Sandra Cuerpo (HCB) Alejandra López (HCB) 2017 93.59 15 12 2 1. Agustí A., Noell G., Brugada J., Faner R. Guillaume Noel (FCRB) Lung function in early adulthood and

TECHNICIANS health in later life: a transgenerational Tamara García (CIBER) cohort analysis. THE LANCET. Gemma Sunyer (CIBER) RESPIRATORY MEDICINE. 5(12):935-945. TEAM INVOLVED IN I.F.: 19.287 CIBERES COLLABORATORS Ángela Guirao (HCB) 2. Noell, Guillaume; Cosio, Borja G.; Faner, Laureano Molins (HCB) Rosa; Monso, Eduard; Peces-Barba, German; de Diego, Alfredo; Esteban, Cristobal; Gea,

AWARDS Stars Among Us: Brilliant Science of Alvar Agustí Institution: ATS NEWS Awardee/s: Dr. Alvar Agustí Garcia-Navarro Alvar Agustí TEAM

131 AREA 2 RESPIRATORY, CARDIOVASCULAR AND RENAL PATHOBIOLOGY AND BIOENGINEERING

Joaquim; Rodriguez-Roisin, Robert; transduction alter lung injury in a CARDIO-THORACIC SURGERY. Garcia-Nunez, Marian; Pozo-Rodriguez, bleomycin model. AMERICAN JOURNAL OF 52(6):1206-1210. I.F.: 3.759 Francisco; Kalko, Susana G.; Agusti, Alvar. PHYSIOLOGY - LUNG CELLULAR AND Multi-level differential network analysis of MOLECULAR PHYSIOLOGY. 313(1):L92-L103. 12. Celli B., Blasi F., Gaga M., Singh D., COPD exacerbations. EUROPEAN I.F.: 4.281 Vogelmeier C., Pegoraro V., Caputo N., Agusti RESPIRATORY JOURNAL. 50(3):1700075. A. Perception of symptoms and quality of I.F.: 10.569 8. Obeidat M, Nie Y, Fishbane N, Li X, Bossé Y, life - comparison of patients’ and Joubert P, Nickle DC, Hao K, Postma DS, physicians’ views in the COPD MIRROR 3. McDonald, Merry-Lynn Noelle; Won, Timens W, Sze MA, Shannon CP, Hollander Z, study. INTERNATIONAL JOURNAL OF Sungho; Mattheisen, Manuel; Castaldi, Peter J.; Ng RT, McManus B, Miller BE, Rennard S, COPD. 12:2189-2196. I.F.: 3.157 Cho, Michael H.; Rutten, Erica; Hardin, Megan; Spira A, Hackett TL, Lam W, Lam S, Faner R, Yip, Wai-Ki; Rennard, Stephen I.; Lomas, David Agusti A, Hogg JC, Sin DD, Paré PD. 13. Agustí A., Fernández-Villar A., Capelaste- A.; Wouters, Emiel F. M.; Agusti, Alvar; Integrative Genomics of Emphysema gui A., García-Losa M., Velasco B., Sánchez G. Casaburi, Richard; Lange, Christoph P.; Associated Genes Reveals Potential Validity Study of Catalan, Galician and O'Connor, George; Hersh, Craig P.; Silverman, Disease Biomarkers. AMERICAN JOURNAL Basque Language Versions of the COPD Edwin K. Body mass index change in OF RESPIRATORY CELL AND MOLECULAR Assessment Test and Equivalence With gastrointestinal cancer and chronic BIOLOGY. 57(4):411-418. I.F.: 4.100 the Spanish Version. ARCHIVOS DE obstructive pulmonary disease is BRONCONEUMOLOGIA. 53(6):311-317. associated with Dedicator of Cytokinesis 1. 9. Busch R, Hobbs BD, Zhou J, Castaldi PJ, I.F.: 2.979 JOURNAL OF CACHEXIA, SARCOPENIA McGeachie MJ, Hardin ME, Hawrylkiewicz I, AND MUSCLE. 8(3):428-436. I.F.: 9.697 Sliwinski P, Yim JJ, Kim WJ, Kim DK, Agusti A, 14. Agustí A., Compte A., Faner R., Garcia-Ay- Make BJ, Crapo JD, Calverley PM, Donner CF, merich J., Noell G., Cosio B., Rodriguez-Roisin 4. Castaldi PJ, Benet M, Petersen H, Rafaels N, Lomas DA, Wouters EF, Vestbo J, Tal-Singer R., Celli B., Anto J. The EASI model: A first Finigan J, Paoletti M, Marike Boezen H, Vonk R, Bakke P, Gulsvik A, Litonjua AA, Sparrow D, integrative computational approximation JM, Bowler R, Pistolesi M, Puhan MA, Anto J, Paré PD, Levy RD, Rennard SI, Beaty TH, to the natural history of COPD. PLOS ONE. Wauters E, Lambrechts D, Janssens W, Hokanson J, Silverman EK, Cho MH, National 12(10):e0185502. I.F.: 2.806 Bigazzi F, Camiciottoli G, Cho MH, Hersh CP, Emphysema Treatment Trial Genetics, Barnes K, Rennard S, Boorgula MP, Dy J, Evaluation of COPD Longitudinally to Identify 15. Leeming D., Byrjalsen I., Sand J., Bihlet A., Hansel NN, Crapo JD, Tesfaigzi Y, Agusti A, Predictive Surrogate End-Points, International Lange P., Thal-Singer R., Miller B., Karsdal M., Silverman EK, Garcia-Aymerich J. Do COPD COPD Genetics Network, COPDGene Vestbo J., Ivanov Y., Kostov K., Bourbeau J., subtypes really exist? COPD Investigators. Genetic Association and Risk Fitzgerald M., Hernández P., Killian K., Levy R., heterogeneity and clustering in 10 Scores in a COPD Meta-Analysis of 16,707 Maltais F., O'Donnell D., Krepelka J., Wouters independent cohorts. THORAX. Subjects. AM J RESPIR CELL MOL BIOL. E., Quinn D., Bakke P., Kosnik M., Agusti A., … …, 72(11):998-1006. I.F.: 8.272 57(1):35-46. I.F.: 4.100 Krepelka J. Biomarkers of collagen turnover are related to annual change in 5. Scioscia G, Blanco I, Arismendi E, Burgos F, 10. Hardin M, Cho MH, Sharma S, Glass K, FEV1 in patients with chronic obstructive Gistau C, Foschino Barbaro MP, Celli B, Castaldi PJ, McDonald ML, Aschard H, pulmonary disease within the ECLIPSE O'Donnell DE, Agustí A. Different dyspnoea Senter-Sylvia J, Tantisira K, Weiss ST, Hersh study. BMC PULMONARY MEDICINE. 17:164. perception in COPD patients with frequent CP, Morrow JD, Lomas D, Agusti A, Bakke P, I.F.: 2.435 and infrequent exacerbations. THORAX. Gulsvik A, O'Connor GT, Dupuis J, Hokanson J, 72(2):117-121. I.F.: 8.272 Crapo JD, Beaty TH, Laird N, Silverman EK, DeMeo DL, COPDGene and Evaluation of Review / I.F.: 64.357 6. Smid DE, Franssen FME, Gonik M, COPD Longitudinally to Identify Predictive Miravitlles M, Casanova C, Cosio BG, de Surrogate End-Points Investigators. 1. Agusti, Alvar; Celli, Bartolome; Faner, Rosa. Lucas-Ramos P, Marin JM, Martinez C, Mir I, Sex-Based Genetic Association Study What does endotyping mean for treatment Soriano JB, de Torres JP, Agusti A, … …, Spruit Identifies CELSR1 as a Possible Chronic in chronic obstructive pulmonary disease? MA. Redefining Cut-Points for High Obstructive Pulmonary Disease Risk LANCET. 390(10098):980-987. I.F.: 47.831 Symptom Burden of the Global Initiative Locus among Women. AMERICAN for Chronic Obstructive Lung Disease JOURNAL OF RESPIRATORY CELL AND 2. Faner R, Sibila O, Agustí A, Bernasconi E, Classification in 18,577 Patients With MOLECULAR BIOLOGY. 56(3):332-341. Chalmers JD, Huffnagle GB, Manichanh C, Chronic Obstructive Pulmonary Disease. I.F.: 4.100 Molyneaux PL, Paredes R, Pérez Brocal V, JOURNAL OF THE AMERICAN MEDICAL Ponomarenko J, Sethi S, Dorca J, Monsó E. DIRECTORS ASSOCIATION. 11. Guirao Montes, Angela; Molins The microbiome in respiratory medicine: 18(12):1097.e11-1097.e24. I.F.: 5.775 Lopez-Rodo, Laureano; Ramon Rodriguez, current challenges and future perspecti- Ingrid; Sunyer Dequigiovanni, Gemma; Vinolas ves. EUROPEAN RESPIRATORY JOURNAL. 7. Huleihel, Luai; Sellares, Jacobo; Cardenes, Segarra, Nuria; Marrades Sicart, Ramon Maria; 49(4):1602086. I.F.: 10.569 Nayra; Alvarez, Diana; Faner, Rosa; Sakamoto, Hernandez Ferrandez, Jorge; Fibla Alfara, Koji; Yu, Guoying; Kapetanaki, Maria G.; Juan Jose; Agusti Garcia-Navarro, Alvaro. 3. Budinger GRS, Kohanski RA, Gan W, Kobor Kaminski, Naftali; Rojas, Mauricio. Modified Lung cancer diagnosis by trained dogs. MS, Amaral LA, Armanios M, Kelsey KT, Pardo mesenchymal stem cells using miRNA EUROPEAN JOURNAL OF A, Tuder R, Macian F, Chandel N, Vaughan D,

132 INFLAMMATION AND REPAIR IN RESPIRATORY ILLNESSES 2.9

Rojas M, Mora AL, Kovacs E, Duncan SR, Clinical Guidelines / I.F.: 30.008 GRANTS FOR RESEARCH IN PROGRESS Finkel T, Choi A, Eickelberg O, Chen D, Agusti A, Selman M, Balch WE, Busse P, Lin A, 1. Vogelmeier CF, Criner GJ, Martinez FJ, Agustí A. Análisis multinivel en red de las Morimoto R, Sznajder JI, Thannickal VJ. The Anzueto A, Barnes PJ, Bourbeau J, Celli BR, similitudes y diferencias moleculares entre Intersection Of Aging Biology and The Chen R, Decramer M, Fabbri LM, Frith P, enﬁsema y cáncer de pulmón en pacientes Pathobiology of Lung Diseases: A Joint Halpin DM, López Varela MV, Nishimura M, con enfermedad pulmonar obstructiva NHLBI/NIA Workshop. JOURNALS OF Roche N, Rodriguez-Roisin R, Sin DD, Singh D, crónica: papel de la respuesta inmune y de GERONTOLOGY - SERIES A BIOLOGICAL Stockley R, Vestbo J, Wedzicha JA, Agustí A. las células madre mesenquimales SCIENCES AND MEDICAL SCIENCES. Global Strategy for the Diagnosis, pulmonares. 72(1):1492-1500. I.F.: 5.957 Management, and Prevention of Chronic Sponsored by: Instituto de Salud Carlos III. Obstructive Lung Disease 2017 Report. PI15/00799 GOLD Executive Summary. AMERICAN Duration: 01/01/2016-31/12/2018 Letters / I.F.: 40.425 JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE. 195(5):557-582. I.F.: 13.204 Sellares J. Asociación de la deﬁciencia de la 1. Agustí A, Dekhuijzen PR. Maximal vía de la MBL (Mannose-binging lectin) y bronchodilation: a therapeutic target in 2.Vogelmeier CF, Criner GJ, Martinez FJ, los serotipos de neumococo en la COPD? THE LANCET. RESPIRATORY Anzueto A, Barnes PJ, Bourbeau J, Celli BR, enfermedad invasiva neumocócica. MEDICINE. 5(7):540-542. I.F.: 19.287 Chen R, Decramer M, Fabbri LM, Frith P, Sponsored by: Instituto de Salud Carlos III. Halpin DM, López Varela MV, Nishimura M, PI13/01227 2. Kerkhof M, Sonnappa S, Postma DS, Roche N, Rodriguez-Roisin R, Sin DD, Singh D, Duration: 01/01/2014-30/06/2017 Brusselle G, Agustí A, Anzueto A, Jones R, Stockley R, Vestbo J, Wedzicha JA, Agusti A. Papi A, Pavord I, Pizzichini E, Popov T, Roche Global Strategy for the Diagnosis, N, Ryan D, Thomas M, Vogelmeier C, Management, and Prevention of Chronic DOCTORAL THESES Chisholm A, Freeman D, Bafadhel M, Hillyer Obstructive Lung Disease 2017 Report: EV, Price DB. Blood eosinophil count and GOLD Executive Summary. EUR RESPIR J. García-Navarro A, Faner R. Characteri- exacerbation risk in patients with COPD. 49(3):1700214. I.F.: 10.569 zation of the pulmonary and systemic EUROPEAN RESPIRATORY JOURNAL. immune response in relation with lung 50(1):1700761. I.F.: 10.569 3. Vogelmeier CF, Criner GJ, Martinez FJ, stem cells in patients with COPD. Anzueto A, Barnes PJ, Bourbeau J, Celli BR, PhD student: Tamara Cruz Santa Cruz 3. Agustí A, Bafadhel M, Beasley R, Bel EH, Chen R, Decramer M, Fabbri LM, Frith P, Faner R, Gibson PG, Louis R, McDonald VM, Halpin DM, López Varela MV, Nishimura M, Sterk PJ, Thomas M, Vogelmeier C, Pavord ID, Roche N, Rodriguez-Roisin R, Sin DD, Singh D, on behalf of all participants in the seminar. Stockley R, Vestbo J, Wedzicha JA, Agusti A. Precision medicine in airway diseases: Global Strategy for the Diagnosis, moving to clinical practice. EUROPEAN Management and Prevention of Chronic RESPIRATORY JOURNAL. 50(4):1701655. Obstructive Lung Disease 2017 Report: I.F.: 10.569 GOLD Executive Summary. RESPIROLOGY. 22(3):575-601. I.F.: 3.256

Editorial / I.F.: 31.707 4. Vogelmeier CF, Criner GJ, Martínez FJ, Anzueto A, Barnes PJ, Bourbeau J, Celli BR, 1. Faner R., Agustí A. COPD: Algorithms and Chen R, Decramer M, Fabbri LM, Frith P, clinical management. EUROPEAN Halpin DM, López Varela MV, Nishimura M, RESPIRATORY JOURNAL. 50(5):1701733. Roche N, Rodríguez-Roisin R, Sin DD, Singh D, I.F.: 10.569 Stockley R, Vestbo J, Wedzicha JA, Agustí A. Global Strategy for the Diagnosis, 2. Agustí A. Predicting the future from the Management, and Prevention of Chronic past. EUR RESPIR J. 49(1):1601854 . I.F.: Obstructive Lung Disease 2017 Report: 10.569 GOLD Executive Summary. ARCHIVOS DE BRONCONEUMOLOGIA. 53(3):128-149. 3. Rodriguez-Roisin R, Rabe KF, Vestbo J, I.F.: 2.979 Vogelmeier C, Agustí A, all previous and current members of the Science Committee and the Board of Directors of GOLD (goldcopd.org/committees/). Global Initiative for Chronic Obstructive Lung Disease (GOLD) 20th Anniversary: a brief history of time. EUROPEAN RESPIRATORY JOURNAL. 50(1):1700671 I.F.: 10.569

133 AREA 2 RESPIRATORY, CARDIOVASCULAR AND RENAL PATHOBIOLOGY AND BIOENGINEERING

Genetics 2.10 and urologic tumors

TEAM LEADER STRATEGIC OBJECTIVES Antonio Alcaraz (HCB) LOCATION T. 93 227 55 45 The group is focused on the translational CELLEX building 2B [email protected] research in urological oncology, aimed at generating knowledge that provides a direct beneﬁt to patients.

RESEARCHERS 1. Develop non-invasive tools for the Laura Izquierdo (HCB-IDIBAPS) diagnosis and prognosis of bladder, upper KEYWORDS Lourdes Mengual (IDIBAPS-FCRB) urinary tract and prostate cancer. 1. Bladder cancer Mireia Musquera (HCB-IDIBAPS) 2. Prostate cancer Maria José Ribal (HCB-IDIBAPS) 2. Identify biomarkers to predict the response 3. Upper tract urothelial carcinoma to chemotherapy in bladder cancer. 4. Kidney cancer PRE-DOCTORAL RESEARCHERS 5. Biomarkers for diagnosis, Maria Mercedes Ingelmo (IDIBAPS) 3. Determine molecular prognostic factors in prognosis and treatment response Ruth Montalbo (FCRB) bladder, upper urinary tract, kidney and prostate cancer. TECHNICIANS Raquel Carrasco (FCRB) MAIN LINES OF RESEARCH ADMINISTRATIVE STAFF Original publications Maria Teresa Dalet (FCRB) 1. Non-invasive diagnosis and prognosis from 2015 to 2017 of bladder tumors. COLLABORATORS - Development of a gene/miRNA expression YEAR I.F. TOTAL Q1 Q2 Agustín Franco (HCB) signatures in urine samples. Francisco Lozano (HCB-UB) 2015 33.55 12 5 1 - Identiﬁcation of DNA aneuploidies in urine Begoña Mellado (HCB) samples by FISH. 2016 28.18 10 4 2 Aleix Prat (HCB) - Determination of methylation proﬁles of 2017 64.02 12 6 2 urine samples. VISITING SCIENTISTS Veronica Castillo (Hospital universitario 2. Predictive biomarkers of prognosis and Virgen de Arrixaca, Spain) response to treatments. Marco Franco (Università Degli Studi di Napoli - Markers of disseminated cells from bladder TEAM INVOLVED IN “Federico II”, Italy) tumours in lymph nodes and peripheral blood. AGAUR_SGR14 Caroline Sieverink (Radboud University - Markers of response to neoadjuvant AGAUR_SGR17 Nijmegen Medical Center, The Netherlands ) chemotherapy in bladder cancer patients. - Prognostic markers in bladder, kidney and upper urinary tract tumors.

3. Non-invasive diagnosis and prognosis of prostate tumours. - Development of a gene/miRNA expression signature in post-prostatic massage urine samples. - Prognostic biomrakers for prostate cancer.

PUBLICATIONS

Originals / I.F.: 64.024

1. Azzouzi AR, Vincendeau S, Barret E, Cicco A, Kleinclauss F, van der Poel HG, Stief CG, Rassweiler J, Salomon G, Solsona E, Alcaraz A, Tammela TT, Rosario DJ, Gomez-Veiga F, Ahlgren G, Benzaghou F, Gaillac B, Amzal B, Debruyne FM, Fromont G, Gratzke C, Emberton M, PCM301 Study Group. Padeliporﬁn vascular-targeted photodynamic therapy

134 GENETICS AND UROLOGIC TUMORS 2.10

versus active surveillance in men with treated surgically. WORLD J UROL. and treatment for clinically localized prostate low-risk prostate cancer (CLIN1001 35(1):51-56. I.F.: 2.743 cancer. Adherence to the European PCM301): an open-label, phase 3, Association of Urology clinical guidelines randomised controlled trial. LANCET 8. Borgmann H, Musquera M, Haferkamp A, in a nationwide population-based study - ONCOLOGY. 18(2):181-191. I.F.: 33.900 Vilaseca A, Klatte T, Shariat SF, Scavuzzo A, GESCAP group. ACTAS UROLOGICAS Jimenez Rios MA, Wolff I, Capitanio U, ESPANOLAS. 41(6):359-367. I.F.: 1.181 2. Izquierdo L, Montalbo R, Ingelmo-Torres M, Dell'Oglio P, Krabbe LM, Herrmann E, Ecke T, Mallofré C, Ramírez-Backhaus M, Rubio J, Van Vergho D, Huck N, Wagener N, Pahernik S, der Heijden AG, Schaafsma E, Lopez-Beltran Zastrow S, Wirth M, Surcel C, Mirvald C, Review / I.F.: 5.62 A, Blanca A, Lawrentschuk N, Alcaraz A, Prochazkova K, Hutterer G, Zigeuner R, Mengual L. Prognostic microRNAs in upper Cindolo L, Hora M, Stief CG, May M, 1. Veskimäe E., Neuzillet Y., Rouanne M., tract urothelial carcinoma: multicenter and Brookman-May SD. Prognostic significance MacLennan S., Lam T., Yuan Y., Compérat E., international validation study. of Fuhrman grade and age for cancer- Cowan N., Gakis G., van der Heijden A., Ribal ONCOTARGET. 8(31):51522-51529. I.F.: 5.168 specific and overall survival in patients M., Witjes J., Lebrét T. Systematic review of with papillary renal cell carcinoma: results the oncological and functional outcomes 3. Ingelmo-Torres M, Lozano JJ, Izquierdo L, of an international multi-institutional study of pelvic organ-preserving radical Carrion A, Costa M, Gómez L, Ribal MJ, on 2189 patients. WORLD JOURNAL OF cystectomy (RC) compared with standard Alcaraz A, Mengual L. Urinary cell UROLOGY. 35(12):1891-1897. I.F.: 2.743 RC in women who undergo curative microRNA-based prognostic classifier for surgery and orthotopic neobladder non-muscle invasive bladder cancer. 9. Beardo P., Truan Cacho D., Izquierdo L., substitution for bladder cancer. BJU ONCOTARGET. 8(11):18238-18247. I.F.: 5.168 Alcover-Garcia J., Alcaraz A., Extramiana J., INTERNATIONAL. 120(1):12-24. I.F.: 4.439 Mallofré C. Cancer-Specific Survival 4. Sanchez-Escuredo, Ana; Sagasta, Amaia; Stratification Derived from Tumor 2. Gomez-Veiga, F.; Alcaraz-Asensio, A.; Revuelta, Ignacio; Rodas, Lida M.; Paredes, Expression of Tissue Inhibitor of Metallo- Burgos-Revilla, J.; Cozar-Olmo, J. M. David; Musquera, Mireia; Diekmann, Fritz; proteinase-2 in Non-Metastatic Renal Cell Developments in urologic oncology Campistol, Josep M.; Sole, Manel; Carcinoma. PATHOLOGY ONCOLOGY "OncoForum": The best of 2016. ACTAS Oppenheimer, Federico. Histopathological RESEARCH. I.F.: 1.736 UROLOGICAS ESPANOLAS. 41(9):543-551. evaluation of pretransplant donor biopsies I.F.: 1.181 in expanded criteria donors with high 10. May M., Surcel C., Capitanio U., Dell’Oglio kidney donor profile index a retrospective P., Klatte T., Shariat S., Ecke T., Wolff I., Vergho observational cohort study. TRANSPLANT D., Wagener N., Huck N., Pahernik S., Zastrow Letters / I.F.: 4.439 INTERNATIONAL. 30(10):975-986. I.F.: 3.079 S., Wirth M., Borgmann H., Haferkamp A., Musquera M., Krabbe L., Herrmann E., 1. Loeb S., Roupret M., Van Oort I., N'dow J., 5. Vilaseca, Antoni; Campillo, Noelia; Torres, Scavuzzo A., Mirvald C., Hutterer G., Zigeuner van Gurp M., Bloemberg J., Darraugh J., Ribal Marta; Musquera, Mireia; Gozal, David; R., Stief C., Waidelich R., Cindolo L., Kalusova M. Novel use of Twitter to disseminate and Montserrat, Josep M.; Alcaraz, Antonio; K., Brookman-May S., Riedmiller H., Jimenez evaluate adherence to clinical guidelines Touijer, Karim A.; Farre, Ramon; Almendros, Rios M., Vilaseca A. Prognostic and by the European Association of Urology. Isaac. Intermittent hypoxia increases discriminative power of the 7th TNM BJU INTERNATIONAL. 119(6):820-822. kidney tumor vascularization in a murine classification for patients with surgically I.F.: 4.439 model of sleep apnea. PLOS ONE. treated papillary renal cell carcinoma: 12(6):e0179444. I.F.: 2.806 results of a multi-institutional validation study (CORONA subtype project). Editorial / I.F.: 16.265 6. Wagener, Nina; Edelmann, Dominic; Benner, SCANDINAVIAN JOURNAL OF UROLOGY. Axel; Zigeuner, Richard; Borgmann, Hendrik; 51(4):269-276. I.F.: 1.513 1. Alcaraz A., Peri L., Izquierdo L., Musquera M. Wolff, Ingmar; Krabbe, Laura M.; Musquera, Is Robotic Kidney Transplant the Near Mireia; Dell'Oglio, Paolo; Capitanio, Umberto; 11. Gómez-Rivas J., Rodríguez-Socarrás M., Future? EUROPEAN UROLOGY. Klatte, Tobias; Cindolo, Luca; May, Matthias; Tortolero-Blanco L., Garcia-Sanz M., 72(2):218-219. I.F.: 16.265 Brookman-May, Sabine D.;EAU YAU Kidney Alvarez-Maestro M., Ribal M., Cózar-Olmo M. Canc Grp. Outcome of papillary versus Influence of social networks on congres- clear cell renal cell carcinoma varies ses of urological societies and associa- Clinical Guidelines / I.F.: 16.265 significantly in non-metastatic disease. tions: Results of the 81th National PLOS ONE. 12(9):e0184173. I.F.: 2.806 Congress of the Spanish Urological 1. Alfred Witjes J., Lebret T., Compérat E., Association. ACTAS UROLOGICAS Cowan N., De Santis M., Bruins H., Hernández 7. Vilaseca A, Nguyen DP, Vertosick EA, ESPANOLAS. 41(3):181-187. I.F.: 1.181 V., Espinós E., Dunn J., Rouanne M., Neuzillet Corradi RB, Musquera M, Pérez M, Fossati N, Y., Veskimäe E., van der Heijden A., Gakis G., Sjoberg DD, Farré R, Almendros I, Montserrat 12. Gómez-Veiga F, Rodríguez-Antolín A, Ribal M. Updated 2016 EAU Guidelines on JM, Benfante NE, Hakimi AA, Skanderup AJ, Miñana B, Hernández C, Suárez JF, Fernán- Muscle-invasive and Metastatic Bladder Russo P, Alcaraz A, Touijer KA. Obstructive dez-Gómez JM, Unda M, Burgos J, Alcaraz A, Cancer. EUROPEAN UROLOGY. sleep apnea and Fuhrman grade in Rodríguez P, Medina R, Castiñeiras J, Moreno 71(3):462-475. I.F.: 16.265 patients with clear cell renal cell carcinoma C, Pedrosa E, Cózar JM, GESCAP. Diagnosis

135 AREA 2 RESPIRATORY, CARDIOVASCULAR AND RENAL PATHOBIOLOGY AND BIOENGINEERING

GRANTS FOR RESEARCH IN PROGRESS

Alcaraz A. Validación Clínica Robot Quirúrgico. Sponsored by: Ministerio de Economía y Competitividad. RTC-2015-3926-1 Duration: 01/03/2015- 30/06/2018

Mengual L. Caracterización de los perﬁles de expresión génica del tumor vesical no músculo invasivo de bajo riesgo en orinas. Desarrollo de un modelo diagnóstico no invasivo para el cáncer vesical. Sponsored by: Instituto de Salud Carlos III (ISCIII). PI13/00284 Duration: 01/01/2014-30/06/2017

DOCTORAL THESES

Musquera M, Almendros I. Molecular and clinical response of renal cell carcinoma to intermittent hypoxia. PhD student: Antoni Vilaseca Cabo

Alcaraz J, Lloreta J. Análisis de la expresión de las moléculas relacionadas con el complejo principal de histocompatibilidad de clase I Gen A (MICA) y de NKG2D como respuesta al estrés celular en el cáncer urotelial de vejiga. PhD student: Enrique Antonio Rijo Mora

Alcaraz J, Luque Mª. El uso de la TAC abdominal para el diagnóstico de los estadios tempranos del desarrollo de la enfermedad litiásica. PhD student: Alexandru Ciudin

136 ANNUAL SCIENTIFIC REPORT 2017

AREA 3

LIVER, DIGESTIVE SYSTEM AND METABOLISM 3

LIVER, DIGESTIVE SYSTEM AND METABOLISM

3.1 Gynecological endocrinology and human reproduction 140 María Ángeles Martínez Zamora

3.2 Fetal and perinatal medicine 143 Eduard Gratacós

3.3 Viral, toxic and metabolic hepatopathies 149 Xavier Forns

3.4 Mechanisms of liver disease and complications of cirrhosis 153 Pere Ginès

3.5 Hepatic oncology 159 Jordi Bruix

3.6 Hepatic hemodynamics and portal hypertension. Hemorrhage from ruptured gastroesophageal varices 164 Jaume Bosch

3.7 Inﬂammatory bowel disease 170 Julià Panés

3.8 Cholestasis and bone pathology 173 Albert Parés / Núria Guañabens

3.9 Mitochondrial regulation of cell death and steatohepatitis 176 José Carlos Fernández-Checa

3.10 Liver transplantation and graft viability 178 Miquel Navasa

3.11 Gastrointestinal and pancreatic oncology 182 Antoni Castells

3.12 Inherited metabolic diseases 189 Antonia Ribes 3.13 Genomic programming of beta cells and diabetes 191 Jorge Ferrer

3.14 Diabetes: metabolic and molecular networks 193 Josep Vidal

3.15 Pathogenesis and prevention of diabetes 199 Anna Novials

139 AREA 3 LIVER, DIGESTIVE SYSTEM AND METABOLISM

Gynecological endocrinology 3.1 and human reproduction

TEAM LEADER 3. Optimization of the surgical María Ángeles Martínez Zamora (HCB) management of diseases of LOCATION T. 93 227 54 36 the reproductive apparatus HCB building [email protected] To analyze the role of the surgical variables allowing improvement of the results and reduction of the morbidity in the surgical RESEARCHERS treatment of benign and malignant Immaculada Alonso (HCB) gynaecological disorders. To deﬁne the Francesc Carmona (HCB) prognostic value of human papillomavirus KEYWORDS Camil Castelo-Branco (HCB) detection and viral typing as progression 1. Human papillomavirus Montserrat Creus (HCB) markers of precancerous lesions of the 2. Endometrial cancer Marta del Pino (HCB) cervix, vagina and vulva. 3. Assisted reproductive technologies Francisco J Fábregues (HCB) 4. Recurrent miscarriage Dolors Manau (HCB)

5. Gynecological laparoscopy Jaume Pahisa (HCB) PUBLICATIONS 6. Endometriosis Bienvenido Puerto (HCB) Aureli Torné (HCB) Originals / I.F.: 68.24

1. Paredes P, Vidal-Sicart S, Campos F, Tapias A, Sánchez N, Martínez S, Carballo L, Pahisa J, STRATEGIC OBJECTIVES Torné A, Ordi J, Carmona F, Lomeña F. Role Original publications of ICG-(99m)Tc-nanocolloid for sentinel The global aim of this research group for the from 2015 to 2017 lymph node detection in cervical cancer: a coming years is to advance in the knowledge pilot study. EUROPEAN JOURNAL OF YEAR I.F. TOTAL Q1 Q2 of different aspects relating to the NUCLEAR MEDICINE AND MOLECULAR physiopathology of human reproduction: from 2015 51.33 17 10 4 IMAGING. 44(11):1853-1861. I.F.: 7.277 endocrinological considerations to the most 2016 30.28 10 5 1 important benign and malignant pathological 2. Rakislova N., Clavero O., Alemany L., Saco 2017 68.24 19 10 5 processes of the female reproductive system, A., Quirós B., Lloveras B., Alejo M., Pawlita M., as well as the investigation and treatment of Quint W., del Pino M., de Sanjose S., Ordi J. human reproduction failure. Histological characteristics of HPV-associated and -independent squamous cell carcinomas of the vulva: A MAIN LINES OF RESEARCH study of 1,594 cases. INTERNATIONAL JOURNAL OF CANCER. 141(12):2517-2527. 1. Reproductive failure markers. I.F.: 6.513 To ﬁnd new markers of hemostasis alterations in early and advanced 3. Sanchez-Cid, Lourdes; Pons, Monica; Jose pregnancy in patients with or without Lozano, Juan; Rubio, Nuria; Guerra-Rebollo, antiphospholipid syndrome and in Marta; Soriano, Aroa; Paris-Coderch, Laia; endometriosis patients. To assess the Segura, Miquel F.; Fueyo, Raquel; Arguimbau, usefulness of immunohistochemical and Judit; Zodda, Erika; Bermudo, Raquel; Alonso, proteomic parameters in the human Immaculada; Caparros, Xavier; Cascante, endometrium as markers of endometrial Marta; Raﬁi, Arash; Kang, Yibin; receptiveness. Martiez-Balbas, Marian; Weiss, Stephen J.; Blanco, Jeronimo; Munoz, Montserrat; Fernandez, Pedro L.; Thomson, Timothy M. 2. Ovarian dysfunction and stimulation/ MicroRNA-200, associated with hyperstimulation . metastatic breast cancer, promotes Investigation of the possibilities of traits of mammary luminal progenitor cells. ultrasound, hormonal, endocrinemetabolic ONCOTARGET. 8(48):83384-83406. I.F.: 5.168 and genetic markers in relation to the prediction of ovarian response. To assess 4. Fernandez-Martinez A., Pascual T., Perrone the role of the ovarian follicular cells in the G., Morales S., de la Haba J., González- pathogenesis of ovarian hyperstimulation Rivera M., Galván P., Zalfa F., Amato M., syndrome in order to improve the results of Gonzalez L., Prats M., Rojo F., Manso L., Paré assisted reproduction techniques. L., Alonso I., Albanell J., Vivancos A., González A., Matito J., González S., Fernandez P., Adamo B., Muñoz M., Viladot M., Font C., Aya F., Vidal M., Caballero R.,

140 GYNECOLOGICAL ENDOCRINOLOGY AND HUMAN REPRODUCTION 3.1

Carrasco E., Altomare V., Tonini G., Prat A., 10. Saco A, Diaz A, Hernandez M, Martinez D, JOURNAL OF VIROLOGICAL METHODS. Martin M. Limitations in predicting Montironi C, Castillo P, Rakislova N, Del Pino M, 248:238-243. I.F.: 1.693 PAM50 intrinsic subtype and risk of Martinez A, Ordi J. Validation of whole-slide relapse score with Ki67 in estrogen imaging in the primary diagnosis of liver 17. Perello, Maria; Martinez-Zamora, Maria A.; receptor-positive HER2- negative breast biopsies in a University Hospital. Torres, Ximena; Munros, Jordina; Llecha, cancer. ONCOTARGET. DIGESTIVE AND LIVER DISEASE. Silvia; De lazzari, Elisa; Balasch, Juan; 8(13):21930-21937. I.F.: 5.168 49(11):1240-1246. I.F.: 3.061 Carmona, Francisco. Markers of deep infiltrating endometriosis in patients with 5. Munmany M, Marimon L, Cardona M, Nonell 11. Ros, Cristina; Jose Martinez-Serrano, ovarian endometrioma: a predictive R, Juiz M, Astudillo R, Ordi J, Torné A, Del Pino Maria; Rius, Mariona; Abrao, Mauricio Simoes; model. EUROPEAN JOURNAL OF M. Small lesion size measured by Munros, Jordina; Angeles Martinez-Zamora, OBSTETRICS, GYNECOLOGY AND colposcopy may predict absence of Ma; Gracia, Meritxell; Carmona, Francisco. REPRODUCTIVE BIOLOGY. 209:55-60. cervical intraepithelial neoplasia in a large Bowel Preparation Improves the Accuracy I.F.: 1.666 loop excision of the transformation zone of Transvaginal Ultrasound in the specimen. BJOG: AN INTERNATIONAL Diagnosis of Rectosigmoid Deep 18. Francesca Perello, Maria; Angeles JOURNAL OF OBSTETRICS AND Infiltrating Endometriosis: A Prospective Martinez-Zamora, Maria; Torres, Ximena; GYNAECOLOGY. 124(3):495-502. I.F.: 5.051 Study. JOURNAL OF MINIMALLY INVASIVE Munros, Jordina; Balasch Cortina, Juan; GYNECOLOGY. 24(7):1145-1151. I.F.: 3.061 Carmona, Francisco. Endometriotic Pain 6. Leeman A, Del Pino M, Molijn A, Rodriguez Is Associated with Adenomyosis but Not A, Torné A, de Koning M, Ordi J, van 12. Perelló M, González-Foruria I, Castillo P, with the Compartments Affected by Kemenade F, Jenkins D, Quint W. HPV testing Martínez-Florensa M, Lozano F, Balasch J, Deep Infiltrating Endometriosis. in first-void urine provides sensitivity for Carmona F. Oral Administration of GYNECOLOGIC AND OBSTETRIC CIN2+ detection comparable with a smear Pentoxifylline Reduces INVESTIGATION. 82(3):240-246. I.F.: 1.415 taken by a clinician or a brush-based Endometriosis-Like Lesions in a Nude self-sample: cross-sectional data from a Mouse Model. REPRODUCTIVE 19. Duro Gomez, Jorge; Garrido Oyarzun, triage population. BJOG: AN SCIENCES. 24(6):911-918. I.F.: 2.443 Maria Fernanda; Rodriguez Marin, Ana INTERNATIONAL JOURNAL OF Belen; de la Torre Gonzalez, Antonio Jesus; OBSTETRICS AND GYNAECOLOGY. 13. Palacios, S.; Cancelo, M. J.; Castelo Arjona Berral, Jose Eduardo; 124(9):1356-1363. I.F.: 5.051 Branco, C.; Llaneza, P.; Molero, F.; Sanchez Castelo-Branco, Camil. Vaginal Borrego, R. Vulvar and vaginal atrophy as misoprostol and cervical ripening 7. Munrós J, Martínez-Zamora MA, Tàssies D, viewed by the Spanish REVIVE balloon for induction of labor in late-term Coloma JL, Torrente MA, Reverter JC, participants: symptoms, management pregnancies. JOURNAL OF OBSTETRICS Carmona F, Balasch J. Total circulating and treatment perceptions. AND GYNAECOLOGY RESEARCH. microparticle levels are increased in CLIMACTERIC. 20(1):55-61. 43(1):87-91. I.F.: 1.099 patients with deep infiltrating I.F.: 2.271 endometriosis. HUM REPROD. 32(2):325-331. I.F.: 5.020 14. Duro-Gómez J., Garrido-Oyarzún M., Review / I.F.: 6.419 Rodríguez-Marín A., de la Torre González A., 8. Almanza-Aguilera, Enrique; Urpi-Sarda, Arjona-Berral J., Castelo-Branco C. Efficacy 1. Vannuccini, Silvia; Tosti, Claudia; Carmona, Mireia; Llorach, Rafael; Vazquez-Fresno, Rosa; and safety of misoprostol, dinoprostone Francisco; Huang, S. Joseph; Chapron, Garcia-Aloy, Mar; Carmona, Francesc; and Cook’s balloon for labour induction in Charles; Guo, Sun-Wei; Petraglia, Felice. Sanchez, Alex; Madrid-Gambin, Francisco; women with foetal growth restriction at Pathogenesis of adenomyosis: an update Estruch, Ramon; Corella, Dolores; term. ARCHIVES OF GYNECOLOGY AND on molecular mechanisms. Andres-Lacueva, Cristina. Microbial OBSTETRICS. 296(4):777-781. I.F.: 2.090 REPRODUCTIVE BIOMEDICINE ONLINE. metabolites are associated with a high 35(5):592-601. I.F.: 3.249 adherence to a Mediterranean dietary 15. Duro-Gómez J, Garrido-Oyarzún MF, pattern using a 1H-NMR-based untargeted Rodríguez-Marín AB, de la Torre González AJ, 2. Oyarzún M., Castelo-Branco C. Local metabolomics approach. JOURNAL OF Arjona-Berral JE, Castelo-Branco C. What hormone therapy for genitourinary NUTRITIONAL BIOCHEMISTRY. 48:36-43. can we do to reduce the associated costs syndrome of menopause in breast cancer I.F.: 4.518 in induction of labour of intrauterine patients: is it safe? GYNECOLOGICAL growth restriction foetuses at term? ENDOCRINOLOGY. 33(6):418-420. I.F.: 1.585 9. González-Foruria I, Santulli P, Chouzenoux A cost-analysis study. ARCHIVES OF S, Carmona F, Chapron C, Batteux F. GYNECOLOGY AND OBSTETRICS. 3. Garrido Oyarzun, Maria Fernanda; Dysregulation of the ADAM17/Notch 296(3):483-488. I.F.: 2.090 Castelo-Branco, Camil. Use of hormone signalling pathways in endometriosis: from therapy for menopausal symptoms and oxidative stress to fibrosis. MOLECULAR 16. Del Pino M, Alonso I, Rodriguez-Trujillo A, quality of life in breast cancer survivors. HUMAN REPRODUCTION. 23(7):488-499. Bernal S, Geraets D, Guimerà N, Torne A, Ordi Safe and ethical? GYNECOLOGICAL I.F.: 3.585 J. Comparison of the analytical and clinical ENDOCRINOLOGY. 33(1):10-15. I.F.: 1.585 performance of five tests for the detection of human papillomavirus genital infection.

141 AREA 3 LIVER, DIGESTIVE SYSTEM AND METABOLISM

GRANTS FOR RESEARCH IN PROGRESS

Torné A. Estudi multicèntric sobre el procés assistencial del càncer d'ovari a l'atenció primària de Catalunya: avaluació de dues intervencions per reduir el retard diagnòstic. Sponsored by: Generalitat de Catalunya (PERIS). SLT002/16/00200 Duration: 27/03/2017-31/12/2019

DOCTORAL THESES

Carmona F, Martínez Zamora MA. Nous marcadors clínics i tractament immunològic de l´endometriosi. PhD student: Maria Francesca Perelló Serra

Fàbregues F, Vassena R. Individualized training in ART. PhD student: Amelia Rodriguez Aranda

142 FETAL AND PERINATAL MEDICINE 3.2

Fetal and perinatal 3.2 medicine

PRE-DOCTORAL RESEARCHERS Nuria Baños (HCB) LOCATION Tri Rahmat Basuki (UB) Maternitat building Francesca Crovetto (CIBER) Laura Garcia (HCB) Gülcin Gumus (UB) Nadine Hahner (UB)

WEB Eduardo Herreros (UB) www.medicinafetalbarcelona.org Mari Kinoshita (UB) Talita Micheletti (UB) Ana Moreno (UB) TEAM LEADER Eduard Gratacós (HCB) Cristina Paules (IDIBAPS) Sergio Quesada (FCRB) T. 93 227 99 46 Marta Rial (IDIBAPS) [email protected] Mérida Rodríguez (UB) KEYWORDS Álvaro Sepúlveda (UB) 1. Prenatal diseases Ximena Torres (HCB) 2. Intrauterine growth restriction RESEARCHERS Kilian Vellvé (FCRB) 3. Fetal programming Antoni Borrell (HCB) Lina Youssef (UB) 4. Fetal brain damage Francesc Botet (HCB) 5. Prematurity Elena Casals (HCB) TECHNICIANS Maria Teresa Cobo (HCB) Carla Loreiro (FCRB) Fátima Crispi (HCB-IDIBAPS) Miriam Osorio (IDIBAPS) Elisenda Eixarch (HCB-IDIBAPS) Nuria Rierola (FCRB) Francesc Figueras (HCB) Ana Belén Sánchez (FCRB) Josep Figueras (HCB) Original publications Oscar Garcia Algar (HCB) ADMINISTRATIVE STAFF from 2015 to 2017 Olga Gomez (HCB-IDIBAPS) Maria Teresa Aguilera (FCRB) Anna Gonce (HCB-IDIBAPS) Mercedes Alonso (FCRB) YEAR I.F. TOTAL Q1 Q2 Jose Mª Martinez-Crespo (HCB) Estefania Callado (FCRB) 2015 112.21 30 29 1 Montserrat Palacio (HCB) Ester Cardet (FCRB)

2016 149.32 44 33 5 Luis Enrique Enciso (FCRB) POST-DOCTORAL RESEARCHERS Pedro Lorente (FCRB) 2017 182.64 51 28 18 Ángela Arranz (HCB) Paula Navarro (FCRB) Marta López (HCB-IDIBAPS) Isil Tekeli (FCRB) Narcís Masoller (HCB) Nathalia Torrico (FCRB) Monica Zamora (FCRB)

TEAM INVOLVED IN CIBERER AGAUR_SGR14 Eduard Gratacós

TEAM

143 AREA 3 LIVER, DIGESTIVE SYSTEM AND METABOLISM

NURSING STAFF restriction and to develop new technological Martínez-Terrón M., Gratacós E., Martínez S., Alba Camacho (FCRB) solutions for fetal surgery. Gómez Roig D., Bonet-Carné E., Palacio M., Marta Garcia (FCRB) Bonet-Carne E., Cobo T., Perez-Moreno A., Nadia Rojas (FCRB) Sabrià J., Richter J., Kacerovsky M., PUBLICATIONS Jacobsson B., García-Posada R., Bugatto F., VISITING SCIENTISTS Santisteve R., Vives À., Parra-Cordero M., Giulia Casu (Policlinico di Milano, Italy) Originals / I.F.: 181.59 Hernandez-Andrade E., Bartha J., Ayako Nakaki (National Hospital Organization Carretero-Lucena P., Tan K., Cruz-Martínez Kyoto Medical Center, Japan) 1. Sarvari SI, Rodriguez-Lopez M, R., Burke M., Vavilala S., Iruretagoyena I., Nuñez-Garcia M, Sitges M, Sepulveda- Delgado J., Schenone M., Vilanova J., Botet F., Martinez A, Camara O, Butakoff C, Gratacos Yeo G., Hyett J., Deprest J., Romero R., STRATEGIC OBJECTIVES E, Bijnens B, Crispi F. Persistence of Cardiac Gratacos E., López M., Castro D., Piraquive J., Remodeling in Preadolescents With Fetal Ramírez J., Migliorelli F., Martínez-Terrón M., Our main objectives are to develop new Growth Restriction. CIRC CARDIOVASC Gratacós E. Prediction of neonatal imaging and molecular tools for early IMAGING. 10(1):e005270. I.F.: 6.803 respiratory morbidity by quantitative diagnosis and monitoring prenatal diseases, ultrasound lung texture analysis: A to provide new clinical solutions for improving 2. Padilla, Nelly; Fransson, Peter; Donaire, multicenter study. AMERICAN JOURNAL fetal growth, to develop and validate new Antonio; Figueras, Francesc; Arranz, Angela; OF OBSTETRICS AND GYNECOLOGY. technological solutions for fetal surgery and Sanz-Cortes, Magdalena; Tenorio, Violeta; 217(2):196.e1-196.e14. I.F.: 5.226 to consolidate animal models for better Bargallo, Nuria; Junque, Carme; Lagercrantz, characterizing fetal programming. Hugo; Aden, Ulrika; Gratacos, Eduard. 6. Jiménez JA, Eixarch E, DeKoninck P, Intrinsic Functional Connectivity in Bennini JR, Devlieger R, Peralta CF, Gratacos Preterm Infants with Fetal Growth E, Deprest J. Balloon removal after MAIN LINES OF RESEARCH Restriction Evaluated at 12 Months fetoscopic endoluminal tracheal occlusion Corrected Age. CEREBRAL CORTEX. for congenital diaphragmatic hernia. 1. Prematurity: This line focuses on patients 27(10):4750-4758. I.F.: 6.559 AMERICAN JOURNAL OF OBSTETRICS AND at risk of preterm labor, investigating GYNECOLOGY. 217(1):78.e1-78.e11. I.F.: 5.226 non-invasive diagnostic tools such as 3. Gonzalez-Tendero A, Zhang C, Balicevic V, quantitative ultrasound textures analysis Cárdenes R, Loncaric S, Butakoff C, Paun B, 7. Guitart-Mampel, Mariona; Sandra and biomarkers for intraamniotic Bonnin A, Garcia-Cañadilla P, Muñoz-Moreno Hernandez, A.; Moren, Constanza; inflammation and infection. E, Gratacós E, Crispi F, Bijnens B. Whole Catalan-Garcia, Marc; Tobias, Ester; heart detailed and quantitative anatomy, Gonzalez-Casacuberta, Ingrid; Juarez-Flores, 2. Placental Disease. We aim to identify myofibre structure and vasculature from Diana L.; Gatell, Josep M.; Cardellach, suboptimal fetal growth before birth X-ray phase-contrast synchrotron Francesc; Milisenda, Jose C.; Grau, Josep M.; providing new diagnosis tools for the radiation-based micro computed Gratacos, Eduard; Figueras, Francesc; correct classification of small babies at tomography. EUROPEAN HEART Garrabou, Gloria. Imbalance in highest perinatal risk and optimal timing to JOURNAL-CARDIOVASCULAR IMAGING. mitochondrial dynamics and apoptosis in delivery. 18(7):732-741. I.F.: 5.990 pregnancies among HIV-infected women on HAART with obstetric complications. 3. Fetal Brain Development. We aim to 4. Simões RV, Muñoz-Moreno E, Cruz-Lemini JOURNAL OF ANTIMICROBIAL develop quantitative imaging biomarkers M, Eixarch E, Bargalló N, Sanz-Cortés M, CHEMOTHERAPY. 72(9):2578-2586. for early diagnosis of neurodevelopmental Gratacós E. Brain metabolite alterations in I.F.: 5.071 disorders of prenatal origin based on infants born preterm with intrauterine ultrasound and magnetic resonance. growth restriction: association with 8. Ruiz A, Cruz-Lemini M, Masoller N, structural changes and Sanz-Cortés M, Ferrer Q, Ribera I, Martínez 4. Fetal Programming. We focus on the neurodevelopmental outcome. AM J JM, Crispi F, Arévalo S, Gómez O, long-term impact of prenatal conditions OBSTET GYNECOL. 216(1):62.e1-62.e14. Pérez-Hoyos S, Carreras E, Gratacós E, such as fetal growth restriction, I.F.: 5.226 Llurba E. Longitudinal changes in fetal preeclampsia, assisted reproductive biometries and cerebroplacental technologies, perinatal infections or 5. Palacio M., Bonet-Carne E., Cobo T., haemodynamics in fetuses with congenital congenital heart disease, providing a Perez-Moreno A., Sabrià J., Richter J., heart disease. ULTRASOUND IN better phenotypic characterization and Kacerovsky M., Jacobsson B., García-Posada OBSTETRICS AND GYNECOLOGY. testing preventive strategies for fetal R., Bugatto F., Santisteve R., Vives À., 49(3):379-386. I.F.: 4.710 growth restriction. Parra-Cordero M., Hernandez-Andrade E., Bartha J., Carretero-Lucena P., Tan K., 9. Rodríguez-López M, Cruz-Lemini M, 5. Fetal Therapy and Surgery. This Cruz-Martínez R., Burke M., Vavilala S., Valenzuela-Alcaraz B, Garcia-Otero L, Sitges research line aims to characterize Iruretagoyena I., Delgado J., Schenone M., M, Bijnens B, Gratacós E, Crispi F. neuroprotective therapies that could Vilanova J., Botet F., Yeo G., Hyett J., Deprest Descriptive analysis of the different mitigate the neurodevelopmental J., Romero R., Gratacos E., López M., Castro phenotypes of cardiac remodeling in fetal impairment related to fetal growth D., Piraquive J., Ramírez J., Migliorelli F., growth restriction. ULTRASOUND IN

144 FETAL AND PERINATAL MEDICINE 3.2

OBSTETRICS AND GYNECOLOGY. perinatal outcomes by feto-placental 23. Mazarico E, Llurba E, Cumplido R, Valls A, 50(2):207-214. I.F.: 4.710 Doppler at 37 weeks' gestation. Melchor JC, Iglesias M, Cabero L, Gratacós E, ULTRASOUND IN OBSTETRICS AND Gómez-Roig MD. Neural injury markers in 10. Valenzuela-Alcaraz B, Crispi F, GYNECOLOGY. 49(3):364-371. I.F.: 4.710 intrauterine growth restriction and their Cruz-Lemini M, Bijnens B, García-Otero L, relation to perinatal outcomes. PEDIATRIC Sitges M, Balasch J, Gratacós E. Differential 17. Triunfo S, Crovetto F, Rodriguez-Sureda RESEARCH. 83(3):452-457. I.F.: 2.882 effect of assisted reproductive V, Scazzocchio E, Crispi F, Dominguez C, technologies and small for gestational age Gratacos E, Figueras F. Changes in uterine 24. Sabra S., Malmqvist E., Saborit A., on fetal cardiac remodeling. ULTRASOUND artery Doppler velocimetry and circulating Gratacós E., Gomez Roig M. Heavy metals IN OBSTETRICS AND GYNECOLOGY. angiogenic factors in the first half of exposure levels and their correlation with 50(1):63-70. I.F.: 4.710 pregnancies delivering small for different clinical forms of fetal growth gestational age neonates. ULTRASOUND IN restriction. PLOS ONE. 12(10):e0185645. I.F.: 11. Ros C, Martínez-Franco E, Wozniak MM, OBSTETRICS AND GYNECOLOGY. 2.806 Cassado J, Santoro GA, Elías N, López M, 49(3):357-363. I.F.: 4.710 Palacio M, Wieczorek AP, Espuña-Pons M. 25. Garcia-Canadilla P., Rodriguez J., Palazzi Postpartum 2D and 3D ultrasound 18. Berghella V, Palacio M, Ness A, Alfirevic Z, M., Gonzalez-Tendero A., Schönleitner P., evaluation of the anal sphincter complex in Nicolaides KH, Saccone G. Cervical length Balicevic V., Loncaric S., Luiken J., Ceresa M., women with obstetric anal sphincter screening for prevention of preterm birth Camara O., Antoons G., Crispi F., Gratacos E., injuries. ULTRASOUND IN OBSTETRICS in singleton pregnancy with threatened Bijnens B. A two dimensional AND GYNECOLOGY. 49:508-514. I.F.: 4.710 preterm labor: systematic review and electromechanical model of a meta-analysis of randomized controlled cardiomyocyte to assess Intra-cellular 12. Miranda J, Rodriguez-Lopez M, Triunfo S, trials using individual patient-level data. regional mechanical heterogeneities. Sairanen M, Kouru H, Parra-Saavedra M, ULTRASOUND IN OBSTETRICS AND PLOS ONE. 12(8):e0182915. I.F.: 2.806 Crovetto F, Figueras F, Crispi F, Gratacós E. GYNECOLOGY. 49(3):322-329. I.F.: 4.710 Prediction of fetal growth restriction using 26. Rodriguez-Lopez M., Wagner P., estimated fetal weight vs a combined 19. Scazzocchio E, Crovetto F, Triunfo S, Perez-Vicente R., Crispi F., Merlo J. Revisiting screening model in the third trimester. Gratacós E, Figueras F. Validation of a the discriminatory accuracy of traditional ULTRASOUND IN OBSTETRICS AND first-trimester screening model for risk factors in preeclampsia screening. GYNECOLOGY. 50(5):603-611. I.F.: 4.710 pre-eclampsia in an unselected PLOS ONE. 12(5):1120. I.F.: 2.806 population. ULTRASOUND IN OBSTETRICS 13. Miranda J, Triunfo S, Rodriguez-Lopez M, AND GYNECOLOGY. 49(2):188-193. I.F.: 4.710 27. Sanchez-Luna M; Burgos-Pol R; Oyagüez Sairanen M, Kouru H, Parra-Saavedra M, I; Figueras-Aloy J; Sanchez-Solis M; Crovetto F, Figueras F, Crispi F, Gratacós E. 20. Hernandez S; Morén C; Catalán-Garcia Martinón-Torres F; Carbonell-Estrany X. Performance of a third trimester combined M; Lopez M; Guitart-Mampel M; Coll O; Garcia Cost-utility analysis of Palivizumab for screening model for the prediction of L; Milisenda J; Justamante A; Gatell JM; Respiratory Syncytial Virus infection adverse perinatal outcome. ULTRASOUND Cardellach F; Gratacos E; Miro O; Garrabou prophylaxis in preterm infants: Update IN OBSTETRICS AND GYNECOLOGY. G. Mitochondrial toxicity and caspase based on the clinical evidence in Spain. 50(3):353-360. I.F.: 4.710 activation in HIV pregnant women. BMC INFECTIOUS DISEASES. 17(1):1120. JOURNAL OF CELLULAR AND MOLECULAR I.F.: 2.768 14. Scazzocchio E, Oros D, Diaz D, Ramirez MEDICINE. 21(1):26-34. I.F.: 4.499 JC, Ricart M, Meler E, González de Agüero R, 28. Illa M., Brito V., Pla L., Eixarch E., Gratacos E, Figueras F. Impact of aspirin on 21. Zimmer V., Glocker B., Hahner N., Eixarch Arbat-Plana A., Batallé D., Muñoz-Moreno E., trophoblastic invasion in women with E., Sanroma G., Gratacós E., Rueckert D., Crispi F., Udina E., Figueras F., Ginés S., abnormal uterine artery Doppler at 11 - 14 González Ballester M., Piella G. Learning and Gratacós E. Early Environmental weeks: A randomized controlled study combining image neighborhoods using Enrichment Enhances Abnormal Brain (ASAP). ULTRASOUND IN OBSTETRICS random forests for neonatal brain disease Connectivity in a Rabbit Model of AND GYNECOLOGY. 49(4):435-441. I.F.: 4.710 classification. MEDICAL IMAGE ANALYSIS. Intrauterine Growth Restriction. FETAL 42:189-199. I.F.: 4.188 DIAGNOSIS AND THERAPY. I.F.: 2.699 15. Crovetto F, Triunfo S, Crispi F, Rodriguez-Sureda V, Dominguez C, Figueras 22. Hernández S, Catalán-García M, Morén C, 29. Borrell A; Grande M; Meler E; Sabria J; F, Gratacos E. Differential performance of García-Otero L, López M, Guitart-Mampel M, Mazarico E; Munoz A; Rodriguez-Revenga L; first trimester screening in predicting small Milisenda J, Coll O, Cardellach F, Gratacós E, Badenas C; Figueras F. Genomic Microarray for gestational age neonates or fetal Miró Ò, Garrabou G. Placental in Fetuses with Early Growth Restriction: A growth restriction. ULTRASOUND IN Mitochondrial Toxicity, Oxidative Stress, Multicenter Study. FETAL DIAGNOSIS AND OBSTETRICS AND GYNECOLOGY. Apoptosis And Adverse Perinatal THERAPY. 42(3):174-180. I.F.: 2.699 49(3):349-356. I.F.: 4.710 Outcomes In Hiv-Pregnancies Under Antiretroviral Treatment Containing 30. Grande M, Stergiotou I, Pauta M, Marquès 16. Triunfo S, Crispi F, Gratacos E, Figueras F. Zidovudine. JOURNAL OF ACQUIRED B, Badenas C, Soler A, Yaron Y, Borrell A. Prediction of delivery of small for IMMUNE DEFICIENCY SYNDROMES. Parental Origin of the Retained X gestational age neonates and adverse 75(4):E113-E119. I.F.: 3.935 Chromosome in Monosomy X

145 AREA 3 LIVER, DIGESTIVE SYSTEM AND METABOLISM

Miscarriages and Ongoing Pregnancies. by Severity Criteria. FETAL DIAGNOSIS Krofta L., Lubusky M., Rogelio C., Mónica C., FETAL DIAGNOSIS AND THERAPY. I.F.: 2.699 AND THERAPY. I.F.: 2.699 Miguel M., Socias P., Aleuanlli C., Cordero M. Revealed versus concealed criteria for 31. Sanz Cortes M, Bargallo N, Arranz A, 38. Caradeux J., Murillo C., Julià C., Escura S., placental insufficiency in an unselected Simoes R, Figueras F, Gratacos E. Feasibility Ferrero S., Cobo T., Gratacós E., Palacio M. obstetric population in late pregnancy and Success Rate of a Fetal MRI and MR Follow-Up of Asymptomatic High-Risk (RATIO37): Randomised controlled trial Spectroscopy Research Protocol Patients with Normal Cervical Length to study protocol. BMJ OPEN. 7(6):e014835. Performed at Term Using a 3.0-Tesla Predict Recurrence of Preterm Birth. I.F.: 2.369 Scanner. FETAL DIAGNOSIS AND FETAL DIAGNOSIS AND THERAPY. I.F.: 2.699 THERAPY. 41(2):127-135. I.F.: 2.699 46. Spencer, Rebecca; Ambler, Gareth; 39. Torres X., Bennasar M., Eixarch E., Rueda Brodszki, Jana; Diemert, Anke; Figueras, 32. Galindo A., Gómez-Montes E., Gómez O., C., Goncé A., Muñoz M., Marimón E., Martínez Francesc; Gratacos, Eduard; Hansson, Stefan Bennasar M., Crispi F., Herraiz I., Mendoza A., J., Gratacós E., Figueras F. Gender-Specific R.; Hecher, Kurt; Huertas-Ceballos, Angela; Escribano D., García-Torres E., Carretero J., Antenatal Growth Reference Charts in Marlow, Neil; Marsal, Karel; Morsing, Eva; Gratacós E., Martínez J. Fetal Aortic Monochorionic Twins. FETAL DIAGNOSIS Peebles, Donald; Rossi, Carlo; Sebire, Neil J.; Valvuloplasty: Experience and Results of AND THERAPY. I.F.: 2.699 Timms, John F.; David, Anna L.;EVERREST Two Tertiary Centers in Spain. FETAL Consortium. EVERREST prospective study: DIAGNOSIS AND THERAPY. 42( 4): 262-270. 40. Schipke J, Gonzalez-Tendero A, Cornejo a 6-year prospective study to define the I.F.: 2.699 L, Willführ A, Bijnens B, Crispi F, Mühlfeld C, clinical and biological characteristics of Gratacós E. Experimentally induced pregnancies affected by severe early 33. Illa M, Eixarch E, Muñoz-Moreno E, Batalle intrauterine growth restriction in rabbits onset fetal growth restriction. BMC D, Leal-Campanario R, Gruart A, leads to differential remodelling of left PREGNANCY AND CHILDBIRTH. 17(1):43. Delgado-García JM, Figueras F, Gratacós E. versus right ventricular myocardial I.F.: 2.263 Neurodevelopmental Effects of microstructure. HISTOCHEMISTRY AND Undernutrition and Placental CELL BIOLOGY. 148(5):557-567. I.F.: 2.553 47. Baranov A, Gratacós E, Vikhareva O, Underperfusion in Fetal Growth Figueras F. Validation of the prediction Restriction Rabbit Models. FETAL DIAGN 41. Chalouhi GE, Morency AM, De Vlieger R, model for success of vaginal birth after THER. 42(3):189-197. I.F.: 2.699 Martinez JM, Blanc T, Hodges R, Gueneuc A, cesarean delivery at the university hospital Ryan G, Deprest J, Gratacos E, Ville Y. in Barcelona. J MATERN FETAL NEONATAL 34. Baños N, Perez-Moreno A, Migliorelli F, Prenatal incision of ureterocele causing MED. 30(24):2998-3003. I.F.: 1.826 Triginer L, Cobo T, Bonet-Carne E, Gratacos bladder outlet obstruction - A multicenter E, Palacio M. Quantitative Analysis of the case series. PRENATAL DIAGNOSIS. 48. Porta R, Capdevila E, Botet F, Verd S, Cervical Texture by Ultrasound and 37(10):968-974. I.F.: 2.523 Ginovart G, Moliner E, Nicolàs M, Rios J. Correlation with Gestational Age. FETAL Morbidity and mortality of very low birth DIAGNOSIS AND THERAPY. 41(4). I.F.: 2.699 42. Figueroa H., Alvarado C., Cifuentes J., weight multiples compared with Lozano M., Rocco J., Cabezas C., Illanes S., singletons. THE JOURNAL OF 35. Ortiz, Javier U.; Masoller, Narcis; Gomez, Eixarch E., Hernández-Andrade E., Gratacós MATERNAL-FETAL & NEONATAL Olga; Bennasar, Mar; Eixarch, Elisenda; E., Irarrazabal C. Oxidative damage and MEDICINE: THE OFFICIAL JOURNAL OF THE Lobmaier, Silvia M.; Crispi, Fatima; Gratacos, nitric oxide synthase induction by surgical EUROPEAN ASSOCIATION OF PERINATAL Eduard; Maria Martinez, Josep;. Rate and uteroplacental circulation restriction in the MEDICINE, THE FEDERATION OF ASIA AND Outcomes of Pulmonary Stenosis and rabbit fetal heart. PRENATAL DIAGNOSIS. OCEANIA PERINATAL SOCIETIES, THE Functional Pulmonary Atresia in Recipient 37(5):453-459. I.F.: 2.523 INTERNATIONAL SO. 22:1-9. I.F.: 1.826 Twins with Twin-Twin Transfusion Syndrome. FETAL DIAGNOSIS AND 43. Sabria J, Guirado L, Miró I, Gómez-Roig 49. Grande M, Stergiotou I, Borobio V, Sabrià THERAPY. 41(3):191-196. I.F.: 2.699 M, Borrell A. Crown-rump length audit plots J, Soler A, Borrell A. Heterotrisomy with the use of operator-specific PAPP-A recurrence risk: a practical maternal 36. Garcia-Canadilla P, Crispi F, Cruz-Lemini and ?-hCG median MoM. PRENATAL age-dependent approach for excess M, Valenzuela-Alcaraz B, Rudenick PA, DIAGNOSIS. 37(3):229-234. I.F.: 2.523 trisomy 21 risk calculation after a previous Gratacos E, Bijnens BH. Understanding the autosomal trisomy. THE JOURNAL OF Aortic Isthmus Doppler Profile and Its 44. Cobo T., Vives I., Rodríguez-Trujillo A., MATERNAL-FETAL & NEONATAL Changes with Gestational Age Using a Murillo C., Ángeles M., Bosch J., Vergara A., MEDICINE: THE OFFICIAL JOURNAL OF THE Lumped Model of the Fetal Circulation. Gratacós E., Palacio M. Impact of microbial EUROPEAN ASSOCIATION OF PERINATAL FETAL DIAGNOSIS AND THERAPY. invasion of amniotic cavity and the type of MEDICINE, THE FEDERATION OF ASIA AND 41(1):41-50. I.F.: 2.699 microorganisms on short-term neonatal OCEANIA PERINATAL SOCIETIES, THE outcome in women with preterm labor INTERNATIONAL SO. 30(13):1613-1615. 37. Perez-Cruz M., Crispi F., Fernández M., and intact membranes. ACTA I.F.: 1.826 Parra J., Valls A., Gomez Roig M., Gratacós E. OBSTETRICIA ET GYNECOLOGICA Cord Blood Biomarkers of Cardiac SCANDINAVICA. 96(5):570-579. I.F.: 2.480 50. Rodríguez-Trujillo A., Ríos J., Ángeles M., Dysfunction and Damage in Term Posadas D., Murillo C., Rueda C., Botet F., Growth-Restricted Fetuses Classified 45. Figueras F., Gratacos E., Rial M., Gull I., Bosch J., Vergara A., Gratacós E., Palacio M.,

146 FETAL AND PERINATAL MEDICINE 3.2

Cobo T. Influence of perinatal Laudanski, Piotr; Peelen, Myrthe J. C. S.; Gratacós E. EVERREST - Does vascular inflammation on the neurodevelopmental Helmer, Hanns; Lamont, Ronald F.; Takeda, endothelial growth factor gene therapy outcome of premature infants. THE Jun; Lapointe, Jerome; Torloni, Maria Regina; safely improve outcome in severe JOURNAL OF MATERNAL-FETAL & Zhong, Nanbert; Menon, Ramkumar. early-onset fetal growth restriction? NEONATAL MEDICINE : THE OFFICIAL Biomarkers of spontaneous preterm birth: Sponsored by: European Commission (FP7). JOURNAL OF THE EUROPEAN a systematic review of studies using 305823 ASSOCIATION OF PERINATAL MEDICINE, multiplex analysis. JOURNAL OF Duration: 01/01/2013-31/12/2018 THE FEDERATION OF ASIA AND OCEANIA PERINATAL MEDICINE. 45(1):71-84. I.F.: 1.577 PERINATAL SOCIETIES, THE Gratacós E. Preventing the neurological INTERNATIONAL SO. 1-9. I.F.: 1.826 and cardiovascular consequences of fetal GRANTS FOR RESEARCH IN PROGRESS growth restriction. 51. Soler A., Morales C., Mademont-Soler I., Sponsored by: Obra Social Fundació Margarit E., Borrell A., Borobio V., Munõz M., Borrell A. Pérdida gestacional precoz: La Caixa. CP041691 Sánchez A. Overview of Chromosome causas genéticas y riesgo de recurrencia. Duration: 01/01/2015 - 31/12/2018 Abnormalities in First Trimester Sponsored by: Instituto de Salud Carlos III Miscarriages: A Series of 1,011 (ISCIII). PI14/00588 Gratacós E. Identificación de moduladores Consecutive Chorionic Villi Sample Duration: 01/01/2015-31/12/2018 y dianas terapéuticas en el remodelado y Karyotypes. CYTOGENETIC AND GENOME enfermedad cardiovascular del adulto RESEARCH. 152(2):81-89. I.F.: 1.354 Cobo T. Validación de biomarcadores asociada a retraso de crecimiento proteómicos y metabolómicos de intrauterino. inflamación intraamniótica en el parto Sponsored by: Instituto de Salud Carlos III Review / I.F.: 17.204 prematuro en muestras cervico-vaginales (ISCIII). PI15/00130 y desarrollo de algoritmos clínicos Duration: 01/01/2016-31/12/2018 1. Benkarim O; Sanromà G; Zimmer V; predictores. Muñoz-Moreno E; Hahner N; Eixarch E; Sponsored by: Instituto de Salud Carlos III Garcia Algar O. Red de salud materno Camara O; González Ballester M; Piella G. (ISCIII). PI15/00344 infantil y del desarrollo. Toward the automatic quantification of in Duration: 01/01/2016-31/12/2018 Sponsored by: Instituto de Salud Carlos III utero brain development in 3D structural (ISCIII). RD12/0026/0003 MRI: A review. HUMAN BRAIN MAPPING. Crispi F. Impacto de la restricción de Duration: 04/01/2017-31/12/2017 38(5):2772-2787. I.F.: 4.530 crecimiento intrauterino en la dinámica del remodelado cardiovascular en las Garcia Algar O. Efectos clínicos de la 2. Bennasar M, Eixarch E, Martinez JM, diferentes etapas de la vida. exposición prenatal al alcohol: Gratacós E. Selective intrauterine growth Sponsored by: Instituto de Salud Carlos III seguimiento de una cohort. restriction in monochorionic diamniotic (ISCIII). PI14/00226 Sponsored by: Instituto de Salud Carlos III twin pregnancies. SEMINARS IN FETAL Duration: 01/01/2015-31/12/2018 (ISCIII). PI13/01135 AND NEONATAL MEDICINE. 22(6):376-382. Duration: 08/02/2017-31/12/2017 I.F.: 3.330 Eixarch E. Desarrollo de biomarcadores basados en conectividad cerebral para el Garcia Algar O. Red de Salud 3. Figueras F, Gratacos E. An integrated diagnóstico precoz de las alteraciones del Materno-Infantil y del desarrollo. approach to fetal growth restriction. BEST neurodesarrollo de origen prenatal. Sponsored by: Instituto de Salud Carlos III PRACT RES CLIN OBSTET GYNAECOL. Sponsored by: Instituto de Salud Carlos III (ISCIII). RD16/0022/0002 38:48-58. I.F.: 2.755 (ISCIII).PI13/01018 Duration:04/01/2017-31/12/2021 Duration: 01/01/2014-31/12/2017 4. Sabra, Sally; Gratacos, Eduard; Gomez Garcia Algar O. Alteraciones epigenéticas Roig, Maria Dolores. Smoking-Induced Eixarch E. Desarrollo de herramientas generadas por exposición prenatal al Changes in the Maternal Immune, predictivas para la identificación precoz de alcohol en pacientes con SAF (síndrome Endocrine, and Metabolic Pathways and las alteraciones del neurodesarrollo de alcohol fetal). Antioxidante Their Impact on Fetal Growth: A Topical origen prenatal basadas en el estudio del epigalocatequina (EGCG) como Review. FETAL DIAGNOSIS AND THERAPY. desarrollo cortical fetal. herramienta terapéutica. 41(4):241-250. I.F.: 2.699 Sponsored by: Instituto de Salud Carlos III Sponsored by: Instituto de Salud Carlos III (ISCIII). PI16/00861 (ISCIII). PI16/00566 5. Sehgal, A.; Crispi, F.; Skilton, M. R.; de Duration: 01/01/2017-31/12/2019 Duration: 17/03/2017-31/12/2019 Boode, W-P. Clinician performed ultrasound in fetal growth restriction: fetal, Figueras F. Papel del factor de crecimineto Gomez del Rincon O. Evaluación pronóstica neonatal and pediatric aspects. JOURNAL placentario en el manejo de la de las cardiopatías congénitas desde la OF PERINATOLOGY. 37(12):1251-1258. preeclampsia no severa: estudio etapa prenatal mediante ecocardiografía I.F.: 2.313 aleatorizado. Estudio MAP. avanzada y biomarcadores plasmáticos. Sponsored by: Instituto de Salud Carlos III Sponsored by: Instituto de Salud Carlos III 6. Polettini, Jossimara; Cobo, Teresa; (ISCIII). PI15/00903 (ISCIII). PI15/00263 Kacerovsky, Marian; Vinturache, Angela E.; Duration: 01/01/2016-31/12/2018 Duration: 01/01/2016-31/12/2018

147 AREA 3 LIVER, DIGESTIVE SYSTEM AND METABOLISM

DOCTORAL THESES

Gratacós E, Figueras F. Development of combined screening test for the prediction of preeclampsia and intrauterine growth restriction in the ﬁrst trimester of pregnancy. PhD student: Francesca Crovetto

Gratacós E, Figueras F. Brain effects of fetal growth restriction and their prevention in an animal model. PhD student: Miriam Illa Armengol

Borrell A. Valor de la translucencia nucal y ductus venoso, en la detección de malformaciones, translocaciones disbalanceadas y enfermedades monogénicas en la ecografía de las 11-14 semanas. PhD student: Marta Arigita Lastra

Crispi F, Gratacós E. Dynamics of cardiovascular remodeling in relation to fetal growth restriction across life course. PhD student: Mérida Rodriguez López

Botet F, Gratacós E. Evaluación de un programa de intervención prenatal para embarazadas con fetos pequeños para la edad gestacional. PhD student: Angela Arranz Betegón

Palacio M, Gratacós E. Cervical consistency index and quantitative cervical texture analysis by ultrasound to predict spontaneous preterm birth. PhD student: Núria Baños López

Vikhareva O, Figueras F. Scarred Uterus: Subsequent pregnancy and delivery. PhD student: Anton Baranov

148 VIRAL, TOXIC AND METABOLIC HEPATOPATHIES 3.3

Viral, toxic and 3.3 metabolic hepatopathies

NURSING STAFF Concepció Bartres (HCB) LOCATION

CEK building ﬂoor 4 COLLABORATORS Marta Montero (CIBER)

STRATEGIC OBJECTIVES

KEYWORDS - Inﬂuence of virological and immunological 1. Hepatitis C virus factors on the natural history and treatment TEAM LEADER 2. Direct-acting antivirals (DAA) Xavier Forns (HCB) response in chronic hepatitis B and C. - Characterization of the life cycle of HBV 3. Hepatitis B virus T. 93 227 54 99 and HCV using cell culture models. 4. Antiviral immune responses [email protected] 5. Wilson’s Disease - Efficacy of new antiviral regimens against 6. DILI HCV and its impact on the natural history of the disease. RESEARCHERS Josep Costa (HCB) Sabela Lens (HCB) MAIN LINES OF RESEARCH Maria Carlota Londoño (HCB) Zoe Mariño (HCB) - Natural history of chronic HBV infection in Original publications Sofía Pérez del Pulgar (CIBER) inactive carriers and patients in the “gray from 2015 to 2017 zone”. POST-DOCTORAL RESEARCHERS YEAR I.F. TOTAL Q1 Q2 - Molecular mechanisms and clinical Georgios Koutsoudakis (FCRB) signiﬁcance of cccDNA persistence in HBV 2015 186.06 23 15 7 infection, with particular emphasis on its 2016 135.49 22 18 2 PRE-DOCTORAL RESEARCHERS role in the recurrence of the infection after

2017 175.86 25 20 3 Martin Bonacci (CIBER) treatment interruption. Mireia García (IDIBAPS) - Validation of non-invasive diagnostic Elena Perpiñán (CIBER) methods of liver ﬁbrosis in HBV-infected Sergio Rodríguez (HCB) patients. - Cell culture of HBV using a microﬂuidic

TEAM INVOLVED IN TECHNICIANS bioreactor that simulates the hepatic CIBEREHD Patricia González (CIBER) microenvironment. AGAUR_SGR14 Thais Leonel (FCRB)

AWARDS Emili Letang ﬁ de residència Institution: HCB Awardee/s: Sergio Rodríguez-Tajes

Beca per a la Iniciació a Recerca Institution: Societat Catalana de Digestologia Awardee/s: Sergio Rodríguez-Tajes Xavier Forns

TEAM

149 AREA 3 LIVER, DIGESTIVE SYSTEM AND METABOLISM

- Inﬂuence of viral and host factors in the Calleja JL. Treatment of hepatitis C virus 8. Bonacci M, Lens S, Londoño MC, Mariño Z, natural history and response to treatment in infection in patients with cirrhosis and Cid MC, Ramos-Casals M, Sánchez-Tapias chronic hepatitis B. predictive value of model for end-stage JM, Forns X, Hernández-Rodríguez J. - Dynamics of resistance-associated liver disease: Analysis of data from the Virologic, Clinical, and Immune Response variants during therapy with direct-acting Hepa-C registry. HEPATOLOGY. Outcomes of Patients With Hepatitis C antivirals by massive sequencing. 65(6):1810-1822. I.F.: 13.246 Virus-Associated Cryoglobulinemia - Study of the innate and adaptive immune Treated With Direct-Acting Antivirals. responses in patients with chronic hepatitis 4. Pascasio JM, Vinaixa C, Ferrer MT, CLINICAL GASTROENTEROLOGY AND C receiving direct-acting antivirals. Colmenero J, Rubin A, Castells L, Manzano HEPATOLOGY. 15(4):575-583. I.F.: 7.398 - Impact of HCV elimination on the natural ML, Lorente S, Testillano M, Xiol X, Molina E, history of the disease and on González-Diéguez L, Otón E, Pascual S, 9. Crespo J., Calleja J., Fernández I., Sacristan hepatocellular carcinoma. Santos B, Herrero JI, Salcedo M, Montero JL, B., Ruiz-Antorán B., Ampuero J., - Natural history of chronic hepatitis C: Sánchez-Antolín G, Narváez I, Nogueras F, Hernández-Conde M., García-Samaniego J., development of predictive models of risk of Giráldez Á, Prieto M, Forns X, Londoño MC. Gea F., Buti M., Cabezas J., Lens S., Morillas R., progression to cirrhosis. Clinical outcomes of patients undergoing Salcines J., Pascasio J., Turnes J., - Clinical and virological analysis of antiviral therapy while awaiting liver Sáez-Royuela F., Arenas J., Rincón D., Prieto population outbreaks of hepatitis A in transplantation. JOURNAL OF M., Jorquera F., Sanchez Ruano J., Navascués Barcelona. HEPATOLOGY. 67(6):1168-1176. I.F.: 12.486 C., Molina E., Moya A., Moreno-Planas J., - Interplay between HBV, HDV and host Montoliu S., Serra M., Andrade R., Fernandez factors: impact on liver disease progression 5. Calleja JL, Crespo J, Rincón D, C., Fernández Bermejo M., Simon M., Bonet L., Ruiz-Antorán B, Fernandez I, Perelló C, Gea F, de la Vega J., Diago M., Fernández J., Sanchez Lens S, García-Samaniego J, Sacristán B, Antolin G. Real-World Effectiveness and García-Eliz M, Llerena S, Pascasio JM, Turnes Safety of Oral Combination Antiviral PUBLICATIONS J, Torras X, Morillas RM, Llaneras J, Serra MA, Therapy for Hepatitis C Virus Genotype 4 Diago M, Rodriguez CF, Ampuero J, Jorquera Infection. CLINICAL GASTROENTEROLOGY Originals / I.F.: 175.856 F, Simon MA, Arenas J, Navascues CA, AND HEPATOLOGY. 15(6):945-949.e1. Bañares R, Muñoz R, Albillos A, Mariño Z, I.F.: 7.398 1. Forns X, Lee SS, Valdes J, Lens S, Ghalib R, NULL Spanish Group for the Study of the Use of Aguilar H, Felizarta F, Hassanein T, Hinrichsen Direct-acting Drugs Hepatitis C Collaborating 10. Londoño MC, Lens S, Mariño Z, Bonacci H, Rincon D, Morillas R, Zeuzem S, Horsmans Group. Effectiveness, safety and clinical M, Ariza X, Broquetas T, Pla A, Bartres C, Y, Nelson DR, Yu Y, Krishnan P, Lin CW, Kort outcomes of direct-acting antiviral therapy in Adriani MV, Rodríguez-Tajes S, Costa J, JJ, Mensa FJ. Glecaprevir plus pibrentasvir HCV genotype 1 infection: Results from a Carrión JA, Pérez-Del-Pulgar S, Forns X. for chronic hepatitis C virus genotype 1, 2, Spanish real-world cohort. JOURNAL OF Hepatitis B reactivation in patients with 4, 5, or 6 infection in adults with HEPATOLOGY. 66(6):1138-1148-1148. chronic hepatitis C undergoing anti-viral compensated cirrhosis (EXPEDITION-1): a I.F.: 12.486 therapy with an interferon-free regimen. single-arm, open-label, multicentre phase ALIMENTARY PHARMACOLOGY AND 3 trial. LANCET INFECTIOUS DISEASES, 6. Fernandez, Inmaculada; Munoz-Gomez, THERAPEUTICS. 45(8):1156-1161. I.F.: 7.286 THE. 17(10):1062-1068. I.F.: 19.864 Raquel; Pascasio, Juan M.; Baliellas, Carme; Polanco, Natalia; Esforzado, Nuria; Arias, Ana; 11. Buti, M.; Calleja, J. L.; Lens, S.; Diago, M.; 2. Lens S, Alvarado-Tapias E, Mariño Z, Prieto, Martin; Castells, Lluis; Cuervas-Mons, Ortega, E.; Crespo, J.; Planas, R.; Londoño MC, LLop E, Martinez J, Fortea JI, Valentin; Hernandez, Olga; Crespo, Javier; Romero-Gomez, M.; Rodriguez, F. G.; Ibañez L, Ariza X, Baiges A, Gallego A, Bañares Calleja, Jose L.; Forns, Xavier; Londono, Pascasio, J. M.; Fevery, B.; Kurland, D.; Corbett, R, Puente A, Albillos A, Calleja JL, Torras X, Maria-Carlota. Efficacy and tolerability of C.; Kalmeijer, R.; Jessner, W. Simeprevir in Hernández-Gea V, Bosch J, Villanueva C, interferon-free antiviral therapy in kidney combination with sofosbuvir in treatment- Forns X, García-Pagán JC. Effects of All-oral transplant recipients with chronic hepatitis naïve and -experienced patients with Anti-viral Therapy on HVPG and Systemic C. J HEPATOL. 66(4):718-723. I.F.: 12.486 hepatitis C virus genotype 4 infection: a Hemodynamics in Patients with Hepatitis Phase III, open-label, single-arm study C Virus-associated Cirrhosis. 7. Lens S, Fernández I, Rodríguez-Tajes S, (PLUTO). ALIMENT PHARMACOL THER. GASTROENTEROLOGY. 153(5):1273-1283. Hontangas V, Vergara M, Forné M, Calleja JL, 45(3):468-475. I.F.: 7.286 I.F.: 18.392 Diago M, Llaneras J, Llerena S, Torras X, Sacristán B, Roget M, Fernández-Rodríguez 12. Koutsoudakis G, Paris de León A, Herrera 3. Fernández Carrillo C, Lens S, Llop E, CM, Navascués MC, Fuentes J, Sánchez- C, Dorner M, Pérez-Vilaró G, Lyonnais S, Pascasio JM, Crespo J, Arenas J, Fernández I, Ruano JJ, Simón MÁ, Sáez-Royuela F, Baliellas Grijalvo S, Eritja R, Meyerhans A, Mirambeau Baliellas C, Carrión JA, de la Mata M, Buti M, C, Morillas R, Forns X, Spanish Group for the G, Díez J. Oligonucleotide-Lipid Conjugates Castells L, Albillos A, Romero M, Turnes J, Study of the Use of Direct-acting Drugs Hepatitis Forming G-Quadruplex Structures Are Pons C, Moreno-Planas JM, Moreno- C Collaborating Group. Interferon-Free Potent and Pangenotypic Hepatitis C Virus Palomares JJ, Fernández-Rodriguez C, Therapy in Elderly Patients With Advanced Entry Inhibitors In Vitro and Ex Vivo. García-Samaniego J, Prieto M, Fernández Liver Disease. AMERICAN JOURNAL OF ANTIMICROBIAL AGENTS AND Bermejo M, Salmerón J, Badia E, Salcedo M, GASTROENTEROLOGY. 112(9):1400-1409. CHEMOTHERAPY. 61(5):e02354-16. Herrero JI, Granados R, Blé M, Mariño Z, I.F.: 9.566 I.F.: 4.302

150 VIRAL, TOXIC AND METABOLIC HEPATOPATHIES 3.3

13. Cano A, Mariño Z, Millet O, 17. Mariño Z, Pascasio-Acevedo JM, Gallego JOURNAL OF CLINICAL VIROLOGY. Martínez-Arranz I, Navasa M, Falcón-Pérez A, Diago M, Baliellas C, Morillas R, Prieto M, 92:42-47. I.F.: 3.051 JM, Pérez-Cormenzana M, Caballería J, Moreno JM, Sánchez-Antolín G, Vergara M, Embade N, Forns X, Bosch J, Castro A, Mato Forné M, Fernández I, Castro MA, Pascual S, 22. Riveiro-Barciela, Mar; Tabernero, David; JM. A Metabolomics Signature Linked To Gómez A, Castells L, Montero JL, Crespo J, Calleja, Jose L.; Lens, Sabela; Manzano, Maria Liver Fibrosis In The Serum Of Calleja JL, García-Samaniego J, Carrión JA, L.; Gea Rodriguez, Francisco; Crespo, Javier; Transplanted Hepatitis C Patients. Arencibia AC, Blasco A, López-Núñez C, Piqueras, Belen; Pascasio, Juan M.; Comas, SCIENTIFIC REPORTS. 7(1):10497. I.F.: 4.259 Sánchez-Ruano JJ, Gea-Rodríguez F, Carmen; Gutierrez, Maria L.; Aguirre, Alberto; Giráldez Á, Cabezas J, Hontangas V, Torras X, Suarez, Emilio; Garcia-Samaniego, Javier; 14. Afdhal N, Everson GT, Calleja JL, Castellote J, Romero-Gómez M, Turnes J, de Rivero, Miguel; Acero, Doroteo; McCaughan GW, Bosch J, Brainard DM, Artaza T, Narváez I, Cuervas-Mons V, Forns X. Fernandez-Bermejo, Miguel; Moreno, Diego; McHutchison JG, De-Oertel S, An D, Charlton High efficacy of Sofosbuvir plus Sanchez-Pobre, Pilar; de Cuenca, Beatriz; M, Reddy KR, Asselah T, Gane E, Curry MP, Simeprevir in a large cohort of Spanish Moreno-Palomares, J. J.; Esteban, Rafael; Buti, Forns X. Effect of viral suppression on cirrhotic patients infected with genotypes Maria. Effectiveness and Safety of hepatic venous pressure gradient in 1 and 4. LIVER INTERNATIONAL. Entecavir or Tenofovir in a Spanish Cohort hepatitis C with cirrhosis and portal 37(12):1823-1832. I.F.: 4.116 of Chronic Hepatitis B Patients: Validation hypertension. JOURNAL OF VIRAL of the Page-B Score to Predict HEPATITIS. 24(10):823-831. I.F.: 4.122 18. Fernández Carrillo C, Crespo G, de la Hepatocellular Carcinoma. DIG DIS SCI. Revilla J, Castells L, Buti M, Montero JL, 62(3):784-793. I.F.: 2.875 15. Alonso S., Riveiro-Barciela M., Fernandez I., Fábrega E, Fernández I, Serrano-Millán C, Rincón D., Real Y., Llerena S., Gea F., Olveira A., Hernández V, Calleja JL, Londoño MC. 23. Garriga C., Manzanares-Laya S., García Fernandez-Carrillo C., Polo B., Carrión J., Successful Continuation of HCV De Olalla P., Gorrindo P., Lens S., Solà R., Gómez A., Devesa M., Baliellas C., Castro, Treatment After Liver Transplantation. Martínez-Rebollar M., Laguno M., Navarro J., Ampuero J., Granados R., Pascasio J., Rubín TRANSPLANTATION. 101(5):1009-1012. Torras X., Gurguí M., Barberá M., Quer J., A., Salmeron J., Badia E., Planas J., Lens S., I.F.: 3.678 Masdeu E., Simón P., Ros M., De Andrés A., Turnes J., Montero J., Buti M., Esteban R., Caylà J. Evolution of acute hepatitis C virus Fernández-Rodríguez C. Effectiveness and 19. Dlouhy I, Torrente MÁ, Lens S, Rovira J, infection in a large European city: Trends safety of sofosbuvir-based regimens plus Magnano L, Giné E, Delgado J, Balagué O, and new patterns. PLOS ONE. an NS5A inhibitor for patients with HCV Martínez A, Campo E, Forns X, 12(11):e0187893. I.F.: 2.806 genotype 3 infection and cirrhosis. Results Sánchez-Tapias JM, López-Guillermo A. of a multicenter real-life cohort. JOURNAL OF Clinico-biological characteristics and 24. Coto-Llerena M, Koutsoudakis G, Boix L, VIRAL HEPATITIS. 24(4):304-311. I.F.: 4.122 outcome of hepatitis C virus-positive López-Oliva JM, Caro-Pérez N, patients with diffuse large B-cell Fernández-Carrillo C, González P, 16. Perelló C., Carrión J., Ruiz-Antorán B., lymphoma treated with Gastaminza P, Bruix J, Forns X, Crespo J., Turnes J., Llaneras J., Lens S., immunochemotherapy. ANNALS OF Pérez-Del-Pulgar S. Permissiveness of Delgado M., García-Samaniego J., HEMATOLOGY. 96(3):405-410. I.F.: 3.083 human hepatocellular carcinoma cell lines García-Paredes F., Fernández I., Morillas R., for hepatitis C virus entry and replication. Rincón D., Porres J., Prieto M., Lázaro Ríos M., 20. Salcedo M, Prieto M, Castells L, Pascasio VIRUS RESEARCH. 240:35-46. I.F.: 2.628 Fernández-Rodríguez C., Hermo J., Rodríguez JM, Montero Alvarez JL, Fernández I, M., Herrero J., Ruiz P., Fernández J., Macías M., Sánchez-Antolín G, González-Diéguez L, 25. Forns X; Berenguer M; Herzer K; Sterneck Pascasio J., Moreno J., Serra M., Arenas J., García-Gonzalez M, Otero A, Lorente S, M; Donato M; Andreone P; Fagiuoli S; Cieciura Real Y., Jorquera F., Calleja J., Sáez Rayuela F., Espinosa MD, Testillano M, González A, T; Durlik M; Calleja J; Marino Z; Shukla U; Simón M., González J., Muñoz E., González M., Castellote J, Casafont F, Londoño MC, Pons Verbinnen T; Lenz O; Ouwerkerk-Mahadevan Jiménez M., Moran S., Vergara-Gómez M., JA, Molina Pérez E, Cuervas-Mons V, Pascual S; Peeters M; Janssen K; Kalmeijer R; Jessner Jiménez F., García R., Perelló C., Carrión J., S, Herrero JI, Narváez I, Vinaixa C, Llaneras J, W. Efficacy, safety, and pharmacokinetics Ruiz-Antorán B., Crespo J., Turnes J., Llaneras J., Sousa JM, Bañares R. Efficacy and safety of of simeprevir, daclatasvir, and ribavirin in Lens S., Delgado M., García-Samaniego J., daclatasvir-based antiviral therapy in HCV patients with recurrent hepatitis C virus García-Paredes F., Fernández I., Morillas R., recurrence after liver transplantation. Role genotype 1b infection after orthotopic liver Rincón D., Porres J., Prieto M., Lázaro Ríos M., of cirrhosis and genotype 3. A multi-centre transplantation: The Phase II SATURN Fernández-Rodríguez C., Hermo J., Rodríguez cohort study. TRANSPLANT study. TRANSPLANT INFECTIOUS DISEASE. M., Herrero J., Ruiz P., Fernández J., Macías M., INTERNATIONAL. 30(10):1041-1050. I.F.: 3.079 19(3). I.F.: 1.719 Pascasio J., Moreno J., Serra M., Arenas J., Real Y., Jorquera F., Calleja J., Sáez Rayuela F., Simón 21. Caro-Pérez N; Martínez-Rebollar M; M., González J., Muñoz E. Effectiveness and Gregori J; Quer J; González P; Gambato M; Review / I.F.: 7.275 safety of ombitasvir, paritaprevir, ritonavir ± García-González N; González-Candelas F; dasabuvir ± ribavirin: An early access Costa J; Esteban J; Mallolas J; Forns X; 1. Reig M, Boix L, Mariño Z, Torres F, Forns X, programme for Spanish patients with Laguno M; Perez-Del-Pulgar S. Phylogenetic Bruix J. Liver Cancer Emergence genotype 1/4 chronic hepatitis C virus analysis of an epidemic outbreak of acute Associated with Antiviral Treatment: An infection. JOURNAL OF VIRAL HEPATITIS. hepatitis C in HIV-infected patients by Immune Surveillance Failure? SEMINARS 24(3):226-237. I.F.: 4.122 ultra-deep pyrosequencing. IN LIVER DISEASE. 37(2):109-118. I.F.: 5.500

151 AREA 3 LIVER, DIGESTIVE SYSTEM AND METABOLISM

2. Lens S, Rodriguez-Tajes S, Llovet LP, GRANTS FOR RESEARCH IN PROGRESS DOCTORAL THESES Maduell F, Londoño MC. Treating Hepatitis C in Patients with Renal Failure. DIGESTIVE Forns X. Human monoclonal antibody Pérez del Pulgar S, Diez J. Nuevos factores DISEASES. 35(4):339-346. I.F.: 1.775 therapy to prevent hepatitis C virus del hospedador en la ﬁsiopatología y la reinfection of liver transplants: advancing respuesta al tratamiento antiviral de la lead monoclonal antibodies into clinical infección por el virus de la hepatitis C. Letters / I.F.: 40.396 trial. PhD student: Carlos Fernández Carrillo Sponsored by: European Commission (FP7). 1. Forns X, Mensa F. Proton-pump inhibitors 305600 Pérez del Pulgar S, Londoño MC. Factores and glecaprevir plus pibrentasvir in HCV Duration: 01/01/2013-31/12/2017 virológicos, inmunológicos y infection – Authors' reply. LANCET epidemiológicos relacionados con la INFECTIOUS DISEASES, THE. 17(12):1240. Forns X. Estudio de los factores virológicos hepatitis C y su tratamiento. I.F.: 19.864 e inmunológicos relacionados con la PhD student: Noelia Caro Pérez recurrencia de la infección por los virus 2. Forns, Xavier;Liver Unit. Juan Rodes, MD, de la hepatitis C y B tras la interrupción Ph.D. (1938-2017): Excellence and del tratamiento antiviral. Leadership OBITUARY. HEPATOLOGY. Sponsored by: Instituto de Salud Carlos III 65(6):2137-2138. I.F.: 13.246 (ISCIII). PI15/00151 Duration: 01/01/2016-31/12/2018 3. Londoño MC, Carrión JA, Forns X. Letter: hepatitis B reactivation in patients with Londoño MC. Lesiones inﬂamatorias en el chronic hepatitis C during direct-acting injerto tras la erradicación del virus de la antiviral therapy-authors' reply. hepatitis C con antivirales directos en ALIMENTARY PHARMACOLOGY AND receptores de trasplante hepático. THERAPEUTICS. 45(12):1559-1560. I.F.: 7.286 Sponsored by: CIBER de Enfermedades Hepáticas y Digestivas Duration: 01/02/2017-31/01/2019 Editorial / I.F.: 24.557 Pérez del Pulgar S. Factores virológicos 1. Koutsoudakis G, Pérez-Del-Pulgar S, Forns e inmunológicos relacionados con el X. Occult Hepatitis C Virus Infection: Are tratamiento antiviral y la recurrencia de We Digging Too Deep? la hepatitis C después del trasplante GASTROENTEROLOGY. 152(3):472-474. hepático. I.F.: 18.392 Sponsored by: Instituto de Salud Carlos III (ISCIII). PI13/00155 2. Fishman JA, Forns X. HCV-positive Donor Duration: 01/01/2014-31/03/2017 Organs in Solid Organ Transplantation: Mind the Gap! AMERICAN JOURNAL OF Pérez del Pulgar S. Estudio de la TRANSPLANTATION. 17(11):2755-2756. persistencia del cccDNA durante la I.F.: 6.165 infección por el VHB in vivo, e in vitro mediante un bioreactor que simula el microambiente hepático. Case Reports / I.F.: 1.678 Sponsored by: Instituto de Salud Carlos III (ISCIII). PI16/00111 1. Senin, Alicia; Broquetas, Teresa; Lens, Duration: 01/01/2017-31/12/2019 Sabela; Canete, Nuria; Londono, Maria-Carlota; Ferraro, Mariana; Forns, Xavier; Forns X. Virological and immunological Salar, Antonio; Carrion, Jose A. Aplastic factors associated with hepatitis C and Anemia and Severe Myelosuppression hepatitis B virus infection recurrence with Boceprevir or Simeprevir-Containing after treatment discontinuation. Hepatitis C Virus Treatment. ANNALS OF Sponsored by: Gilead. GLD15/00274 HEPATOLOGY. 16(2):312-317. I.F.: 1.678 Duration: 07/03/2016-06/03/2018

Clinical Guidelines / I.F.: 12.486

1. European Ass Study Liver. EASL Recommendations on Treatment of Hepatitis C 2016. JOURNAL OF HEPATOLOGY. 66(1):153-194. I.F.: 12.486

152 MECHANISMS OF LIVER DISEASE AND COMPLICATIONS OF CIRRHOSIS 3.4

Mechanisms of liver disease 3.4 and complications of cirrhosis

Marta Duran-Güell (FCRB) Roger Flores-Costa (FCRB) LOCATION Patricia Huelin (FCRB) CEK building ﬂoor 3 Laura Napoleone (IDIBAPS) Marina Parra (HCB) Luis Perea (IDIBAPS) Meritxell Perramon (IDIBAPS) Elisa Pose (IDIBAPS) Cristina Sole (HCB) KEYWORDS Julia Vallverdú (IDIBAPS) 1. Cirrhosis TEAM LEADER 2. Non-alcoholic steatohepatitis Pere Ginès (HCB) TECHNICIANS 3. Liver stem cells T. 93 227 17 13 Montse Bernat (HCB) 4. Kidney failure [email protected] Carmen Cano (HCB) 5. Chronic liver diseases Cristina Díez (HCB) Anabel Martínez (FCRB) Albert Salvatella (FCRB) GROUP LEADERS Joan Clària (HCB) ADMINISTRATIVE STAFF T. 93 227 5400 (Ext.: 4784) Rosario Poblet (IDIBAPS) Original publications [email protected] Nicki Van Berckel (HCB-FCRB) from 2015 to 2017 Pere Ginès (HCB) NURSING STAFF YEAR I.F. TOTAL Q1 Q2 T. 93 227 17 13 Marta Carol (IDIBAPS) 2015 171.20 23 19 3 [email protected] Gloria de Prada (HCB)

2016 182.19 25 21 2 Wladimiro Jiménez (HCB) COLLABORATORS 2017 140.22 23 17 2 T. 93 227 5400 (Ext.: 2199) Bernardino González (HCB) [email protected] Enric Reverter (HCB) Esther Titos (CIBER) Pau Sancho-Bru (IDIBAPS) T. 93 2275400 (Ext.: 3371) TEAM INVOLVED IN [email protected] STRATEGIC OBJECTIVES CIBEREHD AGAUR_SGR14 To investigate new therapeutic and diagnostic AGAUR_SGR17 EMERITUS strategies in the most common complications Vicente Arroyo (HCB) present in chronic liver diseases. The basic and translational studies investigate the RESEARCHERS mechanisms implicated in disease Gregori Casals (HCB) progression of chronic liver diseases as well as Núria Fabrellas (UB) the role of progenitor cells in liver regeneration AWARDS Javier Fernández-Gómez (HCB) and tissue repair. To assess the role of International Albus Award Manuel Morales (HCB) bioactive lipid mediators on the onset and Institution: Grifols resolution of systemic and tissue inﬂammatory Awardee/s: Joan Clària POST-DOCTORAL RESEARCHERS responses in chronic liver disease. Maria del Mar Coll (CIBER) ICREA Academia Guillermo Fernández-Varo (CIBER) Institution: Institut Catalana de Recerca Isabel Graupera (HCB) MAIN LINES OF RESEARCH i Estudis Avançats Cristina López-Vicario (FCRB) Awardee/s: Pere Ginès Pedro Melgar (FCRB) 1. To explore new therapeutic targets Jordi Ribera (CIBER) useful in the treatment of endothelial Elsa Solà (HCB) dysfunction, vascular remodeling, hepatic ﬁbrosis and the characteristic PRE-DOCTORAL RESEARCHERS hemodynamic disturbances of chronic Beatriz Aguilar (IDIBAPS) liver diseases. José Alcaraz-Quiles (HCB) 2. To search for molecular strategies to Delia Blaya (IDIBAPS) stimulate a functional liver regeneration. Silvia Carvajal (FCRB) 3. To identify novel serum biomarkers of liver Mireia Casulleras (FCRB) disease progression and complications of Bernat Cordoba (IDIBAPS) cirrhosis.

153 154 AREA 3 inAcute-on-ChronicLiverFailure. and cellstohomeostasis. of inflammationandthereturntissues mediators thatcontrolthetimelyresolution recently-characterized pro-resolvinglipid Special attentionisgiventothe an uncontrolledinflammatoryresponse. series andtheirroleintheprogressionof fatty acidsofbothomega-6andomega-3 mediators generatedfrompolyunsaturated inflammatory mediators,especiallylipid Our mainfocusisonthestudyof to patientsafflictedwithchronicliverdisease. and experimentalstudiestotranslatethem Our researchgroupconductsbothbasic Joan Clària GROUP LEADER AND LIVERDISEASE INFLAMMATION RESEARCH GROUP 9. 8. particularlynon-alcoholicsteatohepatitis. obesity-associatedcomplications, inadiposetissueanditsrelationshipwith 7. andomega-3polyunsaturatedfattyacids. mediatorsgeneratedfrombothomega-6 particularemphasisontheroleoflipid 6. andprogenitorcellsinliverdisease. 5. ACLF. (ACLF)andidentifynewbiomarkersof acute-on-chronicliverfailuredevelopment 4. livercellsfordiseasemodeling. Mechanisms ofresolutioninflammation Toinvestigatetheroleoflivercellplasticity Tostudytheroleofsystemicinflammation ToexplorethepotentialofiPSC-derived ehnsso ie namto,wt Mechanismsofliverinflammation,with oivsiaemlclrptwy f Toinvestigatemolecularpathwaysof

LIVER, DIGESTIVE SYSTEM ANDMETABOLISM (HCB)

GROUP Joan Clària GROUP Pere Ginès basic-translational studies. advance diseaseviaclinicaland chronicliver diseasesandprogressionto Our groupfocusesonthestudyof Pere Ginès GROUP LEADER CLINICAL CONSEQUENCES MOLECULAR MECHANISMSAND CHRONIC LIVERDISEASES: RESEARCH GROUP (HCB)

diseases. during Role andmechanismsofliverprogenitorcells of cirrhosis. using cellculturesandexperimentalmodels Identifying pointsofinterventionincirrhosis and possibleinﬂuenceofextrahepaticfactors. networks relevanttodiseaseprogression stages ofdiseasetoassessmolecular ACLF. Analysisofliversamplesatvarying simvastatin asatreatmentforpreventionof Efficacy andsafetyofrifaximin stages oflivercirrhosis,particularlyinACLF. Intestinal microbiomeinpatientswithdifferent biomarkers anddiseaseprogression. dysfunction incirrhosis.Inﬂammatory treatment ofrenal diagnosis and Main areas: liver regenerationinend-stage Roleofurinebiomarkersin MECHANISMS OF LIVER DISEASE AND COMPLICATIONS OF CIRRHOSIS 3.4

RESEARCH GROUP TRANSLATIONAL RESEARCH IN NEW THERAPEUTIC AND DIAGNOSTIC STRATEGIES IN LIVER DISEASES

GROUP LEADER Wladimiro Jiménez (HCB)

Our group have an extensive research experience on the pathophysiological and molecular bases of the most common complications present in patients with chronic liver disease. The projects have a profound Wladimiro Jiménez translational character, with special interest in

identifying new therapeutic tools to stop or GROUP reverse the progression of the ﬁbroproliferative events. We also intend that the knowledge generated in these studies result in substantial improvements in the biochemical diagnosis of patients, which also constitutes a substantial part of our activity. This would represent an improvement from the point of view of comfort, diagnosis, monitoring and treatment of patients with liver disease.

RESEARCH GROUP LIVER PLASTICITY AND TISSUE REPAIR Pau Sánchez-Bru

GROUP GROUP LEADER Pau Sancho-Bru (IDIBAPS) exploring the potential of iPSC-derived liver Polymorphisms in the IL-1 gene cluster Liver regeneration and tissue repair are cells for the generation of multicellular in vitro influence systemic inflammation in complex and well-orchestrated processes models of liver disease. patients at risk for acute-on-chronic liver that become deregulated in chronic liver failure. HEPATOLOGY. 65(1):202-216. disease. By using human samples, animal I.F.: 13.246 models as well as primary and stem cell-based PUBLICATIONS in vitro approaches we aim at identifying those 2. Perea L, Coll M, Sanjurjo L, Blaya D, factors leading to deficient liver regeneration Originals / I.F.: 140.223 Taghdouini AE, Rodrigo-Torres D, Altamirano and tissue repair and to develop means to J, Graupera I, Aguilar-Bravo B, Llopis M, enhance liver function in chronic liver disease. 1. Alcaraz-Quiles J, Titos E, Casulleras M, Vallverdú J, Caballeria J, van Grunsven LA, Our group is particularly interested in Pavesi M, López-Vicario C, Rius B, Lopategi A, Sarrias MR, Ginès P, Sancho-Bru P. understanding cell plasticity and inflammatory de Gottardi A, Graziadei I, Gronbaek H, Ginès Pentraxin-3 Modulates LPS-induced responses in chronic liver injury, as well as P, Bernardi M, Arroyo V, Clària J. Inflammatory Response and Attenuates

155 AREA 3 LIVER, DIGESTIVE SYSTEM AND METABOLISM

Liver Injury. HEPATOLOGY. 66(3):953-968. The specialized pro-resolving lipid 15. Fernandez, Javier; Acevedo, Juan; Prado, I.F.: 13.246 mediator maresin 1 protects hepatocytes Veronica; Mercado, Mario; Castro, Miriam; from lipotoxic and hypoxia-induced Pavesi, Marco; Arteaga, Mireya; Sastre, Lydia; 3. Bissonnette J, Altamirano J, Devue C, Roux endoplasmic reticulum stress. FASEB Juanola, Adria; Gines, Pere; Arroyo, Vicente. O, Payancé A, Lebrec D, Bedossa P, Valla D, JOURNAL. 31(12):5384-5398. I.F.: 5.498 Clinical course and short-term mortality of Durand F, Ait-Oufella H, Sancho-Bru P, cirrhotic patients with infections other Caballeria J, Ginès P, Boulanger CM, Bataller 10. Kerbert, Annarein J. C.; Verspaget, Hein W.; than spontaneous bacterial peritonitis. R, Rautou PE. A Prospective study of the Navarro, Alex Amoros; Jalan, Rajiv; Sola, Elsa; LIVER INTERNATIONAL. 37(3):385-395. utility of plasma biomarkers to diagnose Benten, Daniel; Durand, Francois; Gines, Pere; I.F.: 4.116 alcoholic hepatitis. HEPATOLOGY. van der Reijden, Johan J.; van Hoek, Bart; 66(2):555-563. I.F.: 13.246 Coenraad, Minneke J.; EASL-CLIF 16. Solà E, Sanchez-Cabús S, Rodriguez E, Consortium. Copeptin in acute Elia C, Cela R, Moreira R, Pose E, 4. Altamirano J, López-Pelayo H, Michelena J, decompensation of liver cirrhosis: Sánchez-Delgado J, Cañete N, Morales-Ruiz Jones PD, Ortega L, Ginès P, Caballería J, Gual relationship with acute-on-chronic liver M, Campos F, Balust J, Guevara M, A, Bataller R, Lligoña A. Alcohol abstinence failure and short-term survival. CRITICAL García-Valdecasas JC, Ginès P. Effects of in patients surviving an episode of CARE. 21(1):321. I.F.: 5.358 alfapump™ system on kidney and alcoholic hepatitis: Prediction and impact circulatory function in patients with on long-term survival. HEPATOLOGY. 11. Penela D, Acosta J, Andreu D, Ortiz-Perez cirrhosis and refractory ascites. LIVER 66(6):1842-1853. I.F.: 13.246 JT, Bosch X, Perea RJ, de Caralt TM, TRANSPLANTATION. 23(5):583-593. Fernández-Armenta J, Soto-Iglesias D, I.F.: 3.910 5. Marin V, Poulsen K, Odena G, McMullen MR, Prat-Gonzalez S, Borràs R, Mont L, Hervas V, Altamirano J, Sancho-Bru P, Tiribelli C, Morales-Ruiz M, Jiménez W, Mira A, Donnelly 17. Ribera J, Pauta M, Melgar-Lesmes P, Caballeria J, Rosso N, Bataller R, Nagy LE. J, Ekinci O, Lasalvia L, Berruezo A. Córdoba B, Bosch A, Calvo M, Rodrigo-Torres Hepatocyte-derived macrophage Identification of the Potentially D, Sancho-Bru P, Mira A, Jiménez W, migration inhibitory factor mediates Arrhythmogenic Substrate in the Acute Morales-Ruiz M. A small population of liver alcohol-induced liver injury in mice and Phase of ST-elevation Myocardial endothelial cells undergoes endothelial to patients. JOURNAL OF HEPATOLOGY. Infarction. HEART RHYTHM. 14(4):592-598. mesenchymal transition in response to 67(5):1018-1025. I.F.: 12.486 I.F.: 4.866 chronic liver injury. AMERICAN JOURNAL OF PHYSIOLOGY - GASTROINTESTINAL 6. Puthumana J, Ariza X, Belcher JM, 12. Sánchez E., Nieto J., Vidal S., Santiago A., AND LIVER PHYSIOLOGY. Graupera I, Ginès P, Parikh CR. Urine Martinez X., Sancho F., Sancho-Bru P., Mirelis 313(5):G492-G504. I.F.: 3.468 Interleukin 18 and Lipocalin 2 are B., Corominola H., Juárez C., Manichanh C., Biomarkers of Acute Tubular Necrosis in Guarner C., Soriano G. Fermented milk 18. Soto M; Sampietro-Colom L; Lasalvia L; Patients With Cirrhosis: A Systematic containing Lactobacillus paracasei subsp. Mira A; Jimenez W; Navasa M. Cost- Review and Meta-Analysis. CLINICAL paracasei CNCM I-1518 reduces bacterial effectiveness of enhanced liver fibrosis GASTROENTEROLOGY AND translocation in rats treated with carbon test to assess liver fibrosis in chronic HEPATOLOGY. 15(7):1003-1013. I.F.: 7.398 tetrachloride. SCIENTIFIC REPORTS. hepatitis C virus and alcoholic liver disease 7:45712. I.F.: 4.259 patients. WORLD JOURNAL OF 7. Huelin P., Piano S., Solà E., Stanco M., Solé GASTROENTEROLOGY. 23(17):3163-3173. C., Moreira R., Pose E., Fasolato S., Fabrellas 13. Lopez-Vicario, Cristina; Rius, Bibiana; I.F.: 3.365 N., de Prada G., Pilutti C., Graupera I., Ariza X., Alcaraz-Quiles, Jose; Gonzalez-Periz, Ana; Romano A., Elia C., Cárdenas A., Fernández J., Isabel Martinez-Puchol, Ana; Casulleras, 19. Aranda, Gloria; Lopez, Cristina; Angeli P., Ginès P. Validation of a Staging Mireia; Duran-Guell, Marta; Ibarzabal, Ainitze; Fernandez-Ruiz, Rebeca; Esteban, Yaiza; System for Acute Kidney Injury in Patients Corcelles, Ricard; Laguna-Fernandez, Andres; Garcia-Eguren, Guillermo; Mora, Mireia; With Cirrhosis and Association With Back, Magnus; Titos, Esther; Claria, Joan. Halperin, Irene; Casals, Gregori; Ensenat, Acute-on-Chronic Liver Failure. CLINICAL Association of a variant in the gene Joaquim; Hanzu, Felicia A. Circulatory GASTROENTEROLOGY AND encoding for ERV1/ChemR23 with Immune Cells in Cushing Syndrome: HEPATOLOGY. 15(3):438-445. I.F.: 7.398 reduced inflammation in visceral adipose Bystanders or Active Contributors to tissue from morbidly obese individuals. Atherometabolic Injury? A Study of 8. Pose E., Solà E., Piano S., Gola E., Graupera SCIENTIFIC REPORTS. 7(1):15724. Adhesion and Activation of Cell Surface I., Guevara M., Cárdenas A., Angeli P., Ginès P. I.F.: 4.259 Markers. INTERNATIONAL JOURNAL Limited Efficacy of Tolvaptan in Patients OF ENDOCRINOLOGY. 2017:2912763 with Cirrhosis and Severe Hyponatremia: 14. Graupera I, Coll M, Pose E, Elia C, Piano S, I.F.: 2.510 Real-Life Experience. AMERICAN Solà E, Blaya D, Huelin P, Solé C, Moreira R, de JOURNAL OF MEDICINE. 130(3):372-375. Prada G, Fabrellas N, Juanola A, Morales-Ruiz 20. Sans-Roselló J, Casals G, Rossello X, I.F.: 5.550 M, Sancho-Bru P, Villanueva C, Ginès P. González de la Presa B, Vila M, Duran-Cambra Adipocyte Fatty-Acid Binding Protein is A, Morales-Ruiz M, Ferrero-Gregori A, 9. Rius B, Duran-Güell M, Flores-Costa R, Overexpressed in Cirrhosis and Correlates Jiménez W, Sionis A. Prognostic value of López-Vicario C, Lopategi A, Alcaraz-Quiles J, with Clinical Outcomes. SCIENTIFIC plasma apelin concentrations at admission Casulleras M, Lozano JJ, Titos E, Clària J. REPORTS. 7(1):1829. I.F.: 4.259 in patients with ST-segment elevation

156 MECHANISMS OF LIVER DISEASE AND COMPLICATIONS OF CIRRHOSIS 3.4

acute myocardial infarction. 5. Almeida J., Solà-Valls N., Pose E., Blanco Y., GRANTS FOR RESEARCH IN PROGRESS CLIN BIOCHEM. 50(6):279-284. I.F.: 2.434 Sepúlveda M., Llufriu S., Gines P., Saiz A. Liver injury and glatiramer acetate, an Casals G. Evaluación de las propiedades 21. Reyes A, Marti J, Marfà S, Jiménez W, uncommon association: Case report and antioxidantes y antiinﬂamatorias de las Reichenbach V, Pelegrina A, Fondevila C, literature review. THERAPEUTIC nanopartículas de óxido de cerio como Garcia Valdecasas JC, Fuster J. Prognostic ADVANCES IN NEUROLOGICAL nueva estrategia terapéutica en la prediction by liver tissue proteomic DISORDERS. 10(11):367-372. I.F.: 4.192 esteatosis hepática. proﬁling in patients with colorectal liver Sponsored by: Instituto de Salud Carlos III metastases. FUTURE ONCOLOGY. (ISCIII). PI15/00777 13(10):875-882. I.F.: 2.131 Letters / I.F.: 18.733 Duration: 01/01/2016-31/12/2018

22. Miró Ò, González de la Presa B, 1. Sola, Elsa; Kerbert, Annarein; Coenraad, Claria J. Mecanismos moleculares Herrero-Puente P, Fernández Bonifacio R, Minneke; Gines, Pere. Reply to: Are we still determinantes de la resolución Möckel M, Mueller C, Casals G, Sandalinas S, searching for the fifth element of MELD? inadecuada de la inflamación en tejido Llorens P, Martín-Sánchez FJ, Jacob J, Bedini JOURNAL OF HEPATOLOGY. 66(1):247-248. adiposo obeso. Nuevas oportunidades en JL, Gil V. The GALA study: relationship I.F.: 12.486 la prevención de comorbilidades between galectin-3 serum levels and metabólicas. short- and long-term outcomes of patients 2. Fernandez, Javier; Acevedo, Juan; Arroyo, Sponsored by: Ministerio de Economia y with acute heart failure. BIOMARKERS. Vicente. Response to the clinical course Competitividad. SAF2015-63674-R 22(8):731-739. I.F.: 2.006 and short-term mortality of cirrhotic Duration: 01/01/2016-31/12/2019 patients with non-spontaneous bacterial 23. Kerbert AJ, Schaapman JJ, van der peritonitis infections. LIVER Claria J. Identification of novel modulators Reijden JJ, Amorós Navarro À, McCormick A, INTERNATIONAL. 37(4):623. I.F.: 4.116 of chronic inflammation in prevalent van Hoek B, Arroyo V, Ginès P, Jalan R, Vargas diseases: unveiling divergent mechanisms V, Stauber R, Verspaget HW, Coenraad MJ, 3. Reyes A, Marti J, Marfa S, Jimenez W, of disease. CANONIC Study Investigators of the Reichenbach V, Pelegrina A, Fondevila C, Sponsored by: Instituto de Salud Carlos III EASL-CLIF Consortium. Impact of genetic Valdecasas JC, Fuster J. Letter in reply: (ISCIII). PIE14/00045 variation in the vasopressin 1a receptor on Prognostic prediction by liver tissue Duration: 01/01/2015-31/12/2017 the development of organ failure in proteomic profiling in patients with patients admitted for acute colorectal liver metastases. FUTURE Fernández Gómez J. Impacto clinico y decompensation of liver cirrhosis. ONCOLOGY. 13(3):1135-1136. I.F.: 2.131 coste/eficacia de estrategias de vigilancia EUR J GASTROENTEROL HEPATOL. epidemiológica y de optimización 29(5):535-538. I.F.: 1.968 farmacoterapéutica antibiótica en la Editorial / I.F.: 37.428 cirrosis descompensada. Sponsored by: Instituto de Salud Carlos III Review / I.F.: 38.465 1. Ginès P. Juan Rodés-In Memoriam. (ISCIII). PI16/00885 GASTROENTEROLOGY. 152(6):1249-1250. Duration: 01/01/2017-31/12/2019 1. Hernaez R., Solà E., Moreau R., Ginès P. I.F.: 18.392 Acute-on-chronic liver failure: An update. Ginès P. Insuficiencia hepática crónica GUT. 66(3):541-552. I.F.: 16.658 2. Colmenero J; Sancho-Bru P. agudizada y disfunción multiorgánica: Mesenchymal stromal cells for Mecanismos moleculares y evaluación de 2. Casals E, Gusta MF, Piella J, Casals G, immunomodulatory cell therapy in liver nuevos métodos diagnósticos y Jiménez W, Puntes V. Intrinsic and Extrinsic transplantation: One step at a time. terapéuticos. Properties Affecting Innate Immune JOURNAL OF HEPATOLOGY. 67(1):7-9. Sponsored by: Instituto de Salud Carlos III Responses to Nanoparticles: The Case of I.F.: 12.486 (ISCIII). PI12/00330 Cerium Oxide. FRONTIERS IN Duration: 01/01/2013-31/12/2018 IMMUNOLOGY. 8:970. I.F.: 6.429 3. Solà E, Ginès P. Pro: Acute-on-chronic liver failure. LIVER TRANSPLANTATION. Ginès P. Clinical evaluation of carbons of 3. Claria J; López-Vicario C; Rius B; Titos E. 23(10):1318-1324. I.F.: 3.910 controlled porosity as a new therapy for Pro-resolving actions of SPM in adipose the treatment of liver cirrhosis and tissue biology. MOLECULAR ASPECTS OF 4. Steinhilber, Dieter; Uydes-Dogan, B. non-alcoholic fatty liver disease. MEDICINE. 58:83-92. I.F.: 5.686 Sonmez; Topal, Gokce; Claria, Joan; Norel, Sponsored by: European Commission Xavier; Schebb, Nils Helge; Bannenberg, (H2020_PHC14). 634579-2 4. Morales-Ruiz, Manuel; Santel, Ansgar; Gerard. Editorial-Special issue of the 6th Duration: 01/05/2015-31/10/2019 Ribera, Jordi; Jimenez, Wladimiro. The Role of European Workshop on Lipid Mediators. Akt in Chronic Liver Disease and Liver PROSTAGLANDINS AND OTHER LIPID Ginès P. Síndrome de insuficiencia hepatica Regeneration. SEMINARS IN LIVER MEDIATORS. 133:1-3. I.F.: 2.640 cronica agudizada en la cirrhosis. Relación DISEASE. 37(1):11-16. I.F.: 5.500 con el microbioma y la inflamación. Sponsored by: Instituto de Salud Carlos III (ISCIII). PI16/00043

157 AREA 3 LIVER, DIGESTIVE SYSTEM AND METABOLISM

Duration: 01/01/2017 -31/12/2019 Jiménez W. Detección e identiﬁcación de biomarcadores precoces de ﬁbrosis Ginès P. LIVERHOPE: SIMVASTIN and hepática mediante técnicas proteómicas RIFAXIMIN as New Therapy for patients de alto rendimiento. with decompensated cirrhosis. PhD student: Santiago Marfà Bruix Sponsored by: European Commission (H2020_SC1). 731875 Duration: 01/01/2017-31/12/2021

Jiménez W, Fernández-Varo G. Utilidad terapéutica de las Nanopartículas de Óxido de Cerio en las enfermedades hepáticas. Sponsored by: Ministerio de Economia y Competitividad. SAF2015-64126-R Duration: 01/01/2016-31/12/2018

Morales M. Potencialidad terapéutica del fosfoproteoma de Akt/PKB en la regeneración hepática y en la cirrosis. Sponsored by: Ministerio de Economia y Competitividad. SAF13-41840-R Duration: 01/01/2014-31/05/2017

Morales M. Estimulación de la regeneración funcional de hígados cirróticos mediante la normalización vascular intrahepática y la modulación de dianas de Akt. Sponsored by: Ministerio de Economia y Competitividad. SAF2016-75358-R Duration: 30/12/2016-29/12/2019

Sancho-Bru P. Papel de las células progenitoras hepáticas en la hepatitis alcohólica y su potencial como nueva diana terapéutica. Sponsored by: Instituto de Salud Carlos III (ISCIII). PI14/00320 Duration: 01/01/2015-30/06/2018

DOCTORAL THESES

Clària J. Role of specialized pro-resolving lipid mediators and ER stress in obesity derived non-alcoholic fatty liver disease. PhD student: Bibiana Rius Boadas

Ginés P. Villanueva C. Inﬂamació sistémica i cirrosi. Valor pronòstic de biomarcadors inﬂammatoris enla cirrosi descompensada. PhD Student: Isabel Graupera Garcia-Milà

Sancho-Bru P. Ginés P. Estudio de los microRNAs en la ﬁsiopatología de la hepatitis alcoholic. PhD student: Delia Blaya Diez de Revenga

158 HEPATIC ONCOLOGY 3.5

Hepatic 3.5 oncology

PRE-DOCTORAL RESEARCHERS Carmen Andreu (IDIBAPS) LOCATION Blanca Cucarull (IIBB-CSIC) HCB building Robert Montal (IDIBAPS) CEK building ﬂoor 3 Carla Montironi (HCB) Sara Torrecilla (IDIBAPS) Laura Torrens (CIBER) Anna Tutusaus (IIBB-CSIC)

WEB TECHNICIANS www.bclc.cat Laia Cabellos (IDIBAPS) TEAM LEADER Josep Corominas (FCRB) Jordi Bruix (HCB) Cristina Millán (FCRB) T. 93 227 98 03 Judit Peix (CIBER) [email protected] Esther Samper (FCRB) Víctor Sapena (CIBER) KEYWORDS 1. Hepatocellular carcinoma ADMINISTRATIVE STAFF GROUP LEADERS Celia Cortez (IDIBAPS) 2. Intrahepatic cholangiocarcinoma Josep M. Llovet (ICREA-IDIBAPS) Ariadna Farré (IDIBAPS) 3. Biomarker proﬁling T 93 227 91 55 Núria Pérez (FCRB) 4. Treatment [email protected]

5. Outcomes research COLLABORATORS Albert Morales (IIBB-CSIC) Bernardino González de la Presa (HCB) T 93 363 83 00 (Ext.: 363) Enric Reverter (HCB) [email protected] Elsa Sola (HCB) Esther Titos (CIBER)

Original publications RESEARCHERS M. Carmen Ayuso (HCB) from 2015 to 2017 STRATEGIC OBJECTIVES Conxita Bru (HCB) YEAR I.F. TOTAL Q1 Q2 Alejandro Forner (HCB) It is a multidisciplinary team, known Josep Fuster (HCB) 2015 173.09 13 13 - internationally as “Barcelona Clinic Liver Maria Reig (HCB-FCRB) 2016 186.48 17 16 1 Cancer (BCLC) group”, which develops an Ramon Vilana (HCB) intense clinical and translational research in 2017 186.91 22 12 2 liver cancer. The aim of the team is to POST-DOCTORAL RESEARCHERS investigate the efficacy of clinical and Laia Bassaganyas (IDIBAPS) therapeutic interventions as well as the Agrin Moeini (IDIBAPS) mechanisms regulating the disease Roser Pinyol (IDIBAPS) progression. TEAM INVOLVED IN Milica Stefanovic (IDIBAPS) CIBEREHD AGAUR_SGR14 AGAUR_SGR17

AWARDS "The World's most inﬂuential Scientiﬁc Minds 2017" (top 1% most cited Investigators) Institution: Thomson Reuters Awardee/s: Jordi Bruix, Josep M Llovet Jordi Bruix

TEAM

159 AREA 3 LIVER, DIGESTIVE SYSTEM AND METABOLISM

MAIN LINES OF RESEARCH 4. Characterization of immune subclasses in Our work is focused on identifying cellular HCC and the impact of checkpoint inhibitor targets with therapeutic potential in liver The team investigates how to reﬁne the in treatment response. cancer and the development of prognostic selection criteria for potentially curative markers of antitumor efficacy for the treatment (surgical resection, transplantation, treatment of the hepatocellular carcinoma percutaneous approach with ablation) with RESEARCH GROUP (HCC). the aim of ensuring maximum efficacy in HEPATOCELULAR SIGNALING In particular, mitochondrial-directed and terms of survival. Evaluations are made of AND CANCER lipid-based therapies that may improve the options for improving the efficacy of current HCC management, and help to non-curative therapies which have been overcome sorafenib/regorafenib resistance, shown to improve survival (arterial are under present evaluation. chemoembolization, sorafenib, regorafenib). Protein and RNA signatures that categorize In this sense, phase 1, 2 and 3 studies are potential candidates for each speciﬁc carried out and led at international level treatment are another area of interest in our together with the Biomedical Industry, with research. a view to determining the efficacy of new GROUP LEADER molecular agents in phase 1, 2 and 3. Albert Morales (IIBB-CSIC) The team is also actively involved in studies about diagnosis and treatment of cholangiocarcinoma. Major projects in clinical research are developed as investigator initiated trials or in collaboration with the pharmaceutical industry. These include clinical and translational activity unit BCLC human cell lines, while the two subgroups coordinated by JM Llovet and A Morales base their activity in bench studies to advance knowledge in the pathogenesis and signalling pathways in hepatocyte and cholangiocte proliferation and liver cancer.

RESEARCH GROUP TRANSLATIONAL RESEARCH IN HEPATIC ONCOLOGY Albert Morales

GROUP

GROUP LEADER Josep M. Llovet (ICREA-IDIBAPS)

The group aims to identify new therapeutic targets. There are several lines of research within two international consortiums involving the BCLC-IDIBAPS, the Mount Sinai School of Medicine, the Dana-Farber Cancer Institute, the Broad Institute (Boston), INSERM (Paris), the National Tumor Institute (Milan), and several others. These explore:

1. Molecular classiﬁcation of hepatocellular carcinoma and Intrahepatic cholangiocarcinoma. 2. Drivers and signalling pathways. Josep Maria Llobet 3. Role of co-morbidities in the pathogenesis

of HCC (EU-grant HEP-CAR). GROUP

160 HEPATIC ONCOLOGY 3.5

PUBLICATIONS 6. Torrecilla S, Sia D, Harrington AN, Zhang Z, Romero CJ, Moreno A, Rimola A, Miro JM, Cabellos L, Cornella H, Moeini A, Camprecios FIPSE Investigators. Human Originals / I.F.: 186.907 G, Leow WQ, Fiel MI, Hao K, Bassaganyas L, immunodeficiency virus-infected liver Mahajan M, Thung SN, Villanueva A, Florman transplant recipients with incidental 1. Bruix, Jordi; Qin, Shukui; Merle, Philippe; S, Schwartz ME, Llovet JM. Trunk events hepatocellular carcinoma: A prospective Granito, Alessandro; Huang, Yi-Hsiang; present minimal intra- and inter-tumoral multicenter nationwide cohort study. Bodoky, Gyrogy; Pracht, Marc; Yokosuka, heterogeneity in hepatocellular LIVER TRANSPL. 23(5):645-651. I.F.: 3.910 Osamu; Rosmorduc, Olivier; Breder, Valeriy; carcinoma. JOURNAL OF HEPATOLOGY. Gerolami, Rene; Masi, Gianluca; Ross, Paul J.; 67(6):1222-1231. I.F.: 12.486 13. Solms A, Reinecke I, Fiala-Buskies S, Song, Tianqiang; Bronowicki, Jean-Pierre; Keunecke A, Drenth HJ, Bruix J, Meinhardt G, Ollivier-Hourmand, Isabelle; Kudo, Masatoshi; 7. Lencioni R, Montal R, Torres F, Park JW, Cleton A, Ploeger B. Exposure-response Cheng, Ann-Lii; Llovet, Josep M.; Finn, Richard Decaens T, Raoul JL, Kudo M, Chang C, Ríos J, relationship of regorafenib efficacy in S.; LeBerre, Marie-Aude; Baumhauer, Annette; Boige V, Assenat E, Kang YK, Lim HY, Walters patients with hepatocellular carcinoma. Meinhardt, Gerold; Han, Guohong; Resorce I, Llovet JM. Objective response by EUROPEAN JOURNAL OF Investigators. Regorafenib for patients with mRECIST as a predictor and potential PHARMACEUTICAL SCIENCES. hepatocellular carcinoma who progressed surrogate end-point of overall survival in 109S:S149-S153. I.F.: 3.756 on sorafenib treatment (RESORCE): a advanced HCC. JOURNAL OF randomised, double-blind, placebo- HEPATOLOGY. 66(6):1166-1172. I.F.: 12.486 14. Coto-Llerena M, Koutsoudakis G, Boix L, controlled, phase 3 trial. LANCET. López-Oliva JM, Caro-Pérez N, 389(10064):56-66. I.F.: 47.831 8. Moeini A, Sia D, Zhang Z, Camprecios G, Fernández-Carrillo C, González P, Stueck A, Dong H, Montal R, Torrens L, Gastaminza P, Bruix J, Forns X, 2. Sia D, Jiao Y, Martinez-Quetglas I, Kuchuk Martinez-Quetglas I, Fiel MI, Hao K, Villanueva Pérez-Del-Pulgar S. Permissiveness of O, Villacorta-Martin C, Castro de Moura M, A, Thung SN, Schwartz ME, Llovet JM. Mixed human hepatocellular carcinoma cell lines Putra J, Camprecios G, Bassaganyas L, Akers hepatocellular cholangiocarcinoma for hepatitis C virus entry and replication. N, Losic B, Waxman S, Thung SN, Mazzaferro tumors: Cholangiolocellular carcinoma is a VIRUS RESEARCH. 240:35-46. I.F.: 2.628 V, Esteller M, Friedman SL, Schwartz M, distinct molecular entity. JOURNAL OF Villanueva A, Llovet JM. Identification of an HEPATOLOGY. 66(5):952-961. I.F.: 12.486 15. Carrera C., Gual A., DIáz A., Puig-Butillé J., Immune-specific Class of Hepatocellular Noguès S., Vilalta A., Conill C., Rull R., Vilana R., Carcinoma, Based on Molecular Features. 9. Urtasun N., Boces-Pascual C., Boix L., Bruix Arguis P., Vidal-Sicart S., Alós L., Palou J., GASTROENTEROLOGY. 153(3):812-826. J., Pastor-Anglada M., Pérez-Torras S. Role Castel T., Malvehy J., Puig S. Prognostic role I.F.: 18.392 of drug-dependent transporter modulation of the histological subtype of melanoma on the chemosensitivity of on the hands and feet in Caucasians. 3. Bollard J, Miguela V, Ruiz de Galarreta M, cholangiocarcinoma. ONCOTARGET. MELANOMA RESEARCH. 27(4):315-320. Venkatesh A, Bian CB, Roberto MP, Tovar V, 8(52):90185-90196. I.F.: 5.168 I.F.: 2.615 Sia D, Molina-Sánchez P, Nguyen CB, Nakagawa S, Llovet JM, Hoshida Y, Lujambio 10. Rimola, Jordi; Alvarez-Cofino, Almudena; 16. Molina V, Sampson J, Ferrer J, Díaz A, A. Palbociclib (PD-0332991), a selective Perez-Jeldres, Tamara; Ayuso, Carmen; Ayuso JR, Sánchez-Cabús S, Fuster J, CDK4/6 inhibitor, restricts tumour growth Alfaro, Ignacio; Rodriguez, Sonia; Ricart, Elena; García-Valdecasas JC. Surgical treatment in preclinical models of hepatocellular Ordas, Ingrid; Panes, Julian. Comparison of of perihilar cholangiocarcinoma: early carcinoma. GUT. 66(7):1286-1296. I.F.: 16.658 three magnetic resonance enterography results of en bloc portal vein resection. indices for grading activity in Crohn’s LANGENBECKS ARCHIVES OF SURGERY. 4. Tovar, Victoria; Cornella, Helena; Moeini, disease. JOURNAL OF 402(1):95-104. I.F.: 2.203 Agrin; Vidal, Samuel; Hoshida, Yujin; Sia, GASTROENTEROLOGY. 52(5):585-593. Daniela; Peix, Judit; Cabellos, Laia; Alsinet, I.F.: 4.493 17. Reyes A, Marti J, Marfà S, Jiménez W, Clara; Torrecilla, Sara; Martinez-Quetglas, Iris; Reichenbach V, Pelegrina A, Fondevila C, Jose Lozano, Juan; Desbois-Mouthon, 11. Taouli B., Hoshida Y., Kakite S., Chen X., Tan Garcia Valdecasas JC, Fuster J. Prognostic Christele; Sole, Manel; Domingo-Domenech, P., Sun X., Kihira S., Kojima K., Toffanin S., Fiel prediction by liver tissue proteomic Josep; Villanueva, Augusto; Llovet, Josep M. M., Hirschfield H., Wagner M., Llovet J. profiling in patients with colorectal liver Tumour initiating cells and IGF/FGF Imaging-based surrogate markers of metastases. FUTURE ONCOLOGY. signalling contribute to sorafenib transcriptome subclasses and signatures 13(10):875-882. I.F.: 2.131 resistance in hepatocellular carcinoma. in hepatocellular carcinoma: preliminary GUT. 66(3):530-539. I.F.: 16.658 results. EUROPEAN RADIOLOGY. 18. Pelegrina A, Martí J, Miquel R, Ferrer J, 27(11):4472-4481. I.F.: 3.967 Hernández-Gea V, Diaz A, Nadal C, 5. Bruix J, Cheng AL, Meinhardt G, Nakajima García-Valdecasas JC, Fuster J. Changes of K, De Sanctis Y, Llovet J. Prognostic Factors 12. Agüero F, Forner A, Valdivieso A, Blanes M, liver hemodynamic and elastography and Predictors of Sorafenib Benefit in Barcena R, Manzardo C, Rafecas A, Castells L, parameters in patients with colorectal liver Patients With Hepatocellular Carcinoma: Abradelo M, Barrera-Baena P, metastases receiving preoperative Analysis of Two Phase 3 Studies. González-Diéguez L, Salcedo M, Serrano T, chemotherapy: "a note of caution". JOURNAL OF HEPATOLOGY. Jiménez-Pérez M, Herrero JI, Gastaca M, WORLD JOURNAL OF SURGICAL 67(5):999-1008. I.F.: 12.486 Aguilera V, Fabregat J, Del Campo S, Bilbao I, ONCOLOGY. 15(1):224-224. I.F.: 1.600

161 AREA 3 LIVER, DIGESTIVE SYSTEM AND METABOLISM

19. Ferrer J., Molina V., Rull R., López-Boado 4. Reig M, Boix L, Bruix J. The impact of regeneration and fibrosis treatment in M., Sánchez S., García R., Ricart M., direct antiviral agents on the liver injury. HEPATOBILIARY SURGERY Ventura-Aguiar P., García-Criado Á., Esmatjes development and recurrence of AND NUTRITION. 6(6):414-416. I.F.: 3.451 E., Fuster J., Garcia-Valdecasas J. Pancreas hepatocellular carcinoma. LIVER INT. transplantation: Advantages of a 37(Suppl.1):136-139. I.F.: 4.116 retroperitoneal graft position. CIRUGIA GRANTS FOR RESEARCH IN PROGRESS ESPANOLA. 95(9):513-520. I.F.: 1.276 Letters / I.F.: 31.66 Bruix J. Influencia de la heterogeneidad del 20. Calatayud D., Sánchez Cabús S., 1. Sia D, Llovet JM. Liver cancer: Translating micro-ambiente tumoral en la respuesta Sampson J., Resendiz A., Molina V., Fondevila '-omics' results into precision medicine for terapéutica del carcinoma hepatocelular C., Fuster J., García-Valdecasas J. Hepatic hepatocellular carcinoma. NATURE humano (CHC). resection: a safe and effective surgery. REVIEWS GASTROENTEROLOGY AND Sponsored by: Instituto de Salud Carlos III CIRUGIA ESPANOLA. 95(8):437-446. HEPATOLOGY. 14(10):571-572. I.F.: 13.678 (ISCIII). PI14/00962 I.F.: 1.276 Duration: 01/01/2015-30/06/2018 2. Montal R, Lencioni R, Llovet JM. Reply to: 21. Sánchez Cabús S., Estalella L., Pavel M., "mRECIST for systemic therapies: more Bruix J. Molecular regulation of the Calatayud D., Molina V., Ferrer J., Fondevila C., evidence is required before progression from hepatic steatosis to Fuster J., García-Valdecasas J. Analysis of recommendations could be made". cirrhosis and hepatocellular carcinoma: the long-term results of living donor liver JOURNAL OF HEPATOLOGY. 67(1):196-197. Role and therapeutic potential of CPEB transplantation in adults. CIRUGIA I.F.: 12.486 proteins. ESPANOLA. 95(6):313-320. I.F.: 1.276 Sponsored by: Asociación Española Contra el 3. Rimassa, Lorenza; Reig, Maria; Abbadessa, Cáncer (AECC_2015) 22. Rodríguez de Lope C., Reig M., Matilla A., Giovanni; Peck-Radosavljevic, Markus; Harris, Duration: 01/09/2015-31/08/2020 Ferrer M., Dueñas E., Mínguez B., F. William; Zagonel, Vittorina; Pastorelli, Davide; Castroagudín J., Ortiz I., Pascual S., Lledó J., Caremoli, Elena Rota; Porta, Camillo; Forner, A. Papel de las células tumorales Gallego A., Arenas J., Aracil C., Forne M., Damjanov, Nevena; Patel, Hitendra; Daniele, circulantes (CTCs) para predecir Muñoz C., Pons F., Sala M., Iñarrairaegui M., Bruno; Lamar, Maria; Schwartz, Brian; diseminación tumoral en el carcinoma Martin-Llahi M., Andreu V., Garre C., Rendón P., Goldberg, Terri; Santoro, Armando; Bruix, hepatocelular. Fuentes J., Crespo J., Rodríguez M., Bruix J., Jordi. Tumor biopsy and patient enrollment Sponsored by: Instituto de Salud Carlos III Varela M. Clinical characteristics of in clinical trials for advanced (ISCIII). PI13/01229 hepatocellular carcinoma in Spain. hepatocellular carcinoma. WORLD Duration: 01/01/2014-30/06/2017 Comparison with the 2008-2009 period JOURNAL OF GASTROENTEROLOGY. and analysis of the causes of diagnosis out 23(13):2448-2452. I.F.: 3.365 Llovet J.M. Integrative Genomic Analysis of of screening programs. Analysis of 686 Human Intrahepatic Cholangiocarcinoma. cases in 73 centers. MEDICINA CLINICA. 4. Reyes A, Marti J, Marfa S, Jimenez W, Sponsored by: Asociación Española Contra el 149(2):61-71. I.F.: 1.125 Reichenbach V, Pelegrina A, Fondevila C, Cáncer (AECC_2011) Valdecasas JC, Fuster J. Letter in reply: Duration: 01/09/2011-31/08/2018 Prognostic prediction by liver tissue Review / I.F.: 41.686 proteomic profiling in patients with Llovet J.M. Identificación de nuevas colorectal liver metastases. FUTURE alteraciones moleculares asociadas a mal 1. Sia D, Villanueva A, Friedman SL, Llovet JM. ONCOLOGY. 13(3):1135-1136. I.F.: 2.131 pronóstico y evaluación como dianas Liver Cancer Cell of Origin, Molecular terapeuticas en el carcinoma Class, and Effects on Patient Prognosis. hepatocelular. GASTROENTEROLOGY. 152(4):745-761. Editorial / I.F.: 17.654 Sponsored by: Ministerio de Economía y I.F.: 18.392 Competitividad. SAF2013-41027-R 1. Bruix J, Reig M, Sangro B. Assessment of Duration: 01/01/2014-31/12/2017 2. Sapisochin G, Bruix J. Liver treatment efficacy in hepatocellular transplantation for hepatocellular carcinoma: response rate, delay in Llovet JM. Mecanismos de resistencia carcinoma: outcomes and novel surgical progression or none of them. JOURNAL adquirida a sorafenib en el carcinoma approaches. NAT REV GASTROENTEROL OF HEPATOLOGY. 66(6):1114-1117. I.F.: 12.486 hepatocelular. HEPATOL. 14(4):203-217. I.F.: 13.678 Sponsored by: Ministerio de Economía y 2. Reig M., Díaz-González Á., Bruix J.. The Competitividad. SAF2016-76390-R 3. Reig M, Boix L, Mariño Z, Torres F, Forns X, success of regorafenib in hepatocellular Duration: 30/12/2016-29/12/2019 Bruix J. Liver Cancer Emergence carcinoma in a world of failures. Learnings for Associated with Antiviral Treatment: future developments. ONCOTARGET. Llovet J.M. Mechanisms underlying An Immune Surveillance Failure? 8(63):106151-106152. I.F.: 5.168 hepatocellular carcinoma pathogenesis SEMINARS IN LIVER DISEASE. 37(2):109-118. and impact of co-morbidities . I.F.: 5.500 3. Mari, Montserrat; Morales, Albert. Bone Sponsored by: European Commission morphogenetic protein-9/activin-like (H2020_PHC-2015). 667273-2 kinase 1 axis a new target for hepatic Duration: 01/01/2016-31/12/2019

162 HEPATIC ONCOLOGY 3.5

Llovet J.M. Identiﬁcación de biomarcadores de respuesta a inmunoterapias en carcinoma hepatocellular. Sponsored by: Ministerio de Economía y Competitividad (MINECO). EUIN2017-87932. Duration: 01/01/2017-13/02/2017

Morales A. Regulación terapéutica de la transición EMT/MET y la quimioresistencia en enfermedad hepática crónica. Sponsored by: Ministerio de Economía y Competitividad. SAF2015-66515-R Duration: 01/01/2016-31/12/2018

Reig M. Evaluación clínica prospectiva del perﬁl genético-inmuno/inﬂamatorio en el tratamiento del carcinoma hepatocelular con sorafenib para predecir tolerancia y supervivencia. Sponsored by: Instituto de Salud Carlos III (ISCIII). PI115/00145 Duration: 23/05/2016-31/12/2018

DOCTORAL THESES

Llovet JM. Liver cancer: Molecular classiﬁcation of Cholangiocarcinoma. PhD student: Agrin Moeini Mortazavi

Bruix J. Caracterización de células tumorales circulantes en pacientes con carcinoma hepatocelular. Función de EpCAM en la metástasis. PhD student: Ana Carolina Rhodes Cabrerizo

Bruix J, Forner A. Evaluación y optimización del tratamiento de los tumores hepáticos primarios de pequeño tamaño (< 2 cm). PhD student: Carlos Rodríguez de Lope López.

Forner A. Estudio proteómico en pacientes con metástasis hepáticas de cáncer colo-rectal. Identiﬁcación de diferentes perﬁles proteómicos en relación a los criterios clínico patológicos convencionales de gravedad. PhD student: Adalgiza Reyes Romero

163 AREA 3 LIVER, DIGESTIVE SYSTEM AND METABOLISM

Hepatic hemodynamics and portal hypertension. 3.6 Hemorrhage from ruptured gastroesophageal varices

TECHNICIANS Genís Campreciós (CIBER) LOCATION Javier Gallego (CIBER) CEK building ﬂoor 4 Ester García (CIBER) Hector García (CIBER) Montserrat Monclús (IDIBAPS)

NURSING STAFF Lara Orts (CIBER) KEYWORDS

1. Portal hypertension TEAM LEADER 2. Cirrhosis of the liver Juan Carlos García-Pagán (HCB) STRATEGIC OBJECTIVES 3. Angiogenesis T. 93 227 54 00 (Ext.: 2824) 4. Obesity [email protected] Translational research aimed at advancing

5. Liver sinusoidal endothelial cells in the knowledge of the pathophysiology of 6. Vascular liver diseases portal hypertension, which represents the GROUP LEADERS main complication of chronic liver diseases. Mercedes Fernández Lobato (IDIBAPS) Discovery of new therapeutic targets, T. 606 958 606 introduction of new treatments for this [email protected] syndrome, and development of new non-invasive techniques for its clinical Juan Carlos García-Pagán (HCB) evaluation. Original publications T. 93 227 54 00 (Ext.: 2824) In addition, the group is active in the ﬁelds of from 2015 to 2017 [email protected] vascular liver diseases, angiogenesis

YEAR I.F. TOTAL Q1 Q2 abnormalities in liver disease and on organ Jordi Gracia-Sancho (IDIBAPS) preservation. 2015 223.61 26 22 2 T. 93 227 54 00 (Ext.: 4306) 2016 151.24 16 16 - [email protected] 2017 219.10 27 22 4 MAIN LINES OF RESEARCH

1. Factors regulating liver microcirculation RESEARCHERS under normal conditions and in cirrhosis, Jaume Bosch (IDIBAPS) based on isolated liver perfusion studies

TEAM INVOLVED IN Ramon Deulofeu (HCB) and studies in isolated liver sinusoid CIBEREHD Angels Escorsell (HCB) endothelial cells. AGAUR_SGR14 M. Rosa Gilabert (HCB) 2. Regulation of the phenotype of liver Virginia Hernández-Gea (HCB) sinusoidal endothelial cells: relevance in the Montserrat Mari (IIBB-CSIC) pathophysiology of chronic liver disease, portal hypertension, liver preservation, and POST-DOCTORAL RESEARCHERS in the complications of cirrhosis. Anabel Fernández (IDIBAPS) 3. Liver protection from external injury in Marc Mejías (CIBER) healthy and cirrhotic livers. Salvador Naranjo (IDIBAPS) 4. Angiogenesis in chronic liver disease: Dinesh Mani Tripathi (IDIBAPS) function, regulation/dysregulation and Marina Vilaseca (IDIBAPS) therapeutic potential. 5. Impact of obesity on chronic liver disease: PRE-DOCTORAL RESEARCHERS pathogenic mechanisms and therapeutic Anna Baiges (HCB-FCRB) implications. Michel Ble (HCB) 6. Molecular regulation of the progression Estefania de Gregorio (IDIBAPS) from liver steatosis to cirrhosis and liver Jose Alberto Ferrusquñia (HCB) cancer. Identiﬁcation of new therapeutic Erica Lafoz (FCRB) targets. Raquel Maeso (IDIBAPS) 7. New non-invasive methods for evaluating Nico Manicardi (IDIBAPS) cirrhosis. MartÍ Ortega (IDIBAPS) 8. Randomized clinical studies of novel Nuria Pell (IDIBAPS) Marta Ramirez (IDIBAPS) treatments for portal hypertension. Maria Ruart (IDIBAPS) 9. Hepatic vascular diseases (Budd-Chiari Fanny Turon (HCB) syndrome, Portal Vein Thrombosis; Idiopathic non-cirrhotic portal hypertension).

164 cirrhosis. implications pathogenicmechanismsandtherapeutic targets. cancer:identificationofnewtherapeutic fromliversteatosistocirrhosisand 3. 2. 1. Our specificresearchprojectsinclude: avenues toimprovehumanhealth. facilitate theidentificationofnoveltherapeutic pathogenetic mechanismsofdisease,andto This isessentialtofullyelucidateunresolved death andlivertransplantationworldwide. humans beingsandareleadingcausesof liver andcancer,whichaffectmillionsof chronic liverdiseases,includingcirrhosisofthe on identifyingthecausesanddriversof (www.mercedesfernandezlab.com) focuses Our research Mercedes FernándezLobato GROUP LEADER ANGIOGENESIS INLIVERDISEASES RESEARCH GROUP risk-stratification. idiopathicportalhypertensionandfor 11. 10. ucin euaindseuainad therapeutic function,regulation/dysregulationand potential; Agoeei ncrnclvrdsae Angiogenesisinchronicliverdisease: Impact ofobesityonchronicliverdisease: Molecular regulationoftheprogression Discovery ofdiagnosticbiomarkersfor rvnino eopnaino Prevention ofdecompensation HEPATIC HEMODYNAMICS ANDPORTAL HYPERTENSION. HEMORRHAGE FROMRUPTUREDGASTROESOPHAGEAL VARICES (IDIBAPS)

GROUP Juan Carlos García-Pagán and Jordi Gràcia-Sancho (UP) GROUP Mercedes Fernández Lobato VASCULAR DISEASES CIRRHOSIS ANDHEPATIC MICROCIRCULATION IN REGULATION OFLIVER RESEARCH GROUP Juan CarlosGarcía-Pagán GROUP LEADER (HCB) (prognosis, diagnosis and illne group hasservedasareferencecenter forthese portal hypertension.Foranumberof yearsour portal hypertension,areinfrequent causes of non-cirrhotic portalthrombosisand idiopathic disorders, particularlyBudd-Chiarisyndrome, treatment ofportalhypertension.Liver vascular us todesignnewtherapeuticstrategies forthe cirrhosis andtheirpotentialmodulationwillallow in theincreasedintrahepaticresistance Better understandingthemechanismsinvolved development ofportalhypertensionincirrhosis. the mainmechanismsresponsiblefor Increased hepaticvascularresistanceisoneof sses allowingustoadvance intheir treatment). knowledge 3.6 165 166 AREA 3 Shunts inPatients WithPortal Transjugular Intrahepatic Portosystemic Pressure GradientAfterPlacement of Timing AffectsMeasurementof Portal Hernandez-Gea V,BoschJ,Garcia-Pagan JC. García-Criado Á,BlasiA,TorresF, 1. Originals / PUBLICATIONS big data. liver-on-a-chip technology,andanalysisof disease, cellco-culturebymeansof and rodents,invivo/invitromodelsofliver tissues andprimarycells,bothfromhuman range ofexperimentalmethodsthatinclude order toachieveourgoals,weuseawide microcirculation, ﬁbrosisandfunction.In of newtherapiestoimproveliver Our resultsarethebasisfordevelopment and fattyliver),inageing. liver damage,inchronicdisease(cirrhosis mechanisms, inhealth,responsetoacute hepatic intercellularcommunication phenotype ofthesesinusoidalcells,andthe biomechanical processesthatregulatethe Our researchgroupstudiesthemolecularand with liverdamage. the treatmentandimprovementofpatients represent animportanttherapeutictargetfor progression ofliverdiseases,andtherefore cells), playakeyroleinthedevelopmentand cells andresidentmacrophages(Kupffer principally sinusoidalendothelialcells,stellate The cellsofthelivermicrocirculation, Jordi Gracia-Sancho GROUP LEADER VASCULAR BIOLOGYOFTHELIVER RESEARCH GROUP 2. 19(2):94-105. I.F.:20.060 stress. to counteracthepaticsteatosisunderER CPEB4 mediatesatranslationalresponse Circadian- andUPR-dependentcontrolof Antonio; Fernandez,Mercedes;Mendez,Raul. Garcia-Rocha, Mar;Reina,Oscar;Zorzano, David; Hernandez-Alvarez,Maribel; Maillo, Carlos;Martin,Judit;Sebastian, Silva-JuniorG,TuronF,BaigesA,Cerda E,

NATURE CELLBIOLOGY. LIVER, DIGESTIVE SYSTEM ANDMETABOLISM I.F.:219.095 (IDIBAPS)

GROUP 152(6):1358-1365. I.F.:18.392 Hypertension. 4. 3. 6. 5. hypertension. neov stem/progenitor cellsinpathological therapeutic potentialofvascular Mendez R,FernandezM. Fernandez-Miranda G,PardalR,BoschJ, I.F.: 18.392 GASTROENTEROLOGY. C Virus-associatedCirrhosis. Hemodynamics inPatientswithHepatitis Anti-viral TherapyonHVPGandSystemic Expanding theBaveno VIcriteriaforthe Berzigotti A,Abraldes JG,GenescàJ. Tsochatzis E,WestbrookRH,Bosch J, Stefanescu H,NeyM,BlascoProcopet B, hepatic stellatecells. cirrhotic ratsmainlybydeactivating rivaroxaban lowersportalhypertensionin García-Pagán J. J., Hernández-GeaV.,Gracia-Sancho García-Irigoyen O.,AvilaM.,ReverterJ.,Bosch Forns X,García-PagánJC. Hernández-Gea V,BoschJ,VillanuevaC, R, PuenteA,AlbillosCallejaJL,TorrasX, Ibañez L,ArizaX,BaigesA,GallegoBañares Londoño MC,LLopE,MartinezJ,ForteaJI, 65(6):2031-2044. I.F.:13.246 Jordi Gracia-Sancho AugustinS,PonsM,MauriceJB,Bureau C, Garcia-PrasE,GallegoJ,CochL,MejiasM, Lens S,Alvarado-TapiasE,MariñoZ, Vilaseca M.,García-CalderóH.,LafozE., ascularisation duringchronicportal GUT. GASTROENTEROLOGY. The anticoagulant 66(7):1306-1320. I.F.:16.658 HEPATOLOGY. Role and 153(5):1273-1283. Effects ofAll-oral

10. 9. 8. 7. 67(3):501-507. I.F.:12.486 study. vein thrombosis:Aprospectivecohort gene mutationsinpatientswithsplanchnic diseases. French nationalnetworkforvascular liver Casadevall N,VallaDC,RautouPE, MarzacC, Colomer D,DurandF,Garcia-PaganJC, O, ZekriniK,BureauC,LorreF,Cervantes Cassinat B,AndreoliA,DeRaucourtE,Goria HEPATOLOGY. an individualpatientmeta-analysis. recurrent varicealhemorrhage:Resultsof Stratifying riskinthepreventionof Garcia-Tsao G,BavenoCooperation. GH, SarinS,SharmaB,AbraldesJG,BoschJ, Ahmad I,De-la-PeñaJ,Garcia-PagánJC,Lo I.F.: 13.246 disease. compensated advancedchronicliver screening ofvaricesinpatientswith HEPATOLOGY. obesity: Thesportdietstudy. hypertension inpatientswithcirrhosisand intervention programonportal Group. Bosch J,CiberehdSportDietCollaborative Bañares R,García-PagánJC,MesoneroF, Genescá J,ArdevolA,AugustínS,CallejaJL, PoissonJ,PlessierA,KiladjianJJ,TuronF, Albillos A,ZamoraJ,MartínezArroyoD, Berzigotti A,AlbillosVillanuevaC, Guixé-Muntet S,de MesquitaFC,VilaS, JOURNAL OFHEPATOLOGY. Effects ofanintensivelifestyle HEPATOLOGY. Selective testingforcalreticulin 66(4):1219-1231.I.F.:13.246 65(4):1293-1305. I.F.:13.246 66(6):1980-1988.

HEPATIC HEMODYNAMICS AND PORTAL HYPERTENSION. HEMORRHAGE FROM RUPTURED GASTROESOPHAGEAL VARICES 3.6

Hernández-Gea V, Peralta C, García-Pagán SCIENTIFIC REPORTS. 7(1):3255. I.F.: 4.259 Emilio; Sala-Vila, Aleix. Red Blood Cell JC, Bosch J, Gracia-Sancho J. Cross-talk Eicosapentaenoic Acid Inversely Relates between autophagy and KLF2 determines 17. Gallego J., Garcia-Pras E., Mejias M., Pell N., to MRI-Assessed Carotid Plaque Lipid endothelial cell phenotype and Schaeper U., Fernandez M. Therapeutic Core Burden in Elders at High microvascular function in acute liver injury. siRNA targeting endothelial KDR Cardiovascular Risk. NUTRIENTS. J HEPATOL. 66(1):86-94. I.F.: 12.486 decreases portosystemic collateralization 9(9):E1036. I.F.: 3.550 in portal hypertension. SCIENTIFIC 11. Amor, Antonio J.; Ortega, Emilio; Perea, REPORTS. 7(1):14791. I.F.: 4.259 23. Zimmermann Meireles, Cintia; Pasarin, Veronica; Cofan, Montserrat; Sala-Vila, Aleix; Marcos; Jose Lozano, Juan; Garcia-Caldero, Nunez, Isabel; Gilabert, Rosa; Ros, Emilio. 18. Sydor, Svenja; Manka, Paul; Best, Jan; Hector; Gracia-Sancho, Jordi; Carlos Relationship Between Total Serum Jafoui, Sami; Sowa, Jan-Peter; Zoubek, Miguel Garcia-Pagan, Juan; Bosch, Jaime; Abraldes, Bilirubin Levels and Carotid and Femoral Eugenio; Hernandez-Gea, Virginia; Javier Juan G. Simvastatin Attenuates Liver Injury Atherosclerosis in Familial Dyslipidemia. Cubero, Francisco; Kaelsch, Julia; Vetter, in Rodents with Biliary Cirrhosis Submitted ARTERIOSCLEROSIS, THROMBOSIS, AND Diana; Fiel, Maria Isabel; Hoshida, Yujin; Bian, C. to Hemorrhage/Resuscitation. SHOCK. VASCULAR BIOLOGY. 37(12):2356-2363. Billie; Nelson, Leonard J.; Moshage, Han; 47(3):370-377. I.F.: 3.113 I.F.: 6.607 Faber, Klaas Nico; Paul, Andreas; Baba, Hideo A.; Gerken, Guido; Friedman, Scott L.; Canbay, 24. Klinger C., Riecken B., Schmidt A., De 12. Amor A., Pinyol M., Solà E., Catalan M., Ali; Bechmann, Lars P. Kruppel-like factor 6 Gottardi A., Meier B., Bosch J., Caca K. Cofán M., Herreras Z., Amigó N., Gilabert R., is a transcriptional activator of autophagy Transjugular local thrombolysis Sala-Vila A., Ros E., Ortega E. Relationship in acute liver injury. SCIENTIFIC REPORTS. with/without TIPS in patients with acute between noninvasive scores of 7(1):8119. I.F.: 4.259 non-cirrhotic, non-malignant portal vein nonalcoholic fatty liver disease and thrombosis. DIGESTIVE AND LIVER nuclear magnetic resonance lipoprotein 19. Afdhal N, Everson GT, Calleja JL, DISEASE. 49(12):1345-1352. I.F.: 3.061 abnormalities: A focus on atherogenic McCaughan GW, Bosch J, Brainard DM, dyslipidemia. JOURNAL OF CLINICAL McHutchison JG, De-Oertel S, An D, Charlton 25. Burrel M., Barrufet M., Sebastia M., LIPIDOLOGY. 11(2):551-561. I.F.: 5.812 M, Reddy KR, Asselah T, Gane E, Curry MP, Joudanin J., Buñesch L., Bermudez P., Blasco Forns X. Effect of viral suppression on J., Gilabert R. Diffuse Renal Cortical 13. Jimenez-Castro M; Negrete-Sánchez E; hepatic venous pressure gradient in Hemorrhage in the Setting of Subcapsular Casillas-Ramirez A; Gulfo J; Álvarez-Mercado hepatitis C with cirrhosis and portal Hematoma: Diagnosis and Treatment with A; Cornide-Petronio M; Gracia-Sancho J; hypertension. JOURNAL OF VIRAL Embolization. JOURNAL OF VASCULAR Rodés J; Peralta C. The effect of cortisol in HEPATITIS. 24(10):823-831. I.F.: 4.122 AND INTERVENTIONAL RADIOLOGY. rat steatotic and non-steatotic liver 28(11):1557-1562. I.F.: 2.780 transplantation from brain-dead donors. 20. Vilaseca M, García-Calderó H, Lafoz E, CLINICAL SCIENCE. 131(8):733-746. I.F.: 4.936 Ruart M, López-Sanjurjo CI, Murphy MP, 26. Collado S, Coll E, Nicolau C, Azqueta M, Deulofeu R, Bosch J, Hernández-Gea V, Pons M, Cruzado JM, de la Torre B, Deulofeu 14. Cornide-Petronio M; Bujaldon E; Gracia-Sancho J, García-Pagán JC. R, Mojal S, Pascual J, Cases A. Serum Mendes-Braz M; Avalos de León C; Mitochondria-targeted antioxidant osteoprotegerin in prevalent hemodialysis Jimenez-Castro M; Álvarez-Mercado A; mitoquinone deactivates human and rat patients: associations with mortality, Gracia-Sancho J; Rodés J; Peralta C. HSC and reduces portal hypertension in atherosclerosis and cardiac function. BMC The impact of cortisol in steatotic and cirrhotic rats. LIVER INTERNATIONAL. NEPHROLOGY. 18(1):290. I.F.: 2.289 non-steatotic liver surgery. JOURNAL OF 37(7):1002-1012. I.F.: 4.116 CELLULAR AND MOLECULAR MEDICINE. 27. Pelegrina A, Martí J, Miquel R, Ferrer J, 21(10):2344-2358. I.F.: 4.499 21. De Gottardi A., Trebicka J., Klinger C., Hernández-Gea V, Diaz A, Nadal C, Plessier A., Seijo S., Terziroli B., Magenta L., García-Valdecasas JC, Fuster J. Changes of 15. Cano A, Mariño Z, Millet O, Semela D., Buscarini E., Langlet P., Görtzen J., liver hemodynamic and elastography Martínez-Arranz I, Navasa M, Falcón-Pérez Puente A., Müllhaupt B., Navascuès C., Nery F., parameters in patients with colorectal liver JM, Pérez-Cormenzana M, Caballería J, Deltenre P., Turon F., Engelmann C., Arya R., metastases receiving preoperative Embade N, Forns X, Bosch J, Castro A, Mato Caca K., Peck-Radosavljevic M., Leebeek F., chemotherapy: "a note of caution". WORLD JM. A Metabolomics Signature Linked To Valla D., Garcia-Pagan J., VALDIG JOURNAL OF SURGICAL ONCOLOGY. Liver Fibrosis In The Serum Of Investigators. Antithrombotic treatment 15(1):224. I.F.: 1.600 Transplanted Hepatitis C Patients. with direct-acting oral anticoagulants in SCIENTIFIC REPORTS. 7(1):10497. I.F.: 4.259 patients with splanchnic vein thrombosis and cirrhosis. LIVER INTERNATIONAL. Review / I.F.: 4.116 16. De Mesquita FC, Guixé-Muntet S, 37(5):694-699. I.F.: 4.116 Fernández-Iglesias A, Maeso-Díaz R, Vila S, 1. Brunner F, Berzigotti A, Bosch J. Prevention Hide D, Ortega-Ribera M, Rosa JL, 22. Bargallo, Nuria; Gilabert, Rosa; and treatment of variceal haemorrhage in García-Pagán JC, Bosch J, de Oliveira JR, Romero-Mamani, Edwin-Saul; Cofan, 2017. LIVER INT. 37(suppl 1):104-115. I.F.: 4.116 Gracia-Sancho J. Liraglutide improves liver Montserrat; Calder, Philip C.; Fito, Montserrat; microvascular dysfunction in cirrhosis: Corella, Dolores; Salas-Salvado, Jordi; Evidence from translational studies. Ruiz-Canela, Miguel; Estruch, Ramon; Ros,

167 AREA 3 LIVER, DIGESTIVE SYSTEM AND METABOLISM

Letters / I.F.: 72.942 4. Reverter E, Escorsell A, Fernández J . Renal Sponsored by: Instituto de Salud Carlos III replacement therapy in critically ill (ISCIII). PI14/00392 1. Garcia-Tsao G., Abraldes J., Berzigotti A., cirrhotic patients: A challenging balance Duration: 01/01/2015-31/12/2018 Bosch J. Reply. HEPATOLOGY. between efficacy and futility.LIVER 66(1):302-303. I.F.: 13.246 INTERNATIONAL. 37(6):817-819. I.F.: 4.116 Fernandez M. Mecanismos moleculares y celulares implicados en la interacción 2. Escorsell À., Pavel O., Cárdenas A., Morillas 5. Mari, Montserrat; Morales, Albert. Bone entre obesidad y enfermedad hepática R., Llop E., Villanueva C., Garcia-Pagan J., morphogenetic protein-9/activin-like crónica: papel y potencial terapéutico de Bosch J. Reply. HEPATOLOGY. kinase 1 axis a new target for hepatic la angiogénesis y proteínas CPEB. 65(6):2121-2122. I.F.: 13.246 regeneration and fibrosis treatment in liver Sponsored by: Ministerio de Economía y injury. HEPATOBILIARY SURGERY AND Competitividad (SAF2014-55473-R) 3. Escorsell A., Bosch J. Reply. NUTRITION. 6(6):414-416. I.F.: 3.451 Duration: 01/01/2015-30/06/2018 HEPATOLOGY. 65(1):386-387. I.F.: 13.246 Fernandez M. Regulación molecular de la 4. Poisson J, Turon F, Marzac C, Valla DC, Case Reports / I.F.: 1.401 interacción obesidad- enfermedad Garcia-Pagan JC, Rautou PE. Response to: hepática crónica. Letter "Calreticulin mutations and their 1. Romero-Mascarell, Cristina; Juan Carlos Sponsored by: Ministerio de Economía y importance in Budd-Chiari syndrome". Garcia-Pagan, Juan; Karina Araujo, Isis; Llach, Competitividad. BES2015-071399 JOURNAL OF HEPATOLOGY. 67(5):1112-1113. Josep; Gonzalez-Suarez, Begona. Pyogenic Duration: 01/01/2015-01/01/2019 I.F.: 12.486 granuloma in the jejunum successfully removed by single-balloon enteroscopy. Fernandez M. Molecular regulation of the 5. Poisson, Johanne; Turon, Fanny; Marzac, REVISTA ESPANOLA DE ENFERMEDADES progression from hepatic steatosis to Christophe; Valla, Dominique-Charles; DIGESTIVAS. 109(2):152-154. I.F.: 1.401 cirrhosis and hepatocellular carcinoma: Garcia-Pagan, Juan-Carlos; Rautou, Role and therapeutic potential of CPEB Pierre-Emmanuel. Reply to: Calreticulin proteins. mutations and their importance in Clinical Guidelines / I.F.: 13.246 Sponsored by: Asociación Española Contra el Budd-Chiari syndrome. JOURNAL OF Cáncer (AECC_2015). HEPATOLOGY. 67(5):1112-1113. I.F.: 12.486 1. Garcia-Tsao G, Abraldes JG, Berzigotti A, Duration: 01/09/2015-31/08/2020 Bosch J. Portal hypertensive bleeding in 6. De Gottardi, Andrea; Garcia-Pagan, Juan cirrhosis: Risk stratification, diagnosis, and Fernandez M. Role and therapeutic Carlos; VALDIG Investigators. Risk of management: 2016 practice guidance by potential of CPEB proteins in the transition bleeding in cirrhotic patients treated with the American Association for the study of from cirrhosis to hepatocellular rivaroxaban. LIVER INTERNATIONAL. liver diseases. HEPATOLOGY. 65(1):310-335. carcinoma. 37(10):1575-1576. I.F.: 4.116 I.F.: 13.246 Sponsored by: Worldwide Cancer Research. 16-0026 7. De Gottardi A, Garcia-Pagan JC, VALDIG Duration: 01/01/2016-31/12/2018 Investigators. The anticoagulant efficacy of GRANTS FOR RESEARCH IN PROGRESS rivaroxaban may be attenuated in cirrhotic García-Pagán J.C. Estudio prospectivo patients. LIVER INTERNATIONAL. Bosch J. Contrast-enhanced uLtrasound multicéntrico, aleatorizado del efecto de 37(8):1252. I.F.: 4.116 for livEr-disease eValuation: development Rivaroxaban sobre la supervivencia y el and validation of a novel E-Health-software desarrollo de complicaciones de la for Risk-stratification (CLEVER). hipertensión portal en pacientes con Editorial / I.F.: 31.149 Sponsored by: European Commission cirrosis. (FP7_PEOPLE-2013). 612273 Sponsored by: Instituto de Salud Carlos III 1. Tsochatzis EA, Bosch J. Statins in Duration: 01/10/2013-30/09/2018 (ISCIII). ICI14/00133 cirrhosis - ready for prime time. Duration: 01/01/2015-30/06/2019 HEPATOLOGY. 66(3):697-699. I.F.: 13.246 Bosch J. Proyecto Integrado de Excelencia - Understanding obesity (Ob), metabolic García-Pagán JC. Proyecto Integrado de 2. Bosch, J. Editorial: improving in-hospital syndrome (MetS), type 2 diabetes (T2DM) Excelencia. Targeting endothelial management of decompensated cirrhosis and fatty liver disease (FL): a dysfunction in highly prevalent diseases: by a 'care bundle' - hope, frustration, and multidisciplinary approach. characterization and validation of lessons to learn. ALIMENTARY Sponsored by: Instituto de Salud Carlos III prognostic biomarkers and identification PHARMACOLOGY AND THERAPEUTICS. (ISCIII). PIE14/00031 of potential therapeutic strategies. 45(5):754-755. I.F.: 7.286 Duration: 01/01/2014-28/02/2017 Sponsored by: Instituto de Salud Carlos III (ISCIII). PIE15/00027 3. Bosch J. EUS-guided intrahepatic Escorsell A. Eficacia de la derivación Duration: 01/01/2016-31/12/2018 portosystemic shunt: A real alternative to portosistémica intrahepática (TIPS) en el transjugular intrahepatic portalsystemic tratamiento de la hemorragia aguda por García-Pagán JC. Hipertensión Portal shunt? GASTROINTEST ENDOSC. varices gástricas: estudio aleatorizado y Idiopática. Fisiopatología e identificación 85(1):248-249. I.F.: 6.501 controlado vs tratamiento convencional. de dianas terapéuticas.

168 HEPATIC HEMODYNAMICS AND PORTAL HYPERTENSION. HEMORRHAGE FROM RUPTURED GASTROESOPHAGEAL VARICES 3.6

Sponsored by: Ministerio de Economía y mecanismes involucrats i noves dianes Competitividad. SAF2016-75767-R terapèutiques. Duration: 30/12/2016-29/12/2019 PhD student: Sergi Guixé Muntet

Gracia-Sancho J. El sinusoide hepático en la García-Pagán JC, Gracia-Sancho J. vejez: caracterización de los mecanismos Mecanismes involucrats en la regulació celulares ﬁsiopatológicos para el de la resistència vascular intrahepàtica desarrollo de nuevas estrategias en la cirrosi: paper dels anticoagulants terapéuticas. i antioxidants. Sponsored by: Instituto de Salud Carlos III PhD student: Marina Vilsaeca Barceló (ISCIII). FIS PI14/00029 Duration: 01/01/2015-31/12/2017

Gracia-Sancho J. Exosomes in liver diseases. Sponsored by: CIBEREHD intramural competitive grant. Duration: 01/11/2016 -31/12/2018

Gracia-Sancho J. ExoLiver: Liver on a Chip platform for toxicology and drug development. Sponsored by: Fundació La Caixa (CaixaImpulse_2016). Duration: 01/05/2017-30/06/2018

Gracia-Sancho J. Capillarization of the liver sinusoidal endothelium: Orchestration by miRNAs. Sponsored by: Gilead Sciences. International Research Scholars Program in Liver Disease. GILEAD_IRS_16_02 Duration: 02/08/2016-01/08/2019

Hernandez-Gea V. Papel de la autofagia en la modulación de la disfunción endotelial y la ﬁbrosis: caracterización de una nueva diana terapéutica para el desarrollo de nuevos tratamientos antiﬁbróticos. Sponsored by: Instituto de Salud Carlos III (ISCIII). FIS PI14/00182 Duration: 01/01/2015-31/12/2018

Marí M. Caracterización y potencial terapéutico del eje Catepsina-Sirtuina 1 en ﬁbrosis e inﬂamación hepática. Sponsored by: Instituto de Salud Carlos III (ISCIII). PI3/00374 Duration: 01/01/2014-31/12/2017

DOCTORAL THESES

Bosch J. Simvastatina como fármaco hepatoprotector. PhD student: Cintia Zimerman De Meireles

Gracia-Sancho J, Bosch J. Disfunció microcirculatòria sinusoïdal hepàtica en la cirrosi i dany per isquèmia/reperfusió:

169 AREA 3 LIVER, DIGESTIVE SYSTEM AND METABOLISM

Inﬂammatory 3.7 bowel disease

TECHNICIANS Montserrat Arroyes (IDIBAPS) LOCATION Miriam Esteller (CIBER) CEK building ﬂoor 3 Alba Garrido (CIBER) Maica Masamunt (CIBER) Lluís Revilla (IDIBAPS)

NURSING STAFF WEB www.ibd-bcn.org Rebeca Barastegui (HCB) Marta Gallego (HCB) TEAM LEADER Àngel Giner (CIBER) Julián Panés (HCB) Alejandro Vara (HCB) T. 93 227 54 18 [email protected]

KEYWORDS STRATEGIC OBJECTIVES 1. Inflammatory bowel diseases 2. Crohn’s disease RESEARCHERS Faust Feu (HCB) This IDIBAPS research team has a 3. Ulcerative colitis Glòria Lacima (HCB) translational orientation, aimed at generating 4. Cell therapy Josep Llach (HCB) knowledge in the area of inflammatory bowel 5. Cross-sectional imaging Ingrid Ordás (HCB) diseases to provide a benefit to patients Elena Ricart (HCB) suffering from Crohn’s disease or ulcerative Maria Azucena Salas (IDIBAPS) colitis in the near future, with a special emphasis on the discovery of disease POST-DOCTORAL RESEARCHERS biomarkers, new molecular and cellular Isabella Dotti (IDIBAPS) targets, as well as imaging techniques for Original publications Marisol Veny (IDIBAPS) diagnosis and monitoring. from 2015 to 2017 PRE-DOCTORAL RESEARCHERS YEAR I.F. TOTAL Q1 Q2 Helena Bassolas (IDIBAPS) MAIN LINES OF RESEARCH 2015 166.72 15 14 - Jesús Castro (HCB) 1. 2016 229.49 20 17 2 Ana Corraliza (IDIBAPS) Autologous hematopoietic stem cell Agnès Fernández (IDIBAPS) transplantation in refractory Crohn’s 2017 247.99 17 13 3 Elena Ferrer (IDIBAPS) disease. Role of host, immune and Aida Mayorgas (IDIBAPS) intestinal microbiota related factors on Núria Planell (CIBER) the therapeutic response.

TEAM INVOLVED IN CIBEREHD AGAUR_SGR14 Julián Panés

TEAM

170 INFLAMMATORY BOWEL DISEASE 3.7

2. Evaluation of the efficacy and safety of placebo-controlled phase 2 study. Bowel Disease: Data from the GETECCU treatment with autologous tolerogenic LANCET. 389(10080):1699-1709. I.F.: 47.831 Eneida Registry. AMERICAN JOURNAL OF dendritic cells derived from peripheral GASTROENTEROLOGY. 112(7):1135-1143. blood monocytes in refractory Crohn’s 3. Hebbandi Nanjundappa R., Ronchi F., Wang I.F.: 9.566 disease. J., Clemente-Casares X., Yamanouchi J., Sokke Umeshappa C., Yang Y., Blanco J., 8. Esteve-Sole, Ana; Deya-Martinez, Angela; 3. Efficacy of mesenchymal stem cells for Bassolas-Molina H., Salas A., Khan H., Slattery Teixido, Irene; Ricart, Elena; Gompertz, treatment of fistulizing Crohn’s disease. R., Wyss M., Mooser C., Macpherson A., Sycuro Macarena; Torradeflot, Maria; de Moner, L., Serra P., McKay D., McCoy K., Santamaria P. Noemi; Azucena Gonzalez, Europa; Maria 4. Development and optimization of intestinal A Gut Microbial Mimic that Hijacks Plaza-Martin, Ana; Yague, Jordi; Juan, Manel; epithelial stem cells production. Application Diabetogenic Autoreactivity to Suppress Alsina, Laia. Immunological Changes in of the technology for characterization of Colitis. CELL. 171(3):655-667. I.F.: 30.410 Blood of Newborns Exposed to pathobiological aspects of inflammatory Anti-TNF-alpha during Pregnancy. bowel diseases and vitro drug testiing. 4. Panés J, Sandborn WJ, Schreiber S, Sands FRONTIERS IN IMMUNOLOGY. 8(SEP):1123. BE, Vermeire S, D'Haens G, Panaccione R, I.F.: 6.429 5. Transcriptional analysis in IBD as a tool to Higgins PDR, Colombel JF, Feagan BG, Chan understand the pathophysiology of IBD G, Moscariello M, Wang W, Niezychowski W, 9. López-García A, Rovira M, and to evaluate therapeutic responses. Marren A, Healey P, Maller E. Tofacitinib for Jauregui-Amezaga A, Marín P, Barastegui R, induction and maintenance therapy of Salas A, Ribas V, Feu F, Elizalde JI, 7. Microbial antigen specific responses in the Crohn's disease: results of two phase IIb Fernández-Avilés F, Martínez C, Gutiérrez G, pathophysiology of Crohn’s disease. randomised placebo-controlled trials. GUT. Rosiñol L, Carreras E, Urbano A, Lozano M, 66(6):1049-1059. I.F.: 16.658 Cid J, Suárez-Lledó M, Masamunt MC, Comas 6. Optimization of cross sectional imaging D, Giner A, Gallego M, Alfaro I, Ordás I, Panés J, techniques, for evaluation of the extent, 5. Dotti I., Mora-Buch R., Ferrer-Picón E., Ricart E. Autologous Hematopoietic Stem severity and prognosis of the inflammatory Planell N., Jung P., Masamunt M., Leal R., De Cell Transplantation for Refractory lesions in Crohn’s disease. Study Carpi J., Llach J., Ordás I., Batlle E., Panés J., Crohn's Disease: Efficacy in a Single-Centre permanent damage in ulcerative colitis. Salas A. Alterations in the epithelial stem Cohort. JOURNAL OF CROHNS AND COLITIS. cell compartment could contribute to 11(10):1161-1168. I.F.: 5.813 7. Advanced endoscopic techniques for permanent changes in the mucosa of diagnosis and treatment of IBD. patients with ulcerative colitis. GUT. 10. Planell, Nuria; Carme Masamunt, M.; 66(12):2069-2079. I.F.: 16.658 Franco Leal, Raquel; Rodriguez, Lorena; Esteller, Miriam; Lozano, Juan J.; Ramirez, 6. Ordás I, Domènech E, Mañosa M, Anna; Setsuko Ayrizono, Maria de Lourdes; PUBLICATIONS García-Sánchez V, Iglesias-Flores E, Peñalva Rodrigues Coy, Claudio Saddy; Alfaro, Ignacio; M, Cañas-Ventura A, Merino O, Ordas, Ingrid; Visvanathan, Sudha; Ricart, Originals / I.F.: 247.994 Fernández-Bañares F, Gomollón F, Vera M, Elena; Guardiola, Jordi; Panes, Julian; Salas, Gutiérrez A, Garcia-Planella E, Chaparro M, Azucena. Usefulness of Transcriptional 1. Sandborn, William J.; Su, Chinyu; Sands, Aguas M, Gento E, Muñoz F, Aguirresarobe M, Blood Biomarkers as a Non-invasive Bruce E.; D'Haens, Geert R.; Vermeire, Muñoz C, Fernández L, Calvet X, Jiménez CE, Surrogate Marker of Mucosal Healing and Severine; Schreiber, Stefan; Danese, Silvio; Montoro MA, Mir A, De Castro ML, Endoscopic Response in Ulcerative Colitis. Feagan, Brian G.; Reinisch, Walter; García-Sepulcre MF, Bermejo F, Panés J, JOURNAL OF CROHNS AND COLITIS. Niezychowski, Wojciech; Friedman, Gary; Esteve M. Long-Term Efficacy and Safety 11(11):1335-1346. I.F.: 5.813 Lawendy, Nervin; Yu, Dahong; Woodworth, of Cyclosporine in a Cohort of Deborah; Mukherjee, Arnab; Zhang, Haiying; Steroid-Refractory Acute Severe 11. D'Haens G, Reinisch W, Colombel JF, Healey, Paul; Panes, Julian; OCTAVE Ulcerative Colitis Patients from the Panes J, Ghosh S, Prantera C, Lindgren S, Induction 1 OCTAVE Inductio. Tofacitinib as ENEIDA Registry (1989-2013): A Hommes DW, Huang Z, Boice J, Huyck S, Induction and Maintenance Therapy for Nationwide Multicenter Study. AMERICAN Cornillie F, ENCORE investigators. Five-year Ulcerative Colitis. NEW ENGLAND JOURNAL JOURNAL OF GASTROENTEROLOGY. Safety Data From ENCORE, a European OF MEDICINE. 376(18):1723-1736. I.F.: 72.406 112(11):1709-1718. I.F.: 9.566 Observational Safety Registry for Adults With Crohn's Disease Treated With 2. Feagan BG, Sandborn WJ, D'Haens G, 7. Chaparro M, Ramas M, Benítez JM, Infliximab. JOURNAL OF CROHN'S AND Panés J, Kaser A, Ferrante M, Louis E, López-García A, Juan A, Guardiola J, Mínguez COLITIS. 11(6):680-689. I.F.: 5.813 Franchimont D, Dewit O, Seidler U, Kim KJ, M, Calvet X, Márquez L, Fernández Salazar LI, Neurath MF, Schreiber S, Scholl P, Pamulapati Bujanda L, García C, Zabana Y, Lorente R, 12. Rubin DT, Dubinsky MC, Martino S, Hewett C, Lalovic B, Visvanathan S, Padula SJ, Barrio J, Hinojosa E, Iborra M, Cajal MD, Van KA, Panés J. Communication Between Herichova I, Soaita A, Hall DB, Böcher WO. Domselaar M, García-Sepulcre MF, Gomollón Physicians and Patients with Ulcerative Induction therapy with the selective F, Piqueras M, Alcaín G, García-Sánchez V, Colitis: Reflections and Insights from a interleukin-23 inhibitor risankizumab in Panés J, Domènech E, García-Esquinas E, Qualitative Study of In-Office patients with moderate-to-severe Crohn's Rodríguez-Artalejo F, Gisbert JP. Patient-Physician Visits. INFLAMMATORY disease: a randomised, double-blind, Extracolonic Cancer in Inflammatory BOWEL DISEASES. 23(4):494-501. I.F.: 4.525

171 AREA 3 LIVER, DIGESTIVE SYSTEM AND METABOLISM

13. Rimola, Jordi; Alvarez-Cofino, Almudena; Review / I.F.: 46.966 Case Reports / I.F.: 1.401 Perez-Jeldres, Tamara; Ayuso, Carmen; Alfaro, Ignacio; Rodriguez, Sonia; Ricart, Elena; 1. Panes J, Jairath V, Levesque BG. Advances 1. Castro, Jesus; Cuatrecasas, Miriam; Ordas, Ingrid; Panes, Julian. Comparison of in Use of Endoscopy, Radiology, and Balaguer, Francesc; Ricart, Elena; Pellise, three magnetic resonance enterography Biomarkers to Monitor Inflammatory Maria. Serrated polyposis syndrome indices for grading activity in Crohn’s Bowel Diseases. GASTROENTEROLOGY. associated with long-standing disease. JOURNAL OF 152(2):362-373. I.F.: 18.392 inflammatory bowel disease. REVISTA GASTROENTEROLOGY. 52(5):585-593. ESPANOLA DE ENFERMEDADES I.F.: 4.493 2. Panés J, Rimola J. Perianal fistulizing DIGESTIVAS. 109(11):796-798. I.F.: 1.401 Crohn's disease: pathogenesis, diagnosis 14. Westera, Liset; van Viegen, Tanja; and therapy. NATURE REVIEWS Jeyarajah, Jenny; Azad, Azar; Bilsborough, GASTROENTEROLOGY AND Clinical Guidelines / I.F.: 13.099 Janine; van den Brink, Gijs R.; Cremer, HEPATOLOGY. 14(11):652-664. I.F.: 13.678 Jonathan; Danese, Silvio; D'Haens, Geert; 1. Vuitton L., Peyrin-Biroulet L., Colombel J., Eckmann, Lars; Faubion, William; Filice, 3. Villanacci V, Baert F, Cornillie F, De Hertogh Pariente B., Pineton de Chambrun G., Walsh A., Melissa; Korf, Hannelie; McGovern, Dermot; G, Panés J. Challenges faced by Panes J., Travis S., Mary J., Marteau Panes, Julian; Salas, Azucena; Sandborn, cross-sectional imaging and histological P.Defining endoscopic response and William J.; Silverberg, Mark S.; Smith, Michelle I.; endpoints in clinical trials. JOURNAL OF remission in ulcerative colitis clinical trials: Vermeire, Severine; Vetrano, Stefania; CROHN'S AND COLITIS. an international consensus. ALIMENTARY Shackelton, Lisa M.; Stitt, Larry; Jairath, Vipul; 11(suppl_2):S586-S592. I.F.: 5.813 PHARMACOLOGY AND THERAPEUTICS. Levesque, Barrett G.; Spencer, David M.; 45(6):801-813. I.F.: 7.286 Feagan, Brian G.; Casteele, Niels Vande. 4. Jairath V, Levesque BG, Vande Casteele N, Centrally Determined Standardization of Khanna R, Mosli M, Hindryckx P, Travis S, 2. Danese S., Fiorino G., Raine T., Ferrante M., Flow Cytometry Methods Reduces Duijvenstein M, Rimola J, Panes J, D'Haens G, Kemp K., Kierkus J., Lakatos P., Mantzaris G., Interlaboratory Variation in a Prospective Sandborn WJ, Feagan BG. Evolving van der Woude J., Panes J., Peyrin-Biroulet L. Multicenter Study. CLINICAL AND concepts in Phase I and II Drug ECCO Position statement on the use of TRANSLATIONAL GASTROENTEROLOGY. Development for Crohn's Disease. biosimilars for inflammatory bowel 8(11):e126. I.F.: 3.923 JOURNAL OF CROHN'S AND COLITIS. disease-an update. JOURNAL OF CROHNS 11(2):246-255. I.F.: 5.813 AND COLITIS. 11(1):26-34. I.F.: 5.813 15. Panés J, Domènech E, Aguas Peris M, Nos P, Riestra S, Juliá de Páramo B, Cea-Calvo L, 5. Panés J, Alfaro I. New treatment Romero C, Marín-Jiménez I. Association strategies for ulcerative colitis. EXPERT GRANTS FOR RESEARCH IN PROGRESS between disease activity and quality of life REVIEW OF CLINICAL IMMUNOLOGY. in ulcerative colitis: Results from the 13(10):963-973. I.F.: 3.270 Salas A. Transplante autólogo de células CRONICA-UC study. JOURNAL OF madre hematopoyéticas en la enfermedad GASTROENTEROLOGY AND de crohn: factores moleculares, inmunes y HEPATOLOGY. 32(11):1818-1824. I.F.: 3.452 Letters / I.F.: 78.219 microbiológicos implicados en el control de la enfermedad. 16. Reinisch W, Jahnsen J, Schreiber S, 1. Sandborn W., Su C., Panes J. Tofacitinib as Sponsored by: Ministerio de Economía y Danese S, Panés J, Balsa A, Park W, Kim J, induction and maintenance therapy for Competitividad. SAF2015-66379-R Lee JU, Yoo DH. Evaluation of the ulcerative colitis. NEW ENGLAND JOURNAL Duration: 01/01/2016 - 31/12/2018 Cross-reactivity of Antidrug Antibodies to OF MEDICINE. 377(5):496-497. I.F.: 72.406 CT-P13 and Infliximab Reference Product Salas A. New siRNA Nanotherapy for (Remicade): An Analysis Using 2. Lindsay J., Irving P., Mantzaris G., Panés J., Inflammatory Bowel Diseases, targeting Immunoassays Tagged with Both Agents. López-Sanromán A., Katsanos K., Juillerat P., Janus kinase 3. BIODRUGS. 31(3):223-227. I.F.: 2.835 Maconi G., Lakatos P., Annese V., Armuzzi A., Sponsored by: European Commission Bager P., Bettenworth D., Chauhan U., Ding N., (H2020_NMBP16_17). 17. Fernández-Gutiérrez B., Perrotti P., Gisbert Feakins R., Fiorino G., Gisbert J., Kierkus J., Duration: 01/01/2017-31/12/2020 J., Domènech E., Fernández-Nebro A., Cañete Levine A., Panes J., Peyrin-Biroulet L., Rieder J., Ferrándiz C., Tornero J., García-Sánchez V., F., Russell R., Siegmund B., Spinelli A., Sturm A., Panés J., Fonseca E., Blanco F., Turner D., Van Rheenen P., Vavricka S., DOCTORAL THESES Rodríguez-Moreno J., Carreira P., Julià A., Zagorowicz E., Högenauer C., Bossuyt P., Marsal S., Rodriguez-Rodriguez L., IMID Bogut A., Knudsen T., af Bjorkesten C., Panés J. Diagnostic and therapeutic Consortium. Cardiovascular disease in Molander P., Bourreille A., Koutroubakis J., Ellul strategies in inflammatory bowel disease. immune-mediated inflammatory diseases: P., Lindsay J., Irving P., Mantzaris G., Panés J., PhD student: Orlando García-Bosch A cross-sectional analysis of 6 cohorts. López-Sanromán A., Katsanos K.. ECCO IBD MEDICINE (UNITED STATES). 96(26):e7308. curriculum. JOURNAL OF CROHNS AND Panés J. Autologous hematopoyetic stem I.F.: 1.803 COLITIS. 11(9):1039-1043. I.F.: 5.813 cell transplant in refractory Crohn’s disease. PhD student: Alícia López García

172 CHOLESTASIS AND BONE PATHOLOGY 3.8

Cholestasis 3.8 and bone pathology

RESEARCHERS Lluisa Álvarez (HCB) LOCATION Ana Isabel Monegal (HCB) HCB building Pilar Peris (HCB)

PRE-DOCTORAL RESEARCHERS Anna Reig (FCRB)

NURSING STAFF KEYWORDS Pilar Sesé (HCP) 1. Primary biliary cholangitis TEAM LEADER 2. Primary sclerosing cholangitis Albert Parés (HCB) COLLABORATORS Sílvia Ruiz (CIBER) 3. Autoimmune hepatitis T. 93 227 57 53 4. Osteoporosis [email protected] 5. Bone metabolism 6. Pruritus STRATEGIC OBJECTIVES 1. Epidemiology, natural history and treatment in cholestatic diseases 2. Natural history diagnosis, prognosis and treatment of autoimmune hepatitis 3. Phenotype and prognosis in primary Original publications sclerosing cholangitis from 2015 to 2017 4. Itching of cholestasis.

YEAR I.F. TOTAL Q1 Q2 5. Presentation forms of autoimmune hepatitis 2015 74.38 9 6 2 6. Osteoporosis in cholestatic diseases 2016 41.48 7 6 1 7. Osteoporosis in premenopausal women TEAM LEADER 2017 87.79 11 6 4 Núria Guañabens (HCB) and men 8. Bone remodelling in liver transplantation T. 93 227 54 00 (Ext.: 2235) 9. Management of vertebral fractures in [email protected] osteoporosis 10. Rare bone diseases

TEAM INVOLVED IN CIBEREHD AGAUR_SGR14 Albert Parés and Núria Guañabens

TEAM

173 AREA 3 LIVER, DIGESTIVE SYSTEM AND METABOLISM

MAIN LINES OF RESEARCH RESEARCH GROUP Gotthardt D, Färkkilä MA, Marschall HU, BONE METABOLIC DISEASE Thorburn D, Weersma RK, Fevery J, Mueller T, 1. Epidemiology, natural history and Chazouillères O, Schulze K, Lazaridis KN, therapeutic response of chronic Almer S, Pereira SP, Levy C, Mason A, Naess cholestatic disorders in adults. S, Bowlus CL, Floreani A, Halilbasic E, Yimam 2. Evaluation of the factors of treatment KK, Milkiewicz P, Beuers U, Huynh DK, Pares response, and new treatment regimens in A, Manser CN, Dalekos GN, Eksteen B, patients withsuboptimal response to Invernizzi P, Berg CP, Kirchner GI, Sarrazin C, ursodeoxycholic acid. Zimmer V, Fabris L, Braun F, Marzioni M, Juran 3. Development of new prognostic scores in GROUP LEADER BD, Said K, Rupp C, Jokelainen K, Benito de primary biliary cholangitis. Núria Guañabens (HCB) Valle M, Saffioti F, Cheung A, Trauner M, 4. Pruritus in chronic cholestasis: Schramm C, Chapman RW, Karlsen TH, Pathogenesis and treatment. The research group consists of Schrumpf E, Strassburg CP, Manns MP, 5. Pathogenesis of osteoporosis and fracture rheumatologists specialized in metabolic bone Lindor KD, Hirschfield GM, Hansen BE, development in primary biliary cholangitis disease, a specialist in clinical analysis and a Boberg KM, International PSC Study Group. and other chronic cholestatic disorders. biologist who is dedicated specifically to Patient Age, Sex, and Inflammatory Bowel 6. Course and prognosis in primary studies in cell cultures. Disease Phenotype Associate With sclerosing cholangitis. The group is a world leader in bone pathology Course of Primary Sclerosing Cholangitis. 7. Presentation, course and prognosis of of liver diseases and liver transplantation, as GASTROENTEROLOGY. 152(8):1975-1984. autoimmune hepatitis. well as in male osteoporosis and bone I.F.: 18.392 8. Osteoporosis in premenopausal women turnover markers. It has a close collaboration and in males. Study of the clinical with the group of cholestasis. 3. Floreani A., Mangini C., Reig A., Franceschet characteristics and mechanisms involved I., Cazzagon N., Perini L., Caballería L., Cocchio in the development of the disorder. S., Baldo V., Parés A. Thyroid Dysfunction in 9. Osteoporosis in primary biliary cholangitis. Primary Biliary Cholangitis: A Comparative Clinical and experimental evaluation. PUBLICATIONS Study at Two European Centers. 10. Osteoporosis in liver transplantation. AMERICAN JOURNAL OF 11. Evaluation of bone remodelling regulators Originals / I.F.: 87.789 GASTROENTEROLOGY. 112(1):114-119. in the pathogenesis of osteoporosis. I.F.: 9.566 12. Biomarkers in Paget disease. 1. Ji SG, Juran BD, Mucha S, Folseraas T, Jostins L, Melum E, Kumasaka N, Atkinson EJ, 4. Efe C, Hagström H, Ytting H, Bhanji RA, Schlicht EM, Liu JZ, Shah T, Gutierrez-Achury Müller NF, Wang Q, Purnak T, Muratori L, J, Boberg KM, Bergquist A, Vermeire S, Werner M, Marschall HU, Muratori P, Gunşar F, RESEARCH GROUP Eksteen B, Durie PR, Farkkila M, Müller T, Klintman D, Parés A, Heurgué-Berlot A, CHOLESTASIS Schramm C, Sterneck M, Weismüller TJ, Schiano TD, Cengiz M, May-Sien Tana M, Ma Gotthardt DN, Ellinghaus D, Braun F, Teufel A, X, Montano-Loza AJ, Berg T, Verma S, Larsen Laudes M, Lieb W, Jacobs G, Beuers U, FS, Ozaslan E, Heneghan MA, Yoshida EM, Weersma RK, Wijmenga C, Marschall HU, Wahlin S. Efficacy and Safety of Milkiewicz P, Pares A, Kontula K, Chazouillères Mycophenolate Mofetil and Tacrolimus as O, Invernizzi P, Goode E, Spiess K, Moore C, Second-line Therapy for Patients with Sambrook J, Ouwehand WH, Roberts DJ, Autoimmune Hepatitis. CLINICAL Danesh J, Floreani A, Gulamhusein AF, Eaton GASTROENTEROLOGY AND GROUP LEADER JE, Schreiber S, Coltescu C, Bowlus CL, HEPATOLOGY. 15(12):1950-1956. I.F.: 7.398 Albert Parés (HCB) Luketic VA, Odin JA, Chopra KB, Kowdley KV, Chalasani N, Manns MP, Srivastava B, Mells G, 5. Rodriguez AJ, Fink HA, Mirigian L, The research group consist of clinicians Sandford RN, Alexander G, Gaffney DJ, Guañabens N, Eastell R, Akesson K, Bauer (hepatologists) who follow a large number Chapman RW, Hirschfield GM, de Andrade M, DC, Ebeling PR. Pain, quality of life and of patients with autoimmune cholestatic Rushbrook SM, Franke A, Karlsen TH, safety outcomes of kyphoplasty for diseases, basically primary biliary cholangitis, Lazaridis KN, Anderson CA UK-PSC vertebral compression fractures: report of autoimmune hepatitis and primary sclerosing Consortium, International IBD Genetics a task force of the American Society for cholangitis. Consortium, International PSC Study Group. Bone and Mineral Research. JOURNAL OF The group actively participates in international Genome-wide association study of BONE AND MINERAL RESEARCH. research groups in these diseases and they primary sclerosing cholangitis identifies 32(9):1935-1944. I.F.: 6.284 contribute in the knowledge of the phenotype, new risk loci and quantifies the genetic natural history, diagnosis, prognosis and relationship with inflammatory bowel 6. De Vries E., Färkkilä M., Milkiewicz P., Hov J., treatment of these diseases. disease. NATURE GENETICS. 49(2):269-273. Eksteen B., Thorburn D., Chazouillères O., Close collaboration with the bone I.F.: 27.959 Pares A., Nygård S., Gilja O., Wunsch E., pathology group. Invernizzi P., Carbone M., Bernuzzi F., 2. Weismüller TJ, Trivedi PJ, Bergquist A, Boberg K., Røsjø H., Rosenberg W., Beuers U., Imam M, Lenzen H, Ponsioen CY, Holm K, Ponsioen C., Karlsen T., Vesterhus M..

174 CHOLESTASIS AND BONE PATHOLOGY 3.8

Enhanced liver fibrosis test predicts 2. Tsourdi E, Langdahl B, Cohen-Solal M, GRANTS FOR RESEARCH IN PROGRESS transplant-free survival in primary Aubry-Rozier B, Eriksen EF, Guañabens N, sclerosing cholangitis, a multi-centre Obermayer-Pietsch B, Ralston SH, Eastell R, Parés A. Prurito de la colestasis. Análisis study. LIVER INTERNATIONAL. Zillikens MC. Discontinuation of metabólico. 37(10):1554-1561. I.F.: 4.116 Denosumab therapy for osteoporosis: A Sponsored by: Instituto de Salud Carlos III systematic review and position statement (ISCIII). PI12/01448 7. Gifre L., Ruiz-Gaspà S., Carrasco J., Portell by ECTS. BONE. 105:11-17. I.F.: 4.140 Duration: 01/01/2013-30/06/2017 E., Vidal J., Muxi A., Monegal A., Guañabens N., Peris P. Effect of recent spinal cord injury Parés A. Development of antigen-specific on the OPG/RANKL system and its Letters / I.F.: 47.831 T-regulatory cell-expanding relationship with bone loss and the nanomedicines for autoimmune diseases: response to denosumab therapy. 1. Pares, Albert. An appealing new agent for Translational studies in human OSTEOPOROSIS INTERNATIONAL. treating cholestatic pruritus. LANCET. lymphocyte-engrafted hosts. 28(9):2707-2715. I.F.: 3.591 389(10074):1078-1080. I.F.: 47.831 Sponsored by: Instituto de Salud Carlos III (ISCIII). PIE14/00027 8. Peris P, Filella X, Monegal A, Guañabens N, Duration: 01/01/2015-31/12/2017 Foj L, Bonet M, Boquet D, Casado E, Cerdá D, Clinical Guidelines / I.F.: 3.591 Erra A, Gómez-Vaquero C, Martínez S, Guañabens N. Efectos de la bilirrubina y Montalá N, Pittarch C, Kanterewicz E, Sala M, 1. Diez-Perez A., Naylor K., Abrahamsen B., ácidos biliares sobre las células Suris X, Carrasco JL, LabOscat Study Group. Agnusdei D., Brandi M., Cooper C., Dennison reguladoras del remodelado óseo. Estudio Comparison of total, free and bioavailable E., Eriksen E., Gold D., Guañabens N., Hadji P., in vitro en células osteocitarias 25-OH vitamin D determinations to Hiligsmann M., Horne R., Josse R., Kanis J., MLO-A5/MLO-Y4. evaluate its biological activity in healthy Obermayer-Pietsch B., Prieto-Alhambra D., Sponsored by: Instituto de Salud Carlos III adults: the LabOscat study. Reginster J., Rizzoli R., Silverman S., Zillikens (ISCIII). PI14/00478 OSTEOPOROSIS INTERNATIONAL. M., Eastell R. International Osteoporosis Duration: 01/01/2015-31/12/2018 28(8):2457-2464. I.F.: 3.591 Foundation and European Calcified Tissue Society Working Group. Parés A. Efecto del bezafibrato sobre el 9. Peris P., Filella X., Monegal A., Guañabens Recommendations for the screening of prurito de la colestasis. Mecanismos N., Foj L., Bonet M., Boquet D., Casado E., adherence to oral bisphosphonates. patogénicos. Cerdá D., Erra A., Gómez-Vaquero C., OSTEOPOROSIS INTERNATIONAL. Sponsored by: Instituto de Salud Carlos III Martínez S., Montalá N., Pittarch C., 28(3):767-774. I.F.: 3.591 (ISCIII). PI15/00797 Kanterewicz E., Sala M., Suris X., Carrasco J.. Duration: 01/01/2016-31/12/2018 Concordance between direct and indirect measurements of free 25-OH vitamin D. Consortium Publications / I.F.: 7.286 CLINICA CHIMICA ACTA. 475:169-171. I.F.: 2.873 1. Liberal R., de Boer Y., Andrade R., Bouma G., Dalekos G., Floreani A., Gleeson D., Hirschfield 10. Valduvieco I, Biete A, Moreno LA, Gallart X, G., Invernizzi P., Lenzi M., Lohse A., Macedo G., Rovirosa A, Saez J, Plana C, Peris P. Is Milkiewicz P., Terziroli B., van Hoek B., Vierling anti-inflammatory radiotherapy an J., Heneghan M., Pares A., Montano-Loza A., effective treatment in trochanteritis?BR J Granito A., Kremer A., Schramm C., Lammert RADIOL. 90(1069):20160520. I.F.: 2.050 C., Cancado E., Bjornsson E., Lammert F., Hirschflield G., Hofer H., Mackay I., Neuberger 11. Bolier R, de Vries ES, Parés A, Helder J, J., Drenth J., van Nieuwkerk C., Muratori L., Kemper EM, Zwinderman K, Elferink RPO, Swain M., Zeniya M., Chazouilleres O., Gines P., Beuers U, Netherlands Association for the Chapman R., Berg T., van Buuren H., Liberal R. Study of the Liver (NASL) Cholestatic Liver Expert clinical management of Diseases Study Group. Fibrates for the autoimmune hepatitis in the real world. treatment of cholestatic itch (FITCH): ALIMENTARY PHARMACOLOGY AND study protocol for a randomized controlled THERAPEUTICS. 45(5):723-732. I.F.: 7.286 trial. TRIALS. 18(1):230. I.F.: 1.969

Review / I.F.: 9.640

1. Pares, Albert. Novel Treatment Strategies for Primary Biliary Cholangitis. SEMINARS IN LIVER DISEASE. 37(1):60-72. I.F.: 5.500

175 AREA 3 LIVER, DIGESTIVE SYSTEM AND METABOLISM

Mitochondrial regulation of 3.9 cell death and steatohepatitis

STRATEGIC OBJECTIVES

LOCATION The overall aim is to examine the cell biology CEK building floor 4 of lipids and cholesterol trafficking in liver diseases and neurodegeneration. This includes the role of mitochondrial cholesterol and sphingolipids in steatohepatitis, liver cancer, liver fibrogenesis, hepatic ischemia/reperfusion injury, Alzheimer’s KEYWORDS disease and lysosomal storage disorders. 1. Cholesterol/sphingolipids TEAM LEADER 2. Mitochondrial death José Carlos Fernández-Checa (IIBB-CSIC) 3. Oxidative stress T. 93 227 57 09 MAIN LINES OF RESEARCH 4. Alcoholic and non-alcoholic [email protected] steatohepatitis (ASH/NASH) 1. Sphingolipid and mitochondrial 5. Lipid therapies oxidative-stress regulation of cell death. RESEARCHERS 2. Mechanisms responsible for cholesterol Joan Caballeria (HCB) transport to the mitochondria and role in M. Carmen García (IIBB-CSIC) NASH, hepatocellular carcinoma and Alzheimer’s disease. POST-DOCTORAL RESEARCHERS 3. Translational research in nonalcoholic Original publications Cristina Alarcón (IIBB-CSIC) steatohepatitis (NASH): Development of from 2015 to 2017 Fabián Octavio Arenas (IIBB-CSIC) NASH in a humanized mouse model to Laura Conde de la Rosa (CIBER) identify potential targets in human NASH. YEAR I.F. TOTAL Q1 Q2 Raquel Fucho (IIBB-CSIC) 4. Contribution of acid sphingomyelinase in 2015 90.78 10 10 - Vicente Ribas (IIBB-CSIC) acetaminophen induced acute liver failure. 5. Development of non-invasive diagnostic 2016 62.32 8 7 1 PRE-DOCTORAL RESEARCHERS methods for diagnosis and prognosis in 2017 101.61 10 10 - Naroa Insausti (IIBB-CSIC) alcohol-induced liver disease. David Robles (IIBB-CSIC) 6. Mitochondrial cholesterol and Estel Solsona (IIBB-CSIC) glycosphingolipids in liver fibrosis. Sandra Torres (IIBB-CSIC) Reciprocal regulation between HIF1a and StARD1 in steatohepatitis and TEAM INVOLVED IN TECHNICIANS hepatocellular carcinoma. CIBEREHD Gemma Gay (IIBB-CSIC) 7. Establishment of a mouse model with a AGAUR_SGR14 Susana Núñez (CIBER) humanized liver to study ALD and NASH. COST Action CA17112 Jose Antonio Ramos (IIBB-CSIC) José Carlos Fernández-Checa

TEAM

176 MITOCHONDRIAL REGULATION OF CELL DEATH AND STEATOHEPATITIS 3.9

8. ER stress-mitochondrial cholesterol axis in alcohol-induced liver injury in mice and 3. Augustin S, Graupera I, Caballeria J, . obesity-associated insulin resistance and patients. JOURNAL OF HEPATOLOGY. Non-alcoholic fatty liver disease: A poorly comorbidities 67(5):1018-1025. I.F.: 12.486 known pandemic. MEDICINA CLINICA. 149(12):542-548. I.F.: 1.125 7. Balboa E, Castro J, Pinochet MJ, Cancino PUBLICATIONS GI, Matías N, José Sáez P, Martínez A, Álvarez AR, Garcia-Ruiz C, Fernandez-Checa JC, Originals / I.F.: 101.614 Zanlungo S. MLN64 induces mitochondrial GRANTS FOR RESEARCH IN PROGRESS dysfunction associated with increased 1. Perea L, Coll M, Sanjurjo L, Blaya D, mitochondrial cholesterol content. REDOX Caballería J. Análisis de la disfunción Taghdouini AE, Rodrigo-Torres D, Altamirano BIOLOGY. 12:274-284. I.F.: 6.337 endotelial y miRNAs en el pronóstico de la J, Graupera I, Aguilar-Bravo B, Llopis M, hepatitis alcoholic. Vallverdú J, Caballeria J, van Grunsven LA, 8. Torres S, Matías N, Baulies A, Nuñez S, Sponsored by: Instituto de Salud Carlos III Sarrias MR, Ginès P, Sancho-Bru P. Alarcon-Vila C, Martinez L, Nuño N, Fernandez (ISCIII). PI12/01265 Pentraxin-3 Modulates LPS-induced A, Caballeria J, Levade T, Gonzalez- Duration: 01/01/2013-30/06/2017 Inflammatory Response and Attenuates Franquesa A, Garcia-Rovés P, Balboa E, Liver Injury. HEPATOLOGY. 66(3):953-968. Zanlungo S, Fabrías G, Casas J, Enrich C, Fernández-Checa J.C. Regulation and I.F.: 13.246 Garcia-Ruiz C, Fernández-Checa JC. contribution of HIF-1 and StARD1 to Mitochondrial GSH replenishment as a steatohepatitis and hepatocellular 2. Bissonnette J, Altamirano J, Devue C, Roux potential therapeutic approach for carcinoma. O, Payancé A, Lebrec D, Bedossa P, Valla D, Niemann Pick type C disease. REDOX Sponsored by: Ministerio de Economía y Durand F, Ait-Oufella H, Sancho-Bru P, BIOLOGY. 11:60-72. I.F.: 6.337 Competitividad. SAF2015-069944 Caballeria J, Ginès P, Boulanger CM, Bataller Duration: 01/01/2016-31/12/2019 R, Rautou PE. A Prospective study of the 9. Alvarez-Sola, Gloria; Uriarte, Iker; Latasa, utility of plasma biomarkers to diagnose Maria U.; Jimenez, Maddalen; Barcena-Varela, García-Ruiz C. Colesterol mitocondrial libre alcoholic hepatitis. HEPATOLOGY. Marina; Santamaria, Eva; Urtasun, Raquel; y acetilación del gangliósido GD3 en 66(2):555-563. I.F.: 13.246 Rodriguez-Ortigosa, Carlos; Prieto, Jesus; esteatohepatitis y fibrosis Hepática. Corrales, Fernando J.; Baulies, Anna; Sponsored by: Ministerio de Economía y 3. Altamirano J, López-Pelayo H, Michelena J, Garcia-Ruiz, Carmen; Fernandez-Checa, Jose Competitividad. SAF2014-57674-R Jones PD, Ortega L, Ginès P, Caballería J, Gual C.; Berraondo, Pedro; Fernandez-Barrena, Duration: 01/01/2015-31/12/2017 A, Bataller R, Lligoña A. Alcohol abstinence Maite G.; Berasain, Carmen; Avila, Matias A. in patients surviving an episode of Engineered fibroblast growth factor 19 Ribas Serra V. Papel de colesterol alcoholic hepatitis: Prediction and impact protects from acetaminophen-induced mitocondrial en carcinoma hepatocelular. on long-term survival. HEPATOLOGY. liver injury and stimulates aged liver Sponsored by: Ministerio de Economía y 66(6):1842-1853. I.F.: 13.246 regeneration in mice. CELL DEATH DIS. Competitividad. SAF2015-735579-JIN 8(10):3083. I.F.: 5.965 Duration: 01/01/2017-31/12/2019 4. Zubiete-Franco I, Fernández-Tussy P, Barbier-Torres L, Simon J, Fernández-Ramos 10. Cano A, Mariño Z, Millet O, D, Lopitz-Otsoa F, Gutiérrez-de Juan V, de Martínez-Arranz I, Navasa M, Falcón-Pérez DOCTORAL THESES Davalillo SL, Duce AM, Iruzubieta P, Taibo D, JM, Pérez-Cormenzana M, Caballería J, Crespo J, Caballeria J, Villa E, Aurrekoetxea I, Embade N, Forns X, Bosch J, Castro A, Mato Fernández-Checa JC, García-Ruiz MC. Aspichueta P, Varela-Rey M, Lu SC, Mato JM, JM. A Metabolomics Signature Linked Functional and metabolic interplay Beraza N, Delgado TC, Martínez-Chantar ML. To Liver Fibrosis In The Serum Of between methionine metabolites, acid Deregulated neddylation in liver fibrosis. Transplanted Hepatitis C Patients. sphingomyelinase and HEPATOLOGY. 65(2):694-709. I.F.: 13.246 SCIENTIFIC REPORTS. 7(1):10497. I.F.: 4.259 phosphatidylcholine: Impact in steatohepatitis. 5. Jang JE, Park HS, Yoo HJ, Baek IJ, Yoon JE, PhD student: Cristina Alarcón Vila Ko MS, Kim AR, Kim HS, Lee SE, Kim SW, Kim Review / I.F.: 10.335 SJ, Leem J, Kang YM, Jung MK, Pack CG, Kim García-Ruiz MC, Fernández-Checa JC. CJ, Sung CO, Lee IK, Park JY, Fernández- 1. Arenas F., Garcia-Ruiz C., Fernandez-Checa Interacción cholesterol-gangliósido GD3 Checa JC, Koh EH, Lee KU. Protective role J. Intracellular cholesterol trafficking and en fibrosis hepática. of endogenous plasmalogens against impact in neurodegeneration. FRONTIERS PhD student: Mª del Carmen Vallejo Valdivia hepatic steatosis and steatohepatitis. IN MOLECULAR NEUROSCIENCE. 10:382. HEPATOLOGY. 66(2):416-431. I.F.: 13.246 I.F.: 5.076

6. Marin V, Poulsen K, Odena G, McMullen 2. Torres S., Balboa E., Zanlungo S., Enrich C., MR, Altamirano J, Sancho-Bru P, Tiribelli C, Garcia-Ruiz C., Fernandez-Checa J. Caballeria J, Rosso N, Bataller R, Nagy LE. Lysosomal and mitochondrial liaisons in Hepatocyte-derived macrophage Niemann-Pick disease. FRONTIERS IN migration inhibitory factor mediates PHYSIOLOGY. 8(NOV):982. I.F.: 4.134

177 AREA 3 LIVER, DIGESTIVE SYSTEM AND METABOLISM

Liver transplantation 3.10 and graft viability

PRE-DOCTORAL RESEARCHERS Cindy Ávalos (IDIBAPS) LOCATION Esther Bujaldon (IDIBAPS) CEK building ﬂoor 3 Amelia Judith Hessheimer (HCB) Ana Teresa Menjívar (FCRB) Javier Muñoz (CIBER) Elsa Negrete (IDIBAPS) Floriana Rotondo (IDIBAPS)

KEYWORDS TECHNICIANS 1. Liver transplantation TEAM LEADER Marta Martinez (IDIBAPS) 2. Graft viability Miquel Navasa (HCB) David Sabater (CIBER) 3. Immunosuppression T. 93 227 57 53 (Ext.: 4406) 4. Allograft tolerance [email protected] COLLABORATORS

5. Hepatic ischemia-reperfusion injury Arany Casillas (IDIBAPS) Mariana Mendes (IDIBAPS) GROUP LEADER Carmen Peralta (IDIBAPS) T. 93 227 54 00 (Ext.: 4177) STRATEGIC OBJECTIVES [email protected] Aloimmune response and Original publications RESEARCHERS immunosuppression. Operational Tolerance. from 2015 to 2017 Annabel Blasi (HCB) Ischemic reperfussion injury. Evaluation of YEAR I.F. TOTAL Q1 Q2 Mercedes Brunet (HCB) new ways of graft preservation. Ex-vivo Jordi Felix Colmenero (HCB) perfusion devices. 2015 52.09 11 62 Gonzalo Crespo (HCB) Hepatitis C recurrence. Study of ﬁbrosis 2016 106.38 22 14 3 Constantino Fondevila (HCB) regression after antiviral treatment. 2017 94.43 25 11 8 Juan Carlos García-Valdecasas (HCB) Complications of immunosuppression. Antoni Rimola (HCB) Prevention and treatment of cardiovascular Joan Rosello (IIBB-CSIC) risk factors after liver transplantation.

POST-DOCTORAL RESEARCHERS TEAM INVOLVED IN Ana Isabel Álvarez (IDIBAPS) MAIN LINES OF RESEARCH CIBEREHD María Eugenia Cornide (IDIBAPS) AGAUR_SGR17 Jose Gulfo (CIBER) 1. Evaluation of the impact of alloreactivity in Mónica Jiménez (IDIBAPS) graft outcome. Diferent studies are ongoing Olga Millán (CIBER) aimed at investigating the role of different Miquel Navasa

TEAM

178 LIVER TRANSPLANTATION AND GRAFT VIABILITY 3.10

markers of the immunosuppressive PUBLICATIONS 4. Nicolás D, Ambrosioni J, Sued O, Brunet M, balance and graft outcome after LT. A López-Diéguez M, Manzardo C, Agüero F, prospective, multicentre, European trial has Originals / I.F.: 94.433 Tuset M, Plana M, Guardo AC, Mosquera MM, been started to translate the results of the Muñoz-Fernández MÁ, Caballero M, Marcos studies done by the group in operational 1. Guixé-Muntet S, de Mesquita FC, Vila S, MÁ, Gatell JM, de Lazzari E, Gallart T, Miró JM. tolerance into clinical practice. Hernández-Gea V, Peralta C, García-Pagán Cyclosporine A in addition to standard JC, Bosch J, Gracia-Sancho J. Cross-talk ART during primary HIV-1 infection: pilot 2. In the field of organ retrieval, we are between autophagy and KLF2 determines randomized clinical trial. JOURNAL OF characterizing new targets based on endothelial cell phenotype and ANTIMICROBIAL CHEMOTHERAPY. adipocytokines modulation and microvascular function in acute liver injury. 72(3):829-836. I.F.: 5.071 investigating the protective effect of J HEPATOL. 66(1):86-94. I.F.: 12.486 polyethilenglycol in the preservation 5. Jiménez-Castro M., Negrete-Sánchez E., solutions. We are conducting several 2. Pascasio JM, Vinaixa C, Ferrer MT, Casillas-Ramírez A., Gulfo J., Álvarez- studies evaluating ex-vivo perfusion Colmenero J, Rubin A, Castells L, Manzano Mercado A., Cornide-Petronio M., Gracia- devices. ML, Lorente S, Testillano M, Xiol X, Molina E, Sancho J., Rodés J., Peralta C. The effect of González-Diéguez L, Otón E, Pascual S, cortisol in rat steatotic and non-steatotic 3. Studies of liver fibrosis regression after Santos B, Herrero JI, Salcedo M, Montero JL, liver transplantation from brain-dead antiviral treatment in liver transplant Sánchez-Antolín G, Narváez I, Nogueras F, donors. CLINICAL SCIENCE. 131(8):733-746. patients, have characterized the evolution Giráldez Á, Prieto M, Forns X, Londoño MC. I.F.: 4.936 of liver fibrosis in these patients Clinical outcomes of patients undergoing antiviral therapy while awaiting liver 6. Cornide-Petronio M., Bujaldon E., 4. Prevention and treatment of cardiovascular transplantation. JOURNAL OF Mendes-Braz M., Avalos de León C., risk factors after liver transplantation. HEPATOLOGY. 67(6):1168-1176. I.F.: 12.486 Jiménez-Castro M., Álvarez-Mercado A., Studies on cardiovascular risk factors in Gracia-Sancho J., Rodés J., Peralta C. patients with liver transplantation are 3. Pericàs JM, García-de-la-Mària C, Brunet The impact of cortisol in steatotic and ongoing. M, Armero Y, García-González J, Casals G, non-steatotic liver surgery. JOURNAL OF Almela M, Quintana E, Falces C, Ninot S, CELLULAR AND MOLECULAR MEDICINE. Fuster D, Llopis J, Marco F, Moreno A, Miró 21(10):2344-2358. I.F.: 4.499 RESEARCH GROUP JM, Hospital Clinic Endocarditis Study Group. PROTECTIVE STRATEGIES AGAINST Early in vitro development of daptomycin 7. Cano A, Mariño Z, Millet O, Martínez-Arranz HEPATIC ISCHEMIA-REPERFUSION non-susceptibility in high-level I, Navasa M, Falcón-Pérez JM, INJURY aminoglycoside-resistant Enterococcus Pérez-Cormenzana M, Caballería J, Embade faecalis predicts the efficacy of the N, Forns X, Bosch J, Castro A, Mato JM. A combination of high-dose daptomycin plus Metabolomics Signature Linked To Liver ampicillin in an in vivo model of Fibrosis In The Serum Of Transplanted experimental endocarditis. J ANTIMICROB Hepatitis C Patients. SCIENTIFIC REPORTS. CHEMOTHER. 72(6):1714-1722. I.F.: 5.071 7(1):10497. I.F.: 4.259

GROUP LEADER Carmen Peralta (IDIBAPS)

The investigations led by Carmen Peralta are pioneers in the study of experimental surgical, technological and pharmacological strategies (in vivo pharmacological treatments, improvements in preservation solutions, ischemic preconditioning, etc.) that protect livers against damage induced by ischemia-reperfusion and increase the tolerance of steatotic livers and reduced-size liver grafts against the risk that show these liver types to damage and regenerative failure when they are submitted to transplantation or hepatic resections. Carmen Peralta GROUP

179 AREA 3 LIVER, DIGESTIVE SYSTEM AND METABOLISM

8. Solà E, Sanchez-Cabús S, Rodriguez E, Elia OF GASTROENTEROLOGY. the liver transplantation waiting list. C, Cela R, Moreira R, Pose E, 23(23):4211-4221. I.F.: 3.365 CLINICAL TRANSPLANTATION. 31(7):e13001. Sánchez-Delgado J, Cañete N, Morales-Ruiz I.F.: 1.865 M, Campos F, Balust J, Guevara M, 14. Nacif L., Hessheimer A., Gómez S., García-Valdecasas JC, Ginès P. Effects of Montironi C., Fondevila C. Infiltrative 21. Martínez C, Millán O, Rovira M, alfapump™ system on kidney and xanthogranulomatous cholecystitis Fernández-Avilés F, López A, Suárez-Lledó M, circulatory function in patients with mimicking aggressive gallbladder Carreras E, Urbano-Ispízua Á, Brunet M. cirrhosis and refractory ascites. LIVER carcinoma: A diagnostic and therapeutic Pharmacodynamics of T cell function for TRANSPLANTATION. 23(5):583-593. I.F.: 3.910 dilemma. WORLD JOURNAL OF monitoring pharmacologic GASTROENTEROLOGY. 23(48):8671-8678. immunosuppression after allogeneic 9. Agüero F, Forner A, Valdivieso A, Blanes M, I.F.: 3.365 hematopoietic stem cell transplantation. Barcena R, Manzardo C, Rafecas A, Castells L, INTERNATIONAL JOURNAL OF Abradelo M, Barrera-Baena P, 15. Panisello-Roselló A., Verde E., Zaouali M., HEMATOLOGY. 105(4):497-505. I.F.: 1.610 González-Diéguez L, Salcedo M, Serrano T, Flores M., Alva N., Lopez A., Folch-Puy E., Jiménez-Pérez M, Herrero JI, Gastaca M, Carbonell T., Hotter G., Adam R., 22. Pelegrina A, Martí J, Miquel R, Ferrer J, Aguilera V, Fabregat J, Del Campo S, Bilbao I, Roselló-Catafau J. The relevance of the UPS Hernández-Gea V, Diaz A, Nadal C, Romero CJ, Moreno A, Rimola A, Miro JM, in fatty liver graft preservation: A new García-Valdecasas JC, Fuster J. Changes of FIPSE Investigators. Human approach for IGL-1 and HTK solutions. liver hemodynamic and elastography immunodeficiency virus-infected liver INTERNATIONAL JOURNAL OF MOLECULAR parameters in patients with colorectal liver transplant recipients with incidental SCIENCES. 18(11):2287. I.F.: 3.226 metastases receiving preoperative hepatocellular carcinoma: A prospective chemotherapy: "a note of caution". multicenter nationwide cohort study. 16. Vidal O., Saavedra-Perez D., Valentini M., WORLD JOURNAL OF SURGICAL LIVER TRANSPL. 23(5):645-651. I.F.: 3.910 Astudillo E., Fernández-Cruz L., ONCOLOGY. 15(1):224. I.F.: 1.600 García-Valdecasas J. Surgical outcomes of 10. Fernández Carrillo C, Crespo G, de la total thyroidectomy using the LigaSure™ 23. Ferrer J., Molina V., Rull R., López-Boado Revilla J, Castells L, Buti M, Montero JL, Small Jaw versus LigaSure Precise™: A M., Sánchez S., García R., Ricart M., Fábrega E, Fernández I, Serrano-Millán C, retrospective study of 2000 consecutive Ventura-Aguiar P., García-Criado Á., Esmatjes Hernández V, Calleja JL, Londoño MC. patients. INTERNATIONAL JOURNAL OF E., Fuster J., Garcia-Valdecasas J. Pancreas Successful Continuation of HCV SURGERY (LONDON, ENGLAND). 37( ):8-12. transplantation: Advantages of a Treatment After Liver Transplantation. I.F.: 2.211 retroperitoneal graft position. CIRUGIA TRANSPLANTATION. 101(5):1009-1012. ESPANOLA. 95(9):513-520. I.F.: 1.276 I.F.: 3.678 17. Molina V, Sampson J, Ferrer J, Díaz A, Ayuso JR, Sánchez-Cabús S, Fuster J, 24. Calatayud D., Sánchez Cabús S., 11. Millán O, Budde K, Sommerer C, Aliart I, García-Valdecasas JC. Surgical treatment Sampson J., Resendiz A., Molina V., Fondevila Rissling O, Bardaji B, Matz M, Zeier M, Silva I, of perihilar cholangiocarcinoma: early C., Fuster J., García-Valdecasas J. Hepatic Guirado L, Brunet M. Urinary miR-155-5p results of en bloc portal vein resection. resection: a safe and effective surgery. and CXCL10 as prognostic and predictive LANGENBECKS ARCHIVES OF SURGERY. CIRUGIA ESPANOLA. 95(8):437-446. biomarkers of rejection, graft outcome and 402(1):95-104. I.F.: 2.203 I.F.: 1.276 treatment response in kidney transplantation. BRITISH JOURNAL OF 18. Reyes A, Marti J, Marfà S, Jiménez W, 25. Sánchez Cabús S., Estalella L., Pavel M., CLINICAL PHARMACOLOGY. Reichenbach V, Pelegrina A, Fondevila C, Calatayud D., Molina V., Ferrer J., Fondevila C., 83(12):2636-2650. Garcia Valdecasas JC, Fuster J. Prognostic Fuster J., García-Valdecasas J. Analysis of I.F.: 3.493 prediction by liver tissue proteomic the long-term results of living donor liver profiling in patients with colorectal liver transplantation in adults. CIRUGIA 12. Soto M; Sampietro-Colom L; Lasalvia L; metastases. FUTURE ONCOLOGY. ESPANOLA. 95(6):313-320. I.F.: 1.276 Mira A; Jimenez W; Navasa M. 13(10):875-882. I.F.: 2.131 Cost-effectiveness of enhanced liver fibrosis test to assess liver fibrosis in 19. Rodríguez-Perálvarez M, De Luca L, Review / I.F.: 4.349 chronic hepatitis C virus and alcoholic liver Crespo G, Rubin Á, Marín S, Benlloch S, disease patients. WORLD JOURNAL OF Colmenero J, Berenguer M, Navasa M, 1. Hessheimer, Amelia J.; Fondevila, GASTROENTEROLOGY. 23(17):3163-3173. Tsochatzis E, De la Mata M. An objective Constantino. Liver perfusion devices: I.F.: 3.365 definition for clinical suspicion of T-cell how close are we to widespread mediated rejection after liver application? CURRENT OPINION IN 13. Zaouali M., Panisello-Roselló A., Lopez A., transplantation. CLINICAL ORGAN TRANSPLANTATION. 22(2):105-111. Benítez C., Folch-Puy E., García-Gil A., TRANSPLANTATION. 31(7):e13005. I.F.: 1.865 I.F.: 3.073 Carbonell T., Adam R., Roselló-Catafau J. Relevance of proteolysis and proteasome 20. Ruiz P, Sastre L, Crespo G, Blasi A, 2. Hessheimer A., Nacif L., Flores Villalba E., activation in fatty liver graft preservation: Colmenero J, García-Valdecasas JC, Navasa Fondevila C. Liver transplantation for acute An Institut Georges Lopez-1 vs University M. Increased risk of portal vein thrombosis liver failure. CIRUGIA ESPANOLA. of Wisconsin appraisal. WORLD JOURNAL in patients with autoimmune hepatitis on 95(4):181-189. I.F.: 1.276

180 LIVER TRANSPLANTATION AND GRAFT VIABILITY 3.10

Letters / I.F.: 2.131 GRANTS FOR RESEARCH IN (ISCIII). PI41/01055 PROGRESS Duration: 01/01/2015-31/12/2017 1. Reyes A, Marti J, Marfa S, Jimenez W, Reichenbach V, Pelegrina A, Fondevila C, Brunet M. Evaluación del impacto de la Peralta C. Nuevas tecnologías de Valdecasas JC, Fuster J. Letter in reply: aloreactividad en la evolución del injerto preservación y transporte de órganos Prognostic prediction by liver tissue y de la reversibilidad de la ﬁbrosis tras el abdominales – Proyecto ALBA proteomic proﬁling in patients with tratamiento de la hepatitis C Sponsored by: Ministerio de Economía y colorectal liver metastases. FUTURE post-transplante hepático. Competitividad. Retos-Colaboración 2015. ONCOLOGY. 13(3):1135-1136. I.F.: 2.131 Sponsored by: Instituto de Salud Carlos III 2015-3859-1 (ISCIII). PI14/01055 Duration: 01/03/2015-30/06/2018 Duration: 01/01/2015-30/06/2019 Editorial / I.F.: 12.486 Peralta C. La hormona de crecimiento Fondevila C. Evaluación de la en el trasplante de injertos hepáticos 1. Colmenero J; Sancho-Bru P. regeneración hepatocelular tras esteatósicos y no esteatósicos Mesenchymal stromal cells for hepatectomía mayor en un modelo procedentes de donantes con muerte immunomodulatory cell therapy in liver clínico y otro experimental. Utilidad del cerebral. transplantation: One step at a time. tratamiento con somatostanina y Sponsored by: Ministerio de Economía y JOURNAL OF HEPATOLOGY. 67(1):7-9. I.F.: debutamina en un modelo porcino de Competitividad. SAF15-64857-R 12.486 cirugía hepática extrema. Duration: 01/01/2016-31/12/2018 Sponsored by: Instituto de Salud Carlos III (ISCIII). PI15/01092 Consortium Publications / I.F.: 9.594 Duration: 01/01/2016-31/12/2018

1. Pericàs JM, Messina JA, Garcia-Valdecasas J.C. Consortium on Garcia-de-la-Mària C, Park L, organ preservation in Europe (COPE). Sharma-Kuinkel BK, Marco F, Wray D, Sponsored by: European Commission Kanafani ZA, Carugati M, Durante-Mangoni (FP7_HEALTH_IN1-2012) 305934 E, Tattevin P, Chu VH, Moreno A, Fowler VG, Duration: 01/09/2013-30/06/2018 Miró JM, International Collaboration on Endocarditis Microbiology Investigators. García-Valdecasas JC. Evaluation of the Inﬂuence of Vancomycin Minimum feasibilty of normothermic regional Inhibitory Concentration on the perfusion followed by ex-vivo Outcome of Methicillin-Susceptible normothermic machine perfusion in Staphylococcus aureus Left-Sided Type II DCD (Donation after Cardiac Infective Endocarditis Treated with Death) Anti-staphylococcal Beta-Lactam Liver Transplants. Antibiotics; a Prospective Cohort Study Sponsored by: Fundació La Caixa. by the International Collaboration on Duration: 01/05/2016-30/04/2018 Endocarditis. CLIN MICROBIOL INFECT. 23(8):544-549. I.F.: 5.292 Manyalich M. Evolución psicosocial del donante vivo renal. Estudio de cohortes. 2. Castañeda X, García-de-la-Mària C, Sponsored by: Instituto de Salud Carlos III. Gasch O, Pericas JM, Armero Y, Soy D, PI14/00693 García-González J, Falces C, Ninot S, Duration: 01/01/2015-30/06/2019 Almela M, Ambrosioni J, Quintana E, Vidal B, Fuster D, Llopis J, Soto S, Moreno A, Marco Manyalich M. The Effect of Differing Kidney F, Miró JM, Hospital Clinic Endocarditis Disease Treatment Modalities and Organ Study Group. AUC/MIC Donation and Transplantation Practices Pharmacodynamic Target Is Not a Good on Health Expenditure and Patient Predictor of Vancomycin Efficacy in Outcomes. Methicillin-Resistant Staphylococcus Sponsored by: European Commission_2016. aureus Experimental Endocarditis. 739495 ANTIMICROBIAL AGENTS AND Duration: 01/01/2017-31/12/2019 CHEMOTHERAPY. 61(6):e02486. I.F.: 4.302 Navasa M. Evaluación del impacto de la aloreactividad en la evolución del injerto y de la reversibilidad de la ﬁbrosis tras el tratamiento de la hepatitis C post-trasplante hepático. Sponsored by: Instituto de Salud Carlos III

181 AREA 3 LIVER, DIGESTIVE SYSTEM AND METABOLISM

Gastrointestinal 3.11 and pancreatic oncology

POST-DOCTORAL RESEARCHERS Josep Maria Augé (HCB) LOCATION Laia Bonjoch (FCRB) CEK building ﬂoor 4 Henry Nelson Cordova (HCB) Eva Hernández (FCRB) Jeronimo Luna (IDIBAPS) Leticia Moreira (HCB) Isabel Quintanilla (FCRB) Oriol Sendino (HCB) KEYWORDS Maria Vila (IDIBAPS) 1. Colorectal cancer TEAM LEADER 2. Pancreatic cancer Antoni Castells (HCB) PRE-DOCTORAL RESEARCHERS 3. Genetics T. 93 227 57 03 Isis Karina Acuña (HCB) 4. Inherited disorders [email protected] Coral Arnau (FCRB)

5. Susceptibility to cancer Pau Brugada (IDIBAPS) Sabela Carballal (HCB) GROUP LEADERS Marcos Diaz (IDIBAPS) Sergi Castellví-Bel (IDIBAPS) Saray Duran (CIBER) T. 93 227 54 00 (Ext.: 4183/2915) Sebastian Franch (FCRB-CIBER) [email protected] Claudia Galofre (CIBER) Maria Marcuello (CIBER) Original publications Cristina Fillat (IDIBAPS) Estela Nuñez (IDIBAPS) from 2015 to 2017 T. 93 227 54 00 (Ext.: 4579) Giulia Raimondi (IDIBAPS)

YEAR I.F. TOTAL Q1 Q2 cﬁ[email protected] Liseth Rivero (FCRB) Maria Rovira (IDIBAPS) 2015 331.26 49 38 2 Cristina Sanchez (IDIBAPS) 2016 295.29 44 39 3 RESEARCHERS Ariadna Sánchez (HCB) 2017 261.86 49 32 10 Juan Ramon Ayuso (HCB) Irene Sangrador (FCRB-CIBER) Francesc Balaguer (HCB) Keyvan Torabi (IDIBAPS-FCRB) Jordi Camps (IDIBAPS) Elena Vila (CIBER) Jose Ignacio Elizalde (HCB) Glòria Fernàndez (HCB) TECHNICIANS

TEAM INVOLVED IN Àngels Ginès (HCB) Elena Asensio (IDIBAPS) CIBEREHD Meritxell Gironella (CIBER) Manuel Dominguez (CIBER) CIBERER Antonio M. Lacy (HCB) Lorena Moreno (FCRB) AGAUR_SGR14 Maria Pellise (HCB) Jennifer Muñoz (CIBER) AGAUR_SGR17 Santiago Sánchez (HCB) Eva Cristina Vaquero (HCB) ADMINISTRATIVE STAFF Oscar Vidal (HCB) Diana Patricia Vargas (HCB)

AWARDS Extraordinary Master Prize 2017 (Biomedicine) Institution: Universitat de Barcelona Awardee/s: Marcos Díaz Gay Antoni Castells

TEAM

182 TO COLORECTALCANCER GENETIC PREDISPOSITION RESEARCH GROUP 4. - Endoscopic therapies. Advanceddiagnostictechniques. - - Endoscopic ultrasound. 3. cancer. localandmetastaticspreadofpancreatic Epithelial-mesenchymaltransition inthe - cancer. ImplicationofmicroRNAsinpancreatic - 2. 1. correspond todifferentlinesofinvestigation: is dividedintofourareas,andtheseinturn Gastrointestinal andPancreaticOncology The activityoftheresearchgroupin MAIN LINESOFRESEARCH preventive strategies. to deﬁningnewdiagnostic,therapeuticand/or premalignant andmalignantlesions,withaview progression ofgastrointestinalandpancreatic mechanisms underlyingthedevelopmentand The gainingofin-depthknowledgethe STRATEGIC OBJECTIVES Anna Serradesanferm(HCB) Cristina Rodriguez(FCRB) Àngels Pozo(HCB) Teresa Ocaña(HCB) Mireia Diaz(HCB) NURSING STAFF led bySergiCastellví-Bel hasthemain gastrointestinal cancer” isaresearchgroup The “Geneticpredispositiontocolorectal Sergi Castellví-Bel GROUP LEADER Surgeryforpancreaticcancer. - Surgeryforcolorectalcancer. - Epigeneticsofcolorectalcancer. - Geneticsusceptibilityincolorectal cancer. - screeningandsurveillance. Hereditaryformsofcolorectalcancer, -

Research andinnovationinendoscopy: Physiopathology ofcolorectalcancer: Physiopathology ofpancreaticcancer: Research andinnovationinsurgery: (IDIBAPS)

GROUP Sergi Castellví -Bel GROUP Cristina Fillat fptet,icuigtervlei establishing ofpatients,includingtheirvaluein prognosis geneticvariantswithclinicalcharacteristics 4. 3. 2. predispositiongenesforCRCandGC 1. usinggeneeditingincellularmodels functionalitystudiesforgeneticvariants variantsforCRCandadvancedadenomarisk The mainresearchlinesare: management ofpatients. explore itsapplicationintheclinical cancer (CRC)andgastric(GC),to involved ingermlinesusceptibilitytocolorectal objective ofidentifyinggeneticvariants Genetic associationstudies:newgenetic Saeo-h-r iempigad State-of-the-art Finemappingand Genotype-phenotype correlation of the Genotype-phenotypecorrelationofthe etgnrto eunig e Next generationsequencing:new GASTROINTESTINAL ANDPANCREATIC ONCOLOGY GENE THERAPYANDCANCER RESEARCH GROUP moleculestopancreaticcarcinogenesis; therapeuticstrategiesbasedonengineered 1. Main researchlines: gene therapystrategiesforrarediseases. pancreatic cancerandinthedevelopmentof Our groupmainresearchinterestsfocuson Cristina Fillat GROUP LEADER 2. nesadtecnrbto fseic Understand thecontributionofspeciﬁc Rationally designandpreclinicallyevaluate (IDIBAPS) 3.11 183 AREA 3 LIVER, DIGESTIVE SYSTEM AND METABOLISM

oncolytic adenovirus. Understand the host Wei X, Yu H. GeMSTONE: orchestrated DIABETES. 66(12):3029-3040. I.F.: 8.684 contribution to the oncolytic virus effect and prioritization of human germline mutations identify biological interfaces between in the cloud. NUCLEIC ACIDS RESEARCH. 10. Benyamine, Audrey; Loncle, Celine; viruses and tumors to maximize 45(W1):W207-W214. I.F.: 10.162 Foucher, Etienne; Blazquez, Juan-Luis; effective therapeutic viruses and/or Castanier, Celine; Chretien, Anne-Sophie; chemical-biological combination therapies. 6. Aminian A., Brethauer S., Andalib A., Modesti, Mauro; Secq, Veronique; Chouaib, 3. Develop gene therapy and genome editing Nowacki A., Jimenez A., Corcelles R., Hanipah Salem; Gironella, Meritxell; Vila-Navarro, Elena; strategies for metabolic defects Z., Punchai S., Bhatt D., Kashyap S., Burguera Montalto, Giuseppe; Dagorn, Jean-Charles; B., Lacy A., Vidal J., Schauer P. Individualized Dusetti, Nelson; Iovanna, Juan; Olive, Daniel. Metabolic Surgery Score: Procedure BTN3A is a prognosis marker and a Selection Based on Diabetes Severity. promising target for V gamma 9V delta 2 T PUBLICATIONS ANNALS OF SURGERY. 266(4):650-657. cells based-immunotherapy in pancreatic I.F.: 8.980 ductal adenocarcinoma (PDAC). Originals / I.F.: 261.864 ONCOIMMUNOLOGY. 7(1):e1372080. 7. Vila-Navarro E, Vila-Casadesús M, Moreira I.F.: 7.719 1. Egoavil C., Juárez M., Guarinos C., L, Duran-Sanchon S, Sinha R, Ginés À, Rodríguez-Soler M., Hernández-Illán E., Fernández-Esparrach G, Miquel R, 11. Codony-Servat J, Cuatrecasas M, Asensio Alenda C., Payá A., Castillejo A., Cuatrecasas M, Castells A, Lozano JJ, E, Montironi C, Martínez-Cardús A, Serradesanferm A., Bujanda L., Gironella M. MicroRNAs for Detection of Marín-Aguilera M, Horndler C, Martínez- Fernández-Bañares F., Cubiella J., de-Castro Pancreatic Neoplasia: Biomarker Balibrea E, Rubini M, Jares P, Reig O, Victoria I, L., Guerra A., Aguirre E., Herreros-de-Tejada Discovery by Next-generation Sequencing Gaba L, Martín-Richard M, Alonso V, A., Bessa X., Herráiz M., Marín-Gabriel J., and Validation in 2 Independent Cohorts. Escudero P, Fernández-Martos C, Feliu J, Balmaña J., Piñol V., Rodríguez Moranta F., ANNALS OF SURGERY. 265(6):1226-1234. Méndez JC, Méndez M, Gallego J, Salud A, Nicolás-Pérez D., Cuatrecasas M., Balaguer F., I.F.: 8.980 Rojo F, Castells A, Prat A, Rosell R, Castells A., Soto J., Zapater P., Jover R. García-Albéniz X, Camps J, Maurel J. Nuclear Increased Risk of Colorectal Cancer in 8. Van Hilst J, de Rooij T, Klompmaker S, IGF-1R predicts chemotherapy and Patients With Multiple Serrated Polyps and Rawashdeh M, Aleotti F, Al-Sarireh B, Alseidi targeted therapy resistance in metastatic Their First-Degree Relatives. A, Ateeb Z, Balzano G, Berrevoet F, Björnsson colorectal cancer. BRITISH JOURNAL OF GASTROENTEROLOGY. 153(1):106-112. B, Boggi U, Busch OR, Butturini G, Casadei R, CANCER. 117(12):1777-1768. I.F.: 6.176 I.F.: 18.392 Del Chiaro M, Chikhladze S, Cipriani F, van Dam R, Damoli I, van Dieren S, Dokmak S, 12. Schubert SA, Ruano D, Elsayed FA, Boot 2. De Barrios O., Gyorffy B., Edwin B, van Eijck C, Fabre JM, Falconi M, A, Crobach S, Sarasqueta AF, Wolffenbuttel B, Fernández-Aceñero M., Sánchez-Tilló E., Farges O, Fernández-Cruz L, Forgione A, van der Klauw MM, Oosting J, Tops CM, van Sánchez-Moral L., Siles L., Esteve-Arenys A., Frigerio I, Fuks D, Gavazzi F, Gayet B, Giardino Eijk R, Vasen HF, Vossen RH, Nielsen M, Roué G., Casal J., Darling D., Castells A., A, Bas Groot K, Hackert T, Hassenpﬂug M, Castellví-Bel S, Ruiz-Ponte C, Tomlinson I, Postigo A. ZEB1-induced tumourigenesis Kabir I, Keck T, Khatkov I, Kusar M, Lombardo Dunlop MG, Vodicka P, Wijnen JT, Hes FJ, requires senescence inhibition via C, Marchegiani G, Marshall R, Menon KV, Morreau H, de Miranda NF, Sijmons RH, van activation of DKK1/mutant Montorsi M, Orville M, de Pastena M, Wezel T. Evidence for genetic association p53/Mdm2/CtBP and repression of Pietrabissa A, Poves I, Primrose J, Pugliese R, between chromosome 1q loci and macroH2A1. GUT. 66(4):666-682. I.F.: 16.658 Ricci C, Roberts K, Røsok B, Sahakyan MA, predisposition to colorectal neoplasia. Sánchez-Cabús S, Sandström P, Scovel L, BRITISH JOURNAL OF CANCER. 3. IJspeert JEG, Bevan R, Senore C, Kaminski Solaini L, Soonawalla Z, Souche FR, Sutcliffe 117(6):1215-1223. I.F.: 6.176 MF, Kuipers EJ, Mroz A, Bessa X, Cassoni P, RP, Tiberio GA, Tomazic A, Troisi R, Wellner U, Hassan C, Repici A, Balaguer F, Rees CJ, White S, Wittel UA, Zerbi A, Bassi C, Besselink 13. Rivero-Sanchez L, Lopez-Ceron M, Dekker E. Detection rate of serrated polyps MG, Abu Hilal M, European Consortium on Carballal S, Moreira L, Bessa X, and serrated polyposis syndrome in Minimally Invasive Pancreatic Surgery Serradesanferm A, Pozo A, Augé JM, Ocaña colorectal cancer screening cohorts: a (E-MIPS) European Consortium on Minimally T, Sánchez A, Leoz ML, Cuatrecasas M, Grau European overview. GUT. 66(7):1225-1232. Invasive Pancreatic Surgery (E-MIPS). J, Llach J, Castells A, Balaguer F, Pellisé M, I.F.: 16.658 Minimally Invasive versus Open Distal Procolon Group. Reassessment Pancreatectomy for Ductal colonoscopy to diagnose serrated 4. Villanueva, Eneko; Navarro, Pilar; Adenocarcinoma (DIPLOMA): A polyposis syndrome in a colorectal cancer Rovira-Rigau, Maria; Sibilio, Annarita; Mendez, Pan-European Propensity Score Matched screening population. ENDOSCOPY. Raul; Fillat, Cristina. Translational Study. ANNALS OF SURGERY. I.F.: 8.980 49(1):44-53. I.F.: 6.107 reprogramming in tumour cells can generate oncoselectivity in viral therapies. 9. Rodríguez-Comas J, Moreno-Asso A, 14. Brady R., Chapman S., Atallah S., Chand M., NATURE COMMUNICATIONS. 8:14833. Moreno-Vedia J, Martín M, Castaño C, Mayol J., Lacy A., Wexner S. I.F.: 12.124 Marzà-Florensa A, Boﬁll-De Ros X, Mir-Coll J, #colorectalsurgery. BRITISH JOURNAL OF Montané J, Fillat C, Gasa R, Novials A, Servitja SURGERY. 104(11):1470-1476. I.F.: 5.899 5. Chen S, Beltrán JF, Esteban-Jurado C, JM. Stress-Induced MicroRNA-708 Franch-Expósito S, Castellví-Bel S, Lipkin S, Impairs β-Cell Function and Growth.

184 GASTROINTESTINAL AND PANCREATIC ONCOLOGY 3.11

15. Nigri J, Gironella M, Bressy C, Vila-Navarro 21. Pericàs J., Corredoira J., Moreno A., TRANSACTIONS ON MEDICAL IMAGING. E, Roques J, Lac S, Bontemps C, Kozaczyk C, García-País M., Falces C., Rabuñal R., Mestres 36(6):1231-1249. I.F.: 3.942 Cros J, Pietrasz D, Maréchal R, Van Laethem C., Alonso M., Marco F., Quintana E., Almela M., JL, Iovanna J, Bachet JB, Folch-Puy E, Paré J., Llopis J., Castells A., Miró J. 27. Solà E, Sanchez-Cabús S, Rodriguez E, Tomasini R. PAP/REG3A favors perineural Relationship Between Enterococcus Elia C, Cela R, Moreira R, Pose E, invasion in pancreatic adenocarcinoma faecalis Infective Endocarditis and Sánchez-Delgado J, Cañete N, Morales-Ruiz and serves as a prognostic marker. Colorectal Neoplasm: Preliminary Results M, Campos F, Balust J, Guevara M, CELLULAR AND MOLECULAR LIFE From a Cohort of 154 Patients. REVISTA García-Valdecasas JC, Ginès P. Effects of SCIENCES. 74(22):4231-4243. I.F.: 5.788 ESPAÑOLA DE CARDIOLOGIA. alfapump™ system on kidney and 70(6):451-458. I.F.: 4.485 circulatory function in patients with 16. Esteban-Jurado C., Giménez-Zaragoza D., cirrhosis and refractory ascites. LIVER Muñoz J., Franch-Expósito S., álvarez-Barona 22. Torabi K., Wangsa D., Ponsa I., Brown M., TRANSPLANTATION. 23(5):583-593 M., Ocaña T., Cuatrecasas M., Carballal S., Bosch A., Vila-Casadesús M., Karpova T., I.F.: 3.910 López-Cerón M., Marti-Solano M., Díaz-Gay Calvo M., Castells A., Miró R., Ried T., Camps J. M., Wezel T., Castells A., Bujanda L., Balmaña Transcription-dependent radial 28. Rakislova N., Montironi C., Aldecoa I., J., Gonzalo V., Llort G., Ruiz-Ponte C., Cubiella distribution of TCF7L2 regulated genes in Fernandez E., Bombi J., Jimeno M., Balaguer J., Balaguer F., Aligué R., Castellví-Bel S. POLE chromosome territories. CHROMOSOMA. F., Pellise M., Castells A., Cuatrecasas M. and POLD1 screening in 155 patients with 126(5):1-13. I.F.: 4.414 Lymph node pooling: A feasible and multiple polyps and early-onset colorectal efficient method of lymph node molecular cancer. ONCOTARGET. 8(16):26732-26743. 23. Bonjoch L, Gironella M, Iovanna JL, Closa staging in colorectal carcinoma. JOURNAL I.F.: 5.168 D. REG3β modiﬁes cell tumor function by OF TRANSLATIONAL MEDICINE. 15(1):14. impairing extracellular vesicle uptake. I.F.: 3.786 17. Mato-Berciano A, Raimondi G, Maliandi SCIENTIFIC REPORTS. 7(1):3143. I.F.: 4.259 MV, Alemany R, Montoliu L, Fillat C. A 29. Aldecoa I, Montironi C, Planell N, Pellise M, NOTCH-sensitive uPAR-regulated 24. Kandimalla R., Linnekamp J., Van Hooff S., Fernandez-Esparrach G, Gines A, Delgado S, oncolytic adenovirus effectively Castells A., Llor X., Andreu M., Jover R., Goel A., Momblan D, Moreira L, Lopez-Ceron M, suppresses pancreatic tumor growth and Medema J. Methylation of WNT target Rakislova N, Martinez-Palli G, Balust J, Bombi triggers synergistic anticancer effects with genes AXIN2 and DKK1 as robust JA, de Lacy A, Castells A, Balaguer F, gemcitabine and nab-paclitaxel. biomarkers for recurrence prediction in Cuatrecasas M. Endoscopic tattooing of ONCOTARGET. 8(14):22700-22715. I.F.: 5.168 stage II colon cancer. ONCOGENESIS. early colon carcinoma enhances detection 6(4):e308. I.F.: 4.143 of lymph nodes most prone to harbor 18. Carrera-Lasfuentes P, Lanas A, Lanas A, tumor burden. SURGICAL ENDOSCOPY. Lanas A, Lanas A, Bujanda L, Bujanda L, 25. Larrea-Baz N., Michel A., Romero B., 31(2):723-733. I.F.: 3.747 Strunk M, Strunk M, Quintero E, Santolaria S, Pérez-Gómez B., Moreno V., Martín V., Benito R, Benito R, Benito R, Sopeña F, Dierssen-Sotos T., Jiménez-Moleón J., Castilla 30. Trépanier J., Arroyave M., Bravo R., Sopeña F, Sopeña F, Piazuelo E, Piazuelo E, J., Tardón A., Ruiz I., Peiró R., Tejada A., Jiménez-Toscano M., DeLacy F., Piazuelo E, Thomson C, Pérez-Aisa A, Chirlaque M., Butt J., Olmedo-Requena R., Fernandez-Hevia M., Lacy A. Transanal Nicolás-Pérez D, Hijona E, Hijona E, Espinel J, Gómez-Acebo I., Linares P., Boldo E., Castells Hartmann’s colostomy reversal assisted Campo R, Manzano M, Geijo F, Pellise M, A., Pawlita M., Castaño-Vinyals G., Kogevinas by laparoscopy: outcomes of the ﬁrst 10 Pellise M, Zaballa M, González-Huix F, Espinós M., de Sanjosé S., Pollán M., del Campo R., patients. SURGICAL ENDOSCOPY. J, Titó L, Barranco L, D'Amato M, Waterboer T., Aragonés N. Helicobacter 31(12):4981-4987. I.F.: 3.747 García-González MA, García-González MA, pylori antibody reactivities and colorectal García-González MA. Relevance of DNA cancer risk in a case-control study in Spain. 31. Arezzo A., Passera R., Bullano A., Mintz Y., repair gene polymorphisms to gastric FRONTIERS IN MICROBIOLOGY. 8:888. Kedar A., Boni L., Cassinotti E., Rosati R., cancer risk and phenotype. ONCOTARGET. I.F.: 4.076 Fumagalli Romario U., Sorrentino M., Brizzolari 8(22):35848-35862. I.F.: 5.168 M., Di Lorenzo N., Gaspari A., Andreone D., De 26. Bernal, Jorge; Tajkbaksh, Nima; Sanchez, Stefani E., Navarra G., Lazzara S., Degiuli M., 19. Ghio B., Jiménez A., Corcelles R., Flores L., Francisco Javier; Matuszewski, Bogdan J.; Shishin K., Khatkov I., Kazakov I., Schrittwieser Lacy A., Vidal J. Midterm effects of bariatric Chen, Hao; Yu, Lequan; Angermann, Quentin; R., Carus T., Corradi A., Sitzman G., Lacy A., surgery in patients with insulin-treated Romain, Olivier; Rustad, Bjorn; Balasingham, Uranues S., Szold A., Morino M. Multi-port type 2 diabetes. SURGERY FOR OBESITY Ilangko; Pogorelov, Konstantin; Choi, Sungbin; versus single-port cholecystectomy: AND RELATED DISEASES. Debard, Quentin; Maier-Hein, Lena; Speidel, results of a multi-centre, randomised 13(12):2004-2009. I.F.: 4.496 Stefanie; Stoyanov, Danail; Brandao, Patrick; controlled trial (MUSIC trial). SURGICAL Cordova, Henry; Sanchez-Montes, Cristina; ENDOSCOPY. 31(7):2872-2880. I.F.: 3.747 20. Navarrete A., Corcelles R., del Gobbo G., Gurudu, Suryakanth R.; Fernandez-Esparrach, Perez S., Vidal J., Lacy A. Sleeve Gloria; Dray, Xavier; Liang, Jianming; Histace, 32. Van der Pas, Martijn H. G. M.; Deijen, gastrectomy in the elderly: A case-control Aymeric. Comparative Validation of Polyp Charlotte L.; Abis, Gabor S. A.; de Lange-de study with long-term follow-up of 3 years. Detection Methods in Video Colonoscopy: Klerk, Elly S. M.; Haglind, Eva; Fuerst, Alois; SURGERY FOR OBESITY AND RELATED Results From the MICCAI 2015 Lacy, Antonio M.; Cuesta, Miguel A.; Bonjer, DISEASES. 13(4):575-580. I.F.: 4.496 Endoscopic Vision Challenge. IEEE Hendrik J.; COLOR II Study Grp. Conversions

185 AREA 3 LIVER, DIGESTIVE SYSTEM AND METABOLISM

in laparoscopic surgery for rectal cancer. 38. Lewis MA, Sharabash N, Miao ZF, Lyons spot regions segmentation and SURGICAL ENDOSCOPY. 31(5):2263-2270. LN, Piccirillo J, Kallogjeri D, Schootman M, classification for specular highlights I.F.: 3.747 Mutch M, Yan Y, Levin MS, Castells A, detection in colonoscopy videos. MACHINE Cuatrecasas M, Mills JC, Wang ZN, Rubin DC. VISION AND APPLICATIONS. 28(8):917-936. 33. Cubiella, Joaquin; Castells, Antoni; Andreu, Increased IFRD1 Expression in Human I.F.: 2.005 Montserrat; Bujanda, Luis; Carballo, Fernando; Colon Cancers Predicts Reduced Patient Jover, Rodrigo; Lanas, Angel; Diego Morillas, Survival. DIGESTIVE DISEASES AND 45. Alvarez-Urturi, Cristina; Juan; Salas, Dolores; Quintero, Enrique; SCIENCES. 62(12):3460-3467. I.F.: 2.875 Fernandez-Esparrach, Gloria; Ana Ibanez, COLONPREV study investigators. Ines; Rodriguez de Miguel, Cristina; Maria Correlation between adenoma detection 39. Buron A., Auge J., Sala M., Román M., Dedeu, Josep; Bessa, Xavier; Cordova, Henry; rate in colonoscopy- and fecal Castells A., Macià F., Comas M., Guiriguet C., Pellise, Maria; Balaguer, Francesc; Gines, immunochemical testing-based colorectal Bessa X., Castells X. Association between Angels; Barranco, Luis; Araujo, Isis K.; Andreu, cancer screening programs. UNITED EUR socioeconomic deprivation and colorectal Montserrat; Llach, Josep; Castells, Antoni; GASTROENT. 5(2):255-260. I.F.: 3.673 cancer screening outcomes: Low uptake Gonzalez-Suarez, Begona. Accuracy of rates among the most and least deprived Colon Capsule Endoscopy in Detecting 34. Pineda, Estela; Salud, A.; Vila-Navarro, E.; people. PLOS ONE. 12(6):e0179864. Colorectal Polyps in Individuals with Safont, M. J.; Llorente, Beatriz; Aparicio, J.; I.F.: 2.806 Familial Colorectal Cancer: Could We Vera, R.; Escudero, P.; Casado, E.; Bosch, C.; Avoid Colonoscopies? Bohn, U.; Perez-Carrion, R.; Carmona, A.; 40. Alberghina N, Sánchez-Montes C, Tuñón GASTROENTEROLOGY RESEARCH AND Ayuso, J. R.; Ripolles, T.; Bouzas, R.; Gironella, C, Maurel J, Araujo IK, Ferrer J, Sendino O, PRACTICE. 1507914:1-7. I.F.: 1.863 M.; Garcia-Albeniz, X.; Feliu, J.; Maurel, J. Córdova H, Vaquero EC, González-Suárez B, Dynamic soluble changes in sVEGFR1, Martínez-Palli G, Ginès À, 46. González-Acosta M., del Valle J., Navarro HGF, and VEGF promote chemotherapy Fernández-Esparrach G. Endoscopic M., Thompson B., Iglesias S., Sanjuan X., Paúles and bevacizumab resistance: A ultrasonography can avoid unnecessary M., Padilla N., Fernández A., Cuesta R., Teulé prospective translational study in the laparotomies in patients with pancreatic À., Plotz G., Cadiñanos J., de la Cruz X., BECOX (GEMCAD 09-01) trial. TUMOR adenocarcinoma and undetected Balaguer F., Lázaro C., Pineda M., Capellá G. BIOLOGY. 39(6):1010428317705509. peritoneal carcinomatosis. Elucidating the clinical significance of two I.F.: 3.650 PANCREATOLOGY. 17(5):858-864. I.F.: 2.580 PMS2 missense variants coexisting in a family fulfilling hereditary cancer criteria. 35. Arroyave M., DeLacy F., Lacy A. 41. Brea-Fernandez A., Fernandez-Rozadilla FAMILIAL CANCER. 16(4):501-507. I.F.: 1.660 Transanal total mesorectal excision C., Alvarez-Barona M., Azuara D., Ginesta M., (TaTME) for rectal cancer: Step by step Clofent J., de Castro L., Gonzalez D., Andreu 47. Ferrer J., Molina V., Rull R., López-Boado description of the surgical technique for a M., Bessa X., Llor X., Xicola R., Jover R., Castells M., Sánchez S., García R., Ricart M., two-teams approach. EUROPEAN A., Castellvi-Bel S., Capella G., Carracedo A., Ventura-Aguiar P., García-Criado Á., Esmatjes JOURNAL OF SURGICAL ONCOLOGY. Ruiz-Ponte C. Candidate predisposing E., Fuster J., Garcia-Valdecasas J. Pancreas 43(2):502-505. I.F.: 3.522 germline copy number variants in early transplantation: Advantages of a onset colorectal cancer patients. CLINICAL retroperitoneal graft position. CIRUGIA 36. Córdova H., Argüello L., Loras C., Naranjo AND TRANSLATIONAL ONCOLOGY. ESPANOLA. 95(9):513-520. I.F.: 1.276 Rodríguez A., Riu Pons F., Gornals J., 19(5):625-632. I.F.: 2.353 Nicolás-Pérez D., Andújar Murcia X., 48. Calatayud D., Sánchez Cabús S., Hernández L., Santolaria S., Leal C., Pons C., 42. Vidal O., Saavedra-Perez D., Valentini M., Sampson J., Resendiz A., Molina V., Fondevila Pérez-Cuadrado-Robles E., García-Bosch O., Astudillo E., Fernández-Cruz L., C., Fuster J., García-Valdecasas J. Hepatic Papo Berger M., Ulla Rocha J., García-Valdecasas J. Surgical outcomes of resection: a safe and effective surgery. Sánchez-Montes C., Fernández-Esparrach G. total thyroidectomy using the LigaSure™ CIRUGIA ESPANOLA. 95(8):437-446. I.F.: 1.276 Rate of adverse events of gastroduodenal Small Jaw versus LigaSure Precise™: A snare polypectomy for non-flat polyp is retrospective study of 2000 consecutive 49. Sánchez Cabús S., Estalella L., Pavel M., low: A prospective and multicenter study. patients. INTERNATIONAL JOURNAL OF Calatayud D., Molina V., Ferrer J., Fondevila C., WORLD JOURNAL OF SURGERY (LONDON, ENGLAND). 37( 1):8-12. Fuster J., García-Valdecasas J. Analysis of GASTROENTEROLOGY. 23(47):8405-8414. I.F.: 2.211 the long-term results of living donor liver I.F.: 3.365 transplantation in adults. CIRUGIA 43. Molina V, Sampson J, Ferrer J, Díaz A, ESPANOLA. 95(6):313-320. I.F.: 1.276 37. Guiriguet C., Pera G., Castells A., Toran P., Ayuso JR, Sánchez-Cabús S, Fuster J, Grau J., Rivero I., Buron A., Macià F., García-Valdecasas JC. Surgical treatment Vela-Vallespín C., Vilarrubí-Estrella M., of perihilar cholangiocarcinoma: early Review / I.F.: 22.808 Marzo-Castillejo M. Impact of comorbid results of en bloc portal vein resection. conditions on participation in an organised LANGENBECKS ARCHIVES OF SURGERY. 1. Vidal J, Corcelles R, Jiménez A, Flores L, colorectal cancer screening programme: 402(1):95-104. I.F.: 2.203 Lacy AM. Metabolic and Bariatric Surgery A cross-sectional study. BMC CANCER. for Obesity. GASTROENTEROLOGY. 17(1):524. I.F.: 3.288 44. Sánchez F., Bernal J., Sánchez-Montes C., 152(7):1780-1790. I.F.: 18.392 de Miguel C., Fernández-Esparrach G. Bright

186 GASTROINTESTINAL AND PANCREATIC ONCOLOGY 3.11

2. Boﬁll-De Ros, Xavier; Rovira-Rigau, Maria; 4. Castro, Jesus; Cuatrecasas, Miriam; Hilal, Mohammad; Besselink, Marc G.; Braga, Fillat, Cristina. Implications of MicroRNAs in Balaguer, Francesc; Ricart, Elena; Pellise, Marco; Fabre, Jean-Michel; Fernandez-Cruz, Oncolytic Virtherapy. FRONTIERS IN Maria. Serrated polyposis syndrome Laureano; Gayet, Brice; Kim, Song Cheol; ONCOLOGY. 7:142. I.F.: 4,416 associated with long-standing Khatkov, Igor E.; EAES Consensus inﬂammatory bowel disease. REVISTA Conference. Laparoscopic surgery for ESPANOLA DE ENFERMEDADES pancreatic neoplasms: the European Letters / I.F.: 27.847 DIGESTIVAS. 109(11):796-798. I.F.: 1.401 association for endoscopic surgery clinical consensus conference. SURGICAL 1. Bretthauer M., Kaminski M., Hassan C., 5. Navarrete A., Almenara R., Momblán D., ENDOSCOPY. 31(5):2023-2041. I.F.: 3.747 Kalager M., Holme Ø., Hoff G., Løberg M., Lacy A. Laparoscopic resection of a Regula J., Castells A., Adami H. America, we paraganglioma in the organ of 3. Deijen, Charlotte L.; Vasmel, Jeanine E.; de are confused: The updated U.S. preventive Zuckerkand123-metaiodobenzylguanidin Lange-de Klerk, Elly S. M.; Cuesta, Miguel A.; services task force recommendation on e guided by gamma probe. CIRUGIA Coene, Peter-Paul L. O.; Lange, Johan F.; colorectal cancer screening. ANNALS OF ESPANOLA. 95(4):239-241. I.F.: 1.276 Meijerink, W. J. H. Jeroen; Jakimowicz, Jack J.; INTERNAL MEDICINE. 166(2):139-140. Jeekel, Johannes; Kazemier, Geert; Janssen, I.F.: 17.202 Ignace M. C.; Pahlman, Lars; Haglind, Eva; Clinical Guidelines / I.F.: 12.214 Bonjer, H. Jaap; COLOR COlon Canc 2. Koedam T., Jaap Bonjer H., Lacy A. Laparoscopic Open. Ten-year outcomes of Pathologic outcomes of laparoscopic vs 1. Polkowski, Marcin; Jenssen, Christian; Kaye, a randomised trial of laparoscopic versus open mesorectal excision for rectal Philip; Carrara, Silvia; Deprez, Pierre; Gines, open surgery for colon cancer. SURGICAL cancer. JAMA SURGERY. 152(10):986. I.F.: 7.956 Angels; Fernandez-Esparrach, Gloria; ENDOSCOPY. 31(6):2607-2615. I.F.: 3.747 Eisendrath, Pierre; Aithal, Guruprasad P.; 3. Lacy A., Martin-Perez B., Diaz-DelGobbo G., Arcidiacono, Paolo; Barthet, Marc; Bastos, DeLacy H., Cahill R., Wexner S. The present Pedro; Fornelli, Adele; Napoleon, Bertrand; GRANTS FOR RESEARCH IN PROGRESS and future of surgical education – a video Iglesias-Garcia, Julio; Seicean, Andrada; vignette. COLORECTAL DISEASE. Larghi, Alberto; Hassan, Cesare; van Hooft, Balaguer F. Desarrollo de biomarcadores 19(3):303-304. I.F.: 2.689 Jeanin E.; Dumonceau, Jean-Marc. Technical de metilación en suero para la detección aspects of endoscopic ultrasound precoz de neoplasia colorrectal. (EUS)-guided sampling in Sponsored by: Instituto de Salud Carlos III Editorial / I.F.: 6.501 gastroenterology: European Society of (ISCIII). PI13/00719 Gastrointestinal Endoscopy (ESGE) Duration: 01/01/2014-30/06/2018 1. Pellise M, Rivero-Sanchez L. Retained clips: Technical Guideline March 2017. A new challenge for post-EMR surveillance? ENDOSCOPY. 49(10):989-1006. I.F.: 6.107 Balaguer F. Análisis del defecto de campo GASTROINTESTINAL ENDOSCOPY. mediado por metilación aberrante del ADN 85(3):535-537. I.F.: 6.501 2. Dumonceau JM, Deprez PH, Jenssen C, en el síndrome de poliposis serrada. Iglesias-Garcia J, Larghi A, Vanbiervliet G, Sponsored by: Instituto de Salud Carlos III Aithal GP, Arcidiacono PG, Bastos P, Carrara (ISCIII). PI16/00766 Case Reports / I.F.: 14.483 S, Czakó L, Fernández-Esparrach G, Fockens Duration: 01/01/2017-31/12/2019 P, Ginès À, Havre RF, Hassan C, Vilmann P, 1. Araujo I., Pages M., Romero C., Castells A., van Hooft JE, Polkowski M. Indications, Camps J. Implications of copy number González-Suárez B. Twelve-year results, and clinical impact of endoscopic variants of the genome in the etiology and asymptomatic retention of a colon capsule ultrasound (EUS)-guided sampling in progression of colorectal cancer. endoscope. GASTROINTESTINAL gastroenterology: European Society of Sponsored by: European Commission ENDOSCOPY. 85(3):681-682. I.F.: 6.501 Gastrointestinal Endoscopy (ESGE) (FP7_PEOPLE_2012). 321937 Clinical Guideline - Updated January 2017. Duration: 01/12/2013-30/11/2017 2. Navarrete A., Momblán D., Almenara R., ENDOSCOPY. 49:695-714. I.F.: 6.107 Lacy A.Giant Gastric Gastrointestinal Camps J. Implications of genomic copy Stromal Tumor (GIST). JOURNAL OF number variants in the etiology, GASTROINTESTINAL SURGERY. Consortium Publications / I.F.: 16.474 progression, and response to treatment of 21(1):202-204. I.F.: 2.963 colorectal cancer. 1. Penna, Marta; Hompes, Roel; Arnold, Steve; Sponsored by: Instituto de Salud Carlos III 3. Bravo R., Trépanier J., Arroyave M., Wynn, Greg; Austin, Ralph; Warusavitarne, (ISCIII). CP13/00160 Fernández-Hevia M., Pigazzi A., Lacy A. Janindra; Moran, Brendan; Hanna, George B.; Duration: 01/02/2014-31/01/2017 Combined transanal total mesorectal Mortensen, Neil J.; Tekkis, Paris P.;TaTME excision (taTME) with laparoscopic Registry Collaborative. Transanal Total Camps J. Implicaciones de la instruments and abdominal robotic Mesorectal Excision International Registry heterogeneidad intratumoral en la surgery in rectal cancer. TECHNIQUES IN Results of the First 720 Cases. ANNALS OF respuesta al tratamiento de COLOPROCTOLOGY. 21(3):233-235. SURGERY. 266(1):111-117. I.F.: 8.980 quimio-radioterapia neoadyuvante en I.F.: 2.342 pacientes con cáncer de recto. 2. Edwin, Bjorn; Sahakyan, Mushegh A.; Abu Sponsored by: Instituto de Salud Carlos III

187 AREA 3 LIVER, DIGESTIVE SYSTEM AND METABOLISM

(ISCIII). PI14/00783 enhancement strategies in pancreatic Castells A, Caballeria L. Efectividad de una Duration: 01/01/2015-31/12/2018 tumors. alerta en la historia clínica informatizada Sponsored by: Ministerio de Economía y de atención primaria para aumentar la Castells A. Identificación de nuevos Competitividad. BIO2014-57716-C2-2-R participación en un programa poblacional biomarcadores para la prevención del Duration: 01/01/2015-30/06/2018 de cribado de cárcer colorectal. cáncer colorrectal. Phd student: Carolina Guiriguet Capdevila Sponsored by: Asociación Española Contra el Fillat C. Recubrimiento polimérico Cáncer (AECC_2013). GCB13131592CAST multicapa de adenovirus oncolíticos para Fernández Esparrach G, Ginés MA. Pólipos Duration: 01/10/2013-30/09/2019 la regulación de su tropismo en el gástricos: tipos, tratamiento endoscópico tratamiento del adenocarcinoma de y complicaciones asociadas. Castells A. Diseño y puesta a punto de kits páncreas. Phd student: Lidia Argüello Viudez para el diagnóstico del cáncer de colon en Sponsored by: Ministerio de Economía y sangre basados en plataformas multiplex. Competitividad (RetosColaboración_2015). Fillat C. Adenovirus oncoselectius pel Sponsored by: Ministerio de Economía y RTC-2015-4189-1 tractament de càncer de pàncrees. Competitividad (RetosColaboración_2014). Duration: 01/09/2015-31/03/2018 Combinació d’estratègies de RTC-2014-1518-1 direccionament a tumor i bioselecció de Duration: 28/01/2014-19/05/2017 Fillat C. Desarrollo de una estrategia de microRNAs potenciadors de l’activitat terapia génica para el tratamiento de la adenoviral. Castells A. Detección de miRNA en heces acidúria glutárica tipo I y valoración de la PhD student: Maria Rovira Rigau con nueva estrategia de cribado del cancer eficacia de edición genómica in vivo. colorrectal: identificación y validación en Sponsored by: CIBER Enfermedades Raras. Lozano J, Gironella M. Design of población de riesgo medio. ACCI-2016-19 Bioinformatic Tools for Integrative Sponsored by: Ministerio de Economía y Duration: 01/01/2017-31/12/2018 Analysis of microRNA-mRNA interactome Competitividad. SAF2014-54453-R applied to digestive cancers. Duration: 01/01/2015-31/12/2018 Pellisé M. Impacto de las técnicas de Phd student: Maria Vila Casadesús endoscopia avanzada y de los miRNAs en Castells A. Desarollo de un kit de el diagnóstico y manejo de la neoplasia Postigo A, Castells A. Role of ZEB1 in tumor diagnóstico precoz de cáncer colorrectal colorrectal asociada a la enfermedad progression: regulation of cell invasion and mediante método no invsivo en plasma inflamatoria intestinal de larga evolución. senescence. basado en la expresión de miRNAs. Sponsored by: Instituto de Salud Carlos III Phd student: Oriol de Barrios Barri Sponsored by: Ministerio de Economia y (ISCIII). PI12/01481 Competitividad (RetosColaboración_2015). Duration: 01/01/2013-30/06/2017 RTC-2015-3850-1 Duration: 25/05/2015-31/12/2018 Vaquero E.C. Regulación mediada por ZEB1 del estroma tumoral: Implicaciones en el Castellví-Bel S. Identificación de genes de desarrollo y la quioresistencia en el cáncer predisposición germinal en un subgrupo de páncreas. de cáncer colorrectal: el síndrome de Sponsored by: Instituto de Salud Carlos III poliposis serrada en el punto de mira. (ISCIII). PI12/01430 Sponsored by: Instituto de Salud Carlos III Duration: 01/01/2013-30/06/2017 (ISCIII). PI14/00173 Duration: 01/01/2015-31/12/2017 DOCTORAL THESES Castellví-Bel S. Cooperation studies on inherited susceptibility to colorectal Pellisé M, Camps J. New insignhts into cancer. the colorectal carciongenesis: from early Sponsored by: European Commission precursor lesions to the roele of (COST_2012). OC-2012-1-11711 aneuploidy. Duration: 01/06/2013-29/09/2017 Phd student: Isabel Quintanilla

Fernandez-Esparrach G. Intelligent in-Vivo Camps J, Miró R, Ponsa I. La disomia Endoscopic Diagnosis and Intervention uniparental adquirida en el càncer Support Systems (iVENDIS). colorectal. Sponsored by: Ministerio de Economía y Phd student: Keyvan Torabi Asensio Competitividad. DPI2015-65286-R. RETOS 2015. Castells A, Molina R. Estimació del risc de Duration: 01/01/2016-31/12/2017 neoplàsia colorectal avançada a partir de la quantiﬁcació de l'hemoglobina fecal en Fillat C. Increasing the efficacy of oncolytic el cribratge del càncer de còlon i recte. adenovirus through replication Phd student: Josep Maria Augé Fradera

188 INHERITED METABOLIC DISEASES 3.12

Inherited metabolic 3.12 diseases

STRATEGIC OBJECTIVES

LOCATION The strategic objective of our group is to HCB building investigate the genetic and biochemical bases, as well as the physiopathological mechanisms, of a group of rare diseases called “inherited metabolic diseases or inborn errors of metabolism”. The ultimate aim is to develop new diagnostic and therapeutic KEYWORDS strategies. On the other hand, we conduct 1. Mitochondrial diseases TEAM LEADER translational research, stimulating the transfer 2. Mitochondrial cofactors Antonia Ribes (HCB) of knowledge from basic research to the 3. Lysosomal diseases T. 93 227 54 00 (Ext.: 9340) clinical practice, and vice versa. 4. Inherited metabolic diseases [email protected] 5. Inborn errors of metabolism 6. Organic acidurias MAIN LINES OF RESEARCH

Within the general line of inherited metabolic RESEARCHERS diseases, our specific research lines are: Mª José Coll (HCB) Judit García (HCB) 1. Identification of genes responsible for Original publications Laura Gort (HCB) Mendelian disorders, particularly in patients from 2015 to 2017 Rosa Mª López (HCB) with defects of the mitochondrial energy metabolism. These patients are YEAR I.F. TOTAL Q1 Q2 POST-DOCTORAL RESEARCHERS preselected on the basis of their clinical and Angela Arias (FCRB) biochemical characteristics. Within this line 2015 25.92 7 25 Laura Texido (CIBER) we aim to identify new defects to generate 2016 51.81 11 7 4 Frederic Tort (CIBER) knowledge that could be implemented to 2017 12.73 3 3 - the diagnosis and to the design of PRE-DOCTORAL RESEARCHERS therapeutic options. Sonia Pajares (FCRB) Olatz Ugarteburu (FCRB) 2. Physiopathology of the identified diseases. In addition to the classical methodologies TEAM INVOLVED IN COLLABORATORS we aim to introduce the study of lipidomics, CIBERER Marisa Girós (HCB) organelle-organelle interaction, AGAUR_SGR14 José Luís Marín (HCB) mitochondrial dynamics, mitochondrial supercomplexes and high resolution respirometry. Antonia Ribes

TEAM

189 AREA 3 LIVER, DIGESTIVE SYSTEM AND METABOLISM

3. Therapeutic approaches. This line involves Felipe A; Gutiérrez-Solana L; MacAya A; the testing of chemical and peptide libraries. Pérez-Dueñas B; Serrano M; Miranda M; Selection has been made of Carratalá F; Poo M; Robles B; Couce M; Girõs disease-causing missense mutations M; Gort L; Montero R; Artuch R; Perez-Cerda previously identiﬁed by our group in a wide C; Muchart J; Perez B. A quantitative range of diseases. We are particularly assessment of the evolution of cerebellar interested in compounds with chaperone syndrome in children with action and compounds capable of inducing phosphomannomutase-deﬁciency lysosomal exocytosis and autophagy (PMM2-CDG). ORPHANET JOURNAL OF promotion. RARE DISEASES. 12(1):155. I.F.: 3.507

PUBLICATIONS GRANTS FOR RESEARCH IN PROGRESS

Originals / I.F.: 12.734 Coll MJ. An EU rare diseases registry for Niemann-Pick Disease type A, B and C. 1. Matalonga L, Bravo M, Serra-Peinado C, Sponsored by: European Commission García-Pelegrí E, Ugarteburu O, Vidal S, (SANCO_2012). 55785 Llambrich M, Quintana E, Fuster-Jorge P, Duration: 01/04/2017-17/01/2018 Gonzalez-Bravo MN, Beltran S, Dopazo J, Garcia-Garcia F, Foulquier F, Matthijs G, Mills Ribes A. Identiﬁcación y caracterización de P, Ribes A, Egea G, Briones P, Tort F, Girós M. nuevos defectos del metabolismo Mutations in TRAPPC11 are associated energético mitocondrial asociados a with a congenital disorder of glycosylation. aciduria 3-metilglutacónica. HUM MUTAT. 38(2):148-151. I.F.: 4.601 Sponsored by: Instituto de Salud Carlos III (ISCIII). PI 16/01048 2. Yubero D, Adin A, Montero R, Jou C, Duration: 01/01/ 2017-31/12/2019 Jiménez-Mallebrera C, García-Cazorla A, Nascimento A, O'Callaghan M, Montoya J, Ribes A. Implementació de la medicina Gort L, Navas P, Ribes A, Ugarte M, Artuch R. personalitzada basada en la genómica en A statistical algorithm showing coenzyme malalties minoritaries neurologiques no Q10 and citrate synthase as biomarkers for diagnosticades. mitochondrial respiratory chain enzyme Sponsored by: Generalitat de Catalunya activities. SCIENTIFIC REPORTS. 6(1):15. (PERIS_2016). SLT002/16/00174 94981 I.F.: 4.259 Duration: 01/01/ 2017-31/12/2019

3. Perez-Cerda C; Girõs M; Serrano M; Ecay M; Gort L; Pérez Dueñas B; Medrano C; DOCTORAL THESES García-Alix A; Artuch R; Briones P; Perez B. A Population-Based Study on Congenital Ribes A. Identiﬁcació de mutacions en gens Disorders of Protein N- and Combined with implicats en el metabolisme de l’àcid lipòic O-Glycosylation Experience in Clinical and en l’acidúrica 3- metilglutacònica. Genetic Diagnosis. JOURNAL OF PhD student: Xènia Ferrer Cortès PEDIATRICS. 183:170-177.e1. I.F.: 3.874

Review / I.F.: 3.970

1. Matalonga L, Gort L, Ribes A. Small molecules as therapeutic agents for inborn errors of metabolism. JOURNAL OF INHERITED METABOLIC DISEASE. 40(2):177-193. I.F.: 3.970

Consortium Publications / I.F.: 3.507

1. Serrano N; De Diego V; Cuadras D; Martinez Monseny A; Velázquez-Fragua R; López L;

190 GENOMIC PROGRAMMING OF BETA CELLS AND DIABETES 3.13

Genomic programming 3.13 of beta cells and diabetes

STRATEGIC OBJECTIVES

LOCATION A study has been published that deﬁnes the CEK building ﬂoor 5 function of long non-coding RNAs (lncRNAs) in genetic networks involved in type 2 diabetes

WEB MAIN LINES OF RESEARCH www.imperial.ac.uk/medicine/ beta-cell-genome-regulation- 1. Dissection of the genetic mechanisms laboratory TEAM LEADER underlying the pathogenesis of human Jorge Ferrer diabetes. (IDIBAPS / Imperial College London) T. 93 227 54 00 (Ext.: 4542) 2. Understanding the epigenome of [email protected] pancreatic beta cells and its implications for the development, plasticity and growth of

KEYWORDS beta cells. 1. Epigenetics 2. Mouse genetic analysis POST-DOCTORAL RESEARCHERS 3. Mouse genetic analysis of beta-cell gene of beta cells regulation Edgar Bernardo (IDIBAPS) regulation. Miguel Ángel Maestro (CIBER) 3. Genomic regulation Irene Miguel-Escalada (IDIBAPS) 4. The regeneration of pancreatic beta cells. of pancreatic beta cells

4. Pancreas regeneration PRE-DOCTORAL RESEARCHERS 5. Type 2 diabetes Mar Armengol (IDIBAPS) PUBLICATIONS 6. Molecular pathophysiology Goutham Atla (IDIBAPS) Originals / I.F.: 29.654 TECHNICIANS Xavi García (CIBER) 1. Akerman I., Tu Z., Beucher A., Rolando D., Vanessa Grau (CIBER) Sauty-Colace C., Benazra M., Nakic N., Yang J., Victor López (CIBER) Wang H., Pasquali L., Moran I., Garcia-Hurtado Original publications J., Castro N., Gonzalez-Franco R., Stewart A., from 2015 to 2017 ADMINISTRATIVE STAFF Bonner C., Piemonti L., Berney T., Groop L., Carme Sanahuja (CIBER) Kerr-Conte J., Pattou F., Argmann C., Schadt YEAR I.F. TOTAL Q1 Q2 E., Ravassard P., Ferrer J. Human Pancreatic 2015 161.05 9 9 - β Cell lncRNAs Control Cell-Speciﬁc Regulatory Networks. CELL METABOLISM. 2016 16.03 2 2 - 25(2):400-411. I.F.: 18.164 2017 29.65 3 3 -

TEAM INVOLVED IN CIBERDEM AGAUR_SGR14

AWARDS Albert Renold Prize Institution: European Foundation for the Study of Diabetes (EFSD) Awardee/s: Jorge Ferrer Jorge Ferrer TEAM

191 AREA 3 LIVER, DIGESTIVE SYSTEM AND METABOLISM

2. Mercader JM; Liao RG; Bell AD; Dymek Z; identiﬁcation, prevention and treatment of Estrada K; Tukiainen T; Huerta-Chagoya A; type 2 diabetes. Moreno-Macías H; Jablonski KA; Hanson RL; Sponsored by: European Commission Walford GA; Moran I; Chen L; Agarwala V; (H2020_PHC_2015). 667191 Ordóñez-Sánchez ML; Rodríguez-Guillen R; Duration: 01/01/2016-31/12/2019 Rodríguez-Torres M; Segura-Kato Y; García-Ortiz H; Centeno-Cruz F; Ferrer J. Modeling three-dimensional Barajas-Olmos F; Caulkins L; Puppala S; chromosomal structure in beta cells to Fontanillas P; Williams AL; Bonàs-Guarch S; identify genetic mechanisms underlying Hartl C; Ripke S. A Loss-of-Function Splice type 2 diabetes. Acceptor Variant in IGF2 Is Protective for Sponsored by: Fundació La Marató de TV3. Type 2 Diabetes. DIABETES. 201611-30 66(11):2903-2914. I.F.: 8.684 Duration: 31/03/2017-30/03/2020

3. Van Arensbergen J., Dussaud S., Pardanaud-Glavieux C., García-Hurtado J., Sauty C., Guerci A., Ferrer J., Ravassard P. A distal intergenic region controls pancreatic endocrine differentiation by acting as a transcriptional enhancer and as a polycomb response element. PLOS ONE. 12(2):e0171508. I.F.: 2.806

GRANTS FOR RESEARCH IN PROGRESS

Ferrer J. Empleo de epigenomas celulares para optimizar la terapia celular a partir de células madre. Sponsored by: Ministerio de Ciencia e Innovación. PLE2009-0162 Duration: 01/11/2009-01/11/2017

Ferrer J. Diabetes Research on patients Tratiﬁcation. Sponsored by: European Commission (Innovative Medicines Initiative). IMI/115317 Duration: 01/02/2012-31/01/2019

Ferrer J. Genome regulators as targets for enhancing beta cell regeneration and function / Evaluación de reguladores genómicos como dianas para estimular la regeneración y función de las células beta (Betareg). Sponsored by: Ministerio de Economía y Competitividad. BFU2014-54284-R Duration: 01/01/2015-31/12/2018

Ferrer J. Computational and functional annotation of genomic elements during development of the model vertebrate zebraﬁsh (Zencode). Sponsored by: European Commission (H2020_MSCA_ITN_2014). 643062 Duration: 01/01/2015-31/12/2018

Ferrer J. Development of a systems biomedicine approach for risk

192 DIABETES: METABOLIC AND MOLECULAR NETWORKS 3.14

Diabetes: metabolic 3.14 and molecular networks

PRE-DOCTORAL RESEARCHERS Hugo Alves (FCRB) LOCATION Gloria Beatriz Aranda (IDIBAPS) CEK building ﬂoor 5 Antonio Jesús Blanco (IDIBAPS) Iñigo Chivite (IDIBAPS) Diana Alicia Diaz (IDIBAPS) Guillermo Eguren (IDIBAPS) Marta Fontcuberta (IDIBAPS) Josep Garnica (IDIBAPS) KEYWORDS Joan Ignasi Mir (IDIBAPS) 1. Type 1 diabetes Javier José Montaño (IDIBAPS) TEAM LEADER Berta Serra (IDIBAPS) 2. Type 2 diabetes Josep Vidal (HCB) Patricia Solé (IDIBAPS) 3. Obesity T. 93 227 57 39 4. Autoimmunity [email protected] 5. Pancreatic islets TECHNICIANS Luis Miguel Carrasco (IDIBAPS) Immaculada Creus (IDIBAPS)

GROUP LEADERS Melek Denizli (IDIBAPS) Marc Claret (IDIBAPS) Yaiza Esteban (CIBER) T. 93 227 54 00 (Ext.: 4552) César Fandos (IDIBAPS) [email protected] Ainhoa García (CIBER) Original publications Elena Lopez (IDIBAPS) from 2015 to 2017 Ramon Gomis (HCB-IDIBAPS) T. 93 227 54 00 (Ext.: 4180) YEAR I.F. TOTAL Q1 Q2 ADMINISTRATIVE STAFF [email protected] Kimberly Katte (CIBER) 2015 120.81 27 16 9

2016 168.97 32 24 3 Felicia Alexandra Hanzu (HCB-IDIBAPS) NURSING STAFF T. 93 227 54 00 (Ext.: 9846) 2017 153.32 18 12 3 Alberto Fernández (IDIBAPS) [email protected]

Pere Santamaria (IDIBAPS) STRATEGIC OBJECTIVES T. 93 227 54 00 (Ext.: 4558)

TEAM INVOLVED IN [email protected] 1. To evaluate the molecular, genetic, and CIBERDEM environmental contribution to the AGAUR_SGR14 Josep Vidal (HCB) determinants of different endocrinological T. 93 227 57 39 diseases. [email protected] 2. To understand the contribution and interaction of central and peripheral factors in the regulation of glucose homeostasis RESEARCHERS and energy balance. Ignasi Conget (HCB) 3. To translate new concepts in AWARDS Enrique Esmatjes (HCB) immunobiology into clinical studies. Doctor Honoris Causa Rosa Maria Gasa (IDIBAPS) Institution: Universitat Rovira i Virgili Marga Gimenez (HCB) Awardee/s: Ramon Gomis Amanda Jiménez (HCB) MAIN LINES OF RESEARCH Pau Serra (IDIBAPS) Second Prize, “Vanguàrdia de la Ciència” 1. Investigation of the mechanisms involved in Institution: La Vanguardia, POST-DOCTORAL RESEARCHERS the destruction, survival and proliferation of Fundació Catalunya-La Pedrera Rebeca Fernandez (CIBER) pancreatic beta-cells Awardee/s: Pere Santamaria Alicia Garcia (IDIBAPS) 2. Manipulation of deﬁned populations of Irene Gracia (IDIBAPS) neurons in the central nervous system in Fellow of the Royal Society of Canada Óscar Osorio (CIBER) order to correlate the function of a particular Institution: Royal Society of Canada Macarena Pozo (IDIBAPS) protein with speciﬁc physiological and Sara Ramirez (IDIBAPS) Awardee/s: Pere Santamaria behavioural outputs. Meritxell Tort (IDIBAPS) 3. Bariatric surgery and the resolution of Javier Vega (IDIBAPS) comorbidites associated with obesity.

193 AREA 3 LIVER, DIGESTIVE SYSTEM AND METABOLISM

4. Mediterranean dietary patterns and other RESEARCH GROUP pancreatic beta-cell, the molecules that nutritional strategies for the prevention of PANCREATIC ISLETS: BIOMARKERS participate in these processes, and how the type 2 diabetes and cardiovascular disease. AND FUNCTION activation or inhibition of these molecules may 5. Study of the molecular and epigenetic help recover beta-cell mass as therapeutic mechanisms of cardiometabolic memory in targets for treating diabetes; the second one humans and animal models of seeks to obtain insulin-producing cells from hypercortisolism human skin fibroblasts and to analyze their 6. Depiction of nanomedicine-based function, revascularization process and strategies to efficiently suppress the capacity for reversing diabetes when progression of several different transplanted into experimental models of autoimmune disorders without GROUP LEADER diabetes. compromising systemic immunity Ramon Gomis (HCB-IDIBAPS) In addition, the group participates in research 7. Translation of knowledge gained on projects in collaboration with Alícia Foundation immunobiology into clinical studies for Our team conducts two main research that focus on investigating different nutritional chronic inflammatory disorders such as programs: the first one is aimed at strategies for preventing diabetes. type 1 diabetes investigating the mechanisms involved in the 8. To improve algorithms of insulin delivery destruction, survival and proliferation of the that may help reduce the burden of hyperglycemia in subjects with type 1 diabetes.

RESEARCH GROUP NEURONAL CONTROL OF METABOLISM (NEUCOME)

GROUP LEADER Marc Claret (IDIBAPS)

Our general research interests are focused on the study of the molecular mechanisms by

which particular neurocircuits control food Ramon Gomis

intake, body weight and glucose metabolism. GROUP To achieve this aim, our group uses a combination of neuroanatomy, molecular and genetic tools to manipulate defined populations of neurons in order to correlate the function of a particular protein with specific physiological and behavioural outputs. Understanding the physiological mechanisms controlling energy balance and the pathophysiological alterations leading to obesity and diabetes, are the first steps towards developing new and more effective therapeutic approaches for the treatment of these metabolic conditions. Marc Claret GROUP

194 DIABETES: METABOLIC AND MOLECULAR NETWORKS 3.14

50/50 PROGRAM ENDOCRINE DISORDERS: CROSSTALK BETWEEN MOLECULAR AND METABOLIC DETERMINANTS

GROUP LEADER Felicia Hanzu (HCB-IDIBAPS)

Our group studies the determinants underlying physiopathological mechanisms of endocrine tumors and gender dysphoria. The aim is to translate knowledge from the basic research into the clinical practice by focusing on the development of new diagnostic and treatment strategies. Felicia Hanzu GROUP Translational research: 1. Study of molecular and epigenetic mechanisms of the cardiometabolic memory in hypercortisolism. Focus on cellular plasticity and function of adipose tissue. 2. Study of cardiovascular effects of gonadal steroid treatment in gender identity disorders.

Technological Innovation: 1. Development of new diagnostic and treatment techniques of thyroid nodular disease.

RESEARCH GROUP PATHOGENESIS AND TREATMENT OF AUTOIMMUNITY Josep Vidal GROUP

RESEARCH GROUP The main aim of our research group is to gain a

GROUP LEADER TRANSLATIONAL RESEARCH greater understanding of the mechanisms that Pere Santamaria (IDIBAPS) IN DIABETES, LIPIDS associate excess weight and dietary patterns AND OBESITY with the development of metabolic disorders. Our group pursues translational studies on the For this purpose, we develop clinical and basic immunobiology of a novel therapeutic approach lines of research that seek to analyze for chronic inﬂammatory disorders based on metabolic adaptation response to situations nanomedicine. This therapeutic approach including weight gain, exposure to certain triggers the formation of extensive antigen- and dietary patterns, and weight loss in human disease-speciﬁc networks of regulatory T and subjects and animal models. At present, our B-cells that efficiently suppress the progression studies involving human subjects focus on the of several different autoimmune disorders GROUP LEADER Mediterranean diet model, and also weight without compromising systemic immunity. Josep Vidal (HCB) loss associated with bariatric surgery.

195 AREA 3 LIVER, DIGESTIVE SYSTEM AND METABOLISM

PUBLICATIONS 6. Metzger M., Castañeda J., Reznik Y., 12. Raccah, Denis; Chou, Engels; Colagiuri, Giorgino F., Conget I., Aronson R., de Portu S., Stephen; Gaal, Zsolt; Lavalle, Fernando; Originals / I.F.: 153.327 Runzis S., Lee S., Cohen O. Factors Mkrtumyan, Ashot; Nikonova, Elena; associated with improved glycemic Tentolouris, Nikolaos; Vidal, Josep; Davies, 1. Singha S., Shao K., Yang Y., control following continuous Melanie. A global study of the unmet Clemente-Casares X., Solé P., Clemente A., subcutaneous insulin infusion therapy in need for glycemic control and predictor Blanco J., Dai Q., Song F., Liu S., Yamanouchi patients with type 2 diabetes uncontrolled factors among patients with type 2 J., Umeshappa C., Nanjundappa R., Detampel with bolus-basal insulin regimens: An diabetes mellitus who have achieved P., Amrein M., Fandos C., Tanguay R., analysis from the OpT2mise randomized optimal fasting plasma glucose control Newbigging S., Serra P., Khadra A., Chan W., trial. DIABETES, OBESITY AND on basal insulin. DIABETES/METABOLISM Santamaria P. Peptide–MHC-based METABOLISM. 19(10):1490-1494. I.F.: 6.715 RESEARCH AND REVIEWS. 33(3). nanomedicines for autoimmunity function I.F.: 3.263 as T-cell receptor microclustering devices. 7. Jimenez, Amanda; Pegueroles, Jordi; NATURE NANOTECHNOLOGY. Carmona-Iragui, Maria; Vilaplana, Eduard; 13. Perea V., Orois A., Amor A., Jansà M., Vidal 12(7):701-710. I.F.: 38.986 Montal, Victor; Alcolea, Daniel; Videla, Laura; M., Gimenez M., Conget I., Vinagre I. Detailed Illan-Gala, Ignacio; Pane, Adriana; Casajoana, description of a prepregnancy care 2. Hebbandi Nanjundappa R., Ronchi F., Anna; Belbin, Olivia; Clarimon, Jordi; Moize, program and its impact on maternal Wang J., Clemente-Casares X., Yamanouchi Violeta; Vidal, Josep; Lleo, Alberto; Fortea, glucose control, weight gain, and dropouts. J., Sokke Umeshappa C., Yang Y., Blanco J., Juan; Blesa, Rafael; Alzheimer's Dis DIABETES/METABOLISM RESEARCH AND Bassolas-Molina H., Salas A., Khan H., Neuroimaging Ini. Weight loss in the healthy REVIEWS. 33(2):e2838. I.F.: 3.263 Slattery R., Wyss M., Mooser C., Macpherson elderly might be a non-cognitive sign of A., Sycuro L., Serra P., McKay D., McCoy K., preclinical Alzheimer's disease. 14. Rosique-Esteban, Nuria; Diaz-Lopez, Santamaria P. A Gut Microbial Mimic that ONCOTARGET. 8(62):104706-104716. Andres; Martinez-Gonzalez, Miguel A.; Corella, Hijacks Diabetogenic Autoreactivity to I.F.: 5.168 Dolores; Goday, Albert; Alfredo Martinez, J.; Suppress Colitis. CELL. 171(3):655-667. Romaguera, Dora; Vioque, Jesus; Aros, I.F.: 30.410 8. Aranda G; Fernandez-Rebollo E; Fernando; Garcia-Rios, Antonio; Tinahones, Pradas-Juni M; Hanzu F; Kalko S; Halperin I; Francisco; Estruch, Ramon; Carlos 3. Ramírez S, Gómez-Valadés AG, Mora M. Effects of sex steroids on the Fernandez-Garcia, Jose; Lapetra, Jose; Schneeberger M, Varela L, Haddad-Tóvolli R, pattern of methylation and expression of Serra-Majem, Luis; Pinto, Xavier; Tur, Josep A.; Altirriba J, Noguera E, Drougard A, the promoter region of estrogen and Bueno-Cavanillas, Aurora; Vidal, Josep; Flores-Martínez Á, Imbernón M, Chivite I, Pozo androgen receptors in people with gender Delgado-Rodriguez, Miguel; Daimiel, Lidia; M, Vidal-Itriago A, Garcia A, Cervantes S, Gasa dysphoria under cross-sex hormone Vazquez, Clotilde; Angel Rubio, Miguel; Ros, R, Nogueiras R, Gama-Pérez P, Garcia-Roves treatment. JOURNAL OF STEROID Emilio; Salas-Salvado, Jordi; PM, Cano DA, Knauf C, Servitja JM, Horvath BIOCHEMISTRY AND MOLECULAR PREDIMED-PLUS Investigators. TL, Gomis R, Zorzano A, Claret M. BIOLOGY. 172:20-28. I.F.: 4.561 Leisure-time physical activity, sedentary Mitochondrial Dynamics Mediated by behaviors, sleep, and cardiometabolic risk Mitofusin 1 Is Required for POMC Neuron 9. Ghio, Belen; Jimenez, Amanda; Corcelles, factors at baseline in the PREDIMED-PLUS Glucose-Sensing and Insulin Release Ricard; Flores, Lilliam; Lacy, Antonio; Vidal, intervention trial: A cross-sectional Control. CELL METABOLISM. Josep. Midterm effects of bariatric surgery analysis. PLOS ONE. 12(3):e0172253. 25(6):1390-1399. I.F.: 18.164 in patients with insulin-treated type 2 I.F.: 2.806 diabetes. SURGERY FOR OBESITY AND 4. Aminian, Ali; Brethauer, Stacy A.; Andalib, RELATED DISEASES. 13(12):2004-2009. 15. Rossetti P., Quirós C., Moscardó V., Comas Amin; Nowacki, Amy S.; Jimenez, Amanda; I.F.: 4.496 A., Giménez M., Ampudia-Blasco F., León F., Corcelles, Ricard; Hanipah, Zubaidah Nor; Montaser E., Conget I., Bondia J., Vehí J. Punchai, Suriya; Bhatt, Deepak L.; Kashyap, 10. Navarrete, Andres; Corcelles, Ricard; Diaz Closed-Loop Control of Postprandial Sangeeta R.; Burguera, Bartolome; Lacy, del Gobbo, Gabriel; Perez, Soﬁa; Vidal, Josep; Glycemia Using an Insulin-on-Board Antonio M.; Vidal, Josep; Schauer, Philip R. Lacy, Antonio. Sleeve gastrectomy in the Limitation Through Continuous Action on Individualized Metabolic Surgery Score: elderly: A case-control study with Glucose Target. DIABETES TECHNOLOGY Procedure Selection Based on Diabetes long-term follow-up of 3 years. SURGERY AND THERAPEUTICS. 19(6):355-362. Severity. ANNALS OF SURGERY. FOR OBESITY AND RELATED DISEASES. I.F.: 2.698 266(4):650-657. I.F.: 8.980 13(4):575-580. I.F.: 4.496 16. García S., Reyes L., Roldán P., Torales J., 5. Rodríguez-Comas J, Moreno-Asso A, 11. Cervantes, Sara; Fontcuberta-PiSunyer, Halperin I., Hanzu F., Langdon C., Alobid I., Moreno-Vedia J, Martín M, Castaño C, Marta; Servitja, Joan-Marc; Fernandez-Ruiz, Enseñat J. Does Low-Field Intraoperative Marzà-Florensa A, Boﬁll-De Ros X, Mir-Coll J, Rebeca; Garcia, Ainhoa; Sanchez, Lidia; Lee, Magnetic Resonance Improve the Results Montané J, Fillat C, Gasa R, Novials A, Servitja Young-Sook; Gomis, Ramon; Gasa, Rosa. of Endoscopic Pituitary Surgery? JM. Stress-Induced MicroRNA-708 Late-stage differentiation of embryonic Experience of the Implementation of a Impairs β-Cell Function and Growth. pancreatic beta-cells requires Jarid2. New Device in a Referral Center. WORLD DIABETES. 66(12):3029-3040. I.F.: 8.684 SCIENTIFIC REPORTS. 7(1):11643. I.F.: 4.259 NEUROSURGERY. 102:102-110. I.F.: 2.592

196 DIABETES: METABOLIC AND MOLECULAR NETWORKS 3.14

17. Aranda, Gloria; Lopez, Cristina; Diagnostic tests for Cushing's syndrome Gasa R. Terapia cellular en diabetes: nuevas Fernandez-Ruiz, Rebeca; Esteban, Yaiza; differ from published guidelines: Data from estrategias para generar células beta Garcia-Eguren, Guillermo; Mora, Mireia; ERCUSYN. EUROPEAN JOURNAL OF sustitutas y optimización del transplante. Halperin, Irene; Casals, Gregori; Ensenat, ENDOCRINOLOGY. 176(5):613-624. I.F.: 4.101 Sponsored by: Fundación DiabetesCERO Joaquim; Hanzu, Felicia A. Circulatory Duration: 01/06/2017-31/05/2018 Immune Cells in Cushing Syndrome: Bystanders or Active Contributors to GRANTS FOR RESEARCH IN PROGRESS Gomis R. Understanding obesity, metabolic Atherometabolic Injury? A Study of syndrome type 2 diabetes and fatty liver Adhesion and Activation of Cell Surface Claret M. Rutas de control de calidad diseases: A multidisciplinary approach. Markers. INTERNATIONAL JOURNAL OF mitocondriales en neurocircuitos Sponsored by: Instituto de Salud Carlos III ENDOCRINOLOGY. 2017:2912763. I.F.: 2.510 hipotalámicos: descifrando unevos (ISCIII). PIE14/00031 mecanismos de regulación para el control Duration: 01/01/2015-31/03/2018 18. Ferrer J., Molina V., Rull R., López-Boado sistémico del metabolismo. M., Sánchez S., García R., Ricart M., Sponsored: Ministerio de Educación y Ciencia Gomis R. Laser and Ultrasound Ventura-Aguiar P., García-Criado Á., Esmatjes (Europa Excelencia 2015). Co-Analyzer for thyroid nodules. E., Fuster J., Garcia-Valdecasas J. SAF2015-71661-ERC Sponsored by: European Commission Pancreas transplantation: Advantages Duration: 01/11/2015-30/04/2017 (H2020_ICT_2015). 688303 of a retroperitoneal graft position. Duration: 01/02/2016-31/01/2020 CIRUGIA ESPAÑOLA. 95(9):513-520. I.F.: 1.276 Claret M. Estudio del papel de la fusión mitocondrial en neuronas hipotalámicas Gomis R. Efectes beneficiosos de la quinoa sobre el control del apetito y la regulación (Chenopodium quinoa Willd) en la Review / I.F.: 18.392 del peso corporal: Orpa1 como potencial prevenció de la Diabetis Mellitus tipus 2. diana terapéutica para el tratamiento de la Sponsored by: Associació Catalana de 1. Vidal J, Corcelles R, Jiménez A, Flores L, obesidad. Diabetis. Ajut a la Recerca Gonçal Lloveras i Lacy AM. Metabolic and Bariatric Surgery Sponsored: Fundación BBVA. Vallès. for Obesity. GASTROENTEROLOGY. BBM-MED-1172 Duration: 01/07/2017-30/06/2020 152(7):1780-1790. I.F.: 18.392 Duration: 11/11/2015-30/01/2018 Hanzu F. Cambios epigenéticos inducidos Claret M. Decoding mitochondrial por el síndrome cushing en la plasticidad y Letters / I.F.: 5.752 nutrient-sensing programs in POMC el kinoma del tejido adipso. Modelo animal neurons as key determinants of metabolic y estudio en humanos. 1. Schütz-Fuhrmann I., Castañeda J., Reznik Y., health. Sponsored by: Instituto de Salud Carlos III Aronson R., Conget I., Liabat S., Runzis S., de Sponsored by:European Commission (ISCIII). PI15/00859 Portu S., Cohen O. Factors affecting the (H2020_ERC Consolidator Grant 2016). Duration: 01/01/2016-31/12/2018 benefit of insulin dose intensification in 725004 people with Type 2 diabetes: an analysis Duration: 01/04/2017-31/03/2022 Jiménez A. Malaltia d'Alzheimer preclínica, from the OpT2mise randomized trial. diabetis mellitus tipus 2 i obesitat. Efectes DIABETIC MEDICINE. 34(2):291-292. I.F.: 3.054 Claret M. Investigando el papel de los de la cirurgia bariàtrica: un estudi neuroesteroides derivados de las multimodal. 2. Viñals C., Pané A., Quirós C., Giménez M., neuronas POMC hipotalámicas como Sponsored by: Fundació La Marató TV3. Conget I. Severe Hypoglycemia before reguladores críticos del balance 201614.30.31 Landing in a Patient with Type 1 Diabetes energético y el metabolismo. Duration: 10/03/2017-09/03/2020 Using Sensor-Augmented Pump Therapy. Sponsored by: Instituto de Salud Carlos III DIABETES TECHNOLOGY AND (ISCIII). PI16/00963 Santamaria P. Advancing human THERAPEUTICS. 19(8):491-492. I.F.: 2.698 Duration: 01/01/2017-31/12/2019 antigen-specific T-regulatory cell expanding nanomedicines for autoimmune Claret M. Neuronas POMC: ¿en la interfaz disease: Translational studies in humanized Consortium Publications / I.F.: 4.101 entre la detección de energía y el mice. comportamiento altruista? Sponsored by: Instituto de Salud Carlos III (ISCIII). 1. Valassi E; Franz H; Brue T; Feelders R; Sponsored by: Ministerio de Economía y PIE14/00027 Netea-Maier R; Tsagarakis S; Webb S; Yaneva Competitividad (Explora Ciencia 2015). Duration: 01/01/2015-31/12/2017 M; Reincke M; Droste M; Komerdus I; Maiter D; BFU2015-72486-EXP Kastelan D; Chanson P; Pfeifer M; Strasburger Duration: 01/05/2017-30/04/2019 Santamaría P. Advancing an antigen- C; Toth M; Chabre O; Tabarin A; Krsek M; specific nanomedicine for the treatment Fajardo C; Bolanowski M; Santos A; Wass J; Gasa R. Proliferación de la célula β of central nervous system autoimmunity. Trainer P; Ambrogio A; Aranda G; Arosio M; pancreática: impacto de nuevos Sponsored by: Ministerio de Economía y Balomenaki M; Beck-Peccoz P; Berr-Kirmair reguladores. Competitividad. ERA-NET NEURON II C; Bollerslev J; Carvalho D; Cavagnini F; Christ Sponsored by: Instituto de Salud Carlos III Duration: 01/01/2015-31/12/2017 E; Demtröder F; Denes J; Dimopoulou C; (ISCIII). PI16/00774. Dreval A; Dusek T. Duration: 01/01/2017-31/12/2019

197 AREA 3 LIVER, DIGESTIVE SYSTEM AND METABOLISM

Santamaria P. El papel de la autofagia celular en la tolerancia central y activación periférica de células TCD4+ diabetogénicas. Sponsored by: Ministerio de Economia y Competitividad. SAF2015-68187-R Duration: 01/01/2016-31/12/2018

Santamaria P. Red Temática de Investigación Cooperativa en Salud - Esclerosis múltiple. Sponsored by: Instituto de Salud Carlos III (ISCIII). RD16/0015/0020 Duration: 01/01/2017-31/12/20121

Serra P. Nanomedicines to expand type 1 diabetes speciﬁc T-regulatory-1 type cells: mechanistic and translational studies. Sponsored by: Juvenile Diabetes Res.Foundation. 5-CDA-2014-214-A-N Duration: 01/06/2014-31/05/2019

Vidal J. PREDIMED+DM Efecto de una dieta mediterránea hipocalórica y promoción de la actividad física en prevenciones de diabetes tipo 2 en personas con síndrome metabólico. Sponsored by. Instituto de Salud Carlos III (ISCIII). PI14/00728 Duration: 01/01/2015-30/06/2018

DOCTORAL THESES

Gomis R. The impact of nutrients on clock genes and metabolism: their role for the prevention and treatment of metabolic diseases. PhD student: Ana Lucía Castillo Figueroa

Gomis R. Diabetes mellitus tipus 2: impacte metabòlic d'una dieta rica en sardina. PhD student: Mariona Balfegó Díaz

198 PATHOGENESIS AND PREVENTION OF DIABETES 3.15

Pathogenesis and 3.15 prevention of diabetes

STRATEGIC OBJECTIVES

LOCATION 1. To study metabolic and molecular CEK building ﬂoor 5 responses to exercise and nutrition in diabetes. 2. To identify circulating microRNAs as potential biomarkers and mediators of prediabetes and vascular complications in diabetes. KEYWORDS 3. To investigate the mechanisms of 1. Islet amyloid polypeptide TEAM LEADER endothelial dysfunction in diabetes. (IAPP)/amylin Anna Novials (IDIBAPS) 4. To investigate the mechanisms of beta-cell 2. Beta-cell dysfunction T. 93 227 54 00 (Ext.: 4153) dysfunction in the search for new 3. Circulating microRNAs [email protected] therapeutic targets. 4. Endothelial dysfunction 5. Exercise and nutrition MAIN LINES OF RESEARCH RESEARCHERS Antonio Ceriello (IDIBAPS) 1. Mechanisms of pancreatic islet dysfunction Marcelina Párrizas (CIBER) in type 2 diabetes mellitus: potential Joan Marc Servitja (IDIBAPS) protective effects of endoplasmic reticulum Original publications stress inhibitors and anti-inﬂammatory from 2015 to 2017 POST-DOCTORAL RESEARCHERS molecules against amyloid-induced Gema Alcarraz (IDIBAPS) beta-cell dysfunction. YEAR I.F. TOTAL Q1 Q2 Laura Brugnara (CIBER) 2. New therapeutic targets for the treatment

2015 77.45 20 11 6 Valeria de Nigris (IDIBAPS) of type 2 diabetes and obesity: role of the Francesco Prattichizzio (IDIBAPS) protease Bace2 in the control of glucose 2016 76.92 19 9 9 homeostasis and body weight. 2017 87.38 17 12 3 PRE-DOCTORAL RESEARCHERS 3. Modulation of signalling and transcriptional Sara de Pablo (CIBER) networks in pancreatic islets in response to Juan Moreno (FCRB) metabolic stress and proinﬂammatory Serafín Murillo (CIBER) cytokines. Júlia Rodríguez (IDIBAPS) 4. Impact of lifestyle on diabetes: metabolic TEAM INVOLVED IN and molecular responses to exercise and CIBERDEM nutrition in diabetic patients and animal AGAUR_SGR14 models. 5. Role of circulating exosomal microRNAs in

AWARDS Hellmut Mehnert Award Institution: German Center for Diabetes Research (DZD) Awardee/s: Antonio Ceriello Anna Novials TEAM

199 AREA 3 LIVER, DIGESTIVE SYSTEM AND METABOLISM

the pathogenesis of type 2 diabetes and the 5. Montane, Joel; de Pablo, Sara; Castano, Guida, Pietro; Pontremoli, Roberto; De Cosmo, control of lipid metabolism: impact of Carlos; Rodriguez-Comas, Julia; Cadavez, Salvatore; AMD-Annals Study Grp. exercise intervention. Lisa; Obach, Merce; Visa, Montse; Epidemiology of diabetic kidney disease in 6. Circulating microRNAs as potential Alcarraz-Vizan, Gema; Sanchez-Martinez, adult patients with type 1 diabetes in Italy: biomarkers of micro- and macrovascular Melchor; Nonell-Canals, Alfons; Parrizas, The AMD-Annals initiative. complications in diabetes. Marcelina; Servitja, Joan-Marc; Novials, Anna. DIABETES/METABOLISM RESEARCH AND 7. Impact of glucose oscillations on Amyloid-induced beta-cell dysfunction REVIEWS. 33(4):e2873. I.F.: 3.263 cardiovascular complications of diabetes: and islet inflammation are ameliorated by mechanisms of endothelial dysfunction. 4-phenylbutyrate (PBA) treatment. FASEB 12. Giorda, Carlo; Forlani, Gabriele; Manti, 8. Potential beneficial effects of GLP-1 and JOURNAL. 31(12):5296-5306. I.F.: 5.498 Roberta; Mazzella, Natalia; De Cosmo, DPP-4 inhibitors in endothelial cells Salvatore; Rossi, Maria Chiara; Nicolucci, exposed to hyperglycemic conditions. 6. Gentile, Sandro; Piscitelli, Pamela; Viazzi, Antonio; Russo, Giuseppina; Di Bartolo, Paolo; Francesca; Russo, Giuseppina; Ceriello, Ceriello, Antonio; Guida, Piero;AMD-Annals Antonio; Giorda, Carlo; Guida, Piero; Fioretto, Study Grp. Occurrence over time and PUBLICATIONS Paola; Pontremoli, Roberto; Strollo, Felice; De regression of nonalcholic fatty liver Cosmo, Salvatore; AMD-Annals Study Grp. disease in type 2 diabetes. Originals / I.F.: 87.381 Antihyperglycemic treatment in patients DIABETES/METABOLISM RESEARCH AND with type 2 diabetes in Italy: the impact of REVIEWS. 33(4):e2878. I.F.: 3.263 1. Ramírez S, Gómez-Valadés AG, age and kidney function. ONCOTARGET. Schneeberger M, Varela L, Haddad-Tóvolli R, 8(37):62039-62048. I.F.: 5.168 13. Pujadas G, De Nigris V, Prattichizzo F, La Altirriba J, Noguera E, Drougard A, Sala L, Testa R, Ceriello A. The dipeptidyl Flores-Martínez Á, Imbernón M, Chivite I, Pozo 7. Viazzi F, Piscitelli P, Ceriello A, Fioretto P, peptidase-4 (DPP-4) inhibitor teneligliptin M, Vidal-Itriago A, Garcia A, Cervantes S, Gasa Giorda C, Guida P, Russo G, De Cosmo S, functions as antioxidant on human R, Nogueiras R, Gama-Pérez P, Garcia-Roves Pontremoli R, AMD?Annals Study Group. endothelial cells exposed to chronic PM, Cano DA, Knauf C, Servitja JM, Horvath Resistant Hypertension, Time-Updated hyperglycemia and metabolic TL, Gomis R, Zorzano A, Claret M. Blood Pressure Values and Renal high-glucose memory. ENDOCRINE. Mitochondrial Dynamics Mediated by Outcome in Type 2 Diabetes Mellitus. 56(3):509-520. I.F.: 3.131 Mitofusin 1 Is Required for POMC Neuron JOURNAL OF THE AMERICAN HEART Glucose-Sensing and Insulin Release ASSOCIATION. 6(9):e006745. I.F.: 4.425 14. De Candia, Paola; Spinetti, Gaia; Specchia, Control. CELL METABOLISM. Claudia; Sangalli, Elena; La Sala, Lucia; 25(6):1390-1399. I.F.: 18.164 8. Cervantes, Sara; Fontcuberta-PiSunyer, Uccellatore, Annachiara; Lupini, Silvia; Marta; Servitja, Joan-Marc; Fernandez-Ruiz, Genovese, Stefano; Matarese, Giuseppe; 2. Rodríguez-Comas J, Moreno-Asso A, Rebeca; Garcia, Ainhoa; Sanchez, Lidia; Lee, Ceriello, Antonio. A unique plasma Moreno-Vedia J, Martín M, Castaño C, Young-Sook; Gomis, Ramon; Gasa, Rosa. microRNA profile defines type 2 diabetes Marzà-Florensa A, Bofill-De Ros X, Mir-Coll J, Late-stage differentiation of embryonic progression. PLOS ONE. 12(12):e0188980. Montané J, Fillat C, Gasa R, Novials A, Servitja pancreatic beta-cells requires Jarid2. I.F.: 2.806 JM. Stress-Induced MicroRNA-708 SCIENTIFIC REPORTS. 7(1):11643. I.F.: 4.259 Impairs β-Cell Function and Growth. 15. Viazzi, Francesca; Piscitelli, Pamela; DIABETES. 66(12):3029-3040. I.F.: 8.684 9. Piscitelli, Pamela; Viazzi, Francesca; Giorda, Carlo; Ceriello, Antonio; Genovese, Fioretto, Paola; Giorda, Carlo; Ceriello, Antonio; Stefano; Russo, Giuseppina; Guida, Pietro; 3. Ceriello, Antonio; De Cosmo, Salvatore; Genovese, Stefano; Russo, Giuseppina; Fioretto, Paola; De Cosmo, Salvatore; Rossi, Maria Chiara; Lucisano, Giuseppe; Guida, Pietro; Pontremoli, Roberto; De De Pontremoli, Roberto; AMD-Annals Study Grp. Genovese, Stefano; Pontremoli, Roberto; Cosmo, Salvatore. Predictors of chronic Metabolic syndrome, serum uric acid and Fioretto, Paola; Giorda, Carlo; Pacilli, Antonio; kidney disease in type 1 diabetes: a renal risk in patients with T2D. PLOS ONE. Viazzi, Francesca; Russo, Giuseppina; longitudinal study from the AMD Annals 12(4):e0176058. I.F.: 2.806 Nicolucci, Antonio; AMD-Annals Study Grp. initiative. SCIENTIFIC REPORTS. 7(1):3313. Variability in HbA1c, blood pressure, lipid I.F.: 4.259 16. Viazzi, Francesca; Piscitelli, Pamela; parameters and serum uric acid, and risk of Giorda, Carlo; Ceriello, Antonio; Genovese, development of chronic kidney disease in 10. Lansink M, Hofman Z, Genovese S, Rouws Stefano; Russo, Giuseppina T.; Fioretto, Paola; type 2 diabetes. DIABETES, OBESITY AND CHFC, Ceriello A. Improved Glucose Profile Guida, Pietro; De Cosmo, Salvatore; METABOLISM. 19(11):1570-1578. I.F.: 6.715 in Patients With Type 2 Diabetes With a Pontremoli, Roberto;AMD-Annals Study Grp. New, High-Protein, Diabetes-Specific Association of kidney disease measures 4. Alcarraz-Vizán G, Castaño C, Visa M, Tube Feed During 4 Hours of Continuous with risk of renal function worsening in Montane J, Servitja JM, Novials A. BACE2 Feeding. JOURNAL OF PARENTERAL AND patients with hypertension and type 2 suppression promotes β-cell survival and ENTERAL NUTRITION. 41(6):968-975. diabetes. JOURNAL OF DIABETES AND ITS function in a model of type 2 diabetes I.F.: 4.220 COMPLICATIONS. 31(2):419-426. I.F.: 2.734 induced by human islet amyloid polypeptide overexpression. CELLULAR 11. Pacilli, Antonio; Viazzi, Francesca; Fioretto, 17. Cattaneo M, La Sala L, Rondinelli M, AND MOLECULAR LIFE SCIENCES. Paola; Giorda, Carlo; Ceriello, Antonio; Errichiello E, Zuffardi O, Puca AA, Genovese S, 74(15):2827-2838. I.F.: 5.788 Genovese, Stefano; Russo, Giuseppina; Ceriello A. A donor splice site mutation in

200 PATHOGENESIS AND PREVENTION OF DIABETES 3.15

CISD2 generates multiple truncated, of type 2 diabetes mellitus, with Sponsored by: Instituto de Salud Carlos III non-functional isoforms in Wolfram consideration of Asian patient populations. (ISCIII). PIE14/0061 syndrome type 2 patients. BMC MEDICAL J DIABETES INVEST. 8(1):19-28. I.F.: 3.039 Duration: 01/01/2015-31/12/2017 GENETICS. 18(1):147. I.F.: 2.198 8. Ceriello A .Targeting One-Hour Postmeal Glucose: Is It Time for a Paradigm Switch in DOCTORAL THESES Review / I.F.: 46.289 Diabetes Management? DIABETES TECHNOLOGY AND THERAPEUTICS. Novials A, Franch N. Evolución de la 1. Standl, Eberhard; Schnell, Oliver; McGuire, 19(9):493-497. I.F.: 2.698 atención a la diabetes tipo 2 en Catalunya, Darren K.; Ceriello, Antonio; Ryden, Lars. 1993-2013. Integration of recent evidence into PhD student: Manel Mata Cases management of patients with Letters / I.F.: 13.191 atherosclerotic cardiovascular disease and type 2 diabetes. THE LANCET. 1. Cnop M, Klupa T, Tentolouris N, Novials A, DIABETES & ENDOCRINOLOGY. Burcelin R, van Eimeren M. Europe has to 5(5):391-402. I.F.: 19.742 step up its efforts to produce innovative and safe diabetes technology. 2. Luconi M, Cantini G, Ceriello A, Mannucci E. DIABETOLOGIA. 60(12):2532-2533. I.F.: 6.080 Perspectives on cardiovascular effects of incretin-based drugs: From bedside to 2. Mannucci E, Monami M, Ceriello A, Rotella bench, return trip. INTERNATIONAL CM. Back to glycemic control: An JOURNAL OF CARDIOLOGY. 241:302-310. alternative look at the results of I.F.: 6.189 cardiovascular outcome trials in type 2 diabetes. NUTRITION, METABOLISM AND 3. Schnell, Oliver; Ryden, Lars; Standl, CARDIOVASCULAR DISEASES. Eberhard; Ceriello, Antonio;D&CVD EASD 27(4):375-377. I.F.: 3.679 Study Grp. Updates on cardiovascular outcome trials in diabetes. 3. Testa, Roberto; Ceriotti, Ferruccio; Guerra, CARDIOVASCULAR DIABETOLOGY. Elena; Bonﬁgli, Anna Rita; Boemi, Massimo; 16(1):128. I.F.: 4.752 Cucchi, Michela; Di Gaetano, Nicola; Santini, Gabriele; Genovese, Stefano; Ceriello, 4. Testa R, Bonﬁgli AR, Prattichizzo F, La Sala Antonio. Glycated albumin: Correlation to L, De Nigris V, Ceriello A . The "Metabolic HbA1c and preliminary reference interval Memory" Theory and the Early Treatment evaluation. CLINICAL CHEMISTRY AND of Hyperglycemia in Prevention of Diabetic LABORATORY MEDICINE. 55(2):e31-e33. Complications. NUTRIENTS. 9(5):437. I.F.: 3.432 I.F.: 3.550

5. Giuliani, Angelica; Prattichizzo, Francesco; GRANTS FOR RESEARCH IN PROGRESS Micolucci, Luigina; Ceriello, Antonio; Procopio, Antonio Domenico; Rippo, Maria Rita. Ceriello A. Role of released and exosomial Mitochondrial (Dys) Function in microRNAs, inflammatory and diabetes Inflammaging: Do MitomiRs Influence the associated (REx-MIDAs), in endothelial Energetic, Oxidative, and Inflammatory metabolic memory. Status of Senescent Cells? MEDIATORS Sponsored by: Fundació La Marató de TV3. OF INFLAMMATION. 2017. I.F.: 3.232 201606.10 Duration: 10/03/2017-09/03/2020 6. Prattichizzo, Francesco; Micolucci, Luigina; Cricca, Monica; De Carolis, Sabrina; Mensa, Novials A; Servitja JM. New strategies for Emanuela; Ceriello, Antonio; Procopio, Antonio the treatment of diabetes: targeting Domenico; Bonafe, Massimiliano; Olivieri, endoplasmic reticulum stress and Fabiola. Exosome-based inflammation induced by amyloid deposits immunomodulation during aging: A in pancreatic islets. nano-perspective on inflamm-aging. Sponsored by: Instituto de Salud Carlos III MECHANISMS OF AGEING AND (ISCIII). PI14/00447 DEVELOPMENT. 168:44-53. I.F.: 3.087 Duration: 01/01/2015-30/04/2018

7. Ceriello, Antonio; Inagaki, Nobuya. Novials A. Molecular links between Pharmacokinetic and pharmacodynamic diabetes and neurodegenerative evaluation of linagliptin for the treatment disorders.

201 ANNUAL SCIENTIFIC REPORT 2017

AREA 4

CLINICAL AND EXPERIMENTAL NEUROSCIENCE 4

CLINICAL AND EXPERIMENTAL NEUROSCIENCE

4.1 Neuropharmacology and experimental neuropathology 204 Guadalupe Mengod

4.2 Brain ischemia: Clinical and experimental studies 209 Ángel Chamorro

4.3 Parkinson disease and other neurodegenerative movement disorders: clinical and experimental research 212 Eduardo Tolosa

4.4 Neurophysiology and functional studies of the nervous system 216 Josep Valls

4.5 Muscle research and mitochondrial function 220 Josep Maria Grau

4.6 Pathophysiology and treatment of neurodegenerative disorders 224 Jordi Alberch

4.7 Biological bases of psychiatric disorders and nuclear psychiatry 227 Miquel Bernardo

4.8 Neuropsychology 239 Carme Junqué

4.9 Systems neuroscience 242 Maria Victoria Sánchez Vives

4.10 Clinical and experimental neuroimmunology 246 Josep Dalmau 4.11 Neurobiology Unit 251 Ramon Trullàs

4.12 Alzheimer’s disease and other cognitive disorders 253 José Luís Molinuevo

203 AREA 4 CLINICAL AND EXPERIMENTAL NEUROSCIENCE

Neuropharmacology and 4.1 experimental neuropathology

TECHNICIANS Leticia Campa (IIBB-CSIC) LOCATION Elisa García (IIBB-CSIC) IIBB-CSIC labs Felipe Jiménez (IIBB-CSIC) UB School of Medicine Rocío Martin (CIBER) Lluís Miquel (IIBB-CSIC) Ruth Montes (IIBB-CSIC) Albert Parull (IIBB-CSIC) Verónica Paz (CIBER) WEB www.iibb.csic.es Esther Ruiz (IDIBAPS) TEAM LEADER Rosario Ruiz (UB) www.ciberisciii.es Guadalupe Mengod (IIBB-CSIC) Silvia Serrano (CIBER) www.cibersam.es T. 93 363 83 23 www.ciberesp.es [email protected] ADMINISTRATIVE STAFF www.ciberned.es María Jaramillo (CIBER) www.ub.edu/portal/web/dp-

biomedicalsciences/neuroinﬂamacio. GROUP LEADERS COLLABORATORS -ip-josep-saura-marti Francesc Artigas (IIBB-CSIC) Noemí Santana (CIBER) T. 93 363 83 15 Jose Manuel Vidal (UB) francesc.artigas @iibb.csic.es

Guadalupe Mengod (IIBB-CSIC) STRATEGIC OBJECTIVES T. 93 363 83 23 KEYWORDS [email protected] Furthering of knowledge of the 1. Neuropsychopharmacology physiopathological mechanisms of 2. Brain aging and neurotoxicity Josep Saura (UB) neurological and psychiatric diseases and 3. Neurodegeneration T. 93 402 19 20 neurotoxic and aging processes of the central 4. Neuroinﬂammation [email protected] nervous system, with a view to identifying new cellular and functional targets and proposing Cristina Suñol (IIBB-CSIC) new treatments. T. 93 363 83 18 [email protected] MAIN LINES OF RESEARCH

Original publications - The Systems Neuropharmacology Group from 2015 to 2017 RESEARCHERS studies the brain circuits and neural

YEAR I.F. TOTAL Q1 Q2 Analia Bortolozzi (IDIBAPS) elements involved in the physiopathology Anna Castañé (IIBB-CSIC) and treatment of depression, schizophrenia 2015 63.54 13 11 1 Maria Paz Celada (IDIBAPS) and Parkinson’s disease. 2016 115.44 21 18 2 Roser Cortés (IIBB-CSIC) 2017 110.30 24 19 4 Eduardo Rodríguez (IIBB-CSIC) - The Molecular Neuropharmacology group Coral Sanfeliu (IIBB-CSIC) studies the involvement of the cAMP Joan Serratosa (IIBB-CSIC) cascade in the polarization of microglia and Carme Solà (IIBB-CSIC) macrophage toward anti- or Mª Teresa Vilaró (IIBB-CSIC) pro-inﬂammatory phenotypes both in cell

TEAM INVOLVED IN culture with cell lines and primary cultures CIBERNED POST-DOCTORAL RESEARCHERS and in the CNS of EAE (experimental CIBERSAM Rubén Corpas (IIBB-CSIC) autoimmune encephalomyelitis) mice, a CIBERESP Júlia Gasull (IIBB-CSIC) multiple sclerosis animal model. AGAUR_SGR14 Maurizio Riga (IDIBAPS) - The aim of the Cellular Neurobiology group AGAUR_SGR17 PRE-DOCTORAL RESEARCHERS is the study of novel targets to modulate Diana Alarcón (IDIBAPS) neuroinﬂammation. The group is focused María Neus Fullana (IIBB-CSIC) on the role of transcription factors and Elena López (IIBB-CSIC) neuronal-microglial communication Rubén Pavia (IDIBAPS) molecules in microglial activation and in Neus Rabaneda (IIBB-CSIC) microglial-induced neurotoxicity. Mireia Tarrés (IIBB-CSIC) - The Neurotoxicity and Neurodegeneration Mechanisms group carries out studies on

204 NEUROPHARMACOLOGY AND EXPERIMENTAL NEUROPATHOLOGY 4.1

nerve cell death and stress response, synaptic and cognitive functions, genomics and proteomics, for the determination of targets in toxicity and pathological aging. The goal is ﬁnding neuroprotective treatments.

RESEARCH GROUP SYSTEMS NEUROPHARMACOLOGY

GROUP LEADER Francesc Artigas (IIBB-CSIC) Francesc Artigas The group research is focused on the characterization of the brain circuits and GROUP neural elements involved in the physiopathology and treatment of mental (major depression, schizophrenia) and neurological disorders (Parkinson’s disease). Using a variety of experimental models, we identify new therapeutic targets in order to improve treatments. Recent key ﬁndings are the development of electrophysiological models to detect antipsychotic activity and the identiﬁcation of a key role of ventral areas of the prefrontal cortex in major depression. Moreover, new therapeutic strategies based on RNAi have been developed for the treatment of major depression and Parkinson disease.

RESEARCH GROUP MOLECULAR NEUROPHARMACOLOGY Guadalupe Mengod

GROUP

2. Role of components of the cAMP signaling cascade on cell polarization toward GROUP LEADER pro-inﬂammatory (M1) or anti-inﬂammatory Guadalupe Mengod (IIBB-CSIC) (M2) phenotype.

Neurotransmission and anatomical, cellular 3. Agonists for serotonin 5-HT4 receptors as and molecular aspects of neurodegenerative treatment for Alzheimer’s disease in a triple disorders with an inﬂammatory component: transgenic mouse model for this disease.

1. cAMP regulation of cells involved in neuroinﬂammation in CNS in a multiple sclerosis mouse model EAE.

205 AREA 4 CLINICAL AND EXPERIMENTAL NEUROSCIENCE

RESEARCH GROUP CELLULAR NEUROBIOLOGY

GROUP LEADER Josep Saura (UB)

The aim of the Cellular Neurobiology group is the study of novel targets to modulate neuroinﬂammation. We are focused on the role of transcription factors of the C/EBP family and of neuronal-microglial communication molecules (CD200, CD200R, TREM2) in microglial activation and in microglial-induced neurotoxicity. We use Josep Saura primary cell cultures (murine mixed glial,

astroglial and microglial-enriched, neuronal, GROUP mixed neuron-glial; human monocyte-derived microglia-like cultures), cell lines, in vivo models of neuroinﬂammation and neurodegeneration, and human samples.

RESEARCH GROUP NEUROTOXICITY AND NEURODEGENERATION MECHANISMS

GROUP LEADER Cristina Suñol (IIBB-CSIC)

The group studies molecular targets in neurotoxicity and pathological brain aging by Cristina Suñol using in vivo and in vitro experimental models and human tissues. Mechanisms of GROUP neurotoxicity are focused in environmental contaminants as ubiquitous exposures, whereas age-related neurodegeneration is PUBLICATIONS AP, Serrano J, Calero P, Futch HS, Corpas R, centred in Alzheimer's disease as the main Sanfeliu C, Perea G, Araque A. cause of dementia. Neuroprotective Originals / I.F.: 110.303 Neuron-astrocyte signaling is preserved in the mechanisms analysed include those activated aging brain. GLIA. 65(4):569-580. I.F.: 6.200 by lifestyles of physical exercise and dietary 1. Santana N, Artigas F. Expression of components. This basic research will Serotonin2C Receptors in Pyramidal and 3. Corpas R., Revilla S., Ursulet S., contribute to the design of new strategies and GABAergic Neurons of Rat Prefrontal Cortex: Castro-Freire M., Kaliman P., Petegnief V., pharmacological treatments for increasing A Comparison with Striatum. CEREBRAL Giménez-Llort L., Sarkis C., Pallàs M., Sanfeliu brain resilience against nerve cell injury and CORTEX. 27(6):3125-3139. I.F.: 6.559 C. SIRT1 Overexpression in Mouse age-related neurodegeneration, speciﬁcally Hippocampus Induces Cognitive Alzheimer's disease. 2. Gómez-Gonzalo M, Martin-Fernandez M, Enhancement Through Proteostatic and Martínez-Murillo R, Mederos S, Hernández- Neurotrophic Mechanisms. MOLECULAR Vivanco A, Jamison S, Fernandez NEUROBIOLOGY. 54(7):5604-5619. I.F.: 6.190

206 NEUROPHARMACOLOGY AND EXPERIMENTAL NEUROPATHOLOGY 4.1

4. Palomera-Avalos V, Griñán-Ferré C, Ortega-Aznar A., Comellas F., de la Rosa E., Rocio; Garcia, Idoia; Matheu, Ander; Corpas, Puigoriol-Ilamola D, Camins A, Sanfeliu C, Sanfeliu C. Proinsulin protects against Ruben; Dotti, Carlos G.; Esteban, Jose A.; Canudas AM, Pallàs M. Resveratrol Protects age-related cognitive loss through Sanfeliu, Coral; Nebreda, Angel R. Neuronal SAMP8 Brain Under Metabolic Stress: anti-inflammatory convergent pathways. p38 alpha mediates synaptic and cognitive Focus on Mitochondrial Function and Wnt NEUROPHARMACOLOGY. 123:221-232. dysfunction in an Alzheimer's mouse Pathway. MOLECULAR NEUROBIOLOGY. I.F.: 5.012 model by controlling beta-amyloid 54(3):1661-1676. I.F.: 6.190 production. SCIENTIFIC REPORTS. 7:45306. 11. Devroye C., Haddjeri N., Cathala A., Rovera I.F.: 4.259 5. Cosín-Tomás M., Antonell A., Lladó A., R., Drago F., Piazza P., Artigas F., Spampinato Alcolea D., Fortea J., Ezquerra M., Lleó A., Martí U. Opposite control of mesocortical and 18. Van den Munkhof HE, Arnt J, Celada P, M., Pallàs M., Sanchez-Valle R., Molinuevo J., mesoaccumbal dopamine pathways by Artigas F. The antipsychotic drug Sanfeliu C., Kaliman P. Plasma miR-34a-5p serotonin2B receptor blockade: brexpiprazole reverses and miR-545-3p as Early Biomarkers of Involvement of medial prefrontal cortex phencyclidine-induced disruptions of Alzheimer’s Disease: Potential and serotonin1A receptors. thalamocortical networks. EUROPEAN Limitations. MOLECULAR NEUROBIOLOGY. NEUROPHARMACOLOGY. 119:91-99. I.F.: 5.012 NEUROPSYCHOPHARMACOLOGY. 54(7):5550-5562. I.F.: 6.190 27(12):1248-1257. I.F.: 4.239 12. Riga MS, Teruel-Martí V, Sánchez C, 6. Didriksen M., Fejgin K., Nilsson S., Birknow Celada P, Artigas F. Subchronic vortioxetine 19. Merchán A, Navarro SV, Klein AB, Aznar S, M., Grayton H., Larsen P., Lauridsen J., Nielsen treatment -but not escitalopram- Campa L, Suñol C, Moreno M, Flores P. V., Celada P., Santana N., Kallunki P., enhances pyramidal neuron activity in the Tryptophan depletion affects compulsive Christensen K., Werge T., Stensbøl T., rat prefrontal cortex. behaviour in rats: strain dependent effects Egebjerg J., Gastambide F., Artigas F., NEUROPHARMACOLOGY. 113(pt a):148-155. and associated neuromechanisms. Bastlund J., Nielsen J. Persistent gating I.F.: 5.012 PSYCHOPHARMACOLOGY. deficit and increased sensitivity to NMDA 234(8):1223-1236. I.F.: 3.308 receptor antagonism after puberty in a 13. Gasull-Camós J, Tarrés-Gatius M, Artigas new mouse model of the human 22q11.2 F, Castañé A. Glial GLT-1 blockade in 20. Caballero B; Olguin N; Campos F; Farina microdeletion syndrome: A study in male infralimbic cortex as a new strategy to M; Ballester F; Lopez-Espinosa M-J; Llop S; mice. JOURNAL OF PSYCHIATRY AND evoke rapid antidepressant-like effects in Rodríguez-Farré E; Suñol C. Methylmercury- NEUROSCIENCE. 42(1):48-58. I.F.: 5.165 rats. TRANSLATIONAL PSYCHIATRY. induced developmental toxicity is 7(2):e1038. I.F.: 4.730 associated with oxidative stress and cofilin 7. Pulido-Salgado M., Vidal-Taboada J., Garcia phosphorylation. Cellular and human Diaz-Barriga G., Serratosa J., Valente T., 14. Gasull-Camós J, Soto-Montenegro ML, studies. NEUROTOXICOLOGY. 59:197-209. Castillo P., Matalonga J., Straccia M., Canals J., Casquero-Veiga M, Desco M, Artigas F, I.F.: 3.100 Valledor A., Solà C., Saura J. Myeloid C/EBPβ Castañé A. Differential Patterns of deficiency reshapes microglial gene Subcortical Activity Evoked by Glial GLT-1 21. Valdés-Moreno MI, Alcántara-Alonso V, expression and is protective in Blockade in Prelimbic and Infralimbic Estrada-Camarena E, Mengod G, Amaya MI, experimental autoimmune Cortex: Relationship to Matamoros-Trejo G, de Gortari P. encephalomyelitis. JOURNAL OF Antidepressant-Like Effects in Rats. Phosphodiesterase-7 inhibition affects NEUROINFLAMMATION. 14(1):54. I.F.: 5.102 INTERNATIONAL JOURNAL OF accumbal and hypothalamic NEUROPSYCHOPHARMACOLOGY. thyrotropin-releasing hormone 8. Flores-Burgess A, Millón C, Gago B, 20(12):988-993. I.F.: 4.712 expression, feeding and anxiety behavior Narváez M, Borroto-Escuela DO, Mengod G, of rats. BEHAV BRAIN RES. 319:165-173. Narváez JA, Fuxe K, Santín L, Díaz-Cabiale Z. 15. Valente T; Serratosa J; Perpiñá U; Saura J; I.F.: 3.002 Galanin (1-15) enhancement of the Solá C. Alterations in CD200-CD200R1 behavioral effects of Fluoxetine in the system during EAE already manifest at 22. Palomera-Avalos, Veronica; Grinan-Ferre, forced swimming test gives a new presymptomatic stages. FRONTIERS IN Christian; Izquierdo, Vanesa; Camins, Antonio; therapeutic strategy against depression. CELLULAR NEUROSCIENCE. 11:129. I.F.: 4.555 Sanfeliu, Coral; Pallas, Merce. Metabolic NEUROPHARMACOLOGY. 118:233-241. Stress Induces Cognitive Disturbances I.F.: 5.012 16. Zeinolabediny Y, Caccuri F, Colombo L, and Inflammation in Aged Mice: Protective Morelli F, Romeo M, Rossi A, Schiarea S, Role of Resveratrol. REJUVENATION 9. Riga M., Lladó-Pelfort L., Artigas F., Celada Ciaramelli C, Airoldi C, Weston R, Donghui L, RESEARCH. 20(3):202-217. I.F.: 2.827 P. The serotonin hallucinogen 5-MeO-DMT Krupinski J, Corpas R, García-Lara E, Sarroca alters cortico-thalamic activity in freely S, Sanfeliu C, Slevin M, Caruso A, Salmona M, 23. Rieger DK, Dos Santos AA, Suñol C, Farina moving mice: Regionally-selective Diomede L. HIV-1 matrix protein p17 M. Involvement of superoxide in involvement of 5-HT1Aand misfolding forms toxic amyloidogenic malaoxon-induced toxicity in primary 5-HT2Areceptors. assemblies that induce neurocognitive cultures of cortical neurons. JOURNAL OF NEUROPHARMACOLOGY. :1-12. I.F.: 5.012 disorders. SCIENTIFIC REPORTS. TOXICOLOGY AND ENVIRONMENTAL 7(1):10313. I.F.: 4.259 HEALTH - PART A: CURRENT ISSUES. 10. Corpas R., Hernández-Pinto A., Porquet D., 80(19-21):1106-1115. I.F.: 2.731 Hernández-Sánchez C., Bosch F., 17. Colie, Sandra; Sarroca, Sara; Palenzuela,

207 AREA 4 CLINICAL AND EXPERIMENTAL NEUROSCIENCE

24. Martín-Álvarez R, Paúl-Fernández N, GRANTS FOR RESEARCH IN PROGRESS Sponsored by: Ministerio de Economía y Palomo V, Gil C, Martínez A, Mengod G. Competitividad. SAF2016-77703-C2-2 A preliminary investigation of Artigas F. Alteraciones de la corteza Duration: 30/12/2016-29/12/2019 phoshodiesterase 7 inhibitor VP3.15 as infralímbica en depresión: mecanismo de therapeutic agent for the treatment of acción de nuevas estrategias Saura J. Nanoparticle delivery system for experimental autoimmune antidepresivas. neurodegenerative disorders. encephalomyelitis mice. JOURNAL OF Sponsoredby: Ministerio de Economía y Sponsored by: Instituto de Salud Carlos III CHEMICAL NEUROANATOMY. 80:27-36. Competitividad. SAF2015-68346-P (ISCIII). AC14/00016 I.F.: 1.925 Duration: 01/01/2016-31/12/2019 Duration: 01/01/2015-30/06/2019

Bortolozzi A. Nuevas estrategias Saura J. C/EBPs microgliales como Review / I.F.: 3.267 terapéuticas para el tratamiento de potencial diana terapéutica en la sinucleinopatías. endermedad de Parkinson. 1. Santana, Noemi; Artigas, Francesc. Sponsoredby: Ministerio de Economía y Sponsored by: Instituto de Salud Carlos III Laminar and Cellular Distribution of Competitividad. RTC-2014-2812-1 (ISCIII). PI14/00302 Monoamine Receptors in Rat Medial Duration: 04/02/2014-30/06/2018 Duration: 01/01/2015-30/06/2019 Prefrontal Cortex. FRONTIERS IN NEUROANATOMY. 11(87). I.F.: 3.267 Bortolozzi A. Sinucleínas, depresión y Solà C. El sistema CD200-CD200R1 como enfermedad de Parkinson. Nuevas diana terapéutica y biomarcador en estrategias terapéuticas basadas en enfermedades neurológicas: la Letters / I.F.: 68.412 ácidos nucleicos de interferencia. enfermedad de Parkinson. Sponsored by: Instituto de Salud Carlos III Sponsored by: Instituto de Salud Carlos III 1. Artigas F, Schenker E, Celada P, Spedding (ISCIII). PI13/01390 (ISCIII). PI15/00033 M, Lladó-Pelfort L, Jurado N, Núñez M, Duration: 01/01/2014-30/06/2017 Duration: 01/01/2016-31/12/2018 Santana N, Troyano-Rodriguez E, Riga MS, van den Munkhof H, Castañé A, Shaban H, Jay Bortolozzi A. Sinucleinopatías y TM, Tripathi A, Godsil BP, Sebban C, Mariani J, oligonucleótidos inhibitorios: rol de alfa y DOCTORAL THESES Faure P, Takkilah S, Hughes ZA, Siok CJ, gama sinucleínas en la regulación de la Hajos M, Wicke K, Gass N, Weber-Fahr W, función cognitiva. Artigas F, Castañé A. Role of the infralimbic Sartorius A, Becker R, Didriksen M, Bastlund Sponsored by: Ministerio de Economia y cortex in depression: Functional JF, Tricklebank M, Risterucci C, Meyer- Competitividad. SAF2016-75797-R connectivity and behavioral phenotypes. Lindenberg A, Schwarz AJ. Defining the Duration: 30/12/2016-29/12/2019 PhD student: Júlia Gasull Camós brain circuits involved in psychiatric disorders: IMI-NEWMEDS. NAT REV DRUG Celada MP. Actividad de la corteza DISCOV. 16(1):1-2. I.F.: 57.000 prefrontal en nuevas estrategias antidepresivas. 2. Artigas F., Bortolozzi A. Therapeutic Sponsored by: Instituto de Salud Carlos III Potential of Conjugated siRNAs for the (ISCIII). PI12/00156 Treatment of Major Depressive Disorder. Duration: 01/01/2013-31/12/2017 BIOLOGICAL PSYCHIATRY. 42(1):371-372. I.F.: 11.412 Celada MP. Modulación de circuitos cortico-mesencefálicos y cortico-límbicos por nuevas terapias antidepresivas. Consortium Publications / I.F.: 10.162 Sponsored by: Instituto de Salud Carlos III (ISCIII). PI16/00287 1. Marchese, Domenica; Botta-Orfila, Teresa; Duration: 01/01/2017-31/12/2019 Cirillo, Davide; Antonio Rodriguez, Juan; Maria Livi, Carmen; Fernandez-Santiago, Ruben; Mengod G. ¿Están implicados los cambios Ezquerra, Mario; Marti, Maria J.; Bechara, Elias; fenotípicos de las microglía/macrófagos en Gaetano Tartaglia, Gian. Discovering the 3 ' los efectos beneficiosos de los inhibidores UTR-mediated regulation of de PDEs del AMPc en la EAE crónica? alpha-synuclein. NUCLEIC ACIDS Sponsored by: Instituto de Salud Carlos III (ISCIII). RESEARCH. 45(22):12888-12903. I.F.: 10.162 PI15/00148 Duration: 01/01/2016-31/12/2018

Sanfeliu C. Estudio de la epóxido hidrolasa soluble como nueva diana farmacológica para la enfermedad de Alzheimer: Modulacion de las vias de inﬂamacion y proteólisis.

208 BRAIN ISCHEMIA: CLINICAL AND EXPERIMENTAL STUDIES 4.2

Brain ischemia: Clinical 4.2 and experimental studies

ADMINISTRATIVE STAFF Martha Vargas (HCB-FCRB) LOCATION

HCB building NURSING STAFF IIBB-CSIC labs Elisabet Gonzalez (HCB)

COLLABORATORS Laura Llull (FCRB) Víctor Obach (FCRB) Arturo Renú (FCRB) KEYWORDS Yashu Zhao (IDIBAPS-UB) TEAM LEADER 1. Brain Ángel Chamorro (HCB) 2. Stroke T. 93 227 54 00 (Ext.: 2118) STRATEGIC OBJECTIVES 3. Cerebrovascular diseases [email protected] 4. Neuroinﬂammation 5. Oxidative stress Study of cerebrovascular pathology from the clinical and basic perspective, with special RESEARCHERS emphasis on inﬂammation, immune response, Sergio Amaro (HCB-IDIBAPS) and oxidative stress, as well as on the use of Carles Justicia (IIBB-CSIC) neuroimaging techniques. Translational Valérie Petegnief (IIBB-CSIC) research integrating experimental models and Anna Planas (IIBB-CSIC) clinical studies. The ultimate aim is to develop Original publications Xabier Urra (HCB-IDIBAPS) therapeutic strategies in application to stroke. from 2015 to 2017

YEAR I.F. TOTAL Q1 Q2 POST-DOCTORAL RESEARCHERS Francesc Antoni Miró (FCRB) MAIN LINES OF RESEARCH 2015 162.17 19 17 2

2016 97.32 12 11 1 PRE-DOCTORAL RESEARCHERS Inﬂammation and immunity in stroke

2017 121.22 21 15 5 Laura Díaz (IDIBAPS) - Immunological mechanisms in the Mattia Gallizioli (FCRB) progression of stroke and infectious Carlos Laredo (IDIBAPS) complications. Amaia Otxoa (IIBB-CSIC) - Cerebral inﬁltration of myeloid cells and Jordi Pedragosa (IDIBAPS) lymphocytes after ischemic stroke: role in

TEAM INVOLVED IN Salvatore Rudilosso (FCRB) brain damage and repair. RED INVICTUSPLUS Angelica Maria Salas (FCRB) - Innate immunity in stroke: the lectin AGAUR_SGR14 pathway of complement activation. AGAUR_SGR17 TECHNICIANS - Inﬂammatory and immune responses as Francisca Ruiz (IDIBAPS) targets for stroke treatment. Ángel Chamorro

TEAM

209 AREA 4 CLINICAL AND EXPERIMENTAL NEUROSCIENCE

Vascular damage MOLECULAR NEUROBIOLOGY. Laura; Oleaga, Laura; Amaro, Sergio; - Endothelial damage and blood-brain barrier 54(8):6572-6580. I.F.: 6.190 Chamorro, Angel. Brain hemorrhage after disruption, after recanalization therapies. endovascular reperfusion therapy of - Hemorrhagic transformation after acute 5. Corpas R., Revilla S., Ursulet S., ischemic stroke: a threshold-finding ischemic stroke Castro-Freire M., Kaliman P., Petegnief V., whole-brain perfusion CT study. JOURNAL - Brain hemorrhage Giménez-Llort L., Sarkis C., Pallàs M., Sanfeliu OF CEREBRAL BLOOD FLOW AND - Vascular dementia C. SIRT1 Overexpression in Mouse METABOLISM. 37(1):153-165. I.F.: 5.081 Hippocampus Induces Cognitive Brain protection and repair Enhancement Through Proteostatic and 12. Purroy F, Vena A, Cánovas D, Cardona P, - Antioxidant treatments in stroke (Uric acid). Neurotrophic Mechanisms. MOLECULAR Cocho D, Cuadrado-Godia E, Chamorro A, - Functional recovery by rehabilitation NEUROBIOLOGY. 54(7):5604-5619. I.F.: 6.190 Dávalos A, Garcés M, Gomis M, Krupinski J, therapies. Palomeras E, Ribó M, Roquer J, Rubiera M, 6. Renú A, Laredo C, Lopez-Rueda A, Llull L, Sanahuja J, Saura J, Serena J, Ustrell X, Multimodal neuroimaging in Stroke Tudela R, San-Roman L, Urra X, Blasco J, Vargas M, Benabdelhak I, Abilleira S, Gallofré - Magnetic resonance imaging (MRI), Macho J, Oleaga L, Chamorro A, Amaro S. M, Catalan Stroke Code and Reperfusion CT/perfusion, optical imaging techniques. Vessel Wall Enhancement and Consortium. Influence of Hospital Type on Blood-Cerebrospinal Fluid Barrier Outcomes of Individuals Aged 80 and Disruption After Mechanical Older with Stroke Treated Using Thrombectomy in Acute Ischemic Stroke. Intravenous Thrombolysis. JOURNAL OF PUBLICATIONS STROKE. 48(3):651-657. I.F.: 6.032 THE AMERICAN GERIATRICS SOCIETY. 65(9):E117-E122. I.F.: 4.388 Originals / I.F.: 128.217 7. Abilleira S, Ribera A, Cardona P, Rubiera M, López-Cancio E, Amaro S, 13. Chamorro, Angel; Blasco, Jordi; Lopez, 1. Dávalos A, Cobo E, Molina CA, Chamorro A, Rodríguez-Campello A, Camps-Renom P, Antonio; Amaro, Sergio; San Roman, Luis; Llull, de Miquel MA, Román LS, Serena J, Cánovas D, de Miquel MA, Tomasello A, Laura; Renu, Arturo; Rudilosso, Salvatore; López-Cancio E, Ribó M, Millán M, Urra X, Remollo S, López-Rueda A, Vivas E, Laredo, Carlos; Obach, Victor; Urra, Xabier; Cardona P, Tomasello A, Castaño C, Blasco J, Perendreu J, Gallofré M, Catalan Stroke Code Planas, Anna M.; Leira, Enrique C.; Macho, Aja L, Rubiera M, Gomis M, Renú A, Lara B, and Reperfusion Consortium. Outcomes Juan. Complete reperfusion is required for Martí-Fàbregas J, Jankowitz B, Cerdà N, Jovin After Direct Thrombectomy or Combined maximal benefits of mechanical TG, REVASCAT Trial Investigators. Safety Intravenous and Endovascular Treatment thrombectomy in stroke patients. and efficacy of thrombectomy in acute Are Not Different.STROKE. 48(2):375-378. SCIENTIFIC REPORTS. 7(1):11636-1120. ischaemic stroke (REVASCAT): 1-year I.F.: 6.032 I.F.: 4.259 follow-up of a randomised open-label trial. LANCET NEUROLOGY, THE. 8. Urra X., Laredo C., Zhao Y., Amaro S., 14. Argibay B., Trekker J., Himmelreich U., 16(5):369-376-376. I.F.: 26.284 Rudilosso S., Renú A., Prats-Galino A., Planas Beiras A., Topete A., Taboada P., Pérez-Mato A., Oleaga L., Chamorro Á. Neuroanatomical M., Vieites-Prado A., Iglesias-Rey R., Rivas J., 2. Wang B., Liu Y., Huang L., Chen J., Li J., correlates of stroke-associated infection Planas A., Sobrino T., Castillo J., Campos F. Wang R., Kim E., Chen Y., Justicia C., Sakata K., and stroke-induced immunodepression. Intraarterial route increases the risk of Chen H., Planas A., Ostrom R., Li W., Yang G., BRAIN, BEHAVIOR, AND IMMUNITY. cerebral lesions after mesenchymal cell McDonald M., Chen R., Heck D., Liao F. A 60:142-150. I.F.: 5.964 administration in animal model of CNS-permeable Hsp90 inhibitor rescues ischemia. SCIENTIFIC REPORTS. 7:40758. synaptic dysfunction and memory loss in 9. Meissner A, Miro F, Jiménez-Altayó F, I.F.: 4.259 APP-overexpressing Alzheimer's mouse Jurado A, Vila E, Planas AM. model via an HSF1-mediated mechanism. Sphingosine-1-phosphate signalling-a key 15. Meissner A., Minnerup J., Soria G., Planas MOLECULAR PSYCHIATRY. 22(7):990-1001. player in the pathogenesis of Angiotensin A. Structural and functional brain I.F.: 13.204 II-induced hypertension. CARDIOVASC alterations in a murine model of RES. 113(2):123-133. I.F.: 5.878 Angiotensin II-induced hypertension. 3. Justicia C., Salas-Perdomo A., JOURNAL OF NEUROCHEMISTRY. Pérez-de-Puig I., Deddens L., van Tilborg G., 10. Bonfill-Teixidor E, Bonfill-Teixidor E, 140(3):509-521. I.F.: 4.083 Castellví C., Dijkhuizen R., Chamorro Á., Planas Otxoa-de-Amezaga A, Otxoa-de-Amezaga A, A. Uric Acid Is Protective After Cerebral Font-Nieves M, Sans-Fons MG, Planas AM, 16. Giralt-Steinhauer E, Ois A, Abilleira S, Urra Ischemia/Reperfusion in Hyperglycemic Planas AM, Planas AM. Differential X, Cardona-Portela P, Gomis M, Castellanos Mice. TRANSL STROKE RES. 8(3):294-305. expression of E-type prostanoid receptors M, Molina C, Martí-Fàbregas J, Pellisé A, I.F.: 8.266 2 and 4 in microglia stimulated with Cànovas D, Gómez-Choco M, Kuprinski J, lipopolysaccharide. JOURNAL OF Cocho D, Roquer J, Cat-SCR Consortium. 4. Llull L, Thiel S, Amaro S, Cervera Á, Planas NEUROINFLAMMATION. 14(1):3-1120. Frequency and outcome of total anterior AM, Chamorro Á. Ficolin-1 Levels in Patients I.F.: 5.102 circulation strokes without intracranial Developing Vasospasm and Cerebral large-vessel occlusion. EUR J NEUROL. Ischemia After Spontaneous 11. Renu, Arturo; Laredo, Carlos; Tudela, Raul; 24(1):11-17-1120. I.F.: 3.988 Subarachnoid Hemorrhage. Urra, Xabier; Lopez-Rueda, Antonio; Llull,

210 BRAIN ISCHEMIA: CLINICAL AND EXPERIMENTAL STUDIES 4.2

17. Chamorro Á, Amaro S, Castellanos M, Trueman RC, Whitfield L, Wong R, Macrae IM. Duration: 01/01/2016-31/12/2019 Gomis M, Urra X, Blasco J, Arenillas JF, Román The IMPROVE Guidelines (Ischaemia LS, Muñoz R, Macho J, Cánovas D, Models: Procedural Refinements Of in Vivo Planas AM. Imaging of Neuroinflammation Marti-Fabregas J, Leira EC, Planas AM, Experiments). JOURNAL OF CEREBRAL in Neurodegenerative Diseases. URICO-ICTUS Investigators. Uric acid BLOOD FLOW AND METABOLISM. Sponsored by: European Commission. therapy improves the outcomes of stroke 37(11):3488-3517. I.F.: 5.081 FP7-HEALTH-11 patients treated with intravenous tissue Duration: 01/03/2012-28/02/2018 plasminogen activator and mechanical thrombectomy. INTERNATIONAL Case Reports / I.F.: 1.517 Planas AM. Neuroinflammation. JOURNAL OF STROKE. 12(4):377-382. Sponsored by: European Commission I.F.: 3.314 1. Rudilosso S., Laredo C., Urra X., Chamorro Á. FP7-PEOPLE-13 Different Perfusion Patterns in a Patient Duration: 01/09/2013-31/08/2017 18. Abboud H, Sissani L, Labreuche J, Arauz A, with Acute Ischemic Stroke. JOURNAL OF Bousser MG, Bryer A, Chamorro A, Fisher M, STROKE AND CEREBROVASCULAR Planas AM. Benefits and risks of the Ford I, Fox KM, Hennerici MG, Lavados PM, DISEASES. 26(5):E83-E84. I.F.: 1.517 immune response to stroke. Massaro A, Mattle HP, Munoz Collazos M, Sponsored by: Ministerio de Economía y Rothwell PM, Steg PG, Vicaut E, Yamouth B, Competitividad (MINECO). Amarenco P, OPTIC Registry and PERFORM GRANTS FOR RESEARCH IN PROGRESS SAF2014-56279-R Trial Investigators. Specificities of Ischemic Duration: 01/01/2015-31/12/2017 Stroke Risk Factors in Arab-Speaking Amaro S. Daño de la pared arterial en el Countries. CEREBROVASCULAR ictus isquémico agudo: detección con RM Planas AM. New therapeutic strategies in DISEASES. 43(3-4):169-177. I.F.: 2.974 avanzada, mecanismos subyacentes y the treatment of traumatic brain injury by valor pronóstico. targeting the LEctin Activation Pathway of 19. Amarenco P, Sissani L, Labreuche J, Sponsored by: Instituto de Salud Carlos III complement. Vicaut E, Bousser MG, Chamorro A, Fisher M, (ISCIII). PI16/00711 Sponsored by: Ministerio de Ciencia e Ford I, Fox KM, Hennerici MG, Mattle H, Duration: 01/01/2017-31/12/2019 Innovación (MICINN). Rothwell PM, Steg PG, Diener HC, Sacco RL, NEURON9-FP-044/PCIN-2017-035 Greving JP, Algra A, PERFORM and Chamorro A. Enfermedades vasculares Duration: 01/11/2017-31/10/2020 PRoFESS Committees and Investigators. The cerebrales (Ictus). Intracranial-B2LEED3S Score and the Risk of Intracranial (ISCIII). RD12/0014/0011 DOCTORAL THESES Hemorrhage in Ischemic Stroke Patients Duration: 01/01/2013-31/03/2017 under Antiplatelet Treatment. Chamorro Á, Amaro S. Daño de la barrera CEREBROVASCULAR DISEASES. Chamorro A. La respuesta inmune en el hematoencefálica en el ictus isquémico 43(3-4):145-151. I.F.: 2.974 ictus: Papel de la especificidad antigénica. agudo: Marcadores de neuroimagen y Sponsored by: Instituto de Salud Carlos III significado pronóstico. 20. Blanco I., Zirak P., Dragojevic T., Castellvi (ISCIII). PI12/01437 PhD student: Arturo Renú Jornet C., Durduran T., Justicia C. Longitudinal, Duration: 01/01/2013-06/02/2017 transcranial measurement of functional activation in the rat brain by diffuse Chamorro A. Respuesta inmune y estrés correlation spectroscopy. oxidativa en la hemorragia cerebral. NEUROPHOTONICS. 4(4):045006. I.F.: 2.740 Sponsored by: Instituto de Salud Carlos III (ISCIII). PI15/00430 21. Rudilosso S., San Román L., Blasco J., Duration: 01/01/2016-31/12/2018 Hernández-Pérez M., Urra X., Chamorro Á. Evaluation of white matter hypodensities Chamorro A. Redes Temáticas de on computed tomography in stroke Investigación Cooperativa en Salud patients using the Fazekas score. (RETICS) del Instituto de Salud Carlos III. CLINICAL IMAGING. 46:24-27. I.F.: 1.015 Red de Enfermedades Vasculares Cerebrales: Red INVICTUSplus. Sponsored by: Instituto de Salud Carlos III Review / I.F.: 5.081 (ISCIII). RD16/0019/0014 Duration: 01/01/2017-31/12/2021 1. Percie du Sert N, Alfieri A, Allan SM, Carswell HV, Deuchar GA, Farr TD, Flecknell P, Justicia C. Cambios vasculares durante el Gallagher L, Gibson CL, Haley MJ, Macleod envejecimiento y en modelos animales de MR, McColl BW, McCabe C, Morancho A, demencia de origen vascular. Moon LD, O'Neill MJ, Pérez de Puig I, Planas A, Sponsored by: Ministerio de Ciencia e Ragan CI, Rosell A, Roy LA, Ryder KO, Simats Innovación (MICINN). A, Sena ES, Sutherland BA, Tricklebank MD, DPI-2015-64358-C2-2-R

211 AREA 4 CLINICAL AND EXPERIMENTAL NEUROSCIENCE

Parkinson disease and other neurodegenerative movement disorders: clinical and 4.3 experimental research

TEAM LEADER MAIN LINES OF RESEARCH M. Josep Martí Domenech (HCB) LOCATION T. 93 227 57 85 In 2017 we described a new mutation in HCB building [email protected] CELLEX building 3B the gene ACMSD, that causes Parkinson’s disease and detected the presence of

EMERITUS pathological aggregates of synuclein in Eduard Tolosa (UB) gonadal tissue in patients with this disorder. In another study we described the RESEARCHERS presence of numerous transcriptome KEYWORDS Yaroslau Compta (HCB) alterations in dermal ﬁbroblasts from 1. Parkinson disease Mario Antonio Ezquerra (IDIBAPS) patients with Parkinson’s disease and 2. Alzheimer disease Rubén Fernández (IDIBAPS) showed that the disease is systemic and 3. Degenerative neurological diseases Jose Esteban Muñoz (HCB) affects peripheral non-neuronal tissues. Francesc Valldeoriola (HCB) We are currently working towards deepening our knowledge of existing POST-DOCTORAL RESEARCHERS models of PD epigenetic alterations by Pilar Santacruz (FCRB) using iPSC-DAn models and patient blood samples. We continued our work on Original publications PRE-DOCTORAL RESEARCHERS Alicia Garrido (FCRB) biomarkers in parkinsonism cerebrospinal from 2015 to 2017 Darly Milena Giraldo (FCRB) ﬂuid (CSF), published a longitudinal study YEAR I.F. TOTAL Q1 Q2 Lluis Planellas (FCRB) correlating tau and amyloid in CSF derived Almudena Sánchez (HCB-FCRB) from patients with Parkinson’s disease to 2015 286.11 49 38 8 Cristina Simonet (FCRB) motor and non-motor dysfunction a 2016 125.66 22 17 1 cross-sectional study on reduced Coenzy- 2017 172.56 29 21 3 TECHNICIANS me Q10 levels in multiple system atrophy. Manel Fernández (IDIBAPS) These latter two studies were carried out as part of the ‘Catalan registry of multiple ADMINISTRATIVE STAFF system atrophy’ study funded by the TV3 Laura Maragall (CIBER) TEAM INVOLVED IN Marató.Funding from the Fondo de Investigación en Salud (Fund for Health CIBERNED NURSING STAFF Ana Cámara (HCB) Research) has also been granted to us for a new study on the aggregation of different proteins in brain tissues and CSF. STRATEGIC OBJECTIVES

1. Development of research projects with PUBLICATIONS results aimed at impacting in a better diagnosis and treatment of Parkinson Originals / I.F.: 172.563 Disease (PD) and related neurodegenerative movement disorders. 1. Stokholm MG, Iranzo A, Østergaard K, 2. Identification of clinical, molecular and Serradell M, Otto M, Svendsen KB, Garrido A, imaging biomarkers specific for the Vilas D, Borghammer P, Santamaria J, Møller preclinical and prodromal phase of PD, as A, Gaig C, Brooks DJ, Tolosa E, Pavese N. well as for the motor phase of disease. Assessment of neuroinflammation in patients 3. Recruitment of cohorts of PD patients and with idiopathic rapid-eye-movement sleep subjects at-risk of PD and establishment of behaviour disorder: a case-control study. biorepositories useful for state-of-the-art LANCET NEUROLOGY, THE. research in movement disorders. 16(10):789-796. I.F.: 26.284 4. Identification of clinical, molecular and imaging biomarkers of atypical 2. Marchese, Domenica; Botta-Orfila, Teresa; parkinsonism. Cirillo, Davide; Antonio Rodriguez, Juan; Maria Livi, Carmen; Fernandez-Santiago, Ruben; Ezquerra, Mario; Marti, Maria J.; Bechara, Elias; Gaetano Tartaglia, Gian. Discovering the 3 ' UTR-mediated regulation of alpha-synuclein. NUCLEIC ACIDS RESEARCH. 45(22):12888-12903. I.F.: 10.162

212 PARKINSON DISEASE AND OTHER NEURODEGENERATIVE MOVEMENT DISORDERS: CLINICAL AND EXPERIMENTAL RESEARCH 4.3

3. Iranzo, Alex; Santamaria, Joan; Valldeoriola, Cohort Consortium. Penetrance estimate of and miR-545-3p as Early Biomarkers of Francesc; Serradell, Monica; Salamero, Manel; LRRK2 p.G2019S mutation in individuals of Alzheimer’s Disease: Potential and Gaig, Carles; Ninerola-Baizan, Aida; non-Ashkenazi Jewish ancestry. Limitations. MOLECULAR NEUROBIOLOGY. Sanchez-Valle, Raquel; Llado, Albert; De MOVEMENT DISORDERS. 32(10):1432-1438. 54(7):5550-5562. I.F.: 6.190 Marzi, Roberto; Stefani, Ambra; Seppi, Klaus; I.F.: 7.072 Pavia, Javier; Hoegl, Birgit; Poewe, Werner; 13. Dangla-Valls A, Molinuevo JL, Altirriba J, Tolosa, Eduard; Lomena, Francisco. 9. Höglinger GU, Respondek G, Stamelou M, Sánchez-Valle R, Alcolea D, Fortea J, Rami L, Dopamine Transporter Imaging Deficit Kurz C, Josephs KA, Lang AE, Mollenhauer B, Balasa M, Muñoz-García C, Ezquerra M, Predicts Early Transition to Müller U, Nilsson C, Whitwell JL, Arzberger T, Fernández-Santiago R, Lleó A, Lladó A, Synucleinopathy in Idiopathic Rapid Eye Englund E, Gelpi E, Giese A, Irwin DJ, Meissner Antonell A. CSF microRNA Profiling in Movement Sleep Behavior Disorder. WG, Pantelyat A, Rajput A, van Swieten JC, Alzheimer's Disease: a Screening and ANNALS OF NEUROLOGY. 82(3):419-428. Troakes C, Antonini A, Bhatia KP, Bordelon Y, Validation Study. MOLECULAR I.F.: 9.890 Compta Y, Corvol JC, Colosimo C, Dickson NEUROBIOLOGY. 54(9):6647-6654. DW, Dodel R, Ferguson L, Grossman M, I.F.: 6.190 4. Gaig C, Graus F, Compta Y, Högl B, Bataller Kassubek J, Krismer F, Levin J, Lorenzl S, L, Brüggemann N, Giordana C, Heidbreder A, Morris HR, Nestor P, Oertel WH, Poewe W, 14. Kun-Rodrigues C, Ross OA, Orme T, Kotschet K, Lewerenz J, Macher S, Martí MJ, Rabinovici G, Rowe JB, Schellenberg GD, Shepherd C, Parkkinen L, Darwent L, Montojo T, Pérez-Pérez J, Puertas I, Seitz C, Seppi K, van Eimeren T, Wenning GK, Boxer Hernandez D, Ansorge O, Clark LN, Honig LS, Simabukuro M, Téllez N, Wandinger KP, Iranzo AL, Golbe LI, Litvan I, Movement Disorder Marder K, Lemstra A, Scheltens P, van der A, Ercilla G, Sabater L, Santamaría J, Dalmau J. Society-endorsed PSP Study Group. Clinical Flier W, Louwersheimer E, Holstege H, Clinical manifestations of the anti-IgLON5 diagnosis of progressive supranuclear Rogaeva E, St George-Hyslop P, Londos E, disease. NEUROLOGY. 88(18):1736-1743. I.F.: 8.320 palsy: The movement disorder society Zetterberg H, Barber I, Braae A, Brown K, criteria. MOVEMENT DISORDERS. Morgan K, Maetzler W, Berg D, Troakes C, 5. Iranzo A, Stefani A, Serradell M, Martí MJ, 32(6):853-864. I.F.: 7.072 Al-Sarraj S, Lashley T, Holton J, Compta Y, Lomeña F, Mahlknecht P, Stockner H, Gaig C, Van Deerlin V, Trojanowski JQ, Serrano GE, Fernández-Arcos A, Poewe W, Tolosa E, Högl 10. Pont-Sunyer, Claustre; Tolosa, Eduardo; Beach TG, Clarimon J, Lleó A, Morenas- B, Santamaria J, SINBAR (Sleep Innsbruck Caspell-Garcia, Chelsea; Coffey, Christopher; Rodríguez E, Lesage S, Galasko D, Masliah E, Barcelona) group. Characterization of Alcalay, Roy N.; Chan, Piu; Duda, John E.; Santana I, Diez M, Pastor P, Tienari PJ, patients with longstanding idiopathic REM Facheris, Maurizio; Fernandez-Santiago, Myllykangas L, Oinas M, Revesz T, Lees A, sleep behavior disorder. NEUROLOGY. Ruben; Marek, Kenneth; Lomena, Francisco; Boeve BF, Petersen RC, Ferman TJ, 89(3):242-248. I.F.: 8.320 Marras, Connie; Mondragon, Elisabet; Escott-Price V, Graff-Radford N, Cairns NJ, Saunders-Pullman, Rachel; Waro, Morris JC, Stone DJ, Pickering-Brown S, 6. Alcolea D, Vilaplana E, Suárez-Calvet M, Bjorg;LRRK2 Cohort Consortium. The Mann D, Dickson DW, Halliday GM, Singleton Illán-Gala I, Blesa R, Clarimón J, Lladó A, Prodromal Phase of Leucine-Rich Repeat A, Guerreiro R, Bras J. Analysis of C9orf72 Sánchez-Valle R, Molinuevo JL, García-Ribas Kinase 2-Associated Parkinson Disease: repeat expansions in a large international G, Compta Y, Martí MJ, Piñol-Ripoll G, Clinical and Imaging Studies. MOVEMENT cohort of dementia with Lewy bodies. Amer-Ferrer G, Noguera A, García-Martín A, DISORDERS. 32(5):726-738. I.F.: 7.072 NEUROBIOL AGING. 49:214. I.F.: 5.117 Fortea J, Lleó A. CSF sAPPβ, YKL-40, and neurofilament light in frontotemporal lobar 11. Darling A, Tello C, Martí MJ, Garrido C, 15. Giri A, Mok KY, Jansen I, Sharma M, degeneration. NEUROLOGY. 89(2):178-188. Aguilera-Albesa S, Tomás Vila M, Gastón I, Tesson C, Mangone G, Lesage S, Bras JM, I.F.: 8.320 Madruga M, González Gutiérrez L, Ramos Shulman JM, Sheerin UM, , Díez-Fairen M, Lizana J, Pujol M, Gavilán Iglesias T, Tustin K, Pastor P, Martí MJ, Ezquerra M, Tolosa E, 7. Mollenhauer, Brit; Caspell-Garcia, Chelsea Lin JP, Zorzi G, Nardocci N, Martorell L, Correia-Guedes L, Ferreira J, Amin N, van J.; Coffey, Christopher S.; Taylor, Peggy; Shaw, Lorenzo Sanz G, Gutiérrez F, García PJ, Vela Duijn CM, van Rooij J, Uitterlinden AG, Kraaij R, Leslie M.; Trojanowski, John Q.; Singleton, L, Hernández Lahoz C, Ortigoza Escobar JD, Nalls M, Simón-Sánchez J International Andy; Frasier, Mark; Marek, Kenneth; Galasko, Martí Sánchez L, Moreira F, Coelho M, Correia Parkinson's Disease Consortium (IPDGC). Douglas;Progression Marker Initiative. Guedes L, Castro Caldas A, Ferreira J, Pires P, Lack of evidence for a role of genetic Longitudinal CSF biomarkers in patients Costa C, Rego P, Magalhães M, Stamelou M, variation in TMEM230 in the risk for with early Parkinson disease and healthy Cuadras Pallejà D, Rodríguez-Blazquez C, Parkinson's disease in the Caucasian controls. NEUROLOGY. 89(19):1959-1969. Martínez-Martín P, Lupo V, Stefanis L, Pons R, population. NEUROBIOL AGING. I.F.: 8.320 Espinós C, Temudo T, Pérez Dueñas B. 50:167-167.e13. I.F.: 5.117 Clinical rating scale for pantothenate 8. Lee A., Wang Y., Alcalay R., Mejia-Santana kinase-associated neurodegeneration: A 16. Campabadal A., Uribe C., Segura B., H., Saunders-Pullman R., Bressman S., Corvol pilot study. MOVEMENT DISORDERS. Baggio H., Abos A., Garcia-Diaz A., Marti M., J., Brice A., Lesage S., Mangone G., Tolosa E., 32(11):1620-1630. I.F.: 7.072 Valldeoriola F., Compta Y., Bargallo N., Junque Pont-Sunyer C., Vilas D., Schüle B., Kausar F., C. Brain correlates of progressive olfactory Foroud T., Berg D., Brockmann K., Goldwurm 12. Cosín-Tomás M., Antonell A., Lladó A., loss in Parkinson's disease. S., Siri C., Asselta R., Ruiz-Martinez J., Alcolea D., Fortea J., Ezquerra M., Lleó A., Martí PARKINSONISM AND RELATED Mondragón E., Marras C., Ghate T., Giladi N., M., Pallàs M., Sanchez-Valle R., Molinuevo J., DISORDERS. 41:44-50. I.F.: 4.484 Mirelman A., Marder K, Michael J. Fox LRRK2 Sanfeliu C., Kaliman P. Plasma miR-34a-5p

213 AREA 4 CLINICAL AND EXPERIMENTAL NEUROSCIENCE

17. Antonini A, Poewe W, Chaudhuri KR, Jech 23. Hamel W., Köppen J., Alesch F., Antonini 29. Luquin, Maria-Rosario; Kulisevsky, Jaime; R, Pickut B, Pirtošek Z, Szasz J, Valldeoriola F, A., Barcia J., Bergman H., Chabardes S., Martinez-Martin, Pablo; Mir, Pablo; Tolosa, Winkler C, Bergmann L, Yegin A, Onuk K, Contarino M., Cornu P., Demmel W., Deuschl Eduardo S. Consensus on the Definition of Barch D, Odin P, GLORIA study G., Fasano A., Kühn A., Limousin P., McIntyre Advanced Parkinson's Disease: A co-investigators. Levodopa-carbidopa C., Mehdorn H., Pilleri M., Pollak P., Neurologists-Based Delphi Study (CEPA intestinal gel in advanced Parkinson's: Rodríguez-Oroz M., Rumià J., Samuel M., Study). PARKINSONS DISEASE. 4047392. Final results of the GLORIA registry. Timmermann L., Valldeoriola F., Vesper J., I.F.: 1.702 PARKINSONISM AND RELATED Visser-Vandewalle V., Volkmann J., Lozano A. DISORDERS. 45:13-20. I.F.: 4.484 Targeting of the Subthalamic Nucleus for Deep Brain Stimulation: A Survey Among Review / I.F.: 20.845 18. Abós A, Baggio HC, Segura B, García-Díaz Parkinson Disease Specialists. WORLD AI, Compta Y, Martí MJ, Valldeoriola F, Junqué NEUROSURGERY. 99:41-46. I.F.: 2.592 1. Obeso J., Stamelou M., Goetz C., Poewe W., C. Discriminating cognitive status in Lang A., Weintraub D., Burn D., Halliday G., Parkinson's disease through functional 24. Vilas, Dolores; Fernandez-Santiago, Bezard E., Przedborski S., Lehericy S., Brooks connectomics and machine learning. Ruben; Sanchez, Elena; Azcona, Luis J.; D., Rothwell J., Hallett M., DeLong M., Marras SCIENTIFIC REPORTS. 7:45347. I.F.: 4.259 Santos-Montes, Meritxell; Casquero, Pilar; C., Tanner C., Ross G., Langston J., Klein C., Argandona, Lucia; Tolosa, Eduardo; Bonifati V., Jankovic J., Lozano A., Deuschl G., 19. Brockmann K, Schulte C, Paisan-Ruiz, Coro. A Novel p. Glu298Lys Bergman H., Tolosa E., Rodriguez-Violante M., Schneiderhan-Marra N, Apel A, Pont-Sunyer Mutation in the ACMSD Gene in Sporadic Fahn S., Postuma R., Berg D., Marek K., C, Vilas D, Ruiz-Martinez J, Langkamp M, Parkinson's Disease. JOURNAL OF Standaert D., Surmeier D., Olanow C., Corvol JC, Cormier F, Knorpp T, Joos TO, PARKINSONS DISEASE. 7(3):459-463. Kordower J., Calabresi P., Schapira A., Stoessl Bernard A, Gasser T, Marras C, Schüle B, I.F.: 2.538 A. Past, present, and future of Parkinson's Aasly JO, Foroud T, Marti-Masso JF, Brice A, disease: A special essay on the 200th Tolosa E, Berg D, Maetzler W. Inflammatory 25. Modreanu R., Cerquera S., Martí M., Ríos J., Anniversary of the Shaking Palsy. profile discriminates clinical subtypes in Sánchez-Gómez A., Cámara A., Fernández M., MOVEMENT DISORDERS. 32(9):1264-1310. LRRK2-associated Parkinson's disease. Compta Y. Cross-sectional and longitudinal I.F.: 7.072 EUR J NEUROL. 24(2):427-e6. I.F.: 3.988 associations of motor fluctuations and non-motor predominance with 2. Respondek G, Kurz C, Arzberger T, Compta 20. Buongiorno, Mariateresa; Antonelli, cerebrospinal τ and Aβ as well as Y, Englund E, Ferguson LW, Gelpi E, Giese A, Francesca; Compta, Yaroslau; Fernandez, dementia-risk in Parkinson's disease. Irwin DJ, Meissner WG, Nilsson C, Pantelyat A, Yolanda; Pavia, Javier; Lomena, Francisco; JOURNAL OF THE NEUROLOGICAL Rajput A, van Swieten JC, Troakes C, Josephs Rios, Jose; Ramirez, Isabel; Ramon Garcia, SCIENCES. 373:223-229. I.F.: 2.295 KA, Lang AE, Mollenhauer B, Müller U, Jose; Soler, Marina; Camara, Ana; Fernandez, Whitwell JL, Antonini A, Bhatia KP, Bordelon Y, Manel; Basora, Misericordia; Salazar, Fatima; 26. Valldeoriola F., Santacruz P., Ríos J., Corvol JC, Colosimo C, Dodel R, Grossman M, Sanchez-Etayo, Gerard; Valldeoriola, Compta Y., Rumià J., Muñoz J., Martí M., Tolosa Kassubek J, Krismer F, Levin J, Lorenzl S, Francesc; Raul Barrio, Jorge; Jose Marti, E. l-Dopa/carbidopa intestinal gel and Morris H, Nestor P, Oertel WH, Rabinovici GD, Maria. Cross-Sectional and Longitudinal subthalamic nucleus stimulation: Effects Rowe JB, van Eimeren T, Wenning GK, Boxer Cognitive Correlates of FDDNP PET and on cognition and behavior. A, Golbe LI, Litvan I, Stamelou M, Höglinger CSF Amyloid-beta and Tau in Parkinson's BRAIN AND BEHAVIOR. 7(11):e00848-1120. GU, Movement Disorder Society-Endorsed Disease. JOURNAL OF ALZHEIMER'S I.F.: 2.157 PSP Study Group. Which ante mortem DISEASE. 55(3):1261-1272. I.F.: 3.731 clinical features predict progressive 27. Montori-Palacín E, Prieto-González S, supranuclear palsy pathology? 21. Colom-Cadena, Marti; Grau-Rivera, Oriol; Carrasco-Miserachs I, Altes-Capella J, MOVEMENT DISORDERS. 32(7):995-1005. Planellas, Lluis; Cerquera, Catalina; Morenas, Compta Y, López-Soto A, Bosch X. Quick I.F.: 7.072 Estrella; Helgueta, Sergio; Munoz, Laia; outpatient diagnosis in small district or Kulisevsky, Jaime; Jose Marti, Maria; Tolosa, general tertiary hospitals: A comparative 3. Contarino, Maria Fiorella; Van den Dool, Eduard; Clarimon, Jordi; Lleo, Alberto; Gelpi, observational study. MEDICINE (UNITED Joost; Balash, Yacov; Bhatia, Kailash; Giladi, Ellen. Regional Overlap of Pathologies in STATES). 96(22):e6886. I.F.: 1.804 Nir; Koelman, Johannes H.; Lokkegaard, Lewy Body Disorders. JOURNAL OF Annemette; Marti, Maria J.; Postma, Miranda; NEUROPATHOLOGY AND EXPERIMENTAL 28. Moren, C.; Gonzalez-Casacuberta, I.; Relja, Maja; Skorvanek, Matej; Speelman, NEUROLOGY. 76(3):216-224. I.F.: 3.503 Navarro-Otano, J.; Juarez-Flores, D.; Vilas, D.; Johannes D.; Zoons, Evelien; Ferreira, Garrabou, G.; Milisenda, J. C.; Pont-Sunyer, C.; Joaquim J.; Vidailhet, Marie; Albanese, Alberto; 22. Barrantes S, Sánchez Egea AJ, González Catalan-Garcia, M.; Guitart-Mampel, M.; Tijssen, Marina A. J. Clinical Practice: Rojas HA, Martí MJ, Compta Y, Valldeoriola F, Tobias, E.; Cardellach, F.; Valldeoriola, F.; evidence-Based Recommendations for Simo Mezquita E, Tolosa E, Valls-Solè J. Iranzo, A.; Tolosa, E. Colonic Oxidative and the Treatment of Cervical Dystonia with Differential diagnosis between Mitochondrial Function in Parkinson's Botulinum Toxin. FRONTIERS IN Parkinson's disease and essential tremor Disease and Idiopathic REM Sleep NEUROLOGY. 8(35):35. I.F.: 3.552 using the smartphone's accelerometer. Behavior Disorder. PARKINSONS DISEASE. PLOS ONE. 12(8):e0183843. I.F.: 2.806 9816095. I.F.: 1.702 4. Lees AJ, Ferreira J, Rascol O, Reichmann H, Stocchi F, Tolosa E, Poewe W. Opicapone for

214 PARKINSON DISEASE AND OTHER NEURODEGENERATIVE MOVEMENT DISORDERS: CLINICAL AND EXPERIMENTAL RESEARCH 4.3

the management of end-of-dose motor GRANTS FOR RESEARCH IN PROGRESS Martí MJ. Identification of fluctuations in patients with Parkinson's pathophysiological pathways and disease treated with L-DOPA. EXPERT Compta Y. FAIR-PARK-II A multicentre, candidate biomarkers in the prediagnostic REVIEW OF NEUROTHERAPEUTICS. parallel group, randomized, phase of Parkinson’s disease. Instituto 17(7):649-659. I.F.: 3.149 placebo-controlled trial of deferiprone de Salud Carlos III (ISCIII). CIBERNED (DFP) 15 mg/kg BID. Duration: 02/03/2016-01/03/2018 Sponsored by: European commission Letters / I.F.: 30.591 H2020-PHC-2014 Tolosa E. The Parkinson’s progression Duration: 01/05/2015-30/04/2020 Markers Initiative (PPMI). 1. Gelpi, Ellen; Botta-Orfila, Teresa; Bodi, Laia; Sponsored by: Michael J. Fox Foundation Marti, Stefanie; Kovacs, Gabor; Grau-Rivera, Ezquerra M. Epigenetic analysis of for Parkinson. MJFF_2013 Oriol; Lozano, Manuel; Sanchez-Valle, Raquel; iPSC-derived dopaminergic neurons and Duration: 21/05/2013-31/12/2018 Munoz, Esteban; Valldeoriola, Francesc; blood cells in Parkinson disease. Pagonabarraga, Javier; Tartaglia, Sponsored by: Instituto de Salud Carlos III Valldeoriola F. El sistema nervioso Gian-Gaetano; Mila, Montserrat. Neuronal (ISCIII). PI14/00426 autónomo entérico como biomarcador intranuclear (hyaline) inclusion disease Duration: 01/01/2015-31/12/2018 precoz en la Enfermedad de Parkinson. and fragile X-associated tremor/ataxia Sponsored by: Instituto de Salud Carlos III syndrome: a morphological and molecular Ezquerra M. MicroRNAs as biomarkers of (ISCIII). PI13/01455 dilemma. BRAIN; A JOURNAL OF the prodromal stage of Parkinson disease. Duration: 01/01/2014-31/12/2017 NEUROLOGY. 140(8):e51-+. I.F.: 10.292 Sponsored bay: Michael J. Fox Foundation for Parkinson. MJFF_2015 2. Garrido A., Aldecoa I., Gelpi E., Tolosa E. Duration: 16/06/2016-15/06/2018 Aggregation of α-synuclein in the gonadal tissue of 2 patients with Parkinson disease. Fernández Santiago R. MicroRNAs as JAMA NEUROLOGY. 74(5):606-607. biomarkers of the prodromal stage of I.F.: 10.029 Parkinson disease. Sponsored by: Michael J. Fox Foundation for 3. Compta Y, Ramos-Campoy O, Grau-Rivera Parkinson. MJFF_2015 O, Colom-Cadena M, Clarimón J, Martí MJ, Duration: 16/06/2016-15/06/2018 Gelpi E. Conjoint FTLD-FUS of the neuronal intermediate filament inclusion disease Fernández Santiago R. The beginnings of type, progressive supranuclear palsy and Parkinson Disease: a study of early disease alzheimer's pathology presenting as mechanisms in a humanized in-vitro parkinsonism with early falls and late model. hallucinations, psychosis and dementia. Sponsored by: Ministerio de Economía y NEUROPATHOLOGY AND APPLIED Competitividad (MINECO). NEUROBIOLOGY. 43(4):352-357.I.F.: 5.347 SAF2015-73508-JIN Duration: 01/01/2017-31/12/2019 4. Mahlknecht, Philipp; Iranzo, Alex; Stefani, Ambra; Serradell, Monica; Santamaria, Joan; Martí MJ. Fox Trial Finder. Tolosa, Eduardo; Hogl, Birgit; Poewe, Werner. Sponsored by: Michael J. Fox Foundation for Caveats of Neurodegenerative Risk Parkinson. MJFF_2014_01-11937 Stratification in Idiopathic REM Sleep Duration: 01/09/2015-30/06/2017 Behavior Disorder by Use of the MDS Research for Prodromal Parkinson's Martí MJ. Catalan Network of Multiple Disease. SLEEP. 40(10). I.F.: 4.923 System Atrophy: Biomarkers and Pathophysiology. Sponsored by: Fundació Marató TV3. Editorial / I.F.: 20.257 20142730 Duration: 03/06/2015-30/09/2018 1. Compta Y, Martí MJ. Parkinson disease: What goes around comes around: Martí MJ. LRRK2 peripheral blood cognitive impairment as prodromal mononuclear cells and urine bisample parkinsonism? NATURE REVIEWS collection. NEUROLOGY. 13(12):709-710. I.F.: 20.257 Sponsored by: Michael J. Fox Foundation for Parkinson. MJFF_2015 Duration: 01/02/2016-31/01/2018

215 AREA 4 CLINICAL AND EXPERIMENTAL NEUROSCIENCE

Neurophysiology and functional studies 4.4 of the nervous system

Marta Fernandez (UB) Andreea Larisa Turcu (UB) LOCATION HCB building ADMINISTRATIVE STAFF UB Medical School Mònica Serradell (FCRB)

COLLABORATORS Núria Comes (UB) WEB Carles Gaig (HCB) www.ub.edu/neuroﬁsiologia Francisco Gil (HCB) Esther Gratacós (UB) TEAM LEADER Judith Navarro (HCB) Josep Valls Solé (HCB) Jordi Pales (UB) T. 93 227 54 13 Ana Tercero (HCB) [email protected]

KEYWORDS 1. Neurophysiology STRATEGIC OBJECTIVES GROUP LEADER 2. Motor control and sensorimotor Xavier Gasull (UB) integration Our goal is to expand on scientiﬁc knowledge T. 93 402 45 19 of functional aspects of the nervous system, 3. Neuropathic pain [email protected] with maximum integration of basic and clinical Sleep 4. aspects, fundamentally using 5. Epilepsy neurophysiological techniques. Key words of 6. Glutamate receptors RESEARCHERS our research include motor control, sensory Maria del Mar Carreño (HCB) perception, pain, sleep, epilepsy, neuronal Jordi Casanova (HCB) excitability, ion channels, dry eye and Antonio Jesús Donaire (HCB) glaucoma. Arcadi Gual (UB) Alejandro Iranzo (HCB) Original publications Joan Santamaria (HCB) MAIN LINES OF RESEARCH from 2015 to 2017 David Soto (UB) 1. The participation of subcortical motor YEAR I.F. TOTAL Q1 Q2 POST-DOCTORAL RESEARCHERS systems in the execution of movements, 2015 110.97 27 11 12 Aida Castellanos (IDIBAPS) postural maintenance and reﬂex control. Ana Fernandez (FCRB) 2016 129.87 28 15 8 Startle and prepulse phenomena. 2. Physiology and physiopathology of 2017 123.29 20 15 2 PRE-DOCTORAL RESEARCHERS neuropathic pain. Nociceptive evoked Alba Andres (UB)

TEAM INVOLVED IN OFTARED AGAUR_SGR14 AGAUR_SGR17 Josep Valls Solé

TEAM

216 NEUROPHYSIOLOGY AND FUNCTIONAL STUDIES OF THE NERVOUS SYSTEM 4.4

potentials and reflex reactions to pain. PUBLICATIONS A, Mayer G, Foldvary-Schaefer N, Postuma R, Conscious sensory perception. Oertel W, Lasch S, Marek K, Simuni T, 3. Study of sleep and its disturbances. Originals / I.F.: 123.287 Parkinson’s Progression Markers Initiative. Narcolepsy. Excessive daytime sleepiness Longitudinal assessment of excessive and REM sleep behaviour disorder. 1. Stokholm MG, Iranzo A, Østergaard K, daytime sleepiness in early Parkinson's Restless legs syndrome. Periodic leg Serradell M, Otto M, Svendsen KB, Garrido A, disease. JOURNAL OF NEUROLOGY movements during sleep. Vilas D, Borghammer P, Santamaria J, Møller NEUROSURGERY AND PSYCHIATRY. 4. Epileptic phenomena and their treatment. A, Gaig C, Brooks DJ, Tolosa E, Pavese N. 88(8):653-662. I.F.: 7.349 Status epilepticus. Monitoring of epileptic Assessment of neuroinflammation in seizures. Video-EEG and epidural patients with idiopathic 7. Padilla, Nelly; Fransson, Peter; Donaire, recording. rapid-eye-movement sleep behaviour Antonio; Figueras, Francesc; Arranz, Angela; 5. Characterization of ion channels involved in disorder: a case-control study. LANCET Sanz-Cortes, Magdalena; Tenorio, Violeta; neuronal excitability. Study of sensory NEUROLOGY, THE. 16(10):789-796. Bargallo, Nuria; Junque, Carme; Lagercrantz, transduction and the generation of I.F.: 26.284 Hugo; Aden, Ulrika; Gratacos, Eduard. inflammatory and neuropathic pain. Intrinsic Functional Connectivity in 6. Physiology of aqueous humour drainage 2. Iranzo, Alex; Santamaria, Joan; Valldeoriola, Preterm Infants with Fetal Growth and physiopathology of glaucoma. Ocular Francesc; Serradell, Monica; Salamero, Manel; Restriction Evaluated at 12 Months pathology in aging. Physiology of the ocular Gaig, Carles; Ninerola-Baizan, Aida; Corrected Age. CEREBRAL CORTEX. trabecular meshwork. Physiopathology of Sanchez-Valle, Raquel; Llado, Albert; De 27(10):4750-4758. I.F.: 6.559 dry eye. Marzi, Roberto; Stefani, Ambra; Seppi, Klaus; 7. Axonal excitability and physiology of Pavia, Javier; Hoegl, Birgit; Poewe, Werner; 8. Sirisi S, Elorza-Vidal X, Arnedo T, peripheral nerve reactions to local Tolosa, Eduard; Lomena, Francisco. Armand-Ugón M, Callejo G, Capdevila-Nortes anaesthetics or other types of axonal Dopamine Transporter Imaging Deficit X, López-Hernández T, Schulte U, blocks. Predicts Early Transition to Barrallo-Gimeno A, Nunes V, Gasull X, Estévez 8. Role of glutamate receptors and new Synucleinopathy in Idiopathic Rapid Eye R. Depolarization causes the formation of a accessory proteins. Role of mutations in Movement Sleep Behavior Disorder. ternary complex between GlialCAM, MLC1 these proteins producing neurological ANNALS OF NEUROLOGY. 82(3):419-428. and ClC-2 in astrocytes: implications in diseases. I.F.: 9.890 megalencephalic leukoencephalopathy. HUMAN MOLECULAR GENETICS. 3. Toledano P., Orueta R., Rodríguez-Pintó I., 26(13):2436-2450. I.F.: 5.340 RESEARCH GROUP Valls-Solé J., Cervera R., Espinosa G. NEUROPHYSIOLOGY Peripheral nervous system involvement in 9. Fernández-Arcos A, Iranzo A, Serradell M, systemic lupus erythematosus: Gaig C, Guaita M, Salamero M, Santamaria J. Prevalence, clinical and immunological Diagnostic Value of Isolated Mentalis characteristics, treatment and outcome of Versus Mentalis Plus Upper Limb a large cohort from a single centre. Electromyography in Idiopathic REM AUTOIMMUNITY REVIEWS. 16(7):750-755. Sleep Behavior Disorder Patients I.F.: 8.961 Eventually Developing a Neurodegenerative Syndrome. SLEEP. GROUP LEADER 4. Gaig C, Graus F, Compta Y, Högl B, Bataller 40(4). I.F.: 4.923 Xavier Gasull (UB) L, Brüggemann N, Giordana C, Heidbreder A, Kotschet K, Lewerenz J, Macher S, Martí MJ, 10. Gaig, Carles; Iranzo, Alex; Pujol, Within the field of neurophysiology, the group Montojo T, Pérez-Pérez J, Puertas I, Seitz C, Montserrat; Perez, Hernando; Santamaria, is interested in establishing the role of different Simabukuro M, Téllez N, Wandinger KP, Iranzo Joan. Periodic Limb Movements During ion channels implicated in shaping the A, Ercilla G, Sabater L, Santamaría J, Dalmau J. Sleep Mimicking REM Sleep Behavior excitability of sensory neurons of the dorsal Clinical manifestations of the anti-IgLON5 Disorder: A New Form of Periodic Limb root and trigeminal ganglia, and determining disease. NEUROLOGY. 88(18):1736-1743. Movement Disorder. SLEEP. 40(3). I.F.: 4.923 which alterations occur during inflammatory I.F.: 8.320 and neuropathic pain states. We are especially 11. Martinez-Nicolas A, Guaita M, Santamaría interested on ocular pain after inflammation, 5. Iranzo A, Stefani A, Serradell M, Martí MJ, J, Montserrat JM, Rol MÁ, Madrid JA. injury or dry eye disease. Lomeña F, Mahlknecht P, Stockner H, Gaig C, Circadian impairment of distal skin On the other hand, in trabecular cells that Fernández-Arcos A, Poewe W, Tolosa E, Högl temperature rhythm in patients with sleep regulate aqueous humor flow in the eye and B, Santamaria J, SINBAR (Sleep Innsbruck disordered breathing: The effect of CPAP. intraocular pressure, we are exploring the role Barcelona) group. Characterization of SLEEP. 40(6). I.F.: 4.923 of ion channels that regulate contraction, patients with longstanding idiopathic REM shape and cell volume and how this is related sleep behavior disorder. NEUROLOGY. 12. Gaitán-Peñas H, Apaja PM, Arnedo T, to the physiopathology of glaucoma. 89(3):242-248. I.F.: 8.320 Castellanos A, Elorza-Vidal X, Soto D, Gasull X, Lukacs GL, Estévez R. 6. Amara AW, Chahine LM, Caspell-Garcia C, Leukoencephalopathy -causing CLCN2 Long JD, Coffey C, Högl B, Videnovic A, Iranzo mutations are associated with impaired Cl-

217 AREA 4 CLINICAL AND EXPERIMENTAL NEUROSCIENCE

channel function and trafficking. JOURNAL Navarro-Otano, J.; Juarez-Flores, D.; Vilas, D.; Carreño M., Santamaria J., Iranzo A. Periodic OF PHYSIOLOGY. 595(22):6993-7008. Garrabou, G.; Milisenda, J. C.; Pont-Sunyer, C.; neck myoclonus during sleep. SLEEP I.F.: 4.739 Catalan-Garcia, M.; Guitart-Mampel, M.; MEDICINE. 38:71-72. I.F.: 3.391 Tobias, E.; Cardellach, F.; Valldeoriola, F.; 13. Carreon, Teresia A.; Castellanos, Aida; Iranzo, A.; Tolosa, E. Colonic Oxidative and 3. Matos, Nuria; Gaig, Carles; Santamaria, Gasull, Xavier; Bhattacharya, Sanjoy K. Mitochondrial Function in Parkinson's Joan; Iranzo, Alex. Cataplexy causing Interaction of cochlin and Disease and Idiopathic REM Sleep subdural hematomas. SLEEP MEDICINE. mechanosensitive channel TREK-1 in Behavior Disorder. PARKINSONS DISEASE. 30:15-16. I.F.: 3.391 trabecular meshwork cells inﬂuences the 9816095. I.F.: 1.702 regulation of intraocular pressure. 4. Ramos-Campoy, Oscar; Gaig, Carles; Villas, SCIENTIFIC REPORTS. 7(1):452. I.F.: 4.259 Monica; Iranzo, Alex; Santamaria, Joan. REM Review / I.F.: 2.605 sleep behavior disorder causing subdural 14. Mirallave, Ana; Morales, Merche; Cabib, hematoma. SLEEP MEDICINE. 30:43-44. Christopher; Munoz, Esteban J.; Santacruz, 1. Leote J, Pereira P, Valls-Sole J. Double I.F.: 3.391 Pilar; Gasull, Xavier; Valls-Sole, Josep. peak sensory nerve action potentials to Sensory processing in Huntington's single stimuli in nerve conduction studies. disease. CLINICAL NEUROPHYSIOLOGY. MUSCLE AND NERVE. 55(5):619-625. 128(5):689-696. I.F.: 3.866 I.F.: 2.605 GRANTS FOR RESEARCH IN PROGRESS

15. Pujol M., Pujol J., Alonso T., Fuentes A., Carreño MM. Eficacia y seguridad de la Pallerola M., Freixenet J., Barbé F., Salamero Letters / I.F.: 9.846 estimulación trigeminal externa como M., Santamaría J., Iranzo A. Idiopathic REM tratamiento de la epilepsia resistente a sleep behavior disorder in the elderly 1. Iranzo, Alex; Serradell, Monica; Santamaria, fármacos. Spanish community: A primary care center Joan. Excessive Daytime Sleepiness Does Sponsored by: Instituto de Salud Carlos III study with a two-stage design using video- Not Predict Neurodegeneration in (ISCIII). PI13/00509 polysomnography. SLEEP MEDICINE. Idiopathic REM Sleep Behavior Disorder. Duration: 01/01/2014-30/06/2018 40:116-121. I.F.: 3.391 SLEEP. 40(12). I.F.: 4.923 Casanova-Molla J. Caracterización del daño 16. Barrantes S, Sánchez Egea AJ, González 2. Mahlknecht, Philipp; Iranzo, Alex; Stefani, axonal en la neuropatía por quimioterapia: Rojas HA, Martí MJ, Compta Y, Valldeoriola F, Ambra; Serradell, Monica; Santamaria, Joan; perfil temporal de la degeneración y Simo Mezquita E, Tolosa E, Valls-Solè J. Tolosa, Eduardo; Hogl, Birgit; Poewe, Werner. regeneración axonal y su repercusión en Differential diagnosis between Caveats of Neurodegenerative Risk los diferentes sistemas funcionales. Parkinson's disease and essential tremor Stratification in Idiopathic REM Sleep Sponsored by: Instituto de Salud Carlos III using the smartphone's accelerometer. Behavior Disorder by Use of the MDS (ISCIII). PI 16/00984 PLOS ONE. 12(8):e0183843. I.F.: 2.806 Research for Prodromal Parkinson's Duration: 01/01/2017-31/12/2019 Disease. SLEEP. 40(10). I.F.: 4.923 17. Carreño M., Bien C., Asadi-Pooya A., Gasull X. Bases fisiopatológicas del dolor Marusic P., Pimentel J., Wehner T., Mohanraj crónico: foco en enfermedades R., Uranga J., Gómez-Ibáñez A., Bargalló N., Editorial / I.F.: 10.463 inflamatorias crónicas de la superficie Rumià J., Setoain X., Pintor L., Bailles E., Falip ocular. M., Dalmau J., Gil F., Sperling M., Elisak M., 1. Iranzo A., Silber M. Stop, look, and listen: Sponsored by: Instituto de Salud Carlos III Villanueva V., Roldán P., Boget T., Donaire A., Sleep in movement disorders. MOVEMENT (ISCIII). PI14/00141 Aparicio J., Graus F. Epilepsy surgery in drug DISORDERS. 32(5):633-635. I.F.: 7.072 Duration: 01/01/2015-31/12/2017 resistant temporal lobe epilepsy associated with neuronal antibodies. 2. Stefani A, Iranzo A, Santamaria J, Högl B, Gasull X. RETIC Oftared: Prevencion, EPILEPSY RESEARCH. 129:101-105. I.F.: 2.367 SINBAR (Sleep Innsbruck Barcelona) group. deteccion precoz, tratamiento y Description of sleep paralysis in The rehabilitacion de las patologias oculares. 18. Cisternas A, Aguilar F, Montserrat JM, Àvila Brothers Karamazov by Dostoevsky. Sponsored by: Instituto de Salud Carlos III M, Torres M, Iranzo A, Berenguer J, Vilaseca I. SLEEP MEDICINE. 32:198-200. I.F.: 3.391 (ISCIII). RD16/0008/0014 Effects of CPAP in patients with Duration: 01/01/2017-31/12/2021 obstructive apnoea: is the presence of allergic rhinitis relevant? SLEEP AND Case Reports / I.F.: 13.564 Iranzo A. Detección in-vivo de BREATHING. 21(4):893-900. I.F.: 2.288 alfa-sinucleina en biopsia de glándulas 1. Perez-Carbonell, L.; Silva, C.; Matos, N.; Gaig, salivares menores en pacientes con 19. Casajuana C, López-Pelayo H, Mercedes C.; Iranzo, A.; Santamaria, J. Actigraphy: a trastorno de conducta del sueño REM, Balcells M, Miquel L, Teixidó L, Colom J, Gual useful tool to monitor sleep-related como modelo premotor de la enfermedad A. Working on a Standard Joint Unit: A pilot hypermotor seizures. SLEEP MEDICINE. de Parkinson. test. ADICCIONES. 29(4):227-232. I.F.: 2.077 40:1-3. I.F.: 3.391 Sponsored by: Instituto de Salud Carlos III (ISCIII). PI16/01050 20. Moren, C.; Gonzalez-Casacuberta, I.; 2. Pérez-Carbonell L., Silva C., Gaig C., Duration: 01/01/2017-31/12/2019

218 NEUROPHYSIOLOGY AND FUNCTIONAL STUDIES OF THE NERVOUS SYSTEM 4.4

Valls-Sole J. Estudio de respuestas preconscientes y conscientes al dolor evocado en sujetos sanos y en pacien.tes con polineuropatía de ﬁbra ﬁna. Sponsored by: Instituto de Salud Carlos III (ISCIII). PI13 0526 Duration: 01/01/2014-30/09/2017

Santamaria J. Ictal brain SPECT in the premotor stage of Parkinson disease. Sponsored by: Fundació la Marató TV3. 20143910 Duration: 1/8/2015-31/07/2017

Soto D. Modulación de receptores AMPA por CPT1C: papel en la ﬁsiología neuronal. Sponsored by: Ministerio de Economía y Competitividad. BFU2014-57562-P Duration: 01/01/2015-31/12/2017

DOCTORAL THESES

Gasull X. Role of K2p channel TRESK in nocicepive and chronic pain. PhDstudent: Aida Castellanos Esparraguera

219 AREA 4 CLINICAL AND EXPERIMENTAL NEUROSCIENCE

Muscle research 4.5 and mitochondrial function

TECHNICIANS Esther Tobias (UB) LOCATION

CELLEX building 4B COLLABORATORS Faculty of Medicine Xavier Bosch (HCB) University of Barcelona VISITING SCIENTISTS Sofya Pozdniakova (Institute of Gender in Medicine, Center for Cardiovascular Research, Charite, Germany)

KEYWORDS TEAM LEADER 1. Muscle Josep M. Grau Junyent (HCB) STRATEGIC OBJECTIVES 2. Mitochondria T. 93 227 55 39

3. Cardiomyopathy [email protected] 1. Management of patients with rare diseases 4. Chronic fatigue syndrome (metabolic, mitochondrial and neuromuscular). 5. Septic shock RESEARCHERS 2. Mitochondrial, inﬂammatory, autoimmune Francesc Cardellach (HCB) and toxic muscle disease. Pedro Castro (HCB) 3. Mitotoxicity. Joaquim Fernandez (HCB) 4. Mitochondrial involvement in Gloria Garrabou (CIBER) neurodegeneration and psychiatrics. Josep M Nicolas (HCB) 5. Mitochondrial basis of obstetric outcome. Original publications 6. Cardiomyopathy in alcoholism and from 2015 to 2017 POST-DOCTORAL RESEARCHERS hypertension. 7. YEAR I.F. TOTAL Q1 Q2 Marc Catalán (CIBER) Chronic fatigue syndrome (CFS). Anna Sandra Hernández (HCB) 8. Septic shock and organ failure. 2015 89.97 15 11 2 Constanza Isabel Morén (CIBER) 9. Journalology. 2016 62.86 15 9 6 PRE-DOCTORAL RESEARCHERS 2017 60.31 16 9 4 Sara Fernández (HCB) MAIN LINES OF RESEARCH Laura García (HCB) Ingrid González (FCRB) 1. Diagnosis and management of patients Mariona Guitart (IDIBAPS) with rare diseases, inborn errors of

TEAM INVOLVED IN Diana Luz Juárez (CONACYT) metabolism or neuromuscular disorders CIBERER José Milisenda (HCB) (coordinating 42 groups). Research, CIBEROBN Pedro Juan Moreno (HCB) training, register and biobanking. AGAUR_SGR2017 Anna Peguero (HCB) Josep M. Grau Junyent

TEAM

220 MUSCLE RESEARCH AND MITOCHONDRIAL FUNCTION 4.5

2. Etiology, biomarkers and therapeutics in Antunez-Jorge, Emilia; Fernandez-Rodriguez, 6. Garrabou G, Soriano À, Pinós T, muscle pathology; special focus in inclusion Camino-M.; Alvela-Suarez, Lucia; Casanova-Mollà J, Pacheu-Grau D, Morén C, body myositis, myopathy secondary to Fidalgo-Navarro, Alba; Marcos, García-Arumí E, Morales M, Ruiz-Pesini E, statins and mtDNA Miguel;Wernicke-SEMI Grp; Alcohol Catalán-Garcia M, Milisenda JC, Lozano E, mantainance-syndromes. Alcoholism Grp; Spanish Soc Internal Med Andreu AL, Montoya J, Mensa J, Cardellach F. 3. Mitochondrial toxicity induced by drugs SEMI. Differences Between Alcoholic and Influence of Mitochondrial Genetics on the (antiretrovirals, antibiotics, antipsychotics) Nonalcoholic Patients With Wernicke Mitochondrial Toxicity of Linezolid in or toxic agents (HIV, CO, tobacco). Encephalopathy: A Multicenter Blood Cells and Skin Nerve Fibers. 4. Etiology, biomarkers and therapeutics in Observational Study. MAYO CLINIC ANTIMICROBIAL AGENTS AND neurodegeneration and psychiatrics: PROCEEDINGS. 92(6):899-907. I.F.: 6.686 CHEMOTHERAPY. 61(9): e00542-17. Parkinson disease (familial Parkin and I.F.: 4.302 LRRK2 or idiopathic forms), X-Fragile 2. Alvarez-Mora MI; Rodriguez-Revenga L; syndrome, schizophrenia and autism. Madrigal I; Guitart-Mampel M; Garrabou G; 7. Suárez-Calvet X., Gallardo E., 5. Etiology, biomarkers and therapeutics in Mila M. Impaired Mitochondrial Function Pinal-Fernandez I., De Luna N., Lleixà C., preeclampsia.and intrauterine growth and Dynamics in the Pathogenesis of Díaz-Manera J., Rojas-García R., Castellví I., restriction with associated cardiovascular FXTAS. MOLECULAR NEUROBIOLOGY. Martínez M., Grau J., Selva-O'Callaghan A., Illa fetal remodeling. 54(9):6896-6902. I.F.: 6.190 I. RIG-I expression in perifascicular 6. Pathological mechanisms of alcohol and myofibers is a reliable biomarker of hypertension at cardiocirculatory level: (i) 3. Romero-Moya D, Santos-Ocaña C, dermatomyositis. ARTHRITIS RESEARCH Prognosis of myocardiopathy and Santos-Ocaña C, Castaño J, Garrabou G, AND THERAPY. 19(1):174. I.F.: 4.121 management options; (ii) Muscle and Garrabou G, Rodríguez-Gómez JA, myocardial apoptosis; (iii) Myocardial Ruiz-Bonilla V, Ruiz-Bonilla V, Bueno C, 8. Hernández S, Catalán-García M, Morén C, regeneration and fibrosis; (iv) and Myocyte González-Rodríguez P, González-Rodríguez García-Otero L, López M, Guitart-Mampel M, hyperthrophy (myostatin, IGF-1, Titin, P, Giorgetti A, Perdiguero E, Perdiguero E, Milisenda J, Coll O, Cardellach F, Gratacós E, FGF-21). Prieto C, Moren-Nuñez C, Moren-Nuñez C, Miró Ò, Garrabou G. Placental Mitochondrial 7. Clinical and functional repercussions of Fernández-Ayala DJ, Fernández-Ayala DJ, Toxicity, Oxidative Stress, Apoptosis And CFS. (i) Long-term multidisciplinar therapy, Victoria Cascajo M, Victoria Cascajo M, Adverse Perinatal Outcomes In (ii) Role of co-morbidity, (iii) Influence of Velasco I, Velasco I, Canals JM, Canals JM, Hiv-Pregnancies Under Antiretroviral chemicals and environment. Canals JM, Canals JM, Montero R, Montero R, Treatment Containing Zidovudine. 8. Clinical and translational research on septic Yubero D, Jou C, Jou C, López-Barneo J, JOURNAL OF ACQUIRED IMMUNE shock and multiorgan failure. Research on López-Barneo J, Cardellach F, Cardellach F, DEFICIENCY SYNDROMES. 75(4):E113-E119. antibiotic policies in critically-ill patients. Muñoz-Cánoves P, Muñoz-Cánoves P, I.F.: 3.935 Critical care issues of special populations: Muñoz-Cánoves P, Muñoz-Cánoves P, Artuch elderly patients, hemato-oncological R, Artuch R, Navas P, Navas P, Menendez P, 9. Santacatterina F., Sánchez-Aragó M., patients, patients with autoimmune Menendez P, Menendez P. Genetic rescue of Catalán-García M., Garrabou G., Arenas C., diseases, patients with Human Mitochondrial and Skeletal Muscle Grau J., Cardellach F., Cuezva J. Pyruvate Immunodeficiency infection, patients with Impairment in an IPSCs Model of kinase M2 and the mitochondrial ATPase imported tropical diseases and others. Coenzyme Q10 Deficiency. STEM CELLS. Inhibitory Factor 1 provide novel 9. Journalology of biomedical journals: 35(7):1687-1703. I.F.: 5.599 biomarkers of dermatomyositis: A research of editorial and ethical policies of metabolic link to oncogenesis. JOURNAL biomedical journals. 4. Hernandez S., Moren C., Catalán-García M., OF TRANSLATIONAL MEDICINE. 15(1):29. Lopez M., Guitart-Mampel M., Coll O., Garcia I.F.: 3.786 L., Milisenda J., Justamante A., Gatell J., PUBLICATIONS Cardellach F., Gratacos E., Miro Ò., Garrabou 10. Torrell H., Alonso Y., Garrabou G., Mulet D., G. Mitochondrial toxicity and caspase Catalán M., Valiente-Pallejà A., Carreño-Gago Originals / I.F.: 60.311 activation in HIV pregnant women. L., García-Arumí E., Montaña E., Vilella E., JOURNAL OF CELLULAR AND MOLECULAR Martorell L. Mitochondrial dysfunction in a 1. Chamorro, Antonio J.; Roson-Hernandez, MEDICINE. 21(1):26-34. I.F.: 4.499 family with psychosis and chronic fatigue Beatriz; Medina-Garcia, Jose-A.; syndrome. MITOCHONDRION. 34:1-8. Muga-Bustamante, Roberto; Fernandez-Sola, 5. Morén C., González-Casacuberta I., I.F.: 3.704 Joaquin; Martin-Gonzalez, M. -Candelaria; Álvarez-Fernández C., Bañó M., Seco-Hernandez, Elena; Novo-Veleiro, Catalán-Garcia M., Guitart-Mampel M., 11. Bosch X, Montori E, Guerra-García M, Ignacio; Suarez-Cuervo, Carlos; Mateos-Diaz, Juárez-Flores D., Tobías E., Milisenda J., Costa-Rodríguez J, Quintanilla MH, Ana M.; Monte-Secades, Rafael; Cardellach F., Gatell J., Sánchez-Palomino S., Tolosa-Chapasian PE, Moreno P, Guasch N, Machado-Prieto, Begona; Puerta-Louro, Garrabou G. HIV-1 promonocytic and López-Soto A. A comprehensive evaluation Ruben; Prada-Gonzalez, Cristina; lymphoid cell lines: An in vitro model of in of the gastrointestinal tract in Fernandez-Rial, Alvaro; Sabio-Repiso, vivo mitochondrial and apoptotic lesion. iron-deficiency anemia with predefined Patricia; Vazquez-Vigo, Rocio; Antoli-Royo, JOURNAL OF CELLULAR AND MOLECULAR hemoglobin below 9mg/dL: A prospective Ana-C.; Gomila-Grange, Aina; Felipe-Perez, MEDICINE. 21(2):402-409. I.F.: 4.499 cohort study. DIGESTIVE AND LIVER Nieves-C.; Sanvisens-Berge, Arantza; DISEASE. 49(4):417-426. I.F.: 3.061

221 AREA 4 CLINICAL AND EXPERIMENTAL NEUROSCIENCE

12. Bosch X., Monclús E., Escoda O., Letters / I.F.: 8.306 GRANTS FOR RESEARCH IN PROGRESS Guerra-García M., Moreno P., Guasch N., López-Soto A. Unintentional weight loss: 1. Puigví L, Baumann T, Fernández S, Castro P, Cardellach F. Molecular links between Clinical characteristics and outcomes in a Pereira A, Merino A. Massive diabetes and neurodegenerative prospective cohort of 2677 patients. PLOS erythrophagocytosis by peripheral disorders. ONE. 12(4):e0175125. I.F.: 2.806 monocytes and neutrophils in Sponsored by: Instituto de Salud Carlos III parvovirus-B19 autoimmune hemolytic (ISCIII). PIE14/00061 13. Bosch X., Montori E., Guerra-García M., anemia. ANNALS OF HEMATOLOGY. Duration: 01/01/2015-31/12/2018 Costa-Rodríguez J., Quintanilla M., 96(5):881-882. I.F.: 3.083 Tolosa-Chapasian P., Moreno P., Guasch N., Cardellach F. Influencia de la dieta en la López-Soto A. Haemoglobin responses to 2. Fernandez, Sara; Nicolas, David; Pericas, modulación mitocondrial y de transfusion in severe iron deficiency Juan M.; Castro Rebollo, Pedro; Vila, Jordi; cardiomiocinas del remodelado anaemia: potential impact of Miro, Josep M.; Blanco, Jose L.; Nicolas, Josep cardiovascular fetal asociado al gastrointestinal disorders. VOX M. A case of Mycoplasma hominis crecimiento intrauterino restringido. SANGUINIS. 112(3):257-267. I.F.: 2.192 disseminated infection in a human Sponsored by: Instituto de Salud Carlos III immunodeficiency virus-1-infected (ISCIII). PI15/00817 14. Santolaya M, Aldea M, Grau J, Estrada M, pregnant woman with Duration: 01/01/2016-31/12/2018 Barau M, Buron A, Francesc M, Castell A, hypogammaglobulinemia. JOURNAL OF Rodriguez C, Gascón P, Rius P, MICROBIOLOGY, IMMUNOLOGY AND Cardellach F. Elaboración de un modelo in Guayta-Escolies R, PROCOLON research INFECTION. 50(1):118-119. I.F.: 2.973 vitro de neuonas dopaminérgicas group (all members of this group are listed in derivadas de pacientes con enfermedad Author Note). Evaluating the 3. Zamora C; Tomas X; Milisenda J. Focal de Parkinson: plataforma para estudios appropriateness of a community myositis associated to radiculopathy. moleculares y terapéuticos Investigador. pharmacy model for a colorectal cancer MEDICINA CLINICA. 149(8):371-372. I.F.: 1.125 Sponsored by: Fundación Privada Cellex. screening program in Catalonia (Spain). 17/420 JOURNAL OF ONCOLOGY PHARMACY 4. Poch E; Garrabou G; Alcubilla-Prats P. Duration: 29/05/2017-31/12/2018 PRACTICE. 23(1):26-32. I.F.: 1.735 Reply. MEDICINA CLINICA. 149(6):271-272. I.F.: 1.125 Castro P. Caracterización de la disfunción 15. Moren, C.; Gonzalez-Casacuberta, I.; endotelial en los síndromes sépticos e Navarro-Otano, J.; Juarez-Flores, D.; Vilas, D.; influencia del defibrotide. Garrabou, G.; Milisenda, J. C.; Pont-Sunyer, C.; Case Reports / I.F.: 8.538 Sponsored by: Instituto de Salud Carlos III Catalan-Garcia, M.; Guitart-Mampel, M.; (ISCIII). PI12/00832 Tobias, E.; Cardellach, F.; Valldeoriola, F.; 1. Gomez-Junyent, Joan; Jesus Pinazo, Maria; Duration: 01/01/2013-31/06/2017 Iranzo, A.; Tolosa, E. Colonic Oxidative and Castro, Pedro; Fernandez, Sara; Mas, Jordi; Mitochondrial Function in Parkinson's Chaguaceda, Cristian; Pellice, Martina; Fernandez-Solà J. Cell Death in Alcoholic Disease and Idiopathic REM Sleep Gascon, Joaquim; Munoz, Jose. Human Heart and Muscle. Behavior Disorder. PARKINSONS DISEASE. African Trypanosomiasis in a Spanish Sponsored by: National Institutes of Health (NIH). 9816095. I.F.: 1.702 traveler returning from Tanzania. PLOS 1 U01 AA021122 NEGLECTED TROPICAL DISEASES. Duration: 01/05/2015-30/04/2017 16. Cochon L, Ovalle A, Nicolás JM, Baez AA. 11(3):e0005324. I.F.: 3.834 Acute Care Diagnostic Collaboration: Fernàndez-Solà J. Paper de les noves Bayesian modeling comparative 2. Fervienza A., Bodro M., Castro P., cardiomiocines FGF21 i Metrnl en el dany diagnostic assessment of lactate, Hernández S., Teixidó I., Espinosa G., Cervera cardíac induït per l'alcoholisme i la procalcitonin and CRP in risk stratified R. Brain abscess due to Listeria hipertensió arterial. population by Mortality in ED (MEDS) monocytogenes after HELLP syndrome in Sponsored by: Fundació la Marató de TV3. score. AMERICAN JOURNAL OF a patient with antiphospholipid syndrome. 20153331 EMERGENCY MEDICINE. 35(4):564-568. LUPUS. 26(9):1002-1004. I.F.: 2.454 Duration: 29/06/2016-28/06/2019 I.F.: 1.494 3. Milisenda J., Rico Caballero V., García A., Garrabou G, Moren C. Alteraciones Tomás X., Grau J. «Extended» Beevor's sing mitocondriales en modelos celular de la Review / I.F.: 1.47 as a new clinical sign in sporadic inclusion Enfermedad de Parkinson. body myositis. MEDICINA CLINICA. Sponsored by: Consejo Nacional de 1. Planavila, Anna; Fernandez-Sola, 148(8):e43. I.F.: 1.125 Ciencia y Tecnología (CONACYT). 328988 Joaquim; Villarroya, Francesc. Cardiokines Duration: 01/01/2014-31/12/2017 as Modulators of Stress-Induced Cardiac 4. Alcubilla-Prats, Pau; Sole, Manel; Botey, Disorders. ADVANCES IN PROTEIN Albert; Maria Grau, Josep; Garrabou, Gloria; Grau JM. Identificación de nuevos antígenos CHEMISTRY AND STRUCTURAL BIOLOGY. Poch, Esteban. Kidney involvement in en pacientes con miopatía inflamatoria. 108:227-256. I.F.: 1.470 MELAS syndrome: Description of 2 cases. Sponsored by: Instituto de Salud Carlos III (ISCIII). MEDICINA CLINICA. 148(8):357-361. 15/02100 I.F.: 1.125 Duration: 01/01/2015-31/12/2018

222 MUSCLE RESEARCH AND MITOCHONDRIAL FUNCTION 4.5

DOCTORAL THESES

Grau JM, Garrabou G. Mitochondrial proﬁle and amyloidogenic molecules in sporadic inclusion body myositis. PhD student: Marc Catalán Garcia

Coll O, Garrabou G. Perinatal outcomes, mitochondrial toxicity and apoptosis in hiv-treated pregnant women and in utero exposed newborns. PhD student: Anna Sandra Hernández Aguado

223 AREA 4 CLINICAL AND EXPERIMENTAL NEUROSCIENCE

Pathophysiology and treatment of 4.6 neurodegenerative disorders

Marta García (UB) Ened Rodríguez (UB) LOCATION Cristina Salado (UB) CELLEX building 3B Nuria Suelves (UB) UB School of Medicine

TECHNICIANS Georgina Bombau (IDIBAPS) Mireia Galofré (IDIBAPS) Cristina Herranz (UB) Ana López (CIBER) KEYWORDS Maite Muñoz (UB) 1. Huntington’s disease TEAM LEADER Unai Perpiña (UB) 2. Motor and cognitive function Jordi Alberch (UB) 3. Psychiatric disturbances T. 93 403 52 85

4. Neuroprotection [email protected] STRATEGIC OBJECTIVES 5. Trophic factors 6. Stem cells 1. Study of the cellular and molecular bases RESEARCHERS involved in neuronal dysfunction and death Josep M Canals (UB) associated to motor, psychiatric and Silvia Ginés (UB) cognitive alterations in basal ganglia Esther Pérez (UB) neurodegenerative disorders. 2. Use of stem cell technology to differentiate POST-DOCTORAL RESEARCHERS Original publications neurons for using in regenerative medicine Glòria Blázquez (UB) for neurodegenerative disorders. from 2015 to 2017 Verónica Brito (UB)

YEAR I.F. TOTAL Q1 Q2 Albert Giralt (UB) Giovanni Iacono (IDIBAPS) MAIN LINES OF RESEARCH 2015 49.83 9 8 1 Mercè Massana (IDIBAPS) 2016 73.96 15 11 4 Andrés Míguez (IDIBAPS) 1. Group of neuroprotection and neuronal Ana Saavedra (CIBER) 2017 91.75 14 13 1 plasticity in Huntington’s disease. PI: Philip Gordon Thomas Sanders (IDIBAPS) Jordi Alberch: To study the mechanisms that modulate cortico-striatal connectivity PRE-DOCTORAL RESEARCHERS for understanding the intracellular Elena Álvarez (CIBER) mechanisms to develop molecules that TEAM INVOLVED IN Andrea Comella (UB) modulate neuronal plasticity for the CIBERNED Jordi Creus (UB) treatment of Huntington’s disease. HD-iPSCs Consortium Sara Fernández (UB) AGAUR_SGR14 Gerardo García (UB) Jordi Alberch

TEAM

224 PATHOPHYSIOLOGY AND TREATMENT OF NEURODE GENERATIVE DISORDERS 4.6

2. Group of kinases and phosphatases in Gines S., Lawrence Marsh J., Conforti P., JOURNAL OF NEUROINFLAMMATION. neuronal function and dysfunction. PI: Cattaneo E., Santimone I., Squitieri F., Lashuel 14(1):54. I.F.: 5.102 Esther Pérez-Navarro: The group is H., Petricca L., Caricasole A. Phosphorylation interested in studying the involvement of of huntingtin at residue T3 is decreased in 8. Giralt A., Gómez-Climent M., Alcalá R., kinases and phosphatases in the control of Huntington’s disease and modulates Bretin S., Bertrand D., María Delgado-García J., motor and cognitive processes in mutant huntingtin protein conformation. Pérez-Navarro E., Alberch J., Gruart A. The Huntington’s disease. PROCEEDINGS OF THE NATIONAL AMPA receptor positive allosteric 3. Group of neurodegeneration and ACADEMY OF SCIENCES OF THE UNITED modulator S 47445 rescues in vivo cognitive dysfunction in Huntington’s STATES OF AMERICA. CA3-CA1 long-term potentiation and Disease. PI: Silvia Ginés: The research 114(50):E10809-E10818. I.F.: 9.661 structural synaptic changes in old mice. group is interested in defining the molecular NEUROPHARMACOLOGY. 123:395-409. mechanisms involved in depressive, 4. Martín-Ibáñez R., Pardo M., Giralt A., Miguez I.F.: 5.012 cognitive and motor disorders in A., Guardia I., Marion-Poll L., Herranz C., Huntington’s disease. Esgleas M., Barriga G., Edel M., Vicario-Abejón 9. Martín-Ibáñez R, Guardia I, Pardo M, 4. Group of stem cells and regenerative C., Alberch J., Girault J., Chan S., Kastner P., Herranz C, Zietlow R, Vinh NN, Rosser A, medicine. PI: Josep M. Canals: To study the Canals J. Helios expression coordinates Canals JM. Insights in spatio-temporal mechanisms underlying the differentiation the development of a subset of characterization of human fetal neural of stem cells into neurons, for exploring the striatopallidal medium spiny neurons. stem cells. EXPERIMENTAL NEUROLOGY. cellular mechanisms involved in DEVELOPMENT. 144(8):1566-1577. I.F.: 5.843 291:20-35. I.F.: 4.706 Huntington’s and Parkinson’s disease. Another line of research is the 5. Romero-Moya D, Santos-Ocaña C, 10. Saavedra A, Fernández-García S, Cases characterization of extrinsic factors and Santos-Ocaña C, Castaño J, Garrabou G, S, Puigdellívol M, Alcalá-Vida R, Martín-Flores new transcription factors of human and Garrabou G, Rodríguez-Gómez JA, N, Alberch J, Ginés S, Malagelada C, mouse brain development. Ruiz-Bonilla V, Ruiz-Bonilla V, Bueno C, Pérez-Navarro E. Chelerythrine promotes González-Rodríguez P, González-Rodríguez Ca(2+)-dependent calpain activation in P, Giorgetti A, Perdiguero E, Perdiguero E, neuronal cells in a PKC-independent PUBLICATIONS Prieto C, Moren-Nuñez C, Moren-Nuñez C, manner. BIOCHIMICA ET BIOPHYSICA Fernández-Ayala DJ, Fernández-Ayala DJ, ACTA-GENERAL SUBJECTS. Originals / I.F.: 91.748 Victoria Cascajo M, Victoria Cascajo M, 1861(4):922-935. I.F.: 4.702 Velasco I, Velasco I, Canals JM, Canals JM, 1. Lim R., Salazar L., Wilton D., King A., Canals JM, Canals JM, Montero R, Montero R, 11. Lao-Peregrín C., Ballesteros J., Fernández Stocksdale J., Sharifabad D., Lau A., Stevens Yubero D, Jou C, Jou C, López-Barneo J, M., Zamora-Moratalla A., Saavedra A., Gómez B., Reidling J., Winokur S., Casale M., López-Barneo J, Cardellach F, Cardellach F, Lázaro M., Pérez-Navarro E., Burks D., Martín Thompson L., Pardo M., Díaz-Barriga A., Muñoz-Cánoves P, Muñoz-Cánoves P, E. Caffeine-mediated BDNF release Straccia M., Sanders P., Alberch J., Canals J., Muñoz-Cánoves P, Muñoz-Cánoves P, Artuch regulates long-term synaptic plasticity Kaye J., Dunlap M., Jo L., May H., Mount E., R, Artuch R, Navas P, Navas P, Menendez P, through activation of IRS2 signaling. Anderson-Bergman C., Haston K., Finkbeiner Menendez P, Menendez P. Genetic rescue of ADDICTION BIOLOGY. 22(6):1706-1718. S., Kedaigle A., Gipson T., Yildirim F., Ng C., Mitochondrial and Skeletal Muscle I.F.: 4.603 Milani P., Housman D., Fraenkel E., Allen N., Impairment in an IPSCs Model of Kemp P., Atwal R., Biagioli M., Gusella J., Coenzyme Q10 Deficiency. STEM CELLS. 12. Suelves N, Kirkham-McCarthy L, Lahue MacDonald M., Akimov S., Lim R., Salazar L., 35(7):1687-1703. I.F.: 5.599 RS, Ginés S. A selective inhibitor of histone Wilton D., King A., Stocksdale J., Sharifabad D., deacetylase 3 prevents cognitive deficits Lau A., Stevens B., Reidling J., Winokur S., 6. García-Díaz Barriga G, Giralt A, and suppresses striatal CAG repeat Casale M. Developmental alterations in Anglada-Huguet M, Gaja-Capdevila N, Orlandi expansions in Huntington's disease mice. Huntington's disease neural cells and JG, Soriano J, Canals JM, Alberch J. 7,8 SCIENTIFIC REPORTS. 7(1):6082. I.F.: 4.259 pharmacological rescue in cells and mice. Dihydroxyflavone ameliorates cognitive NATURE NEUROSCIENCE. 20(5):648-660. and motor deficits in a Huntington's 13. Daldin M., Fodale V., Cariulo C., Azzollini L., I.F.: 17.839 disease mouse model through specific Verani M., Martufi P., Spiezia M., Deguire S., activation of the PLCγ1 pathway. HUMAN Cherubini M., MacDonald D., Weiss A., 2. Giralt A, Brito V, Chevy Q, Simonnet C, Otsu MOLECULAR GENETICS. 26(16):3144-3160. Bresciani A., Vonsattel J., Petricca L., Marsh J., Y, Cifuentes-Díaz C, de Pins B, Coura R, I.F.: 5.340 Gines S., Santimone I., Marano M., Lashuel H., Alberch J, Ginés S, Poncer JC, Girault JA. Squitieri F., Caricasole A. Polyglutamine Pyk2 modulates hippocampal excitatory 7. Pulido-Salgado M., Vidal-Taboada J., Garcia expansion affects huntingtin conformation synapses and contributes to cognitive Diaz-Barriga G., Serratosa J., Valente T., in multiple Huntington's disease models. deficits in a Huntington's disease model. Castillo P., Matalonga J., Straccia M., Canals J., SCIENTIFIC REPORTS. 7(1):5070. I.F.: 4.259 NATURE COMMUNICATIONS. 8:15592. Valledor A., Solà C., Saura J. Myeloid C/EBPβ I.F.: 12.124 deficiency reshapes microglial gene 14. Illa M., Brito V., Pla L., Eixarch E., expression and is protective in Arbat-Plana A., Batallé D., Muñoz-Moreno E., 3. Cariulo C., Azzollini L., Verani M., Martufi P., experimental autoimmune Crispi F., Udina E., Figueras F., Ginés S., Boggio R., Chiki A., Deguire S., Cherubini M., encephalomyelitis. Gratacós E. Early Environmental

225 AREA 4 CLINICAL AND EXPERIMENTAL NEUROSCIENCE

Enrichment Enhances Abnormal Brain Gines S. Cdk5 como nueva diana Connectivity in a Rabbit Model of terapéutica y biomarcador del trastorno Intrauterine Growth Restriction. FETAL depresivo en la enfermedad de DIAGNOSIS AND THERAPY. I.F.: 2.699 Huntington. Sponsored by: Ministerio de Economía y Competitividad. SAF2015-67474-R Review / I.F.: 2.466 Duration: 01/12/2015-31/01/2018

1. Cherubini M., Ginés S. Mitochondrial Pérez E. Optimización y desarrollo de un fragmentation in neuronal degeneration: agente terapéutico basado en ácidos Toward an understanding of HD striatal nucleicos para el tratamiento de la susceptibility. BIOCHEMICAL AND enfermedad de Huntington. BIOPHYSICAL RESEARCH Sponsored by: Ministerio de Economía y COMMUNICATIONS. 483(4):1063-1068. Competitividad. RTC-2015-3731-1 I.F.: 2.466 Duration: 29/09/2015-31/12/2017

Pérez E. Evaluación de la eﬁcacia de GRANTS FOR RESEARCH IN PROGRESS inhibidores epigenéticos en modelos experimentales de patologías humanas. Alberch J. Enfermedades Sponsored by: Ministerio de Economía y neurodegenerativas: enfermedad de Competitividad. RTC-2015-3898-1 Huntington. Duration: 29/09/2015-31/12/2017 Sponsored by: Ministerio de Economía y Competitividad. CIBERNED Pérez E. Alteraciones de la lámina nuclear y Duration: 01/01/2006-31/12/2019 de la traducción proteica como nuevos mecanismos patogénicos en la Alberch J. Modulation of synaptic plasticity enfermedad de Huntington. deﬁcits as a therapeutic strategy for Sponsored by: Ministerio de Economía y Huntington’s disease. Competitividad. SAF2016-0873R Sponsored by: Fundació la Marató de TV3. Duration: 30/12/2016-30/12/2019 Duration: 04/03/2015-28/02/2018

Canals JM. Desarrollo, diferenciación y DOCTORAL THESES maduración neuronal en la enfermedad de Huntington. Pérez E. PKC and nuclear lamina Sponsored by: Ministerio de Ciencia e alterations: Involvement in Huntington’s Innovación. SAF2015-66505-R disease pathophysiology. Duration: 01/01/2016-31/12/2019 PhD student: Rafael Alcalá Vida

Canals JM. Centre per a la producció i Canals JM, Martín R. Caracterización de validació de teràpies avançades - ub factores implicados en el desarrollo (cat-ub). estriatal. Sponsored by: Agència per a la Competitivitat PhD student: Inés Guardia Pena de l'Empresa (ACCIÓ). TECDTP15-1-0022 Duration: 01/01/2016-31/12/2017

Canals JM. ADVANCECAT: acceleradora pel desenvolupament de teràpies avançades a Catalunya (ADVANCECAT: accelerating development for advanced therapies in Catalonia). Sponsored by: Agència per a la Competitivitat de l'Empresa. RIS3CAT Duration: 01/01/2016-31/12/2019

Canals JM. Red de Terapia Celular. Sponsored by: Instituto de Salud Carlos III (ISCIII). RD16/0011/0012 Duration: 01/01/2017-31/12/2021

226 BIOLOGICAL BASES OF PSYCHIATRIC DISORDERS AND NUCLEAR PSYCHIATRY 4.7

Biological bases of psychiatric disorders 4.7 and nuclear psychiatry

Mercè Torra (HCB) Manuel Valdés (HCB) LOCATION HCB building POST-DOCTORAL RESEARCHERS Mercè Balcells (HCB-FCRB) Pablo Barrio (HCB) KEYWORDS Ana Blazquez (HCB) 1. Schizophrenia Caterina del Mar Bonnín (FCRB) 2. Bipolar disorders Bibiana Cabrera (CIBER) 3. Psychiatry Silvia Cañizares (HCB) 4. Addiction TEAM LEADER Myriam Cavero (HCB) 5. Child and adolescent psychiatry Miquel Bernardo (HCB) Elena de la Serna (CIBER) and psychology T. 93 227 54 00 (Ext.: 3142) Itziar Flamarique (HCB) 6. Depression [email protected] Iria Grande (HCB) Diego Hidalgo (IDIBAPS) Ester Jiménez (IDIBAPS) Gisela Mezquida (UB) GROUP LEADERS Miquel Monràs (HCB) Original publications Miquel Bernardo (HCB) from 2015 to 2017 Andrea Murru (HCB) T. 93 227 54 00 (Ext.: 3142) Isabella Pacchiarotti (HCB) [email protected] YEAR I.F. TOTAL Q1 Q2 Olga Puig (HCB) Soledad Romero (HCB) 2015 243.58 66 32 27 Joseﬁna Castro (HCB) Mireia Rosa (IDIBAPS) 2016 424.43 89 62 14 T. 93 227 20 70 Brissa Sole (IDIBAPS) [email protected] 2017 301.37 84 51 28 Carla Torrent (IDIBAPS) Imma Torres (CIBER) Antoni Gual (HCB) Anna Torres (HCB) TEAM INVOLVED IN T. 93 227 54 00 (Ext.: 3167) Marc Valenti (HCB) CIBERSAM [email protected]

AGAUR_SGR14 PRE-DOCTORAL RESEARCHERS Red de Trastornos Adictivos Gisela Sugranyes (HCB-IDIBAPS) Silvia Amoretti (CIBER) (RTA-RETICS) T. 93 227 54 00 (Ext.: 4187) Daniel Boloc (IDIBAPS-UB) [email protected] Pol Bruguera (HCB-FCRB) Adriana Fortea (HCB) Eduard Vieta (HCB) Marina Garriga (IDIBAPS) T. 93 227 54 00 (Ext.: 3130) Daniel Ilzarbe (IDIBAPS) AWARDS [email protected] Premi excel.lència professional Maria Luisa Imaz (HCB) Institution: Col·legi Oﬁcial de Metges de Barcelona Hugo López (HCB-FCRB) (COMB) Laia Miquel (HCB-IDIBAPS) Awardee/s: Miquel Bernardo Laura Nuño (HCB) RESEARCHERS Giovanni Oriolo (HCB) 2017 Research award in the area of Susana Andrés (HCB) biological psychiatry Maria Teresa Plana (HCB) Inmaculada Baeza (HCB) Estela Salagre (CIBER) Institution: World Federation of Societies of Antonio Benabarre (HCB) Biological Psychiatry (WFSBP) Jose Sánchez (CIBER) Miquel Bioque (HCB) Awardee/s: Eduard Vieta Elia Valls (CIBER) Rosa Catalán (HCB-UB) The 2017 Simon Bolivar Award on behalf Luisa Garcia-Esteve (HCB) of the APA - APAF TECHNICIANS Clemente Garcia (HCB) Fleur Marie Booth Braddick (FCRB) Institution: The American Psychiatric Association Jose Manuel Goikolea (HCB) (APA) Awardee/s: Eduard Vieta Álvaro Castañón (FCRB) Fernando Gutierrez (HCB) Alicia Durán (FCRB) The Samuel Gershon Awards for Amalia Lafuente (UB) Junior Investigators Silvia Matrai (FCRB) Luisa Lazaro (HCB) Rosa Maria Palaus (FCRB) Institution: International Society for Bipolar Disorders Francesc Lomeña (HCB) Awardee/s: Esther Jimenez Martinez Ana Isabel Martinez (HCB) ADMINISTRATIVE STAFF NARSAD Young Investigator Award Rocío Martín-Santos (HCB) Anna Folch (CIBER) Institution: Brain and Behaviour Research Sergi Mas (UB) Foundation, US. Guillem Masana (HCB) Awardee/s: Gisela Sugranyes NURSING STAFF Astrid Morer (HCB) Ana Esmeralda Meseguer (CIBER) Emili Letang 2017-2018 Eduard Parellada (HCB-UB) Lídia Teixidó (HCB) Institution: HCB Rafael Penadés (HCB-UB) Awardee/s: Giovanni Oriolo Luis Pintor (HCB-UB)

227 228

GROUP GROUP AREA 4 Joseﬁna Castro-Fornieles Miquel Bernardo therapeutical approaches. neuroimaging), aswellpsychologicaland hormone factors,molecularpsychiatryand the disease(genetics,neuromodulators, mechanisms involvedinthedevelopmentof neurobiological, anatomofunctional from thedifferentsperspectives: Our groupstudyseverepsychiatricdisorders STRATEGIC OBJECTIVES Lluïsa Ortega(HCB) Clara Oliveras(HCB) Ricard Navinés(HCB) Sílvia Mondón(HCB) Ana IsabelLopez(HCB) Anna Lligoña(HCB) Patricia Gassó(UB) Neus Freixa(HCB) Emilio Fernández-Egea(CIBER) COLLABORATORS

CLINICAL ANDEXPERIMENTAL NEUROSCIENCE thecourseofillness. associatedwithtreatmentresponseand neurobiologicalbasesandclinicalindicators Thedepressiongroupstudiesthe - childrenandadolescents. thedevelopmentofpsychoticdisordersin studyoftheneuralmechanismsunderlying neurodevelopmentaldisorders,andthe obsessive-compulsivedisorder, disorders,eating psychologyfocuseson:psychotic Thechildandadolescentpsychiatry - schizophrenia. episodes,resistantandcomorbid unitfocusesonfirstandsecondpsychotic TheSchizophreniaandrelateddisorders - detectionandpreventionofrecurrences. efficacyoftreatmentsfortheearly theneurobiologicalmechanismsand Thebipolardisordersgroupinvestigates - MAIN LINESOFRESEARCH SCHIZOPHRENIA RESEARCH GROUP psychiatric instruments),perinatalandgenderrelated disorders. adjustmentandvalidationofnew theirrelationshiptoenvironmental personalitydisorders(diagnosticsystems, Othermainresearchlinesfocuseson - aspectsinthemainneurologicaldiseases. focusesonpsychiatricandpsychological usedisorders.Theliaisonpsychiatry biomarkersofbrainimpairmentincannabis noveltherapeuticapproachesand usedisorders,aswellondeveloping detectionandbriefinteventionsinalcohol Theaddictiongroupfocusesonearly - Psychiatry oftheNeuroscience Instituteofthe Department ofChild andAdolescent This researchgroup isintegratedinthe Josefina Castro-Fornieles GROUP LEADER PSYCHIATRY ANDPSYCHOLOGY CHILD ANDADOLESCENT RESEARCH GROUP relationship toAmericanresearchnetworks. research inschizophreniaandmaintainclose We collaboratewithaEuropeannetworkof international researchgroups. with otherIDIBAPS,CIBERSAM,and in translationalandinnovativeinvestigation) have activecollaboration(multicenterstudies resistant andcomorbidschizophrenia.We episodes, childhoodandadolescent-onset, The researchiscenteredonthestudyoffirst care, researchandteaching. schizophrenia andrelateddisordersinclinical This interdisciplinarygroupfocuseson Miquel Bernardo GROUP LEADER (HCB) (HCB) We havedescribed age-relatedchangesin development ofpsychotic disordersinyouth. neural mechanismsunderlyingthe Dr. Sugranyes’groupaimstounderstand the Gisela Sugranyes GROUP LEADER RISK ANDEARLYPSYCHOSIS MULTIMODAL NEUROIMAGINGINHIGH 50/50 PROGRAM cannabis dependentindividuals. treatment monitorizationandrehabilitationof biomarkers ofchroniccannabismisusefor social healthproblems,togetherwithidentifying use” thatmightleadtophysical,mentaland In CUD,weaimtodefinetheconceptof“risky found inalcoholicpatients. treating cognitiveimpairmentscommonly as wellonnoveltherapeuticmethodsfor early detectionandbriefinterventionsinAUD, respectively). Morespecifically,weworkon cannabis usedisorders(AUDandCUD Our groupfocusesmainlyonalcoholuseand Antoni Gual GROUP LEADER ADDICTIONS GROUP RESEARCH GROUP Adolescent PsychiatryCenterofYale. Pittsburgh (UnitedStates),andtheChild Neuopsychopharmacology, theUniversityof collaborates withtheEuropeanCollegeof At theinternationallevelgroup with othercenterswithintheCIBERSAM. departments inthesamecenteraswell collaborations withotherneuroscience The grouphasestablishedimportant neuroimaging andneurobiology. with groupsspecializedingenetics, facilitate clinicalresearchandtocollaborate Hospital ClinicofBarcelona.Theaimisto (HCB) (HCB-IDIBAPS)

GROUP Gisela Sugranyes GROUP Antoni Gual functional outcomes. factors predictingtransitiontopsychosisand level, priorityisgiventotheidentiﬁcationof and cognitivephenotypes.Onatranslational between neuroimagingmeasuresandclinical ﬁndings, andtoexploretherelationship neurochemical underpinningsofthese We havenowsetouttoexplorethe to highercognitivefunctions. early stagesofpsychosisinbrainareasrelated structure inchildrenandadolescentsthe group-related changesinfunctionand brain functioninhealthyparticipants,and BIOLOGICAL BASES OFPSYCHIATRIC DISORDERSANDNUCLEARPSYCHIATRY 4.7 229 230 3. BULLETIN. and BipolarDisorder. Offspring ofProbandsWithSchizophrenia Neurodevelopmental Continuumin Neuroimaging Evidenceofa Castro-Fornieles J. E, MorenoC,BernardoM,D,Vieta Baeza I,Díaz-CanejaCM,Rodriguez-Toscano Sanchez-Gistau V,ParienteJC,RomeroS, 2. 66(6):1842-1853. I.F.:13.246 on long-termsurvival. alcoholic hepatitis:Predictionandimpact in patientssurvivinganepisodeof A, BatallerR,LligoñaA. Jones PD,OrtegaL,GinèsP,CaballeríaJ,Gual 1. Originals / PUBLICATIONS detection andpreventionofrecurrences. psychological interventionsfortheearly treatments andnoveltherapies, consequences, theefficacyofdrug course andneuropsychological neuroimaging) anditsrelapses,theclinical neuromodulators, hormonefactorsand the developmentofdisease(genetics, anatomofunctional mechanismsinvolvedin investigates theneurobiologicaland The bipolardisordersprogrammainly Eduard Vieta GROUP LEADER BIPOLAR DISORDERS RESEARCH GROUP 4. 136(4):362-372. I.F.:6.790 PSYCHIATRICA SCANDINAVICA. with bipolarityandmixedfeatures. neglected symptompossiblyassociated Group. Vieta E,PacchiarottiI,BRIDGE-II-Mix Study Young AH,BarbutiM,GuisoG,Popovic D, Angst J,AzorinJM,BowdenCL,MosolovS, AREA 4 Altamirano J,López-PelayoH,Michelena VerdoliniN,PerugiG,SamalinL,MurruA, Sugranyes G,delaSernaE,BorrasR, Bachmann CJ,Aagaard L,BernardoM,

Aggressiveness indepression:a CLINICAL ANDEXPERIMENTAL NEUROSCIENCE 43(6):1208-1219.I.F.:7.575 I.F.:301.369 (HCB) Clinical, Cognitive,and

Alcohol abstinence SCHIZOPHRENIA HEPATOLOGY.

ACTA

Bernardo M,Castro-Fornieles J,PEPsGroup. E, BobesJ,Usall ContrerasF,CuestaMJ, González-Pinto A,ParelladaM,Corripio I,Vieta Mezquida G,BioqueM,LoboA, 7. 78(8):e924-E932. I.F.:5.291 JOURNAL OFCLINICALPSYCHIATRY. A Cross-SectionalandLongitudinal Study. Functioning inEuthymicBipolarPatients: Impact ofObesityonCognitive Teres M,ForcadaI,VietaE,MurM. 6. 56(1):79-88. I.F.:6.442 ACAD CHILDADOLESCPSYCHIATRY. Schizophrenia orBipolarDisorder. Young OffspringofPatientsWith Cortical MorphologyCharacteristicsof Moreno D,BaezaI,Castro-FornielesJ. Garcia-Rizo C,GoikoleaJM,BargalloN, E, BorrasR,RomeroS,Sanchez-GistauV, 5. 136(1):37-51. I.F.:6.790 PSYCHIATRICA SCANDINAVICA. use: astudyin17countries. Taylor D. Verdoux H,WangLJ,ZaraYahniC,Zoëga CCM, ShyuYC,SiskindD,SkurtveitS, Saastamoinen LK,SatoI,Schuiling-Veninga Mahesri M,NishtalaPS,PiovaniD,ReutforsJ, Machado-Alba JE,Machado-DuqueME, Kawakami K,KielerH,KinoshitaT,LópezSC, Hollingworth S,HuybrechtsKF,KalverdijkLJ, A, FuruK,GaruolienéHoffmannF, Brandt L,CartabiaM,ClavennaA,ComaFusté GROUP Eduard Vieta MoraE,PortellaMJ,Martinez-AlonsoM, Puig O,BaezaI,delaSernaE,Cabrera B, Sugranyes G,Solé-PadullésC,delaSerna International trendsinclozapine ACTA The J AM Onset. Differences BetweenEarlyandAdult and SocialFunctioningCorrelates First-Episode Psychosis:EarlyCognitive Persistent NegativeSymptomsin 11. BIOLOGY. ganglia incannabisusers. frontal andsensoryinputstothe basal M, DeusJ,Martín-SantosR. Macià D,BatallaA,NoguéS,Torrens M,Farré 10. 15(4):335-340. I.F.:4.917 Trial. ODHIN 5-CountryClusterRandomized Drinking inPrimaryCare:Outcomesofthe Delivery ofBriefInterventionsforHeavy Colin; Gual,Antoni. Okulicz-Kozaryn, Katarzyna;Drummond, Newbury-Birch, Dorothy;Parkinson,Kathryn; Mierzecki, Artur;Deluca,Paolo; Reynolds, Jillian;Segura,Lidia;Wojnar,Marcin; Eileen; Bendtsen,Preben;Kloda,Karolina; 9. I.F.: 5.102 OF NEUROINFLAMMATION. obsessive-compulsive disorder. in pediatricpatientswith Inﬂammatory dysregulationofmonocytes García-Cerro S.,MasGassóP.,LázaroL. E., Serra-PagesC.,BolocD.,TorresT., 8. PSYCHIATRY. Anderson,Peter;Coulton,Simon;Kaner, Rodríguez N.,MorerA.,González-Navarro Jimenez,Esther;Sole, Brisa;Arias,Barbara; Blanco-Hinojo L,PujolJ,HarrisonBJ, ANNALS OFFAMILYMEDICINE.

JOURNAL OFCLINICAL 22(4):1036-1047. I.F.:4.603 78(9):1414-1422.I.F.:5.291 Attenuated ADDICTION 14(1):261. JOURNAL BIOLOGICAL BASES OF PSYCHIATRIC DISORDERS AND NUCLEAR PSYCHIATRY 4.7

Mitjans, Marina; Varo, Cristina; Reinares, Maria; Selva-Vera G, Arranz B, Amann BL, Saiz-Ruiz Rosa; Gutierrez, Silvia; Lazaro, Luisa; Graell, del Mar Bonnin, Caterina; Ruiz, Victoria; J, Pérez-Blanco J, Vieta E. Efficacy of Montserrat; Guisasola, Maria; Luisa Dorado, Alejandra Saiz, Pilar; Paz Garcia-Portilla, M.; quetiapine XR vs. placebo as concomitant Maria; Boada, Leticia; Romo, Jose; Dulin, Buron, Patricia; Bobes, Julio; Amann, Benedikt treatment to mood stabilizers in the Elena; Sanz, Inmaculada; Arango, Celso; L.; Martinez-Aran, Anabel; Torrent, Carla; Vieta, control of subthreshold symptoms of Moreno, Carmen. Randomized trial of Eduard; Benabarre, Antoni. Impact of bipolar disorder: Results from a pilot, omega-3 for autism spectrum disorders: childhood trauma on cognitive profile in randomized controlled trial. EUROPEAN Effect on cell membrane composition and bipolar disorder. BIPOLAR DISORDERS. NEUROPSYCHOPHARMACOLOGY. behavior. EUROPEAN 19(5):363-374. I.F.: 4.531 27(10):959-969. I.F.: 4.239 NEUROPSYCHOPHARMACOLOGY. 27(12):1319-1330. I.F.: 4.239 12. Torres I, Sole B, Corrales M, Jiménez E, 18. Vieta E., Loft H., Florea I. Effectiveness of Rotger S, Serra-Pla JF, Forcada I, Richarte V, long-term vortioxetine treatment of 23. Mas S., Gassó P., Torra M., Bioque M., Mora E, Jacas C, Gómez N, Mur M, Colom F, patients with major depressive disorder. Lobo A., González-Pinto A., Olmeda M., Vieta E, Casas M, Martinez-Aran A, Goikolea EUROPEAN Corripio I., Vieta E., Castro-Fornieles J., JM, Ramos-Quiroga JA. Are patients with NEUROPSYCHOPHARMACOLOGY. Rodriguez-Jimenez R., Bobes J., Usall J., bipolar disorder and comorbid 27(9):877-884. I.F.: 4.239 Llerena A., Saiz-Ruiz J., Bernardo M., Lafuente attention-deficit hyperactivity disorder A., PEPs Group. Intuitive pharmacogenetic more neurocognitively impaired? BIPOLAR 19. Murru A, Torra M, Callari A, Pacchiarotti I, dosing of risperidone according to DISORDERS. 19(8):637-650. I.F.: 4.531 Romero S, Gonzalez de la Presa B, Varo C, CYP2D6 phenotype extrapolated from Goikolea JM, Pérez-Sola V, Vieta E, Colom F. genotype in a cohort of first episode 13. Petri E, Bacci O, Barbuti M, Pacchiarotti I, A study on the bioequivalence of lithium psychosis patients. EUROPEAN Azorin JM, Angst J, Bowden CL, Mosolov S, and valproate salivary and blood levels in NEUROPSYCHOPHARMACOLOGY. Vieta E, Young AH, Perugi G, BRIDGE-II-Mix the treatment of bipolar disorder. 27(7):647-656. I.F.: 4.239 Study Group. Obesity in patients with major EUROPEAN depression is related to bipolarity and NEUROPSYCHOPHARMACOLOGY. 24. Hálfdánarson Ó., Zoëga H., Aagaard L., mixed features: evidence from the 27(8):744-750. I.F.: 4.239 Bernardo M., Brandt L., Fusté A., Furu K., BRIDGE-II-Mix study. BIPOLAR Garuoliené K., Hoffmann F., Huybrechts K., DISORDERS. 19(6):458-464. I.F.: 4.531 20. Thase ME, Danchenko N, Brignone M, Kalverdijk L., Kawakami K., Kieler H., Kinoshita Florea I, Diamand F, Jacobsen PL, Vieta E. T., Litchfield M., López S., Machado-Alba J., 14. Miskowiak KW, Kjaerstad HL, Støttrup Comparative evaluation of vortioxetine as Machado-Duque M., Mahesri M., Nishtala P., MM, Svendsen AM, Demant KM, Hoeffding a switch therapy in patients with major Pearson S., Reutfors J., Saastamoinen L., Sato LK, Werge TM, Burdick KE, Domschke K, depressive disorder. EUROPEAN I., Schuiling-Veninga C., Shyu Y., Skurtveit S., Carvalho AF, Vieta E, Vinberg M, Kessing LV, NEUROPSYCHOPHARMACOLOGY. Verdoux H., Wang L., Yahni C., Bachmann C. Siebner HR, Macoveanu J. The 27(8):773-781. I.F.: 4.239 International trends in antipsychotic use: catechol-O-methyltransferase (COMT) A study in 16 countries, 2005-2014. Val158Met genotype modulates working 21. Sanchez-Moreno J., Bonnín C., EUROPEAN memory-related dorsolateral prefrontal González-Pinto A., Amann B., Solé B., NEUROPSYCHOPHARMACOLOGY. response and performance in bipolar Balanzá-Martínez V., Arango C., Jimenez E., 27(10):1064-1076. I.F.: 4.239 disorder. BIPOLAR DISORDERS. Tabarés-Seisdedos R., Garcia-Portilla M., 19(3):214-224. I.F.: 4.531 Ibáñez A., Crespo J., Ayuso-Mateos J., Vieta E., 25. Li D., Tseng P., Stubbs B., Chu C., Chang H., Alegría A., Martinez-Aran A., Al-Halabi S., Vieta E., Fornaro M., Carvalho A., Solmi M., 15. Lopez-Jaramillo, Carlos; Vargas, Cristian; Torrent C., Alonso-Lana S., Anaya C., Barbeito Veronese N., Chen T., Chen Y., Lin P., Chow P. Diaz-Zuluaga, Ana M.; Palacio, Juan David; S., Bobes J., Chiclana G., Cerrillo E., Colom F., Efficacy, safety and tolerability of Castrillon, Gabriel; Bearden, Carrie; Vieta, Correa P., Custal N., Fernández P., Fernández aripiprazole in bipolar disorder: An updated Eduard. Increased hippocampal, thalamus M., Fuentes-Durá I., Galván G., systematic review and meta-analysis of and amygdala volume in long-term González-Ortega I., Isella S., Landín-Romero randomized controlled trials. lithium-treated bipolar I disorder patients R., Manuel Menchón J., Merchan-Naranjo J., PROGRESS IN compared with unmedicated patients and Ortiz-Gil J., Pacchiarotti I., Reyes R., Rosa A., NEURO-PSYCHOPHARMACOLOGY AND healthy subjects. BIPOLAR DISORDERS. Sanchez-Moreno J., Bonnín C., BIOLOGICAL PSYCHIATRY. 79(pt b):289-301. 19(1):41-49. I.F.: 4.531 González-Pinto A., Amann B., Solé B., I.F.: 4.187 Balanzá-Martínez V., Arango C., Jimenez E., 16. Rodríguez-Cano E., Alonso-Lana S., Sarró Tabarés-Seisdedos R., Garcia-Portilla M., 26. Chye Y, Solowij N, Ganella EP, Suo C, S., Fernández-Corcuera P., Goikolea J., Vieta Ibáñez A., Crespo J. Do patients with bipolar Yücel M, Batalla A, Cousijn J, Goudriaan AE, E., Maristany T., Salvador R., McKenna P., disorder and subsyndromal symptoms Martin-Santos R, Whittle S, Bartholomeusz Pomarol-Clotet E. Differential failure to benefit from functional remediation? A CF, Lorenzetti V. Role of orbitofrontal deactivate the default mode network in 12-month follow-up study. EUROPEAN sulcogyral pattern on lifetime cannabis use unipolar and bipolar depression. BIPOLAR NEUROPSYCHOPHARMACOLOGY. and depressive symptoms. PROGRESS IN DISORDERS. 19(5):386-395. I.F.: 4.531 27(4):350-359. I.F.: 4.239 NEURO-PSYCHOPHARMACOLOGY AND BIOLOGICAL PSYCHIATRY. 79(pt 17. Garriga M, Solé E, González-Pinto A, 22. Parellada, Mara; Llorente, Cloe; Calvo, B):392-400. I.F.: 4.187

231 AREA 4 CLINICAL AND EXPERIMENTAL NEUROSCIENCE

27. Gassó P., Rodríguez N., Monteagudo A., 32. Fraguas D., Díaz-Caneja C., Corripio I., JM, Angst J, Bowden CL, Mosolov S, Young Boloc D., Lafuente A., Arnaiz J., Mas S., González-Pinto A., Lobo A., Bioque M., Cuesta AH, Perugi G, BRIDGE-II-Mix Study Group. Blázquez A., Plana M., Lázaro L. Epigenetic M., Sanjuán J., Rodríguez-Toscano E., Arias B., Antidepressant-induced and genetic variants in the HTR1B gene Sarró S., Cabrera B., Bulbena A., Vieta E., hypomania/mania in patients with major and clinical improvement in children and Castro-Fornieles J., Arango C., Bernardo M., depression: Evidence from the adolescents treated with fluoxetine. Parellada M. Gene-environment interaction BRIDGE-II-MIX study. JOURNAL OF PROGRESS IN as a predictor of early adjustment in first AFFECTIVE DISORDERS. 219:187-192. NEURO-PSYCHOPHARMACOLOGY AND episode psychosis. SCHIZOPHRENIA I.F.: 3.432 BIOLOGICAL PSYCHIATRY. 75:28-34. RESEARCH. 189:196-203. I.F.: 3.986 I.F.: 4.187 39. Varo C., Jimenez E., Solé B., Bonnín C., 33. De la Serna E, Sugranyes G, Torrent C., Valls E., Morilla I., Lahera G., 28. Gassó P., Rodríguez N., Boloc D., Blázquez Sanchez-Gistau V, Rodriguez-Toscano E, Martínez-Arán A., Vieta E., Reinares M. Social A., Torres T., Gortat A., Plana M., Lafuente A., Baeza I, Vila M, Romero S, Sanchez-Gutierrez cognition in bipolar disorder: Focus on Mas S., Arnaiz J., Lázaro L. Association of T, Penzol MJ, Moreno D, Castro-Fornieles J. emotional intelligence. JOURNAL OF regulatory TPH2 polymorphisms with Neuropsychological characteristics of AFFECTIVE DISORDERS. 217:210-217. higher reduction in depressive symptoms child and adolescent offspring of patients I.F.: 3.432 in children and adolescents treated with with schizophrenia or bipolar disorder. fluoxetine. PROGRESS IN SCHIZOPHR RES. 183:110-115. I.F.: 3.986 40. Earley W, Durgam S, Lu K, Debelle M, NEURO-PSYCHOPHARMACOLOGY AND Laszlovszky I, Vieta E, Yatham LN. BIOLOGICAL PSYCHIATRY. 77:236-240. 34. Espinosa A, Alegret M, Pesini P, Valero S, Tolerability of cariprazine in the treatment I.F.: 4.187 Lafuente A, Buendía M, San José I, Ibarria M, of acute bipolar I mania: A pooled post hoc Tejero MA, Giménez J, Ruiz S, Hernández I, analysis of 3 phase II/III studies. JOURNAL 29. Gassó P., Mas S., Rodríguez N., Boloc D., Pujadas F, Martínez-Lage P, Munuera J, OF AFFECTIVE DISORDERS. 215:205-212. García-Cerro S., Bernardo M., Lafuente A., Arbizu J, Tárraga L, Hendrix SB, Ruiz A, I.F.: 3.432 Parellada E. Microarray gene-expression Becker JT, Landau SM, Sotolongo-Grau O, study in fibroblast and lymphoblastoid cell Sarasa M, Boada M, AB255 Study Group, 41. Correa-Ghisays P, Balanzá-Martínez V, lines from antipsychotic-naïve Alzheimer’s Disease Neuroimaging Initiative. Selva-Vera G, Vila-Francés J, Soria-Olivas E, first-episode schizophrenia patients. Cognitive Composites Domain Scores Vivas-Lalinde J, San Martín C, Borrás AM, JOURNAL OF PSYCHIATRIC RESEARCH. Related to Neuroimaging Biomarkers Ayesa-Arriola R, Sanchez-Moreno J, 95:91-101. I.F.: 4.183 within Probable-Amnestic Mild Cognitive Sánchez-Ort J, Crespo-Facorro B, Vieta E, Impairment-Storage Subtype. JOURNAL Tabarés-Seisdedos R. Manual motor speed 30. Mezquida G., Cabrera B., Bioque M., OF ALZHEIMERS DISEASE. 57(2):447-459. dysfunction as a neurocognitive Amoretti S., Lobo A., González-Pinto A., I.F.: 3.731 endophenotype in euthymic bipolar Espliego A., Corripio I., Vieta E., disorder patients and their healthy Castro-Fornieles J., Bergé D., Escartí M., 35. Murru A, Pacchiarotti I, Verdolini N, relatives. Evidence from a 5-year follow-up Ibañez Á., Penadés R., Sánchez-Torres A., Reinares M, Torrent C, Geoffroy PA, Bellivier F, study. JOURNAL OF AFFECTIVE Bernardo M., Meseguer A., Fernandez-Egea Llorca PM, Vieta E, Samalin L. Modifiable and DISORDERS. 215:156-162. I.F.: 3.432 E., Vidal J., Parellada M., Alonso A., Rabella M., non-modifiable factors associated with Vega P., Ugarte A., Andrés-Bergareche H., functional impairment during the 42. Lima AB, Köhler CA, Stubbs B, Quevedo J, Modrego F., Sanjuan J., Aguilar E., Bulbena A., inter-episodic periods of bipolar disorder. Hyphantis TN, Koyanagi A, Marazziti D, Mané A., Garriga M., Morilla I., Baeza I., de la EUROPEAN ARCHIVES OF PSYCHIATRY Soares JC, Vieta E, Carvalho AF. An Serna E., Contreras F., Albacete A., Bobes J., AND CLINICAL NEUROSCIENCE. I.F.: 3.569 exploratory study of the heterogeneity of García-Portilla M., Gutiérrez M., Segarra R., the jealousy phenomenon and its Mezquida G., Cabrera B., Bioque M., Amoretti 36. Hidalgo-Mazzei D, Reinares M, Mateu A, associations with affective temperaments S., Lobo A., González-Pinto A., Espliego A., Juruena MF, Young AH, Pérez-Sola V, Vieta E, and psychopathological dimensions in a Corripio I. The course of negative Colom F. Is a SIMPLe smartphone large Brazilian sample. JOURNAL OF symptoms in first-episode schizophrenia application capable of improving biological AFFECTIVE DISORDERS. 212:10-16. I.F.: 3.432 and its predictors: A prospective two-year rhythms in bipolar disorder? JOURNAL OF follow-up study. SCHIZOPHRENIA AFFECTIVE DISORDERS. 223:10-16. I.F.: 3.432 43. Samalin L, Boyer L, Murru A, Pacchiarotti I, RESEARCH. 189:84-90. I.F.: 3.986 Reinares M, Bonnin CM, Torrent C, Verdolini N, 37. Jiménez-López E., Aparicio A., Pancheri C, de Chazeron I, Boucekine M, 31. Bernardo M., Bioque M., Cabrera B., Lobo Sánchez-Morla E., Rodriguez-Jimenez R., Geoffroy PA, Bellivier F, Llorca PM, Vieta E. A., González-Pinto A., Pina L., Corripio I., Vieta E., Santos J. Neurocognition in Residual depressive symptoms, sleep Sanjuán J., Mané A., Castro-Fornieles J., Vieta patients with psychotic and non-psychotic disturbance and perceived cognitive E., Arango C., Mezquida G., Gassó P., bipolar I disorder. A comparative study impairment as determinants of functioning Parellada M., Saiz-Ruiz J., Cuesta M., Mas S. with individuals with schizophrenia. in patients with bipolar disorder. J AFFECT Modelling gene-environment interaction in JOURNAL OF AFFECTIVE DISORDERS. DISORD. 210:280-286. I.F.: 3.432 first episodes of psychosis. 222:169-176. I.F.: 3.432 SCHIZOPHRENIA RESEARCH. 189:181-189. 44. Grande, I.; Sanchez-Moreno, J.; Sole, B.; I.F.: 3.986 38. Barbuti M, Pacchiarotti I, Vieta E, Azorin Jimenez, E.; Torrent, C.; Bonnin, C. M.; Varo, C.;

232 BIOLOGICAL BASES OF PSYCHIATRIC DISORDERS AND NUCLEAR PSYCHIATRY 4.7

Tabares-Seisdedos, R.; Balanza-Martinez, V.; López-Pelayo H, Miquel L, Teixidó L, Colom J, 57. Barrio P, Mondon S, Teixidor L, Ortega L, Valls, E.; Morilla, I.; Carvalho, A. F.; Nutt DJ, Rehm J, Gual A. The Standard Joint Vieta E, Gual A. One Year Clinical Correlates Ayuso-Mateos, J. L.; Vieta, E.; Martinez-Aran, Unit. DRUG AND ALCOHOL DEPENDENCE. of EtG Positive Urine Screening in A. High cognitive reserve in bipolar 176:109-116. I.F.: 3.222 Alcohol-Dependent Patients: A Survival disorders as a moderator of Analysis. ALCOHOL AND ALCOHOLISM. neurocognitive impairment. JOURNAL OF 51. Garcia-Rizo C., Fernandez-Egea E., 52(4):460-465. I.F.: 2.757 AFFECTIVE DISORDERS. 208:621-627. Oliveira C., Meseguer A., Cabrera B., Mezquida I.F.: 3.432 G., Bioque M., Penades R., Parellada E., 58. Miquel, Laia; Gual, Antoni; Vela, Emili; Bernardo M., Kirkpatrick B. Metabolic Lligona, Anna; Bustins, Montserrat; Colom, 45. González-Rodríguez A, Bernardo M, syndrome or glucose challenge in ﬁrst Joan; Rehm, Juergen. Alcohol Consumption Penadés R, Arias B, Ruiz Cortés V, Seeman episode of psychosis? EUROPEAN and Inpatient Health Service Utilization in a MV, Catalán R. Do FSH/LH ratio and PSYCHIATRY. 41:42-46. I.F.: 3.123 Cohort of Patients With Alcohol gonadal hormone levels predict clinical Dependence After 20 Years of Follow-up. improvement in postmenopausal 52. Verdolini N, Murru A, Attademo L, Garinella ALCOHOL AND ALCOHOLISM. schizophrenia women? ARCHIVES OF R, Pacchiarotti I, Bonnin CDM, Samalin L, 52(2):227-233. I.F.: 2.757 WOMENS MENTAL HEALTH. 20(5):613-620. Pauselli L, Piselli M, Tamantini A, Quartesan R, I.F.: 3.397 Carvalho AF, Vieta E, Tortorella A. The 59. San, L.; Estrada, G.; Oudovenko, N.; Vieta, aggressor at the mirror: Psychiatric E. Rationale and design of the PLACID 46. Chye Y, Solowij N, Suo C, Batalla A, correlates of deliberate self-harm in male study: a randomised trial comparing the Cousijn J, Goudriaan AE, Martin-Santos R, prison inmates. EUROPEAN PSYCHIATRY. efficacy and safety of inhaled loxapine Whittle S, Lorenzetti V, Yücel M. Orbitofrontal 44:153-160. I.F.: 3.123 versus IM aripiprazole in acutely agitated and caudate volumes in cannabis users: a patients with schizophrenia or bipolar multi-site mega-analysis comparing 53. Gutierrez F; Aluja A; Peri J; Calvo N; Ferrer disorder. BMC PSYCHIATRY. 17(1):126. dependent versus non-dependent users. M; Baillés E; Gutiérrez-Zotes J; Gárriz M; I.F.: 2.613 PSYCHOPHARMACOLOGY. Caseras X; Markon K; Krueger R. 234(13):1985-1995. I.F.: 3.308 Psychometric Properties of the Spanish 60. Pérez V, Salavert A, Espadaler J, Tuson M, PID-5 in a Clinical and a Community Saiz-Ruiz J, Sáez-Navarro C, Bobes J, 47. Baeza I, Vigo L, de la Serna E, Sample. ASSESSMENT. 24(3):326-336. Baca-García E, Vieta E, Olivares JM, Calvo-Escalona R, Merchán-Naranjo J, I.F.: 3.062 Rodriguez-Jimenez R, Villagrán JM, Gascón J, Rodríguez-Latorre P, Arango C, Cañete-Crespillo J, Solé M, Saiz PA, Ibáñez Á, Castro-Fornieles J. The effects of 54. Berrocal-Izquierdo N, Bioque M, Bernardo de Diego-Adeliño J, Menchón JM AB-GEN antipsychotics on weight gain, M. Is cerebrovascular disease a silent Collaborative Group. Efficacy of prospective weight-related hormones and condition in patients with chronic pharmacogenetic testing in the treatment homocysteine in children and adolescents: schizophrenia-related disorders? of major depressive disorder: results of a a 1-year follow-up study. EUROPEAN CHILD INTERNATIONAL CLINICAL randomized, double-blind clinical trial. AND ADOLESCENT PSYCHIATRY. PSYCHOPHARMACOLOGY. 32(2):80-86. BMC PSYCHIATRY. 17(1):250. I.F.: 2.613 26(1):35-46. I.F.: 3.295 I.F.: 2.968 61. Vieta E, Garriga M, Cardete L, Bernardo M, 48. Solé-Padullés C, Castro-Fornieles J, de la 55. Salvador, Raymond; Radua, Joaquim; Lombraña M, Blanch J, Catalán R, Vázquez M, Serna E, Sánchez-Gistau V, Romero S, Puig O, Canales-Rodriguez, Erick J.; Solanes, Aleix; Soler V, Ortuño N, Martínez-Arán A. Protocol Calvo A, Bargalló N, Baeza I, Sugranyes G. Sarro, Salvador; Goikolea, Jose M.; Valiente, for the management of psychiatric Intrinsic functional connectivity of Alicia; Monte, Gemma C.; del Carmen patients with psychomotor agitation. BMC fronto-temporal networks in adolescents Natividad, Maria; Guerrero-Pedraza, Amalia; PSYCHIATRY. 17(1):328. I.F.: 2.613 with early psychosis. Moro, Noemi; Fernandez-Corcuera, Paloma; EUR CHILD ADOLESC PSYCHIATRY. Amann, Benedikt L.; Maristany, Teresa; Vieta, 62. Toyoshima K., Fujii Y., Mitsui N., Kako Y., 26(6):669-679. I.F.: 3.295 Eduard; McKenna, Peter J.; Pomarol-Clotet, Asakura S., Martinez-Aran A., Vieta E., Kusumi Edith. Evaluation of machine learning I. Validity and reliability of the Cognitive 49. Morón-Nozaleda M., Díaz-Caneja C., algorithms and structural features for Complaints in Bipolar Disorder Rating Rodríguez-Toscano E., Arango C., optimal MRI-based diagnostic prediction in Assessment (COBRA) in Japanese Castro-Fornieles J., de la Serna E., Espliego A., psychosis. PLOS ONE. 12(4):0175683. patients with bipolar disorder. Sanchez-Gistau V., Romero S., Baeza I., I.F.: 2.806 PSYCHIATRY RESEARCH. 254:85-89. Sugranyes G., Moreno C., Moreno D. I.F.: 2.528 A developmental approach to dimensional 56. Hanschmidt F, Manthey J, Kraus L, expression of psychopathology in child Scafato E, Gual A, Grimm C, Rehm J. Barriers 63. Garrido G., Penadés R., Barrios M., Aragay and adolescent offspring of parents with to Alcohol Screening Among Hypertensive N., Ramos I., Vallès V., Faixa C., Vendrell J. bipolar disorder. EUROPEAN CHILD AND Patients and the Role of Stigma: Lessons Computer-assisted cognitive remediation ADOLESCENT PSYCHIATRY. for the Implementation of Screening and therapy in schizophrenia: Durability of the 26(10):1165-1175. I.F.: 3.295 Brief Interventions in European Primary effects and cost-utility analysis. PSYCHIATRY Care Settings. ALCOHOL AND RESEARCH. 254:198-204. I.F.: 2.528 50. Casajuana Kögel C, Balcells-Olivero MM, ALCOHOLISM. 52(5):572-579. I.F.: 2.757

233 AREA 4 CLINICAL AND EXPERIMENTAL NEUROSCIENCE

64. Mané A., Penzol M., Parellada M., Bioque Sanjuán J, Arango C. Effectiveness, 77. Garrido JM, Sánchez-Moreno J, Vázquez M., Lobo A., González-Pinto A., Corripio I., efficiency and efficacy in the M, Hidalgo D, Valentí M, Goikolea JM, Sánchez-Torres A., Saiz-Ruiz J., Bergé D., multidimensional treatment of Benabarre A, Ylla A, Grande I, Vieta E, Trilla A. Cabrera B., Bernardo M. Cannabis use, schizophrenia: Rethinking project. Evaluation of Patient Satisfaction in a State COMT, BDNF and age at first-episode REVISTA DE PSIQUIATRIA Y SALUD Reference Center of Bipolar Disorder. psychosis. PSYCHIATRY RESEARCH. MENTAL. 10(1):4-20. I.F.: 2.227 JOURNAL OF BEHAVIORAL HEALTH 250:38-43. I.F.: 2.528 SERVICES AND RESEARCH. I.F.: 2.024 71. Chang, Han-Yung; Tseng, Ping-Tao; 65. Garcia-Rizo C, Casanovas M, Stubbs, Brendon; Chu, Che-Sheng; Li, 78. Piqueras JA, Rodríguez-Jiménez T, Ortiz Fernandez-Egea E, Oliveira C, Meseguer A, Dian-Jeng; Fornaro, Michele; Carvalho, Andre; AG, Moreno E, Lázaro L, Storch EA. Factor Cabrera B, Mezquida G, Bioque M, Kirkpatrick Solmi, Marco; Veronese, Nicola; Vieta, Eduard; Structure, Reliability, and Validity of the B, Bernardo M. Blood cell count in Chen, Tien-Yu; Chen, Yen-Wen; Lin, Pao-Yen; Spanish Version of the Children's Florida antipsychotic-naive patients with Chow, Philip Chik-Keung. The Efficacy and Obsessive Compulsive Inventory non-affective psychosis.EARLY Tolerability of Paliperidone in Mania of (C-FOCI). CHILD PSYCHIATRY AND HUMAN INTERVENTION IN PSYCHIATRY. I.F.: 2.400 Bipolar Disorder: A Preliminary DEVELOPMENT. 48(1):166-179. I.F.: 2.012 Meta-Analysis. EXPERIMENTAL AND 66. Carreño M., Bien C., Asadi-Pooya A., CLINICAL PSYCHOPHARMACOLOGY. 79. Moreno-Alcázar A., Radua J., Marusic P., Pimentel J., Wehner T., Mohanraj 25(5):422-433. I.F.: 2.186 Landín-Romero R., Blanco L., Madre M., R., Uranga J., Gómez-Ibáñez A., Bargalló N., Reinares M., Comes M., Jiménez E., Crespo J., Rumià J., Setoain X., Pintor L., Bailles E., Falip 72. Barrio P, Teixidor L, Ortega L, Balcells M, Vieta E., Pérez V., Novo P., Doñate M., Cortizo M., Dalmau J., Gil F., Sperling M., Elisak M., Vieta E, Gual A. Patients' Knowledge and R., Valiente-Gómez A., Lupo W., McKenna P., Villanueva V., Roldán P., Boget T., Donaire A., Attitudes Towards Regular Alcohol Urine Pomarol-Clotet E., Amann B. Eye movement Aparicio J., Graus F. Epilepsy surgery in drug Screening: A Survey Study. JOURNAL OF desensitization and reprocessing therapy resistant temporal lobe epilepsy ADDICTION MEDICINE. 11(4):300-307. versus supportive therapy in affective associated with neuronal antibodies. I.F.: 2.129 relapse prevention in bipolar patients with EPILEPSY RESEARCH. 129:101-105. I.F.: 2.367 a history of trauma: Study protocol for a 73. Anderson P., Kaner E., Keurhorst M., randomized controlled trial. TRIALS. 67. Salvador Sanchez, Javier; Delia David, Bendtsen P., Van Steenkiste B., Reynolds J., 18(1):160. I.F.: 1.969 Monica; Torrent Seto, Aurora; Martinez Segura L., Wojnar M., K?oda K., Parkinson K., Alonso, Montserrat; Portella Moll, Maria J.; Drummond C., Okulicz-Kozaryn K., Mierzecki 80. Comes M, Rosa A, Reinares M, Torrent C, Pifarre Paredero, Josep; Vieta Pascual, A., Laurant M., Newbury-Birch D., Gual A. Vieta E. Functional Impairment in Older Eduard; Mur Lain, Maria. Electroconvulsive Attitudes and learning through practice Adults With Bipolar Disorder. JOURNAL OF therapy clinical database: Influence of age are key to delivering brief interventions for NERVOUS AND MENTAL DISEASE. and gender on the electrical charge. heavy drinking in primary health care: 205(6):443-447. I.F.: 1.860 REVISTA DE PSIQUIATRIA Y SALUD Analyses from the ODHIN five country MENTAL. I.F.: 2.227 cluster randomized factorial trial. 81. Zugliani MM, Martin-Santos R, Nardi AE, INTERNATIONAL JOURNAL OF Freire RC. Personality Traits in Panic 68. Bernardo M, Cañas F, Herrera B, García ENVIRONMENTAL RESEARCH AND PUBLIC Disorder Patients With and Without Dorado M. Adherence predicts HEALTH. 14(2). I.F.: 2.101 Comorbidities. JOURNAL OF NERVOUS symptomatic and psychosocial remission AND MENTAL DISEASE. 205(11):855-858. in schizophrenia: Naturalistic study of 74. Casajuana C, López-Pelayo H, Mercedes I.F.: 1.860 patient integration in the community. Balcells M, Miquel L, Teixidó L, Colom J, Gual REVISTA DE PSIQUIATRIA Y SALUD A. Working on a Standard Joint Unit: A pilot 82. Barrio P, Ortega L, López H, Gual A. MENTAL. 10(3):149-159. I.F.: 2.227 test. ADICCIONES. 29(4):227-232. I.F.: 2.077 Self-management and Shared Decision-Making in Alcohol Dependence 69. Sanz-Fuentenebro, Javier; Vera, Ignacio; 75. Sanvisens A, Zuluaga P, Rivas I, Rubio G, via a Mobile App: a Pilot Study. Verdura, Ernesto; Urretavizcaya, Mikel; Gual A, Torrens M, Short A, Álvarez FJ, Tor J, INTERNATIONAL JOURNAL OF Martinez-Amoros, Erika; Soria, Virginia; Farré M, Rodríguez de Fonseca F, Muga R. BEHAVIORAL MEDICINE. 24(5):722-727. Bernardo, Miguel. Pattern of Patients with alcohol use disorder: initial I.F.: 1.846 electroconvulsive therapy use in Spain: results from a prospective multicenter Proposals for an optimal practice and registry in the Spanish Network on 83. Bauer R, Conell J, Conell J, Glenn T, Alda equitable access. REVISTA DE Addiction Disorders. CohRTA Study. M, Ardau R, Baune BT, Berk M, Berk M, Berk PSIQUIATRIA Y SALUD MENTAL. 10(2):87-95. ADICCIONES. 0(0):931. I.F.: 2.077 M, Berk M, Berk M, Bersudsky Y, Bilderbeck A, I.F.: 2.227 Bocchetta A, Bossini L, Castro AMP, Castro 76. Cristina Casajuana, Hugo López Pelayo, AMP, Cheung EYW, Chillotti C, Choppin S, 70. Crespo-Facorro B, Bernardo M, Argimon María Mercedes Balcells Oliveró, Laía Miquel Zompo MD, Dias R, Dodd S, Dodd S, Dodd S, JM, Arrojo M, Bravo-Ortiz MF, de Montagut, Lídia Teixidó, Joan Colom i Duffy A, Etain B, Fagiolini A, Hernandez MF, Cabrera-Cifuentes A, Carretero-Román J, Farran, Antoni Gual Solé. Estableciendo la Garnham J, Geddes J, Gildebro J, Franco-Martín MA, García-Portilla P, Haro JM, unidad de porro estándar: estudio piloto. Gonzalez-Pinto A, Goodwin GM, Grof P, Grof Olivares JM, Penadés R, Del Pino-Montes J, ADICCIONES. 29(4):227-232. I.F.: 2.077 P, Harima H, Hassel S, Henry C, Henry C,

234 BIOLOGICAL BASES OF PSYCHIATRIC DISORDERS AND NUCLEAR PSYCHIATRY 4.7

Hidalgo-Mazzei D, Kapur V, Kunigiri G, Lafer B, genetic-neuroimaging studies. Neuropsychopharmacology (CINP) Larsen ER, Lewitzka U, Licht RW, Licht RW, NEUROSCIENCE AND BIOBEHAVIORAL Treatment Guidelines for Bipolar Disorder Hvenegaard Lund A, Misiak B, Piotrowski P, REVIEWS. 79:87-109. I.F.: 8.299 in Adults (CINP-BD-2017), Part 4: Unmet Monteith S, Munoz R, Nakanotani T, Nielsen Needs in the Treatment of Bipolar Disorder RE, O'donovan C, Okamura Y, Osher Y, Reif A, 4. Bauer M, Glenn T, Alda M, Aleksandrovich and Recommendations for Future Ritter P, Rybakowski JK, Sagduyu K, Sawchuk MA, Andreassen OA, Angelopoulos E, Ardau Research. INTERNATIONAL JOURNAL OF B, Schwartz E, Scippa ÂM, Slaney C, Sulaiman R, Ayhan Y, Baethge C, Bharathram SR, Bauer NEUROPSYCHOPHARMACOLOGY. AH, Suominen K, Suwalska A, Tam P, R, Baune BT, Becerra-Palars C, Bellivier F, 20(2):196-205. I.F.: 4.712 Tatebayashi Y, Tondo L, Tondo L, Vieta E, Belmaker RH, Berk M, Bersudsky Y, Bicakci ?, Vinberg M, Viswanath B, Volkert J, Zetin M, Birabwa-Oketcho H, Bjella TD, Bossini L, 8. Fountoulakis, Konstantinos N.; Grunze, Whybrow PC, Bauer M. International Cabrera J, Cheung EYW, Del Zompo M, Dodd Heinz; Vieta, Eduard; Young, Allan; Yatham, multi-site survey on the use of online S, Donix M, Etain B, Fagiolini A, Fountoulakis Lakshmi; Blier, Pierre; Kasper, Siegfried; support groups in bipolar disorder. KN, Frye MA, Gonzalez-Pinto A, Gottlieb JF, Moeller, Hans Jurgen. The International NORDIC JOURNAL OF PSYCHIATRY. Grof P, Harima H, Henry C, Isometsä ET, College of Neuro-Psychopharmacology 71(6):473-476. I.F.: 1.406 Janno S, Kapczinski F, Kardell M, Khaldi S, (CINP) Treatment Guidelines for Bipolar Kliwicki S, König B, Kot TL, Krogh R, Kunz M, Disorder in Adults (CINP-BD-2017), Part 3: 84. Anderson P, K?oda K, Kaner E, Reynolds Lafer B, Landén M, Larsen ER, Lewitzka U, The Clinical Guidelines. INTERNATIONAL J, Bendtsen P, Pelgrum-Keurhorst MN, Licht RW, Lopez-Jaramillo C, MacQueen G, JOURNAL OF Segura L, Wojnar M, Mierzecki A, Deluca P, Manchia M, Marsh W, Martinez- NEUROPSYCHOPHARMACOLOGY. Newbury-Birch D, Parkinson K, Cengotitabengoa M, Melle I, Meza-Urzúa F, 20(2):180-195. I.F.: 4.712 Okulicz-Kozaryn K, Drummond C, Laurant Yee Ming M, Monteith S, Morken G, Mosca E, MGH, Gual A. Impact of practice, provider Munoz R, Mythri SV, Nacef F, Nadella RK, Nery 9. Fountoulakis, Konstantinos N.; Yatham, and patient characteristics on delivering FG, Nielsen RE, O'Donovan C, Omrani A, Lakshmi; Grunze, Heinz; Vieta, Eduard; Young, screening and brief advice for heavy Osher Y, Østermark Sørensen H, Ouali U, Pica Allan; Blier, Pierre; Kasper, Siegfried; Moeller, drinking in primary healthcare: Secondary Ruiz Y, Pilhatsch M, Pinna M, da Ponte FDR, Hans Jurgen. The International College of analyses of data from the ODHIN Quiroz D, Ramesar R, Rasgon N, Reddy MS, Neuro-Psychopharmacology (CINP) ﬁve-country cluster randomized factorial Reif A, Ritter P, Rybakowski JK, Sagduyu K, Treatment Guidelines for Bipolar Disorder trial. EUROPEAN JOURNAL OF GENERAL Scippa ÂM, Severus E, Simhandl C, Stein DJ, in Adults (CINP-BD-2017), Part 2: Review, PRACTICE. 23(1):241-245. I.F.: 1.274 Strejilevich S, Subramaniam M, Sulaiman AH, Grading of the Evidence, and a Precise Suominen K, Tagata H, Tatebayashi Y, Tondo Algorithm. INTERNATIONAL JOURNAL OF L, Torrent C, Vaaler AE, Veeh J, Vieta E, NEUROPSYCHOPHARMACOLOGY. Review / I.F.: 134.535 Viswanath B, Yoldi-Negrete M, Zetin M, Zgueb 20(2):121-179. I.F.: 4.712 Y, Whybrow PC . Solar insolation in 1. Berk M, Post R, Ratheesh A, Gliddon E, springtime inﬂuences age of onset of 10. Fountoulakis, Konstantinos N.; Young, Singh A, Vieta E, Carvalho AF, Ashton MM, bipolar I disorder. ACTA PSYCHIATRICA Allan; Yatham, Lakshmi; Grunze, Heinz; Vieta, Berk L, Cotton SM, McGorry PD, Fernandes SCANDINAVICA. 136(6):571-582. I.F.: 6.790 Eduard; Blier, Pierre; Moeller, Hans Jurgen; BS, Yatham LN, Dodd S. Staging in bipolar Kasper, Siegfried. The International College disorder: from theoretical framework to 5. Elias LR, Miskowiak KW, Vale AM, Köhler of Neuropsychopharmacology (CINP) clinical utility. WORLD PSYCHIATRY. CA, Kjærstad HL, Stubbs B, Kessing LV, Vieta Treatment Guidelines for Bipolar Disorder 16(3):236-244. I.F.: 26.561 E, Maes M, Goldstein BI, Carvalho AF. in Adults (CINP-BD-2017), Part 1: Cognitive Impairment in Euthymic Background and Methods of the 2. Slyepchenko, Anastasiya; Maes, Michael; Pediatric Bipolar Disorder: A Systematic Development of Guidelines. Jacka, Felice N.; Koehler, Cristiano A.; Review and Meta-Analysis. JOURNAL OF INTERNATIONAL JOURNAL OF Barichello, Tatiana; McIntyre, Roger S.; Berk, THE AMERICAN ACADEMY OF CHILD AND NEUROPSYCHOPHARMACOLOGY. Michael; Grande, Iria; Foster, Jane A.; Vieta, ADOLESCENT PSYCHIATRY. 56(4):286-296. 20(2):98-120. I.F.: 4.712 Eduard; Carvalho, Andre F. Gut Microbiota, I.F.: 6.442 Bacterial Translocation, and Interactions 11. Miskowiak KW, Burdick KE, Martinez-Aran with Diet: Pathophysiological Links 6. Solé B, Jiménez E, Torrent C, Reinares M, A, Bonnin CM, Bowie CR, Carvalho AF, between Major Depressive Disorder and Bonnin CDM, Torres I, Varo C, Grande I, Valls Gallagher P, Lafer B, López-Jaramillo C, Non Communicable Medical E, Salagre E, Sanchez-Moreno J, Sumiyoshi T, McIntyre RS, Schaffer A, Porter Comorbidities. PSYCHOTHERAPY AND Martinez-Aran A, Carvalho AF, Vieta E. RJ, Torres IJ, Yatham LN, Young AH, Kessing PSYCHOSOMATICS. 86(1):31-46. I.F.: 8.964 Cognitive Impairment in Bipolar Disorder: LV, Vieta E. Methodological Treatment and Prevention Strategies. recommendations for cognition trials in 3. Pereira L., Köhler C., de Sousa R., Solmi M., INTERNATIONAL JOURNAL OF bipolar disorder by the International de Freitas B., Fornaro M., Machado-Vieira R., NEUROPSYCHOPHARMACOLOGY. Society for Bipolar Disorders Targeting Miskowiak K., Vieta E., Veronese N., Stubbs B., 20(8):670-680. I.F.: 4.712 Cognition Task Force. BIPOLAR Carvalho A. The relationship between DISORDERS. 19(8):614-626. I.F.: 4.531 genetic risk variants with brain structure 7. Fountoulakis KN, Vieta E, Young A, Yatham and function in bipolar disorder: A L, Grunze H, Blier P, Moeller HJ, Kasper S. 12. Bortolato B, Köhler CA, Evangelou E, systematic review of The International College of León-Caballero J, Solmi M, Stubbs B, Belbasis

235 AREA 4 CLINICAL AND EXPERIMENTAL NEUROSCIENCE

L, Pacchiarotti I, Kessing LV, Berk M, Vieta E, 20. Machado MO, Oriolo G, Bortolato B, Letters / I.F.: 55.493 Carvalho AF. Systematic assessment of Köhler CA, Maes M, Solmi M, Grande I, environmental risk factors for bipolar Martín-Santos R, Vieta E, Carvalho AF. 1. Vieta, Eduard; Sanchez-Moreno, Jose. disorder: an umbrella review of systematic Biological mechanisms of depression Behavioural activation training for reviews and meta-analyses. BIPOLAR following treatment with interferon for depression. LANCET. 389(10067):367. DISORDERS. 19(2):84-96. I.F.: 4.531 chronic hepatitis C: A critical systematic I.F.: 47.831 review. J AFFECT DISORD. 209:235-245. 13. Data-Franco J, Singh A, Popovic D, Ashton I.F.: 3.432 2. Gual A, Ángel Arbesú J, Zarco J, M, Berk M, Vieta E, Figueira ML, Dean OM. Balcells-Oliveró MLM, López-Pelayo H, Beyond the therapeutic shackles of the 21. Salagre E., Vizuete A., Leite M., Brownstein Miquel L, Bobes J. Risky Drinkers monoamines: New mechanisms in bipolar D., McGuinness A., Jacka F., Dodd S., Stubbs Underestimate their Own Alcohol disorder biology. PROGRESS IN B., Köhler C., Vieta E., Carvalho A., Berk M., Consumption. ALCOHOL AND NEURO-PSYCHOPHARMACOLOGY AND Fernandes B. Homocysteine as a peripheral ALCOHOLISM. 52(4):516-517. I.F.: 2.757 BIOLOGICAL PSYCHIATRY. 72:73-86. biomarker in bipolar disorder: A I.F.: 4.187 meta-analysis. EUROPEAN PSYCHIATRY. 3. Fortea A., Espinosa L., Oliveras C., Bruguera 43:81-91. I.F.: 3.123 P., Benabarre A. Ketamine associated with 14. Greenhalgh AM, Gonzalez-Blanco L, electroconvulsive therapy for Garcia-Rizo C, Fernandez-Egea E, Miller B, 22. Barrio P., Reynolds J., García-Altés A., Gual treatment-resistant depression in the Arroyo MB, Kirkpatrick B. Meta-analysis of A., Anderson P. Social costs of illegal drugs, elderly: Two case reports. REVISTA DE glucose tolerance, insulin, and insulin alcohol and tobacco in the European PSIQUIATRIA Y SALUD MENTAL. resistance in antipsychotic-naïve patients Union: A systematic review. DRUG AND 10(2):125-126. I.F.: 2.227 with nonaffective psychosis.SCHIZOPHR ALCOHOL REVIEW. 36(5):578-588. I.F.: 2.822 RES. 179:57-63. I.F.: 3.986 4. Espinosa-Martinez, Laura; Fortea, Adriana; 23. Ilzarbe L., Fàbrega M., Quintero R., Oriolo, Giovanni; Gonzalez-Rodriguez, 15. Sanchez-Moreno, Jose; Martinez-Aran, Bastidas A., Pintor L., García-Campayo J., Alexandre; Brunet, Merce; Fortuna, Virginia; Anabel; Vieta, Eduard. Treatment of Gomollón F., Ilzarbe D. Inﬂammatory Bowel Parellada, Eduard. Antipsychotic treatment Functional Impairment in Patients with Disease and Eating Disorders: A in CYP2D6 slow metabolizers in clinical Bipolar Disorder. CURRENT PSYCHIATRY systematized review of comorbidity. practice: the purpose of a case. ACTAS REPORTS. 19(1):3. I.F.: 3.746 JOURNAL OF PSYCHOSOMATIC ESPANOLAS DE PSIQUIATRIA. RESEARCH. 102:47-53. I.F.: 2.809 45(5):252-255. I.F.: 1.339 16. Solé E., Garriga M., Valentí M., Vieta E. Mixed features in bipolar disorder. CNS 24. Flamarique I, Baeza I, de la Serna E, Pons 5. Espinosa-Martínez L, Fortea A, Oriolo G, SPECTRUMS. 22(2):134-140. I.F.: 3.589 A, Bernardo M, Castro-Fornieles J. Thinking González-Rodríguez A, Brunet M, Fortuna V, About Electroconvulsive Therapy: The Parellada E. Antipsychotic therapy 17. Barbuti M., Murru A., Verdolini N., Guiso G., Opinions of Parents of Adolescents with amongst Cytochrome P450 2D6 poor Vieta E., Pacchiarotti I., Perugi G., Carvalho A., Schizophrenia Spectrum Disorders. metabolizers in the clinical practice: A case Stubbs B., Köhler C., Samalin L., Maes M. JOURNAL OF CHILD AND ADOLESCENT report. ACTAS ESPANOLAS DE Thyroid autoimmunity in bipolar disorder: PSYCHOPHARMACOLOGY. 27(1):75-82. PSIQUIATRIA. 45(5):248-55. I.F.: 1.339 A systematic review. JOURNAL OF I.F.: 2.440 AFFECTIVE DISORDERS. 221:97-106. I.F.: 3.432 25. Alberich S, Martínez-Cengotitabengoa M, Editorial / I.F.: 4.454 18. Salagre E., Solé B., Tomioka Y., Fernandes López P, Zorrilla I, Núñez N, Vieta E, B., Hidalgo-Mazzei D., Garriga M., Jimenez E., González-Pinto A. Efficacy and safety of 1. Salagre, Estela; Vieta, Eduard; Grande, Iria. Sanchez-Moreno J., Vieta E., Grande I. ketamine in bipolar depression: A The visceral brain: Bipolar disorder and Treatment of neurocognitive symptoms in systematic review. REVISTA DE microbiota. REVISTA DE PSIQUIATRIA Y unipolar depression: A systematic review PSIQUIATRIA Y SALUD MENTAL. SALUD MENTAL. 10(2):67-69. I.F.: 2.227 and future perspectives. JOURNAL OF 10(2):104-112. I.F.: 2.227 AFFECTIVE DISORDERS. 221:205-221. 2. Arango, Celso; Bernardo, Miguel; Bonet, I.F.: 3.432 26. Solmi, Marco; Murru, Andrea; Pacchiarotti, Pere; Cabrera, Ana; Crespo-Facorro, Isabella; Undurraga, Juan; Veronese, Nicola; Benedicto; Cuesta, Manuel J.; Gonzalez, Net; 19. Elias LR, Köhler CA, Stubbs B, Maciel BR, Fornaro, Michele; Stubbs, Brendon; Monaco, Parrabera, Silvia; Sanjuan, Julio; Serrano, Cavalcante LM, Vale AM, Gonda X, Quevedo Francesco; Vieta, Eduard; Seeman, Mary V.; Alfonso; Vieta, Eduard; Lennox, Belinda R.; J, Hyphantis TN, Soares JC, Vieta E, Carvalho Correll, Christoph U.; Carvalho, Andre F. Melau, Marianne. When the healthcare does AF. Measuring affective temperaments: a Safety, tolerability, and risks associated not follow the evidence: The case of the systematic review of validation studies of with ﬁrst- and second-generation lack of early intervention programs for the Temperament Evaluation in Memphis antipsychotics: a state-of-the-art clinical psychosis in Spain. REVISTA DE Pisa and San Diego (TEMPS) instruments. review. THER CLIN RISK MANAG. 13:757-777. PSIQUIATRIA Y SALUD MENTAL. 10(2):78-86. JOURNAL OF AFFECTIVE DISORDERS. I.F.: 2.200 I.F.: 2.227 212:25-37. I.F.: 3.432

236 BIOLOGICAL BASES OF PSYCHIATRIC DISORDERS AND NUCLEAR PSYCHIATRY 4.7

Clinical Guidelines / I.F.: 21.111 Duration: 01/01/2013-30/06/2017 estudio de neuroimagen multimodal. Sponsored by: Instituto de Salud Carlos III 1. Montejo, Angel L.; Arango, Celso; Bernardo, Bernardo M. Determinantes clínicos y (ISCIII). PI14/00723 Miquel; Carrasco, Jose L.; Crespo-Facorro, neurobiológicos de segundos episodios de Duration: 01/01/2015-30/06/2019 Benidicto; Cruz, Juan J.; Del Pino-Montes, esquizofrenia. Estudio longitudinal de Javier; Garcia-Escudero, Miguel A.; primeros episodios psicóticos. Grande I. Disbiosis en el trastorno bipolar: Garcia-Rizo, Clemente; Gonzalez-Pinto, Ana; Sponsored by: Instituto de Salud Carlos III MicrObiota Bipolar study (MOB study). Hernandez, Ana I.; Martin-Carrasco, Manuel; (ISCIII) PI11/00325 Sponsored by: Instituto de Salud Carlos III Mayoral-Cleries, Fermin; Mayoral-van Son, Duration: 01/01/2012-27/03/2017 (ISCIII). PI16/00187 Jaqueline; Mories, M. Teresa; Pachiarotti, Duration: 01/01/2017-31/12/2019 Isabella; Perez, Jesus; Ros, Salvador; Vieta, Bernardo M. Estudio de aplicabilidad clínica Eduard. Multidisciplinary consensus on the de un modelo predictivo en recaídas en Gual A. Red de Trastornos Adictivos. therapeutic recommendations for primeros episodios de esquizofrenia. Sponsored by: Instituto de Salud Carlos III iatrogenic hyperprolactinemia secondary Sponsoredby: Instituto de Salud Carlos III (ISCIII). RD12/0028/0016 to antipsychotics. FRONTIERS IN (ISCIII). PI14/00612 Duration: 01/01/2013-31/07/2017 NEUROENDOCRINOLOGY. 45:25-34. I.F.: 9.425 Duration: 01/01/2015-30/06/2019 Gual A. Estudio controlado aleatorizado de 2. Rehm J, Anderson P, Prieto JAA, Armstrong Catalán R. Diferencias de género en la no-inferioridad para el acceso facilitado I, Aubin HJ, Bachmann M, Bastus NB, Brotons respuesta a antipsicóticos: analizando el desde Atención Primaria a una C, Burton R, Cardoso M, Colom J, Duprez D, rol de la menopausia, los cambios Intervención Breve Virtual para la Gmel G, Gual A, Kraus L, Kreutz R, Liira H, epigenéticos en los receptores de reducción de consumo de alcohol Manthey J, Møller L, Okruhlica ?, Roerecke M, estrógenos y los niveles de hormones (EFAR-Spain). Scafato E, Schulte B, Segura-Garcia L, Shield sexuales. Sponsored by: Instituto de Salud Carlos III KD, Sierra C, Vyshinskiy K, Wojnar M, Zarco J . Sponsored by: Instituto de Salud Carlos III (ISCIII). PI13/00540 Towards new recommendations to reduce (ISCIII). PI16/01029 Duration: 01/01/2014-31/12/2017 the burden of alcohol-induced Duration: 01/01/2017-31/12/2019 hypertension in the European Union. BMC Gual A. SCALA - Scale-up of Prevention MEDICINE. 15(1):173. I.F.: 8.097 Castro J. Aggression subtyping for and Management of Alcohol Use Disorders improved insight and treatment innovation and Comorbid Depression in Latin 3. Stahl, Stephen M.; Morrissette, Debbi A.; in psychiatric disorders. America. Faedda, Gianni; Fava, Maurizio; Goldberg, Sponsored by: European Commission Sponsored by: European commission Joseph F.; Keck, Paul E.; Lee, Yena; Malhi, Gin; FP7_HEALTH_13 CE_H2020-SC1_17 Marangoni, Ciro; McElroy, Susan L.; Ostacher, Duration: 01/11/2013-31/10/2018 Duration: 01/12/2017-30/11/2021 Michael; Rosenblat, Joshua D.; Sole, Eva; Suppes, Trisha; Takeshima, Minoru; Thase, Castro J. Multidisciplinary Approaches to Gual A. RTA - Red de Trastornos Michael E.; Vieta, Eduard; Young, Allan; Translational Research In Conduct Adictivos 2017. Zimmerman, Mark; McIntyre, Roger S. Syndromes. Sponsored by: Instituto de Salud Carlos III Guidelines for the recognition and Sponsored by: European Commission (ISCIII). RD16/0017/0009 management of mixed depression. CNS FP7_HEALTH_13 Duration: 01/01/2017-31/12/2021 SPECTRUMS. 22(2):203-219. I.F.: 3.589 Duration: 01/03/2014-28/02/2019 Gual A. Capacity building in the application Castro J. Estudio de seguimiento a 8 años of EU drug research # Training With GRANTS FOR RESEARCH IN PROGRESS de la primera evaluación de niños y Stakeholders. adolescents hijos de pacientes con Sponsored by: European commission Baeza I. Estudio multicéntrico longitudinal esquizofrenia o trastorno bipolar. JUST-2016-AG-DRU sobre marcadores neurobiológicos de Sponsored by: Instituto de Salud Carlos III Duration: 01/06/2017-30/04/2018 estrés en niños y adolescentes con (ISCIII). PI15/00467 síndrome de riesgo de psicosis y la Duration: 01/01/2016-31/12/2018 Gutiérrez F. Un modelo integrado para la transición a psicosis. patología de la personalidad: estructura Sponsored by: Instituto de Salud Carlos III Garcia Rizo C. Evolución metabólica e jerárquica, significación e impacto (ISCIII). PI15/00444 inmune del tratamiento con clozapina: biográfico. Duration: 01/01/2016-31/12/2018 implicaciones terapéuticas. Sponsored by: Instituto de Salud Carlos III Sponsored by: Instituto de Salud Carlos III (ISCIII). PI15/00536 Benabarre A. Identificación de variables (ISCIII). PI14/00753 Duration: 01/01/2016-31/12/2018 predictoras clínicas, neurocognitivas y Duration: 01/01/2015-31/12/2017 genéticas en la emergencia y recurrencia Lafuente A. Mecanismos moleculares de la conducta suicida en el trastorno Goikolea JM. Bases cerebrales de dos implicados en la Farmacogenética del bipolar. intervenciones psicoterapéuticas eficaces síndrome metabólico inducido por Sponsored by: Instituto de Salud Carlos III en el trastorno bipolar: la psicoeducación antipsicóticos. (ISCIII). PI12/00906 grupal y la rehabilitación funcional. Un Sponsored by: Instituto de Salud Carlos III

237 AREA 4 CLINICAL AND EXPERIMENTAL NEUROSCIENCE

(ISCIII). PI16/01222 (ISCIII). PI15/00685 PhD student: Elfi Egmond Duration: 01/01/2017-31/12/2019 Duration: 01/01/2016-31/12/2018 Bernardo M. Neurocognición y Lázaro ML. Genética, epigenética y Sugranyes G. Estudio longitudinal de Biomarcadores Inflamatorios en Primeros desregulación de la microglia derivada de primeros episodios psicóticos en la Episodios Psicóticos. monocitos en pacientes con trastorno infancia y adolescencia. PhD student: Bibiana Cabrera Llorca obsesivo compulsivo de inicio en la Seguimiento a 10 años. infancia. Sponsored by: Instituto de Salud Carlos III Bernardo M. Frecuencia y factores de Sponsored by: Instituto de Salud Carlos III (ISCIII). PI13/00614 riesgo de enfermedad cerebrovascular en (ISCIII). PI13/01767 Duration: 01/01/2014-30/06/2018 pacientes con esquizofrenia y trastornos Duration: 01/01/2014-31/12/2017 relacionados. Torrent C. Efectos de la rehabilitación PhD student: Nuria Berrocal Izquierdo Lázaro ML. Influencia de la genética y la funcional en la neuroplasticidad de epigenética en la eficacia del tratamiento pacientes bipolares. Calvo R, Lázaro L. Caracterísitiques del trastorno obsesivo-Compulsivo con Sponsored by: Instituto de Salud Carlos III clíniques i neuropsicològiques en nens i terapia cognitivo-conductual o (ISCIII). PI12/01498 adolescents amb trastorn de l’espectre tratamiento farmacológico. Duration: 20/10/2015-30/06/2017 autista d’alt funcionament i en els seus Sponsored by: Instituto de Salud Carlos III germans. (ISCIII). PI16/01086 Vieta E. Especificidad de los síntomas PhD: Mireia Rosa Justicia Duration: 01/01/2017- 31/12/2019 prodrómicos en el trastorno bipolar y predicción del curso clínico de la Penadés R, Barrios MT. Estudi de l'eficàcia Martin-Santos R. Estudio de la actividad y enfermedad. d'un programa de rehabilitació conectividad cerebral en el Trastorno de Sponsored by: Instituto de Salud Carlos III neuropsicològica en pacients amb ansiedad social: búsqueda de nuevos (ISCIII). PI12/00912 esquizofrènia. endofenotipos a través de la comparación Duration: 01/01/2013-30/06/2017 PhD student: Gemma Garrido García con el S. Williams-Beuren”. Estudio TASWI. Vieta E. Implicación de variantes del gen Vieta E. Impacto del trastorno bipolar en Sponsored by: Instituto de Salud Carlos III DDR1 en la integridad de la mielina y en la pacientes de edad avanzada. (ISCIII). PI14/01411 velocidad de procesamiento cognitivo en PhD student: Mercè Comes Forastero Duration: 01/01/2015- 31/12/2018 pacientes con trastorno bipolar en fase eutímica. Vieta E. Neuropsicologia i factors Martínez-Arán A. Eficacia de un módulo Sponsored by: Instituto de Salud Carlos III neurobiològics en el trastorn bipolar. e-neurocognitivo como coadyudante a la (ISCIII). PI15/00283 PhD student: Ester Mora Claramunt rehabilitación funcional para pacientes Duration: 01/01/2015-31/12/2018 con trastorno bipolar. Sponsored by: Instituto de Salud Carlos III (ISCIII). PI15/00330 DOCTORAL THESES Duration: 01/01/2016-31/12/2018 Bernardo M, Penadés R. Fenotipo y Morer A. European Multicentre Tics in Genotipo de los Síntomas Negativos en la Children Studies. Esquizofrenia: Conceptualización, Sponsored by: European commission Evaluación y su Relación con el FP7-HEALTH-11 Polimorfismo VAL66MET del BDNF. Duration: 01/12/2011-31/05/2018 PhD student: Gisela Mezquida Mateos

Pacchiarotti I. Bioequivalencia, aplicabilidad Goikolea JM, Martinez-Aran A. clínica y utilidad terapéutica de la Comorbilidad entre el trastorno bipolar monitorización salivar de litio y valproato y el trastorno por déﬁcit de atención e en pacientes bipolares. hiperactividad en el adulto. Sponsored by: Instituto de Salud Carlos III PhD student: Imma Torres Vilamajo (ISCIII). PI12/00910 Duration: 01/01/2013-31/12/2017 Gual A, Vieta E. Ethylglucururoide replacing ethanol in the routine screening Romero S. Estudio multicéntrico del of alcohol depenent outpatients: clinical maltrato infantil en niños y adolescentes implications. con trastornos psiquiátricos: PhD student: Pablo Barrio Gimenez Modiﬁcaciones epigenéticas y correlatos con marcadores periféricos de inmunidad Martín-Santos R, Navinés R. Health innata. related quality of life and risk factors in Sponsored by: Instituto de Salud Carlos III hepatitis C patients.

238 NEUROPSYCHOLOGY 4.8 4.8 Neuropsychology

STRATEGIC OBJECTIVES

LOCATION 1. To study the consequences of cerebral UB School of Medicine lesions and dysfunctions in behavior and cognition.

2. We are involved in the Barcelona Brain WEB Health Initiative project which is framed www.ub.edu/neuropsychology/ within the strategic research line towards a html/portada.html better understanding of the risk and TEAM LEADER protective factors, as well as the brain Carme Junqué (UB) mechanisms, related to preserved T. 93 403 92 98 cognitive function and mental health in late life. [email protected]

KEYWORDS MAIN LINES OF RESEARCH 1. Magnetic resonance imaging 2. Structural and functional connectivity RESEARCHERS 1. Neuropsychology and neuroimaging in 3. Aging and degenerative illness Nuria Bargalló (HCB) Parkinson's disease: This line of research 4. Non-invasive brain stimulation David Bartrés (UB) makes use of combined structural and Teresa Boget (HCB) functional magnetic resonance imaging to 5. Brain plasticity detect early alterations in brain connectivity POST-DOCTORAL RESEARCHERS and its evolution during the degenerative Hugo César Baggio (UB) process. Cristina Sánchez (UB) Bárbara Segura (UB) 2. Cerebral plasticity: In the ﬁeld we study Cristina Solé (UB) changes in brain structure and function Original publications induced by transcranial electric and from 2015 to 2017 PRE-DOCTORAL RESEARCHERS magnetic stimulation through magnetic

YEAR I.F. TOTAL Q1 Q2 Kilian Abellaneda (UB) resonance imaging. Alexandra Abós (UB) 2015 152.00 32 27 5 Anna Campabadal (IDIBAPS) 3. Development of imaging techniques to 2016 125.59 29 24 3 Juan Pablo Martín (UB) study the brain areas implicated in Carme Uribe (UB) higher cognitive function impairment in 2017 94.34 22 14 6 epileptic patients, based on functional magnetic resonance imaging.

TEAM INVOLVED IN AGAUR_SGR14 Carme Junqué

TEAM

239 AREA 4 CLINICAL AND EXPERIMENTAL NEUROSCIENCE

4. Brain changes related to life style in AM J OBSTET GYNECOL. with intelligence quotient and executive normal aging. The objective is to build a 216(1):62.e1-62.e14. I.F.: 5.226 function. NEUROIMAGE: CLINICAL. prospective study cohort of >3.000 15:789-800. I.F.: 4.348 volunteers aged 40 to 65 years to obtain 6. Nathan PJ, Lim YY, Abbott R, Galluzzi S, information as regards lifestyles, and to Marizzoni M, Babiloni C, Albani D, Bartres-Faz 11. Abós A, Baggio HC, Segura B, García-Díaz follow up a group of 1.500 yearly (including D, Didic M, Farotti L, Parnetti L, Salvadori N, AI, Compta Y, Martí MJ, Valldeoriola F, Junqué measures of MRI, EEG,...) and undertake a Müller BW, Forloni G, Girtler N, Hensch T, C. Discriminating cognitive status in non-pharmacological trial intervention to Jovicich J, Leeuwis A, Marra C, Molinuevo JL, Parkinson's disease through functional modify the brain health related habits. Nobili F, Pariente J, Payoux P, Ranjeva JP, connectomics and machine learning. Rolandi E, Rossini PM, Schönknecht P, SCIENTIFIC REPORTS. 7:45347. I.F.: 4.259 Soricelli A, Tsolaki M, Visser PJ, Wiltfang J, PUBLICATIONS Richardson JC, Bordet R, Blin O, Frisoni GB, 12. Cordova-Palomera, Aldo; de Reus, Marcel PharmaCog Consortium. Association A.; Fatjo-Vilas, Mar; Falcon, Carles; Bargallo, Originals / I.F.: 94.342 between CSF biomarkers, hippocampal Nuria; van den Heuvel, Martijn P.; Fananas, volume and cognitive function in patients Lourdes. FKBP5 modulates the 1. Grothe MJ, Villeneuve S, Dyrba M, with amnestic mild cognitive impairment hippocampal connectivity deﬁcits in Bartrés-Faz D, Wirth M, Alzheimer's Disease (MCI). NEUROBIOL AGING. 53:1-10. I.F.: 5.117 depression: a study in twins. BRAIN Neuroimaging Initiative. Multimodal IMAGING AND BEHAVIOR. 11(1):62-75. characterization of older APOE2 carriers 7. Ballester-Plané J., Schmidt R., I.F.: 3.985 reveals selective reduction of amyloid Laporta-Hoyos O., Junqué C., Vázquez É., load. NEUROLOGY. 88(6):569-576. I.F.: 8.320 Delgado I., Zubiaurre-Elorza L., Macaya A., 13. Vaqué-Alcázar L., Sala-Llonch R., Póo P., Toro E., de Reus M., van den Heuvel M., Valls-Pedret C., Vidal-Piñeiro D., 2. Paillère-Martinot M., Galinowski A., Plaze M., Pueyo R. Whole-brain structural Fernández-Cabello S., Bargalló N., Ros E., Andoh J., Bartrés-Faz D., Bellivier F., connectivity in dyskinetic cerebral palsy Bartrés-Faz D. Differential age-related gray Lefaucheur J., Rivière D., Gallarda T., Martinot and its association with motor and and white matter impact mediates J., Artiges E. Active and placebo cognitive function. HUMAN BRAIN educational inﬂuence on elders’ cognition. transcranial magnetic stimulation effects MAPPING. 38(9):4594-4612. I.F.: 4.530 BRAIN IMAGING AND BEHAVIOR. on external and internal auditory 11(2):318-332. I.F.: 3.985 hallucinations of schizophrenia. ACTA 8. Albi A, Pasternak O, Minati L, Marizzoni M, PSYCHIATRICA SCANDINAVICA. Bartrés-Faz D, Bargalló N, Bosch B, Rossini 14. Grau-Rivera O, Calvo A, Bargalló N, Monté 135(3):228-238. I.F.: 6.790 PM, Marra C, Müller B, Fiedler U, Wiltfang J, GC, Nos C, Lladó A, Molinuevo JL, Gelpi E, Roccatagliata L, Picco A, Nobili FM, Blin O, Sánchez-Valle R. Quantitative Magnetic 3. Padilla, Nelly; Fransson, Peter; Donaire, Sein J, Ranjeva JP, Didic M, Bombois S, Lopes Resonance Abnormalities in Antonio; Figueras, Francesc; Arranz, Angela; R, Bordet R, Gros-Dagnac H, Payoux P, Creutzfeldt-Jakob Disease and Fatal Sanz-Cortes, Magdalena; Tenorio, Violeta; Zoccatelli G, Alessandrini F, Beltramello A, Insomnia. JOURNAL OF ALZHEIMER'S Bargallo, Nuria; Junque, Carme; Lagercrantz, Ferretti A, Caulo M, Aiello M, Cavaliere C, DISEASE. 55(1):431-443. I.F.: 3.731 Hugo; Aden, Ulrika; Gratacos, Eduard. Soricelli A, Parnetti L, Tarducci R, Floridi P, Intrinsic Functional Connectivity in Tsolaki M, Constantinidis M, Drevelegas A, 15. Bargallo, Nuria; Gilabert, Rosa; Preterm Infants with Fetal Growth Frisoni G, Jovicich J, PharmaCog Consortium. Romero-Mamani, Edwin-Saul; Cofan, Restriction Evaluated at 12 Months Free water elimination improves Montserrat; Calder, Philip C.; Fito, Montserrat; Corrected Age. CEREBRAL CORTEX. test-retest reproducibility of diffusion Corella, Dolores; Salas-Salvado, Jordi; 27(10):4750-4758. I.F.: 6.559 tensor imaging indices in the brain: A Ruiz-Canela, Miguel; Estruch, Ramon; Ros, longitudinal multisite study of healthy Emilio; Sala-Vila, Aleix. Red Blood Cell 4. Sugranyes G, Solé-Padullés C, de la Serna elderly subjects. HUM BRAIN MAPP. Eicosapentaenoic Acid Inversely Relates E, Borras R, Romero S, Sanchez-Gistau V, 38(1):12-26. I.F.: 4.530 to MRI-Assessed Carotid Plaque Lipid Garcia-Rizo C, Goikolea JM, Bargallo N, Core Burden in Elders at High Moreno D, Baeza I, Castro-Fornieles J. 9. Campabadal A., Uribe C., Segura B., Baggio Cardiovascular Risk. NUTRIENTS. Cortical Morphology Characteristics of H., Abos A., Garcia-Diaz A., Marti M., 9(9):E1036. I.F.: 3.550 Young Offspring of Patients With Valldeoriola F., Compta Y., Bargallo N., Junque Schizophrenia or Bipolar Disorder. J AM C. Brain correlates of progressive olfactory 16. Solé-Padullés C, Castro-Fornieles J, de la ACAD CHILD ADOLESC PSYCHIATRY. loss in Parkinson's disease. Serna E, Sánchez-Gistau V, Romero S, Puig O, 56(1):79-88. I.F.: 6.442 PARKINSONISM AND RELATED Calvo A, Bargalló N, Baeza I, Sugranyes G. DISORDERS. 41:44-50. I.F.: 4.484 Intrinsic functional connectivity of 5. Simões RV, Muñoz-Moreno E, Cruz-Lemini fronto-temporal networks in adolescents M, Eixarch E, Bargalló N, Sanz-Cortés M, 10. Laporta-Hoyos O., Pannek K., with early psychosis. EUR CHILD ADOLESC Gratacós E. Brain metabolite alterations in Ballester-Plané J., Reid L., Vázquez É., PSYCHIATRY. 26(6):669-679. I.F.: 3.295 infants born preterm with intrauterine Delgado I., Zubiaurre-Elorza L., Macaya A., growth restriction: association with Póo P., Meléndez-Plumed M., Junqué C., Boyd 17. Ottino-Gonzalez, Jonatan; Jurado, Maria structural changes and R., Pueyo R. White matter integrity in A.; Garcia-Garcia, Isabel; Segura, Barbara; neurodevelopmental outcome. dyskinetic cerebral palsy: Relationship Marques-Iturria, Idoia; Sender-Palacios, Maria

240 NEUROPSYCHOLOGY 4.8

J.; Tor, Encarnacio; Prats-Soteras, Xavier; CLINICAL NEUROPATHOLOGY. Caldu, Xavier; Junque, Carme; Garolera, Maite. 36(4):162-163. I.F.: 1.532 Allostatic Load Is Linked to Cortical Thickness Changes Depending on Body-Weight Status. FRONTIERS IN GRANTS FOR RESEARCH IN PROGRESS HUMAN NEUROSCIENCE. 11:639. I.F.: 3.209 Bartres D. Efectos del entrenamiento 18. Sanz Cortes M, Bargallo N, Arranz A, cognitivo combinado con estimulación Simoes R, Figueras F, Gratacos E. Feasibility cerebral no-invasiva guiada por and Success Rate of a Fetal MRI and MR información funcional cerebral en el Spectroscopy Research Protocol deterioro cognitivo leve. Performed at Term Using a 3.0-Tesla Sponsored by: Ministerio de Economia y Scanner. FETAL DIAGNOSIS AND Competitividad (MINECO). PSI2015-64227-R THERAPY. 41(2):127-135. I.F.: 2.699 Duration: 01/01/2016-31/12/2018

19. Sarbu N, Toledano P, Calvo A, Roura E, Bartres D. Barcelona Brain Health Initiative. Sarbu MI, Espinosa G, Lladó X, Cervera R, Sponsored by: Obra social La Caixa Bargalló N. Advanced MRI techniques: (Fundació Abertis). biomarkers in neuropsychiatric lupus. Duration: 1/07/2016-1/07/2019 LUPUS. 26(5):510-516. I.F.: 2.454 Bartres D. Breaking new ground in lifespan 20. Brugulat-Serrat A., Rojas S., Bargalló N., cognitive neuroscience. Conesa G., Minguillón C., Fauria K., Gramunt Sponsored by: European commission. H2020 N., Molinuevo J., Gispert J. Incidental ﬁndings Duration: 01/01/2017-31/12/2018 on brain MRI of cognitively normal ﬁrst-degree descendants of patients with Junqué C. Reorganización de las redes Alzheimer's disease: A cross-sectional cerebrales implicadas en la cognición analysis from the ALFA (Alzheimer and durante el proceso degenerativo en la Families) project. BMJ OPEN. 7(3):e013215. enfermedad de Parkinson. I.F.: 2.369 Sponsored by: Ministerio de Economia y Competitividad (MINECO). PSI-2013-41393-P 21. Carreño M., Bien C., Asadi-Pooya A., Duration: 01/01/2014-31/12/2017 Marusic P., Pimentel J., Wehner T., Mohanraj R., Uranga J., Gómez-Ibáñez A., Bargalló N., Junqué C. Brain connectivity changes Rumià J., Setoain X., Pintor L., Bailles E., Falip during the degenerative process in M., Dalmau J., Gil F., Sperling M., Elisak M., Parkinson's disease. Villanueva V., Roldán P., Boget T., Donaire A., Sponsored by: Fundació la marató TV3. Aparicio J., Graus F. Epilepsy surgery in drug 20142310 resistant temporal lobe epilepsy Duration: 22/05/2015-21/05/2018 associated with neuronal antibodies. EPILEPSY RESEARCH. 129:101-105. I.F.: 2.367 DOCTORAL THESES 22. Server A., Bargalló N., Fløisand Y., Sponheim J., Graus F., Hald J. Imaging Bargalló N. Advanced and spectrum of central nervous system conventional magnetic resonance imaging complications of hematopoietic stem cell techniques: biomarkers in reurolupus. and solid organ transplantation. PhD student: Nicola Sarbu NEURORADIOLOGY. 59(2):105-126. I.F.: 2.093 Bargalló N. Resonancia magnética funcional aplicada al manejo de tumores Letters / I.F.: 1.532 cerebrales en el entorno clínico. PhD student: Sofía González Ortiz 1. Guasp-Verdaguer, Mar; Grau-Rivera, Oriol; Prats-Galino, Alberto; Bargallo, Nuria; Sanchez-Valle, Raquel; Gelpi, Ellen; Soria, Guadalupe. Clinical Neuropathology image 4-2017: High-resolution 7 Tesla MRI of postmortem brain specimens: improving neuroimaging-neuropathology correlations.

241 AREA 4 CLINICAL AND EXPERIMENTAL NEUROSCIENCE

Systems 4.9 neuroscience

PRE-DOCTORAL RESEARCHERS Almudena Barbero (IDIBAPS) LOCATION Ainhoa Hermoso (IDIBAPS) CEK building Joao Moura (IDIBAPS) Tíffany Oña (IDIBAPS) Genís Prat (IDIBAPS) David Sánchez (IDIBAPS)

WEB Simon Serca (IDIBAPS) www.sanchez-vives.org Heike Stein (IDIBAPS) neuro.fcrb.es/complab Melodia Torao (IDIBAPS) Julia Franziska Weinert (IDIBAPS) neuro.fcrb.es/delaRochaLab TEAM LEADER María Victoria Sánchez Vives TECHNICIANS (ICREA-IDIBAPS) Rachid Azizi (IDIBAPS) T. 93 227 54 00 (Ext.: 4301) Adrià Galan (IDIBAPS) [email protected] Rafael Marín (FCRB) Álvaro Navarro (IDIBAPS) KEYWORDS Jordi Pastor (IDIBAPS) 1. Cerebral cortex GROUP LEADERS Lorena Pérez (IDIBAPS) 2. Computational neuroscience Albert Compte (IDIBAPS) Jose Valenzuela (IDIBAPS) 3. Oscillations T. 93 227 54 00 (Ext.: 4151) 4. Virtual reality [email protected] ADMINISTRATIVE STAFF 5. Body representation Lejla Bektic (IDIBAPS) 6. Working memory Jaime de la Rocha (IDIBAPS) Arnau Llobet (IDIBAPS) 7. Spatial memory T. 93 227 54 00 (Ext.: 4307) 8. Desision-making [email protected]

POST-DOCTORAL RESEARCHERS Miguel Dasilva (IDIBAPS) Maria Vanessa Fernandez (IDIBAPS) Cristina González (IDIBAPS) Original publications Daniel Linares (FCRB) from 2015 to 2017 Diego Lozano (IDIBAPS)

YEAR I.F. TOTAL Q1 Q2 Marta Matamala (IDIBAPS) Birgit Nierula (IDIBAPS) 2015 55.34 9 63 Beatriz Rebollo (IDIBAPS) 2016 48.56 8 8- Soﬁa Seinfeld (IDIBAPS) 2017 68.79 11 10 1 Bernhard Spanlang (IDIBAPS)

TEAM INVOLVED IN AGAUR_SGR14 María Victoria Sánchez Vives

TEAM

242 SYSTEMS NEUROSCIENCE 4.9

STRATEGIC OBJECTIVES 3. Cortical circuit dynamics. Headed by By building computational models of Dr. de la Rocha: cognitive function and testing model-derived The growing knowledge of synaptic - Neural circuit dynamics during perceptual hypotheses experimentally, we aim at physiology and brain circuits, together decision making and Working Memory providing links between speciﬁc synaptic, with the development of new instruments tasks. cellular and circuit mechanisms and cognitive with which to record, analyze and model the - Network mechanisms underlying and perceptual functions and dysfunctions. activity of a large number of neurons has spontaneous activity and brain state made it possible to address one of the great changes. pending challenges in neuroscience: - The role of hippocampal circuits during spatial to understand the relationship between long term memory acquisition and retrieval. the activity of the neuronal population and behavioral performance. The general objective of the Systems Neuroscience group is to address this RESEARCH GROUP challenge by combining experimental studies THEORETICAL NEUROBIOLOGY in cerebral cortex networks with a combined OF CORTICAL CIRCUITS experimental and theoretical approach.

MAIN LINES OF RESEARCH

1. Cortical networks and EVENT Lab. Headed by Dr. Sánchez-Vives: We study different aspects of spontaneous GROUP LEADER and evoked cortical activity: the Albert Compte (IDIBAPS) mechanisms that regulate it, the information it encodes, its spatiotemporal We investigate the circuit mechanisms that properties and its consequences on the operate in the cerebral cortex during network. Moreover, we explore cortical perceptual and cognitive processes. activity in transgenic mouse models of We focus our efforts on cortical mechanisms neurological disease in the search for the for working memory, and their failure in underlying altered mechanisms and their anti-NMDAR encephalitis and schizophrenia possible reversion. patients. In addition, we are interested in the Our methods include biologically plausible integration of cortical information that gives computational modelling, together with rise to body representation and in the behavioral, electrophysiological and combination of brain-computer interfaces neuroimaging experiments in healthy and virtual reality to understand these human participants and in patients. processes (EVENT lab, www.event-lab.org).

2. Theoretical neurobiology of cortical circuits. Headed by Dr. Compte: - Circuit mechanisms of spatial and feature working memory. - Network basis of cognitive and perceptual alterations in anti- NMDAr encephalitis patients. - Mechanisms of spatial working memory deﬁcits in schizophrenia. Albert Compte

GROUP

243 AREA 4 CLINICAL AND EXPERIMENTAL NEUROSCIENCE

RESEARCH GROUP PUBLICATIONS 6. Capone C, Rebollo B, Muñoz A, Illa X, Del CORTICAL CIRCUIT DYNAMICS Giudice P, Sanchez-Vives MV, Mattia M. Slow Originals / I.F.: 68.788 Waves in Cortical Slices: How Spontaneous Activity is Shaped by 1. Nogueira R., Abolafia J., Drugowitsch J., Laminar Structure. CEREBRAL CORTEX. Balaguer-Ballester E., Sanchez-Vives M., 28:1-17. I.F.: 6.559 Moreno-Bote R. Lateral orbitofrontal cortex anticipates choices and integrates prior 7. Nierula B, Martini M, Matamala-Gomez M, with current information. NATURE Slater M, Sanchez-Vives MV. Seeing an GROUP LEADER COMMUNICATIONS. 8:14823. I.F.: 12.124 Embodied Virtual Hand is Analgesic Jaime de la Rocha (IDIBAPS) Contingent on Colocation. JOURNAL OF 2. D'Amico D, Gener T, de Lagrán MM, PAIN. 18(6):645-655. I.F.: 4.519 We study the neuronal circuit mechanisms Sanchez-Vives MV, Santos M, Dierssen M. underlying cognitive functions such as Infralimbic Neurotrophin-3 Infusion Rescues 8. Castano-Prat P., Perez-Zabalza M., perception, decision making and memory. Fear Extinction Impairment in a Mouse Perez-Mendez L., Escorihuela R., For this, (1) we train rodents to perform Model of Pathological Fear. BIOLOGICAL Sanchez-Vives M. Slow and fast neocortical perceptual discrimination and memory tasks, PSYCHIATRY. 42(2):462-472. I.F.: 11.412 oscillations in the senescence-accelerated (2) we quantitatively characterize the variables mouse model SAMP8. FRONTIERS IN that determine their behavior and (3) identify 3. Jercog D, Roxin A, Barthó P, Luczak A, AGING NEUROSCIENCE. 9(MAY):141. the brain areas where these variables are Compte A, de la Rocha J. UP-DOWN cortical I.F.: 4.504 represented and the detailed circuit dynamics dynamics reflect state transitions in a underlying their processing. bistable network. ELIFE. 6:e22425. I.F.: 7.725 9. Brotons-Mas, R.; Schaffelhofer, S.; Guger, We investigate how expectation is formed C.; O'Mara, S. M.; Sanchez-Vives, M. V. from recent experiences and how it impacts 4. Blaschke, Benno M.; Tort-Colet, Nuria; Heterogeneous spatial representation by the representation of sensory stimuli. Guimera-Brunet, Anton; Weinert, Julia; different subpopulations of neurons in the We use pharmacology, population neural Rousseau, Lionel; Heimann, Axel; Drieschner, subiculum. NEUROSCIENCE. 343:174-189. recordings, quantitative analysis and Simon; Kempski, Oliver; Villa, Rosa; I.F.: 3.277 computational modeling to address these Sanchez-Vives, Maria V.; Garrido, Jose A. questions. Mapping brain activity with flexible 10. Agustí A., Compte A., Faner R., We moreover apply these methods to graphene micro-transistors. 2D Garcia-Aymerich J., Noell G., Cosio B., understand neural disorders such as MATERIALS. 4(2):21-37. I.F.: 6.937 Rodriguez-Roisin R., Celli B., Anto J. The EASI anti-NMDAR encephalitis. model: A first integrative computational 5. Ramirez-Mahaluf JP, Roxin A, Mayberg HS, approximation to the natural history of Compte A. A Computational Model of Major COPD. PLOS ONE. 12(10):e0185502. I.F.: Depression: the Role of Glutamate 2.806 Dysfunction on Cingulo-Frontal Network Dynamics. CEREBRAL CORTEX. 11. Nykamp D., Friedman D., Shaker S., Shinn 27(1):660-679. I.F.: 6.559 M., Vella M., Compte A., Roxin A. Mean-field equations for neuronal networks with arbitrary degree distributions. PHYSICAL REVIEW E - STATISTICAL, NONLINEAR, AND SOFT MATTER PHYSICS. 95(4):042323. I.F.: 2.366

Review / I.F.: 14.024

1. Sanchez-Vives MV, Massimini M, Mattia M. Shaping the Default Activity Pattern of the Cortical Network. NEURON. 94(5):993-1001. I.F.: 14.024

Letters / I.F.: 5.988

1. Barbosa, Joao. Working Memories Are Maintained in a Stable Code. JOURNAL OF NEUROSCIENCE. 37(35):8309-8311.I.F.: 5.988 Jaime de la Rocha

GROUP

244 SYSTEMS NEUROSCIENCE 4.9

GRANTS FOR RESEARCH IN PROGRESS DOCTORAL THESES

Compte A. Prefrontal network Sanchez Vives MV. Synaptic and mechanisms of working memory non-synaptic propagation of slow waves dynamics: from dopamine and their modulation by endogenous neuromodulation to network dysfunction electric fields. in anti-NMDAR encephalitis. PhD student: Beatriz Rebollo González Sponsored by: Ministerio de Economia y Competitividad. BFU2015-65318-R Sanchez Vives MV. The use of Duration: 01/01/2016-31/12/2018 immersive virtual reality in neurorehabilitation and its impact on De la Rocha J. Neural circuit dynamics neuroplasticity. underlying expectation and their impact on PhD student: Marta Matamala Gomez the variability of perceptual choices. Sponsored by: European commission H2020 Sanchez Vives MV. Oscilaciones lentas en la ERC Consolidator Grant 2015. red cortical alterada:una caracterización Duration: 01/09/2016-31/08/2021 de los modelos murinos 3xTg-AD, SAMP8 y Fmr1KO. De la Rocha J. La dinámica de los circuitos PhD student: Patricia Castaño Prat neuronales durante la toma de decisiones perceptuales. Sanchez Vives MV, Slater M. Multisensory Sponsored by: Ministerio de Economia y processing and agency in VR embodiment; Competitividad. SAF2015-70324-R interactions through BCI and their Duration: 01/01/2016-31/12/2018 therapeutic applications. PhD student: Birgit Nierula Sanchez-Vives MV. Cortical organization generated in transgenic models of Sanchez Vives MV, Slater M. Improving cognitive deficit and reversal empathy in domestic violence offenders exploration. (COGITARE). through perspective-taking in immersive Sponsored by: Ministerio de Economia virtual reality. y Competitividad. BFU2014-52467R PhD student: Sofia Seinfeld Duration: 01/01/2015-31/12/2017 Sanchez Vives MV, Mattia M. Emergent Sanchez-Vives MV. Dinámica de las rhythmic activity and functional oscilaciones lentas: experimentos, connectivity in the thalamocortical circuit análisis, modelos e intervenciones at different brain states. terapéuticas (SloW-Dyn). PhD student: Núria Tort Colet Sponsored by: Ministerio de Economia y Competividad (MINECO). PCIN-2015-162-C02-01 Duration: 01/12/2015-30/11/2018

Sanchez-Vives MV. Graphene-based disruptive technologies. Sponsored by: European commission H2020-Adhoc-14-20 Dutarion: 01/04/2016-31/03/2018

Sanchez-Vives MV. Human Brain Project Speciﬁc Grant Agreement 1. Sponsored by: European commission HBP_SCN15 Duration: 01/04/2016-31/03/2018

245 AREA 4 CLINICAL AND EXPERIMENTAL NEUROSCIENCE

Clinical and experimental 4.10 neuroimmunology

Núria Solà (IDIBAPS) Marianna Spatola (IDIBAPS) LOCATION Irati Zubizarreta (IDIBAPS) CELLEX building 3A

TECHNICIANS Esther Aguilar (IDIBAPS) Mercedes Alba (FCRB) WEB Salut Albà (IDIBAPS) www.neuroimmunologybcn.org Montserrat Artola (IDIBAPS) Eva Maria Caballero (FCRB) Begoña Fernández (IDIBAPS) TEAM LEADER Ana Isabel Guerrero (IDIBAPS) Josep Dalmau (ICREA-IDIBAPS) Víctor López (CIBER) T. 93 227 17 38 Rosa Rodríguez (IDIBAPS) [email protected] KEYWORDS Gemma Vila (IDIBAPS) 1. Autoantibodies 2. Encephalitis ADMINISTRATIVE STAFF GROUP LEADERS Gemma Castillo (FCRB) 3. Multiple sclerosis Josep Dalmau (ICREA-IDIBAPS) 4. Paraneoplastic Laura Planas (IDIBAPS) T. 93 227 17 38 Maria Rodés (IDIBAPS) 5. Cancer [email protected]

COLLABORATORS Sara Llufriu (IDIBAPS) Domingo Escudero (HCB) T. 93 227 54 14 Myrna Rosenfeld (IDIBAPS) [email protected] Bernardo Sánchez-Dalmau (HCB)

Original publications Pablo Villoslada (IDIBAPS) VISITING SCIENTISTS from 2015 to 2017 T. 93 227 54 00 (Ext.: 4802) Matteo Gastaldi (University of Pavia, Italy) [email protected] YEAR I.F. TOTAL Q1 Q2 Simone Matozzi (AOU-Sassari, Italy) Benedict Rieger (Heidelberg University, 2015 185.55 35 25 5 Germany) 2016 199.30 32 21 6 EMERITUS Gabriella Secondi (Hospital Sant Joan de Déu, Francesc Graus (HCB) 2017 127.24 23 18 2 Spain)

RESEARCHERS Thais Armangué (IDIBAPS) STRATEGIC OBJECTIVES Yolanda Blanco (HCB) Pedro Luís Gambús (HCB) TEAM INVOLVED IN The principal objective of the Elena Hernández (IDIBAPS) REEM Neuroimmunology Group is the study of Eugenia Maria Martínez (IDIBAPS) autoimmune (inflammatory) diseases of the CIBERER Lidia Sabater (FCRB) AGAUR_SGR14 nervous system and the elucidation of the Albert Saiz (HCB) underlying immunopathogenic mechanisms involved in the inflammatory response. POST-DOCTORAL RESEARCHERS Diseases under study include multiple Helena Ariño (IDIBAPS) sclerosis, neuromyelitis optica, autoimmune Pablo Jercog (IDIBAPS) encephalitis and paraneoplastic neurological Eloy Martínez (IDIBAPS) disorders. AWARDS Marta Pedreño (FCRB) Premio Rey Jaime I in Medical Research/ Jesús Planagumà (IDIBAPS) Clinical Medicine Irene Pulido (IDIBAPS) MAIN LINES OF RESEARCH Institution: Fundación Premios Rey Jaime I Marija Radosevic (IDIBAPS) Awardee/s: Josep Dalmau Elisabeth Solana (IDIBAPS) 1. Identification of novel autoimmune diseases of the nervous system in adults Doctor Honoris Causa PRE-DOCTORAL RESEARCHERS and children and the development of Institution: University of Lyon, France Magí Andorra (IDIBAPS) diagnostic tests for these disorders. Awardee/s: Josep Dalmau Anna Garcia (IDIBAPS) Francesco Mannara (FCRB) 2. Development of biomarkers and new Lucía Morales (IDIBAPS) therapies for multiple sclerosis, Maria del Mar Petit (IDIBAPS) neuromyelitis optica and other Maria Sepúlveda (FCRB) demyelinating diseases.

246 TEAM Sara Llufriu TEAM Josep Dalmau 3. demyelinating mechanismsleadingtobraindamagein diseases. brainimagingtodissecttheimmunological 6. system. autoimmunediseasesofthenervous 5. behavioralandin-silicomodels. advanced synapticfunctionandbrainnetworksusing neuroimaging, 4. disorders. encephalitisandparaneoplasticneurologic mechanismsthatresultinautoimmune Characterizationoftheimmunopathogenic The useofsystemsbiologyandfunctional The developmentofmodels To elucidatehowautoimmunityaffects electrophysiology, NEURONAL DISORDERS PATHOGENESIS OFAUTOIMMUNE RESEARCH GROUP immune-mechanisms, isolationofthe the descriptionofnovelsyn diseases triggeredbycancer.Studiesinclude diseases ofthesynapse Our researchfocusesonimmune-mediated Josep Dalmau GROUP LEADER (ICREA-IDIBAPS) and autoimmunebrain dromes and CLINICAL ANDEXPERIMENTAL NEUROIMMUNOLOGY (IMAGINEM) NEUROIMMUNOLOGICAL DISEASES ADVANCED IMAGINGIN 50/50 PROGRAM vitro, invivo,andin-silicomodeling. the targetproteinsandreceptors,byin antibodies modifythelevelsandfunctionof underlie thedisordersbyexamininghow We areinvestigatingthemechanismsthat plasticity. roles insynaptictransmission,signalingand and synapticreceptorsthatplayimportant with antibodiesthattargetneuronalproteins We haveshownthatthesediseasesassociate diagnostic testsandnewtreatments. target antigensanddevelopmentof Multiple Sclerosis). MAGNIMS (MagneticResonanceImagingin We arepartoftheEuropeannetwork research tothepatient. processing touseinthetranslationof with newsequencesandnovelimage We havedevelopedtechnicalimprovements cognitive rehabilitation. response ofdiseaseevolutionandafter mechanisms ofneuralreorganizationasa Recently, weareinterestedinthestudyof response toconventionalandnewtherapies. physical andcognitivedisabilityof We aimtoidentifyimagingbiomarkersof magnetic resonancetechniques. diseases, throughtheuseofadvanced sclerosis andotherneuroimmunological of thebasisdiseaseevolutioninmultiple Our researchisfocusedontheunderstanding Sara Llufriu GROUP LEADER (IDIBAPS) 4.10 247 AREA 4 CLINICAL AND EXPERIMENTAL NEUROSCIENCE

RESEARCH GROUP 3. Escudero, Domingo; Guasp, Mar; Arino, 9. Peschl P; Schanda K; Zeka B; Given K; PATHOGENESIS AND NEW Helena; Gaig, Carles; Martinez-Hernandez, Böhm D; Ruprecht K; Saiz A; Lutterotti A; TREATMENTS IN MULTIPLE Eugenia; Dalmau, Josep; Graus, Francesc. Rostásy K; Hoftberger R; Berger T; Macklin W; SCLEROSIS Antibody-associated CNS syndromes Lassmann H; Bradl M; Bennett JL; Reindl M. without signs of inflammation in the Human antibodies against the myelin GROUP LEADER elderly. NEUROLOGY. 89(14):1471-1475. oligodendrocyte glycoprotein can cause Pablo Villoslada (IDIBAPS) I.F.: 8.320 complement-dependent demyelination. JOURNAL OF NEUROINFLAMMATION. Our team is pioneering the application of 4. Hara, Makoto; Arino, Helena; Petit-Pedrol, 14(1):208-1120. I.F.: 5.102 Systems Medicine to the study of Multiple Mar; Sabater, Lidia; Titulaer, Maarten J.; Sclerosis (MS) and the development of new Martinez-Hernandez, Eugenia; Schreurs, 10. Sepúlveda M, Fernández-Diez B, tools for personalized medicine. We are Marco W. J.; Rosenfeld, Myrna R.; Graus, Martínez-Lapiscina EH, Llufriu S, Sola-Valls N, developing new therapies such as the trophic Francesc; Dalmau, Josep. Zubizarreta I, Blanco Y, Saiz A, Levy D, factor like drug BN201 or antigen-specific DPPX antibody-associated encephalitis Glimcher P, Villoslada P. Impairment of tolerization. We have developed new Main syndrome and antibody effects. decision-making in multiple sclerosis: A diagnostic tools such as molecular imaging NEUROLOGY. 88(14):1340-1348. I.F.: 8.320 neuroeconomic approach. MULTIPLE of the retina to monitor disease progression. SCLEROSIS. 23(13):1762-1771. I.F.: 4.840 Another of our strategic objectives is the 5. Torres-Vega, Estefania; Mancheno, Nuria; diffusion of knowledge and optimum use Cebrian-Silla, Arantxa; Herranz-Perez, 11. Sepúlveda M, Aldea M, Escudero D, Llufriu of synergies, with a view to transferring the Vicente; Chumillas, Maria J.; Moris, German; S, Arrambide G, Otero-Romero S, advances in research to clinical practice. Joubert, Bastien; Honnorat, Jerome; Sevilla, Sastre-Garriga J, Romero-Pinel L, Lastly, the group has a commitment to Teresa; Vilchez, Juan J.; Dalmau, Josep; Martínez-Yélamos S, Sola-Valls N, Armangué innovation, both in terms of the generation Graus, Francesc; Manuel Garcia-Verdugo, T, Sotoca J, Escartín A, Robles-Cedeño R, of patents and as regards the creation of Jose; Bataller, Luis. Netrin-1 receptor Ramió-Torrentà L, Presas-Rodríguez S, spin-off companies. antibodies in thymoma-associated Ramo-Tello C, Munteis E, Pelayo R, Gubieras neuromyotonia with myasthenia gravis. L, Brieva L, Ortiz N, Hervás M, Mañé-Martínez NEUROLOGY. 88(13):1235-1242. I.F.: 8.320 MA, Cano A, Vela E, Tintoré M, Blanco Y, PUBLICATIONS Montalban X, Graus F, Saiz A. Epidemiology 6. Spatola, Marianna; Petit-Pedrol, Mar; of NMOSD in Catalonia: Influence of the Originals / I.F.: 127.124 Simabukuro, Mateus Mistieri; Armangue, new 2015 criteria in incidence and Thas; Castro, Fernanda J.; Barcelo Artigues, prevalence estimates. MULTIPLE 1. Jézéquel J., Johansson E., Dupuis J., Maria I.; Julia Benique, Maria R.; Benson, Leslie; SCLEROSIS. 1:1352458517735191. I.F.: 4.840 Rogemond V., Gréa H., Kellermayer B., Gorman, Mark; Felipe, Ana; Oblitas, Ruben L. Hamdani N., Le Guen E., Rabu C., Lepleux M., Caparo; Rosenfeld, Myrna R.; Graus, 12. Sepúlveda M, Sola-Valls N, Escudero D, Spatola M., Mathias E., Bouchet D., Ramsey A., Francesc; Dalmau, Josep. Investigations in Rojc B, Barón M, Hernández-Echebarría L, Yolken R., Tamouza R., Dalmau J., Honnorat J., GABAA receptor antibody-associated Gómez B, Dalmau J, Saiz A, Graus F. Clinical Leboyer M., Groc L. Dynamic encephalitis. NEUROLOGY. profile of patients with paraneoplastic disorganization of synaptic NMDA 88(11):1012-1020. I.F.: 8.320 neuromyelitis optica spectrum disorder receptors triggered by autoantibodies and aquaporin-4 antibodies. MULTIPLE from psychotic patients. NATURE 7. Gaig C, Graus F, Compta Y, Högl B, Bataller SCLEROSIS.:1352458517731914-1352458517 COMMUNICATIONS. 8(1):1791. I.F.: 12.124 L, Brüggemann N, Giordana C, Heidbreder A, 731914. I.F.: 4.840 Kotschet K, Lewerenz J, Macher S, Martí MJ, 2. Muraro, Paolo A.; Pasquini, Marcelo; Atkins, Montojo T, Pérez-Pérez J, Puertas I, Seitz C, 13. Kotelnikova E, Kiani NA, Abad E, Harold L.; Bowen, James D.; Farge, Dominique; Simabukuro M, Téllez N, Wandinger KP, Iranzo Martinez-Lapiscina EH, Andorra M, Fassas, Athanasios; Freedman, Mark S.; A, Ercilla G, Sabater L, Santamaría J, Dalmau J. Zubizarreta I, Pulido-Valdeolivas I, Georges, George E.; Gualandi, Francesca; Clinical manifestations of the anti-IgLON5 Pertsovskaya I, Alexopoulos LG, Olsson T, Hamerschlak, Nelson; Havrdova, Eva; disease. NEUROLOGY. 88(18):1736-1743. Martin R, Paul F, Tegnér J, Garcia-Ojalvo J, Kimiskidis, Vassilios K.; Kozak, Tomas; I.F.: 8.320 Villoslada P. Dynamics and heterogeneity of Mancardi, Giovanni L.; Massacesi, Luca; brain damage in multiple sclerosis. PLOS Moraes, Daniela A.; Nash, Richard A.; Pavletic, 8. Moreno M., Pedrosa L., Paré L., Pineda E., COMPUTATIONAL BIOLOGY. Steven; Ouyang, Jian; Rovira, Montserrat; Saiz, Bejarano L., Martínez J., Balasubramaniyan V., 13(10):e1005757. I.F.: 4.542 Albert; Simoes, Belinda; Trneny, Marek; Zhu, Ezhilarasan R., Kallarackal N., Kim S., Wang J., Lin; Badoglio, Manuela; Zhong, Xiaobo; Audia A., Conroy S., Marin M., Ribalta T., Pujol 14. Prckovska, Vesna; Huijbers, Willem; Sormani, Maria Pia; Saccardi, Riccardo; T., Herreros A., Tortosa A., Mira H., Alonso M., Schultz, Aaron; Ortiz-Teran, Laura; Multiple Sclerosis-Autologou. Long-term Gómez-Manzano C., Graus F., Sulman E., Piao Pena-Gomez, Cleofe; Villoslada, Pablo; Outcomes After Autologous X., Nakano I., Prat A., Bhat K., de la Iglesia N. Johnson, Keith; Sperling, Reisa; Sepulcre, Hematopoietic Stem Cell Transplantation GPR56/ADGRG1 Inhibits Mesenchymal Jorge. Epicenters of Dynamic Connectivity for Multiple Sclerosis. JAMA NEUROLOGY. Differentiation and Radioresistance in in the Adaptation of the Ventral Visual 74(4):459-469. I.F.: 10.029 Glioblastoma. CELL REPORTS. System. HUMAN BRAIN MAPPING. 21(8):2183-2197. I.F.: 8.282 38(4):1965-1976. I.F.: 4.530

248 CLINICAL AND EXPERIMENTAL NEUROIMMUNOLOGY 4.10

15. Malviya, Manish; Barman, Sumanta; Rumià J., Setoain X., Pintor L., Bailles E., Falip 4. Spatola M, Dalmau J. Seizures and risk of Golombeck, Kristin S.; Planaguma, Jesus; M., Dalmau J., Gil F., Sperling M., Elisak M., epilepsy in autoimmune and other Mannara, Francesco; Strutz-Seebohm, Villanueva V., Roldán P., Boget T., Donaire A., inflammatory encephalitis. CURRENT Nathalie; Wrzos, Claudia; Demir, Fatih; Aparicio J., Graus F. Epilepsy surgery in drug OPINION IN NEUROLOGY. 30(3):345-353. Baksmeier, Christine; Steckel, Julia; Falk, Kim resistant temporal lobe epilepsy I.F.: 4.699 Kristin; Gross, Catharina C.; Kovac, Stjepana; associated with neuronal antibodies. Boente, Kathrin; Johnen, Andreas; Wandinger, EPILEPSY RESEARCH. 129:101-105. I.F.: 2.367 5. Almeida J., Solà-Valls N., Pose E., Blanco Y., Klaus-Peter; Martin-Garcia, Elena; Becker, Sepúlveda M., Llufriu S., Gines P., Saiz A. Liver Albert J.; Elger, Christian E.; Kloecker, Nikolaj; 21. Melia U, Gabarron E, Agustí M, Souto N, injury and glatiramer acetate, an Wiendl, Heinz; Meuth, Sven G.; Hartung, Pineda P, Fontanet J, Vallverdu M, Jensen EW, uncommon association: Case report and Hans-Peter; Seebohm, Guiscard; Leypoldt, Gambus P. literature review. Frank; Maldonado, Rafael; Stadelmann, Comparison of the qCON and qNOX THERAPEUTIC ADVANCES IN Christine; Dalmau, Josep; Melzer, Nico; indices for the assessment of NEUROLOGICAL DISORDERS. Goebels, Norbert. NMDAR encephalitis: unconsciousness level and noxious 10(11):367-372. I.F.: 4.192 passive transfer from man to mouse by a stimulation response during surgery. recombinant antibody. ANNALS OF JOURNAL OF CLINICAL MONITORING AND 6. Brandt, Alexander U.; Martinez-Lapiscina, CLINICAL AND TRANSLATIONAL COMPUTING. 31:1-9. I.F.: 2.178 Elena H.; Nolan, Rachel; Saidha, Shiv. NEUROLOGY. 4(11):768-783. I.F.: 3.901 Monitoring the Course of MS With Optical 22. Curbelo J., Romeo J., Galván-Román J., Coherence Tomography. CURRENT 16. Van Coevorden-Hameete M; van Vega-Villar J., Martinez-Lapiscina E., TREATMENT OPTIONS IN NEUROLOGY. Beuningen S; Perrenoud M; Will L; Jiménez-Fonseca P., Villacampa T., 19(4):15-1120. I.F.: 2.383 Hulsenboom E; Demonet J; Sabater L; Kros J; Sánchez-Lasheras F., Fernández-Somoano Verschuuren J; Titulaer M; de Graaff E; Sillevis A., Baladrón J. The popularity of neurology Smitt P; Hoogenraad C. Antibodies to in Spain: An analysis of specialty selection. Letters / I.F.: 10.292 TRIM46 are associated with NEUROLOGIA. I.F.: 2.103 paraneoplastic neurological syndromes. 1. Dalmau, Josep. In vitro effects of a human ANNALS OF CLINICAL AND 23. Server A., Bargalló N., Fløisand Y., monoclonal antibody against the TRANSLATIONAL NEUROLOGY. Sponheim J., Graus F., Hald J. Imaging N-methyl-D-aspartate receptor. BRAIN; A 4(9):680-686. I.F.: 3.901 spectrum of central nervous system JOURNAL OF NEUROLOGY. 140(2):e9. complications of hematopoietic stem cell I.F.: 10.292 17. Armangue T., Orsini J., Takanohashi A., and solid organ transplantation. Gavazzi F., Conant A., Ulrick N., Morrissey M., NEURORADIOLOGY. 59(2):105-126. I.F.: 2.093 Nahhas N., Helman G., Gordish-Dressman H., Editorial / I.F.: 34.499 Orcesi S., Tonduti D., Stutterd C., van Haren K., Toro C., Iglesias A., van der Knaap M., Review / I.F.: 85.127 1. Gross R., Worrall B., Amato A., Cascino G., Goldbach Mansky R., Moser A., Jones R., Ciccarelli O., Corboy J., Dalmau J., Gottesman Vanderver A. Neonatal detection of Aicardi 1. Dalmau, Josep; Geis, Christian; Graus, R., Grossman M., Millichap J., Mink J., Pulst S., Goutières Syndrome by increased C26:0 Francesc. Autoantibodies to synaptic Uitti R. Message from the Editors to our lysophosphatidylcholine and interferon receptors and neuronal cell surface Reviewers. NEUROLOGY. 89(1):2-10. signature on newborn screening blood proteins in autoimmune diseases of the I.F.: 8.320 spots. MOLECULAR GENETICS AND central nervous system. PHYSIOLOGICAL METABOLISM. 122(3):134-139. I.F.: 3.769 REVIEWS. 97(2):839-887. I.F.: 27.312 2. Dalmau J, Vincent A. Do we need to measure specific antibodies in patients 18. Quiroga-Varela A., Aguilar E., Iglesias E., 2. Petzold A, Balcer LJ, Calabresi PA, Costello with limbic encephalitis? NEUROLOGY. Obeso J., Marin C. Short- and long-term F, Frohman TC, Frohman EM, 88(6):508-509. I.F.: 8.320 effects induced by repeated 6-OHDA Martinez-Lapiscina EH, Green AJ, Kardon R, intraventricular administration: A new Outteryck O, Paul F, Schippling S, Vermersch 3. Toosy AT, Naismith RT, Villoslada P. OCT progressive and bilateral rodent model of P, Villoslada P, Balk LJ, ERN-EYE as a window to the MS brain: The view Parkinson's disease. NEUROSCIENCE. IMSVISUAL. Retinal layer segmentation in becomes slightly clearer. NEUROLOGY. 361:144-156. I.F.: 3.277 multiple sclerosis: a systematic review and 89(24):2404-2405. I.F.: 8.320 meta-analysis. LANCET NEUROLOGY, THE. 19. Baeza-Yates R, Sangal PM, Villoslada P, 16(10):797-812. I.F.: 26.284 4. Villoslada P, Martinez-Lapiscina E. Time is Villoslada P. Burden of neurological vision: The importance of the early discovery diseases in the US revealed by web 3. Van Sonderen A, Petit-Pedrol M, Dalmau J, and diagnosis of optic neuritis. MULTIPLE searches. PLOS ONE. 12(5):e0178019. I.F.: Titulaer MJ . The value of LGI1, Caspr2 and SCLEROSIS. 23(14):1806-1807. I.F.: 4.840 2.806 voltage-gated potassium channel antibodies in encephalitis. NATURE 5. Graus F. Widening the spectrum of 20. Carreño M., Bien C., Asadi-Pooya A., REVIEWS NEUROLOGY. 13(5):290-301-301. inflammatory disorders of the central Marusic P., Pimentel J., Wehner T., Mohanraj I.F.: 20.257 nervous system. CURRENT OPINION IN R., Uranga J., Gómez-Ibáñez A., Bargalló N., NEUROLOGY. 30(3):292-294-294. I.F.: 4.699

249 AREA 4 CLINICAL AND EXPERIMENTAL NEUROSCIENCE

Case Reports / I.F.: 3.983 Sponsored by: Programa CaixaImpulse. Sponsored by: Instituto de Salud Carlos III CI16-00053 (ISCIII). PI15/00061 1. Sepúlveda M., Martinez-Hernandez E., Gaba Duration: 01/01/2017-30/09/2018 Duration: 01/01/2016-31/12/2018 L., Victoria I., Sola-Valls N., Falgàs N., Casanova-Molla J., Graus F. Motor Graus F. Diagnostic and prognostic Villoslada P. Cuidado personalizado de polyradiculopathy during pembrolizumab biomarkers in pediatric multiple sclerosis salud en la Esclerosis Múltiple usando treatment of metastatic melanoma. MUSCLE and related demyelinating disorders. herramientas de medicina de sistemas AND NERVE. 56(6):E162-E167. I.F.: 2.605 Sponsored by: Fundació La Marató TV3. (Sys4MS). 20141830 Sponsored by: European commission. 2. Tavasoli, Ali; Armangue, Thais; Ho, Duration: 22/05/2015-22/11/2018 Duration: 01/05/2016-31/12/2018 Cheng-Ying; Whitehead, Matthew; Bornhorst, Miriam; Rhee, Jullie; Hwang, Eugene I.; Wells, Graus F. Mecanismos patogénicos de los Villoslada P. Estudio del daño axonal en Elizabeth M.; Packer, Roger; van der Knaap, anticuerpos IgG4 contra antígenos de esclerosis múltiple mediante esudios de Marjo S.; Bugiani, Marianna; Vanderver, superficie neuronal en encefalitis neuroimagen de la vía óptica. Adeline. Alexander Disease: A autoinmunes. Sponsored by: Instituto de Salud Carlos III Leukodystrophy That May Mimic Brain Sponsored by: Instituto de Salud Carlos III (ISCIII). AC15/00052 Tumor. JOURNAL OF CHILD NEUROLOGY. (ISCIII). PI15/00377 Duration: 01/01/2016-31/12/2018 32(2):184-187. I.F.: 1.378 Duration: 01/01/2016-31/12/2018 Villoslada P. Multiple manifestations of Llufriu S. Rehabilitación cognitiva y genetic and non-genetic factors in Multiple plasticidad cerebral en la Esclerosis Sclerosis disentangled with a multi-omics GRANTS FOR RESEARCH IN PROGRESS Múltiple: evaluación a través de un ensayo approach to accelerate personalized clínico aleatorizado y controlado. medicine (MultipleMS). Armangué T. Autoinmunidad en encefalitis Sponsored by: Fundació salud 2000. Sponsored by: European commission. herpética en la infancia: coreoatetosis 17-EM-010 H2020-SC1_16 post-herpética, anticuerpos NMDAR e Duration: 01/06/2017-01/06/2020 Duration: 01/01/2017-31/12/2021 interferon. Sponsored by: Fundación de investigación Martinez-Lapiscina E. Molecular imaging of médica mutua madrileña. AP162572016 the retina in patients with Multiple Duration: 18/07/2016-17/07/2019 Sclerosis by Raman Spectroscopy. DOCTORAL THESES Sponsored by: Fundació La Marató de TV3. Dalmau J. New syndromes, antigens, and 20142030 Graus F, Saiz A. Neurological syndromes mechanisms of synaptic autoimmunity. Duration: 03/06/2015-02/06/2018 associated with antibodies against the Sponsored by: Instituto de Salud Carlos III glutamic acid decarboxylase (GAD). (ISCIII). PI14/00203 Saiz A. Biomarcadores de resonancia PhD student: Helena Ariño Rodríguez Duration: 01/01/2015-31/12/2017 magnética avanzada en esclerosis múltiple: asociación con el perfil clínico Llufriu S, Prats A. Desarrollo de una Dalmau J. Resources for human Studies" evolutivo y sustrato genético. metodología de reconstrucción de fibras vinculat al Projecte "Imaging Synaptic Sponsored by: Instituto de Salud Carlos III de sustancia blanca en difusión por RM y Networks in Freely Behaving Mice. (ISCIII). PI15/00587 su aplicación al estudio de la relación entre Sponsored by: Fundación Privada Cellex. Duration: 01/01/2016-31/12/2018 la conectividad estructural cerebral y el 17/553 rendimiento cognitivo en pacientes con Duration: 01/11/2016-31/12/2018 Saiz A. REEM: Red española de esclerosis EM. múltiple. PhD student: Eloy Martínez de las Heras Dalmau J. Imaging Synaptic Networks in Sponsored by: Instituto de Salud Carlos III Freely Behaving Mice. (ISCIII). RD16/0015/0002 Sponsored by: Fundación Privada Cellex. Duration: 01/01/2017-31/12/2021 17/554 Duration: 30/06/2017-31/12/2018 Villoslada P. Advancing human antigen-specific t-regulatory cell Dalmau J. Inmune-mediated diseases of expanding nanomedicines for the synapse: symptoms, brain networks, autoimmune disease: translational studies and the link to human memory. in humanized mice. Sponsored by: Instituto de Salud Carlos III Sponsored by: Instituto de Salud Carlos III (ISCIII). PIE16/00014 (ISCIII). PIE14/00027 Duration: 01/01/2017-31/12/2019 Duration: 01/05/2015-31/05/2017

Gambús PL. PREDICTHEON: A project to VillosladaP. Estudio del daño axonal en develop predictive Monitoring Systems for esclerosis múltiple mediante estudios de clinical applications. neuroimagen de la vía óptica.

250 NEUROBIOLOGY UNIT 4.11

Neurobiology 4.11 Unit

STRATEGIC OBJECTIVES

LOCATION 1. To determine the role of mitochondrial IIBB-CSIC labs DNA, mitochondrial dynamics and UB Biomedical Sciences mitophagy on synapse elimination and neuronal death in models of neurodegenerative dementias and Parkinson’s disease.

2. To gain knowledge on the mechanisms KEYWORDS regulating neuroinflammation in 1. Neurodegeneration TEAM LEADER Ramon Trullàs (IIBB-CSIC) neurodegenerative disorders. 2. Alzheimer’s disease T. 93 363 83 03 3. Mitochondrial DNA [email protected] 3. To characterize cell-free mitochondrial 4. Microglia DNA as a biomarker for neurodegenerative 5. Neuronal pentraxin diseases. 6. Neuronal deat 7. Mitochondrial dynamics RESEARCHERS Anna Colell (IIBB-CSIC) MAIN LINES OF RESEARCH Nicole Mahy (UB) Petar Podlesniy (CIBER) The Neurobiology Unit group investigates the Manuel Jose Rodriguez (UB) molecular mechanisms of neurodegeneration to identify new targets for therapeutic Original publications PRE-DOCTORAL RESEARCHERS intervention. Specific lines of research aim to: Cristina de Dios (IIBB-CSIC) from 2015 to 2017 Margalida Puigròs (CIBER) 1. Characterize cell-free mitochondrial DNA YEAR I.F. TOTAL Q1 Q2 Vicente Roca (IIBB-CSIC) in cerebrospinal fluid as a biomarker for the 2015 22.52 6 2 3 early detection of Alzheimer’s and TECHNICIANS Parkinson’s diseases. 2016 39.09 5 4 1 Carmen Andrade (UB) 2017 7.37 2 11 Núria Serra (CIBER) 2. Investigate the function of Neuronal Pentraxin 1 in the neuronal death program, with the hypothesis that inhibition of this protein may constitute a new treatment for chronic neurodegenerative disorders. TEAM INVOLVED IN CIBERNED AGAUR_SGR14 AGAUR_SGR17 Ramon Trullàs

TEAM

251 AREA 4 CLINICAL AND EXPERIMENTAL NEUROSCIENCE

3. Study the role of mitochondrial DNA and Trullas R. Mecanismos de regulación del mitochondrial dynamics in ﬁbroblasts from número de copias de ADN mitocondrial patients with Parkinson’s disease and other para el tratamiento del Alzheimer. cellular models of neurodegeneration. Sponsored by Ministerio de Economía y competitividad. SAF2014-56644-R 4. Study the mechanism by which KATP Duration 01/01/2015-31/12/2017 channel participates in the control of microglial activity in different neurological disorders.

5. Investigate the mechanisms whereby CX3CR1 regulates microglial activation in amyotrophic lateral sclerosis.

6. Study the mechanisms that alter the main proteolytic systems, including autophagy, involved in the maintenance of intracellular proteostasis.

7. Study the role of mitochondrial function in neuroinﬂammation and amyloid beta-induced cell death.

PUBLICATIONS

Originals / I.F.: 7.369

1. Podlesniy P, Trullas R. Absolute measurement of gene transcripts with Selﬁe-digital PCR. SCIENTIFIC REPORTS. 7(1):8328. I.F.: 4.259

2. Jorba I., Menal M., Torres M., Gozal D., Piñol-Ripoll G., Colell A., Montserrat J., Navajas D., Farré R., Almendros I. Ageing and chronic intermittent hypoxia mimicking sleep apnea do not modify local brain tissue stiffness in healthy mice. JOURNAL OF THE MECHANICAL BEHAVIOR OF BIOMEDICAL MATERIALS. 71:106-113. I.F.: 3.110

GRANTS FOR RESEARCH IN PROGRESS

Colell A. Papel del colesterol en la eliminación de beta-amiloide como diana terapéutica en la Enfermedad de Alzheimer. Sponsored by: Ministerio de Economia y Competitividad. SAF2013-47246-R Duration: 01/01/2014-30/09/2017

Colell A. Cholesterol and Ab-induced mitochondrial oxidative stress as a causal factors and therapeutic targets in Alzheimer’s Disease. Sponsored by: Fundació La Marató de TV3 Duration: 01/07/2015-31/12/2018

252 ALZHEIMER'S DISEASE AND OTHER COGNITIVE DISORDERS 4.12

Alzheimer's disease and 4.12 other cognitive disorders

TEAM LEADER - Study of genetic dementias in preclinical Raquel Sánchez del Valle (HCB) and early clinical phases. LOCATION [email protected] - Biomarkers for sporadic early onset HCB building Alzheimer’s disease. CELLEX building 3B - Biomarkers for non-Alzheimer dementias (prion diseases, frontotemporal dementia, RESEARCHERS primary progressive aphasia, Lewy body Albert Llado (HCB) dem.). Josep Lluis Molinuevo (HCB) - Non-pharmacological interventions in Lorena Rami (IDIBAPS) neurodegenerative cognitive disorders. KEYWORDS

1. Alzheimer disease POST-DOCTORAL RESEARCHERS 2. Degenerative Anna Antonell (IDIBAPS) neurological deiseases Mircea Balasa (HCB) PUBLICATIONS Beatriz Bosch (IDIBAPS) Oriol Grau (HCB) Originals / I.F.: 140.93

PRE-DOCTORAL RESEARCHERS 1. De Roeck A, Van den Bossche T, van der Sergi Borrego (HCB) Zee J, Verheijen J, De Coster W, Van Dongen Original publications Magda Castellví (HCB) J, Dillen L, Baradaran-Heravi Y, Heeman B, from 2015 to 2017 Nina Coll (IDIBAPS) Sanchez-Valle R, Lladó A, Nacmias B, Sorbi S, Neus Falgàs (FCRB) Gelpi E, Grau-Rivera O, Gómez-Tortosa E, Q1 Q2 YEAR I.F. TOTAL Jaume Olives (FCRB) Pastor P, Ortega-Cubero S, Pastor MA, Graff 2015 ---- Adrià Tort (FCRB) C, Thonberg H, Benussi L, Ghidoni R, Binetti G,

2016 144.23 24 17 5 de Mendonça A, Martins M, Borroni B, TECHNICIANS Padovani A, Almeida MR, Santana I, 2017 140.93 25 17 8 Cristina Munoz (IDIBAPS) Diehl-Schmid J, Alexopoulos P, Clarimon J, Lleó A, Fortea J, Tsolaki M, Koutroumani M, NURSING STAFF Mat?j R, Rohan Z, De Deyn P, Engelborghs S, Clara Coquard (FCRB) Cras P, Van Broeckhoven C, Sleegers K, Guadalupe Fernández (FCRB) European Early-Onset Dementia (EU EOD) TEAM INVOLVED IN consortium. Deleterious ABCA7 mutations AGAUR_SGR17 and transcript rescue mechanisms in early onset Alzheimer’s disease. ACTA STRATEGIC OBJECTIVES NEUROPATHOLOGICA. 134(3):475-487. I.F.: 12.213 - Investigation to improve diagnosis and treatment of neurodegenerative diseases. 2. Iranzo, Alex; Santamaria, Joan; Valldeoriola, AWARDS - Investigations on clinical, molecular and Francesc; Serradell, Monica; Salamero, Manel; Premios CLÍNIC- MSD imaging biomarkers that characterize the Gaig, Carles; Ninerola-Baizan, Aida; Institution: Hospital Clínic preclinical phase of Alzheimer disease. Sanchez-Valle, Raquel; Llado, Albert; De Awardee/s: Neus Falgàs Martínez - Investigation of biological pathways Marzi, Roberto; Stefani, Ambra; Seppi, Klaus; involved in the pathogenesis of Alzheimer’s Pavia, Javier; Hoegl, Birgit; Poewe, Werner; disease and detection of new cognitive, Tolosa, Eduard; Lomena, Francisco. biochemical and neuroimaging markers in Dopamine Transporter Imaging Deﬁcit preclinical and prodromal patients Predicts Early Transition to Synucleinopathy in Idiopathic Rapid Eye Movement Sleep Behavior Disorder. ANNALS OF NEUROLOGY. 82(3):419-428. I.F.: 9.890 MAIN LINES OF RESEARCH 3. Carmona-Iragui M, Balasa M, Benejam B, The main research lines of the Alzheimer’s Alcolea D, Fernández S, Videla L, Sala I, Disease and other Cognitive Disorders Unit Sánchez-Saudinós MB, Morenas-Rodriguez (ADCDU) team are: E, Ribosa-Nogué R, Illán-Gala I, - Healthy aging-Alzheimer’s disease Gonzalez-Ortiz S, Clarimón J, Schmitt F, continuum (subjective cognitive decline, Powell DK, Bosch B, Lladó A, Raﬁi MS, Head E, preclinical and prodromal Alzheimer’s Molinuevo JL, Blesa R, Videla S, Lleó A, disease). Sánchez-Valle R, Fortea J. Cerebral amyloid angiopathy in Down syndrome and

253 AREA 4 CLINICAL AND EXPERIMENTAL NEUROSCIENCE

sporadic and autosomal-dominant M., Pallàs M., Sanchez-Valle R., Molinuevo J., 12. Demirta? M., Falcon C., Tucholka A., Alzheimer's disease. ALZHEIMERS AND Sanfeliu C., Kaliman P. Plasma miR-34a-5p Gispert J., Molinuevo J., Deco G. A DEMENTIA. 13(11):1251-1260. I.F.: 9.478 and miR-545-3p as Early Biomarkers of whole-brain computational modeling Alzheimer’s Disease: Potential and approach to explain the alterations in 4. Molinuevo JL, Rabin LA, Amariglio R, Limitations. MOLECULAR NEUROBIOLOGY. resting-state functional connectivity Buckley R, Dubois B, Ellis KA, Ewers M, 54(7):5550-5562. I.F.: 6.190 during progression of Alzheimer's disease. Hampel H, Klöppel S, Rami L, Reisberg B, NEUROIMAGE: CLINICAL. 16:343-354. Saykin AJ, Sikkes S, Smart CM, Snitz BE, 9. Dangla-Valls A, Molinuevo JL, Altirriba J, I.F.: 4.348 Sperling R, van der Flier WM, Wagner M, Sánchez-Valle R, Alcolea D, Fortea J, Rami L, Jessen F, Subjective Cognitive Decline Balasa M, Muñoz-García C, Ezquerra M, 13. Gispert JD, Monté GC, Suárez-Calvet M, Initiative (SCD-I) Working Group. Fernández-Santiago R, Lleó A, Lladó A, Falcon C, Tucholka A, Rojas S, Rami L, Implementation of subjective cognitive Antonell A. CSF microRNA Profiling in Sánchez-Valle R, Lladó A, Kleinberger G, decline criteria in research studies. Alzheimer's Disease: a Screening and Haass C, Molinuevo JL. The APOE epsilon4 ALZHEIMER'S AND DEMENTIA. 13(3):296-311. Validation Study. MOLECULAR genotype modulates CSF YKL-40 levels I.F.: 9.478 NEUROBIOLOGY. 54(9):6647-6654. I.F.: 6.190 and their structural brain correlates in the continuum of Alzheimer's disease but not 5. Bosco P., Redolfi A., Bocchetta M., Ferrari C., 10. Nathan PJ, Lim YY, Abbott R, Galluzzi S, those of sTREM2. ANTIVIRAL RESEARCH. Mega A., Galluzzi S., Austin M., Chincarini A., Marizzoni M, Babiloni C, Albani D, Bartres-Faz 6:50-59. I.F.: 4.271 Collins D., Duchesne S., Maréchal B., Roche A., D, Didic M, Farotti L, Parnetti L, Salvadori N, Sensi F., Wolz R., Alegret M., Assal F., Balasa Müller BW, Forloni G, Girtler N, Hensch T, 14. García-Ayllón M., Lopez-Font I., Boix C., M., Bastin C., Bougea A., Emek-Sava? D., Jovicich J, Leeuwis A, Marra C, Molinuevo JL, Fortea J., Sánchez-Valle R., Lleó A., Molinuevo Engelborghs S., Grimmer T., Grosu G., Nobili F, Pariente J, Payoux P, Ranjeva JP, J., Zetterberg H., Blennow K., Sáez-Valero J. Kramberger M., Lawlor B., Mandic Rolandi E, Rossini PM, Schönknecht P, C-Terminal fragments of the amyloid Stojmenovic G., Marinescu M., Mecocci P., Soricelli A, Tsolaki M, Visser PJ, Wiltfang J, precursor protein in cerebrospinal fluid as Molinuevo J., Morais R., Niemantsverdriet E., Richardson JC, Bordet R, Blin O, Frisoni GB, potential biomarkers for Alzheimer Nobili F., Ntovas K., O'Dwyer S., Paraskevas G., PharmaCog Consortium. Association disease. SCIENTIFIC REPORTS. Pelini L., Picco A., Salmon E., Santana I., between CSF biomarkers, hippocampal 7(1):2477-1120. I.F.: 4.259 Sotolongo-Grau O., Bosco P., Redolfi A., volume and cognitive function in patients Bocchetta M., Ferrari C., Mega A., Galluzzi S., with amnestic mild cognitive impairment 15. Tell-Marti G, Puig-Butille JA, Potrony M, Austin M. The impact of automated (MCI). NEUROBIOL AGING. 53:1-10. I.F.: 5.117 Plana E, Badenas C, Antonell A, Sanchez-Valle hippocampal volumetry on diagnostic R, Molinuevo JL, Lleó A, Alcolea D, Fortea J, confidence in patients with suspected 11. Van der Zee J, Gijselinck I, Van Mossevelde Fernández-Santiago R, Clarimón J, Lladó A, Alzheimer's disease: An EADC study. S, Perrone F, Dillen L, Heeman B, Bäumer V, Puig S. A Common Variant in the MC1R ALZHEIMERS AND DEMENTIA. Engelborghs S, De Bleecker J, Baets J, Gelpi Gene (p.V92M) is associated with 13(9):1013-1023. I.F.: 9.478 E, Rojas-García R, Clarimón J, Lleó A, Alzheimer's Disease Risk. J ALZHEIMERS Diehl-Schmid J, Alexopoulos P, Perneczky R, DIS. 56(3):1065-1074. I.F.: 3.731 6. Alcolea D, Vilaplana E, Suárez-Calvet M, Synofzik M, Just J, Schöls L, Graff C, Thonberg Illán-Gala I, Blesa R, Clarimón J, Lladó A, H, Borroni B, Padovani A, Jordanova A, 16. Grau-Rivera O, Calvo A, Bargalló N, Monté Sánchez-Valle R, Molinuevo JL, García-Ribas Sarafov S, Tournev I, de Mendonça A, GC, Nos C, Lladó A, Molinuevo JL, Gelpi E, G, Compta Y, Martí MJ, Piñol-Ripoll G, Miltenberger-Miltényi G, Simões do Couto F, Sánchez-Valle R. Quantitative Magnetic Amer-Ferrer G, Noguera A, García-Martín A, Ramirez A, Jessen, Heneka MT, Resonance Abnormalities in Fortea J, Lleó A. CSF sAPPβ, YKL-40, and Gómez-Tortosa E, Danek A, Cras P, Creutzfeldt-Jakob Disease and Fatal neurofilament light in frontotemporal lobar Vandenberghe R, De Jonghe P, De Deyn PP, Insomnia. JOURNAL OF ALZHEIMER'S degeneration. NEUROLOGY. 89(2):178-188. Sleegers K, Cruts M, Van Broeckhoven C, DISEASE. 55(1):431-443. I.F.: 3.731 I.F.: 8.320 Goeman J, Nuytten D, Smets K, Robberecht W, Damme PV, Bleecker J, Santens P, 17. Lewczuk, P; Lelental, N; Lachmann, I; 7. Llorens F, Thüne K, Tahir W, Kanata E, Dermaut B, Versijpt J, Michotte A, Ivanoiu A, Holzer, M; Flach, K; Brandner, S; Engelborghs, Diaz-Lucena D, Xanthopoulos K, Kovatsi E, Deryck O, Bergmans B, Delbeck J, Bruyland S; Teunissen, CE; Zetterberg, H; Mroczko, B; Pleschka C, Garcia-Esparcia P, Schmitz M, M, Willems C, Salmon E, Pastor P, Blennow, K; Popp, J; Parnetti, L; Chiasserini, D; Ozbay D, Correia S, Correia Â, Milosevic I, Ortega-Cubero S, Benussi L, Ghidoni R, Binetti Perret-Liaudet, A; Spitzer, P; Maler, JM; Andréoletti O, Fernández-Borges N, Vorberg G, Hernández I, Boada M, Ruiz A, Sorbi S, Kornhuber, J. Non-Phosphorylated Tau as a IM, Glatzel M, Sklaviadis T, Torres JM, Nacmias B, Bagnoli S, Sorbi S, Sanchez-Valle Potential Biomarker of Alzheimer's Krasemann S, Sánchez-Valle R, Ferrer I, Zerr I. R, Llado A, Santana I, Rosário Almeida M, Disease: Analytical and Diagnostic YKL-40 in the brain and cerebrospinal fluid Frisoni GB, Maetzler W, Matej R, Fraidakis MJ, Characterization. JOURNAL OF of neurodegenerative dementias. Kovacs GG, Fabrizi GM, Testi S. TBK1 ALZHEIMER'S DISEASE. 55(1):159-170. MOLECULAR NEURODEGENERATION. Mutation Spectrum in an Extended I.F.: 3.731 12(1):83-83. I.F.: 6.780 European Patient Cohort with Frontotemporal Dementia and 18. Van Waalwijk van Doorn LJ, Gispert JD, 8. Cosín-Tomás M., Antonell A., Lladó A., Amyotrophic Lateral Sclerosis. HUMAN Kuiperij HB, Claassen JA, Arighi A, Baldeiras I, Alcolea D., Fortea J., Ezquerra M., Lleó A., Martí MUTATION. 38(3):297-309. I.F.: 4.601 Blennow K, Bozzali M, Castelo-Branco M,

254 ALZHEIMER'S DISEASE AND OTHER COGNITIVE DISORDERS 4.12

Cavedo E, Emek-Sava? DD, Eren E, Eusebi P, Lewy Bodies: Molecular Pathology in the Waldemar, Gunhild. Recommendations for Farotti L, Fenoglio C, Ormaechea JF, Frontal Cortex in Typical and Rapidly CSF AD biomarkers in the diagnostic Freund-Levi Y, Frisoni GB, Galimberti D, Genc Progressive Forms. FRONTIERS IN evaluation of dementia. ALZHEIMERS AND S, Greco V, Hampel H, Herukka SK, Liu Y, NEUROLOGY. 8(MAR). I.F.: 3.552 DEMENTIA. 13(3):274-284. I.F.: 9.478 Lladó A, Lleó A, Nobili FM, Oguz KK, Parnetti L, Pereira J, Picco A, Pikkarainen M, de Oliveira 24. Borrego-Écija S, Morgado J, CR, Saka E, Salvadori N, Sanchez-Valle R, Palencia-Madrid L, Grau-Rivera O, Reñé R, Letters / I.F.: 19.248 Santana I, Scarpini E, Scheltens P, Soininen H, Hernández I, Almenar C, Balasa M, Antonell A, Tarducci R, Teunissen C, Tsolaki M, Urbani A, Molinuevo JL, Lladó A, Martínez de Pancorbo 1. Gelpi, Ellen; Botta-Orfila, Teresa; Bodi, Laia; Vilaplana E, Visser PJ, Wallin AK, Yener G, M, Gelpi E, Sánchez-Valle R. Frontotemporal Marti, Stefanie; Kovacs, Gabor; Grau-Rivera, Molinuevo JL, Meulenbroek O, Verbeek MM . Dementia Caused by the P301L Mutation Oriol; Lozano, Manuel; Sanchez-Valle, Raquel; Improved Cerebrospinal Fluid-Based in the MAPT Gene: Clinicopathological Munoz, Esteban; Valldeoriola, Francesc; Discrimination between Alzheimer's Features of 13 Cases from the Same Pagonabarraga, Javier; Tartaglia, Disease Patients and Controls after Geographical Origin in Barcelona, Spain. Gian-Gaetano; Mila, Montserrat. Neuronal Correction for Ventricular Volumes. DEMENTIA AND GERIATRIC COGNITIVE intranuclear (hyaline) inclusion disease J ALZHEIMERS DIS. 56(2):543-555. I.F.: 3.731 DISORDERS. 44(3-4):213-221. I.F.: 3.511 and fragile X-associated tremor/ataxia syndrome: a morphological and molecular 19. Lewczuk, Piotr; Matzen, Anja; Blennow, 25. Colom-Cadena, Marti; Grau-Rivera, Oriol; dilemma. BRAIN; A JOURNAL OF Kaj; Parnetti, Lucilla; Molinuevo, Jose Luis; Planellas, Lluis; Cerquera, Catalina; Morenas, NEUROLOGY. 140(8):e51-+. I.F.: 10.292 Eusebi, Paolo; Kornhuber, Johannes; Morris, Estrella; Helgueta, Sergio; Munoz, Laia; John C.; Fagan, Anne M. Cerebrospinal Fluid Kulisevsky, Jaime; Jose Marti, Maria; Tolosa, 2. Compta Y, Ramos-Campoy O, Grau-Rivera A beta(42/40) Corresponds Better than A Eduard; Clarimon, Jordi; Lleo, Alberto; Gelpi, O, Colom-Cadena M, Clarimón J, Martí MJ, beta(42) to Amyloid PET in Alzheimer's Ellen. Regional Overlap of Pathologies in Gelpi E. Conjoint FTLD-FUS of the neuronal Disease. JOURNAL OF ALZHEIMER'S Lewy Body Disorders. JOURNAL OF intermediate filament inclusion disease DISEASE. 55(2):813-822. I.F.: 3.731 NEUROPATHOLOGY AND EXPERIMENTAL type, progressive supranuclear palsy and NEUROLOGY. 76(3):216-224. I.F.: 3.503 alzheimer's pathology presenting as 20. Tort-Merino A., Valech N., Peñaloza C., parkinsonism with early falls and late Grönholm-Nyman P., León M., Olives J., hallucinations, psychosis and dementia. Estanga A., Ecay-Torres M., Fortea J., Review / I.F.: 18.956 NEUROPATHOLOGY AND APPLIED Martínez-Lage P., Molinuevo J., Laine M., NEUROBIOLOGY. 43(4):352-357. I.F.: 5.347 Rodríguez-Fornells A., Rami L. Early 1. Herukka, Sanna-Kaisa; Simonsen, Anja Detection of Learning Difficulties when Hviid; Andreasen, Niels; Baldeiras, Ines; Bjerke, 3. Fortea, Adriana; Oriolo, Giovanni; Confronted with Novel Information in Maria; Blennow, Kaj; Engelborghs, Sebastiaan; Sanchez-Valle, Raquel; Castellvi, Magda; Preclinical Alzheimer's Disease Stage 1. Frisoni, Giovanni B.; Gabryelewicz, Tomasz; Balcells, Mercedes. Cognitive impairment JOURNAL OF ALZHEIMERS DISEASE. Galluzzi, Samantha; Handels, Ron; induced by benzodiazepine use disorder 58(3):855-870. I.F.: 3.731 Kramberger, Milica G.; Kulczynska, Agnieszka; and its reversibility: a case report. Luis Molinuevo, Jose; Mroczko, Barbara; ADICCIONES. 29(1):61-63. I.F.: 2.077 21. Handels, Ron L. H.; Wimo, Anders; Dodel, Nordberg, Agneta; Oliveira, Catarina Resende; Richard; Kramberger, Milica G.; Visser, Pieter Otto, Markus; Rinne, Juha O.; Rot, Uros; Saka, 4. Guasp-Verdaguer, Mar; Grau-Rivera, Oriol; Jelle; Luis Molinuevo, Jose; Verhey, Frans R. J.; Esen; Soininen, Hilkka; Struyfs, Hanne; Suardi, Prats-Galino, Alberto; Bargallo, Nuria; Winblad, Bengt. Cost-Utility of Using Silvia; Visser, Pieter Jelle; Winblad, Bengt; Sanchez-Valle, Raquel; Gelpi, Ellen; Soria, Alzheimer's Disease Biomarkers in Zetterberg, Henrik; Waldemar, Gunhild. Guadalupe. Clinical Neuropathology image Cerebrospinal Fluid to Predict Progression Recommendations for cerebrospinal fluid 4-2017: High-resolution 7 Tesla MRI of from Mild Cognitive Impairment to Alzheimer's disease biomarkers in the postmortem brain specimens: improving Dementia. JOURNAL OF ALZHEIMERS diagnostic evaluation of mild cognitive neuroimaging-neuropathology DISEASE. 60(4):1477-1487. I.F.: 3.731 impairment. ALZHEIMERS AND DEMENTIA. correlations. CLINICAL 13(3):285-295. I.F.: 9.478 NEUROPATHOLOGY. 36(4):162-163. 22. Mollica MA, Navarra J, Fernández-Prieto I, I.F.: 1.532 Olives J, Tort A, Valech N, Coll-Padrós N, 2. Simonsen, Anja Hviid; Herukka, Molinuevo JL, Rami L. Sanna-Kaisa; Andreasen, Niels; Baldeiras, Subtle visuomotor difficulties in preclinical Ines; Bjerke, Maria; Blennow, Kaj; Engelborghs, Case Reports / I.F.: 4.708 Alzheimer's disease. JOURNAL OF Sebastiaan; Frisoni, Giovanni B.; NEUROPSYCHOLOGY. 11(1):56-73. I.F.: 3.634 Gabryelewicz, Tomasz; Galluzzi, Samantha; 1. Sepúlveda M., Martinez-Hernandez E., Gaba Handels, Ron; Kramberger, Milica G.; L., Victoria I., Sola-Valls N., Falgàs N., 23. Garcia-Esparcia, Paula; Lopez-Gonzalez, Kulczynska, Agnieszka; Luis Molinuevo, Jose; Casanova-Molla J., Graus F. Motor Irene; Grau-Rivera, Oriol; Francisca Mroczko, Barbara; Nordberg, Agneta; Oliveira, polyradiculopathy during pembrolizumab Garcia-Garrido, Maria; Konetti, Anusha; Catarina Resende; Otto, Markus; Rinne, Juha treatment of metastatic melanoma. Llorens, Franc; Zafar, Saima; Carmona, O.; Rot, Uros; Saka, Esen; Soininen, Hilkka; MUSCLE AND NERVE. 56(6):E162-E167. Margarita; Antonio del Rio, Jose; Zerr, Inga; Struyfs, Hanne; Suardi, Silvia; Visser, Pieter I.F.: 2.605 Gelpi, Ellen; Ferrer, Isidro. Dementia with Jelle; Winblad, Bengt; Zetterberg, Henrik;

255 AREA 4 CLINICAL AND EXPERIMENTAL NEUROSCIENCE

2. Falgàs N., Borrego S., Llull L., Espinosa G., Duration: 01/01/2015-31/12/2018 PhD student: Oriol Grau Rivera López-Rueda A., Blasco J., Cervera A. Recurrent dural arteriovenous ﬁstulas in a Sanchez-Valle R. Estudio de portadores patient with Behçet's disease. de mutaciones determinantes de NEUROLOGIA. 32(9):623-626. I.F.: 2.103 enfermedad de Alzheimer genética en fases preclínicas cognición, neuroimagen estructural y funcional y marcadores GRANTS FOR RESEARCH IN PROGRESS bioquímicos. Sponsored by: Instituto de Salud Carlos III Lladó A. Clinical phenotypes and new (ISCIII). PI12/00013 physiopathological, diagnostic and Duration: 01/01/2013-30/06/2017 prognostic biomarkers for early onset Alzheimer’s disease and behavioural Sanchez-Valle R. Organising Knowledge variant of frontotemporal dementia. about Neurodegenerative Disease Sponsored by: Instituto de Salud Carlos III Mechanisms for the Improvement of (ISCIII). PI14/00282 Drug Development and Therapy. Duration:01/01/2015-31/12/2018 Sponsored by: European commission IMI_12 Duration: 01/01/2014-31/12/2018 Molinuevo JL, Rami L. AETIONOMY – Organising knowledge about Sánchez-Valle R. Searching for therapeutic neurodegenerative disease mechanisms interventions in frontotemporal dementia for the improvement of drug development with C9ORF72 repeat expansions in the and therapy. presymptomatic stage (PreFrontALS). Sponsored by: European commission IMI_12 Sponsored by: Instituto de Salud Carlos III Duration: 01/01/2014-31/12/2018 (ISCIII). AC14/00013 Duration: 01/01/2015-30/06/2019 Molinuevo JL. MEDIT-AGEING: Investigating the impact of meditation Sánchez-Valle R. Study of genetic training on mental health and wellbeing in frontotemporal dementia in preclinical the ageing population. and early stages of the disease: cognitive Sponsored by: European commission performance, structural and functional H2020-PHC_15 neuroimaging and biochemical markers Duration: 01/01/2015-31/12/2020 (GENFI2-Barcelona site). Sponsored by: Fundació La Marató de TV3. Rami L. Cambios cognitivos y de 20143810 resonancia magnética en sujetos con Duration: 12/05/2015-11/05/2020 cognición normal y evidencia biológica de enfermedad de Alzheimer. Sánchez-Valle R. Genetic dementia Sponsored by: Instituto de Salud Carlos III (autosomal dominant Alzheimer’s disease (ISCIII). PI11/01071 and genetic prion disease) in preclinical Duration: 01/01/2012-30/06/2018 and early stages of the disease: cognitive performance, neuroimaging and Rami L. Efectos de la pérdida de peso biochemical markers. mediante dieta mediterránea hipocalórica Sponsored by: Instituto de Salud Carlos III y aumento de la actividad física sobre la (ISCIII). PI16/000235 congnición y la estructura y función Duration:01/01/2017-31/12/2019 cerebrales determinados por resonancia magnética funcional en individuos obesos con síndrome metabólico. DOCTORAL THESES Sponsored by: Instituto de Salud Carlos III (ISCIII). PI14/00563 Molinuevo J, Rami L. Nuevos instrumentos Duration: 01/01/2015-31/12/2017 subjetivos y objetivos para evaluar la fase preclínica de la enfermedad de Alzheimer. Rami L. Subjective cognitive decline in PhD student: Maria Antonella Mollica preclinical Alzheimer's Disease: European initiative on harmonization and on a Sanchez-Valle R, Gelpi E.Enfermedades lifestyle-based prevention priónicas y otras demencias rápidamente strategy.(EURO-SCD) progresivas: caracterización clínico- Sponsored by: Instituto de Salud Carlos III patológica, neuroinmunológica y mediante (ISCIII). AC14/00014 neuroimagen por resonancia magnética.

256 ANNUAL SCIENTIFIC REPORT 2017

AREA 5

ONCOLOGY AND HAEMATOLOGY 5

ONCOLOGY AND HAEMATOLOGY

5.1 Oncological molecular pathology 260 Elías Campo

5.2 Diagnosis and therapy in oncology 269 Francesca Pons

5.3 Molecular biology of reproduction and development 272 Rafael Oliva

5.4 Genetics 274 Montserrat Milà

5.5 Melanoma: imaging, genetics and immunology 277 Susana Puig

5.6 Hematopoietic progenitor cell transplantation 282 Álvaro Urbano-Ispizua

5.7 Hematological oncology 285 Francisco Cervantes

5.8 Physiopathology and molecular bases in hematology 293 Dolors Colomer

5.9 Hemotherapy - hemostasis 297 Ginés Escolar

5.10 Molecular and translational oncology 301 Pere Gascón 5.11 Cell proliferation and signaling 303 Oriol Bachs

5.12 Cell compartments and signaling 305 Carles Enrich

5.13 Translational genomics and targeted therapeutics in solid tumors 309 Aleix Prat

259 AREA 5 ONCOLOGY AND HAEMATOLOGY

Oncological molecular 5.1 pathology

Alba Navarro (CIBER) Laura Siles (IDIBAPS) LOCATION

CEK building ﬂoor 2 PRE-DOCTORAL RESEARCHERS Vicente Chapaprieta (UB) Martí Duran (UB) Alvaro Eguileor (IDIBAPS) David Martin (IDIBAPS) M Carmen Martínez (IDIBAPS) KEYWORDS Ferran Nadeu (IDIBAPS) 1. Lymphoid neoplasms TEAM LEADER Chiara Ninfali (IDIBAPS) 2. Epigenome Elías Campo (HCB-UB) Núria Proﬁtós (IDIBAPS) 3. Transcriptional regulation T. 93 227 54 50 Joan Enric Ramis (FCRB) 4. Molecular pathology [email protected] Lidia Sanchez-Moral (FCRB)

5. Solid tumors Roser Vilarrasa-Blasi (UB)

GROUP LEADERS TECHNICIANS Elías Campo (HCB-UB) Cristina Capdevila (IDIBAPS) T. 93 227 54 50 Noelia García (FCRB) [email protected] Silvia Martín (CIBER) Original publications Miriam Prieto (FCRB) Pedro Luis Fernández (HCB-UB) Marta Leonor Rodríguez (IDIBAPS) from 2015 to 2017 T. 93 227 54 50 Nuria Russiñol (FCRB) YEAR I.F. TOTAL Q1 Q2 [email protected] Nuria Verdaguer (UB)

2015 338.96 43 35 6 José Ignacio Martín-Subero (IDIBAPS) ADMINISTRATIVE STAFF 2016 333.82 45 36 5 [email protected] Carmen Muro (FCRB) 2017 421.05 57 46 6 Nathalie Villahoz (FCRB) Antonio Postigo (ICREA - IDIBAPS) [email protected] COLLABORATORS Raquel Bermudo (IDIBAPS) Anna Enjuanes (IDIBAPS) TEAM INVOLVED IN RESEARCHERS Magdalena Pinyol (IDIBAPS) AGAUR_SGR14 Llúcia Alós (HCB-UB) RTICC Virginia Amador (IDIBAPS) CIBERONC Sílvia Margarita Beà (IDIBAPS) STRATEGIC OBJECTIVES ICGC Josep Antoni Bombí (HCB-UB) LLMPP Miriam Cuatrecasas (HCB-UB) Identification of genetic and molecular Blueprint Consortium Luis Hernández (IDIBAPS) mechanisms implicated in the development Pedro Jares (HCB-UB) and progression of human neoplasms. Carme Mallofré (HCB-UB) Development of strategies to transfer to Antonio Martínez (HCB-UB) clinical practice the knowledge generated by Alfons Nadal (HCB-UB) basic research on human tumours. José Francisco Ramírez (HCB-UB) Identification of parameters allowing the Teresa Ribalta (HCB-UB) improved diagnosis and prognosis of Itziar Salaverria (IDIBAPS) neoplastic disease, and the identification of Esther Sánchez (IDIBAPS) possible therapeutic targets. Manel Solé (HCB-UB)

POST-DOCTORAL RESEARCHERS Robert Albero (IDIBAPS) Patricia Balsas (IDIBAPS) Renee Beekman (IDIBAPS) Guillem Clot (IDIBAPS) Marlies Cortes (IDIBAPS) Oriol de Barrios (IDIBAPS) Santiago Demajo (IDIBAPS) Adriana García (HCB) Blanca González (HCB) Marta Kulis (IDIBAPS) Daniel Martínez (HCB)

260 ONCOLOGICAL MOLECULAR PATHOLOGY 5.1

MAIN LINES OF RESEARCH Transcriptional Regulation of Gene RESEARCH GROUP Expression MOLECULAR PATHOLOGY Molecular Pathology of Lymphoid OF LYMPHOID NEOPLASMS Neoplasms a) Study the molecular mechanisms regulating gene expression during normal a) To understand the genetic and molecular cell differentiation and in cancer. mechanisms involved in the development and progression of lymphoid neoplasms b) Characterization of the transcription and to identify parameters that may factors ZEB1 and ZEB2 as prognostic and improve the diagnosis of these disease, predictive biomarkers in cancer (e.g., stratify patients according to biological risk, carcinomas, lymphomas) and other GROUP LEADER and define possible therapeutic targets. diseases (e.g. muscular dystrophies). Elías Campo (HCB) b) To define the complete catalogue of somatic genomic alterations in several Biomedical Epigenomics Lymphoid neoplasias are a very lymphoid neoplasm and their clinical and heterogeneous group of tumors with functional relevance. a) To understand the epigenetic mechanisms remarkable variability in their biological involved both in normal differentiation and behaviour and clinical manifestations. Molecular Pathology of Solid neoplasms neoplastic cell transformation. In particular, Our group aims to understand the genetic, focusing on B cells as cellular model, we epigenetic, and molecular mechanisms a) To study the molecular mechanisms of aim at characterizing and understanding underlying the biological diversity of these invasion and metastasis, transcriptional gene regulation alterations in the initiation tumors and how they may influence the clinical expression profiles implicated in the and evolution of lymphoid malignancies. evolution of the patients. development and progression of different The use of new genomic technologies is human tumours in relation to biological b) To identify novel biomarkers for a better providing new perspectives on the tumors we aggressivity and therapeutic options. We classification and estimation of prognosis in concentrate our research, particularly chronic focus mainly on breast and prostate lymphoid neoplasms as well as to reveal lymphocytic leukemia, mantle cell lymphoma, tumours as neoplasms under hormone novel molecular targets for therapeutic follicular lymphoma and diffuse large B-cell influence, and skin, digestive, urological and interventions. lymphoma. In addition to better understand airway neoplasms. the pathogenesis of these tumors we are b) Study of the possible criteria of treatment generating new approaches to translate this response and prognosis in neurological new information into the clinics. tumours. Elías Campo

GROUP

261 AREA 5 ONCOLOGY AND HAEMATOLOGY

RESEARCH GROUP MOLECULAR PATHOLOGY OF SOLID TUMORS

GROUP LEADER Pedro Luis Fernández (HCB)

Our study of solid neoplasms is mainly focused on breast, urological, digestive, skin, H&N and neurological cancers. We have started massive genomic analysis of breast carcinomas with NGS techniques with special interest in triple-negative tumours and we plan Pedro Luis Fernández to correlate genomic abnormalities with

clinicopathological parameters of the cases. GROUP This type of genomic studies is also being applied to bladder cancer in addition to FISH experiments in order to subclassify transitional carcinomas in advanced stages.

RESEARCH GROUP TRANSCRIPTIONAL REGULATION OF GENE EXPRESSION

GROUP LEADER Antonio Postigo (ICREA-IDIBAPS)

Our group investigates the regulation of gene expression by the ZEB family of transcription factors (ZEB1 and ZEB2). We use cell lines, transgenic mice and human samples to study the role of ZEB factors in the regulation of cell stemness and differentiation and tumor

progression using epithelial (colon, ovarian, Antonio Postigo

breast, lung), skeletal muscle and

hematopoietic systems as models. The group GROUP has received funding from the Spanish and Catalan governments and the EU as well as RESEARCH GROUP emphasis on studying normal and neoplastic from national and international private BIOMEDICAL EPIGENOMICS B cells. A major goal of the group is to foundations (e.g., AECC, La Marató de TV3, understand the molecular determinants of Leukemia Research Foundation, Avon SAU, gene deregulation in lymphoid tumors through Cosmetics, ACMCB, FOT). the integration of different layers of information, i.e., genetic alterations, DNA methylation, histone modiﬁcations, chromatin accessibility and 3D chromatin structure. The ultimate goal is to translate the generated GROUP LEADER epigenomic knowledge into a beneﬁt for José Ignacio Martín-Subero (IDIBAPS) patients, in terms of improved diagnosis, estimation of prognosis and treatment. The biomedical epigenomics group is focused on the application of whole-genome technologies to characterize epigenomic dynamics during cell differentiation and neoplastic transformation, with particular

262 ONCOLOGICAL MOLECULAR PATHOLOGY 5.1

6. Schmidt J, Ramis-Zaldivar JE, Nadeu F, Gonzalez-Farre B, Navarro A, Egan C, Montes-Mojarro IA, Maraﬁoti T, Cabeçadas J, van der Walt J, Dojcinov S, Rosenwald A, Ott G, Bonzheim I, Fend F, Campo E, Jaffe ES, Salaverria I, Quintanilla-Martinez L. Mutations of MAP2K1 are frequent in pediatric-type follicular lymphoma and result in ERK pathway activation. BLOOD. 130(3):323-327. I.F.: 13.164

7. Balsas P, Palomero J, Eguileor Á, Rodríguez ML, Vegliante MC, Planas-Rigol E, Sureda-Gómez M, Cid MC, Campo E, Amador V. SOX11 promotes tumor protective microenvironment interactions through CXCR4 and FAK regulation in mantle cell lymphoma. BLOOD. 130(4):501-513. I.F.: 13.164 José Ignacio Martín-Subero

GROUP 8. San José-Enériz E, Agirre X, Rabal O, Vilas-Zornoza A, Sanchez-Arias JA, Miranda E, Ugarte A, Roa S, Paiva B, Estella-Hermoso PUBLICATIONS 3. Egoavil C., Juárez M., Guarinos C., de Mendoza A, Alvarez RM, Casares N, Rodríguez-Soler M., Hernández-Illán E., Segura V, Martín-Subero JI, Ogi FX, Soule P, Originals / I.F.: 421.050 Alenda C., Payá A., Castillejo A., Santiveri CM, Campos-Olivas R, Castellano G, Serradesanferm A., Bujanda L., de Barrena MGF, Rodriguez-Madoz JR, 1. Scott DW, Abrisqueta P, Wright GW, Slack Fernández-Bañares F., Cubiella J., de-Castro García-Barchino MJ, Lasarte JJ, Avila MA, GW, Mottok A, Villa D, Jares P, L., Guerra A., Aguirre E., Herreros-de-Tejada Martinez-Climent JA, Oyarzabal J, Prosper F. Rauert-Wunderlich H, Royo C, Clot G, Pinyol A., Bessa X., Herráiz M., Marín-Gabriel J., Discovery of ﬁrst-in-class reversible dual M, Boyle M, Chan FC, Braziel RM, Chan WC, Balmaña J., Piñol V., Rodríguez Moranta F., small molecule inhibitors against G9a and Weisenburger DD, Cook JR, Greiner TC, Fu K, Nicolás-Pérez D., Cuatrecasas M., Balaguer F., DNMTs in hematological malignancies. Ott G, Delabie J, Smeland EB, Holte H, Jaffe Castells A., Soto J., Zapater P., Jover R. NATURE COMMUNICATIONS. 8:15424. ES, Steidl C, Connors JM, Gascoyne RD, Increased Risk of Colorectal Cancer in I.F.: 12.124 Rosenwald A, Staudt LM, Campo E, Rimsza Patients With Multiple Serrated Polyps and LM, Lymphoma/Leukemia Molecular Proﬁling Their First-Degree Relatives. 9. Law, Phillip J.; Berndt, Sonja I.; Speedy, Project. New Molecular Assay for the GASTROENTEROLOGY. 153(1):106-112. Helen E.; Camp, Nicola J.; Sava, Georgina P.; Proliferation Signature in Mantle Cell I.F.: 18.392 Skibola, Christine F.; Holroyd, Amy; Joseph, Lymphoma Applicable to Formalin-Fixed Vijai; Sunter, Nicola J.; Nieters, Alexandra; Bea, Paraffin-Embedded Biopsies.JOURNAL 4. De Barrios O., Gyorffy B., Silvia; Monnereau, Alain; Martin-Garcia, David; OF CLINICAL ONCOLOGY. 35(15):1668-1677. Fernández-Aceñero M., Sánchez-Tilló E., … … Rothman, Nathanial; Houlston, Richard; I.F.: 24.008 Sánchez-Moral L., Siles L., Esteve-Arenys A., Slager, Susan L. Genome-wide association Roué G., Casal J., Darling D., Castells A., analysis implicates dysregulation of 2. Zucca E; Conconi A; Martinelli G; Postigo A. ZEB1-induced tumourigenesis immunity genes in chronic lymphocytic Bouabdallah R; Tucci A; Vitolo U; Martelli M; requires senescence inhibition via leukaemia. NATURE COMMUNICATIONS. Pettengell R; Salles G; Sebban C; López activation of DKK1/mutant 8:14175. I.F.: 12.124 Guillermo A; Pinotti G; Devizzi L; p53/Mdm2/CtBP and repression of Morschhauser F; Tilly H; Torri V; Hohaus S; macroH2A1. GUT. 66(4):666-682. I.F.: 16.658 10. Menendez C, Castillo P, Martínez MJ, Ferreri A; Zachee P; Bosly A; Haioun C; Jordao D, Lovane L, Ismail MR, Carrilho C, Stelitano C; Bellei M; Ponzoni M; Moreau A; 5. Bouska A, Bi C, Lone W, Zhang W, Kedwaii Lorenzoni C, Fernandes F, Nhampossa T, Jack A; Campo E; Mazzucchelli L; Cavalli F; A, Heavican T, Lachel C, Yu J, Ferro R, Hurtado JC, Navarro M, Casas I, Santos Johnson P; Thieblemont C. Final results of Eldorghamy N, Greiner T, Vose J, Ritchie P, Bandeira S, Mocumbi S, Jaze Z, the IELSG-19 randomized trial of Weisenburger D, Gascoyne R, Rosenwald A, Mabota F, Munguambe K, Maixenchs M, Sanz mucosa-associated lymphoid tissue Ott G, Campo E, Rimsza L, Jaffe E, Braziel R, A, Mandomando I, Nadal A, Goncé A, lymphoma: Improved event-free and Siebert R, Miles R, Dave S, Reddy A, Delabie J, Muñoz-Almagro C, Quintó L, Vila J, Macete E, progression-free survival with rituximab Staudt L, Song J, McKeithan T, Fu K, Green M, Alonso P, Ordi J, Bassat Q. Validity of a plus chlorambucil versus either Chan W, Iqbal J. Adult high-grade B-cell minimally invasive autopsy for cause of chlorambucil or rituximab monotherapy. lymphoma with Burkitt lymphoma death determination in stillborn babies and JOURNAL OF CLINICAL ONCOLOGY. signature: Genomic features and potential neonates in Mozambique: An 35(17):1905-1912. I.F.: 24.008 therapeutic targets. BLOOD. observational study. PLOS MEDICINE. 130(16):1819-1831. I.F.: 13.164 14(6):e1002318. I.F.: 11.862

263 AREA 5 ONCOLOGY AND HAEMATOLOGY

11. Magnano L, Balagué O, Dlouhy I, Rovira J, Activating mutations and translocations in Gironella M. MicroRNAs for Detection of Karube K, Pinyol M, Rivas-Delgado A, Costa D, the guanine exchange factor VAV1 in Pancreatic Neoplasia: Biomarker Martínez-Trillos A, González-Farre B, peripheral T-cell lymphomas. Discovery by Next-generation Sequencing Martínez-Pozo A, Giné E, Colomer D, Delgado PROCEEDINGS OF THE NATIONAL and Validation in 2 Independent Cohorts. J, Villamor N, Campo E, López-Guillermo A. ACADEMY OF SCIENCES OF THE UNITED ANNALS OF SURGERY. 265(6):1226-1234. Clinicobiological features and prognostic STATES OF AMERICA. 114(4):764-769. I.F.: 8.980 impact of diffuse large B-cell lymphoma I.F.: 9.661 component in the outcome of patients with 21. Postigo A., Ramsden A., Howell M., Way M. previously untreated follicular lymphoma. 17. Matas-Céspedes A, Vidal-Crespo A, Cytoplasmic ATR Activation Promotes ANNALS OF ONCOLOGY. 28(11):2799-2805. Rodriguez V, Villamor N, Delgado J, Giné E, Vaccinia Virus Genome Replication. CELL I.F.: 11.855 Roca-Ho H, Menéndez P, Campo E, REPORTS. 19(5):1022-1032. I.F.: 8.282 López-Guillermo A, Colomer D, Roué G, 12. Bouska A, Zhang W, Gong Q, Iqbal J, Scuto Wiestner A, Parren PW, Doshi P, van Bueren 22. Vidal-Crespo A, Rodriguez V, A, Vose J, Ludvigsen M, Fu K, Weisenburger JL, Pérez-Galán P. The Human CD38 Matas-Cespedes A, Lee E, Rivas-Delgado A, DD, Greiner TC, Gascoyne RD, Rosenwald A, Monoclonal Antibody Daratumumab Giné E, Navarro A, Beà S, Campo E, Ott G, Campo E, Rimsza LM, Delabie J, Jaffe Shows Antitumor Activity and Hampers López-Guillermo A, Lopez-Guerra M, Roué G, ES, Braziel RM, Connors JM, Wu CI, Staudt Leukemia-Microenvironment Interactions Colomer D, Pérez-Galán P. The Bruton LM, D'Amore F, McKeithan TW, Chan WC. in Chronic Lymphocytic Leukemia. tyrosine kinase inhibitor CC-292 shows Combined copy number and mutation CLINICAL CANCER RESEARCH. activity in mantle cell lymphoma and analysis identifies oncogenic pathways 23(6):1493-1505. I.F.: 9.619 synergizes with lenalidomide and NIK associated with transformation of inhibitors depending on nuclear factor-κB follicular lymphoma. LEUKEMIA. 31(1):83-91. 18. Xochelli A, Baliakas P, Kavakiotis I, mutational status. HAEMATOLOGICA. I.F.: 11.702 Agathangelidis A, Sutton LA, Minga E, Ntoufa 102(11):e447-e451. I.F.: 7.702 S, Tausch E, Yan XJ, Shanafelt T, Plevova K, 13. Paiva B, Puig N, Cedena MT, de Jong BG, Boudjogra M, Rossi D, Davis Z, Navarro A, 23. Santamaría G, Bargalló X, Fernández PL, Ruiz Y, Rapado I, Martinez-Lopez J, Cordon L, Sandberg Y, Vojdeman FJ, Scarfo L, Farrús B, Caparrós X, Velasco M. Alignani D, Delgado JA, van Zelm MC, Van Stavroyianni N, Sudarikov A, Veronese S, Neoadjuvant Systemic Therapy in Breast Dongen JJ, Pascual M, Agirre X, Prosper F, Tzenou T, Karan-Djurasevic T, Catherwood Cancer: Association of Martín-Subero JI, Vidriales MB, Gutierrez NC, M, Kienle D, Chatzouli M, Facco M, Bahlo J, Contrast-enhanced MR Imaging Findings, Hernandez MT, Oriol A, Echeveste MA, Pott C, Pedersen LB, Mansouri L, Smedby KE, Diffusion-weighted Imaging Findings, and Gonzalez Y, Johnson SK, Epstein J, Barlogie B, Chu CC, Giudicelli V, Lefranc MP, Panagiotidis Tumor Subtype with Tumor Response. Morgan GJ, Orfao A, Blade J, Mateos MV, P, Juliusson G, Anagnostopoulos A, Vlahavas I, RADIOLOGY. 283(3):663-672. I.F.: 7.296 Lahuerta JJ, San-Miguel JF. Differentiation Antic D, Trentin L, Montillo M, Niemann C, stage of myeloma plasma cells: biological Döhner H, Langerak AW, Pospisilova S, Hallek 24. Balsas P, Esteve-Arenys A, Roldán J, and clinical significance. LEUKEMIA. M, Campo E, Chiorazzi N, Maglaveras N, Jiménez L, Rodríguez V, Valero JG, 31(2):382-392. I.F.: 11.702 Oscier D, Gaidano G, Jelinek DF, Stilgenbauer Chamorro-Jorganes A, de la Bellacasa RP, S, Chouvarda I, Darzentas N, Belessi C, Davi F, Teixidó J, Matas-Céspedes A, Moros A, 14. Carrillo-de-Santa-Pau E, Juan D, Pancaldi Hadzidimitriou A, Rosenquist R, Ghia P, Martínez A, Campo E, Sáez-Borderías A, V, Were F, Martin-Subero I, Rico D, Valencia A, Stamatopoulos K. Chronic lymphocytic Borrell JI, Pérez-Galán P, Colomer D, Roué G. BLUEPRINT Consortium. Automatic leukemia with mutated ighv4-34 Activity of the novel BCR kinase inhibitor identification of informative regions with receptors: shared and distinct IQS019 in preclinical models of B-cell epigenomic changes associated to immunogenetic features and clinical non-Hodgkin lymphoma. JOURNAL OF hematopoiesis. NUCLEIC ACIDS outcomes. CLINICAL CANCER RESEARCH. HEMATOLOGY AND ONCOLOGY. 10(1):80. RESEARCH. 45(16):9244-9259. I.F.: 10.162 23(17):5292-5301. I.F.: 9.619 I.F.: 6.350

15. Cortes, Marlies; Sanchez-Moral, Lidia; de 19. Prat A, Navarro A, Paré L, Reguart N, 25. Codony-Servat J, Cuatrecasas M, Barrios, Oriol; Fernandez-Acenero, Maria J.; Galván P, Pascual T, Martínez A, Nuciforo P, Asensio E, Montironi C, Martínez-Cardús A, Martinez-Campanario, M. C.; Esteve-Codina, Comerma L, Alos L, Pardo N, Cedrés S, Fan C, Marín-Aguilera M, Horndler C, Anna; Darling, Douglas S.; Gyorffy, Balazs; Parker JS, Gaba L, Victoria I, Viñolas N, Martínez-Balibrea E, Rubini M, Jares P, Reig O, Lawrence, Toby; Dean, Douglas C.; Postigo, Vivancos A, Arance A, Felip E. Victoria I, Gaba L, Martín-Richard M, Alonso V, Antonio. Tumor-associated macrophages Immune-Related Gene Expression Escudero P, Fernández-Martos C, Feliu J, (TAMs) depend on ZEB1 for their Proﬁling After PD-1 Blockade in Non-Small Méndez JC, Méndez M, Gallego J, Salud A, cancer-promoting roles. EMBO JOURNAL. Cell Lung Carcinoma, Head and Neck Rojo F, Castells A, Prat A, Rosell R, 36(22):3336-3355. I.F.: 9.792 Squamous Cell Carcinoma, and García-Albéniz X, Camps J, Maurel J. Nuclear Melanoma. CANCER RESEARCH. IGF-1R predicts chemotherapy and 16. Abate F; Da Silva-Almeida A; Zairis S; 77(13):3540-3550. I.F.: 9.122 targeted therapy resistance in metastatic Robles-Valero J; Couronné L; Khiabanian H; colorectal cancer. BRITISH JOURNAL OF Quinn S; Kim M; Laginestra M; Kim C; Fiore D; 20. Vila-Navarro E, Vila-Casadesús M, CANCER. 117(12):1777-1768. I.F.: 6.176 Bhagat G; Piris M; Campo E; Lossos I; Bernard Moreira L, Duran-Sanchon S, Sinha R, Ginés À, O; Inghirami G; Pileri S; Bustelo X; Rabadan R; Fernández-Esparrach G, Miquel R, 26. Rivero-Sanchez L, Lopez-Ceron M, Ferrando A; Palomero T. Cuatrecasas M, Castells A, Lozano JJ, Carballal S, Moreira L, Bessa X,

264 ONCOLOGICAL MOLECULAR PATHOLOGY 5.1

Serradesanferm A, Pozo A, Augé JM, Ocaña MicroRNA-200, associated with Immunological Microenvironment Based T, Sánchez A, Leoz ML, Cuatrecasas M, Grau metastatic breast cancer, promotes traits on Transcriptional Profiles of Follicular J, Llach J, Castells A, Balaguer F, Pellisé M, of mammary luminal progenitor cells. Dendritic Cell Sarcomas. MOLECULAR Procolon Group. Reassessment ONCOTARGET. 8(48):83384-83406. CANCER RESEARCH. 15(5):541-552.I.F.: 4.974 colonoscopy to diagnose serrated I.F.: 5.168 polyposis syndrome in a colorectal cancer 37. Bobi J, Solanes N, Fernández-Jiménez R, screening population. ENDOSCOPY. 32. Lorenzi L, Döring C, Rausch T, Benes V, Galán-Arriola C, Dantas AP, Fernández-Friera 49(1):44-53. I.F.: 6.107 Lonardi S, Bugatti M, Campo E, Cabeçadas J, L, Gálvez-Montón C, Rigol-Monzó E, Agüero J, Simonitsch-Klupp I, Borges A, Mehta J, Ramírez J, Roqué M, Bayés-Genís A, 27. Gonzalez-Farre B, Martinez D, Agostinelli C, Pileri SA, Facchetti F, Hansmann Sánchez-González J, García-Álvarez A, Lopez-Guerra M, Xipell M, Monclus E, Rovira J, ML, Hartmann S. Identification of novel Sabaté M, Roura S, Ibáñez B, Rigol M. Garcia F, Lopez-Guillermo A, Colomo L, follicular dendritic cell sarcoma markers, Intracoronary Administration of Campo E, Martinez A. HHV8-related FDCSP and SRGN, by whole Allogeneic Adipose Tissue-Derived lymphoid proliferations: a broad spectrum transcriptome sequencing. ONCOTARGET. Mesenchymal Stem Cells Improves of lesions from reactive lymphoid 8(10):16463-16472. I.F.: 5.168 Myocardial Perfusion But Not Left hyperplasia to overt lymphoma. MOD Ventricle Function, in a Translational PATHOL. 30(5):745-760. I.F.: 5.728 33. Esteban-Jurado C., Giménez-Zaragoza Model of Acute Myocardial Infarction. D., Muñoz J., Franch-Expósito S., JOURNAL OF THE AMERICAN HEART 28. Höring E., Montraveta A., Heine S., Kleih M., álvarez-Barona M., Ocaña T., Cuatrecasas M., ASSOCIATION. 6(5):e005771. I.F.: 4.425 Schaaf L., Vöhringer M., Esteve-Arenys A., Carballal S., López-Cerón M., Marti-Solano M., Roué G., Colomer D., Campo E., Ott G., Aulitzky Díaz-Gay M., Wezel T., Castells A., Bujanda L., 38. Casabonne D, Gracia E, Espinosa A, W., van der Kuip H. Dual targeting of MCL1 Balmaña J., Gonzalo V., Llort G., Ruiz-Ponte C., Bustamante M, Benavente Y, Robles C, and NOXA as effective strategy for Cubiella J., Balaguer F., Aligué R., Castellví-Bel Costas L, Alonso E, Gonzalez-Barca E, treatment of mantle cell lymphoma. S. POLE and POLD1 screening in 155 Tardón A, Dierssen-Sotos T, Vázquez EG, BRITISH JOURNAL OF HAEMATOLOGY. patients with multiple polyps and Aymerich M, Campo E, Jiménez-Moleón JJ, 177(4):557-561. I.F.: 5.670 early-onset colorectal cancer. Marcos-Gragera R, Castaño-Vinyals G, ONCOTARGET. 8(16):26732-26743. I.F.: 5.168 Aragones N, Pollan M, Kogevinas M, Urtiaga C, 29. Delgado, Julio; Bielig, Torsten; Bonet, Amiano P, Moreno V, de Sanjose S. Fruit and Lizette; Carnero-Montoro, Elena; Puente, 34. Izquierdo L, Montalbo R, Ingelmo-Torres vegetable intake and vitamin C transporter Xose S.; Colomer, Dolors; Bosch, Elena; M, Mallofré C, Ramírez-Backhaus M, Rubio J, gene (SLC23A2) polymorphisms in Campo, Elias; Lozano, Francisco. Impact of Van der Heijden AG, Schaafsma E, chronic lymphocytic leukaemia. the functional CD5 polymorphism A471V Lopez-Beltran A, Blanca A, Lawrentschuk N, EUROPEAN JOURNAL OF NUTRITION. on the response of chronic lymphocytic Alcaraz A, Mengual L. Prognostic 56(3):1123-1133. I.F.: 4.370 leukaemia to conventional chemotherapy microRNAs in upper tract urothelial regimens. BRITISH JOURNAL OF carcinoma: multicenter and international 39. Pouliou E, Xochelli A, Kanellis G, Stalika E, HAEMATOLOGY. 177(1):142-156. I.F.: 5.670 validation study. ONCOTARGET. Sutton LA, Navarro A, Agathangelidis A, 8(31):51522-51529. I.F.: 5.168 Dimosthenous K, Anagnostopoulos A, 30. Colomo L, Vazquez I, Papaleo N, Espinet Patsouris E, Korkolopoulou P, Sundstrom C, B, Ferrer A, Franco C, Comerma L, Hernandez 35. Fernandez-Martinez A., Pascual T., Ghia P, Ponzoni M, Sander B, Campo E, S, Calvo X, Salar A, Climent F, Mate JL, Perrone G., Morales S., de la Haba J., Rosenquist R, Hadzidimitriou A, Forcada P, Mozos A, Nonell L, Martinez A, González-Rivera M., Galván P., Zalfa F., Amato Stamatopoulos K, Papadaki T. Numerous Carrio A, Costa D, Dlouhy I, Salaverria I, M., Gonzalez L., Prats M., Rojo F., Manso L., Ontogenetic Roads to Mantle Cell Martin-Subero JI, Lopez-Guillermo A, Valera Paré L., Alonso I., Albanell J., Vivancos A., Lymphoma: Immunogenetic and A, Campo E, Grup per l’Estudi dels Limfomes González A., Matito J., González S., Fernandez Immunohistochemical Evidence. de Catalunya i Balears (GELCAB). P., Adamo B., Muñoz M., Viladot M., Font C., AMERICAN JOURNAL OF PATHOLOGY. LMO2-negative Expression Predicts the Aya F., Vidal M., Caballero R., Carrasco E., 187(7):1454-1458. I.F.: 4.057 Presence of MYC Translocations in Altomare V., Tonini G., Prat A., Martin M. Aggressive B-Cell Lymphomas. Limitations in predicting PAM50 intrinsic 40. Rakislova N., Montironi C., Aldecoa I., AMERICAN JOURNAL OF SURGICAL subtype and risk of relapse score with Ki67 Fernandez E., Bombi J., Jimeno M., Balaguer PATHOLOGY. 41(7):877-886. I.F.: 5.363 in estrogen receptor-positive HER2- F., Pellise M., Castells A., Cuatrecasas M. negative breast cancer. ONCOTARGET. Lymph node pooling: A feasible and 31. Sanchez-Cid, Lourdes; Pons, Monica; Jose 8(13):21930-21937. I.F.: 5.168 efficient method of lymph node molecular Lozano, Juan; Rubio, Nuria; Guerra-Rebollo, staging in colorectal carcinoma. JOURNAL Marta; Soriano, Aroa; Paris-Coderch, Laia; 36. Laginestra MA, Tripodo C, Agostinelli C, OF TRANSLATIONAL MEDICINE. 15(1):14. Segura, Miquel F.; Fueyo, Raquel; Arguimbau, Motta G, Hartmann S, Döring C, Rossi M, Melle I.F.: 3.786 Judit; Zodda, Erika; Bermudo, Raquel; Alonso, F, Sapienza MR, Tabanelli V, Pileri A, Fuligni F, Immaculada; Caparros, Xavier; Cascante, Gazzola A, Mannu C, Sagramoso CA, Lonardi 41. Aldecoa I, Montironi C, Planell N, Pellise M, Marta; Rafii, Arash; Kang, Yibin; S, Lorenzi L, Bacci F, Sabattini E, Borges A, Fernandez-Esparrach G, Gines A, Delgado S, Martiez-Balbas, Marian; Weiss, Stephen J.; Simonitsch-Klupp I, Cabecadas J, Campo E, Momblan D, Moreira L, Lopez-Ceron M, Blanco, Jeronimo; Munoz, Montserrat; Rosai J, Hansmann ML, Facchetti F, Pileri SA. Rakislova N, Martinez-Palli G, Balust J, Bombi Fernandez, Pedro L.; Thomson, Timothy M. Distinctive Histogenesis and JA, de Lacy A, Castells A, Balaguer F,

265 AREA 5 ONCOLOGY AND HAEMATOLOGY

Cuatrecasas M. Endoscopic tattooing of immunochemotherapy. ANNALS OF hypomethylation at enhancer sites. early colon carcinoma enhances detection HEMATOLOGY. 96(3):405-410. I.F.: 3.083 PEDIATR BLOOD CANCER. 64(3):e26251. of lymph nodes most prone to harbor I.F.: 2.513 tumor burden. SURGICAL ENDOSCOPY. 47. Lewis MA, Sharabash N, Miao ZF, Lyons 31(2):723-733. I.F.: 3.747 LN, Piccirillo J, Kallogjeri D, Schootman M, 53. Nomdedeu, Meritxell; Pereira, Arturo; Mutch M, Yan Y, Levin MS, Castells A, Calvo, Xavier; Colomer, Joan; Sole, Francesc; 42. Erfan G, Puig S, Carrera C, Arance A, Gaba Cuatrecasas M, Mills JC, Wang ZN, Rubin DC. Arias, Amparo; Gomez, Candida; Luno, Elisa; L, Victoria I, Garcia-Herrera A, Alos L, Malvehy Increased IFRD1 Expression in Human Cervera, Jose; Arnan, Montserrat; Pomares, J. Development of Cutaneous Toxicities Colon Cancers Predicts Reduced Patient Helena; Ramos, Fernando; Oiartzabal, Itziar; During Selective Anti-BRAF Therapies: Survival. DIGESTIVE DISEASES AND Espinet, Blanca; Pedro, Carme; Arrizabalaga, Preventive Role of Combination with MEK SCIENCES. 62(12):3460-3467. I.F.: 2.875 Beatriz; Laura Blanco, Maria; Tormo, Mar; Inhibitors. ACTA Maria Hernandez-Rivas, Jesus; DERMATO-VENEREOLOGICA. 48. Companioni, Osmel; Miguel Diez-Campelo, Maria; Ortega, Margarita; 97(2):258-260. I.F.: 3.653 Sanz-Anquela, Jose; Luisa Pardo, Maria; Valcarcel, David; Cedena, Maria-Teresa; Puigdecanet, Eulalia; Nonell, Lara; Garcia, Collado, Rosa; Grau, Javier; Granada, Isabel; 43. Carreras J, Kikuti YY, Beà S, Miyaoka M, Nadia; Parra Blanco, Veronica; Lopez, Sanz, Guillermo; Campo, Elias; Esteve, Jordi; Hiraiwa S, Ikoma H, Nagao R, Tomita S, Consuelo; Andreu, Victoria; Cuatrecasas, Costa, Dolors;Spanish MDS Grp. Clinical and Martin-Garcia D, Salaverria I, Sato A, Ichiki A, Miriam; Garmendia, Maddi; Gisbert, Javier P.; biological significance of isolated Y Roncador G, Garcia JF, Ando K, Campo E, Gonzalez, Carlos A.; Sala, Nuria. Gene chromosome loss in myelodysplastic Nakamura N. Clinicopathological expression study and pathway analysis of syndromes and chronic myelomonocytic characteristics and genomic profile of histological subtypes of intestinal leukemia. A report from the Spanish MDS primary sinonasal tract diffuse large B cell metaplasia that progress to gastric cancer. Group. LEUKEMIA RESEARCH. 63:85-89. lymphoma (DLBCL) reveals gain at 1q31 PLOS ONE. 12(4):e0176043. I.F.: 2.806 I.F.: 2.501 and RGS1 encoding protein; high RGS1 immunohistochemical expression 49. Martínez-Trillos A., Pinyol M., Delgado J., 54. Dlouhy I, Filella X, Rovira J, Magnano L, associates with poor overall survival in Aymerich M., Rozman M., Baumann T., Rivas-Delgado A, Baumann T, Martínez-Trillos DLBCL not otherwise specified (NOS). González-Díaz M., Hernández J., Alcoceba M., A, Balagué O, Martínez A, González-Farre B, HISTOPATHOLOGY. 70(4):595-621. I.F.: 3.523 Muntañola A., Terol M., Navarro B., Giné E., Karube K, Gine E, Delgado J, Campo E, Jares P., Beà S., Navarro A., Colomer D., Nadeu López-Guillermo A. High serum levels of 44. Valls-Mateus, Meritxell; San Roman, Luis; F., Colado E., Payer A., García-Cerecedo T., soluble interleukin-2 receptor (sIL2-R), Macho, Juan; Nadal, Alfons; Puente X., López-Otin C., Campo E., interleukin-6 (IL-6) and tumor necrosis Bernal-Sprekelsen, Manuel; Vilaseca, Isabel. López-Guillermo A., Villamor N. The factor alpha (TNF) are associated with Transoral ultrasonic surgery of mutational landscape of small lymphocytic adverse clinical features and predict poor pharyngolaryngeal giant hemangioma lymphoma compared to non-early stage outcome in diffuse large B-cell lymphoma. after ethylene-vinyl alcohol copolymer chronic lymphocytic leukemia. LEUKEMIA LEUKEMIA RESEARCH. 59:20-25. I.F.: 2.501 (Onyx) embolization. HEAD AND NECK. AND LYMPHOMA. 8:1-9. I.F.: 2.755 39(6):1239-1242. I.F.: 3.376 55. Moisés J, Navarro A, Santasusagna S, 50. Magnano L, Martínez A, Carreras J, Viñolas N, Molins L, Ramirez J, Osorio J, Saco 45. Magnano L., Montoto S., González-Barca Martínez-Trillos A, Giné E, Rovira J, Dlouhy I, A, Castellano JJ, Muñoz C, Morales S, Monzó E., Briones J., Sancho J., Muntañola A., Salar A., Baumann T, Balagué O, Campo E, M, Marrades RM. NKX2-1 expression as a Besalduch J., Escoda L., Moreno C., López-Guillermo A, Villamor N. T-cell subsets prognostic marker in early-stage Domingo-Domenech E., Estany C., Oriol A., in lymph nodes identify a subgroup of non-small-cell lung cancer. BMC Altés A., Pedro C., Gardella S., Asensio A., follicular lymphoma patients with PULMONARY MEDICINE. 17(1):197. I.F.: 2.435 Vivancos P., Fernández de Sevilla A., Ribera J., favorable outcome. LEUKEMIA AND Colomer D., Campo E., López-Guillermo A. LYMPHOMA. 58(4):842-850. I.F.: 2.755 56. El Hadi H, Abdellaoui-Maane I, Kottwitz D, Long-term safety and outcome of El Amrani M, Bouchoutrouch N, Qmichou Z, fludarabine, cyclophosphamide and 51. Carrera C., Gual A., DIáz A., Puig-Butillé J., Karkouri M, ElAttar H, Errihani H, Fernandez mitoxantrone (FCM) regimen in previously Noguès S., Vilalta A., Conill C., Rull R., Vilana R., PL, Bakri Y, Sefrioui H, Moumen A. untreated patients with advanced follicular Arguis P., Vidal-Sicart S., Alós L., Palou J., Development and evaluation of a novel lymphoma: 12 years follow-up of a phase 2 Castel T., Malvehy J., Puig S. Prognostic role RT-qPCR based test for the quantification trial. ANNALS OF HEMATOLOGY. of the histological subtype of melanoma on of HER2 gene expression in breast cancer. 96(4):639-646. I.F.: 3.083 the hands and feet in Caucasians. GENE. 605:114-122. I.F.: 2.415 MELANOMA RESEARCH. 27(4):315-320. 46. Dlouhy I, Torrente MÁ, Lens S, Rovira J, I.F.: 2.615 57. Beardo P., Truan Cacho D., Izquierdo L., Magnano L, Giné E, Delgado J, Balagué O, Alcover-Garcia J., Alcaraz A., Extramiana J., Martínez A, Campo E, Forns X, 52. Bergmann AK, Castellano G, Alten J, Mallofré C. Cancer-Specific Survival Sánchez-Tapias JM, López-Guillermo A. Ammerpohl O, Kolarova J, Nordlund J, Stratification Derived from Tumor Clinico-biological characteristics and Martin-Subero JI, Schrappe M, Siebert R. Expression of Tissue Inhibitor of outcome of hepatitis C virus-positive DNA methylation profiling of pediatric Metalloproteinase-2 in Non-Metastatic patients with diffuse large B-cell B-cell lymphoblastic leukemia with Renal Cell Carcinoma. PATHOLOGY lymphoma treated with KMT2A rearrangement identifies ONCOLOGY RESEARCH. I.F.: 1.736

266 ONCOLOGICAL MOLECULAR PATHOLOGY 5.1

Review / I.F.: 13.706 Case Reports / I.F.: 1.401 (ISCIII). RD12/0036/0036 Duration: 01/01/2013-30/06/2017 1. Rosenquist R, Beà S, Du MQ, Nadel B, 1. Castro, Jesus; Cuatrecasas, Miriam; Pan-Hammarström Q. Genetic landscape Balaguer, Francesc; Ricart, Elena; Pellise, Campo E. Microenvironment Interactions and deregulated pathways in B-cell Maria. Serrated polyposis syndrome in the Pathogenesis of Lymphoid lymphoid malignancies. JOURNAL OF associated with long-standing Neoplasms and Chronic Inflammatory INTERNAL MEDICINE. 282(5):371-394. inflammatory bowel disease. REVISTA Disorders.Identification of Biomarkers and I.F.: 7.980 ESPANOLA DE ENFERMEDADES Design of New Therapeutic Strategies. DIGESTIVAS. 109(11):796-798. I.F.: 1.401 Sponsored by: Instituto de Salud Carlos III 2. Campo E. Pathology and classification of (ISCIII). PIE13/00033 aggressive mature B-cell lymphomas. Duration: 01/01/2014-30/06/2017 HEMATOLOGICAL ONCOLOGY. Clinical Guidelines / I.F.: 11.855 35(S1):80-83. I.F.: 3.118 Campo E. Genetic and cellular intratumor 1. Dreyling M; Campo E; Hermine O; Jerkeman heterogeneity as predictor of chronic 3. Beà S, Amador V. Role of SOX11 and M; Le Gouill S; Rule S; Shpilberg O; Walewski J; lymphocytic leukemia outcome and Genetic Events Cooperating with Cyclin D1 Ladetto M. Newly diagnosed and relapsed treatment. in Mantle Cell Lymphoma. CURRENT mantle cell lymphoma: ESMO Clinical Sponsored by: Instituto de Salud Carlos III ONCOLOGY REPORTS. 19(6):43. I.F.: 2.608 Practice Guidelines for diagnosis, (ISCIII). AC15/00028 treatment and follow-up. ANNALS OF Duration: 01/01/2016- 31/12/2018 ONCOLOGY. 28(suppl_4):iv62-iv71. I.F.: 11.855 Letters / I.F.: 15.475 Campo E. Functional and Clinical Impact of Genomics Analysis in CLL. 1. Navarro A, Clot G, Martínez-Trillos A, Pinyol Sponsored by: Instituto de Salud Carlos III. M, Jares P, González-Farré B, Martínez D, Trim GRANTS FOR RESEARCH IN PROGRESS PMP15/00007 N, Fernández V, Villamor N, Colomer D, Costa Duration: 01/01/2016- 31/12/2019 D, Salaverria I, Martín-Garcia D, Erber W, Amador V. Characterization of the López C, Jayne S, Siebert R, Dyer MJS, oncogenic molecular mechanisms of the Campo E. Impacto Clínico de la Wiestner A, Wilson WH, Aymerich M, SOX11 transcription factor in aggressive Heterogeneidad Genómica y Evolución López-Guillermo A, Sánchez À, Campo E, mantle cell lymphomas. Clonal en Neoplasias Linfoides B. Matutes E, Beà S. Improved classification of Sponsored by: Fundació La Marató de TV3. Definición de Nuevos Modelos leukemic B-cell lymphoproliferative I3/20130110 Diagnósticos y Pronósticos. disorders using a transcriptional and Duration: 15/04/2014-14/04/2017 Sponsored by: Ministerio de Economía y genetic classifier. HAEMATOLOGICA. Competitividad (MINECO). 102(9):e360-e363. I.F.: 7.702 Amador V. Descifrando las redes SAF2015-64885-R moleculares del microambiente protector Duration: 01/01/2016- 31/12/2018 2. Ortiz-Maldonado V, Villamor N, Baumann T, y de las células madre en los linfomas de Aymerich M, Magnano L, Mozas P, células del manto agresivos para innovar Campo E. Study of the tumor Rivas-Delgado A, Martínez-Trillos A, Giné E, en estrategias terapéuticas. heterogeneity and tracking clonal Campo E, López-Guillermo A, Delgado J. Sponsored by: Ministerio de Economía y evolution of mutations in TP53 and other Is there a role for minimal residual disease Competitividad (MINECO). driver genes in B-cell lymphoid neoplasms monitoring in the management of patients BFU2015-64879-R using targeted ultra-deep Next Generation with hairy-cell leukaemia? BRITISH Duration: 01/01/2016-31/12/2018 Sequencing. GLD15/00288. JOURNAL OF HAEMATOLOGY. I.F.: 5.670 Sponsored by: Gilead España Beà S. Comprehensive whole genome and Duration: 01/03/2016- 31/03/2018 3. Morollón N., Rodríguez F., Duarte J., exome sequence analysis in mantle cell Sánchez R., Camacho F., Campo E. Brain lymphoma primary tumors. Campo E. La Medicina Personalitzada a lesions in a long-term kidney transplant Sponsored by: Fundació La Marató de TV3. Catalunya-Càncer (MedPerCan). Estudi recipient: Primary cerebral lymphoma or 20130410 pilot sobre l'impacte de l'anàlisi genòmica cerebral toxoplasmosis? NEUROLOGIA. Duration: 15/04/2014-14/04/2017 en la presa de decisions en oncologia. 32(4):268-270. I.F.: 2.103 Sponsored by: Generalitat de Catalunya Beà S. Estudio genético y molecular de los (PERIS). SLT002/16/00374 linfomas B. Caracterización de entidades y Duration: 27/03/2017-31/12/2019 Editorial / I.F.: 11.855 subtipos, clonalidad y significado pronóstico. Campo E. Impacto clínico y biológico de las 1. Balagué O, Campo E. Refining The Sponsored by: Instituto de Salud Carlos II alteraciones genómicas en neoplasias Prognostic Impact of the Cell Of Origin in (ISCIII). PI14/00571 linfoides. Diffuse Large B-Cell Lymphoma. ANNALS Duration: 01/01/2015-31/12/2017 Sponsored by: Ministerio de Economía y OF ONCOLOGY. 28(5):918-920. I.F.: 11.855 Competitividad (MINECO). Campo E. Red Temática de Investigación SAF2016-81860-REDT Cooperativa en Cáncer. Duration: 01/07/2017-30/06/2019 Sponsored by: Instituto de Salud Carlos III

267 AREA 5 ONCOLOGY AND HAEMATOLOGY

Cuatrecasas M (and Camps J.). Nuevas SAF2014-52874-R Postigo A. Role of ZEB1 in skeletal muscle: estrategias para la estratificación del Duration: 01/01/2015-31/10/2018 regulation of cell differentiation, response riesgo de recidiva en pacientes con cáncer to tissue damage and regeneration. de colon en estadio II: Integración de Salaverria I. Caracterización molecular, PhD Student: Laura Siles Mena perfiles genómicos y carga tumoral genética e inmunofenotípica de los ganglionar. linfomas de centro germinal en pacientes Sponsored by: Instituto de Salud Carlos III pediátricos, adolescentes y jóvenes (ISCIII). PI17/01304. adultos. Duration: 01/01/2018-31/12/2020 Sponsored by: Instituto de Salud Carlos III (ISCIII). PI15/00580 Hernández L. Búsqueda de IncRNAs Duration: 01/01/2016-31/12/2018 relacionados con la polarización de macrófagos pro-tumorogénicos (M2-TAM) en linfomas foliculares/difusos de células grandes y evaluación de su valor DOCTORAL THESES clínico. Sponsored by: Instituto de Salud Carlos III Campo E, Martínez A. Síndromes (ISCIII). PI15/00551 linfoproliferativos asociados a Duration: 01/01/2016-31/12/2018 inmunodeficiencias secundarias: papel de la infección por virus herpes oncogénicos Jares P. Nuevos mecanismos oncogénicos y la diferenciación plasmocelular. de ciclina D1 en linfoma de células del PhD student: Blanca González Farré manto (LCM): Implicación en la regulación transcripcional, la respuesta al daño en el Campo E, Jares P . Mantle Cell Lymphoma ADN y el estrés eplicativo. pathogenesis: another turn of the screw to Sponsored by: Instituto de Salud Carlos III cyclin D1 overexpression. (ISCIII). PI14/00355 PhD student: Robert Albero Gallego Duration: 01/01/2015- 31/12/2017 Campo E, Perez-Galan P. Targeting the Martin-Subero JI. Functional and clinical crosstalk between tumor cells and impact of enhancer DNA methylation in microenvironment: a new therapeutic mantle cell lymphoma. approach for the treatment of lymphoid Sponsored by: European Hematology neoplasms. Association. EHA_FELLOW13SEPT_02 PhD student: Anna Vidal Crespo Duration: 16/11/2014- 15/11/2017 Hernández L, Slavutsky I. Análisis de los Martinez A. SLPC asociados a perfiles de expresión de genes inmunodeficiencia: estudio de la codificantes y no codificantes en transformación secretora y de la linfomas no- Hodgkin. activación litica de los herpesvirus como PhD student: Alejandro Roisman nuevas dianas terapéuticas. Sponsored by: Instituto de Salud Carlos III Martinez A, Roué G. Diferenciación (ISCIII). PI14/00333 plasmocelular en linfomas no-Hodgkin de Duration: 01/01/2015- 31/12/2017 células B: implicaciones clínicas y terapéuticas. Postigo A. ZEB proteins and tumor PhD Student: Carla Solé Cañadas progression. Role of ZEB1 and ZEB2 in oncogenic transformation Ordi J,Ramirez J. Microscopía virtual en benign-malignant transition and cancer diagnóstico y docencia en un hospital cell proliferation and survival. universitario. Sponsored by: Fundació La Marató de TV3. PhD student: Adela Saco Álvarez 20133010 Duration: 15/04/2014-31/01/2018 Postigo A, Castells A. Role of ZEB1 in tumor progression: Regulation of cell invasion Postigo A. Papel de los factores ZEB en la and senescence. especificación y activación PhD student: Oriol de Barrios Barri hematopoyética y en la interacción célula maligna- microambiente en neoplasias Postigo A. Role of ZEB1 in macrophages hematológicas. during homeostasis, inflammation and Sponsored by: Ministerio de Economia y cancer. Competitividad (MINECO). PhD Student: Marlies Cortes Hinojosa

268 5.2 2017 067.017 70.70 23 2016 93.83 2015 AGAUR_SGR14 TEAM INVOLVEDIN Q2 Q1 TOTAL I.F. YEAR from 2015 to 2017 Original publications 5. 4. 3. 2. 1. KEYWORDS HCB building LOCATION

Radiotherapy Breastcancerdiagnosis Sentinellymphnode Positronemissiontomography Oncology molecularstudies 3.316 133.53 13 12 8 6 5 2

TEAM Francesca Pons Pilar Paredes(HCB) Mario Pagés(HCB) Meritxell Molla(HCB) Francisco Lomeña(HCB) Blanca Farrús(HCB) Lluís Donoso(HCB) Francesc Casas(HCB) Sebastián Capurro(HCB) Francisco Campos(HCB) Xavier Bargalló(HCB) COLLABORATORS Sergi Vidal(HCB) Xavier Setoain(HCB) Laura Oleaga(HCB) Maria AfricaMuxí(HCB) Marià Monzó(UB) Fernando Gómez(HCB) David Fuster(HCB) Carlos Conill(HCB) Albert Biete(HCB) RESEARCHERS [email protected] T. 932275773 Francesca Pons TEAM LEADER in oncology Diagnosis andtherapy (HCB)

1. MAIN LINESOFRESEARCH therapies inoncology. Development andapplicationofnew oncological patients. treatment responseassessmentin the diagnosis,prognosticevaluationand Development oftechniquesforimproving STRATEGIC OBJECTIVES Eugènia Verger(HCB) Gorane Santamaría(HCB) Marcelo Sánchez(HCB) Angels Rovirosa(HCB) Sonia Rodríguez(HCB) Teresa Pujol(HCB) Javier Pavía(HCB) 3. conventionalX-raysusedinradiotherapy. actionofsynchrotronradiationwith UAB,comparisonismadeofthebiological theneoplasticcell. 2. speciﬁc tissues,withaviewtoselectingmore treatments. microRNApatternsin pharmacogenomics. tumor cells: systemictreatmentinbreastcancer. topredictpathologicalresponseprimary

DIAGNOSIS ANDTHERAPY INONCOLOGY Breast MRI. Effects ofsynchrotronradiationupon Molecular studiesinembryonicand Tumouruptakeanddiffusion

plctost applications to Carried outjointlywith embryonic andtumor Cmaio f Comparisonof 5.2 269 AREA 5 ONCOLOGY AND HAEMATOLOGY

4. Functional mRI techniques. Studies of 5. Rabbie R, Rashid M, Arance AM, Sánchez 11. Carrera C., Gual A., DIáz A., Puig-Butillé J., perfusion, diffusion and spectroscopy M, Tell-Marti G, Potrony M, Conill C, van Doorn Noguès S., Vilalta A., Conill C., Rull R., Vilana R., applied to the staging and treatment R, Dentro S, Gruis NA, Corrie P, Iyer V, Arguis P., Vidal-Sicart S., Alós L., Palou J., monitoring of brain and head and neck Robles-Espinoza CD, Puig-Butille JA, Puig S, Castel T., Malvehy J., Puig S. Prognostic role tumours. Adams DJ. Genomic analysis and clinical of the histological subtype of melanoma on management of adolescent cutaneous the hands and feet in Caucasians. 5. Scintigraphic detection of the sentinel melanoma. PIGMENT CELL AND MELANOMA RESEARCH. 27(4):315-320. node and hybrid tracers in radioguided MELANOMA RESEARCH. 30(3):307-316. I.F.: 2.615 surgery, applied in different tumours to I.F.: 5.170 avoid unnecessary lymphadenectomies. 12. Garcia, Sergio; Rincon-Torroella, Jordina; Radioguided surgery approaches with new 6. Monzo M, Santasusagna S, Moreno I, Benet, Arnau; Oleaga, Laura; Gonzalez tracers and methodologies. Martinez F, Hernández R, Muñoz C, Castellano Sanchez, Jose Juan. Assessment of White JJ, Moreno J, Navarro A. Exosomal Matter Transgression During 6. Positron Emission Tomography microRNAs isolated from plasma of Neuroendoscopic Procedures Using (PET/CT) for the staging and control of mesenteric veins linked to liver Diffusion Tensor Image Fiber Tracking. treatment response in different types of metastases in resected patients with colon WORLD NEUROSURGERY. 99:232-240. tumors. cancer. ONCOTARGET. 8(19):30859-30869. I.F.: 2.592 I.F.: 5.168 7. Study of bacterial radiosensitivity in E. 13. Moisés J, Navarro A, Santasusagna S, coli, S. epidermidis and S. aureus. 7. Renu, Arturo; Laredo, Carlos; Tudela, Raul; Viñolas N, Molins L, Ramirez J, Osorio J, Saco Urra, Xabier; Lopez-Rueda, Antonio; Llull, A, Castellano JJ, Muñoz C, Morales S, Monzó Laura; Oleaga, Laura; Amaro, Sergio; M, Marrades RM. NKX2-1 expression as a Chamorro, Angel. Brain hemorrhage after prognostic marker in early-stage PUBLICATIONS endovascular reperfusion therapy of non-small-cell lung cancer. BMC ischemic stroke: a threshold-ﬁnding PULMONARY MEDICINE. 17(1):197. I.F.: 2.435 Originals / I.F.: 133.534 whole-brain perfusion CT study. JOURNAL OF CEREBRAL BLOOD FLOW AND 14. Carreño M., Bien C., Asadi-Pooya A., 1. Faries, M. B.; Thompson, J. F.; Cochran, A. J.; METABOLISM. 37(1):153-165. I.F.: 5.081 Marusic P., Pimentel J., Wehner T., Mohanraj Andtbacka, R. H.; Mozzillo, N.; Zager, J. S.; R., Uranga J., Gómez-Ibáñez A., Bargalló N., Jahkola, T.; Bowles, T. L.; Testori, A.; Beitsch, P. 8. Pericàs JM, García-de-la-Mària C, Brunet Rumià J., Setoain X., Pintor L., Bailles E., Falip D.; … …; Elashoff, R. M.Completion Dissection M, Armero Y, García-González J, Casals G, M., Dalmau J., Gil F., Sperling M., Elisak M., or Observation for Sentinel-Node Almela M, Quintana E, Falces C, Ninot S, Villanueva V., Roldán P., Boget T., Donaire A., Metastasis in Melanoma. NEW ENGLAND Fuster D, Llopis J, Marco F, Moreno A, Miró Aparicio J., Graus F. Epilepsy surgery in JOURNAL OF MEDICINE. 376(23):2211-2222. JM, Hospital Clinic Endocarditis Study Group. drug resistant temporal lobe epilepsy I.F.: 72.406 Early in vitro development of daptomycin associated with neuronal antibodies. non-susceptibility in high-level EPILEPSY RESEARCH. 129:101-105. I.F.: 2.367 2. Paredes P, Vidal-Sicart S, Campos F, aminoglycoside-resistant Enterococcus Tapias A, Sánchez N, Martínez S, Carballo L, faecalis predicts the efficacy of the 15. Biete A, Holub K. Haemoglobin Pahisa J, Torné A, Ordi J, Carmona F, Lomeña combination of high-dose daptomycin plus monitoring in endometrial cancer patients F. Role of ICG-(99m)Tc-nanocolloid for ampicillin in an in vivo model of undergoing radiotherapy. CLINICAL AND sentinel lymph node detection in cervical experimental endocarditis. J ANTIMICROB TRANSLATIONAL ONCOLOGY. cancer: a pilot study. EUROPEAN JOURNAL CHEMOTHER. 72(6):1714-1722. I.F.: 5.071 19(12):1518-1523. I.F.: 2.353 OF NUCLEAR MEDICINE AND MOLECULAR IMAGING. 44(11):1853-1861. I.F.: 7.277 9. Gifre, L.; Ruiz-Gaspa, S.; Carrasco, J. L.; 16. Valduvieco I, Biete A, Moreno LA, Gallart X, Portell, E.; Vidal, J.; Muxi, A.; Monegal, A.; Rovirosa A, Saez J, Plana C, Peris P. 3. Renú A, Laredo C, Lopez-Rueda A, Llull L, Guanabens, N.; Peris, P. Effect of recent Is anti-inﬂammatory radiotherapy an Tudela R, San-Roman L, Urra X, Blasco J, spinal cord injury on the OPG/RANKL effective treatment in trochanteritis? Macho J, Oleaga L, Chamorro A, Amaro S. system and its relationship with bone loss BR J RADIOL. 90(1069):20160520. I.F.: 2.050 Vessel Wall Enhancement and and the response to denosumab therapy. Blood-Cerebrospinal Fluid Barrier OSTEOPOROSIS INTERNATIONAL. Disruption After Mechanical 28(9):2707-2715. I.F.: 3.591 Review / I.F.: 21.972 Thrombectomy in Acute Ischemic Stroke. STROKE. 48(3):651-657. I.F.: 6.032 10. Balaña C, Capellades J, Pineda E, Estival A, 1. Wit, Esther M. K.; Acar, Cenk; Grivas, Puig J, Domenech S, Verger E, Pujol T, Nikolaos; Yuan, Cathy; Horenblas, Simon; 4. Urra X., Laredo C., Zhao Y., Amaro S., Martinez-García M, Oleaga L, Velarde J, Mesia Liedberg, Fredrik; Olmos, Renato A. Valdes; Rudilosso S., Renú A., Prats-Galino A., Planas C, Fuentes R, Marruecos J, Del Barco S, Villà S, van Leeuwen, Fijs W. B.; van den Berg, Nynke A., Oleaga L., Chamorro Á. Neuroanatomical Carrato C, Gallego O, Gil-Gil M, Craven-Bartle S.; Winter, Alexander; Wawroschek, correlates of stroke-associated infection J, Alameda F, GLIOCAT Group. Friedhelm; Hruby, Stephan; Janetschek, and stroke-induced immunodepression. Pseudoprogression as an adverse event of Guenter; Vidal-Sicart, Sergi; MacLennan, BRAIN, BEHAVIOR, AND IMMUNITY. glioblastoma therapy. CANCER MEDICINE. Steven; Lam, Thomas B.; van der Poel, Henk G. 60:142-150. I.F.: 5.964 6(12):2858-2866. I.F.: 3.362 Sentinel Node Procedure in Prostate

270 DIAGNOSIS AND THERAPY IN ONCOLOGY 5.2

Cancer: A Systematic Review to Assess Diagnostic Accuracy. EUROPEAN UROLOGY. 71(4):596-605. I.F.: 16.265

2. Cordeiro, Anna; Monzo, Mariano; Navarro, Alfons. Non-Coding RNAs in Hodgkin Lymphoma. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. 18(6):1154. I.F.: 3.226

3. Valdes Olmos, Renato A.; Vidal-Sicart, Sergi; Manca, Gianpiero; Mariani, Giuliano; Leon-Ramirez, Luisa F.; Rubelo, Domenico; Giammarile, Francesco. Advances in radioguided surgery in oncology. THE QUARTERLY JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING. 61(3):247-270. I.F.: 2.481

Editorial / I.F.: 1.125

1. Valdes Olmos, Renato A.; Vidal-Sicart, Sergi. Sentinel node in lung cancer. MEDICINA CLINICA. 148(6):260-261. I.F.: 1.125

GRANTS FOR RESEARCH IN PROGRESS

Fuster D. Evaluación de la PET/TC integrada con TC colonografía en el cáncer colorrectal obstructivo preoperatorio diagnosticado mediante colonoscopia óptica. Sponsored by: Instituto de Salud Carlos III (ISCIII). PI14/00555. Duration: 01/01/2015-31/12/2017

Oleaga L. Predictive geometrical model for personalized ﬂow diverter sizing and interventional planning (PoroVIEW). Sponsored by: Ministerio de Economía y Competitividad (MINECO). RTC-2016-5073-1. Duration: 01/11/2016-31/12/2018

DOCTORAL THESES

Bargalló N, Oleaga L. Resonancia Magnética Funcional aplicada al manejo de tumores cerebrales en el entorno clínico. Phd Student: Sofía González Ortiz

Fuster D, Pons F. Utilidad de PET/TC con 18F-ﬂuorodesoxiglucosa en la detección de infecciones cardiovasculares y embolias sépticas hematógenas. Phd student: Ulises Granados Oliveros

271 AREA 5 ONCOLOGY AND HAEMATOLOGY

Molecular biology of 5.3 reproduction and development

COLLABORATORS Josep Lluís Ballescà (HCB) LOCATION Salvadora Cívico (HCB) UB School of Medicine Marta Guimerà (HCB)

STRATEGIC OBJECTIVES

The mechanisms involved in cell differentiation

KEYWORDS during reproduction and development, with a

1. Germinal cell line TEAM LEADER particular focus on the germinal cell line and 2. Male infertility Rafael Oliva (HCB-UB) the paternal contribution to the embryo, and 3. Proteomics T. 93 402 18 77 / 93 227 55 10 the study of the endocrine disorders and 4. Epigenetics [email protected] / [email protected] cancer cell progression and regression are the main objectives of our research group. 5. Cancer 6. Endocrine system 7. iPSC RESEARCHERS Cristóbal Mezquita (UB) MAIN LINES OF RESEARCH Jovita Mezquita (UB) Josep Oriola (HCB-UB) 1. Genomics, proteomics and epigenetics of the germinal cell line.

POST-DOCTORAL RESEARCHERS Our interests include the study of the Judit Castillo (FCRB) human sperm and seminal plasma Original publications Montserrat Codina (IDIBAPS) proteomes,small RNA content, and the from 2015 to 2017 Michael Edel (UB) sperm cell epigenome to further understand the function and mechanisms YEAR I.F. TOTAL Q1 Q2 Meritxell Jodar (IDIBAPS) Betlem Mezquita (UB) operating in the sperm cell, fertilization and 2015 11.33 4 2- early embryo development, and to enable

2016 10.95 3 2 1 PRE-DOCTORAL RESEARCHERS translational research in male infertility.

2017 11.86 3 2 1 Ferran Barrachina (IDIBAPS) Alberto de la Iglesia (IDIBAPS) 2. Genetics of endocrine disorders. Montserrat Pau (UB) We are studying the genetic aspects of Ada Soler (UB) hereditary endocrine disorders (multiple endocrine neoplasia, congenital adrenal hyperplasia and monogenic diabetes) for TEAM INVOLVED IN ADMINISTRATIVE STAFF which we are a reference centre. Our AGAUR_SGR14 Nuria Roman (UB) interest also contribute to a better understanding of the genotype-phenotype correlations in these syndromes. Rafael Oliva

TEAM

272 MOLECULAR BIOLOGY OF REPRODUCTION AND DEVELOPMENT 5.3

3. Mechanisms involved in Oliva R. Proteómica diferencial de redifferentiation of cancer cells. espermatozoides e identiﬁcación de Oncogenesis is essentially a cell biomarcadores diagnósticos y dedifferentiation process. Molecules that pronósticos en reproducción asistida. induce cell differentiation, such as retinoic Sponsoredby: Instituto de Salud Carlos III acid, have been used for cancer therapy. (ISCIII). PI13/00699. However, we have shown that retinoic acid Duration: 01/01/2014-30/06/2018 activates the pro-invasive pathway Src-Yap-Il6 in MDA-MB-231 triple negative Oliva R. Análisis proteómico y breast cancer cells. At present we study the transcriptómico del semen e identiﬁcación mechanisms used by statins to block the de biomarcadores capaces de evaluar la pro-invasive action of retinoic acid. contribución paterna a la fertilización y la embriogénesis. Sponsored by: Instituto de Salud Carlos III PUBLICATIONS (ISCIII). PI16/00346. Duration: 01/01/2017-31/12/2019 Originals / I.F.: 11.855 Jovita A. Mezquita C. Edel MJ. Mejora de la 1. Martín-Ibáñez R., Pardo M., Giralt A., Miguez calidad y la caracterización de la A., Guardia I., Marion-Poll L., Herranz C., producción de células IPS por substitución Esgleas M., Barriga G., Edel M., Vicario-Abejón de oncogenes por genes del ciclo celular y C., Alberch J., Girault J., Chan S., Kastner P., el análisis de la estabilitad genómica. Canals J. Helios expression coordinates Sponsored b: Ministerio de Economía y the development of a subset of Competitividad (MINECO): striatopallidal medium spiny neurons. BFU2014-54467-P. DEVELOPMENT. 144(8):1566-1577. I.F.: 5.843 Duration: 01/01/2015-31/12/2017

2. Torabi F, Bogle OA, Estanyol JM, Oliva R, Miller D. Zona pellucida-binding protein 2 DOCTORAL THESES (ZPBP2) and several proteins containing BX7B motifs in human sperm may have Bassas L, Oliva R. Caracterización biológica hyaluronic acid binding or recognition y molecular de síndromes properties. MOLECULAR HUMAN teratozoospérmicos causantes REPRODUCTION. 23(12):803-816. I.F.: 3.585 de la infertilidad masculina. PhD student: Olga López Rodrigo 3. Bogle OA, Kumar K, Attardo-Parrinello C, Lewis SE, Estanyol JM, Ballescà JL, Oliva R. Identiﬁcation of protein changes in human spermatozoa throughout the cryopreservation process. ANDROLOGY. 5(1):10-22. I.F.: 2.427

Review / I.F.: 3.914

1. Jodar M, Soler-Ventura A, Oliva R, Molecular Biology of Reproduction and Development Research Group. Semen proteomics and male infertility. JOURNAL OF PROTEOMICS. 162(2017):125-134. I.F.: 3.914

GRANTS FOR RESEARCHIN PROGRESS

Oliva R. Identiﬁcación proteómica de biomarcadores en espermatozoides de pacientes infértiles predictores de los resultados de reproducción asistida. Sponsored by: FUNDACIÓ SALUD 2000. SERONO13_015. Duration: 01/06/2013-01/06/2017

273 AREA 5 ONCOLOGY AND HAEMATOLOGY 5.4 Genetics

STRATEGIC OBJECTIVES

LOCATION To clinically, cytogenetic and molecular HCB building characterize rare genetic diseases. The main research lines are: i) study of molecular basis of intellectual disability using high throughput technologies; ii) identiﬁcation of a biological marker for FXTAS; iii) genotype–phenotype correlation of porphyrias; and iv) discovery of KEYWORDS new biomarkers that might help the diagnosis 1. Intellectual disability TEAM LEADER and prognosis of prostate cancer. 2. Next generation sequencing Montserrat Milà (HCB-UB) 3. Cryptic chromosomal imbalances T. 93 227 54 00 (Ext.: 2784) 4. FMR1 premutation associated [email protected] MAIN LINES OF RESEARCH

pathologies 5. Porphyria 1. Identification of genetic bases of ID. The 6. Prostate cancer RESEARCHERS application of high throughput sequencing Anna Carrió (HCB) to different groups of clinically well Xavier Filella (HCB) characterized ID patients will allow us to Irene Madrigal (HCB) identify new genes and to establish new Laia Rodríguez (HCB) molecular causes of ID. Jordi To (HCB) 2. Fragile X syndrome: Study and better Original publications POST-DOCTORAL RESEARCHERS characterization of FMR1 premutation from 2015 to 2017 Maria Isabel Álvarez (CIBER) associated pathologies. Identification of a YEAR I.F. TOTAL Q1 Q2 susceptibility risk factor for FXTAS. COLLABORATORS 2015 91.44 13 7 3 Laura Foj (HCB) 3. Detection of cryptic chromosomal 2016 78.25 21 10 3 Ester Margarit (HCB) imbalances and identification of new 2017 53.59 14 6 7 Aurora Sanchez (HCB) phenotypes based on cytogenetic – Anna M Soler (HCB) molecular techniques in a prenatal and postnatal diagnostic setting.

4. Study of the genotype-phenotype TEAM INVOLVED IN correlation and expression mechanisms CIBERER of porphyria. AGAUR_SGR14 - Advance in the study of the alterations in iron regulation and metabolism in skin and erythropoietic porphyria. Montserrat Milà

TEAM

274 GENETICS 5.4

- Investigate the role of modifier genes that 5. Lucena C., Rovira M., Gabarrús A., Filella X., Comprehensive analysis of the tryptophan modulate the clinical expression of Martínez C., Domingo R., Torres A., Agustí C. metabolome in urine of patients with acute erythropoietic porphyria. The clinical value of biomarkers in intermittent porphyria. JOURNAL OF - Study of new serum and urine biomarkers respiratory complications in CHROMATOGRAPHY B: ANALYTICAL of acute porphyria severity of use in clinical hematopoietic SCT. BONE MARROW TECHNOLOGIES IN THE BIOMEDICAL AND practice. TRANSPLANTATION. 52(3):415-422. LIFE SCIENCES. 1060:347-354. I.F.: 2.603 I.F.: 3.874 5. Prostate cancer: 13. Dlouhy I, Filella X, Rovira J, Magnano L, - To study the value of miRNAs in urine for 6. Foj L., Ferrer F., Serra M., Arévalo A., Rivas-Delgado A, Baumann T, Martínez-Trillos the detection and prognosis of prostate Gavagnach M., Giménez N., Filella X. A, Balagué O, Martínez A, González-Farre B, cancer. Exosomal and Non-Exosomal Urinary Karube K, Gine E, Delgado J, Campo E, - To isolate exosomes as a source of new miRNAs in Prostate Cancer Detection and López-Guillermo A. High serum levels of biomarkers of prostate cancer. Prognosis. PROSTATE. 77(6):573-583. soluble interleukin-2 receptor (sIL2-R), I.F.: 3.820 interleukin-6 (IL-6) and tumor necrosis factor alpha (TNF) are associated with 7. Peris P, Filella X, Monegal A, Guañabens N, adverse clinical features and predict poor PUBLICATIONS Foj L, Bonet M, Boquet D, Casado E, Cerdá D, outcome in diffuse large B-cell lymphoma. Erra A, Gómez-Vaquero C, Martínez S, LEUKEMIA RESEARCH. 59:20-25. I.F.: 2.501 Originals / I.F.: 53.587 Montalá N, Pittarch C, Kanterewicz E, Sala M, Suris X, Carrasco JL, LabOscat Study Group. 14. Fernandez-Galan, Esther; Lluis Bedini, 1. Tell-Marti G., Puig-Butille J., Gimenez-Xavier Comparison of total, free and bioavailable Josep; Filella, Xavier. Analytical verification P., Segu-Roig A., Potrony M., Badenas C., 25-OH vitamin D determinations to and method comparison of the ADVIA Alvarez V., Millán J., Trujillo-Tiebas M., evaluate its biological activity in healthy Centaur (R) Intact Parathyroid Hormone Ramos-Arroyo M., Milà M., Puig S. The p. adults: the LabOscat study. assay. CLINICAL BIOCHEMISTRY. R151C Polymorphism in MC1R Gene OSTEOPOROSIS INTERNATIONAL. 50(18):1222-1227. I.F.: 2.434 Modifies the Age of Onset in Spanish 28(8):2457-2464. I.F.: 3.591 Huntington’s Disease Patients. MOLECULAR NEUROBIOLOGY. 8. Parra-Robert, Marina; Orois, Aida; Maria Review / I.F.: 3.432 54(5):3906-3910. I.F.: 6.190 Auge, Josep; Halperin, Irene; Filella, Xavier; Molina, Rafael. Utility of proGRP as a tumor 1. Filella X, Foj L. miRNAs as novel 2. Alvarez-Mora MI; Rodriguez-Revenga L; marker in the medullary thyroid biomarkers in the management of prostate Madrigal I; Guitart-Mampel M; Garrabou G; carcinoma. CLINICAL CHEMISTRY AND cancer. CLINICAL CHEMISTRY AND Mila M. Impaired Mitochondrial Function LABORATORY MEDICINE. 55(3):441-446. LABORATORY MEDICINE. 55(5):715-736. and Dynamics in the Pathogenesis of I.F.: 3.432 I.F.: 3.432 FXTAS. MOLECULAR NEUROBIOLOGY. 54(9):6896-6902. I.F.: 6.190 9. López-Mourelo O, Mur E, Madrigal I, Alvarez-Mora MI, Gómez-Ansón B, Letters / I.F.: 14.998 3. Colomo L, Vazquez I, Papaleo N, Espinet B, Pagonabarraga J, Rodriguez-Revenga L, Milà Ferrer A, Franco C, Comerma L, Hernandez S, M. Social anxiety and autism spectrum 1. Gelpi, Ellen; Botta-Orfila, Teresa; Bodi, Laia; Calvo X, Salar A, Climent F, Mate JL, Forcada traits among adult FMR1 premutation Marti, Stefanie; Kovacs, Gabor; Grau-Rivera, P, Mozos A, Nonell L, Martinez A, Carrio A, carriers. CLINICAL GENETICS. 91(1):111-114. Oriol; Lozano, Manuel; Sanchez-Valle, Raquel; Costa D, Dlouhy I, Salaverria I, Martin-Subero I.F.: 3.326 Munoz, Esteban; Valldeoriola, Francesc; JI, Lopez-Guillermo A, Valera A, Campo E, Grup Pagonabarraga, Javier; Tartaglia, per l’Estudi dels Limfomes de Catalunya i 10. Peris P., Filella X., Monegal A., Guañabens Gian-Gaetano; Mila, Montserrat. Neuronal Balears (GELCAB). LMO2-negative N., Foj L., Bonet M., Boquet D., Casado E., intranuclear (hyaline) inclusion disease Expression Predicts the Presence of MYC Cerdá D., Erra A., Gómez-Vaquero C., and fragile X-associated tremor/ataxia Translocations in Aggressive B-Cell Martínez S., Montalá N., Pittarch C., syndrome: a morphological and molecular Lymphomas. AMERICAN JOURNAL OF Kanterewicz E., Sala M., Suris X., Carrasco J. dilemma. BRAIN; A JOURNAL OF SURGICAL PATHOLOGY. 41(7):877-886.I.F.: 5.363 Concordance between direct and indirect NEUROLOGY. 140(8):e51. I.F.: 10.292 measurements of free 25-OH vitamin D. 4. Abekhoukh S, Sahin HB, Grossi M, Zongaro CLINICA CHIMICA ACTA. 475:169-171. I.F.: 2.873 2. Combalia A., To-Figueras J., Laguno M., S, Maurin T, Madrigal I, Kazue-Sugioka D, Martínez-Rebollar M., Aguilera P. Raas-Rothschild A, Doulazmi M, Carrera P, 11. Borrell A; Grande M; Meler E; Sabria J; Direct-acting antivirals for hepatitis C virus Stachon A, Scherer S, Drula Do Nascimento Mazarico E; Munoz A; Rodriguez-Revenga L; induce a rapid clinical and biochemical MR, Trembleau A, Arroyo I, Szatmari P, Smith Badenas C; Figueras F. Genomic Microarray remission of porphyria cutanea tarda. IM, Milà M, Smith AC, Giangrande A, Caillé I, in Fetuses with Early Growth Restriction: A BRITISH JOURNAL OF DERMATOLOGY. Bardoni B. New insights into the regulatory Multicenter Study. FETAL DIAGNOSIS AND 177(5):e183-e184. I.F.: 4.706 function of CYFIP1 in the context of WAVE- THERAPY. 42(3):174-180. I.F.: 2.699 and FMRP-containing complexes. DMM DISEASE MODELS AND MECHANISMS. 12. Gomez-Gomez A., Marcos J., Aguilera P., 10(4):463-474. I.F.: 4.691 To-Figueras J., Pozo O.

275 AREA 5 ONCOLOGY AND HAEMATOLOGY

Case Reports / I.F.: 2.259

1. Alvarez-Mora MI, Guitart M, Rodriguez-Revenga L, Madrigal I, Gabau E, Milà M. Paternal transmission of a FMR1 full mutation allele. AMERICAN JOURNAL OF MEDICAL GENETICS, PART A. 173(10):2795-2797. I.F.: 2.259

Consortium Publications / I.F.: 12.124

1. Fang J, Jia J, Makowski M, Xu M, Wang Z, Zhang T, Hoskins JW, Choi J, Han Y, Zhang M, Thomas J, Kovacs M, Collins I, Dzyadyk M, Thompson A, O'Neill M, Das S, Lan Q, Koster R, , Stolzenberg-Solomon RS, Kraft P, Wolpin BM, Jansen PWTC, Olson S, McGlynn KA, Kanetsky PA, Chatterjee N, Barrett JH, Dunning AM, Taylor JC, Newton-Bishop JA, Bishop DT, Andresson T, Petersen GM, Amos CI, Iles MM, Nathanson KL, Landi MT, Vermeulen M, Brown KM, Amundadottir LT PanScan Consortium, TRICL Consortium, GenoMEL Consortium. Functional characterization of a multi-cancer risk locus on chr5p15.33 reveals regulation of TERT by ZNF148. NATURE COMMUNICATIONS. 8:15034. I.F.: 12.124

GRANTS FOR RESEARCH IN PROGRESS

Madrigal I. Identiﬁcación de genes modiﬁcadores de penetrancia en enfermedades raras hereditatias mediante secuenciación masiva. Sponsored by: Instituto de Salud Carlos III (ISCIII). PI15/00483 Duration: 01/01/2016-31/12/2018

Ribes A. Implementació de la medicina personalitzada basada en la Genòmica en Malalties Minoritàries Neurológiques no Diagnosticades. URDCat (Undiagnosed Rare Diseases Program of Catalonia). Sponsored by: Generalitat de Catalunya (PERIS). SLT002/16/00174 Duration: 27/03/2017-31/12/2019

DOCTORAL THESES

Filella X. Nous biomarcadors per la detecció i pronòstic del càncer de pròstata. PhD student: Laura Foj Capell

276 MELANOMA: IMAGING, GENETICS AND IMMUNOLOGY 5.5

Melanoma: imaging, genetics 5.5 and immunology

TECHNICIANS Beatriz Alejo (FCRB) LOCATION Abel Caño (FCRB) CEK building ﬂoor 2 Mireia Dominguez (FCRB) Daniel Gabriel (FCRB) Pablo Iglesias (FCRB) Judit Mateu (FCRB)

ADMINISTRATIVE STAFF KEYWORDS Lilian Roca (FCRB)

1. Melanoma TEAM LEADER 2. Genetics Susana Puig (HCB) COLLABORATORS 3. Dermoscopy T. 93 227 54 00 (Ext.: 5692) Paula Aguilera (HCB) 4. Confocal microscopy [email protected] Melinda González (FCRB) 5. Susceptibility

RESEARCHERS STRATEGIC OBJECTIVES Celia Badenas (HCB) Cristina Carrera (HCB) 1. Development of non-invasive imaging, Josep Malvehy (HCB) biophotonics and physic techniques for the Joan Anton Puig (HCB) diagnosis of melanoma and Original publications non-melanoma skin cancer. from 2015 to 2017 POST-DOCTORAL RESEARCHERS 2. Study of the genetic bases implicated in YEAR I.F. TOTAL Q1 Q2 Pol Giménez (CIBER) susceptibility to melanoma, photocarcinogenesis and melanoma 2015 117.27 22 21 1 PRE-DOCTORAL RESEARCHERS prognosis. 2016 60.68 14 11 1 Alicia Ines Barreiro (IDIBAPS) 3. Development of treatment strategies in 2017 264.52 37 27 7 Neus Calbet (FCRB) melanoma and skin cancer: speciﬁc Natalia Espinosa (FCRB) molecular target / immunological therapies Priscila Giavedoni (HCB) and photo-protection. Javiera Perez (FCRB) Ramon Pigem (IDIBAPS) Sebastian Podlipnik (UB) MAIN LINES OF RESEARCH Miriam Potrony (IDIBAPS) Gemma Tell (CIBER) 1. Dermoscopy, digital dermoscopy, Oriol Yélamos (FCRB) Confocal microscopy & new photonic and physic technologies. Description of new algorithms, study of the evolution of lesions, Susana Puig

TEAM

277 AREA 5 ONCOLOGY AND HAEMATOLOGY

new classifications and the use of 3. Dreno, Brigitte; Kunstfeld, Rainer; Hauschild, Puig S, van der Stoep N, Wadt KAW, Whitaker telemedicine. Axel; Fosko, Scott; Zloty, David; Labeille, L, Yang XR, Newton Bishop JA, Gruis NA, 2. Giant congenital nevi, global research Bruno; Grob, Jean-Jacques; Puig, Susana; Kanetsky PA, GenoMEL Study Group. approach including clinical, genetics and Gilberg, Frank; Bergstrom, Daniel; Page, Germline variation at CDKN2A and psychological aspects. Damian R.; Rogers, Gary; Schadendorf, Dirk. associations with nevus phenotypes 3. Genetic epidemiology in melanoma and Two intermittent vismodegib dosing among members of melanoma families. non melanoma skin cancer. regimens in patients with multiple JOURNAL OF INVESTIGATIVE 4. Study of the mechanisms involved in basal-cell carcinomas (MIKIE): a DERMATOLOGY. 137(12):2606-2612. carcinogenesis and photocarcinogenesis randomised, regimen-controlled, I.F.: 6.287 in melanoma and non melanoma skin double-blind, phase 2 trial. LANCET cancer. ONCOLOGY. 18(3):404-412. I.F.: 33.900 9. Tell-Marti G., Puig-Butille J., Gimenez-Xavier 5. Development of new treatment strategies P., Segu-Roig A., Potrony M., Badenas C., for melanoma and other skin tumours. 4. Ribas A, Dummer R, Puzanov I, Alvarez V., Millán J., Trujillo-Tiebas M., 6. Evaluation of immune response in VanderWalde A, Andtbacka RHI, Michielin O, Ramos-Arroyo M., Milà M., Puig S. The p. melanoma. Olszanski AJ, Malvehy J, Cebon J, Fernandez R151C Polymorphism in MC1R Gene 7. Identification of genetic prognostic profiles E, Kirkwood JM, Gajewski TF, Chen L, Gorski Modifies the Age of Onset in Spanish in melanoma . KS, Anderson AA, Diede SJ, Lassman ME, Huntington’s Disease Patients. 8. Analysis of the influence of the microbiota in Gansert J, Hodi FS, Long GV. Oncolytic MOLECULAR NEUROBIOLOGY. skin cancer. Virotherapy Promotes Intratumoral T Cell 54(5):3906-3910. I.F.: 6.190 9. Identification of biomarkers for melanoma : Infiltration and Improves Anti-PD-1 study of circulating free DNA (cfDNA) or Immunotherapy. CELL. 170(6):1109-1119. 10. Ribero S, Podlipnik S, Osella-Abate S, isolation of circulating melanoma cells I.F.: 30.410 Sportoletti-Baduel E, Manubens E, Barreiro A, (CMC) and single cell sequencing. Caliendo V, Chavez-Bourgeois M, Carrera C, 5. Martins da Silva VP, Marghoob A, Pigem R, Cassoni P, Malvehy J, Fierro MT, Puig S. Carrera C, Aguilera P, Puig-Butillé JA, Puig S, Ultrasound-based follow-up does not Malvehy J. Patterns of distribution of giant increase survival in early-stage melanoma PUBLICATIONS congenital melanocytic nevi (GCMN): The patients: A comparative cohort study. 6B rule. JOURNAL OF THE AMERICAN EUROPEAN JOURNAL OF CANCER. Originals / I.F.: 264.524 ACADEMY OF DERMATOLOGY. 85:59-66. I.F.: 6.029 76(4):689-694. I.F.: 7.002 1. Huang AC, Postow MA, Orlowski RJ, Mick R, 11. Carrera C, Segura S, Aguilera P, Scalvenzi Bengsch B, Manne S, Xu W, Harmon S, Giles 6. Potrony M, Rebollo-Morell A, M, Longo C, Barreiro A, Broganelli P, JR, Wenz B, Adamow M, Kuk D, Panageas KS, Giménez-Xavier P, Zimmer L, Puig-Butille JA, Cavicchini S, Llambrich A, Zaballos P, Thomas Carrera C, Wong P, Quagliarello F, Tell-Marti G, Sucker A, Badenas C, Carrera C, L, Malvehy J, Puig S, Zalaudek I. Wubbenhorst B, D'Andrea K, Pauken KE, Malvehy J, Schadendorf D, Puig S. IRF4 Dermoscopic Clues for Diagnosing Herati RS, Staupe RP, Schenkel JM, rs12203592 functional variant and Melanomas That Resemble Seborrheic McGettigan S, Kothari S, George SM, melanoma survival. INTERNATIONAL Keratosis. JAMA DERMATOLOGY. Vonderheide RH, Amaravadi RK, Karakousis JOURNAL OF CANCER. 140(8):1845-1849. 153(6):544-551. I.F.: 5.817 GC, Schuchter LM, Xu X, Nathanson KL, I.F.: 6.513 Wolchok JD, Gangadhar TC, Wherry EJ. 12. Gaudy-Marqueste C, Wazaefi Y, Bruneu Y, T-cell invigoration to tumour burden ratio 7. Puig-Butille JA, Vinyals A, Ferreres JR, Triller R, Thomas L, Pellacani G, Malvehy J, associated with anti-PD-1 response. Aguilera P, Cabré E, Tell-Martí G, Marcoval J, Avril MF, Monestier S, Richard MA, Fertil B, NATURE. 545(7652):60-65. I.F.: 40.137 Mateo F, Palomero L, Badenas C, Piulats JM, Grob JJ. Ugly Duckling Sign as a Major Malvehy J, Pujana MA, Puig S, Fabra À. Factor of Efficiency in Melanoma 2. Olmeda, David; Cerezo-Wallis, Daniela; AURKA Overexpression Is Driven by Detection. JAMA DERMATOLOGY. Riveiro-Falkenbach, Erica; Pennacchi, Paula FOXM1 and MAPK/ERK Activation in 153(4):279-284. I.F.: 5.817 C.; Contreras-Alcalde, Marta; Ibarz, Nuria; Melanoma Cells Harboring BRAF or NRAS Cifdaloz, Metehan; Catena, Xavier; Calvo, Mutations: Impact on Melanoma Prognosis 13. O Yélamos, B Hibler, M Cordova, TJ Tonantzin G.; Canon, Estela; Alonso-Curbelo, and Therapy. JOURNAL OF INVESTIGATIVE Hollmann, K Kose, MA Marchetti, PL Direna; Suarez, Javier; Osterloh, Lisa; Grana, DERMATOLOGY. 137(6):1297-1310. I.F.: 6.287 Myskowski, MP Pulitzer, M Rajadhyaksha, A Osvaldo; Mulero, Francisca; Megias, Diego; Rossi, M Jain. Handheld Reflectance Canamero, Marta; Martinez-Torrecuadrada, 8. Taylor NJ, Mitra N, Goldstein AM, Tucker Confocal Microscopy for the Detection of Jorge L.; Mondal, Chandrani; Di Martino, Julie; MA, Avril MF, Azizi E, Bergman W, Bishop DT, Recurrent Extramammary Paget Disease. Lora, David; Martinez-Corral, Ines; Bressac-de Paillerets B, Bruno W, Calista D, JAMA DERMATOL. 153(7):689-693. I.F.: 5.817 Bravo-Cordero, J. Javier; Munoz, Javier; Puig, Cannon-Albright LA, Cuellar F, Cust AE, Susana; Ortiz-Romero, Pablo; Demenais F, Elder DE, Gerdes AM, Ghiorzo P, 14. O Yélamos, M Cordova, N Blank, K Kose, Rodriguez-Peralto, Jose L.; Ortega, Sagrario; Grazziotin TC, Hansson J, Harland M, SW Dusza, E Lee, M Rajadhyaksha, KS Nehal, Soengas, Maria S. Whole-body imaging of Hayward NK, Hocevar M, Höiom V, Ingvar C, AM Rossi. Correlation of Handheld lymphovascular niches identifies Landi MT, Landman G, Larre-Borges A, Reflectance Confocal Microscopy With pre-metastatic roles of midkine. NATURE. Leachman SA, Mann GJ, Nagore E, Olsson H, Radial Video Mosaicing for Margin 546(7660):676-680. I.F.: 40.137 Palmer JM, Peri? B, Pjanova D, Pritchard A, Mapping of Lentigo Maligna and Lentigo

278 MELANOMA: IMAGING, GENETICS AND IMMUNOLOGY 5.5

Maligna Melanoma. JAMA DERMATOL. 21. Erfan G, Puig S, Carrera C, Arance A, Gaba Moscarella E, Piraccini BM, Starace M, 153(12):1278-1284. I.F.: 5.817 L, Victoria I, Garcia-Herrera A, Alos L, Malvehy Argenziano G. Clinical and dermoscopic J. Development of Cutaneous Toxicities clues to differentiate pigmented nail 15. Rabbie R, Rashid M, Arance AM, Sánchez During Selective Anti-BRAF Therapies: bands: an International Dermoscopy M, Tell-Marti G, Potrony M, Conill C, van Doorn Preventive Role of Combination with MEK Society study. JOURNAL OF THE R, Dentro S, Gruis NA, Corrie P, Iyer V, Inhibitors. ACTA DERMATO- EUROPEAN ACADEMY OF DERMATOLOGY Robles-Espinoza CD, Puig-Butille JA, Puig S, VENEREOLOGICA. 97(2):258-260. I.F.: 3.653 AND VENEREOLOGY. 31(4):732-736. Adams DJ. Genomic analysis and clinical I.F.: 3.528 management of adolescent cutaneous 22. Maher NG, Solinas A, Scolyer RA, Puig S, melanoma. PIGMENT CELL AND Pellacani G, Guitera P. Detection of 28. Witkowski A, ?udzik J, Arginelli F, Bassoli MELANOMA RESEARCH. 30(3):307-316. desmoplastic melanoma with dermoscopy S, Benati E, Casari A, De Carvalho N, De Pace I.F.: 5.170 and reflectance confocal microscopy. B, Farnetani F, Losi A, Manfredini M, Reggiani JOURNAL OF THE EUROPEAN ACADEMY C, Malvehy J, Pellacani G. Improving 16. Puig-Butille JA, Gimenez-Xavier P, Visconti OF DERMATOLOGY AND VENEREOLOGY. diagnostic sensitivity of combined A, Nsengimana J, Garcia-García F, Tell-Marti 31(12):2016-2024. I.F.: 3.528 dermoscopy and reflectance confocal G, Escamez MJ, Newton-Bishop J, Bataille V, microscopy imaging through double Del Río M, Dopazo J, Falchi M, Puig S. 23. Bombonato C., Ribero S., Pozzobon F., reader concordance evaluation in Genomic expression differences between Puig-Butille J., Badenas C., Carrera C., telemedicine settings: A retrospective cutaneous cells from red hair color Malvehy J., Moscarella E., Lallas A., Piana S., study of 1000 equivocal cases. PLOS ONE. individuals and black hair color individuals Puig S., Argenziano G., Longo C. Association 12(11):e0187748. I.F.: 2.806 based on bioinformatic analysis. between dermoscopic and reflectance ONCOTARGET. 8(7):11589-11599. I.F.: 5.168 confocal microscopy features of 29. Borrell A; Grande M; Meler E; Sabria J; cutaneous melanoma with BRAF Mazarico E; Munoz A; Rodriguez-Revenga L; 17. Dias-Santagata D, Selim MA, Su Y, Peng Y, mutational status. JOURNAL OF THE Badenas C; Figueras F. Genomic Microarray Vollmer R, Ch?opik A, Tell-Marti G, Paral KM, EUROPEAN ACADEMY OF DERMATOLOGY in Fetuses with Early Growth Restriction: A Shalin SC, Shea CR, Puig S, Fernandez- AND VENEREOLOGY. 31(4):643-649. Multicenter Study. FETAL DIAGNOSIS AND Figueras MT, Biernat W, Ry; J, Marszalek A, I.F.: 3.528 THERAPY. 42(3):174-180. I.F.: 2.699 Hoang MP. KIT Mutations and CD117 Overexpression Are Markers of Better 24. Dirschka T, Pellacani G, Micali G, Malvehy 30. Grande M, Stergiotou I, Pauta M, Marquès Progression-Free Survival in Vulvar J, Stratigos AJ, Casari A, Schmitz L, Gupta G, B, Badenas C, Soler A, Yaron Y, Borrell A. Melanomas. BRITISH JOURNAL OF Athens AK Study Group. A proposed scoring Parental Origin of the Retained X DERMATOLOGY. 177(5):1376-1384. I.F.: 4.706 system for assessing the severity of actinic Chromosome in Monosomy X keratosis on the head: Actinic keratosis Miscarriages and Ongoing Pregnancies. 18. K Kose, M Gou, O Yélamos, M Cordova, A area and severity index. JOURNAL OF THE FETAL DIAGNOSIS AND THERAPY. I.F.: 2.699 Rossi, E Flores, K Nehal, O Camps, J Dy, D EUROPEAN ACADEMY OF DERMATOLOGY Brooks, M Rajadhyaksha. Automated AND VENEREOLOGY. 31(8):1295-1302. 31. Carrera C., Gual A., DIáz A., Puig-Butillé J., video-mosaicking approach for confocal I.F.: 3.528 Noguès S., Vilalta A., Conill C., Rull R., Vilana R., microscopic imaging in-vivo: an approach Arguis P., Vidal-Sicart S., Alós L., Palou J., to address challenges in imaging living 25. Alarcon I., Vinding G., Christensen K., Castel T., Malvehy J., Puig S. tissue and extend field-of-view. SCI REP. Esmann S., Malvehy J., Puig S., Jemec G. Prognostic role of the histological subtype 7(1):10759. I.F.: 4.259 Spanish version of the Actinic Keratosis of melanoma on the hands and feet in Quality of Life questionnaire. JOURNAL Caucasians. MELANOMA RESEARCH. 19. Tell-Marti G, Puig-Butille JA, Potrony M, OF THE EUROPEAN ACADEMY OF 27(4):315-320. I.F.: 2.615 Plana E, Badenas C, Antonell A, Sanchez-Valle DERMATOLOGY AND VENEREOLOGY. R, Molinuevo JL, Lleó A, Alcolea D, Fortea J, 31(6):986-991. I.F.: 3.528 32. Delpueyo X., Vilaseca M., Royo S., Ares M., Fernández-Santiago R, Clarimón J, Lladó A, Rey-Barroso L., Sanabria F., Puig S., Pellacani Puig S. A Common Variant in the MC1R 26. Ribero S, Longo C, Dika E, Fortes C, G., Noguero F., Solomita G., Bosch T. Gene (p.V92M) is associated with Pasquali S, Nagore E, Glass D, Robert C, Multispectral imaging system based on Alzheimer's Disease Risk. J ALZHEIMERS Eggermont AM, Testori A, Quaglino P, Nathan light-emitting diodes for the detection of DIS. 56(3):1065-1074. I.F.: 3.731 P, Argenziano G, Puig S, Bataille V, Members melanomas and basal cell carcinomas: A of the Melanoma Group of the EORTC. pilot study. JOURNAL OF BIOMEDICAL 20. Gomes-Neto A, Aguilera P, Prieto L, Seité Pregnancy and melanoma: a OPTICS. 22(6):079801. I.F.: 2.530 S, Moyal D, Carrera C, Malvehy J, Puig S. European-wide survey to assess current Efficacy of a Daily Protective Moisturizer management and a critical literature 33. N Iftimia, O Yélamos, CS J Chen, G with High UVB and UVA Photoprotection in overview. JOURNAL OF THE EUROPEAN Maguluri, M Cordova, A Sahu, J Park, W Fox, C Decreasing Ultraviolet Damage: ACADEMY OF DERMATOLOGY AND Alessi-Fox, M Rajadhyaksha. Handheld Optical Evaluation by Reflectance Confocal VENEREOLOGY. 31(1):65-69. I.F.: 3.528 Coherence Tomography-Reflectance Microscopy. ACTA DERMATO- Confocal Microscopy Probe for Detection of VENEREOLOGICA. 97(10):1196-1201. 27. Benati E, Ribero S, Longo C, Piana S, Puig Basal Cell Carcinoma and Delineation of I.F.: 3.653 S, Carrera C, Cicero F, Kittler H, Deinlein T, Margins. J BIOMED OPT. 22(7):76006. I.F.: 2.530 Zalaudek I, Stolz W, Scope A, Pellacani G,

279 AREA 5 ONCOLOGY AND HAEMATOLOGY

34. Sierra H, Yélamos O, Cordova M, Chen CJ, and Follow-up of High-risk Skin Cancer 3. B Hibler, O Yélamos, M Cordova, H Sierra, M Rajadhyaksha M. Reflectance confocal Patients. ACTA DERMATO - Rajadhyaksha, K Nehal, A Rossi. Handheld microscopy-guided laser ablation of basal VENEREOLOGICA. 97(218):14-21. I.F.: 3.653 Reflectance Confocal Microscopy to Aid in cell carcinomas: initial clinical experience. the Management of Complex Facial J BIOMED OPT. 22(8):1-13. I.F.: 2.530 4. Harrington K; Michielin O; Malvehy J; Lentigo Maligna. CUTIS. 99(5):346-352. Pezzani Grüter I; Grove L; Frauchiger A; I.F.: 1.173 35. Alarcon I., Pasquali P., Malvehy J., Puig S. Dummer R. A practical guide to the handling Tumor regrowth and development of and administration of talimogene keratinocytic neoplasms in patients under laherparepvec in Europe. ONCOTARGETS Consortium Publications / I.F.: 20.358 smoothened inhibition: In vivo assessment AND THERAPY. 10:3867-3880. I.F.: 2.612 with reflectance confocal microscopy. 1. Fang J, Jia J, Makowski M, Xu M, Wang Z, SKIN RESEARCH AND TECHNOLOGY. 5. Dirschka T., Gupta G., Micali G., Stockfleth Zhang T, Hoskins JW, Choi J, Han Y, Zhang M, 23(3):283-288. I.F.: 1.662 E., Basset-Séguin N., Del Marmol V., Dummer Thomas J, Kovacs M, Collins I, Dzyadyk M, R., Jemec G., Malvehy J., Peris K., Puig S., Thompson A, O'Neill M, Das S, Lan Q, Koster 36. Ribero, Simone; Pampena, Riccardo; Stratigos A., Zalaudek I., Pellacani G. R, , Stolzenberg-Solomon RS, Kraft P, Wolpin Bataille, Veronique; Moscarella, Elvira; Real-world approach to actinic keratosis BM, Jansen PWTC, Olson S, McGlynn KA, Thomas, Luc; Quaglino, Pietro; Potenza, management: practical treatment Kanetsky PA, Chatterjee N, Barrett JH, Concetta; Van Akkooi, Alexander C. J.; Testori, algorithm for office-based dermatology. Dunning AM, Taylor JC, Newton-Bishop JA, Alessandro; Nathan, Paul; Puig, Susana; JOURNAL OF DERMATOLOGICAL Bishop DT, Andresson T, Petersen GM, Amos Zalaudek, Iris; Argenziano, Giuseppe; Longo, TREATMENT. 28(5):431-442. I.F.: 1.890 CI, Iles MM, Nathanson KL, Landi MT, Caterina. Unknown Primary Melanoma: Vermeulen M, Brown KM, Amundadottir LT Worldwide Survey on Clinical PanScan Consortium, TRICL Consortium, Management. DERMATOLOGY. Letters / I.F.: 8.234 GenoMEL Consortium. Functional 232(6):704-707. I.F.: 1.598 characterization of a multi-cancer risk 1. Ribero S, Carrera C, Tell-Marti G, Pastorino locus on chr5p15.33 reveals regulation of 37. Carrera C, Segura S, Aguilera P, Takigami C, Badenas C, Garcia A, Malvehy J, Puig S. TERT by ZNF148. NATURE CM, Gomes A, Barreiro A, Scalvenzi M, Longo Amelanotic melanoma in oculocutaneous COMMUNICATIONS. 8:15034. I.F.: 12.124 C, Cavicchini S, Thomas L, Malvehy J, Puig S, albinism: a genetic, dermoscopic and Zalaudek I. Dermoscopy Improves the reflectance confocal microscopy study. 2. Lallas A., Apalla Z., Ioannides D., Lazaridou E., Diagnostic Accuracy of Melanomas BRITISH JOURNAL OF DERMATOLOGY. Kyrgidis A., Broganelli P., Alfano R., Zalaudek I., Clinically Resembling 177(6):e333-e335. I.F.: 4.706 Argenziano G., Bakos R., Blum A., Braun R., Cabo SeborrheicKeratosis: Cross-Sectional H., Halpern A., Hofmann-Wellenhof R., Kittler H., Study of the Ability to Detect Seborrheic 2. Manubens E., Barreiro A., Bennassar A., Malvehy J., Marghoob A., Menzies S., Moscarella Keratosis-Like Melanomasby a Group of Podlipnik S., Moreno N., Iglesias P., Malvehy J., E., Paoli J., Pellacani G., Puig S., Rabinovitz H., Dermatologists with Varying Degrees of Puig S. Fast evaluation and monitoring of Scope A., Soyer P., Stolz W., Tanaka M., Thomas Experience. DERMATOLOGY. I.F.: 1.598 ingenol mebutate treatment of multiple L., Tschandl P. Update on dermoscopy of basal cell carcinomas by in vivo hand-held Spitz/Reed naevi and management reflectance confocal microscopy. guidelines by the International Dermoscopy Review / I.F.: 17.625 JOURNAL OF THE EUROPEAN ACADEMY Society. BRITISH JOURNAL OF OF DERMATOLOGY AND VENEREOLOGY. DERMATOLOGY. 177(3):645-655. 1. Finnane A, Curiel-Lewandrowski C, 31(6):e284-e286. I.F.: 3.528 I.F.: 4.706 Wimberley G, Caffery L, Katragadda C, Halpern A, Marghoob AA, Malvehy J, Kittler H, 3. Forsea AM, Tschandl P, Zalaudek I, Del Hofmann-Wellenhof R, Abraham I, Soyer HP, Case Reports / I.F.: 8.479 Marmol V, Soyer HP, , Argenziano G, Geller AC International Society of Digital Imaging of the Eurodermoscopy Working Group. The impact Skin (ISDIS) for the International Skin Imaging 1. Giavedoni P., Ririe M., Carrera C., Puig S., of dermoscopy on melanoma detection in Collaboration (ISIC). Proposed Technical Malvehy J. Familial melanoma associated the practice of dermatologists in Europe: Guidelines for the Acquisition of Clinical with li-fraumeni syndrome and atypical results of a pan-European survey. JOURNAL Images of Skin-Related Conditions. JAMA mole syndrome: Total-body digital OF THE EUROPEAN ACADEMY OF DERMATOLOGY. 153(5):453-457. I.F.: 5.817 photography, dermoscopy and confocal DERMATOLOGY AND VENEREOLOGY. microscopy. ACTA DERMATO- 31(7):1148-1156. I.F.: 3.528 2. Malvehy, Josep; Pellacani, Giovanni. VENEREOLOGICA. 97(6):720-723. I.F.: 3.653 Dermoscopy, Confocal Microscopy and other Non-invasive Tools for the Diagnosis 2. Tschandl P, Gambardella A, Boespflug A, of Non-Melanoma Skin Cancers and Other Deinlein T, de Giorgi V, Kittler H, Lallas A, Skin Conditions. ACTA DERMATO- Malvehy J, Moscarella E, Puig S, Scalvenzi M, VENEREOLOGICA. 97(218):22-30. I.F.: 3.653 Thomas L, Zalaudek I, Alfano R, Argenziano G. Seven Non-melanoma Features of Facial 3. Thomas, Luc; Puig, Susana. Dermoscopy, Lesions: A Dermatoscopy Algorithm to Digital Dermoscopy and Other Diagnostic Rule Out Melanoma. ACTA DERMATO- Tools in the Early Detection of Melanoma VENEREOLOGICA. 97(10):1219-1224. I.F.: 3.653

280 MELANOMA: IMAGING, GENETICS AND IMMUNOLOGY 5.5

GRANTS FOR RESEARCH IN PROGRESS

Malvehy J. Identiﬁcación de factores genéticos en individuos con nevus melanocíticos y su inﬂuencia en la determinacón de la mutación BRAF (V600E) en plasma. Sponsored by: Instituto de Salud Carlos III (ISCIII). PI15/00956 Duration: 01/01/2016-31/12/2018.

Malvehy J. El metabolismo de los esﬁngolípidos como diana terapéutica para mejorar la inmunoterapia del melanoma. Sponsored by: Instituto de Salud Carlos III (ISCIII). AC16/00081 Duration: 01/01/2017-31/12/2019.

Puig S. Utilización de las regiones homozigotas del genoma para la identiﬁcación de genes pronósticos en melanoma y el desarrollo de un panel molecular de pronóstico. Sponsored by: Instituto de Salud Carlos III (ISCIII). PI12/00840 Duration: 11/01/2013-30/06/2017

Puig S. Implementation of personalized medicine in cutaneous melanoma based on genomic susceptibility and tumor signatures: Identiﬁcation of new targets for melanoma treatment. Sponsored by: Fundació La Marató de TV3. 20133130 Duration: 07/05/2014-06/05/2017

Puig S. Vías de diseminación metastásica en distintos subtipos del melanoma malign: nuevos biomarcadores tumorales y dianas terapéuticas. Sponsored by: Fundación Cientíﬁca Asociación Española Contra el Cáncer (AECC). GCB1515297850EN Duration: 01/07/2015-30/06/2020

Puig S. Evaluación de las alteraciones inmunológicas subyacentes en el desarrollo, progresión y respuesta a las terapias inmunológicas en melanoma. Implicaión de la microbiota en la inducción de tolerancia y efectos secundarios de las terapias inmunológicas. Sponsored by: Instituto de Salud Carlos III. PI15/00716 Duration: 01/01/2016-31/12/2018

Puig JA. Phenotype and molecular characterization of Large to Giant Congenital Melanocytic Nevi. Sponsored by: RTVE Telemaratón. RTVETELEMARATON14_05 Duration: 01/03/2015-15/03/2017

281 AREA 5 ONCOLOGY AND HAEMATOLOGY

Hematopoietic progenitor 5.6 cell transplantation

2. Evaluation of new transplant modalities, specially: LOCATION - Domiciliary autogenic HPT and allogenic CEK building HPT. - Haploidentical transplantation with unmanipulated bone marrow.

3. Studies addressing the prevention and treatment of the main complications of KEYWORDS HPT. 1. Allogeneic transplantation TEAM LEADER - Prevention and treatment of 2. Immunotherapy Álvaro Urbano-Ispizua (HCB) graft-versus-host disease with new agents 3. Veno-oclussive disease T. 93 227 57 76 and participation in different multicenter 4. Graft versus host disease [email protected] studies.

5. Infectious diseases Basic and translational research lines RESEARCHERS Enrique Carreras (HCB) 1. Study of the post-HPT complications Francesc Fernández-Avilés (HCB) originating from endothelial dysfunction. Pedro Jose Marín (HCB) Our project aims to characterize such Original publications Carmen Martínez (HCB) dysfunction and the early diagnosis of from 2015 to 2017 Montserrat Rovira (HCB) infections then to seek effective preventive in HPT. YEAR I.F. TOTAL Q1 Q2 POST-DOCTORAL RESEARCHERS 2. Study of new techniques for the early Maria Castella (FCRB) diagnosis of infections in HPT. 2015 43.26 10 3 6 Beatriz Martin (IDIBAPS) 3. Development of CARTs using autologous 2016 41.58 6 4 2 T cells and also from NK cells expanded 2017 68.07 16 6 8 PRE-DOCTORAL RESEARCHERS from umbilical cord blood. Maria Suarez (HCB)

TECHNICIANS PUBLICATIONS Lorena Pérez (IDIBAPS) LOCATION Guillermo Suñé (FCRB) Originals / I.F.: 68.067 RTICC_2012 ADMINISTRATIVE STAFF 1. Muraro, Paolo A.; Pasquini, Marcelo; Atkins, Mª José Sánchez (HCB) Harold L.; Bowen, James D.; Farge, Dominique; Carme Torres (HCB) Fassas, Athanasios; Freedman, Mark S.; Georges, George E.; Gualandi, Francesca; Hamerschlak, Nelson; Havrdova, Eva; STRATEGIC OBJECTIVES Kimiskidis, Vassilios K.; Kozak, Tomas; Mancardi, Giovanni L.; Massacesi, Luca; We have started research lines in antitumor Moraes, Daniela A.; Nash, Richard A.; Pavletic, cell therapy (NK and CARTs), and cell immune Steven; Ouyang, Jian; Rovira, Montserrat; Saiz, modulation. Lastly, we plan to develop a line of Albert; Simoes, Belinda; Trneny, Marek; Zhu, research in the ﬁeld of the pharmacokinetics, Lin; Badoglio, Manuela; Zhong, Xiaobo; pharmacodynamics and pharmacogenomics Sormani, Maria Pia; Saccardi, Riccardo; of immune modulators, as well as in the Multiple Sclerosis-Autologou. Long-term development of in vitro predictive models of Outcomes After Autologous graft-versus-host disease. Hematopoietic Stem Cell Transplantation for Multiple Sclerosis. JAMA NEUROLOGY. 74(4):459-469. I.F.: 10.029 MAIN LINES OF RESEARCH 2. Cook, Gordon; Iacobelli, Simona; van Clinical research lines Biezen, Anja; Ziagkos, Dimitris; LeBlond, Veronique; Abraham, Julie; McQuaker, Grant; 1. Assessment of new hematopoietic Schoenland, Stefan; Rambaldi, Alessandro; precursor transplantation (HPT) Halaburda, Kazimierz; Rovira, Maria; Sica, indications. Simona; Byrne, Jenny; Garcia Sanz, Ramon; Nagler, Arnon; van de Donk, Niels W. C. J.; Sinisalo, Marjatta; Cook, Mark; Kroger, Nicolaus; De Witte, Theo; Morris, Curly;

282 HEMATOPOIETIC PROGENITOR CELL TRANSPLANTATION 5.6

Garderet, Laurant. High-dose therapy and Abdel-Azim, H.; Lehmann, L.; Yu, L.; Bitan, M.; Ocular Chronic Graft-Versus-Host autologous stem cell transplantation in Cairo, M. S.; Qayed, M.; Salit, R.; Gale, R. P.; Disease. INVESTIGATIVE patients with POEMS syndrome: a Martino, R.; Jaglowski, S.; Bajel, A.; Savani, B.; OPHTHALMOLOGY AND VISUAL SCIENCE. retrospective study of the Plasma Cell Frangoul, H.; Lewis, I. D.; Storek, J.; Askar, M.; 58(11):4836-4846. I.F.: 3.303 Disorder sub-committee of the Chronic Kharfan-Dabaja, M. A.; Aljurf, M.; Ringden, O.; Malignancy Working Party of the European Reshef, R.; Olsson, R. F.; Hashmi, S.; Seo, S.; 13. Villegas, Ana; Nunez, Ramiro; Gaya, Anna; Society for Blood & Mar row Spitzer, T. R.; MacMillan, M. L.; Lazaryan, A.; Victoria Cuevas-Ruiz, Maria; Miguel Bosch, Transplantation. HAEMATOLOGICA. Spellman, S. R.; Arora, M.; Cutler, C. S. GvHD Jose; Carral, Anna; Arrizabalaga, Beatriz; 102(1):160-167. I.F.: 7.702 after umbilical cord blood transplantation Isabel Gomez-Roncero, Maria; Mora, for acute leukemia: an analysis of risk Asuncion; Bravo, Pilar; Lavilla, Esperanza; 3. López-García A, Rovira M, factors and effect on outcomes.BONE Monteserin, Carmen; Hernandez, Belen; Jauregui-Amezaga A, Marín P, Barastegui R, MARROW TRANSPLANTATION. Martinez-Barranco, Pilar; Jarque, Isidro; Salas A, Ribas V, Feu F, Elizalde JI, 52(3):400-408. I.F.: 3.874 Anunciacion Urquia, Maria; Garcia-Donas, Fernández-Avilés F, Martínez C, Gutiérrez G, Gloria; Brunet, Salut; Ataulfo Gonzalez, Rosiñol L, Carreras E, Urbano A, Lozano M, 8. Martino, R.; Henseler, A.; van Lint, M.; Fernando; Urbano, Alvaro. Presence of acute Cid J, Suárez-Lledó M, Masamunt MC, Comas Schaap, N.; Finke, J.; Beelen, D.; Vigouroux, S.; and chronic renal failure in patients with D, Giner A, Gallego M, Alfaro I, Ordás I, Panés J, Alessandrino, E. P.; Mufti, G. J.; Veelken, J. H.; paroxysmal nocturnal hemoglobinuria: Ricart E. Autologous Hematopoietic Stem Bruno, B.; Yakoub-Agha, I.; Volin, L.; Maertens, results of a retrospective analysis from the Cell Transplantation for Refractory J.; Or, R.; Leblond, V.; Rovira, M.; Kalhs, P.; Spanish PNH Registry. ANNALS OF Crohn's Disease: Efficacy in a Alvarez, A. F.; Vitek, A.; Sierra, J.; Wagner, E.; HEMATOLOGY. 96(10):1727-1733. I.F.: 3.083 Single-Centre Cohort. JOURNAL OF Robin, M.; de Witte, T.; Kroeger, N.; European CROHNS AND COLITIS. 11(10):1161-1168. Blood Marrow Transplant G. Long-term 14. Alejo-Cancho, Izaskun; Fernandez Aviles, I.F.: 5.813 follow-up of a retrospective comparison of Francesc; Capon, Alicia; Rodriguez, Cristina; reduced-intensity conditioning and Barrachina, Josep; Salvador, Pilar; Eugenia 4. Roth-Guepin, Gabrielle; Canaani, Jonathan; conventional high-dose conditioning for Valls, Ma; Alvarez-Martinez, Miriam J.; Ruggeri, Annalisa; Labopin, Myriam; Finke, allogeneic transplantation from matched Zboromyrska, Yuliya; Vila, Jordi; Angeles Juergen; Cornelissen, Jan J.; Delage, Jeremy; related donors in myelodysplastic Marcos, Ma. Evaluation of a multiplex panel Stuhler, Gernot; Rovira, Monserrat; Potter, syndromes. BONE MARROW for the diagnosis of acute infectious Mike; Stadler, Michael; Veelken, Hendrik; TRANSPLANTATION. 52(8):1107-1112. diarrhea in immunocompromised Cahn, Jean Yves; Collin, Matthew; Beguin, I.F.: 3.874 hematologic patients. PLOS ONE. Yves; Giebel, Sebastian; Nagler, Arnon; Mohty, 12(11):e0187458. I.F.: 2.806 Mohamad. Allogeneic stem cell 9. Fernandez De Larrea C; Dávila J; Isola I; transplantation in acute lymphoblastic Ocio E; Rosiñol L; Garcia-Sanz R; Cibeira M; 15. Martínez C, Millán O, Rovira M, leukemia patients older than 60 years: a Tovar N; Rovira M; Mateos M; Miguel J; Blade Fernández-Avilés F, López A, Suárez-Lledó M, survey from the acute leukemia working J. Absence of spontaneous response Carreras E, Urbano-Ispízua Á, Brunet M. party of EBMT. ONCOTARGET. improvement beyond day +100 after Pharmacodynamics of T cell function for 8(68):112972-112979. I.F.: 5.168 autologous stem cell transplantation in monitoring pharmacologic multiple myeloma. BONE MARROW immunosuppression after allogeneic 5. Lucena C., Rovira M., Gabarrús A., Filella X., TRANSPLANTATION. 52(4):567-569. hematopoietic stem cell transplantation. Martínez C., Domingo R., Torres A., Agustí C. I.F.: 3.874 INTERNATIONAL JOURNAL OF The clinical value of biomarkers in HEMATOLOGY. 105(4):497-505. I.F.: 1.610 respiratory complications in 10. Mir E, Palomo M, Rovira M, Pereira A, hematopoietic SCT. BONE MARROW Escolar G, Penack O, Holler E, Carreras E, 16. Bastida C; Corominas N; Sotoca J; Rovira TRANSPLANTATION. 52(3):415-422. Diaz-Ricart M. Endothelial damage is M. Anticoagulation in atrial ﬁbrillation: I.F.: 3.874 aggravated in acute GvHD and could NOAC prescribing in primary health care. predict its development. BONE MARROW INTERNATIONAL JOURNAL OF CLINICAL 6. Van Gelder M., De Wreede L., Bornhäuser TRANSPLANTATION. 52(9):1317-1325. PHARMACY. 39(2):478-482. I.F.: 1.555 M., Niederwieser D., Karas M., Anderson N., I.F.: 3.874 Gramatzki M., Dreger P., Michallet M., Petersen E., … …, Schaap M. Long-term survival of 11. Afelik S, Rovira M. Pancreatic β-cell Review / I.F.: 7.1 patients with CLL after allogeneic regeneration: Facultative or dedicated transplantation: A report from the progenitors? MOLECULAR AND CELLULAR 1. Farge, D.; Burt, R. K.; Oliveira, M-C; European Society for Blood and Marrow ENDOCRINOLOGY. 445(C):85-94. I.F.: 3.754 Mousseaux, E.; Rovira, M.; Marjanovic, Z.; de Transplantation. BONE MARROW Vries-Bouwstra, J.; Del Papa, N.; Saccardi, R.; TRANSPLANTATION. 52(3):372-380. 12. Cocho, Lidia; Fernandez, Itziar; Calonge, Shah, S. J.; Lee, D. C.; Denton, C.; Alexander, T.; I.F.: 3.874 Margarita; Sainz de la Maza, Maite; Rovira, Kiely, D. G.; Snowden, J. A. Cardiopulmonary Montserrat; Stern, Michael E.; assessment of patients with systemic 7. Chen, Y-B; Wang, T.; Hemmer, M. T.; Brady, Garcia-Vazquez, Carmen; Enriquez de sclerosis for hematopoietic stem cell C.; Couriel, D. R.; Alousi, A.; Pidala, J.; Salamanca, Amalia . Prehematopoietic transplantation: recommendations from Urbano-Ispizua, A.; Choi, S. W.; Nishihori, T.; Stem Cell Transplantation Tear Cytokines the European Society for Blood and Teshima, T.; Inamoto, Y.; Wirk, B.; Marks, D. I.; as Potential Susceptibility Biomarkers for Marrow Transplantation Autoimmune

283 AREA 5 ONCOLOGY AND HAEMATOLOGY

Diseases Working Party and collaborating partners. BONE MARROW TRANSPLANTATION. 52(11):1495-1503. I.F.: 3.874

2. Martín-Antonio B., Suñe G., Perez-Amill L., Castella M., Urbano-Ispizua A. Natural killer cells: Angels and devils for immunotherapy. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. 18(9): 1868. I.F.: 3.226

Letters / I.F.: 11.075

1. Urbano-Ispizua Á., Muus P., Schrezenmeier H., Almeida A., Wilson A., Ware R.. Different clinical characteristics of paroxysmal nocturnal hemoglobinuria in pediatric and adult patients. HAEMATOLOGICA. 102(3):e76-e79. I.F.: 7.702

2. Azorín S., Cibeira M., Solé M., Fernández de Larrea C., Rosiñol L., Rovira M., Campistol J., Bladé J. Renal outcomes of autologous stem cell transplantation among patients with light-chain amyloidosis: a single centre Spanish experience. AMYLOID : THE INTERNATIONAL JOURNAL OF EXPERIMENTAL AND CLINICAL INVESTIGATION : THE OFFICIAL JOURNAL OF THE INTERNATIONAL SOCIETY OF AMYLOIDOSIS. 24(sup1):70-71. I.F.: 3.373

GRANTS FOR RESEARCH IN PROGRESS

Urbano A. Actividad antitumoral de células NK mediada por intercambio de lípidos. Potencial uso terapéutico postrasplante hemopoyético en mieloma múltiple. Sponsored by: Instituto de Salud Carlos III (ISCIII). PI14/00798 Duration: 01/01/2015-31/12/2017

284 HEMATOLOGICAL ONCOLOGY 5.7

Hematological 5.7 oncology

ADMINISTRATIVE STAFF Laura Alcolea (HCB) LOCATION Vanessa Arellano (HCB-FCRB) HCB building Maria José Sánchez (HCB)

STRATEGIC OBJECTIVES

The main strategic objectives of our team KEYWORDS are clinical, applied and basic research in

1. Lymphoid neoplasms TEAM LEADER haematological oncology. 2. Genomic proﬁle Francisco Cervantes (HCB) The team is structured into three study groups 3. Multiple myeloma T. 93 227 23 92 of three major disease categories 4. Myeloproliferative neoplasms [email protected] 5. Acute myeloid leukemia MAIN LINES OF RESEARCH

GROUP LEADERS Joan Bladé (HCB) 1. Lymphoid neoplasms T. 93 227 54 00 (Ext.: 3352) - Mechanisms of progression . [email protected] - Genomic proﬁle of diffuse large cell lymphoma. Original publications - New prognostic models in T cell lymphomas . from 2015 to 2017 Francisco Cervantes (HCB) T. 93 227 23 92 - Mechanisms of progression of chronic YEAR I.F. TOTAL Q1 Q2 [email protected] lymphoid leukemia (CLL). - Cellular microenvironment in CLL. 2015 319.39 40 30 4 Carlos Fernández de Larrea (IDIBAPS-HCB) - Cellular proliferation in CLL. 2016 355.42 40 26 10 T. 93 227 54 28 - Project for the Chronic Lymphocytic 2017 511.46 57 40 13 [email protected] Leukemia (CLL) Genome.

Armando López-Guillermo (HCB) 2. Multiple myeloma and other T. 93 227 29 46 monoclonal gammopathies [email protected] - Extramedullary involvement and plasma TEAM INVOLVED IN cell leukemia . RTICC - Immune reconstitution and bone marrow AGAUR_SGR14 RESEARCHERS microenvironment in patients in response Maria Teresa Cibeira (HCB) - Mechanisms of progression and control in Julio Delgado (HCB) asymptomatic gammopathies. Jordi Esteve (HCB) - Impact of microRNA and other non-coding Eva Giné (HCB) RNA. Emili Montserrat (HCB) - Cardiac involvement in AL amyloidosis. Laura Rosiñol (HCB) - Phase I, II and III clinical trials .

POST-DOCTORAL RESEARCHERS 3. Myeloid neoplasms Alberto Álvarez-Larrán (HCB) - Chronic myeloid leukemia (CML): Tycho Stephan Baumann (HCB) European Registry of CML. Marina Díaz (HCB) - Philadelphia-negative myeloproliferative Tania Díaz (IDIBAPS) neoplasms: Mechanisms of thrombosis; Ester Lozano (IDIBAPS) mutational status and prognosis of Natalia Tovar (HCB) myeloﬁbrosis. - Acute myeloid leukemia (AML): Biological

PRE-DOCTORAL RESEARCHERS prognostic factors; expression of Juan Gonzalo Correa (HCB) non-coding RNA; treatment protocols for Ivan Dlouhy (FCRB) the CETLAM group; impact of molecular Daniel Esteban (FCRB) markers in transplantation. Anna Gaya (FCRB) - Myelodysplastic syndromes (MDS): Ignacio Isola (HCB) cytogenetic and molecular abnormalities Raquel Jiménez (FCRB) and prognosis. Laura Carola Magnano (HCB) - Phase I, II and III clinical trials for CML, Alejandra Martínez (FCRB) myeloﬁbrosis, AML, ALL and MDS. Valentín Ortíz (FCRB) Alfredo Rivas (HCB)

285 AREA 5 ONCOLOGY AND HAEMATOLOGY

RESEARCH GROUP MYELOMA AND OTHER MONOCLONAL GAMMAPATHIES

GROUP LEADER Joan Bladé (HCB)

Multiple myeloma and systemic AL amyloidosis. Minimal residual disease, extramedullary involvement in myeloma, cardiac involvement in amyloidosis, and multicentric clinical trials with novel drugs.

RESEARCH GROUP MYELOID NEOPLASMAS Francisco Cervantes

GROUP

GROUP LEADER Francisco Cervantes (HCB)

Natural history and prognosis of chronic myeloid leukemia, myeloproliferative neoplasms, acute myeloid leukemia and myelodysplastic syndromes; prognostic importance of newer molecular markers in these diseases; clinical trials with new drugs.

50/50 PROGRAM MECHANISMS OF PROGRESSION IN MONOCLONAL GAMMOPATHIES Carlos Fernández de Larrea Rodríguez

GROUP LEADER GROUP Carlos Fernández de Larrea Rodríguez (HCB-IDIBAPS) RESEARCH GROUP Study of progression mechanisms of the Mechanisms of progression and control in LYMPHOID NEOPLASMS disease, genome of CLL and lymphoma, patients with multiple myeloma. Molecular and minimum residual disease and biological cellular features of patients with long-lasting prognostic models. stable monoclonal gammopathy of undetermined signiﬁcance and smoldering myeloma. Oligoclonal response and minimal residual disease in myeloma: impact of immune reconstitution and bone marrow GROUP LEADER microenvironment. Immunotherapy in Armando López Guillermo (HCB) monoclonal gammopathies. Clinical trials with novel molecules in Lymphomas, chronic lymphocytic leukemia myeloma and macroglobulinemia. and the other lymphoproliferative disorders:

286 HEMATOLOGICAL ONCOLOGY 5.7

PUBLICATIONS La Rubia J, Orfao A, Mateos M, Blade J, 10. Etxabe, A.; Lara-Castillo, M. C.; San-Miguel J. Depth of response in multiple Cornet-Masana, J. M.; Banus-Mulet, A.; Originals / I.F.: 511.461 myeloma: A pooled analysis of three Nomdedeu, M.; Torrente, M. A.; Pratcorona, M.; PETHEMA/GEM clinical trials. JOURNAL Diaz-Beya, M.; Esteve, J.; Risueno, R. M. 1. Hochhaus, Andreas; Larson, Richard A.; OF CLINICAL ONCOLOGY. 35(25):2900-2910. Inhibition of serotonin receptor type 1 in Guilhot, Francois; Radich, Jerald P.; Branford, I.F.: 24.008 acute myeloid leukemia impairs leukemia Susan; Hughes, Timothy P.; Baccarani, Michele; stem cell functionality: a promising novel Deininger, Michael W.; Cervantes, Francisco; 6. Thieblemont C., Tilly H., Da Silva M., therapeutic target. LEUKEMIA. Fujihara, Satoko; Ortmann, Christine-Elke; Casasnovas R., Fruchart C., Morschhauser F., 31(11):2288-2302. I.F.: 11.702 Menssen, Hans D.; Kantarjian, Hagop; O'Brien, Haioun C., Lazarovici J., Grosicka A., Perrot A., Stephen G.; Druker, Brian J.; IRIS Investigators. Trotman J., Sebban C., Caballero D., Greil R., Van 11. Flores-Montero J, Sanoja-Flores L, Paiva B, Long-Term Outcomes of Imatinib Eygen K., Cohen A., Gonzalez H., Bouabdallah R., Puig N, García-Sánchez O, Böttcher S, Van Der Treatment for Chronic Myeloid Leukemia. Oberic L., Corront B., Choufi B., Lopez-Guillermo Velden V, Pérez-Morán J, Vidriales M, NEW ENGLAND JOURNAL OF MEDICINE. A., Catalano J., Van Hoof A., Briere J., Cabeçadas García-Sanz R, Jimenez C, González M, 376(10):917-927. I.F.: 72.406 J., Salles G., Gaulard P., Bosly A., Coiffier B. Martínez-López J, Corral-Mateos A, Grigore G, Lenalidomide maintenance compared Fluxá R, Pontes R, Caetano J, Sedek L, Del 2. Dimopoulos M; Trotman J; Tedeschi A; with placebo in responding elderly patients Cañizo M, Bladé J, Lahuerta J, Aguilar C, Bárez A, Matous J; Macdonald D; Tam C; Tournilhac O; with diffuse large B-cell lymphoma treated García-Mateo A, Labrador J, Leoz P, Ma S; Oriol A; Heffner L; Shustik C; Garcia-Sanz with first-line rituximab plus Aguilera-Sanz C, San-Miguel J, Mateos M, Durie R; Cornell R; de Larrea C; Castilló J; Granell M; cyclophosphamide, doxorubicin, B, Van Dongen J, Orfao A. Next Generation Kyrtsonis M; Leblond V; Symeonidis A; Kastritis vincristine, and prednisone. JOURNAL OF Flow for highly sensitive and standardized E; Singh P; Li J; Graef T; Bilotti E; Treon S; Buske CLINICAL ONCOLOGY. 35(22):2473-2481. detection of minimal residual disease in C. Ibrutinib for patients with I.F.: 24.008 multiple myeloma. LEUKEMIA. rituximab-refractory Waldenström's 31(10):2094-2103. I.F.: 11.702 macroglobulinaemia (iNNOVATE): An 7. Poisson J, Plessier A, Kiladjian JJ, Turon F, open-label substudy of an international, Cassinat B, Andreoli A, De Raucourt E, Goria O, 12. Rosinol, L.; Oriol, A.; Teruel, A. I.; de la Guia, A. multicentre, phase 3 trial. LANCET Zekrini K, Bureau C, Lorre F, Cervantes F, L.; Blanchard, Ma J.; de la Rubia, J.; Granell, M.; ONCOLOGY. 18(2):241-250. I.F.: 33.900 Colomer D, Durand F, Garcia-Pagan JC, Sampol, Ma A.; Palomera, L.; Gonzalez, Y.; Casadevall N, Valla DC, Rautou PE, Marzac C, Etxebeste, Ma A.; Martinez-Martinez, R.; 3. Zucca E; Conconi A; Martinelli G; Bouabdallah French national network for vascular liver Hernandez, M. T.; de Arriba, F.; Alegre, A.; Cibeira, R; Tucci A; Vitolo U; Martelli M; Pettengell R; diseases. Selective testing for calreticulin Ma T.; Mateos, Ma V.; Martinez-Lopez, J.; Salles G; Sebban C; López Guillermo A; Pinotti G; gene mutations in patients with splanchnic Lahuerta, J. J.; Miguel, J. San; Blade, J. Programa Devizzi L; Morschhauser F; Tilly H; Torri V; vein thrombosis: A prospective cohort Espanol Tratamientos Hema. Bortezomib Hohaus S; Ferreri A; Zachee P; Bosly A; Haioun study. JOURNAL OF HEPATOLOGY. and thalidomide maintenance after stem C; Stelitano C; Bellei M; Ponzoni M; Moreau A; 67(3):501-507. I.F.: 12.486 cell transplantation for multiple myeloma: Jack A; Campo E; Mazzucchelli L; Cavalli F; a PETHEMA/GEM trial. LEUKEMIA. Johnson P; Thieblemont C. Final results of the 8. Magnano L, Balagué O, Dlouhy I, Rovira J, 31(9):1922-1927. I.F.: 11.702 IELSG-19 randomized trial of Karube K, Pinyol M, Rivas-Delgado A, Costa D, mucosa-associated lymphoid tissue Martínez-Trillos A, González-Farre B, 13. Marchetti M, Barosi G, Cervantes F, lymphoma: Improved event-free and Martínez-Pozo A, Giné E, Colomer D, Delgado J, Birgegård G, Griesshammer M, Harrison C, progression-free survival with rituximab Villamor N, Campo E, López-Guillermo A. Hehlmann R, Kiladjian JJ, Kröger N, McMullin MF, plus chlorambucil versus either Clinicobiological features and prognostic Passamonti F, Vannucchi A, Barbui T. Which chlorambucil or rituximab monotherapy. impact of diffuse large B-cell lymphoma patients with myelofibrosis should receive JOURNAL OF CLINICAL ONCOLOGY. component in the outcome of patients with ruxolitinib therapy? ELN-SIE 35(17):1905-1912. I.F.: 24.008 previously untreated follicular lymphoma. evidence-based recommendations. ANNALS OF ONCOLOGY. 28(11):2799-2805. LEUKEMIA. 31(4):882-888. I.F.: 11.702 4. Mesa RA, Kiladjian JJ, Catalano JV, Devos T, I.F.: 11.855 Egyed M, Hellmann A, McLornan D, Shimoda K, 14. Passamonti F, Mora B, Giorgino T, Winton EF, Deng W, Dubowy RL, Maltzman JD, 9. Paiva B, Puig N, Cedena MT, de Jong BG, Ruiz Guglielmelli P, Cazzola M, Maffioli M, Rambaldi A, Cervantes F, Gotlib J. SIMPLIFY-1: A Phase III Y, Rapado I, Martinez-Lopez J, Cordon L, Caramella M, Komrokji R, Gotlib J, Kiladjian JJ, Randomized Trial of Momelotinib Versus Alignani D, Delgado JA, van Zelm MC, Van Cervantes F, Devos T, Palandri F, De Stefano V, Ruxolitinib in Janus Kinase Inhibitor-Naïve Dongen JJ, Pascual M, Agirre X, Prosper F, Ruggeri M, Silver R, Benevolo G, Albano F, Patients With Myelofibrosis. JOURNAL OF Martín-Subero JI, Vidriales MB, Gutierrez NC, Caramazza D, Rumi E, Merli M, Pietra D, CLINICAL ONCOLOGY. 35(34):3844-3850. Hernandez MT, Oriol A, Echeveste MA, Casalone R, Barbui T, Pieri L, Vannucchi AM. I.F.: 24.008 Gonzalez Y, Johnson SK, Epstein J, Barlogie B, Driver mutations' effect in secondary Morgan GJ, Orfao A, Blade J, Mateos MV, myelofibrosis: an international multicenter 5. Lahuerta J, Paiva B, Vidriales M, Cordón L, Lahuerta JJ, San-Miguel JF. Differentiation study based on 781 patients. LEUKEMIA. Cedena M, Puig N, Martinez-Lopez J, Rosiñol L, stage of myeloma plasma cells: biological 31(4):970-973. I.F.: 11.702 Gutierrez N, Martín-Ramos M, Oriol A, Teruel A, and clinical significance. LEUKEMIA. Echeveste M, De Paz R, De Arriba F, Hernandez 31(2):382-392. I.F.: 11.702 15. Moreau P, Joshua D, Chng WJ, Palumbo A, M, Palomera L, Martinez R, Martin A, Alegre A, De Goldschmidt H, Hájek R, Facon T, Ludwig H,

287 AREA 5 ONCOLOGY AND HAEMATOLOGY

Pour L, Niesvizky R, Oriol A, Rosiñol L, Suvorov A, statement from the Acute Leukemia Agha I; Blaise D; Ifrah N; Socie G; Gedde-Dhal T; Gaidano G, Pika T, Weisel K, Goranova- Working Party of the European Society for Schaap N; Cornelissen J; Vigouroux S; Sanz J; Marinova V, Gillenwater HH, Mohamed N, Blood and Marrow Transplantation. Michaux L; Esteve J; Mohty M; Nagler A. Aggarwal S, Feng S, Dimopoulos MA. Impact of HAEMATOLOGICA. 102(11):1810-1822. I.F.: 7.702 Allogeneic stem cell transplantation in prior treatment on patients with relapsed adult patients with acute myeloid multiple myeloma treated with carfilzomib 21. Geyer HL, Kosiorek H, Dueck AC, Scherber leukaemia and 17p abnormalities in first and dexamethasone vs bortezomib and R, Slot S, Zweegman S, Te Boekhorst PA, complete remission: a study from the dexamethasone in the phase 3 Senyak Z, Schouten HC, Sackmann F, Fuentes Acute Leukemia Working Party (ALWP) of ENDEAVOR study. LEUKEMIA. 31:115-122. AK, Hernández-Maraver D, Pahl HL, the European Society for Blood and I.F.: 11.702 Griesshammer M, Stegelmann F, Döhner K, Marrow Transplantation (EBMT). Lehmann T, Bonatz K, Reiter A, Boyer F, Etienne JOURNAL OF HEMATOLOGY AND 16. Passamonti F, Giorgino T, Mora B, G, Ianotto JC, Ranta D, Roy L, Cahn JY, Harrison ONCOLOGY. 10(1):20. I.F.: 6.350 Guglielmelli P, Rumi E, Maffioli M, Rambaldi A, CN, Radia D, Muxi P, Maldonado N, Besses C, Caramella M, Komrokji R, Gotlib J, Kiladjian JJ, Cervantes F, Johansson PL, Barbui T, Barosi G, 26. Brito-Zerón P, Kostov B, Fraile G, Cervantes F, Devos T, Palandri F, De Stefano V, Vannucchi AM, Paoli C, Passamonti F, Caravia-Durán D, Maure B, Rascón FJ, Zamora Ruggeri M, Silver RT, Benevolo G, Albano F, Andreasson B, Ferrari ML, Rambaldi A, M, Casanovas A, Lopez-Dupla M, Ripoll M, Pinilla Caramazza D, Merli M, Pietra D, Casalone R, Samuelsson J, Cannon K, Birgegard G, Xiao Z, B, Fonseca E, Akasbi M, de la Red G, Rotunno G, Barbui T, Cazzola M, Vannucchi AM. Xu Z, Zhang Y, Sun X, Xu J, Kiladjian JJ, Zhang P, Duarte-Millán MA, Fanlo P, Guisado-Vasco P, A clinical-molecular prognostic model to Gale RP, Mesa RA. Associations between Pérez-Alvarez R, Chamorro AJ, Morcillo C, predict survival in patients with post gender, disease features and symptom Jiménez-Heredia I, Sánchez-Berná I, polycythemia vera and post essential burden in the MPN population: An analysis López-Guillermo A, Ramos-Casals M, SS Study thrombocythemia myelofibrosis. by the MPN QOL International Working Group GEAS-SEMI. Characterization and LEUKEMIA. 31(12):2726-2731. I.F.: 11.702 Group. HAEMATOLOGICA. 102(1):85-93. risk estimate of cancer in patients with I.F.: 7.702 primary Sjögren syndrome. JOURNAL OF 17. Vidal-Crespo A, Rodriguez V, HEMATOLOGY AND ONCOLOGY. 10(1):90. Matas-Cespedes A, Lee E, Rivas-Delgado A, 22. Granell M, Calvo X, Garcia-Guiñón A, I.F.: 6.350 Giné E, Navarro A, Beà S, Campo E, Escoda L, Abella E, Martínez CM, Teixidó M, López-Guillermo A, Lopez-Guerra M, Roué G, Gimenez MT, Senín A, Sanz P, Campoy D, Vicent 27. Gonzalez-Farre B, Martinez D, Colomer D, Pérez-Galán P. The Bruton A, Arenillas L, Rosiñol L, Sierra J, Bladé J, de Lopez-Guerra M, Xipell M, Monclus E, Rovira J, tyrosine kinase inhibitor CC-292 shows Larrea CF, GEMMAC (Grup per l’estudi del Garcia F, Lopez-Guillermo A, Colomo L, Campo activity in mantle cell lymphoma and mieloma i l’amiloïdosi de Catalunya). Prognostic E, Martinez A. HHV8-related lymphoid synergizes with lenalidomide and NIK impact of circulating plasma cells in proliferations: a broad spectrum of lesions inhibitors depending on nuclear factor-κB patients with multiple myeloma: from reactive lymphoid hyperplasia to mutational status. HAEMATOLOGICA. implications for plasma cell leukemia overt lymphoma. MOD PATHOL. 102(11):e447-e451. I.F.: 7.702 definition. HAEMATOLOGICA. 30(5):745-760. I.F.: 5.728 102(6):1099-1104. I.F.: 7.702 18. Díaz T, Rodríguez V, Lozano E, Mena MP, 28. Delgado, Julio; Bielig, Torsten; Bonet, Lizette; Calderón M, Rosiñol L, Martínez A, Tovar N, 23. Verstovsek S, Gotlib J, Mesa RA, Vannucchi Carnero-Montoro, Elena; Puente, Xose S.; Pérez-Galán P, Bladé J, Roué G, de Larrea CF. AM, Kiladjian JJ, Cervantes F, Harrison CN, Colomer, Dolors; Bosch, Elena; Campo, Elias; The BET bromodomain inhibitor CPI203 Paquette R, Sun W, Naim A, Langmuir P, Dong T, Lozano, Francisco. Impact of the functional improves lenalidomide and Gopalakrishna P, Gupta V. Long-term survival CD5 polymorphism A471V on the dexamethasone activity in in vitro and in in patients treated with ruxolitinib for response of chronic lymphocytic vivo models of multiple myeloma by myelofibrosis: COMFORT-I and -II pooled leukaemia to conventional chemotherapy blockade of Ikaros and MYC signaling. analyses. JOURNAL OF HEMATOLOGY regimens. BRITISH JOURNAL OF HAEMATOLOGICA. 102(10):1776-1784. AND ONCOLOGY. 10(1):156. I.F.: 6.350 HAEMATOLOGY. 177(1):142-156. I.F.: 5.670 I.F.: 7.702 24. Brissot E, Labopin M, Stelljes M, Ehninger G, 29. Alvarez-Larrán A, Senín A, 19. Munker, Reinhold; Labopin, Myriam; Esteve, Schwerdtfeger R, Finke J, Kolb HJ, Ganser A, Fernández-Rodríguez C, Pereira A, Jordi; Schmid, Christoph; Mohty, Mohamad; Schäfer-Eckart K, Zander AR, Bunjes D, Mielke Arellano-Rodrigo E, Gómez M, Ferrer-Marin F, Nagler, Arnon. Mixed phenotype acute S, Bethge WA, Milpied N, Kalhs P, Blau IW, Kröger Martínez-López J, Camacho L, Colomer D, leukemia: outcomes with allogeneic stem N, Vitek A, Gramatzki M, Holler E, Schmid C, Angona A, Navarro B, Cervantes F, Besses C, cell transplantation. A retrospective study Esteve J, Mohty M, Nagler A. Comparison of Bellosillo B, Hernández-Boluda JC. Impact of from the Acute Leukemia Working Party of matched sibling donors versus unrelated genotype on leukaemic transformation in the EBMT. HAEMATOLOGICA. donors in allogeneic stem cell polycythaemia vera and essential 102(12):2134-2140. I.F.: 7.702 transplantation for primary refractory thrombocythaemia. BRITISH JOURNAL OF acute myeloid leukemia: a study on behalf HAEMATOLOGY. 178(5):764-771. I.F.: 5.670 20. Lee CJ, Savani BN, Mohty M, Labopin M, of the Acute Leukemia Working Party of Ruggeri A, Schmid C, Baron F, Esteve J, Gorin the EBMT. JOURNAL OF HEMATOLOGY 30. Alonso-Álvarez S., Magnano L., Alcoceba NC, Giebel S, Ciceri F, Nagler A. Haploidentical AND ONCOLOGY. 10(1):130. I.F.: 6.350 M., Andrade-Campos M., Espinosa-Lara N., hematopoietic cell transplantation for Rodríguez G., Mercadal S., Carro I., Sancho J., adult acute myeloid leukemia: A position 25. Poiré X; Labopin M; Maertens J; Yakoub- Moreno M., Salar A., García-Pallarols F., Arranz R.,

288 HEMATOLOGICAL ONCOLOGY 5.7

Cannata J., Terol M., Teruel A., Rodríguez A., 34. Delgado J, Doubek M, Baumann T, Garcia-Alvarez, Maria; Chillon, Maria C.; Jiménez-Ubieto A., González de Villambrosia S., Kotaskova J, Molica S, Mozas P, Rivas-Delgado Balanzategui, Ana; Alcoceba, Miguel; Oriol, Bello J., López L., Monsalvo S., Novelli S., de Cabo A, Morabito F, Pospisilova S, Montserrat E. Albert; Rosinol, Laura; Palomera, Luis; Teruel, E., Infante M., Pardal E., García-Álvarez M., Chronic lymphocytic leukemia: A Ana I.; Lahuerta, Juan J.; Blade, Joan; Mateos, Delgado J., González M., Martín A., prognostic model comprising only two Maria V.; Orfao, Alberto; San Miguel, Jesos F.; López-Guillermo A., Caballero M. Risk of, and biomarkers (IGHV mutational status and Gonzalez, Marcos; Gutierrez, Norma C.; survival following, histological FISH cytogenetics) separates patients Garcia-Sanz, Ramon. A Next-Generation transformation in follicular lymphoma in with different outcome and simplifies the Sequencing Strategy for Evaluating the the rituximab era. A retrospective CLL-IPI. AMERICAN JOURNAL OF Most Common Genetic Abnormalities in multicentre study by the Spanish HEMATOLOGY. 92(4):375-380. I.F.: 5.275 Multiple Myeloma. JOURNAL OF GELTAMO group. BRITISH JOURNAL OF MOLECULAR DIAGNOSTICS. 19(1):99-106. HAEMATOLOGY. 178(5):699-708. I.F.: 5.670 35. Puiggros, Anna; Collado, Rosa; Jose I.F.: 4.526 Calasanz, Maria; Ortega, Margarita; Ruiz-Xiville, 31. Laubach JP, Moslehi JJ, Francis SA, San Neus; Rivas-Delgado, Alfredo; Luno, Elisa; 39. Garrabou G, Soriano À, Pinós T, Miguel JF, Sonneveld P, Orlowski RZ, Moreau P, Gonzalez, Teresa; Navarro, Blanca; Garcia-Malo, Casanova-Mollà J, Pacheu-Grau D, Morén C, Rosiñol L, Faber EA, Voorhees P, Mateos MV, MaDolores; Valiente, Alberto; Angel Hernandez, García-Arumí E, Morales M, Ruiz-Pesini E, Marquez L, Feng H, Desai A, van de Velde H, Jose; Teresa Ardanaz, Maria; Angeles Pinan, Catalán-Garcia M, Milisenda JC, Lozano E, Elliott J, Shi H, Dow E, Jobanputra N, Esseltine Maria; Laura Blanco, Maria; Hernandez- Andreu AL, Montoya J, Mensa J, Cardellach F. DL, Niculescu L, Anderson KC, Lonial S, Sanchez, Maria; Batlle-Lopez, Ana; Salgado, Influence of Mitochondrial Genetics on the Richardson PG. A retrospective analysis of Rocio; Salido, Marta; Ferrer, Ana; Abrisqueta, Mitochondrial Toxicity of Linezolid in 3954 patients in phase 2/3 trials of Pau; Gimeno, Eva; Abella, Eugenia; Ferra, Blood Cells and Skin Nerve Fibers. bortezomib for the treatment of multiple Christelle; Jose Terol, Maria; Ortuno, Francisco; ANTIMICROBIAL AGENTS AND myeloma: towards providing a benchmark Costa, Dolors; Moreno, Carol; Carbonell, Felix; CHEMOTHERAPY. 61(9): e00542-17. I.F.: 4.302 for the cardiac safety profile of Bosch, Francesc; Delgado, Julio; Espinet, Blanca. proteasome inhibition in multiple Patients with chronic lymphocytic 40. Fernandez De Larrea C; Dávila J; Isola I; Ocio myeloma. BRITISH JOURNAL OF leukemia and complex karyotype show an E; Rosiñol L; Garcia-Sanz R; Cibeira M; Tovar N; HAEMATOLOGY. 178(4):547-560. I.F.: 5.670 adverse outcome even in absence of Rovira M; Mateos M; Miguel J; Blade J. Absence TP53/ATM FISH deletions. ONCOTARGET. of spontaneous response improvement 32. Montalban, Carlos; Diaz-Lopez, Antonio; 8(33):54297-54303. I.F.: 5.168 beyond day +100 after autologous stem Dlouhy, Ivan; Rovira, Jordina; Lopez-Guillmermo, cell transplantation in multiple myeloma. Armando; Alonso, Sara; Martin, Alejandro; 36. Jiménez-Ubieto A., Grande C., Caballero D., BONE MARROW TRANSPLANTATION. Sancho, Juan M.; Garcia, Olga; Sanchez, Jose M.; Yáñez L., Novelli S., Hernández-Garcia M., 52(4):567-569. I.F.: 3.874 Rodriguez, Mario; Novelli, Silvana; Salar, Antonio; Manzanares M., Arranz R., Ferreiro J., Bobillo S., Gutierrez, Antonio; Rodriguez-Salazar, Maria J.; Mercadal S., Galeo A., López Jiménez J., 41. Pfirrmann M, Evtimova D, Saussele S, Bastos, Mariana; Dominguez, Juan F.; Moraleda J., Vallejo C., Albo C., Pérez E., Marrero Castagnetti F, Cervantes F, Janssen J, Hoffmann Fernandez, Ruben; de Villambrosia, Sonia C., Magnano L., Palomera L., Jarque I., VS, Gugliotta G, Hehlmann R, Hochhaus A, Gonzalez; Queizan, Jose E. A.; Cordoba, Raul; de Martínez-Sánchez P., Martín A., Coria E., Hasford J, Baccarani M. No influence of Ona, Raquel; Lopez-Hernandez, Andres; Freue, López-Guillermo A., Salar A., Lahuerta J. BCR-ABL1 transcript types e13a2 and Julian M.; Garrote, Heidys; Lopez, Lourdes; Autologous Stem Cell Transplantation for e14a2 on long-term survival: results in Martin-Moreno, Ana M.; Rodriguez, Jose; Follicular Lymphoma: Favorable 1494 patients with chronic myeloid Abraira, Victor; Garcia, Juan F.;GELTAMO-IPI Long-Term Survival Irrespective of leukemia treated with imatinib. J CANCER Project Investigators. Validation of the Pretransplantation Rituximab Exposure. RES CLIN ONCOL. 143(5):843-850. I.F.: 3.503 NCCN-IPI for diffuse large B-cell BIOLOGY OF BLOOD AND MARROW lymphoma (DLBCL): The addition of β TRANSPLANTATION. 23(10):1631-1640. 42. Rodríguez-Lobato L; Fernandez De Larrea 2-microglobulin yields a more accurate I.F.: 4.704 C; Cibeira M; Tovar N; Isola I; Aróstegui J; Rosinol GELTAMO-IPI. BRITISH JOURNAL OF L; Diaz T; Lozano E; Yague J; Blade J. HAEMATOLOGY. 176(6):918-928. I.F.: 5.670 37. Rodríguez-Lobato LG, Fernández de Larrea Prognostic impact of immunoparesis at C, Cibeira MT, Tovar N, Aróstegui JI, Rosiñol L, diagnosis and after treatment onset in 33. Colomo L, Vazquez I, Papaleo N, Espinet B, Díaz T, Lozano E, Elena M, Yagüe J, Bladé J. patients with light-chain amyloidosis. Ferrer A, Franco C, Comerma L, Hernandez S, Impact of Autologous Stem Cell AMYLOID: THE INTERNATIONAL JOURNAL Calvo X, Salar A, Climent F, Mate JL, Forcada P, Transplantation on the Incidence and OF EXPERIMENTAL AND CLINICAL Mozos A, Nonell L, Martinez A, Carrio A, Costa D, Outcome of Oligoclonal Bands in Patients INVESTIGATION : THE OFFICIAL JOURNAL Dlouhy I, Salaverria I, Martin-Subero JI, with Light-Chain Amyloidosis. BIOLOGY OF THE INTERNATIONAL SOCIETY OF Lopez-Guillermo A, Valera A, Campo E, Grup per OF BLOOD AND MARROW AMYLOIDOSIS. 24(4):245-252. I.F.: 3.373 l’Estudi dels Limfomes de Catalunya i Balears TRANSPLANTATION. 23(8):1269-1275. (GELCAB). LMO2-negative Expression I.F.: 4.704 43. Jiménez-Ubieto A, Grande C, Caballero D, Predicts the Presence of MYC Yáñez L, Novelli S, Hernández MT, Manzanares Translocations in Aggressive B-Cell 38. Jimenez, Cristina; Jara-Acevedo, Maria; M, Arranz R, Ferreiro JJ, Bobillo S, Mercadal S, Lymphomas. AMERICAN JOURNAL OF Corchete, Luis A.; Castillo, David; Ordonez, Galego A, Jiménez JL, Moraleda JM, Vallejo C, SURGICAL PATHOLOGY. 41(7):877-886. Gonzalo R.; Sarasquete, Maria E.; Puig, Noemi; Albo C, Pérez E, Marrero C, Magnano L, I.F.: 5.363 Martinez-Lopez, Joaquin; Prieto-Conde, Maria I.; Palomera L, Jarque I, Coria E, Rodriguez A,

289 AREA 5 ONCOLOGY AND HAEMATOLOGY

Martín A, López-Guillermo A, Salar A, Lahuerta P., Beà S., Navarro A., Colomer D., Nadeu F., 54. Nomdedeu, Meritxell; Pereira, Arturo; Calvo, JJ, GELTAMO (Grupo Español de Linfomas y Colado E., Payer A., García-Cerecedo T., Puente Xavier; Colomer, Joan; Sole, Francesc; Arias, Trasplantes de Médula Ósea) cooperative study X., López-Otin C., Campo E., López-Guillermo A., Amparo; Gomez, Candida; Luno, Elisa; Cervera, group. Progression-free survival at 2 years Villamor N. The mutational landscape of Jose; Arnan, Montserrat; Pomares, Helena; post-autologous transplant: a surrogate small lymphocytic lymphoma compared to Ramos, Fernando; Oiartzabal, Itziar; Espinet, end point for overall survival in follicular non-early stage chronic lymphocytic Blanca; Pedro, Carme; Arrizabalaga, Beatriz; lymphoma. CANCER MEDICINE. leukemia. LEUKEMIA AND LYMPHOMA. Laura Blanco, Maria; Tormo, Mar; Maria 6(12):2766-2774. I.F.: 3.362 8:1-9. I.F.: 2.755 Hernandez-Rivas, Jesus; Diez-Campelo, Maria; Ortega, Margarita; Valcarcel, David; Cedena, 44. Magnano L., Montoto S., González-Barca E., 49. Magnano L, Martínez A, Carreras J, Maria-Teresa; Collado, Rosa; Grau, Javier; Briones J., Sancho J., Muntañola A., Salar A., Martínez-Trillos A, Giné E, Rovira J, Dlouhy I, Granada, Isabel; Sanz, Guillermo; Campo, Elias; Besalduch J., Escoda L., Moreno C., Baumann T, Balagué O, Campo E, Esteve, Jordi; Costa, Dolors;Spanish MDS Grp. Domingo-Domenech E., Estany C., Oriol A., Altés López-Guillermo A, Villamor N. T-cell subsets Clinical and biological significance of A., Pedro C., Gardella S., Asensio A., Vivancos P., in lymph nodes identify a subgroup of isolated Y chromosome loss in Fernández de Sevilla A., Ribera J., Colomer D., follicular lymphoma patients with myelodysplastic syndromes and chronic Campo E., López-Guillermo A. Long-term favorable outcome. LEUKEMIA AND myelomonocytic leukemia. A report from safety and outcome of fludarabine, LYMPHOMA. 58(4):842-850. I.F.: 2.755 the Spanish MDS Group. LEUKEMIA cyclophosphamide and mitoxantrone RESEARCH. 63:85-89. I.F.: 2.501 (FCM) regimen in previously untreated 50. Bosch, Rosa; Mora, Alba; Puy Vicente, Eva; patients with advanced follicular Ferrer, Gerardo; Jansa, Sonia; Damle, Rajendra; 55. Dlouhy I, Filella X, Rovira J, Magnano L, lymphoma: 12 years follow-up of a phase 2 Gorlatov, Sergey; Rai, Kanti; Montserrat, Emili; Rivas-Delgado A, Baumann T, Martínez-Trillos A, trial. ANNALS OF HEMATOLOGY. Nomdedeu, Josep; Pratcorona, Marta; Blanco, Balagué O, Martínez A, González-Farre B, 96(4):639-646. I.F.: 3.083 Laura; Saavedra, Silvana; Garrido, Ana; Esquirol, Karube K, Gine E, Delgado J, Campo E, Albert; Garcia, Irene; Granell, Miquel; Martino, López-Guillermo A. High serum levels of 45. Cervantes F, Correa JG, Pérez I, Rodrigo; Delgado, Julio; Sierra, Jorge; Chiorazzi, soluble interleukin-2 receptor (sIL2-R), García-Gutiérrez V, Redondo S, Colomer D, Nicholas; Moreno, Carol. FcγRIIb expression interleukin-6 (IL-6) and tumor necrosis Jiménez-Velasco A, Steegmann JL, in early stage chronic lymphocytic factor alpha (TNF) are associated with Sánchez-Guijo F, Ferrer-Marín F, Pereira A, leukemia. LEUKEMIA AND LYMPHOMA. adverse clinical features and predict poor Osorio S, CML Spanish Group (GELMC). 58(11):2642-2648. I.F.: 2.755 outcome in diffuse large B-cell lymphoma. Imatinib dose reduction in patients with LEUKEMIA RESEARCH. 59:20-25. I.F.: 2.501 chronic myeloid leukemia in sustained 51. Manasanch EE, de Larrea CF, Zingone A, deep molecular response. ANNALS OF Steinberg SM, Kwok M, Tageja N, Bhutani M, 56. Scotch A; Kosiorek H; Scherber R; Dueck A; HEMATOLOGY. 96(1):81-85. I.F.: 3.083 Kazandjian D, Roschewski M, Wu P, Carter G, Slot S; Zweegman S; Boekhorst P; Zuchlinski D, Mulquin M, Lamping L, Costello R, Commandeur S; Schouten H; Sackmann F; 46. Dlouhy I, Torrente MÁ, Lens S, Rovira J, Burton D, Gil LA, Figg WD, Maric I, Calvo KR, Fuentes A; Hernandez-Maraver D; Pahl H; Magnano L, Giné E, Delgado J, Balagué O, Yuan C, Stetler-Stevenson M, Korde N, Griesshammer M; Stegelmann F; Dohner K; Martínez A, Campo E, Forns X, Sánchez-Tapias Landgren O. Enzymatic activities of Lehmann T; Bonatz K; Reiter A; Boyer F; Etienne JM, López-Guillermo A. Clinico-biological circulating plasma proteasomes in newly G; Ianotto J; Ranta D; Roy L; Cahn J; Harrison C; characteristics and outcome of hepatitis C diagnosed multiple myeloma patients Radia D; Muxi P; Maldonado N; Besses C; virus-positive patients with diffuse large treated with carfilzomib, lenalidomide and Cervantes F; Johansson P; Barbui T; Barosi G; B-cell lymphoma treated with dexamethasone. LEUK LYMPHOMA. Vannucchi A; Paoli C; Passamonti F; Andreasson immunochemotherapy. ANNALS OF 58(3):639-645. I.F.: 2.755 B; Ferrari M; Rambaldi A. Symptom burden HEMATOLOGY. 96(3):405-410. I.F.: 3.083 profile in myelofibrosis patients with 52. Hernández-Boluda JC, Correa JG, thrombocytopenia: Lessons and unmet 47. García-Noblejas A, Cannata-Ortiz J, Conde García-Delgado R, Martínez-López J, needs. LEUKEMIA RESEARCH. 63:34-40. E, González Barca E, Gutiérrez N, Rojas R, Vidal Alvarez-Larrán A, Fox ML, García-Gutiérrez V, I.F.: 2.501 MJ, Ramírez MJ, Jiménez-Ubieto A, García-Ruiz Pérez-Encinas M, Ferrer-Marín F, JC, Sancho JM, López A, Ríos Rull P, Novelli S, Mata-Vázquez MI, Raya JM, Estrada N, García S, 57. Araujo, Zaida; Palacios, Andrea; Biomon, Albo C, Debén G, López-Guillermo A, Nicolás C, Kerguelen A, Durán MA, Albors M, Cervantes F. Ruben; Rivas-Santiago, Bruno; Judith Serrano, González de Villambrosia S, Mercadal S, Martín Predictive factors for anemia response to Carmen; Enciso-Moreno, Leonor; Ernesto García-Sancho A, Arranz R. Autologous stem erythropoiesis-stimulating agents in Lopez-Ramos, Juan; Wide, Albina; Carlos cell transplantation (ASCT) in patients with myelofibrosis. EUROPEAN JOURNAL OF Jimenez, Juan; Fernandez de larrea, Carlos; mantle cell lymphoma: a retrospective HAEMATOLOGY. 98(4):407-414. I.F.: 2.653 Antonio Enciso-Moreno, Jose. Concordance study of the Spanish lymphoma group between IFN gamma gene+874 A/T (GELTAMO). ANNALS OF HEMATOLOGY. 53. Goel S; Paoli C; Iurlo A; Pereira A; Efficace F; polymorphism and interferon-gamma 96(8):1323-1330. I.F.: 3.083 Barbui T; Tefferi A; Vannucchi A; Cervantes F. expression in a TB-endemic indigenous Socioeconomic burden of participation in setting. REVISTA DA SOCIEDADE 48. Martínez-Trillos A., Pinyol M., Delgado J., clinical trials in patients with BRASILEIRA DE MEDICINA TROPICAL. Aymerich M., Rozman M., Baumann T., myeloproliferative neoplasms. EUROPEAN 50(2):199-207. I.F.: 1.161 González-Díaz M., Hernández J., Alcoceba M., JOURNAL OF HAEMATOLOGY. 99(1):36-41. Muntañola A., Terol M., Navarro B., Giné E., Jares I.F.: 2.653

290 HEMATOLOGICAL ONCOLOGY 5.7

Review / I.F.: 21.574 4. Correa JG; Cibeira MT; Tovar N; Isola I; Duration: 01/01/2015-31/12/2018 Pedrosa F; Diaz T; Lozano E; Magnano L; Rosinol 1. Cervantes F, Pereira A. Does ruxolitinib L; Blade J; Fernandez De Larrea C. Prevalence Esteve J. Ultrasecuenciación de genes prolong the survival of patients with and prognosis implication of MYD88 candidatos en pacientes con leucemia myelofibrosis? BLOOD. 129(7):832-837. L265P mutation in IgM monoclonal mieloide aguda mediante “next generation I.F.: 13.164 gammopathy of undetermined sequencing”: pronóstico, biomarcadores, significance and smouldering análisis de long non-coding RNA. 2. Mueller, Martin C.; Cervantes, Francisco; Waldenström macroglobulinaemia. Sponsored by: Instituto de Salud Carlos III (ISCIII). Hjorth-Hansen, Henrik; Janssen, Jeroen J. W. M.; BRITISH JOURNAL OF HAEMATOLOGY. PI13/00999 Milojkovic, Dragana; Rea, Delphine; Rosti, 179(5):849-851. I.F.: 5.670 Duration: 01/01/2014-31/12/2017 Gianantonio. Ponatinib in chronic myeloid leukemia (CML): Consensus on patient 5. Puigví L, Baumann T, Fernández S, Castro P, Esteve J. Caracterización genética de la treatment and management from a Pereira A, Merino A. Massive leucemia mieloblástica aguda de riesgo European expert panel. CRITICAL erythrophagocytosis by peripheral citogenético intermedio y genotipo REVIEWS IN ONCOLOGY/HEMATOLOGY. monocytes and neutrophils in NPM1/CEBPA/FLT3-ITD triple negativo; 120:52-59. I.F.: 4.971 parvovirus-B19 autoimmune hemolytic análisis mutacional, expresión de anemia. ANNALS OF HEMATOLOGY. IncRNAs. 3. Coiras M, Ambrosioni J, Cervantes F, Miró JM, 96(5):881-882. I.F.: 3.083 Sponsored by: Instituto de Salud Carlos III (ISCIII). Alcamí J. Tyrosine kinase inhibitors: PI16/01027 potential use and safety considerations in 6. Piñeiro GJ, Nicolau C, Gaya A, Buñesch L, Duration: 01/01/2017-31/12/2019 HIV-1 infection. EXPERT OPINION ON DRUG Poch E. Role of kidney MRI to monitoring SAFETY. 16(5):547-559. I.F.: 3.439 clearance of hemosiderin deposits in Esteve J. Estudio post-autorización paroxysmal nocturnal hemoglobinuria. prospectivo de terapia adaptada al riesgo NEFROLOGIA: PUBLICACION OFICIAL DE en la leucemia mieloide aguda y síndromes Letters / I.F.: 41.042 LA SOCIEDAD ESPANOLA NEFROLOGIA. mielodisplásicos de alto riesgo: 37(2):225-227. I.F.: 1.183 importancia del perfil genómico y de la 1. Hughes TP, Leber B, Cervantes F, Spector N, enfermedad residual mínima en la Pasquini R, Clementino NCD, Schwarer AP, asignación del tratamiento. Dorlhiac-Llacer PE, Mahon FX, Rea D, Sponsored by: Generalitat de Catalunya Guerci-Bresler A, Kamel-Reid S, Bendit I, GRANTS FOR RESEARCH IN PROGRESS (PERIS). SLT002/16/00433 Acharya S, Glynos T, Dalal D, Branford S, Lipton Duration: 27/03/2017-31/12/2019 JH. Sustained deep molecular responses in Bladé J. Red Temática de Investigación patients switched to nilotinib due to Cooperativa en Cáncer. Fernández de Larrea, C. Mecanismos de persistent BCR-ABL1 on imatinib: final Sponsored by: Instituto de Salud Carlos III (ISCIII). control inmunológico involucrados en la ENESTcmr randomized trial results. RD12/0036/0046 progresión tras tratamiento en el mieloma LEUKEMIA. 31(11):2529-2531. I.F.: 11.702 Duration: 01/01/2013-30/06/2017 multiple. Sponsored by: Instituto de Salud Carlos III (ISCIII) 2. Martinez-Lopez J, Sanchez-Vega B, Barrio S, Cervantes F. Red Temática de Investigación PI16/00423 Cuenca I, Ruiz-Heredia Y, Alonso R, Rapado I, Cooperativa en Cáncer. Duration: 01/01/2017 a 31/12/2019 Marin C, Cedena M, Paiva B, Puig N, Mateos M, Sponsored by: Instituto de Salud Carlos III (ISCIII). Ayala R, Hernández M, Jimenez C, Rosiñol L, RD12/0036/0010 Fernández de Larrea, C. Reposicionamiento Martínez R, Teruel A, Gutiérrez N, Martin-Ramos Duration: 01/01/2013-30/12/2017 de la Doxiciclina en el tratamiento de la M, Oriol A, Bargay J, Bladé J, San-Miguel J, amiloidosis AL cardiaca. Garcia-Sanz R, Lahuerta J. Analytical and Cibeira MT. Afección cardíaca en la Sponsored by: Instituto de Salud Carlos III (ISCIII) clinical validation of a novel in-house amiloidosis primaria: estudio de AC16/00058 deep-sequencing method for minimal biomarcadores séricos, resonancia Duration: 01/01/2017 a 31/12/2019 residual disease monitoring in a phase II magnética Tesla y caracterización trial for multiple myeloma. LEUKEMIA. genómica de las cadenas ligeras López A. Red Temática de Investigación 31(6):1446-1449. I.F.: 11.702 amiloidogénicas. Cooperativa en Cáncer. Sponsored by: Instituto de Salud Carlos III (ISCIII). Sponsored by: Instituto de Salud Carlos III (ISCIII). 3. Navarro A, Clot G, Martínez-Trillos A, Pinyol M, PI12/01290 RD12/0036/0023 Jares P, González-Farré B, Martínez D, Trim N, Duration: 01/01/2013-30/06/2017 Duration: 01/01/2013-31/12/2017 Fernández V, Villamor N, Colomer D, Costa D, Salaverria I, Martín-Garcia D, Erber W, López C, Delgado J. Estudio piloto de la infusión de López A. Microenvironment Interactions in Jayne S, Siebert R, Dyer MJS, Wiestner A, Wilson linfocitos T autólogos modificados the Pathogenesis of Lymphoid Neoplasms WH, Aymerich M, López-Guillermo A, Sánchez À, genéticamente para expresar anti-CD19 and Chronic Inflammatory Disorders. Campo E, Matutes E, Beà S. Improved en pacientes con leucemia o linfoma Identification of Biomarkers and Design of classification of leukemic B-cell CD19+ resistente o refractario a New Therapeutic Strategies. lymphoproliferative disorders using a tratamiento. Sponsored by: Instituto de Salud Carlos III (ISCIII). transcriptional and genetic classifier. Sponsored by: Instituto de Salud Carlos III (ISCIII) PIE13/00033 HAEMATOLOGICA. 102(9):e360-e363. I.F.: 7.702 ICI 14/00122 Duration: 01/01/2014-31/12/2017

291 AREA 5 ONCOLOGY AND HAEMATOLOGY

López A./Giné E. Estudio longitudinal del perﬁl mutacional del linfoma difuso de células grandes mediante técnicas de biopsia líquida. Signiﬁcado biológico e impacto clínico. Sponsored by: Instituto de Salud Carlos III (ISCIII) PI16/00420 Duration: 01/01/2017 a 31/12/2019

Rosiñol L. Afección medular versus extramedular en el mieloma múltiple: estudio del perﬁl genético y de la expresión de citocinas/quemocinas relacionadas con angiogénesis y microambiente medular. Sponsored by: Instituto de Salud Carlos III (ISCIII). PI12/01093 Duration: 01/01/2013-30/06/2017

DOCTORAL THESES

López Guillermo A. Impacte de la cèl·lula d’origen i de la mutació de MYD88 en la resposta i supervivencia dels pacients amb linfoma difús de cèl·lues grans B. PhD student: Jordina Rovira Solé

292 PHYSIOPATHOLOGY AND MOLECULAR BASES IN HEMATOLOGY 5.8

Physiopathology and molecular bases 5.8 in hematology

PRE-DOCTORAL RESEARCHERS Anna Esteve (IDIBAPS) LOCATION Neus Gimenez (IDIBAPS) CEK building ﬂoor 2 Martina Guerrero (IDIBAPS) Victoria Gutierrez (IDIBAPS) Maria Eriong Lee (FCRB) Esther Llaudet (IDIBAPS) Alba Matas (IDIBAPS) Clara Recasens (IDIBAPS) KEYWORDS Valeria Rizzuto (IDIBAPS)

1. Lymphoid malignancies TEAM LEADER Ana Vidal (IDIBAPS) 2. Targeted therapies Dolors Colomer (HCB) 3. Clinico-biological studies T. 93 227 54 00 (Ext.: 2269) TECHNICIANS 4. Rare anemias [email protected] Sandra Cabezas (FCRB) Ariadna Giro (IDIBAPS) Laura Jiménez (FCRB)

RESEARCHERS Vanina Andrea Rodríguez (IDIBAPS) Marta Aymerich (HCB) Teresa Estrach (HCB) ADMINISTRATIVE STAFF Sonia Dominguez (IDIBAPS) Original publications Patricia Pérez (IDIBAPS) Elena Krishnevskaya (IDIBAPS) from 2015 to 2017 Gael Roue (IDIBAPS) Maria Rozman (HCB) YEAR I.F. TOTAL Q1 Q2 Neus Villamor (HCB) STRATEGIC OBJECTIVES 2015 185.97 23 17 2 Joan Lluís Vives (HCB)

2016 102.06 15 13 2 POST-DOCTORAL RESEARCHERS - Identiﬁcation of potential points of 2017 148.12 25 17 5 Aranzazu Chamorro (IDIBAPS) intervention and development of new Juan Garcia (IDIBAPS) therapeutic strategies and combination Mónica Lopez (FCRB) approaches in lymphoid malignancies. Maria del Mar Mañu (IDIBAPS) - To improve the diagnosis of lymphoid Laia Rosich (IDIBAPS) malignancies using histopathological, TEAM INVOLVED IN immunophenotypic and molecular biology RTICC technologies. AGAUR_SGR14 - To increase the efficacy of diagnosis, CIBERONC treatment and follow up of patients with rare anemias. Dolors Colomer

TEAM

293 AREA 5 ONCOLOGY AND HAEMATOLOGY

MAIN LINES OF RESEARCH Casadevall N, Valla DC, Rautou PE, Marzac C, 7. Vidal-Crespo A, Rodriguez V, French national network for vascular liver Matas-Cespedes A, Lee E, Rivas-Delgado A, 1. New targeted therapiesagainst recurrent diseases. Selective testing for calreticulin Giné E, Navarro A, Beà S, Campo E, alterations in lymphoid malignancies. gene mutations in patients with splanchnic López-Guillermo A, Lopez-Guerra M, Roué G, 2. Characterization of molecular pathways vein thrombosis: A prospective cohort Colomer D, Pérez-Galán P. The Bruton activated by microenvironment in lymphoid study. JOURNAL OF HEPATOLOGY. tyrosine kinase inhibitor CC-292 shows malignancies. 67(3):501-507. I.F.: 12.486 activity in mantle cell lymphoma and 3. New targeted therapies against synergizes with lenalidomide and NIK oncogenes, microenvironment and 3. Magnano L, Balagué O, Dlouhy I, Rovira J, inhibitors depending on nuclear factor-κB epigenetic regulators in lymphoid Karube K, Pinyol M, Rivas-Delgado A, Costa D, mutational status. HAEMATOLOGICA. malignancies. Martínez-Trillos A, González-Farre B, 102(11):e447-e451. I.F.: 7.702 4. Cytological, immunophenotypic and Martínez-Pozo A, Giné E, Colomer D, Delgado molecular study of malignant J, Villamor N, Campo E, López-Guillermo A. 8. Díaz T, Rodríguez V, Lozano E, Mena MP, hematological diseases. Development of Clinicobiological features and prognostic Calderón M, Rosiñol L, Martínez A, Tovar N, new technologies for the diagnosis and impact of diffuse large B-cell lymphoma Pérez-Galán P, Bladé J, Roué G, de Larrea CF. analysis of minimal residual disease (MRD). component in the outcome of patients with The BET bromodomain inhibitor CPI203 5. Promotion of cooperative strategies in the previously untreated follicular lymphoma. improves lenalidomide and molecular diagnostic setting of leukemias ANNALS OF ONCOLOGY. 28(11):2799-2805. dexamethasone activity in in vitro and in and lymphomas. Design and I.F.: 11.855 vivo models of multiple myeloma by implementation of internal and external blockade of Ikaros and MYC signaling. quality control programs. 4. Herman SEM, Montraveta A, Niemann CU, HAEMATOLOGICA. 102(10):1776-1784. 7. Cutaneous T and B cell lymphomas. Mora-Jensen H, Gulrajani M, Krantz F, Mantel I.F.: 7.702 Clinical, histopathological and R, Smith LL, McClanahan F, Harrington BK, immunophenotypic study. Prognostic Colomer D, Covey T, Byrd JC, Izumi R, Kaptein 9. Balsas P, Esteve-Arenys A, Roldán J, factors and epidemiology. A, Ulrich R, Johnson AJ, Lannutti BJ, Wiestner Jiménez L, Rodríguez V, Valero JG, 8. Molecular study of the congenital defects A, Woyach JA. The Bruton Tyrosine Kinase Chamorro-Jorganes A, de la Bellacasa RP, of erythrocytes and erythropoiesis, rare (BTK) Inhibitor Acalabrutinib Teixidó J, Matas-Céspedes A, Moros A, anemias, and physiopathological Demonstrates Potent On-Target Effects Martínez A, Campo E, Sáez-Borderías A, mechanisms intervening in the production and Efficacy in Two Mouse Models of Borrell JI, Pérez-Galán P, Colomer D, Roué G. and senescence of red blood cells (RBC) Chronic Lymphocytic Leukemia. CLINICAL Activity of the novel BCR kinase inhibitor as a cause of anemia or erythrocytosis. CANCER RESEARCH. 23(11):2831-2841. IQS019 in preclinical models of B-cell Analysis of rareanemias with unknown I.F.: 9.619 non-Hodgkin lymphoma. JOURNAL OF aetiology by New Generation Sequencing HEMATOLOGY AND ONCOLOGY. 10(1):80. (NGS). 5. Matas-Céspedes A, Vidal-Crespo A, I.F.: 6.350 9. Genetic and epidemiological study of Rodriguez V, Villamor N, Delgado J, Giné E, hemoglobinopathiesandthalassemias. Roca-Ho H, Menéndez P, Campo E, 10. Gonzalez-Farre B, Martinez D, Development of technologies for the López-Guillermo A, Colomer D, Roué G, Lopez-Guerra M, Xipell M, Monclus E, Rovira J, newborn screening of sickle-cell disease Wiestner A, Parren PW, Doshi P, van Bueren Garcia F, Lopez-Guillermo A, Colomo L, (SCD). JL, Pérez-Galán P. The Human CD38 Campo E, Martinez A. HHV8-related 10.Investigation of (RBC) membrane structure Monoclonal Antibody Daratumumab lymphoid proliferations: a broad spectrum and function. Shows Antitumor Activity and Hampers of lesions from reactive lymphoid Leukemia-Microenvironment Interactions hyperplasia to overt lymphoma. MOD in Chronic Lymphocytic Leukemia. PATHOL. 30(5):745-760. I.F.: 5.728 PUBLICATIONS CLINICAL CANCER RESEARCH. 23(6):1493-1505. I.F.: 9.619 11. Höring E., Montraveta A., Heine S., Kleih M., Originals / I.F.: 148.123 Schaaf L., Vöhringer M., Esteve-Arenys A., 6. Iolascon, Achille; Andolfo, Immacolata; Roué G., Colomer D., Campo E., Ott G., Aulitzky 1. De Barrios O., Gyorffy B., Barcellini, Wilma; Corcione, Francesco; W., van der Kuip H. Dual targeting of MCL1 Fernández-Aceñero M., Sánchez-Tilló E., Garcon, Loic; De Franceschi, Lucia; Pignata, and NOXA as effective strategy for Sánchez-Moral L., Siles L., Esteve-Arenys A., Claudio; Graziadei, Giovanna; Pospisilova, treatment of mantle cell lymphoma. Roué G., Casal J., Darling D., Castells A., Dagmar; Rees, David C.; de Montalembert, BRITISH JOURNAL OF HAEMATOLOGY. Postigo A.. ZEB1-induced tumourigenesis Mariane; Rivella, Stefano; Gambale, Antonella; 177(4):557-561. I.F.: 5.670 requires senescence inhibition via Russo, Roberta; Ribeiro, Leticia; Jules- activation of DKK1/mutant Vives-Corrons; Martinez, Patricia Aguilar; 12. Delgado, Julio; Bielig, Torsten; Bonet, p53/Mdm2/CtBP and repression of Kattamis, Antonis; Gulbis, Beatrice; Cappellini, Lizette; Carnero-Montoro, Elena; Puente, macroH2A1. GUT. 66(4):666-682. I.F.: 16.658 Maria Domenica; Roberts, Irene; Tamary, Xose S.; Colomer, Dolors; Bosch, Elena; Hannah; Working Study Grp Red Cells. Campo, Elias; Lozano, Francisco. Impact of 2. Poisson J, Plessier A, Kiladjian JJ, Turon F, Recommendations regarding the functional CD5 polymorphism A471V Cassinat B, Andreoli A, De Raucourt E, Goria splenectomy in hereditary hemolytic on the response of chronic lymphocytic O, Zekrini K, Bureau C, Lorre F, Cervantes F, anemias. HAEMATOLOGICA. leukaemia to conventional chemotherapy Colomer D, Durand F, Garcia-Pagan JC, 102(8):1304-1313. I.F.: 7.702 regimens.

294 PHYSIOPATHOLOGY AND MOLECULAR BASES IN HEMATOLOGY 5.8

BRITISH JOURNAL OF HAEMATOLOGY. phase. JOURNAL OF CANCER RESEARCH LEUKEMIA AND LYMPHOMA. 58(4):842-850. 177(1):142-156. I.F.: 5.670 AND CLINICAL ONCOLOGY. I.F.: 2.755 143(10):2059-2066. I.F.: 3.503 13. Alvarez-Larrán A, Senín A, 23. Böttcher S, van der Velden VHJ, Villamor Fernández-Rodríguez C, Pereira A, 18. Ceriotti, Ferruccio; Fernandez-Calle, Pilar; N, Ritgen M, Flores-Montero J, Murua Escobar Arellano-Rodrigo E, Gómez M, Ferrer-Marin F, Klee, George G.; Nordin, Gunnar; Sandberg, H, Kalina T, Brüggemann M, Grigore G, Martínez-López J, Camacho L, Colomer D, Sverre; Streichert, Thomas; Vives-Corrons, Martin-Ayuso M, Lecrevisse Q, Pedreira CE, Angona A, Navarro B, Cervantes F, Besses C, Joan-Lluis; Panteghini, Mauro;EFLM Task van Dongen JJM, Orfao A. Lot-to-lot stability Bellosillo B, Hernández-Boluda JC. Impact of Finish Grp Allocation. Criteria for assigning of antibody reagents for flow cytometry. genotype on leukaemic transformation in laboratory measurands to models for JOURNAL OF IMMUNOLOGICAL METHODS. polycythaemia vera and essential analytical performance specifications I.F.: 2.100 thrombocythaemia. BRITISH JOURNAL OF defined in the 1st EFLM Strategic HAEMATOLOGY. 178(5):764-771. I.F.: 5.670 Conference. CLINICAL CHEMISTRY AND 24. Montllor L, Mañú-Pereira MD, LABORATORY MEDICINE. 55(2):189-194. Llaudet-Planas E, Gómez Ramírez P, Sevilla 14. Casabonne D, Gracia E, Espinosa A, I.F.: 3.432 Navarro J, Vives-Corrons JL. Red cell Bustamante M, Benavente Y, Robles C, pyruvate kinase deficiency in Spain: A Costas L, Alonso E, Gonzalez-Barca E, 19. Magnano L., Montoto S., González-Barca study of 15 cases. MEDICINA CLINICA. Tardón A, Dierssen-Sotos T, Vázquez EG, E., Briones J., Sancho J., Muntañola A., Salar A., 148(1):23-27. I.F.: 1.125 Aymerich M, Campo E, Jiménez-Moleón JJ, Besalduch J., Escoda L., Moreno C., Marcos-Gragera R, Castaño-Vinyals G, Domingo-Domenech E., Estany C., Oriol A., 25. Varo R, Sitoe A, Cossa A, Ordi J, Rozman Aragones N, Pollan M, Kogevinas M, Urtiaga C, Altés A., Pedro C., Gardella S., Asensio A., M, Bassat Q. Leukoerythroblastosis in a Amiano P, Moreno V, de Sanjose S. Fruit and Vivancos P., Fernández de Sevilla A., Ribera J., Young Child with Severe Malaria and vegetable intake and vitamin C transporter Colomer D., Campo E., López-Guillermo A. Superimposed Gram Negative Infection. gene (SLC23A2) polymorphisms in Long-term safety and outcome of JOURNAL OF TROPICAL PEDIATRICS. chronic lymphocytic leukaemia. fludarabine, cyclophosphamide and I.F.: 1.093 EUROPEAN JOURNAL OF NUTRITION. mitoxantrone (FCM) regimen in previously 56(3):1123-1133. I.F.: 4.370 untreated patients with advanced follicular lymphoma: 12 years follow-up of a phase 2 Review / I.F.: 3.876 15. Body S, Esteve-Arenys A, Miloudi H, trial. ANNALS OF HEMATOLOGY. Recasens-Zorzo C, Tchakarska G, Moros A, 96(4):639-646. I.F.: 3.083 1. Tripathi R, Lee-Verges E, Higashi M, Bustany S, Vidal-Crespo A, Rodriguez V, Gimenez N, Rosich L, Lopez-Guerra M, Lavigne R, Com E, Casanova I, Mangues R, 20. Cervantes F, Correa JG, Pérez I, Colomer D. New drug discovery Weigert O, Sanjuan-Pla A, Menéndez P, Marcq García-Gutiérrez V, Redondo S, Colomer D, approaches targeting recurrent mutations B, Picquenot JM, Pérez-Galán P, Jardin F, Jiménez-Velasco A, Steegmann JL, in chronic lymphocytic leukemia. EXPERT Roué G, Sola B. Cytoplasmic cyclin D1 Sánchez-Guijo F, Ferrer-Marín F, Pereira A, OPINION ON DRUG DISCOVERY. controls the migration and invasiveness of Osorio S, CML Spanish Group (GELMC). 12(10):1041-1052. I.F.: 3.876 mantle lymphoma cells. SCIENTIFIC Imatinib dose reduction in patients with REPORTS. 7(1):13946. I.F.: 4.259 chronic myeloid leukemia in sustained deep molecular response. ANNALS OF Letters / I.F.: 25.703 16. Hertz, Laura; Huisjes, Rick; Llaudet-Planas, HEMATOLOGY. 96(1):81-85. I.F.: 3.083 Esther; Petkova-Kirova, Polina; Makhro, Asya; 1. Navarro A, Clot G, Martínez-Trillos A, Pinyol Danielczok, Jens G.; Egee, Stephane; del Mar 21. Martínez-Trillos A., Pinyol M., Delgado J., M, Jares P, González-Farré B, Martínez D, Trim Manu-Pereira, Maria; van Wijk, Richard; Vives Aymerich M., Rozman M., Baumann T., N, Fernández V, Villamor N, Colomer D, Costa Corrons, Joan-Lluis; Bogdanova, Anna; González-Díaz M., Hernández J., Alcoceba M., D, Salaverria I, Martín-Garcia D, Erber W, Kaestner, Lars. Is Increased Intracellular Muntañola A., Terol M., Navarro B., Giné E., López C, Jayne S, Siebert R, Dyer MJS, Calcium in Red Blood Cells a Common Jares P., Beà S., Navarro A., Colomer D., Nadeu Wiestner A, Wilson WH, Aymerich M, Component in the Molecular Mechanism F., Colado E., Payer A., García-Cerecedo T., López-Guillermo A, Sánchez À, Campo E, Causing Anemia? FRONTIERS IN Puente X., López-Otin C., Campo E., Matutes E, Beà S. Improved classification of PHYSIOLOGY. 8:673. I.F.: 4.134 López-Guillermo A., Villamor N. The leukemic B-cell lymphoproliferative mutational landscape of small lymphocytic disorders using a transcriptional and 17. Steegmann J; Colomer D; lymphoma compared to non-early stage genetic classifier. HAEMATOLOGICA. Gómez-Casares M; Garcia-Gutierrez V; Orti chronic lymphocytic leukemia. LEUKEMIA 102(9):e360-e363. I.F.: 7.702 G; Ramírez-Payer A; Olavarría E; Vall-Llovera AND LYMPHOMA. 8:1-9. I.F.: 2.755 F; Giraldo P; Conde E; Vallansot R; 2. Ortiz-Maldonado V, Villamor N, Baumann T, López-Lorenzo J; Palomera L; Alvarez-Larran 22. Magnano L, Martínez A, Carreras J, Aymerich M, Magnano L, Mozas P, A; Conesa V; Bautista G; Casas L; Giles F; Martínez-Trillos A, Giné E, Rovira J, Dlouhy I, Rivas-Delgado A, Martínez-Trillos A, Giné E, Hochhaus A; Casado-Montero L. An analysis Baumann T, Balagué O, Campo E, Campo E, López-Guillermo A, Delgado J. Is of the kinetics of molecular response López-Guillermo A, Villamor N. T-cell subsets there a role for minimal residual disease during the first trimester of treatment with in lymph nodes identify a subgroup of monitoring in the management of patients nilotinib in newly diagnosed chronic follicular lymphoma patients with with hairy-cell leukaemia? BRITISH myeloid leukemia patients in chronic favorable outcome. JOURNAL OF HAEMATOLOGY. I.F.: 5.670

295 AREA 5 ONCOLOGY AND HAEMATOLOGY

3. Mañú Pereira MD, Ropero P, Loureiro C, Pérez-Galán P. Targeting proliferation and Vives Corrons JL. Low affinity tumor-microenvironment interactions hemoglobinopathy (Hb Vigo) due to a new using bifunctional compounds against mutation of beta globin gene (c200 A>T; cannabinoid and chemokine receptors. Lys>Ile). A cause of rare anemia Sponsoredby: Fundació la Marató de TV3. misdiagnosis. AMERICAN JOURNAL OF 20132630. HEMATOLOGY. 92(4):E38-E40. I.F.: 5.275 Duration: 27/05/2014-26/05/2017.

4. Combalia, A.; Fusta, X.; Guilabert, A.; Perez-Galán P. Crosstalk between Mascaro, J. M., Jr.; Estrach, T. lymphocytes and their microenvironment Hyperbilirubinaemia: the common in chronic inflammatory diseases and denominator of yellow urticaria. JOURNAL lymphoproliferative disorders as a target OF THE EUROPEAN ACADEMY OF for new therapeutic intervention. DERMATOLOGY AND VENEREOLOGY. Sponsoredby: Ministerio de Economía y 31(12):E533-E533. I.F.: 3.528 Competitividad. SAF2014-57708-R. Duration: 01/01/2015-31/12/2017 5. Combalia, A.; Fusta, X.; Guilabert, A.; Mascaro, J. M., Jr.; Estrach, T. Yellow Pérez-Galán P. Microenvironment urticaria: report of two cases and review of Interactions in the Pathogenesis of the literature. JOURNAL OF THE Lymphoid Neoplasms and Chronic EUROPEAN ACADEMY OF DERMATOLOGY Inflammatory Disorders.Identification of AND VENEREOLOGY. 31(4):E204-E206. Biomarkers and Design of New I.F.: 3.528 Therapeutic Strategies. Sponsoredby: Instituto de Salud Carlos III (ISCIII). PIE13/00033. Editorial / I.F.: 3.834 Duration: 01/01/2014-31/12/2017

1. Camprubi, Daniel; Requena-Mendez, Ana; Roué G. El eje de señalización MYC-EZH2 Rodriguez, Natalia; Eugenia Valls, M.; como nueva diana terapéutica en los Garcia-Herrera, Adriana; Estrach, Teresa; linfomas B de origen centrogerminal. Fusta, Xavier; Garcia-Bernalt Diego, Juan; Sponsoredby: Instituto de Salud Carlos III. Fernandez-Soto, Pedro; Munoz, Jose. A PI15/00102 38-year-old woman with zosteriform skin Duration: 01/01/2016-31/12/2018 lesions. PLOS NEGLECTED TROPICAL DISEASES. 11(11):e0005906. I.F.: 3.834

DOCTORAL THESES

GRANTS FOR RESEARCH IN PROGRESS Perez-Galan P, Campo E. Targeting the crosstalk between tumor cells and Colomer D. Red Temática de Investigación microenvironment: a new therapeutic Cooperativa en Cáncer. approach for the treatment of lymphoid Sponsored by: Instituto de Salud Carlos III neoplasms. (ISCIII). RD12/0036/0004. PhD student: Anna Vidal Crespo Duration: 01/01/2013-30/07/2017 Roué G. Innovative targeted therapies for Colomer D. Estrategias terapéuticas chemo-refractory B cell non-Hodgkin dirigidas contra la heterogeneidad lymphomas. molecular y la resistencia en leucemia PhD student: Anna Esteve Arenys linfática crónica y linfoma de células del manto. Sponsored by: Ministerio de Economía y Competitividad. SAF2015-67633-R Duration: 01/01/2016-31/12/2018

Colomer D. Identiﬁcació de noves estratègies terapéutiques en la leucèmia limfàtica crònica (LLC). Sponsored by: Universitat de Barcelona. 2015-DI-075 Duration: 01/04/2016-31/03/2019

296 HEMOTHERAPY – HEMOSTASIS 5.9 5.9 Hemotherapy - hemostasis

STRATEGIC OBJECTIVES

LOCATION 1. Mechanisms regulating blood cell function HCB building and their interactions with the vascular wall.

2. Characterization of bleeding and thrombotic phenotypes and genotypes. Evaluation of pharmacological/transfusional therapies. KEYWORDS 1. Platelets TEAM LEADER 3. Analysis of the efficacy and safety of new 2. Coagulation Ginés Escolar (HCB) strategies for sparing blood component 3. Thrombosis T. 93 227 54 00 (Ext.: 2571) transfusions. 4. Transfusion [email protected] 5. Aphaeresis 4. Laboratory and animal models of hemostasis. RESEARCHERS Joan Cid (HCB) Maribel Díaz-Ricart (HCB) MAIN LINES OF RESEARCH Pablo García de Frutos (CSIC) Original publications Miguel Lozano (HCB) 1. Study of the molecular mechanisms from 2015 to 2017 Anna M. Merino (HCB) involved in the development of bleeding Juan Monteagudo (HCB) and thrombotic disorders. YEAR I.F. TOTAL Q1 Q2 Artur Pereira (HCB) 2. 2015 75.80 22 99 Juan Carlos Reverter (HCB) Characterization of endothelial dysfunction Cristina Chantal Sanz (HCB) in association with stem cell transplantation 2016 116.91 25 14 5 Mª Dolors Tassies (HCB) and development of early complications. 2017 103.98 23 14 5 Search for biomarkers of graft-versus-host POST-DOCTORAL RESEARCHERS disease (GVHD). Irene López (IDIBAPS) 3. Diagnosis and treatment of thrombotic PRE-DOCTORAL RESEARCHERS microangiopathies. TEAM INVOLVED IN Sara Fernández (HCB) AGAUR_SGR14 Dídac Jerez (FCRB) 4. Evaluation of the physiological and AGAUR_SGR17 Sergi Torramade (IDIBAPS) pathological implications of circulating Barcelona endothelium team BET and/or platelet associated procoagulant TECHNICIANS microparticles in atherothrombosis. Patricia Molina (HCB) Marcos Pino (HCB) Ginés Escolar

TEAM

297 AREA 5 ONCOLOGY AND HAEMATOLOGY

5. New strategies for the treatment of 4. Alvarez-Larrán A, Senín A, Hernandez-Rivas, Jesus; Spanish Grp combined humoral immunity in therapeutic Fernández-Rodríguez C, Pereira A, Myelodysplastic. Multidimensional apheresis. Arellano-Rodrigo E, Gómez M, Ferrer-Marin F, assessment of patient condition and Martínez-López J, Camacho L, Colomer D, mutational analysis in peripheral blood, as 6. Evaluation of the participation of Angona A, Navarro B, Cervantes F, Besses C, tools to improve outcome prediction in serotoninergic and purinergic mechanisms Bellosillo B, Hernández-Boluda JC. Impact of myelodysplastic syndromes: A in platelet function. Study of the genotype on leukaemic transformation in prospective study of the Spanish MDS antithrombotic potential of polycythaemia vera and essential group. AMERICAN JOURNAL OF pharmacological inhibitors. thrombocythaemia. BRITISH JOURNAL OF HEMATOLOGY. 92(9):E534-E541. I.F.: 5.275 HAEMATOLOGY. 178(5):764-771. I.F.: 5.670 7. Role of the phenotype/genotype of 10. Schieber R, Lasserre F, Hans M, fibrinolysis and its repercussions upon 5. Lopez-Vilchez, Irene; Jerez-Dolz, Didac; Fernández-Yagüe M, Díaz-Ricart M, Escolar global or specific functional tests in Diaz-Ricart, Maribel; Navarro, Victor; Zafar, M. G, Ginebra MP, Mücklich F, Pegueroles M. hemorrhagic and thrombotic pathology. Urooj; Zamorano-Leon, Javier; Lopez-Farre, Direct Laser Interference Patterning of Antonio; Badimon, Juan J.; Gasto, Cristobal; CoCr Alloy Surfaces to Control Endothelial 8. Implications of the GAS6 vitamin Escolar, Gines. Escitalopram Impairs Cell and Platelet Response for K-dependent protein in hemostasis and the Thrombin-Induced Platelet Response, Cardiovascular Applications. ADVANCED vascular wall, in knockout mice. Cytoskeletal Assembly and Activation of HEALTHCARE MATERIALS. 6(19):e1700327. Associated Signalling Pathways. I.F.: 5.110 9. Evaluation of antidotes to reverse the THROMBOSIS AND HAEMOSTASIS. anticoagulant action of the new oral 117(12):2312-2321. I.F.: 5.627 11. Munrós J, Martínez-Zamora MA, Tàssies D, antithrombotic agents. Coloma JL, Torrente MA, Reverter JC, 6. Urooj Zafar M., Baber U., Smith D., Sartori S., Carmona F, Balasch J. Total circulating Contreras J., Rey-Mendoza J., microparticle levels are increased in PUBLICATIONS Linares-Koloffon C., Escolar G., Mehran R., patients with deep infiltrating Fuster V., Badimon J. Antithrombotic endometriosis. HUM REPROD. Originals / I.F.: 103.979 potency of ticagrelor versus clopidogrel in 32(2):325-331. I.F.: 5.020 type-2 diabetic patients with 1. Vilaseca M., García-Calderó H., Lafoz E., cardiovascular disease. THROMBOSIS 12. Serafin, V.; Torrente-Rodriguez, R. M.; García-Irigoyen O., Avila M., Reverter J., Bosch AND HAEMOSTASIS. 117(10):1981-1988. Batlle, M.; Garcia de Frutos, P.; Campuzano, S.; J., Hernández-Gea V., Gracia-Sancho J., I.F.: 5.627 Yanez-Sedeno, P.; Pingarron, J. M. García-Pagán J. The anticoagulant Comparative evaluation of the rivaroxaban lowers portal hypertension in 7. Serafin, V.; Torrente-Rodriguez, R. M.; Batlle, performance of electrochemical cirrhotic rats mainly by deactivating M.; Garcia de Frutos, P.; Campuzano, S.; immunosensors using magnetic hepatic stellate cells. HEPATOLOGY. Yanez-Sedeno, P.; Pingarron, J. M. microparticles and nanoparticles. 65(6):2031-2044. I.F.: 13.246 Electrochemical immunosensor for Application to the determination of receptor tyrosine kinase AXL using tyrosine kinase receptor AXL. 2. Zafar, M. Urooj; Smith, Donald A.; Baber, poly(pyrrolepropionic acid)-modified MIKROCHIMICA ACTA. 184(11):4251-4258. Usman; Sartori, Samantha; Chen, Kevin; Lam, disposable electrodes. SENSORS AND I.F.: 4.580 David W.; Linares-Koloffon, Carlos A.; ACTUATORS, B: CHEMICAL. 240:1251-1256. Rey-Mendoza, Juan; Britez, Gustavo Jimenez; I.F.: 5.401 13. Lopez-Ruiz, Elena; Venkateswaran, Escolar, Gines; Fuster, Valentin; Badimon, Seshasailam; Peran, Macarena; Jimenez, Juan J. Impact of Timing on the Functional 8. Nomdedeu M, Pereira A, Ramos F, Gema; Pernagallo, Salvatore; Diaz-Mochon, Recovery Achieved With Platelet Valcárcel D, Costa D, Arnan M, Calvo X, Juan J.; Tura-Ceide, Olga; Arrebola, Francisco; Supplementation After Treatment With Pomares H, Luño E, Díaz-Campelo M, Collado Melchor, Juan; Soto, Juan; Rus, Guillermo; Ticagrelor. CIRCULATION: R, de Paz R, Falantes JF, Pedro C, Marco J, Real, Pedro J.; Diaz-Ricart, Maria; CARDIOVASCULAR INTERVENTIONS. 10(8): Oirtzabal I, Sánchez-García J, Tormo M, Conde-Gonzalez, Antonio; Bradley, Mark; e005120. I.F.: 6.598 Cedena MT, Nomdedeu B, Sanz G, Spanish Marchal, Juan A. Poly (ethylmethacrylate- MDS Group. Excess mortality in the co- diethylaminoethyl acrylate) coating 3. López-García A, Rovira M, myelodysplastic syndromes. AMERICAN improves endothelial repopulation, Jauregui-Amezaga A, Marín P, Barastegui R, JOURNAL OF HEMATOLOGY. 92(2):149-154. bio-mechanical and anti-thrombogenic Salas A, Ribas V, Feu F, Elizalde JI, I.F.: 5.275 properties of decellularized carotid arteries Fernández-Avilés F, Martínez C, Gutiérrez G, for blood vessel replacement. SCIENTIFIC Rosiñol L, Carreras E, Urbano A, Lozano M, Cid J, 9. Ramos, Fernando; Robledo, Cristina; REPORTS. 7(1):407. I.F.: 4.259 Suárez-Lledó M, Masamunt MC, Comas D, Pereira, Arturo; Pedro, Carmen; Benito, Rocio; Giner A, Gallego M, Alfaro I, Ordás I, Panés J, de Paz, Raquel; del Rey, Monica; Insunza, 14. Mir E, Palomo M, Rovira M, Pereira A, Escolar Ricart E. Autologous Hematopoietic Stem Andres; Tormo, Mar; Diez-Campelo, Maria; G, Penack O, Holler E, Carreras E, Diaz-Ricart M. Cell Transplantation for Refractory Crohn's Xicoy, Blanca; Salido, Eduardo; Endothelial damage is aggravated in acute Disease: Efficacy in a Single-Centre Cohort. Sanchez-del-Real, Javier; Arenillas, Leonor; GvHD and could predict its development. JOURNAL OF CROHNS AND COLITIS. Florensa, Lourdes; Luno, Elisa; del Canizo, BONE MARROW TRANSPLANTATION. 11(10):1161-1168. I.F.: 5.813 Consuelo; Sanz, Guillermo F.; Maria 52(9):1317-1325. I.F.: 3.874

298 HEMOTHERAPY – HEMOSTASIS 5.9

15. Yazer MH, Lozano M, Fung M, Kutner J, loss in myelodysplastic syndromes and Vox Sanguinis International Forum on Murphy MF, Oveland Apelseth T, Pog?ód R, chronic myelomonocytic leukemia. A platelet cryopreservation: Summary. VOX Selleng K, Tinmouth A, Wendel S, Yahalom V, report from the Spanish MDS Group. SANGUINIS. 112(7):684-688. I.F.: 2.192 Biomedical Excellence for Safer LEUKEMIA RESEARCH. 63:85-89. I.F.: 2.501 Transfusion (BEST) Collaborative. An international survey on the role of the 21. Van der Meer, P. F.; Devine, D. V.; Biomed Editorial / I.F.: 18.742 hospital transfusion committee. Excellence Safer. Alternatives in blood TRANSFUSION. 57(5):1280-1287. I.F.: 3.386 operations when choosing non-DEHP 1. Diaz-Ricart, Maribel. Indoxyl sulfate, a bags. VOX SANGUINIS. 112(2):183-184. uremic trigger for platelets. BLOOD. 16. Cervantes F, Correa JG, Pérez I, I.F.: 2.192 129(19):2599-2600. I.F.: 13.164 García-Gutiérrez V, Redondo S, Colomer D, Jiménez-Velasco A, Steegmann JL, 22. Romon I, Lozano M. Quality indicators 2. Mustieles, Maria-Jesus; Jimenez, Maria; Sánchez-Guijo F, Ferrer-Marín F, Pereira A, for Transfusion Medicine in Spain: a survey Robles, Veronica; Chamorro, Vanessa; Osorio S, CML Spanish Group (GELMC). among hospital transfusion services. Pereira, Arturo. Closer than expected: Imatinib dose reduction in patients with BLOOD TRANSFUSION. 15(7):207-214. central vein catheters and perplexing chronic myeloid leukemia in sustained I.F.: 1.607 laboratory results. TRANSFUSION. deep molecular response. ANNALS OF 57(3):499-500. I.F.: 3.386 HEMATOLOGY. 96(1):81-85. I.F.: 3.083 23. Meler, Eva; Porta, Roser; Canals, Carme; Serra, Bernat; Lozano, Miguel. Fatal 3. Cohn C., Dumont L., Lozano M., Marks D., 17. Castellanos M., Guillem-Marti J., alloimmune thrombocytopenia due to Johnson L., Ismay S., Bondar N., T'Sas F., Mas-Moruno C., Díaz-Ricart M., Escolar G., anti-HLA alloimmunization in a twin Yokoyama A., Kutner J., Acker J., Bohonek M., Ginebra M., Gil F., Pegueroles M., Manero J. pregnancy: A very infrequent complication Sailliol A., Martinaud C., Pog?ód R., Cell adhesive peptides functionalized on of assisted reproduction. TRANSFUSION Antoniewicz-Papis J., Lachert E., Pun P., Lu J., CoCr alloy stimulate endothelialization and AND APHERESIS SCIENCE. 56(2):165-167. Cid J., Guijarro F., Puig L., Gerber B., Alberio L., prevent thrombogenesis and restenosis. I.F.: 1.300 Schanz U., Buser A., Noorman F., Zoodsma M., JOURNAL OF BIOMEDICAL MATERIALS van der Meer P., de Korte D., Wagner S., O'Neill RESEARCH - PART A. 105(4):973-983. M. Vox Sanguinis International Forum on I.F.: 3.076 Review / I.F.: 15.356 platelet cryopreservation. VOX SANGUINIS. 112(7):e69-e85. I.F.: 2.192 18. Pujadas-Mestres L., Lopez-Vilchez I., 1. Cervantes F, Pereira A. Does ruxolitinib Arellano-Rodrigo E., Reverter J., Lopez-Farre prolong the survival of patients with A., Diaz-Ricart M., Badimon J., Escolar G. myelofibrosis? BLOOD. 129(7):832-837. Differential inhibitory action of apixaban I.F.: 13.164 GRANTS FOR RESEARCH IN PROGRESS on platelet and fibrin components of forming thrombi: Studies with circulating 2. Cid J. Prevention of Diaz Ricart, M. Caracterización genética e blood and in a platelet-based model of transfusion-associated graft-versus-host identificación de nuevos genes diana en el thrombin generation. PLOS ONE. disease with pathogen-reduced platelets diagnóstico de las anemias congénitas no 12(2):e0171486. I.F.: 2.806 with amotosalen and ultraviolet A light: a filiadas. review. VOX SANGUINIS. 112(7):607-613. Sponsored by: Instituto de Salud Carlos III 19. Goel S; Paoli C; Iurlo A; Pereira A; Efficace I.F.: 2.192 (ISCIII). PI14/00772 F; Barbui T; Tefferi A; Vannucchi A; Cervantes Duration: 01/01/2015-30/09/2018 F. Socioeconomic burden of participation in clinical trials in patients with Letters / I.F.: 5.275 Escolar G. Redes Temáticas de Investigación myeloproliferative neoplasms. EUROPEAN Cooperativa en Salud). Cardiovascular JOURNAL OF HAEMATOLOGY. 99(1):36-41. 1. Puigví L, Baumann T, Fernández S, Castro P, Research Network (RIC). Research I.F.: 2.653 Pereira A, Merino A. Massive programme on Genetic and environmental erythrophagocytosis by peripheral determinants of vascular dysfunction. 20. Nomdedeu, Meritxell; Pereira, Arturo; monocytes and neutrophils in HEMATO-IDIBAPS group Calvo, Xavier; Colomer, Joan; Sole, Francesc; parvovirus-B19 autoimmune hemolytic (RD12-0042-0016). Arias, Amparo; Gomez, Candida; Luno, Elisa; anemia. ANNALS OF HEMATOLOGY. Sponsored by: Instituto de Salud Carlos III (ISCIII). Cervera, Jose; Arnan, Montserrat; Pomares, 96(5):881-882. I.F.: 3.083 RD12/0042/0016. Helena; Ramos, Fernando; Oiartzabal, Itziar; Duration: 01/01/2013-31/10/2018 Espinet, Blanca; Pedro, Carme; Arrizabalaga, 2. Cohn, C. S.; Dumont, L. J.; Lozano, M.; Marks, Beatriz; Laura Blanco, Maria; Tormo, Mar; D. C.; Johnson, L.; Ismay, S.; Bondar, N.; T'Sas, Escolar G. El sistema serotoninergico en el Maria Hernandez-Rivas, Jesus; Diez- F.; Yokoyama, A. P. H.; Kutner, J. M.; Acker, J. P.; desarrollo de un fenotipo protrombótico Campelo, Maria; Ortega, Margarita; Valcarcel, Bohonek, M.; Sailliol, A.; Martinaud, C.; Poglod, plaquetario: terapias antitrombóticas David; Cedena, Maria-Teresa; Collado, Rosa; R.; Antoniewicz-Papis, J.; Lachert, E.; Pun, P. B. basadas en la modulación farmacológica de Grau, Javier; Granada, Isabel; Sanz, Guillermo; L.; Lu, J.; Cid, J.; Guijarro, F.; Puig, L.; Gerber, B.; la recaptación serotonina y sus receptores. Campo, Elias; Esteve, Jordi; Costa, Dolors; Alberio, L.; Schanz, U.; Buser, A.; Noorman, F.; Sponsored by: Instituto de Salud Carlos III (ISCIII). Spanish MDS Grp. Clinical and biological Zoodsma, M.; van der Meer, P. F.; de Korte, D.; PI13/00517. significance of isolated Y chromosome Wagner, S.; O'Neill, M. Duration: 01/01/2014-31/08/2018

299 AREA 5 ONCOLOGY AND HAEMATOLOGY

Escolar G (IP: García Pagán JC).Targeting endothelial dysfunction in highly prevalent diseases: characterization and validation of prognostic biomarkers and identiﬁcation of potential therapeutic strategies. Sponsored by: MINECO- Instituto de Salud Carlos III (ISCIII). PIE15/00027 Duration: 01/01/2016-31/12/2018

Escolar G. Microchip-based point of care devices for a global evaluation of hemostasis under ﬂow conditions: application to the screening of bleeding, thrombosis and monitoring of antithrombotic therapies. Sponsored by: Instituto de Salud Carlos III (ISCIII). DTS16/00133. Duration: 01/01/2017-31/12/2018

García de Frutos P/Morales A. Regulación terapéutica de la transición EMT/MET y la quimioresistencia en la enfermedad hepática crónica. Sponsored by: Ministerio de Economía y Competitividad (MINECO). SAF2015-66515-R Duration: 01/01/2016-31/12/2018

García de Frutos P/Hidalgo A/Ortíz JT. Role of resident macrophages and ﬁbroblasts on heart remodeling and healing after myocardial infarction: the contribution of the GAS6-TAM system. Sponsored by: Fundació La Marató de TV3. 201530 30 31 32 Duration: 01/01/2016-31/12/2018

DOCTORAL THESES

Escolar G, López I. Apixaban en la prevención de complicaciones trombóticas: Mecanismos adicionales de su acción antihemostática. PhD student: Lluís Pujades Mestres

Díaz-Ricart M, Escolar G. Inﬂamación, estrés oxidativo y sistema inmune en el desarrollo de disfunción endotelial asociada a enfermedades inﬂamatorias crónicas. PhD student: Susana Martín Rodríguez

300 MOLECULAR AND TRANSLATIONAL ONCOLOGY 5.10

Molecular and 5.10 translational oncology

STRATEGIC OBJECTIVES

LOCATION The overall objective of our team is to CELLEX building 1A understand how the microenvironment, in particular the nervous system, interacts with and influences tumour cells metabolism, proliferation or survival and how these mechanisms contribute to breast cancer progression and therapy resistance. KEYWORDS We want to identify new biomarkers and 1. Inflammation and neuropeptides TEAM LEADER therapeutic targets that could be transferred 2. Tumor microenvironment Pere Gascón (HCB) to the clinical practice. 3. Cell dormancy T. 93 227 54 02 4. Chemotherapy resistance [email protected] 5. Tumor heterogeneity MAIN LINES OF RESEARCH 6. Epigenetic plasticity RESEARCHERS 1. Stress and microenvironment Juan José Grau (HCB) influences in breast cancer.

POST-DOCTORAL RESEARCHERS - Study the role of neuropeptides and Paloma Bragado (IDIBAPS) neurotransmitters in the control of breast Original publications Patricia Fernandez (IDIBAPS) cancer progression. Gemma Fuster (IDIBAPS) - Evaluate the potential of different from 2015 to 2017 Mario Mancino (FCRB) components of the microenvironment such YEAR I.F. TOTAL Q1 Q2 as ﬁbroblasts or bone marrow PRE-DOCTORAL RESEARCHERS mesenchymal stem cells on the generation 2015 34.39 6 6 - Núria Moragas (IDIBAPS) of breast cancer heterogeneity. 2016 69.47 14 1 - Aleix Noguera (UB) - Analyse the role of several stress factors, 2017 23.62 6 2 1 Leire Recalde (UB) such as cathecolamines, glucocorticoids, hormones and neural related system TECHNICIANS factors in the transition of carcinoma ductal Miriam Badia (FCRB) in situ to invasive. Patricia Jauregui (FCRB) TEAM INVOLVED IN Anna López (FCRB) 2. Microenvironmental mechanisms of AGAUR_SGR14 tumour dormancy and metastasis. AGAUR_SGR17 ADMINISTRATIVE STAFF Darya Kulyk (FCRB) - Determine the role of the TAC1 gene in the metastatic process in breast cancer. COLLABORATORS - Study the role of the microenvironment on Mª Ángeles Sierra (IDIBAPS) disseminated tumour cells dormancy, Pere Gascón

TEAM

301 AREA 5 ONCOLOGY AND HAEMATOLOGY

survival and progression to metastasis. (LA-EP2006) compared with reference Gascón P. Red Temática de Investigación - Metastasis pathogenesis. pegfilgrastim in Asian patients with breast Cooperativa en Cáncer. cancer: an exploratory comparison from Sponsored by: Instituto de Salud Carlos III 3. Tumor resistance mechanisms: two Phase III trials. FUTURE ONCOLOGY. (ISCIII). RD12/0036/0055 13(16):1385-1393. I.F.: 2.131 Duration: 01/01/2013-31/12/2017 - Characterization of the mechanisms of epigenetic adaptation and cellular plasticity 6. Santolaya M, Aldea M, Grau J, Estrada M, Gascón P. Descubrimiento y desarollo during the adquisition of chemoresistance. Barau M, Buron A, Francesc M, Castell A, biomarcadores innovadores para - Study the mechanisms of tumour Rodriguez C, Gascón P, Rius P, medicina personalizada y terapias para el progression in breast cancer HER2+ Guayta-Escolies R, PROCOLON research tratamiento eficaz del cáncer de pulmón. induced by the acquisition of resistance to group (all members of this group are listed in Sponsored by: Ministerio de Economía y Trastuzumab and Lapatinib. Role of Author Note). Evaluating the Competitividad (MINECO). RTC-2014-1532-1 fibroblasts on antiHER therapies appropriateness of a community Duration: 01/02/2014-31/12/2017 resistance . pharmacy model for a colorectal cancer screening program in Catalonia (Spain). Gascón P. Role of neuropeptides and JOURNAL OF ONCOLOGY PHARMACY neurotransmitters in the regulation of PRACTICE. 23(1):26-32. I.F.: 1.735 tumorigenesis, disseminated tumour cells PUBLICATIONS biology and metastasis in breast cancer. Sponsored by: Instituto de Salud Carlos III Originals / I.F.: 23.624 Review / I.F.: 2.246 (ISCIII). PI15/00661 Duration: 01/01/2016-31/12/2018 1. Blackwell K, Gascon P, Jones CM, Nixon A, 1. Barni S., Gascòn P., Petrelli F., García-Erce J., Krendyukov A, Nakov R, Li Y, Harbeck N. Pedrazzoli P., Rosti G., Giordano G., Mafodda Pooled analysis of two randomized, A., Múñoz M. Position paper on double-blind trials comparing proposed management of iron deficiency in adult biosimilar LA-EP2006 with reference cancer patients. EXPERT REV HEMATOL. pegfilgrastim in breast cancer. ANNALS OF 10(8):685-695. I.F.: 2.246 ONCOLOGY. 28(9):2272-2277. I.F.: 11.855

2. Aapro M, Bokemeyer C, Ludwig H, Gascón Editorial / I.F.: 3.144 P, Boccadoro M, Denhaerynck K, Gorray M, Krendyukov A, MacDonald K, Abraham I. 1. Teles Alves I, Cohen N, Ersan P, Eyre R, Chemotherapy-induced (febrile) Godet I, Holovanchuk D, Jackstadt R, neutropenia prophylaxis with biosimilar Kyjacova L, Mahal K, Noguera-Castells A, filgrastim in elderly versus non-elderly Recalde-Percaz L, Sleeman J. EACR-MRS cancer patients: Patterns, outcomes, and conference on Seed and Soil: In Vivo determinants (MONITOR-GCSF study). J Models of Metastasis. CLINICAL AND GERIATR ONCOL. 8(2):86-95. I.F.: 2.852 EXPERIMENTAL METASTASIS. 34(8):449-456. I.F.: 3.144 3. Bokemeyer C, Gascón P, Aapro M, Ludwig H, Boccadoro M, Denhaerynck K, Gorray M, Krendyukov A, Abraham I, MacDonald K. Clinical Guidelines / I.F.: 2.353 Over- and under-prophylaxis for chemotherapy-induced (febrile) 1. Guillem, V.; Camps, C.; Carrato, A.; neutropenia relative to evidence-based Diaz-Rubio, E.; Gascon, P. European edition guidelines is associated with differences in of the NCCN clinical practice guidelines: outcomes: findings from the relevance of the translation and adaptation MONITOR-GCSF study. SUPPORT CARE into Spanish. CLINICAL AND CANCER. 25(6):1819-1828. I.F.: 2.698 TRANSLATIONAL ONCOLOGY. 19(3):288-290. I.F.: 2.353 4. Aya F, Fernandez-Martinez A, Gaba L, Victoria I, Tosca M, Pineda E, Gascon P, Prat A, Arance A. Sequential treatment with GRANTS FOR RESEARCH IN PROGRESS immunotherapy and BRAF inhibitors in BRAF-mutant advanced melanoma. Bragado P. Role of the neuroendocrine CLINICAL AND TRANSLATIONAL system in the regulation of disseminated ONCOLOGY. 19(1 ):119-124. I.F.: 2.353 tumour cell dormancy. Sponsored by: Asociación Española contra el 5. Harbeck N, Gascon P, Jones CM, Nixon A, cáncer (AECC). AECC_CAT_14_001 Krendyukov A, Nakov R, Li Y, Blackwell K. Duration: 30/01/2015-01/03/2017 Proposed biosimilar pegfilgrastim

302 CELL PROLIFERATION AND SIGNALING 5.11

Cell proliferation 5.11 and signaling

STRATEGIC OBJECTIVES

LOCATION The aim of the group is to study the UB School of Medicine mechanisms involved in cell cycle regulation and in the cellular responses to different types of stresses. We also aim to analyse the alterations of these mechanisms in different types of cancers as for instance colorectal cancer and leukemias. The knowledge of KEYWORDS these mechanisms will allow improving 1. Cell cycle TEAM LEADER cancer therapy. 2. Signalling Oriol Bachs (UB) 3. Oncogenesis T. 93 403 52 86 [email protected] MAIN LINES OF RESEARCH

Involvement of p27 (Kip1) in cancer RESEARCHERS progression: p27 (Kip1), a classical inhibitor Rosa Aligué (UB) of cyclin dependent kinases, is also a Original publications Maria Jesús Pujol (UB) transcriptional regulator. We are analysing the from 2015 to 2017 mechanisms by which p27 regulates POST-DOCTORAL RESEARCHERS transcription and which are the transcriptional YEAR I.F. TOTAL Q1 Q2 Edurne Gallastegui (IDIBAPS) programs regulated by this protein. p27 is 2015 18.70 3 3 - Judit Macias (UB) decreased in many different types of human Serena Orlando (UB) tumours and this reduction is associated with 2016 16.18 2 2 - Tula Yanze (UB) a worse outcome. Thus, the identiﬁcation of 2017 25.66 4 4 - the transcriptional programs regulated by p27 PRE-DOCTORAL RESEARCHERS helps to understand how p27 participates in Carla Domuro (UB) the progression of malignancy. Júlia Llanes (UB) Ramon Marqués (UB) Protein kinases in cancer: Our research TEAM INVOLVED IN Edgar Martín (UB) focuses on identifying the molecular ProteoRed Jonatan Martínez (UB) mechanism by which the CaMK family CIBERONC Laura Sin (UB) regulate cell cycle control and stress response. We are actually focused in TECHNICIANS dissecting the role of the CaMKK2 in cancer Sara Abelló (UB) development and metabolic stress. Oriol Bachs

TEAM

303 AREA 5 ONCOLOGY AND HAEMATOLOGY

Preliminary results have indicated that, CaMKK2 has a role in glucosae uptake and nutrient homeostasis. The identiﬁcation of Ckk2 substrates through the analysis of phospho-peptides indicates that there is a crosstalk between Ckk2 and TOR pathway.

PUBLICATIONS

Originals / I.F.: 25.655

1. Perearnau A., Orlando S., Islam A., Gallastegui E., Martínez J., Jordan A., Bigas A., Aligué R., Pujol M., Bachs O. P27Kip1, PCAF and PAX5 cooperate in the transcriptional regulation of speciﬁc target genes. NUCLEIC ACIDS RESEARCH. 45(9):5086-5099. I.F.: 10.162

2. Gallastegui E, Biçer A, Orlando S, Besson A, Pujol MJ, Bachs O. p27 represses the Pitx2-mediated expression of p21 and regulates DNA replication during cell cycle progression. ONCOGENE. 36(3):350-361. I.F.: 7.519

3. Esteban-Jurado C., Giménez-Zaragoza D., Muñoz J., Franch-Expósito S., álvarez-Barona M., Ocaña T., Cuatrecasas M., Carballal S., López-Cerón M., Marti-Solano M., Díaz-Gay M., Wezel T., Castells A., Bujanda L., Balmaña J., Gonzalo V., Llort G., Ruiz-Ponte C., Cubiella J., Balaguer F., Aligué R., Castellví-Bel S. POLE and POLD1 screening in 155 patients with multiple polyps and early-onset colorectal cancer. ONCOTARGET. 8(16):26732-26743. I.F.: 5.168

4. Biçer A., Orlando S., Islam A., Gallastegui E., Besson A., Aligué R., Bachs O., Pujol M. ChIP-Seq analysis identiﬁes p27(Kip1)-target genes involved in cell adhesion and cell signalling in mouse embryonic ﬁbroblasts. PLOS ONE. 12(11):e0187891. I.F.: 2.806

GRANTS FOR RESEARCH IN PROGRESS

Bachs O. Red Temática de Investigación Cooperativa en Cáncer. Sponsored by: Instituto de Salud Carlos III (ISCIII). RD12/0036/0054 Duration: 01/01/2013-30/06/2017

304 CELL COMPARTMENTS AND SIGNALING 5.12

Cell compartments 5.12 and signaling

STRATEGIC OBJECTIVES

LOCATION Our objective is to understand how the signals CELLEX building 1B originated in the cell surface are transduced to UB School of Medicine trigger reactions that lead metabolic changes, proliferation, or survival and how these mechanisms are affected during disease. We are currently studying the endocytic

WEB compartment, lipid droplets and the www.celltrafficbcn.cat endoplasmic reticulum, and the signalling TEAM LEADER pathways that regulate the cell cycle and Carles Enrich (UB) apoptosis. T. (34) 93 402 19 08 [email protected] MAIN LINES OF RESEARCH

KEYWORDS 1. Cell biology GROUP LEADERS Endocytosis and intracellular trafficking 2. Endocytosis and exocytosis Neus Agell (UB) of proteins and cholesterol: 3. Lipids transport and storage T. (34) 93 402 19 07 Our objective is the study of the mechanisms [email protected] that regulate the endocytosis and exocytosis 4. Signal transduction of proteins and cholesterol and the signalling 5. Cell cycle Carles Enrich (UB) pathways associated with these processes. T.(34) 93 402 19 08 We focus on determining the role of annexin [email protected] A6 in signalling, membrane trafficking and liver regeneration. Albert Pol (ICREA-IDIBAPS) T. (34) 93 227 54 00 (Ext. 3337) Lipid trafficking and disease: Original publications [email protected] Our objective is to characterize the from 2015 to 2017 intracellular transport and storage of lipids and the implication of these mechanisms in YEAR I.F. TOTAL Q1 Q2 RESEARCHERS disease progression (lipotoxicity). We are 2015 28.10 4 4 - Montserrat Jaumot (UB) Interested in lipid droplet 2016 41.75 7 7 - Francesc Tebar (IDIBAPS-UB) biogenesis/metabolism and the intracellular trafficking of cholesterol mediated by 2017 29.53 7 5 2 POST-DOCTORAL RESEARCHERS caveolins, Marta Bosch (UB) Albert Gubern (IDIBAPS) Signal transduction and cell cycle: Carles Rentero (UB) Our objective is to analyse the signal transduction mechanisms that regulate cell PRE-DOCTORAL RESEARCHERS cycle progression and their alterations in Patricia Blanco (UB) oncogenesis. Speciﬁcally we are studying the Debora Cabot (UB) function and regulation of the Ras and Rho Albert Chavero (UB) family of GTPases and the signal transduction Sònia Feu (UB) pathways regulating replication stress in Eduardo Garrido (UB) normal and tumour cells. Elsa Meneses (UB) Frederic Morales (IDIBAPS) Fernando Unzueta (UB)

TECHNICIANS Sonia Brun (UB) Alba Fajardo (IDIBAPS) María Molinos (UB)

305 AREA 5 ONCOLOGY AND HAEMATOLOGY

RESEARCH GROUP SIGNAL TRANSDUCTION AND CELL CYCLE

GROUP LEADER Neus Agell (UB)

Our group is interested in studying signal transduction pathways activated upon proliferative signals or upon replication stress and their alteration in tumorigenesis. Speciﬁcally we analyse the regulation of GTPases proteins of the Rho and Ras family signalling from different plasma membrane Neus Agell and endocytic platforms, and implications of this signalling compartmentalization in various cellular processes such as proliferation, cell GROUP migration and mobility, and also in oncogenesis. We are also analysing signalling from arrested replication forks that lead to cell cycle arrest and senescence.

RESEARCH GROUP ENDOCYTOSIS AND INTRACELLULAR TRAFFICKING OF PROTEINS AND CHOLESTEROL

GROUP LEADER Carles Enrich (UB)

Our group is interested on the molecular Carles Enrich mechanisms of membrane traffic in

mammalian cells. This basic research is GROUP important for understanding a number of diseases including cancer, diabetes, and heart disease or liver disorders. We study the regulation of a variety of aspects of protein and cholesterol trafficking and signal transduction in the endocytic compartment; a sorting and processing station for proteins internalized by cells as well as of the secretory pathway. We are focus in the study of Annexin A6. Annexins are an evolutionarily conserved multigene family with roles in vesicle trafficking, phospholipid metabolism, actin dynamics, apoptosis and cell transformation.

306 CELL COMPARTMENTS AND SIGNALING 5.12

RESEARCH GROUP LIPID TRAFFICKING AND DISEASE

GROUP LEADER Albert Pol (ICREA-IDIBAPS)

Lipid droplets are organelles that collect, store and supply lipids in all eukaryotic cells. These organelles are also cellular hallmarks of prevalent diseases ranging from obesity to cancer. The cell biology of lipid droplets and its role in pathogenesis are still unclear. Our group is interested in the mechanisms of lipid droplet biogenesis and consumption. Albert Pol Cholesterol accumulation promotes mitochondrial dysfunction and oxidative damage underlying in the pathogenesis of GROUP steatohepatitis, neurodegeneration and atherosclerosis. In this context, we are especially interested in how caveolin-1 4. Soriano-Castell D, Chavero A, Rentero C, Review / I.F.: 8.006 regulates cholesterol trafficking and storage. Bosch M, Vidal-Quadras M, Pol A, Enrich C, Tebar F. ROCK1 is a novel Rac1 effector to 1. Torres S., Balboa E., Zanlungo S., Enrich C., regulate tubular endocytic membrane Garcia-Ruiz C., Fernandez-Checa J. formation during clathrin-independent Lysosomal and mitochondrial liaisons in PUBLICATIONS endocytosis. SCIENTIFIC REPORTS. Niemann-Pick disease. FRONTIERS IN 7(1):6866. I.F.: 4.259 PHYSIOLOGY. 8(NOV):982. I.F.: 4.134 Originals / I.F.: 29.525 5. Krautbauer S., Haberl E., Eisinger K., Pohl R., 2. Grewal T, Hoque M, Conway JR, Reverter 1. Torres S, Matías N, Baulies A, Nuñez S, Rein-Fischboeck L., Rentero C., M, Wahba M, Beevi SS, Timpson P, Enrich C, Alarcon-Vila C, Martinez L, Nuño N, Fernandez Alvarez-Guaita A., Enrich C., Grewal T., Rentero C. Annexin A6 - a multifunctional A, Caballeria J, Levade T, Gonzalez- Buechler C., Neumeier M. Annexin A6 scaffold in cell motility. CELL ADH MIGR. Franquesa A, Garcia-Rovés P, Balboa E, regulates adipocyte lipid storage and 11(3):288-304. I.F.: 3.872 Zanlungo S, Fabrías G, Casas J, Enrich C, adiponectin release. MOLECULAR AND Garcia-Ruiz C, Fernández-Checa JC. CELLULAR ENDOCRINOLOGY. Mitochondrial GSH replenishment as a 438(C):419-430. I.F.: 3.754 GRANTS FOR RESEARCH IN PROGRESS potential therapeutic approach for Niemann Pick type C disease. REDOX 6. Cairns R., Alvarez-Guaita A., Agell N. KRas phosphorylation, its BIOLOGY. 11:60-72. I.F.: 6.337 Martínez-Saludes I., Wason S., Hanh J., interaction with calmodulin, and the Nagarajan S., Hosseini-Beheshti E., response to replication stress, in 2. Enrich C., Rentero C., Grewal T. Annexin Monastyrskaya K., Hoy A., Buechler C., Enrich colorectal cancer progression and the A6 in the liver: From the endocytic C., Rentero C., Grewal T. Role of hepatic design of new therapies. compartment to cellular physiology. Annexin A6 in fatty acid-induced lipid Sponsored by: Ministerio de Economía y BIOCHIMICA ET BIOPHYSICA ACTA - droplet formation. EXPERIMENTAL CELL Competitividad (MINECO). MOLECULAR CELL RESEARCH. RESEARCH. 358(2):397-410. I.F.: 3.546 Duración: 30/12/2016-29/12/2019 1864(6):933-946. I.F.: 4.521 7. Brun S, Abella N, Berciano MT, Tapia O, Enrich C/Tebar F. Contribution of endocytic 3. Fleta-Soriano E, Smutná K, Martínez JP, Jaumot M, Freire R, Lafarga M, Agell N. SUMO compartment to cell migration: regulation Lorca Oró C, Sadiq SK, Mirambeau G, regulates p21Cip1 intracellular distribution by cholesterol, AnxA6 and Rac1. Lopez-Iglesias C, Bosch M, Pol A, Brönstrup and with p21Cip1 facilitates multiprotein Sponsored by: Ministerio de Economía y M, Diez J, Meyerhans A. The myxobacterial complex formation in the nucleolus upon Competitividad (MINECO). metabolite Soraphen A inhibits HIV-1 by DNA damage. PLOS ONE. 12(6):e0178925. BFU2015-66785-P reducing virus production and altering I.F.: 2.806 Duration: 01/01/2016-31/12/2019 virion composition. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY. 61(8):e0073917. I.F.: 4.302

307 AREA 5 ONCOLOGY AND HAEMATOLOGY

Enrich C. (IP group 7). Compartment organization and transport. Sponsored by: Ministerio de Economía y Competitividad (MINECO). BFU2016-81912-REDC Duration: 01/01/2018-31/12/2019.

Enrich C (Grewal T., Murray R., Timpson P). LDL cholesterol regulates cell migration. Sponsored by: National Health Medical Research Council of Australia (NHMRC). Duration: 01/01/2016-31/12/2018.

Pol A. Mammalian lipid droplets: a central role in the organismal antibacterial response? Sponsored by: Human Frontier Science Program (HFSP). RGP0020/2015 Duration: 01/06/2015-31/05/2018

Pol A. Nuevas funciones de ACSL3, CAV1 y colesterol en el retículo endoplásmico: sensores homeostáticos que determinan la supervivencia o la muerte de las células. Sponsored by: Ministerio de Economia y Competitividad. BFU2015-66401-R Duration: 01/01/2016-31/12/2018

Pol A. Lipid Droplet Overloading Promotes Pathogenesis and Progression of Type 2 Diabetes: Identifying New Therapeutic Targets and Applying Upgraded Therapies. Sponsored by: Fundació Marató de TV3. 201625.10. Duration: 24/02/2017-23/02/2020.

DOCTORAL THESES

Agell N, Rubio J. New strategies of inhibition of K-Ras and study of the K-Ras/CaM interaction. PhD student: Eduardo Garrido Sagarzazu

Pol A. ACSL3 role in the metabolism of Lipid Droplets and implications in hepatic regeneration. PhD student: Andrea Fernández Vidal

308 TRANSLATIONAL GENOMICS AND TARGETED THERAPEUTICS IN SOLID TUMORS 5.13

Translational genomics and targeted therapeutics 5.13 in solid tumors

TECHNICIANS Patricia Galván (FCRB) LOCATION Natalia Jiménez (FCRB) CEK building Sandra López (FCRB) Maria Milà (FCRB)

ADMINISTRATIVE STAFF

WEB Eva Paradell (FCRB) www.idibaps.org/recerca/310/ genomica-translacional-i-terapies- COLLABORATORS Montserrat Muñoz (HCB) dirigides-en-tumors-solids TEAM LEADER Aleix Prat (HCB) Núria Viñolas (HCB) T. 93 227 54 00 (Ext.: 2203) [email protected] STRATEGIC OBJECTIVES

RESEARCHERS Use genomic or molecular data to guide KEYWORDS clinical trial design and biomarker 1. Breast cancer Ana Arance (HCB) Nuria de la Iglesia (IDIBAPS) development and study molecular 2. Intrinsic subtypes Joan Maurel (HCB) mechanisms of drug sensitivity in order 3. Biomarkers Begoña Mellado (HCB) to identify optimal treatment regimens for 4. Genomics Noemí Reguart (HCB) patients with solid tumors. 5. Solid tumors Maria Jesús Vidal (HCB) 6. Immunotherapy

POST-DOCTORAL RESEARCHERS MAIN LINES OF RESEARCH Barbara Àdamo (HCB) Fara Brasó (FCRB) Breast cancer Mercedes Marin (FCRB) - To evaluate the impact of the identiﬁcation Laia Pare (FCRB) of the intrinsic molecular subtypes of breast Original publications Cristina Teixidó (IDIBAPS) cancer in the clinical setting. from 2015 to 2017 - To study the mechanisms of drug PRE-DOCTORAL RESEARCHERS resistance and tumor progression in YEAR I.F. TOTAL Q1 Q2 Juan Miguel Cejalvo (IDIBAPS) Luminal A and B breast cancer. 2015 99.21 14 14 - Tomas Pascual (FCRB) - To identify genomic biomarkers predictive of response to anti-HER2 drugs in 2016 124.54 16 15 1 Leire Pedrosa (IDIBAPS) Estela Pineda (HCB) HER2-positive breast cancer. 2017 311.46 31 27 1 Oscar Reig (FCRB)

TEAM INVOLVED IN AGAUR_SGR17

AWARDS Premio al joven talento Institution: Fundación AstraZeneca Awardee/s: Aleix Prat Aleix Prat

TEAM

309 AREA 5 ONCOLOGY AND HAEMATOLOGY

Colorectal cancer - To investigate mechanisms of resistance Favaretto A, Froesch P, Reguart N, Puente J, - To evaluate intrinsic and acquired to anti-angiogenic therapy and Coate L, Barlesi F, Rauch D, Thomas M, mechanisms of resistance to identification of new therapeutic targets in Camps C, Gómez-Codina J, Majem M, Porta chemotherapy and targeted agents in renal cell carcinoma. R, Shah R, Hanrahan E, Kammler R, Ruepp B, metastatic colorectal cancer, in the three Rabaglio M, Kassapian M, Karachaliou N, Tam genotypes (KRAS/NRAS mutant, BRAF R, Shames DS, Molina-Vila MA, Stahel RA, mutant and triple-WT). PUBLICATIONS BELIEF collaborative group. Erlotinib and - To characterize epithelial and bevacizumab in patients with advanced mesenchymal phenotypes in resectable Originals / I.F.: 311.461 non-small-cell lung cancer and activating and metastatic pancreatic carcinoma and EGFR mutations (BELIEF): An it’s correlation with drug resistance. 1. Ascierto P., Del Vecchio M., Robert C., international, multicentre, single-arm, Mackiewicz A., Chiarion-Sileni V., Arance A., phase 2 trial. THE LANCET. RESPIRATORY Melanoma Lebbé C., Bastholt L., Hamid O., Rutkowski P., MEDICINE. 5(5):435-444. I.F.: 19.287 - To evaluate the impact of the immune McNeil C., Garbe C., Loquai C., Dreno B., system in the response to immune Thomas L., Grob J., Liszkay G., Nyakas M., 5. Chaib I, Karachaliou N, Pilotto S, Codony checkpoint inhibitors and BRAF inhibitors. Gutzmer R., Pikiel J., Grange F., Hoeller C., Servat J, Cai X, Li X, Drozdowskyj A, Servat - To study the mechanisms of drug Ferraresi V., Smylie M., Schadendorf D., CC, Yang J, Hu C, Cardona AF, Vivanco GL, resistance and tumor progression. Mortier L., Svane I., Hennicken D., Qureshi A., Vergnenegre A, Sanchez JM, Provencio M, de - To identify genomic biomarkers predictive Maio M. Ipilimumab 10 mg/kg versus Marinis F, Passaro A, Carcereny E, Reguart N, of response to anti-PD1 and anti-CTLA4 ipilimumab 3 mg/kg in patients with Campelo CG, Teixido C, Sperduti I, Rodriguez drugs. unresectable or metastatic melanoma: A S, Lazzari C, Verlicchi A, de Aguirre I, Queralt C, randomised, double-blind, multicentre, Wei J, Estrada R, Puig de la Bellacasa R, Lung cancer phase 3 trial. LANCET ONCOLOGY. Ramirez JL, Jacobson K, Ditzel HJ, Santarpia - Validate novel molecular technologies to 18(5):611-622. I.F.: 33.900 M, Viteri S, Molina MA, Zhou C, Cao P, Ma PC, streamline the screening of targetable Bivona TG, Rosell R. Co-activation of STAT3 biomarkers in non-small cell lung cancer 2. García-Donas J., Font A., Pérez-Valderrama and YES-Associated Protein 1 (YAP1) (NSCLC). B., Virizuela J., Climent M., Hernando-Polo S., Pathway in EGFR-Mutant NSCLC. - Identification of novel fusion gene variants Arranz J., del Mar Llorente M., Lainez N., JOURNAL OF THE NATIONAL CANCER in NSCLC: phenotypic characterization of Villa-Guzmán J., Mellado B., del Alba A., INSTITUTE. 109(9). I.F.: 12.589 targeted population and prospective Castellano D., Gallardo E., Anido U., del Muro clinical validation of their predictive value to X., Domènech M., Puente J., Morales-Barrera 6. Gonzalez-Billalabeitia E, Castellano D, targeted treatments. R., Pérez-Gracia J., Bellmunt J. Maintenance Sobrevilla N, Guma J, Hervas D, Luengo MI, - Characterize the “stroma-tumor cell” therapy with vinflunine plus best Aparicio J, Sanchez-Muñoz A, Mellado B, crosstalk in NSCLC and the role of tumor supportive care versus best supportive Saenz A, Valverde C, Fernandez A, Margeli M, fibroblasts in the tumorigenesis of both care alone in patients with advanced Duran I, Fernandez S, Sastre J, Ros S, Maroto major NSCLC subtypes: adenocarcinoma urothelial carcinoma with a response after P, Manneh R, Cerezuela P, Carmona-Bayonas (ADC) and squamous cell carcinoma first-line chemotherapy (MAJA; SOGUG A, Ayala de la Peña F, Luis Aguilar J, Rivera S, (SQC). This project is being done in 2011/02): A multicentre, randomised, García Del Muro X, Germà-Lluch JR, Spanish collaboration with Dr. Alcaraz at the UB, controlled, open-label, phase 2 trial. Germ Cell Cancer Group/Grupo Germinal Hospital Clinic. LANCET ONCOLOGY. 18(5):672-681. (SGCCG). Prognostic Significance of I.F.: 33.900 Venous Thromboembolic Events in Central nervous system tumors Disseminated Germ Cell Cancer Patients. - Functional characterization of neural stem 3. Llombart-Cussac, Antonio; Cortes, Javier; J NATL CANCER INST. 109(4):djw265. cell factors in the pathogenesis of gliomas. Pare, Laia; Galvan, Patricia; Bermejo, Begona; I.F.: 12.589 - Study of the molecular mechanisms of Martinez, Noelia; Vidal, Maria; Pernas, Sonia; glioblastoma radioresistance Lopez, Rafael; Munoz, Montserrat; Nuciforo, 7. Mayo-de-las-Casas C, Jordana-Ariza N, - Characterization of the biology behind the Paolo; Morales, Serafin; Oliveira, Mafalda; de la Garzón-Ibañez M, Balada-Bel A, intrinsic molecular subtypes of Pena, Lorena; Pelaez, Alexandra; Prat, Aleix. Bertrán-Alamillo J, Viteri-Ramírez S, Reguart N, glioblastoma. HER2-enriched subtype as a predictor of Muñoz-Quintana M, Lianes-Barragan P, Camps pathological complete response following C, Jantús E, Remon-Massip J, Calabuig S, Aguiar Urologic cancer trastuzumab and lapatinib without D, Gil M, Viñolas N, Santos-Rodríguez A, Majem - To study the molecular mechanisms of chemotherapy in early-stage M, García-Peláez B, Villatoro S, Pérez-Rosado A, resistance to taxanes and novel HER2-positive breast cancer (PAMELA): Monasterio J, Ovalle E, Catalán M, Campos R, hormone-therapies in preclinical models, An open-label, single-group, multicentre, Morales-Espinosa D, Martínez-Bueno A, circulating tumor cells and patients with phase 2 trial. LANCET ONCOLOGY. González-Cao M, González X, Moya-Horno I, castration resistant prostate cancer. 18(4):545-554. I.F.: 33.900 Sosa A, Karachaliou N, Rosell R, Molina-Vila M. - To investigate the role of the androgen Large scale, prospective screening of EGFR receptor variants in epithelial to 4. Rosell R, Dafni U, Felip E, Curioni- mutations in the blood of advanced NSCLC mesenchymal transition and progression Fontecedro A, Gautschi O, Peters S, Massutí patients to guide treatment decisions. and therapy resistance in castration B, Palmero R, Aix SP, Carcereny E, Früh M, ANNALS OF ONCOLOGY. 28(9):2248-2255. resistant prostate cancer. Pless M, Popat S, Kotsakis A, Cuffe S, Bidoli P, I.F.: 11.855

310 TRANSLATIONAL GENOMICS AND TARGETED THERAPEUTICS IN SOLID TUMORS 5.13

8. Font C, Carmona-Bayonas A, Beato C, Reig Pelaez-Lorenzo B, Palomero MI, González Del 17. Gómez-Miragaya J., Palafox M., Paré L., Ò, Sáez A, Jiménez-Fonseca P, Plasencia JM, Val R, Cortes J, Fuentes Rivera H, Bretel Yoldi G., Ferrer I., Vila S., Galván P., Pellegrini P., Calvo-Temprano D, Sanchez M, Benegas M, Morales D, Márquez-Rodas I, Perou CM, Pérez-Montoyo H., Igea A., Muñoz P., Esteller Biosca M, Varona D, Vicente MA, Faez L, Solís Wagner JL, Mammen JM, McGinness MK, M., Nebreda A., Urruticoechea A., Morilla I., MD, de la Haba I, Antonio M, Madridano O, Klemp JR, Amin AL, Fabian CJ, Heldstab J, Pernas S., Climent F., Soler-Monso M., Petit A., Castañon E, Martinez MJ, Marchena P, Godwin AK, Jensen RA, Kimler BF, Khan QJ, Serra V., Prat A., González-Suárez E. Ramchandani A, Dominguez A, Puerta A, Martin M. Efficacy of Neoadjuvant Resistance to Taxanes in Triple-Negative Martinez de la Haza D, Pueyo J, Hernandez S, Carboplatin plus Docetaxel in Breast Cancer Associates with the Fernandez-Plaza A, Martinez-Encarnacion L, Triple-Negative Breast Cancer: Combined Dynamics of a CD49f+ Tumor-Initiating Martin M, Marin G, Ayala F, Vicente V, Otero R, Analysis of Two Cohorts. CLINICAL Population. STEM CELL REPORTS. Asociación para la Investigación de la CANCER RESEARCH. 23(3):649-657. 8(5):1392-1407. I.F.: 7.338 Enfermedad Tromboembólica de la región de I.F.: 9.619 Murcia. Clinical features and short-term 18. Codony-Servat J, Cuatrecasas M, Asensio outcomes of cancer patients with 13. Prat A, Navarro A, Paré L, Reguart N, E, Montironi C, Martínez-Cardús A, suspected and unsuspected pulmonary Galván P, Pascual T, Martínez A, Nuciforo P, Marín-Aguilera M, Horndler C, embolism: the EPIPHANY study. Comerma L, Alos L, Pardo N, Cedrés S, Fan C, Martínez-Balibrea E, Rubini M, Jares P, Reig O, EUROPEAN RESPIRATORY JOURNAL. 49(1). Parker JS, Gaba L, Victoria I, Viñolas N, Victoria I, Gaba L, Martín-Richard M, Alonso V, I.F.: 10.569 Vivancos A, Arance A, Felip E. Immune- Escudero P, Fernández-Martos C, Feliu J, Related Gene Expression Profiling After Méndez JC, Méndez M, Gallego J, Salud A, 9. Delord J., Robert C., Nyakas M., McArthur PD-1 Blockade in Non-Small Cell Lung Rojo F, Castells A, Prat A, Rosell R, G., Kudchakar R., Mahipal A., Yamada Y., Carcinoma, Head and Neck Squamous Cell García-Albéniz X, Camps J, Maurel J. Nuclear Sullivan R., Arance A., Kefford R., Carlino M., Carcinoma, and Melanoma. CANCER IGF-1R predicts chemotherapy and Hidalgo M., Gomez-Roca C., Michel D., RESEARCH. 77(13):3540-3550. I.F.: 9.122 targeted therapy resistance in metastatic Seroutou A., Aslanis V., Caponigro G., Stuart D., colorectal cancer. BRITISH JOURNAL OF Moutouh-De Parseval L., Demuth T., Dummer 14. Cejalvo JM, Martínez de Dueñas E, Galván CANCER. 117(12):1777-1768. I.F.: 6.176 R. Phase I dose-escalation and -expansion P, García-Recio S, Burgués Gasión O, Paré L, study of the BRAF inhibitor encorafenib Antolín S, Martinello R, Blancas I, Adamo B, 19. Gabasa M; Ikemori R; Hilberg F; Reguart N; (LGX818) in metastatic BRAF-mutant Guerrero-Zotano Á, Muñoz M, Nucíforo P, Alcaraz J. Nintedanib selectively inhibits melanoma. CLINICAL CANCER RESEARCH. Vidal M, Pérez RM, Chacón López-Muniz JI, the activation and tumour-promoting 23(18):5339-5348. I.F.: 9.619 Caballero R, Peg V, Carrasco E, Rojo F, Perou effects of fibroblasts from lung CM, Cortés J, Adamo V, Albanell J, Gomis RR, adenocarcinoma patients. BRITISH 10. Prat, Aleix; Lluch, Ana; Turnbull, Arran K.; Lluch A, Prat A. Intrinsic subtypes and gene JOURNAL OF CANCER. 117(8):1128-1138. Dunbier, Anita K.; Calvo, Lourdes; Albanell, expression profiles in primary and I.F.: 6.176 Joan; de la Haba-Rodriguez, Juan; Arcusa, metastatic breast cancer. CANCER RES. Angels; Ignacio Chacon, Jose; Sanchez- 77(9):2213-2221. I.F.: 9.122 20. Climent M., Pérez-Valderrama B., Mellado Rovira, Pedro; Plazaola, Arrate; Munoz, B., Fernández Parra E., Fernández Calvo O., Montserrat; Pare, Laia; Parker, Joel S.; Ribelles, 15. Moreno M., Pedrosa L., Paré L., Pineda E., Ochoa de Olza M., Muinelo Romay L., Anido U., Nuria; Jimenez, Begona; Bin Aiderus, Abdul Bejarano L., Martínez J., Balasubramaniyan V., Domenech M., Hernando Polo S., Arranz Arija Aziz; Caballero, Rosalia; Adamo, Barbara; Ezhilarasan R., Kallarackal N., Kim S., Wang J., J., Caballero C., Juan Fita M., Castellano D. Dowsett, Mitch; Carrasco, Eva; Martin, Miguel; Audia A., Conroy S., Marin M., Ribalta T., Pujol Weekly cabazitaxel plus prednisone is Dixon, J. Michael; Perou, Charles M.; Alba, T., Herreros A., Tortosa A., Mira H., Alonso M., effective and less toxic for ‘unfit’ Emilio. A PAM50-Based Chemoendocrine Gómez-Manzano C., Graus F., Sulman E., Piao metastatic castration-resistant prostate Score for Hormone Receptor-Positive X., Nakano I., Prat A., Bhat K., de la Iglesia N. cancer: Phase II Spanish Oncology Breast Cancer with an Intermediate Risk of GPR56/ADGRG1 Inhibits Mesenchymal Genitourinary Group (SOGUG) trial. Relapse. CLINICAL CANCER RESEARCH. Differentiation and Radioresistance in EUROPEAN JOURNAL OF CANCER. 23(12):3035-3044. I.F.: 9.619 Glioblastoma. CELL REPORTS. 87:30-37. I.F.: 6.029 21(8):2183-2197. I.F.: 8.282 11. Samaeekia R., Adorno-Cruz V., Bockhorn 21. Massard C, Chi KN, Castellano D, de Bono J., Chang Y., Huang S., Prat A., Ha N., Kibria G., 16. Reguart N, Teixidó C, Giménez-Capitán A, J, Gravis G, Dirix L, Machiels JP, Mita A, Huo D., Zheng H., Dalton R., Wang Y., Paré L, Galván P, Viteri S, Rodríguez S, Peg V, Gonzalez BM, Turri S, Maier J, Csonka D, Moskalenko G., Liu H. miR-206 inhibits Aldeguer E, Viñolas N, Remon J, Karachaliou Chakravartty A, Fizazi K. Phase Ib stemness and metastasis of breast cancer N, Conde E, Lopez-Rios F, Nadal E, dose-finding study of abiraterone acetate by targeting MKL1/IL11 pathway. CLINICAL Merkelbach-Bruse S, Büttner R, Rosell R, plus buparlisib (BKM120) or dactolisib CANCER RESEARCH. 23(4):1091-1103. Molina-Vila MA, Prat A. Identification of ALK, (BEZ235) in patients with castration- I.F.: 9.619 ROS1 and RET Fusions by a Multiplexed resistant prostate cancer. EUROPEAN mRNA-Based Assay in Formalin-Fixed, JOURNAL OF CANCER. 76:36-44. I.F.: 6.029 12. Sharma P, López-Tarruella S, Paraffin-Embedded Samples from García-Saenz JA, Ward C, Connor CS, Gómez Advanced Non-Small-Cell Lung Cancer 22. Rabbie R, Rashid M, Arance AM, Sánchez HL, Prat A, Moreno F, Jerez-Gilarranz Y, Patients. CLIN CHEM. 63(3):751-760. M, Tell-Marti G, Potrony M, Conill C, van Doorn Barnadas A, Picornell AC, Del Monte-Millán M, I.F.: 8.008 R, Dentro S, Gruis NA, Corrie P, Iyer V, Gonzalez-Rivera M, Massarrah T, Robles-Espinoza CD, Puig-Butille JA, Puig S,

311 AREA 5 ONCOLOGY AND HAEMATOLOGY

Adams DJ. Genomic analysis and clinical TARGETED ONCOLOGY. 12(4):513-523. Letters / I.F.: 42.458 management of adolescent cutaneous I.F.: 3.438 melanoma. PIGMENT CELL AND 1. Prat, Aleix. Pertuzumab Use in the MELANOMA RESEARCH. 30(3):307-316. 28. Esteve-Codina A, Arpi O, Martinez-García Adjuvant Setting: Why Not? JOURNAL OF I.F.: 5.170 M, Pineda E, Mallo M, Gut M, Carrato C, Rovira CLINICAL ONCOLOGY. 35(10):1138. I.F.: 24.008 A, Lopez R, Tortosa A, Dabad M, Del Barco S, 23. Fernandez-Martinez A., Pascual T., Heath S, Bagué S, Ribalta T, Alameda F, de la 2. Aya F, Ruiz-Esquide V, Viladot M, Font C, Perrone G., Morales S., de la Haba J., Iglesia N, Balaña C, GLIOCAT Group. A Prieto-González S, Prat A, Arance A. González-Rivera M., Galván P., Zalfa F., Amato comparison of RNA-Seq results from Vasculitic neuropathy induced by M., Gonzalez L., Prats M., Rojo F., Manso L., paired formalin-fixed paraffin-embedded pembrolizumab. ANNALS OF ONCOLOGY. Paré L., Alonso I., Albanell J., Vivancos A., and fresh-frozen glioblastoma tissue 28(2):433-434. I.F.: 11.855 González A., Matito J., González S., Fernandez samples. PLOS ONE. 12(1):e0170632. P., Adamo B., Muñoz M., Viladot M., Font C., I.F.: 2.806 3. Chic N, Mayo-de-las-Casas C, Reguart N. Aya F., Vidal M., Caballero R., Carrasco E., Successful Treatment with Gefitinib in Altomare V., Tonini G., Prat A., Martin M. 29. Batson S; Mitchell S; Windisch R; Damonte Advanced Non–Small Cell Lung Cancer Limitations in predicting PAM50 intrinsic E; Munk V; Reguart N. Tyrosine kinase after Acquired Resistance to Osimertinib. subtype and risk of relapse score with Ki67 inhibitor combination therapy in first-line JOURNAL OF THORACIC ONCOLOGY. in estrogen receptor-positive HER2- treatment of non-small-cell lung cancer: 12(6):e78-e80. I.F.: 6.595 negative breast cancer. ONCOTARGET. Systematic review and network 8(13):21930-21937. I.F.: 5.168 meta-analysis. ONCOTARGETS AND THERAPY. 10:2473-2482. I.F.: 2.612 Editorial / I.F.: 6.335 24. Cánovas V, Puñal Y, Maggio V, Redondo E, Marín M, Mellado B, Olivan M, Lleonart M, 30. Aya F, Fernandez-Martinez A, Gaba L, 1. Prat, Aleix; Pascual, Tomas; Adamo, Planas J, Morote J, Paciucci R. Prostate Victoria I, Tosca M, Pineda E, Gascon P, Prat A, Barbara. Intrinsic molecular subtypes of Tumor Overexpressed-1 (PTOV1) Arance A. Sequential treatment with HER2+breast cancer. ONCOTARGET. promotes docetaxel-resistance and immunotherapy and BRAF inhibitors in 8(43):73362-73363. I.F.: 5.168 survival of castration resistant prostate BRAF-mutant advanced melanoma. cancer cells. ONCOTARGET. CLINICAL AND TRANSLATIONAL 2. Vilariño N, Reyes R, Teixidó C, Reguart N. 8(35):59165-59180. I.F.: 5.168 ONCOLOGY. 19(1 ):119-124. I.F.: 2.353 Liquid biopsies: Envisioning a future when tissue is avoidable in lung cancer 25. Stanzani, Elisabetta; Martinez-Soler, Fina; 31. Wills B; Cardona A; Rojas L; Ruiz-Patiño A; treatment decision-making. Martin Mateos, Teresa; Vidal, Noemi; Arrieta O; Reguart N; Carranza H; Vargas C; TRANSLATIONAL CANCER RESEARCH. Villanueva, Alberto; Angel Pujana, Miquel; Otero J; Corrales L; Martin C; Cuello M; Pino L; 6(7):S1181-S1186. I.F.: 1.167 Serra-Musach, Jordi; de la Iglesia, Nuria; Rolfo C; Rosell R; Zatarain-Barrón Z. Survival Gimenez-Bonafe, Pepita; Tortosa, Avelina. Outcomes According to TIMP1 and EGFR Radioresistance of mesenchymal Expression in Heavily Treated Patients GRANTS FOR RESEARCH IN PROGRESS glioblastoma initiating cells correlates with with Advanced Non-small Cell Lung patient outcome and is associated with Cancer who Received Biweekly Irinotecan De la Iglesia N. Perfil d'expressió gènica activation of inflammatory program. Plus Bevacizumab. ANTICANCER (gep) del glioblastoma, incloent lincrna ONCOTARGET. 8(43):73640-73653. I.F.: 5.168 RESEARCH. 37(11):6429-6436. I.F.: 1.937 (large intergènic non-coding rna), en una població homogènia: correlació amb 26. Moran T., Palmero R., Provencio M., Insa l'immunofenotip, la radiologia, els A., Majem M., Reguart N., Bosch-Barrera J., Isla Review / I.F.: 7.772 resultats. D., Costa E., Lee C., Puig M., Kraemer S., Sponsored by: Fundació La Marató TV3. Schnell D., Rosell R. A phase Ib trial of 1. Rodriguez-Salas N, Dominguez G, Barderas 20130331 continuous once-daily oral afatinib plus R, Mendiola M, García-Albéniz X, Maurel J, Duration: 07/05/2014-31/12/2017 sirolimus in patients with epidermal Batlle JF. Clinical relevance of colorectal growth factor receptor mutation-positive cancer molecular subtypes. CRIT REV Maurel J. Estudio observacional para non-small cell lung cancer and/or disease ONCOL HEMATOL. 109:9-19. I.F.: 4.971 evaluar la estrategia de uso de las terapias progression following prior erlotinib or dirigidas, en cáncer de colon metastásico. gefitinib. LUNG CANCER. 108:154-160. 2. Veeraraghavan, Jamunarani; De Angelis, Sponsored by: Instituto de Salud Carlos III I.F.: 4.294 Carmine; Reis-Filho, Jorge S.; Pascual, Tomas; (ISCIII). PI13/01728 Prat, Aleix; Rimawi, Mothaffar F.; Osborne, C. Duration: 01/01/2014-30/06/2018 27. Cardona AF, Arrieta O, Zapata MI, Rojas L, Kent; Schiff, Rachel. De-escalation of Wills B, Reguart N, Karachaliou N, Carranza H, treatment in HER2-positive breast Mellado B. Caracterización molecular del Vargas C, Otero J, Archila P, Martín C, Corrales cancer: Determinants of response and cáncer de próstata en función de la L, Cuello M, Ortiz C, Pino LE, Rosell R, mechanisms of resistance. BREAST. expresión de TMPRSS2-ERG: Zatarain-Barrón ZL, CLICaP. Acquired 34(1):S19-S26. I.F.: 2.801 implicaciones terapéuticas. Resistance to Erlotinib in EGFR Sponsored by: Instituto Carlos III (ISCIII). Mutation-Positive Lung Adenocarcinoma PI15/00676 among Hispanics (CLICaP). Duration: 01/01/2016-31/12/2018

312 TRANSLATIONAL GENOMICS AND TARGETED THERAPEUTICS IN SOLID TUMORS 5.13

Prat A. Identiﬁcació d'alteracions moleculars accionables durant la progressió metastàsica del càncer de mama luminal. Sponsored by: Fundación Sociedad Española de Oncología Médica (SEOM_14) Duration: 01/04/2015-30/04/2018

Prat A. Construcción y evaluación de linfocitos T con un receptor quimérico antigénico (CART) anti-HER2 para el tratamiento de tumores. Sponsored by: Fundación Eugenio Rodríguez Pascual. FERP15-12 Duration: 22/12/2015-21/12/2018

Prat A. Identificación y validación de una firma genómica predictiva de beneficio a fármacos anti-PD1 en múltiples tumores sólidos. Sponsored by: Fundación Sociedad Española de Oncología Médica (SEOM_16) Duration: 01/11/2016-31/10/2018

Prat A. Doble bloque HER2 sin quimioterapia en cáncer de mama precoz HER2+. Sponsored by: Instituto de Salud Carlos III (ISCIII). PI16/00904 Duration: 01/01/2017-31/12/2019

Reguart N. Validación de un ensayo multiplex personalizado para la detección de oncogenes y ﬁrmas inmunes en Cáncer de Pulmón (CP): estudio observacional, prospectivo y multicéntrico. Sponsored by: Instituto de Salud Carlos III (ISCIII). PI16/00890 Duration: 01/01/2017-31/12/2019

DOCTORAL THESIS

Maurel J. Papel de la vía de IGF y de metaloproteasa-7 en la resistencia adquirida al tratamiento con quimioterapia y con anticuerpos anti-EGFR en cáncer colorrectal metastático. PhD student: Mª Rosa Gallego Sánchez

Prat A. Implicació pronóstica de la infecció per virus del papiloma humà en tumors d’orofaringe i cavitat oral. localment avançats irresecables. PhD student: Victor Rodriguez Freixinos

Prat A. Marcadores predictivos de respuesta a quimioterapia primaria + trastuzumab en cáncer de mama HER2-positivo. PhD student: Sonia Pernas Simon

313 ANNUAL SCIENTIFIC REPORT 2017

TRANSVERSAL AREA

TRANSVERSAL RESEARCH GROUPS T

TRANSVERSAL RESEARCH GROUPS

T.1 Primary healthcare transversal research group 316 Antoni Sisó

T.2 Research in nursing 319 Adelaida Zabalegui

T.3 Clinical pharmacology 321 Xavier Carné

315 TRANSVERSAL AREA TRANSVERSAL RESEARCH GROUPS

Primary healthcare T.1 transversal research group

Cristina Ramírez (EAP Comte Borrell) Silvia Roura (EAP Casanova) LOCATION Marina Rovira (Farmacia ) EAP Les Corts Antoni Salvà (Pediatria - Casanova) EAP Comte Borrell Núria Sánchez (EAP Comte Borrell) EAP Casanova Mireia Sans (EAP Comte Borrell) Elisenda Sant (EAP Casanova) Ethel Sequeira (EAP Casanova) Josep Miquel Sotoca (Farmacia )

WEB www.idibaps.org/research/7001/ TEAM LEADER PRE-DOCTORAL RESEARCHERS primary-healthcare-transversal- Antoni Sisó Almirall (EAP Les Corts) Maria Antonieta Also (EAP Casanova) research-group T. 93 227 99 24 Laia Cayuelas (EAP Casanova) [email protected] Jaime Costa (EAP Les Corts) Alba Herrero (EAP Casanova) Emma Marianela Morales (AP – Consorci RESEARCHERS Hospital Terrassa) Mª Carmen Alvira (EAP Comte Borrell) Sònia Moreno (PAMEM) August Anguita (EAP Les Corts) KEYWORDS Jaume Benavent (CAPSBE) TECHNICIANS 1. Primary healthcare Lluisa Benito (EAP Les Corts) Belchin Kostov (IDIBAPS) 2. Chronic diseases Esther Blat (EAP Les Corts) Cardiovascular diseases 3. Marta Catalán (EAP Casanova) COLLABORATORS & cardiovascular risk factors Cristina Colungo (EAP Comte Borrell) Pilar Brito (HCB) 4. Health technology assessment Noemí García (EAP Comte Borrell) Diana Diaz (IDIBAPS) 5. Autoimmune & rheumatic diseases Imma Garrell (EAP Comte Borrell) Imma Grau (HCB) Joan Gené (EAP Casanova) Manel Ramos-Casals (HCB) Núria Gimferrer (EAP Comte Borrell) Lluís González (EAP Les Corts) Susanna González (EAP Les Corts) STRATEGIC OBJECTIVES Carmen Herranz (EAP Casanova) Original publications Zoe Herreras (EAP Comte Borrell) Primary care is the point of patient entry from 2015 to 2017 Mireia López (EAP Les Corts) to the healthcare system. Angela Martínez (EAP Casanova) In the research context, the multidisciplinary YEAR I.F. TOTAL Q1 Q2 Ignacio Menacho (EAP Les Corts) and transverse nature of the activities of the 2015 31.95 12 - 9 Pilar Navarrete (EAP Comte Borrell) primary care professional favours a biological, Marta Navarro (EAP Comte Borrell) psychological and social approach to the 2016 56.83 18 7 4 Jacinto Ortiz (EAP Les Corts) patients and their illnesses, in both the 2017 42.58 16 5 6 Anna Pereira (EAP Casanova) consulting office and in the home. Montserrat Pinyol (EAP Les Corts) Antoni Sisó Almirall

TEAM

316 PRIMARY HEALTHCARE TRANSVERSAL RESEARCH GROUP T.1

MAIN LINES OF RESEARCH 2. Amor AJ, Pinyol M, Solà E, Catalan M, Cofán toward hastened death in a palliative care M, Herreras Z, Amigó N, Gilabert R, Sala-Vila A, population. QUAL LIFE RES. 26(1):235-239. Main outcomes: Ros E, Ortega E. Relationship between I.F.: 2.344 - Conduction of population-based studies noninvasive scores of nonalcoholic fatty (both descriptive and evaluating liver disease and nuclear magnetic 9. Martín-Sánchez JC, Bilal U, Clèries R, interventions and follow-up), in an resonance lipoprotein abnormalities: A Lidón-Moyano C, Fu M, González-de Paz L, accessible and well defined population of focus on atherogenic dyslipidemia. J CLIN Franco M, Fernandez E, Martínez-Sánchez subjects, taking advantage of the LIPIDOL. 11(2):551-561. I.F.: 5.812 JM. Modelling lung cancer mortality rates computer-based filing of clinical data. from smoking prevalence: Fill in the gap. - Conduction of research into healthcare 3. Bosch X, Montori E, Guerra-García M, CANCER EPIDEMIOL. 49:19-23. I.F.: 2.343 results or outcomes. Costa-Rodríguez J, Quintanilla MH, - Description of the natural history of the Tolosa-Chapasian PE, Moreno P, Guasch N, 10. Bosch X, Montori E, Guerra-García M, patient and disease from a biological, López-Soto A. A comprehensive Costa-Rodríguez J, Quintanilla MH, psychological and social perspective. evaluation of the gastrointestinal tract in Tolosa-Chapasian PE, Moreno P, Guasch N, - Conduction of studies of risk factors and iron-deficiency anemia with predefined López-Soto A. Haemoglobin responses to preventive medicine. hemoglobin below 9mg/dL: A prospective transfusion in severe iron deficiency - Analysis of the morbidity and mortality of cohort study. DIG LIVER DIS. 49(4):417-426. anaemia: potential impact of the most prevalent disorders. I.F.: 3.061 gastrointestinal disorders. VOX SANG. - Development of collaborative studies with 112(3):257-267. I.F.: 2.192 the administration and research entities or 4. Sisó-Almirall A., Kostov B., González M., groups allowing the implementation of Salami D., Jiménez A., Soleâ R., Saumell C., 11. Gonzalez-Ortega, Maria; Gene-Badia, transversal research. Bach L., Martí M., Paz L., Riera R., Alonso V., Joan; Kostov, Belchin; Garcia-Valdecasas, Acar-Denizli N., Almacellas M., Ramos-Casals Vicente; Perez-Martin, Carmen. Randomized The main lines of research include: M., Àreu J. Abdominal aortic aneurysm trial to reduce emergency visits or hospital - Healthcare continuity and management of screening program using hand-held admissions using telephone coaching to chronic diseases. ultrasound in primary healthcare. PLOS complex patients. FAMILY PRACTICE. - Use of healthcare services. ONE. 12(4):e0176877. I.F.: 2.806 34(2):219-226. I.F.: 1.804 - The fragility – geriatrics – dependency – home care axis. 5. Belhassen-García M, Alonso-Sardón M, 12. Moreno-Chico C, González-de Paz L, - Use of medicines. Martinez-Perez A, Soler C, Carranza- Monforte-Royo C, Arrighi E, Navarro-Rubio - Primary care and autoimmunity. Rodriguez C, Pérez-Arellano JL, Muro A, MD, Gallart Fernández-Puebla A. Adaptation - Atherogenesis, risk factors and Salvador F, Soil-Transmitted Helminths Study to European Spanish and psychometric cardiovascular diseases. Group of the SEMTSI. Surveillance of properties of the Patient Activation - Chronic pain. strongyloidiasis in Spanish in-patients Measure 13 in patients with chronic - Mental health, smoking and other addictions. (1998-2014). PLOS ONE. 12(12): e0189449. diseases. FAM PRACT. 34(5):627-634. - Respiratory diseases. I.F.: 2.806 I.F.: 1.804 - Digestive and liver diseases. - HIV infection-AIDS and other infectious 6. Cano I, Dueñas-Espín I, Hernandez C, de 13. Risco E, Zabalegui A, Miguel S, Farré M, diseases. Batlle J, Benavent J, Contel JC, Baltaxe E, Alvira C, Cabrera E. Aplicación del modelo - 2.0. Health. Escarrabill J, Fernández JM, Garcia-Aymerich Balance of Care en la toma de decisiones J, Mas MÀ, Miralles F, Moharra M, Piera J, acerca del mejor cuidado para las Salas T, Santaeugènia S, Soler N, Torres G, personas con demencia. GAC SANIT. PUBLICATIONS Vargiu E, Vela E, Roca J. Protocol for 31(6):518-523. I.F.: 1.768 regional implementation of Originals / I.F.: 42.579 community-based collaborative 14. Ruiz Morilla, Sans M, Casasa A, Giménez management of complex chronic patients. N. Implementing technology in healthcare: 1. Brito-Zerón P, Kostov B, Fraile G, NPJ PRIM CARE RESPIR MED. 27(1):44. insights from physicians. BMC MED Caravia-Durán D, Maure B, Rascón FJ, I.F.: 2.793 INFORM DECIS MAK. 17(1):92. I.F.: 1.643 Zamora M, Casanovas A, Lopez-Dupla M, Ripoll M, Pinilla B, Fonseca E, Akasbi M, de la 7. Anglada-Martínez H, Martin-Conde M, 15. Bastida C, Corominas N, Sotoca JM, Red G, Duarte-Millán MA, Fanlo P, Rovira-Illamola M, Sotoca-Momblona JM, Rovira M. Anticoagulation in atrial Guisado-Vasco P, Pérez-Alvarez R, Chamorro Sequeira E, Aragunde V, Codina-Jané C. An fibrillation: NOAC prescribing in primary AJ, Morcillo C, Jiménez-Heredia I, Interactive Mobile Phone-Website health care. INT J CLIN PHARM. Sánchez-Berná I, López-Guillermo A, Platform to Facilitate Real-Time 39(2):478-482. I.F.: 1.555 Ramos-Casals M, SS Study Group Management of Medication in Chronically GEAS-SEMI. Characterization and risk ill Patients. J MED SYST. 41(8):122. I.F.:2.456 16. Santesmases-Masana R, González-de estimate of cancer in patients with primary Paz L, Real J, Borràs-Santos A, Sisó-Almirall A, Sjögren syndrome. JOURNAL OF 8. Monforte-Royo C, González-de Paz L, Navarro-Rubio MD. Alfabetización en salud HEMATOLOGY AND ONCOLOGY. 10(1):90. Tomás-Sábado J, Rosenfeld B, Strupp J, Voltz en pacientes con insuficiencia cardiaca I.F.: 6.350 R, Balaguer A. Development of a short form atendidos en atención primaria. ATEN of the Spanish schedule of attitudes PRIMARIA. 49(1):28-34. I.F.:1.042

317 TRANSVERSAL AREA TRANSVERSAL RESEARCH GROUPS

Reviews / I.F.: 5.190 2. Amor AJ, Serra-Mir M, Martínez-González DOCTORAL THESES MA, Corella D, Salas-Salvadó J, Fitó M, 1. Pérez-De-Lis M, Retamozo S, Estruch R, Serra-Majem L, Arós F, Babio N, Sisó A. Ateroesclerosis Preclínica en Flores-Chávez A, Kostov B, Perez-Alvarez R, Ros E, Ortega E; PREDIMED Investigators. pacientes con Diabetes tipo 2 de reciente Brito-Zerón P, Ramos-Casals M. Prediction of Cardiovascular Disease by diagnóstico. Autoimmune diseases induced by the Framingham-REGICOR Equation in the PhD Student: Marta Catalán Adell biological agents. A review of 12,731 cases High-Risk PREDIMED Cohort: Impact of (BIOGEAS Registry). EXPERT OPINION ON the Mediterranean Diet Across Different DRUG SAFETY. 16(11):1255-1271. I.F.: 3.439 Risk Strata. J AM HEART ASSOC. 6(3). I.F.: 4.425 2. Mas Dalmau G, Sant Arderiu E, Enfedaque Montes MB, Solà I, Pequeño Saco S, Alonso 3. Roca Saumell C, Aguilar Margalejo A, Barro Coello P. Patients' and physicians' Lugo S, Sànchez Collado D; COCOOPSI perceptions and attitudes about oral Group. Perception of measures for dealing anticoagulation and atrial ﬁbrillation: a with Ebola disease in primary care. PRIM qualitative systematic review. BMC FAM HEALTH CARE RES DEV. 18(3):282-290. PRACT. 18(1):3. I.F.: 1.751 I.F.: 1.147

Letters / I.F.: 6.273 GRANTS FOR RESEARCH IN PROGRESS

1. Laynez-Roldan P, Herrero-Mateu A, González L. Cuidadores informales de Martin-Conde M, Requena-Méndez A. Reply pacientes que requieren atención to Escobedo et al. J INFECT DIS. domiciliaria: estudio descriptivo 216(9):1181-1182. I.F.: 6.273 transversal. Sponsored by: Consorci d’Atenció Primària de Salut Barcelona Esquerra (CAPSBE) Editorials / I.F.: 1.042 Duration: 01/06/2016-01/06/2017

1. Sequeira E. Atención sanitaria a Herranz C. Avaluació d’una Intervenció refugiados o la historia de una asignatura Comunitària per disminuir la percepció de pendiente. ATEN PRIMARIA. 49(8):448-449. soledat en les persones majors. I.F.: 1.042 Sponsored by: Consorci d’Atenció Primària de Salut Barcelona Esquerra (CAPSBE) Duration: 01/06/2017-01/06/2018 Consortium Publications / I.F.: 18.383 Navarro M. Intervenció multifactorial per 1. Brito-Zerón P, Acar-Denizli N, Zeher M, prevenir el desenvolupament de fragilitat Rasmussen A, Seror R, Theander E, Li X, en pre-fràgils d’edat avançada. Baldini C, Gottenberg JE, Danda D, Sponsored by: Consorci d’Atenció Primària de Quartuccio L, Priori R, Hernandez-Molina G, Salut Barcelona Esquerra (CAPSBE) Kruize AA, Valim V, Kvarnstrom M, Sene D, Duration: 01/06/2016-01/06/2017 Gerli R, Praprotnik S, Isenberg D, Solans R, Rischmueller M, Kwok SK, Nordmark G, Sequeira E. CRIB-MI: cribado en pacientes Suzuki Y, Giacomelli R, Devauchelle-Pensec V, inmigrantes mediante Herramienta Bombardieri M, Hofauer B, Bootsma H, Brun informática adaptada a la historia Clínica JG, Fraile G, Carsons SE, Gheita TA, Morel J, en Atención Primaria. Vollenveider C, Atzeni F, Retamozo S, Horvath Sponsored by: Generalitat de Catalunya IF, Sivils K, Mandl T, Sandhya P, De Vita S, (PERIS). Sanchez-Guerrero J, van der Heijden E, Duration: 01/01/2017-31/12/2019 Trevisani VFM, Wahren-Herlenius M, Mariette X, Ramos-Casals M, EULAR-SS Task Force Sisó A. Validez de un método de Big Data Consortium. Inﬂuence of monitorización de la Presión Arterial geolocation and ethnicity on the de 1 hora frente a los métodos habituales: phenotypic expression of primary estudio de evaluación de tecnología Sjögren's syndrome at diagnosis in 8310 diagnóstica . patients: a cross-sectional study from the Sponsored by: Instituto de Salud Carlos III Big Data Sjögren Project Consortium. ANN (ISCIII). RHEUM DIS. 76(6):1042-1050. I.F.: 12.811 Duration: 01/01/2017-31/12/2019

318 RESEARCH IN NURSING T.2

Research T.2 in nursing

TEAM LEADER methods including extensive literature review, Adelaida Zabalegui (HCB) focus groups, clinical assessments and LOCATION T. 93 227 54 00 (Ext.: 3055) analysis of new interventions in different HCB building [email protected] nursing settings (homecare, institutional long term and hospital.

POST-DOCTORAL RESEARCHERS Innovation: Montserrat Amigó (HCB) As an instrument to improve the efficiency and Ángela Arranz (HCB) quality of care processes involving cardiac KEYWORDS Ester Risco (HCB) and respiratory diseases, as well as other 1. Older people areas of clinical practice. Implementation of 2. Chronic-care / Long-term care PRE-DOCTORAL RESEARCHERS Dedicated Educational Units. 3. Dementia Cindy Esther Frías (HCB) 4. Best practice María Galisteo (HCB) Professional Competencies: 5. Advance nursing practice Marta García (HCB) To determine how hospital nurse staffing, skill Sara Pedragosa (HCB) mix, educational composition, and quality of Sonia Sevilla (HCB) the nurse work environment impact on different hospital outcomes such as mortality, NURSING STAFF failure to rescue, quality of care, and patient Ana Alonso (HCB) satisfaction. These ﬁndings will allow Sheila Baena (HCB) researchers to reﬁne existing nurse workforce. Original publications Lourdes Corominas (HCB) from 2015 to 2017 Marta Farré (HCB) Advanced Practice: YEAR I.F. TOTAL Q1 Q2 Marta García (HCB) To describe and analyse including the Miguel Ángel Giménez (HCB) development of a new instrument to measure 2015 25.91 14 11 - Marta Quintela (HCB) the different dimentions at APNs, the advance 2016 16.96 9 1 3 Dolors Robles (HCB) practice role and competences in nursing. 2017 20.94 6 4 2 Victoria Ruiz (HCB) M. Carmen Sánchez (HCB)

PUBLICATIONS

TEAM INVOLVED IN STRATEGIC OBJECTIVES Originals / I.F.: 20.935 AGAUR_SGR14 Research in nursing is essential for 1. Sutcliffe C, Giebel C, Bleijlevens M, Lethin C, responding to the healing demands of the Stolt M, Saks K, Soto ME, Meyer G, Zabalegui current healthcare system. Its complexity in A, Chester H, Challis D, RightTimePlaceCare the hospital setting is derived from the Consortium. Caring for a Person With associated increase in patient severity upon Dementia on the Margins of Long-Term admission, the reduction in hospital stay, the Care: A Perspective on Burden From 8 incorporation of new technologies, the aging European Countries. JOURNAL OF THE of the population, patient requests for AMERICAN MEDICAL DIRECTORS information, social change, and the global ASSOCIATION. 18(11):967-973. I.F.: 5.775 crisis. 2. Jimenez, Esther; Sole, Brisa; Arias, Barbara; Mitjans, Marina; Varo, Cristina; Reinares, Maria; del Mar Bonnin, Caterina; Ruiz, Victoria; MAIN LINES OF RESEARCH Alejandra Saiz, Pilar; Paz Garcia-Portilla, M.; Buron, Patricia; Bobes, Julio; Amann, Benedikt Empowerment: L.; Martinez-Aran, Anabel; Torrent, Carla; Vieta, The main target is to increase the patient Eduard; Benabarre, Antoni. Impact of empowerment and develop assessment tools childhood trauma on cognitive proﬁle in for educational interventions to improve their bipolar disorder. BIPOLAR DISORDERS. bio-physiological, functional and social 19(5):363-374. I.F.: 4.531 wellbeing. 3. González-Rodríguez A, Bernardo M, Chronic & aging care: Penadés R, Arias B, Ruiz Cortés V, Seeman Dementia care: The main target is to improve MV, Catalán R. Do FSH/LH ratio and health service for people with dementia gonadal hormone levels predict clinical through careful development of best practice improvement in postmenopausal strategies using various data collection schizophrenia women?

319 TRANSVERSAL AREA TRANSVERSAL RESEARCH GROUPS

ARCHIVES OF WOMENS MENTAL HEALTH. 20(5):613-620. I.F.: 3.397

4. Sisó-Almirall A., Kostov B., González M., Salami D., Jiménez A., Soleâ R., Saumell C., Bach L., Martí M., Paz L., Riera R., Alonso V., Acar-Denizli N., Almacellas M., Ramos-Casals M., Àreu J. Abdominal aortic aneurysm screening program using hand-held ultrasound in primary healthcare. PLOS ONE. 12(4):e0176877. I.F.: 2.806

5. Lethin C; Renom-Guiteras A; Zwakhalen S; Soto-Martin M; Saks K; Zabalegui A; Challis D; Nilsson C; Karlsson S. Psychological well-being over time among informal caregivers caring for persons with dementia living at home. AGING AND MENTAL HEALTH. 21(11):1138-1146. I.F.: 2.658

6. Risco E; Zabalegui A; Miguel S; Farré M; Alvira C; Cabrera E. Application of the Balance of Care model in decision-making regarding the best care for patients with dementia. GACETA SANITARIA. 31(6):518-523. I.F.: 1.768

GRANTS FOR RESEARCH IN PROGRESS

Zabalegui A. Avaluació d’una intervenció innovadora informativa, formativa i de suport social (INFOSA-DEM) als cuidadors informals de persones amb demència al domicili. Sponsored by: Fundació La Marató de TV3. 20144410 Duration: 12/05/2015-11/05/2018

DOCTORAL THESES

Zabalegui A. Empoderamiento del paciente con osteoartritis. PhD student: Sara Cano Plans

Zabalegui A, Cabrera E. Calidad de vida y calidad de los cuidados de las personas con demencia y sus cuidadores informales. PhD Student: Susana Miguel González

Zabalegui A, Cabrera E. Conocer las reacciones de los cuidadores informales de pacientes con demencia en un contexto español y europeo. PhD Student: Mª Carmen Alvira Balada

320 CLINICAL PHARMACOLOGY T.3

Clinical T.3 pharmacology

MAIN LINES OF RESEARCH

LOCATION - Ethics in clinical research: Rosselló 138 (rooms 12, 20, 21, 25) Ethics methodological aspects of clinical research currently are of increasing importance; based on the main ethical principals; respect for persons, beneﬁcence, non-maleﬁcence and justice.

KEYWORDS - Clinical trials, design and methodology: 1. Clinical trials, design TEAM LEADER Our aim is to give support to the and methodology Xavier Carné (HCB) investigators of our institution in designing 2. Ethics in clinical research T. 93 227 91 68 and performing academic clinical trials. 3. Drug regulation [email protected] 4. Pharmacoepidemiology - Statistical support of clinical research: Statistics and data management are basic RESEARCHERS aspects of clinical research. We provide Joan Albert Arnaiz (HCB) these tools to the investigators of our Gonzalo Calvo (HCB) institution.

Original publications - Pharmacovigilance and from 2015 to 2017 pharmacoepidemiology: STRATEGIC OBJECTIVES We also provide support to observational YEAR I.F. TOTAL Q1 Q2 studies with the aim to improve the safety 1. We provide support of all technical and of drug use in our institution. 2015 19.80 6 32 administrative aspects related to 2016 35.37 5 4 1 randomized clinical trials carried out in the - Pharmacogenetics and 2017 21.75 6 5 1 Institution. pharmacogenomics: These are important tools to improve the efficient use of drugs in 2. We provide support for the conduction of the context of the personalized medicine. academic-driven clinical trials.

TEAM INVOLVED IN 3. We also offer support activities in SCReN pharmacovigilance and ECRIN pharmacoepidemiology. AGAUR_SGR14 4. Collaboration with the Pharmacology Unit of the UB in pharmacogenetic studies. Xavier Carné

TEAM

321 TRANSVERSAL AREA TRANSVERSAL RESEARCH GROUPS

PUBLICATIONS Review / I.F.: 6.059

Originals / I.F.: 21.754 1. Zannad, Faiez; Pfeffer, Marc A.; Bhatt, Deepak L.; Bonds, Denise E.; Borer, Jeffrey S.; 1. Inciarte, A.; Leal, L.; Gonzalez, E.; Leon, A.; Calvo-Rojas, Gonzalo; Fiore, Louis; Lund, Lars Lucero, C.; Mallolas, J.; Torres, B.; Laguno, M.; H.; Madigan, David; Maggioni, Aldo Pietro; Rojas, J.; Martinez-Rebollar, M.; Meyers, Catherine M.; Rosenberg, Yves; Gonzalez-Cordon, A.; Cruceta, A.; Arnaiz, J. A.; Simon, Tabassome; Stough, Wendy Gattis; Gatell, J. M.; Garcia, F.;STRIBPEP Study Grp. Zalewski, Andrew; Zariffa, Nevine; Temple, Tenofovir disoproxil fumarate/ Robert. Streamlining cardiovascular emtricitabine plus ritonavir-boosted clinical trials to improve efficiency and lopinavir or cobicistat-boosted elvitegravir generalisability. HEART. 103(15):1156-1162. as a single-tablet regimen for HIV I.F.: 6.059 post-exposure. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY. 72(10):2857-2861. I.F.: 5.071 GRANTS FOR RESEARCH IN PROGRESS

2. Gassó P., Rodríguez N., Boloc D., Blázquez Arnaiz JA. Evaluating a combination of A., Torres T., Gortat A., Plana M., Lafuente A., immune-based therapies to achieve a Mas S., Arnaiz J., Lázaro L.Association of functional cure of HIV infection regulatory TPH2 polymorphisms with (HIVACAR). higher reduction in depressive symptoms Sponsored by: European Clinical Research in children and adolescents treated with Infrastructure Network (ECRIN-ERIC). ﬂuoxetine. PROGRESS IN NEURO- H2020-SC1 PSYCHOPHARMACOLOGY AND Duration: 01/01/2017-31/12/2021 BIOLOGICAL PSYCHIATRY. 77:236-240. I.F.: 4.187 Arnaiz JA. Simvastatin and Rifaximin as new therapy for patients with 3. Dal-Re R; Carcas A; Carne X; Wendler D. decompensated cirrhosis (LIVERHOPE). Public preferences on written informed Sponsored by: European Clinical Research consent for low-risk pragmatic clinical Infrastructure Network (ECRIN-ERIC). trials in Spain. BRITISH JOURNAL OF H2020-SC1 CLINICAL PHARMACOLOGY. Duration: 01/01/2017-31/12/2021 83(9):1921-1931. I.F.: 3.493 Calvo G. Plataforma de unidades de 4. Dal-Ré R, Carcas AJ, Carné X, Wendler D. investigación clínica y ensayos clínicos. Patients' beliefs regarding informed Sponsored by: Instituto de Salud Carlos III consent for low-risk pragmatic trials. BMC (ISCIII). PT13/0002/0009 MEDICAL RESEARCH METHODOLOGY. Duration: 01/01/2014-31/12/2018 17(1):145. I.F.: 3.295 Calvo G. Coste-efectividad y coste utilidad 5. Dal-Ré R, Carcas AJ, Carné X. Who is de una estrategia de transfusión de willing to participate in low-risk pragmatic hematíes “liberal” vs. otra “restrictiva” en clinical trials without consent? EUROPEAN pacientes con infarto agudo de miocardio JOURNAL OF CLINICAL PHARMACOLOGY. y anemia. Estudio REALITY. 73(12):1557-1563. I.F.: 2.902 Sponsored by: Instituto de Salud Carlos III (ISCIII). PI15/00915 6. Guardo AC, Gómez CE, Díaz-Brito V, Pich J, Duration: 01/01/2016-31/12/2018 Arnaiz JA, Perdiguero B, García-Arriaza J, González N, Sorzano COS, Jiménez L, Calvo G. ORTHOpedic randomized clinical Jiménez JL, Muñoz-Fernández MÁ, Gatell JM, trial with expanded bone marrow MSC and Alcamí J, Esteban M, López Bernaldo de bioceramics versus autograpt in long bone Quirós JC, García F, Plana M, nonUNIONs (ORTHOUNION). RISVAC02boost study. Safety and Sponsored by: European Clinical Research vaccine-induced HIV-1 immune responses Infrastructure Network (ECRIN-ERIC). in healthy volunteers following a late H2020-SC1 MVA-B boost 4 years after the last Duration: 01/01/2017-31/12/2021 immunization. PLOS ONE. 12(10):e0186602. I.F.: 2.806

322 TEAM AND GROUP LEADERS INDEX

Team and group leaders index

A Alfredo Adán ...... 85 GRJuan Carlos García-Pagán ...... 164-165 Ignacio Revuelta ...... 107 Neus Agell ...... 306 Pere Gascón ...... 301 Antonia Ribes ...... 189 Alvar Agustí ...... 131 Xavier Gasull...... 217 Jordi Alberch ...... 224 Pere Ginès ...... 153-154 S Manel Sabaté ...... 90 Antonio Alcaraz ...... 134 Ramon Gomis...... 194 Maria Victoria Sánchez-Vives ...... 242 Francesc Artigas ...... 205 Jordi Gracia-Sancho ...... 166 Raquel Sánchez del Valle...... 253 Eduard Gratacós ...... 143 Pau Sancho-Bru...... 155 B Oriol Bachs ...... 303 Josep Maria Grau ...... 220 Raimon Sanmartí ...... 52 Joan Albert Barberà ...... 122 Antoni Gual ...... 229 Pere Santamaria ...... 195 Miquel Bernardo ...... 227-228 Núria Guañabens ...... 173-174 Josep Saura ...... 206 Joan Bladé ...... 286 Eduard Guasch ...... 98 Antoni Sisó...... 316 Isabel Blanco ...... 123 Marta Sitges ...... 99 Josep Brugada ...... 96 H Felicia Hanzu ...... 195 Alex Soriano...... 64 Jordi Bruix ...... 159 Gisela Sugranyes...... 229 J Wladimiro Jiménez ...... 155 Cristina Suñol ...... 206 C Elías Campo ...... 260-261 Carme Junqué ...... 239 Xavier Carné ...... 321 T Antoni Torres...... 118 Antoni Castells ...... 182 L Josep M. Llovet ...... 160 Ramon Trullàs...... 251 Sergi Castellví-Bel ...... 183 Sara Llufriu ...... 247 Joseﬁna Castro-Fornieles ...... 228 Armando López-Guillermo ...... 286 U Álvaro Urbano-Ispizua ...... 282 Francisco Cervantes ...... 285-286 Francisco Lozano...... 72 Ricard Cervera ...... 55 V Josep Valls ...... 216 Ángel Chamorro ...... 209 M Josep Mallolas...... 63 Josep Vidal...... 193-195 Maria Cinta Cid ...... 56 M. Josep Martí...... 212 Eduard Vieta...... 230 Marc Claret ...... 194 Jose Ignacio Martín-Subero...... 262 Pablo Villoslada ...... 248 Joan Clària ...... 154 María Ángeles Martínez-Zamora ...... 140 Daniel Closa ...... 83 Guadalupe Mengod ...... 204-205 Y Jordi Yagüe...... 75 Dolors Colomer ...... 293 Montserrat Milà ...... 274 Albert Compte ...... 243 Josep M. Miró ...... 62-63 Z Adelaida Zabalegui ...... 319 Oscar Miró...... 78 D Josep Dalmau ...... 246-247 Lluis Mont ...... 98 Jaime de la Rocha ...... 244 Josep Maria Montserrat...... 119 Fritz Diekmann ...... 106 Albert Morales ...... 160 Asunción Moreno ...... 64 E Gustavo Egea ...... 97 Joaquim Mullol ...... 126-127 Carles Enrich ...... 305-306 Ginés Escolar ...... 297 N Miquel Navasa ...... 178 Ramon Estruch ...... 110 Anna Novials...... 199

F Ramon Farré ...... 115 O Rafael Oliva...... 272 Pedro Luis Fernández ...... 262 José Carlos Fernández-Checa ...... 176 P Julián Panés ...... 170 Carlos Fernández de Larrea ...... 286 Albert Parés ...... 173-174 Mercedes Fernández Lobato...... 165 Carmen Peralta ...... 179 Jorge Ferrer...... 191 Albert Pol ...... 307 Cristina Fillat ...... 183 Francesca Pons ...... 269 Xavier Forns ...... 149 Antonio Postigo...... 262 Aleix Prat...... 309 Susana Puig...... 277

325 Rosselló, 149-153 08036 Barcelona www.idibaps.org [email protected] www.facebook.com/idibaps @idibaps

The mission of IDIBAPS is to combine high-quality clinical research with high-level basic research in order to achieve a more effective transfer of scientiﬁc results in the prevention and treatment of the most common health issues in our country.